<PAGE>
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement [_] Confidential, for Use of the
Commission Only (as permitted by
Rule 14a-6(e)(2))
[X] Definitive Proxy Statement
[_] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-11(c) or Section 240.14a-12
VETERINARY CENTERS OF AMERICA, INC.
- --------------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
- --------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[_] $125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6(i)(1), 14a-6(i)(2)
or Item 22(a)(2) of Schedule 14A.
[_] $500 per each party to the controversy pursuant to Exchange Act Rule
14a-6(i)(3).
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which
the filing fee is calculated and state how it was determined):
-------------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------------
[X] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------------
Notes:
<PAGE>
[VCA LOGO]
June 27, 1996
Dear Stockholder:
As most of you are aware, Veterinary Centers of America, Inc. ("VCA") has
entered into an Agreement and Plan of Reorganization with The Pet Practice,
Inc. At our Annual Meeting on July 19, 1996, you will be asked to consider and
approve the Merger and related items. The attached Joint Proxy
Statement/Prospectus presents the details of this proposed strategic
combination.
VCA's Board of Directors has unanimously approved the Merger and recommends
that you vote FOR all proposals presented.
Our Board believes that VCA through this Merger will be better able to
compete effectively in the companion animal care market. The addition of a
large portfolio of strong, quality animal hospitals, the complementary
geographic locations of these hospitals, the increased market capitalization,
the opportunities for economies of scale and operating efficiencies as well as
the potential expansion of VCA's veterinary diagnostic laboratory and pet food
businesses should all result from the combination of VCA and The Pet Practice,
Inc. For further information regarding the potential benefits of the Merger, I
urge that you read carefully the section "The Merger -- VCA's Reasons for the
Merger; Recommendations of the VCA Board" in the attached document.
Even if you plan to attend the Annual Meeting in person, please complete,
sign and promptly return the enclosed proxy in the enclosed postage-prepaid
envelope.
Sincerely,
Robert L. Antin
Chief Executive Officer
<PAGE>
THE PET PRACTICE, INC.
1018 West Ninth Avenue
King of Prussia, Pennsylvania 19406
June 27, 1996
To our stockholders:
Your Board of Directors has approved an Agreement and Plan of
Reorganization, dated as of March 21, 1996, whereby The Pet Practice, Inc.
("The Pet Practice") would become a wholly owned subsidiary of Veterinary
Centers of America, Inc, ("VCA"). In the merger, each outstanding share of The
Pet Practice common stock will be converted into the right to receive a
fractional number of shares of VCA common stock.
Consummation of the merger is subject to, among other things, the approval
of the stockholders of The Pet Practice voting at a Special Meeting of the
Stockholders on July 19, 1996. Information concerning the Special Meeting, the
merger transaction, and other matters concerning The Pet Practice and VCA is
set forth in the accompanying proxy material. Because of the importance of the
merger to The Pet Practice and its stockholders, we urge you to read this
material carefully.
Your Board of Directors and management have studied the proposed merger and
have recommended that it be approved by the stockholders of The Pet Practice.
Your Board of Directors and management believe that, by combining the
complementary strengths of The Pet Practice and VCA, the merger will enhance
the business prospects of both companies and that stockholders will benefit
from the opportunity for continued equity participation in the combined
enterprise.
Your Board of Directors unanimously recommends that you vote FOR the
merger. Since your vote is important at the Special Meeting of the
Stockholders of The Pet Practice, we ask that you promptly complete, sign,
date, and return the enclosed proxy in the enclosed envelope.
We join with your Board of Directors in urging you to vote FOR the approval
and adoption of the Agreement and Plan of Reorganization.
Sincerely,
STEPHEN F. NAGY PETER J. COHEN
Chairman of the Board President and Chief
Executive Officer
YOUR VOTE IS IMPORTANT
To ensure that your interests will be represented at the Meeting, whether
or not you plan to attend, please complete, date, sign, and mail your proxy
promptly in the enclosed postage-paid envelope. Stockholders who attend the
Meeting in person may revoke their proxies and vote in person if they desire.
<PAGE>
VETERINARY CENTERS OF AMERICA, INC.
___________
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
___________
To Be Held July 19, 1996
TO THE STOCKHOLDERS OF VETERINARY CENTERS OF AMERICA, INC.:
Notice is hereby given that the 1996 Annual Meeting of Stockholders (the
"VCA Annual Meeting") of Veterinary Centers of America, Inc. ("VCA") will be
held at VCA's offices at 3420 Ocean Park Boulevard, Suite 1000, Santa Monica,
California 90405, on July 19, 1996, at 10:00 a.m., Los Angeles time, for the
following purposes:
1. To approve the issuance of shares of Common Stock, par value $.001 per
share, of VCA (the "VCA Common Stock"), pursuant to the Agreement and Plan of
Reorganization, dated as of March 21, 1996, by and among VCA, Golden Merger
Corporation, a Delaware corporation and a wholly owned subsidiary of VCA
("Merger Corp."), and The Pet Practice, Inc., a Delaware corporation ("Pet
Practice"), pursuant to which, among other things, (i) Pet Practice will be
merged with and into Merger Corp., which will be the surviving corporation, and
Pet Practice will become a wholly owned subsidiary of VCA (the "Merger") and
(ii) each outstanding share of Common Stock, par value $.01 per share, of Pet
Practice will be converted into the right to receive a fraction of a share of
VCA Common Stock determined by reference to an Exchange Ratio;
2. To elect two Class II Directors to the Board of Directors of VCA, each
to hold office for three years and until their respective successors are
elected;
3. To amend VCA's Certificate of Incorporation to increase the number of
authorized shares of VCA Common Stock and VCA Preferred Stock;
4. To adopt the VCA 1996 Stock Incentive Plan;
5. To adopt the VCA 1996 Employee Stock Purchase Plan; and
6. To transact such other business as may properly come before the
meeting and any adjournment(s) thereof.
Only holders of record of the VCA Common Stock at the close of business on
May 20, 1996 are entitled to notice of and to vote at the VCA Annual Meeting
and adjournments or postponements thereof.
All stockholders are cordially invited to attend the meeting in person.
However, to ensure your representation at the meeting, you are urged to mark,
sign and return the enclosed Proxy as promptly as possible in the postage-
prepaid envelope enclosed for that purpose. Any stockholder attending the
meeting may vote in person, even though he or she has returned a Proxy.
By Order of the Board of Directors
Arthur J. Antin
Secretary
3420 Ocean Park Boulevard
Santa Monica, CA 90405
June 27, 1996
IN ORDER TO ENSURE YOUR REPRESENTATION AT THE MEETING, YOU ARE REQUESTED TO
COMPLETE, DATE, AND SIGN THE ACCOMPANYING PROXY AS PROMPTLY AS POSSIBLE AND
RETURN IT IN THE ENCLOSED ENVELOPE.
<PAGE>
THE PET PRACTICE, INC.
1018 West Ninth Avenue
King of Prussia, Pennsylvania 19406
Notice of Special Meeting of Stockholders
to be held July 19, 1996
King of Prussia, Pennsylvania
June 27, 1996
To the Holders of Common Stock of
The Pet Practice, Inc.:
A Special Meeting of the Stockholders of The Pet Practice, Inc., a Delaware
corporation ("The Pet Practice"), will be held at the Park Ridge Hotel, 480
North Gulph Road, King of Prussia, Pennsylvania, on July 19, 1996, at 2:00
p.m., for the following purposes, as more fully described in the accompanying
Joint Proxy Statement/Prospectus.
1. To consider and act upon a proposal to approve and adopt the Agreement
and Plan of Reorganization (the "Merger Agreement") dated as of March 21, 1996,
by and among Veterinary Centers of America, Inc., a Delaware corporation
("VCA"), Golden Merger Corporation, a Delaware corporation and a wholly owned
subsidiary of VCA ("Merger Corp."), and The Pet Practice (a copy of the Merger
Agreement is attached as Appendix A to the accompanying Joint Proxy
-------- -
Statement/Prospectus), providing for the merger of The Pet Practice with and
into Merger Corp., whereupon The Pet Practice will become a wholly owned
subsidiary of VCA.
2. To transact such other business as may properly come before the
Meeting or any adjournment or postponements thereof.
The Board of Directors has fixed the close of business on May 20, 1996 as
the record date for the determination of stockholders entitled to notice of,
and to vote at, the Meeting. A list of the stockholders entitled to vote at
the Meeting may be examined at The Pet Practice's executive offices located in
King of Prussia, Pennsylvania, during the ten-day period preceding the Meeting.
By Order of the Board of Directors
Warren D. Barratt
Secretary
YOUR ATTENTION IS DIRECTED TO THE ACCOMPANYING PROXY STATEMENT
You are cordially invited to attend the Meeting in person. If you do not
expect to be present, please promptly mark, sign, and date the enclosed form of
Proxy and mail it in the enclosed return envelope, which requires no postage if
mailed in the United States, so that your vote can be recorded.
<PAGE>
JOINT PROXY STATEMENT
FOR ANNUAL MEETING OF STOCKHOLDERS
OF VETERINARY CENTERS OF AMERICA, INC.
AND
SPECIAL MEETING OF STOCKHOLDERS OF THE PET PRACTICE, INC.
TO BE HELD JULY 19, 1996
_______________
VETERINARY CENTERS OF AMERICA, INC.
PROSPECTUS
______________
This Joint Proxy Statement/Prospectus is being furnished to holders of
common stock of Veterinary Centers of America, Inc., a Delaware corporation
("VCA"), in connection with the solicitation of proxies by the Board of
Directors of VCA (the "VCA Board") for use at the 1996 Annual Meeting of
Stockholders (the "VCA Annual Meeting"), to be held on July 19, 1996 at VCA's
offices at 3420 Ocean Park Boulevard, Suite 1000, Santa Monica, California,
commencing at 10:00 a.m., local time, and at any adjournments or postponements
thereof.
This Joint Proxy Statement/Prospectus is also being furnished to holders of
common stock, par value $.01 per share (the "Pet Practice Common Stock"), of The
Pet Practice, Inc., a Delaware corporation ("Pet Practice"), in connection with
the solicitation of proxies by the Board of Directors of Pet Practice (the "Pet
Practice Board") for use at the Special Meeting of Stockholders of Pet Practice
(the "Pet Practice Special Meeting") to be held on July 19, 1996, at the Park
Ridge Hotel, 480 North Gulph Road, King of Prussia, Pennsylvania, commencing at
2:00 p.m., local time, and at any adjournments or postponements thereof.
VCA has filed a registration statement on Form S-4 (together with all
amendments, exhibits and schedules thereto, the "Registration Statement") under
the Securities Act of 1933, as amended (the "Act"), relating to shares of the
VCA Common Stock that are proposed to be issued in connection with the merger
(the "Merger") of Pet Practice with and into Golden Merger Corporation, a
Delaware corporation and a wholly owned subsidiary of VCA ("Merger Corp."),
pursuant to the Agreement and Plan of Reorganization, dated as of March 21,
1996, among VCA, Merger Corp. and Pet Practice (the "Merger Agreement") in
exchange for outstanding securities of Pet Practice. Pursuant to the Merger
Agreement, each share of Pet Practice Common Stock will be converted into a
fraction of a share of VCA Common Stock based upon the Exchange Ratio described
on page __ hereof under the caption "The Merger Agreement -- Consideration to be
Received in the Merger." Based upon the closing sale price of the VCA Common
Stock ($___) on the Nasdaq National Market on June __, 1996 (the last
practicable day before printing this Joint Proxy Statement/Prospectus) each
share of Pet Practice Common Stock will be converted into the right to receive
___ shares of VCA Common Stock in the Merger. The actual Exchange Ratio will be
determined by reference to the average of the closing sale prices of the VCA
Common Stock over the 20 trading days ending on the third trading day prior to
the day of the VCA Annual Meeting and the Pet Practice Special Meeting (the
"Average Price") and could result in a greater or lower number of shares of VCA
Common Stock issued in the Merger than reflected in the prior sentence.
This Joint Proxy Statement/Prospectus also constitutes the Prospectus of
VCA filed as part of the Registration Statement. This Joint Proxy
Statement/Prospectus and the accompanying form of proxy are first being mailed
to the respective stockholders of VCA and Pet Practice on or about June __,
1996. All information contained in this Joint Proxy Statement/Prospectus
concerning VCA has been furnished by VCA and information with respect to Pet
Practice has been furnished by Pet Practice. Information contained in this Joint
Proxy Statement/Prospectus concerning Pets' Rx, Inc. has been furnished by Pets'
Rx, Inc.
SEE "RISK FACTORS" FOR CERTAIN INFORMATION THAT SHOULD BE CONSIDERED BY VCA
AND PET PRACTICE STOCKHOLDERS COMMENCING ON PAGE 23 AND ENDING ON PAGE 28 OF
THIS JOINT PROXY STATEMENT/PROSPECTUS.
THE SECURITIES TO BE ISSUED PURSUANT TO THIS JOINT PROXY
STATEMENT/PROSPECTUS HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE COMMISSION OR
ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS
JOINT PROXY STATEMENT/PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
This Joint Proxy Statement/Prospectus does not cover any resales of the VCA
Common Stock to be received by the stockholders of Pet Practice upon the
consummation of the transactions contemplated by the Merger Agreement, and no
person is authorized to make any use of this Joint Proxy Statement/Prospectus in
connection with any such resales.
The date of this Joint Proxy Statement/Prospectus is June 27, 1996
________________________________________________________
<PAGE>
No person has been authorized to give any information or to make any
representations not contained herein and the documents incorporated by reference
herein, and any information or representation not contained herein or therein
must not be relied upon as having been authorized by VCA, Merger Corp. or Pet
Practice. Neither the delivery hereof nor any distribution of the securities
being offered pursuant hereto shall, under any circumstances, create an
implication that there has been no change in the information set forth herein
since the date of this Joint Proxy Statement/Prospectus. This Joint Proxy
Statement/Prospectus does not constitute an offer or solicitation by anyone in
any state in which such offer or solicitation is not authorized or in which the
person making such offer or solicitation is not qualified to do so or to anyone
to whom it is unlawful to make such offer or solicitation.
2
<PAGE>
AVAILABLE INFORMATION
VCA and Pet Practice are each subject to the informational requirements of
the Exchange Act, and in accordance therewith file reports, proxy statements and
other information with the Commission. Such reports, proxy statements and other
information filed with the Commission can be inspected and copied at the public
reference facilities maintained by the Commission at Room 1024, 450 Fifth
Street, N.W., Judiciary Plaza, Washington, D.C. 20549 and at the following
Regional Offices of the Commission: Citicorp Center, 500 West Madison Street,
Suite 1400, Chicago, Illinois 60661 and 7 World Trade Center, Suite 1300, New
York, New York 10048. Copies of such material can be obtained at prescribed
rates from the Public Reference Section of the Commission at 450 Fifth Street,
N.W., Judiciary Plaza, Washington, D.C. 20549. VCA Common Stock and Pet Practice
Common Stock are listed on the Nasdaq National Market and such material may also
be inspected at the offices of the National Association of Securities Dealers,
Inc., 1735 K Street, N.W., Washington, D.C. 20006.
VCA has filed with the Commission the Registration Statement relating to
shares of VCA Common Stock that are proposed to be issued in connection with the
Merger to holders of Pet Practice Common Stock. See "THE MERGER AGREEMENT--
Consideration to be Received in the Merger." This Joint Proxy
Statement/Prospectus does not contain all of the information set forth in the
Registration Statement filed by VCA with the Commission, certain portions of
which are omitted in accordance with the rules and regulations of the
Commission. Such additional information is available for inspection and copying
at the offices of the Commission. Statements contained in this Joint Proxy
Statement/Prospectus or in any document incorporated into this Joint Proxy
Statement/Prospectus by reference as to the contents of any contract or other
document referred to herein or therein are not necessarily complete, and in each
instance reference is made to the copy of such contract or other document filed
as an exhibit to the Registration Statement or such other document.
3
<PAGE>
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
<S> <C>
AVAILABLE INFORMATION.................................................................. 3
SUMMARY OF JOINT PROXY STATEMENT/PROSPECTUS............................................ 8
The Companies....................................................................... 8
Meetings of Stockholders............................................................ 9
The Merger.......................................................................... 10
SELECTED HISTORICAL AND UNAUDITED PRO FORMA FINANCIAL DATA............................. 17
MARKET PRICE INFORMATION............................................................... 21
COMPARATIVE PER SHARE DATA............................................................. 22
RISK FACTORS........................................................................... 23
Pending Transactions................................................................ 23
Anticipated Effects of Acquisitions................................................. 24
Rapid Expansion and Management of Growth............................................ 24
Dependence on Acquisitions for Future Growth........................................ 25
Leverage............................................................................ 25
Risks Associated with Intangible Assets............................................. 25
Guaranteed Payments................................................................. 26
Seasonality and Fluctuating Quarterly Results....................................... 26
Dependence on Key Management........................................................ 26
Joint Ventures...................................................................... 27
Competition......................................................................... 27
Government Regulation............................................................... 27
Anti-takeover Effect................................................................ 27
Impact of Shares Eligible for Future Sale........................................... 28
Possible Volatility of Stock Price.................................................. 28
THE MEETINGS OF STOCKHOLDERS........................................................... 29
General............................................................................. 29
Matters to be Considered at the Meetings............................................ 29
Record Dates; Voting Rights; Votes Required for Approval............................ 30
Proxies............................................................................. 31
No Dissenters' Rights............................................................... 32
Proxy Solicitation.................................................................. 32
THE MERGER............................................................................. 32
Background of the Merger............................................................ 32
VCA's Reasons for the Merger; Recommendations of the VCA Board...................... 34
Pet Practice's Reasons for the Merger; Recommendations of the Pet Practice Board.... 36
Opinions of Financial Advisors...................................................... 37
Interests of Certain Persons in the Merger.......................................... 43
Accounting Treatment................................................................ 44
Certain Federal Income Tax Consequences............................................. 44
Resale Restrictions................................................................. 45
Regulatory Matters.................................................................. 46
Nasdaq National Market.............................................................. 46
</TABLE>
4
<PAGE>
<TABLE>
<CAPTION>
PAGE
<S> <C>
THE MERGER AGREEMENT................................................................... 47
General............................................................................. 47
Consideration to be Received in the Merger.......................................... 47
Exchange of Shares.................................................................. 48
Representations and Warranties...................................................... 49
Certain Covenants................................................................... 50
Conditions to the Merger............................................................ 51
Termination of the Merger Agreement................................................. 52
Amendment and Waiver................................................................ 53
BUSINESS OF VCA........................................................................ 53
General............................................................................. 53
Recent Developments................................................................. 53
The Companion Animal Health Care Industry........................................... 54
Business Strategy................................................................... 55
Acquisition Strategy................................................................ 56
Operations and Marketing............................................................ 60
Fees and Sources of Payment......................................................... 60
Systems............................................................................. 60
Competition......................................................................... 60
Joint Venture Agreements............................................................ 61
Government Regulation............................................................... 61
Employees........................................................................... 62
Properties.......................................................................... 62
Legal Proceedings................................................................... 62
Executive Officers and Directors of VCA............................................. 63
Board Meetings and Committees....................................................... 64
Compensation of Directors........................................................... 64
Compensation Committee Interlocks and Insider Participation......................... 65
Report of the Compensation Committee................................................ 65
Summary Compensation Table.......................................................... 67
Option Grants in Last Fiscal Year................................................... 68
Aggregated Option Exercises in Last Fiscal Year and Fiscal Year End Option Values... 68
Employment Agreements............................................................... 69
Compliance with Section 16(a) of the Securities Exchange Act........................ 69
Stock Performance Graph............................................................. 70
Security Ownership of Certain Beneficial Owners and Management of VCA............... 71
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
OF VCA................................................................................ 72
BUSINESS OF PET PRACTICE............................................................... 84
General............................................................................. 84
The Veterinary Services Industry.................................................... 84
Strategy............................................................................ 85
Patient Services.................................................................... 85
Network Development................................................................. 86
Marketing........................................................................... 87
Clinical Leadership................................................................. 88
Employer of Choice Programs......................................................... 88
Management Information Systems...................................................... 88
Competition......................................................................... 89
Licensing and Certification; Professional Associations; Regulation.................. 89
Trademarks.......................................................................... 90
Employees........................................................................... 90
Insurance........................................................................... 90
Properties.......................................................................... 91
</TABLE>
5
<PAGE>
<TABLE>
<CAPTION>
PAGE
<S> <C>
Legal Proceedings................................................................... 91
Executive Officers of Pet Practice.................................................. 91
Security Ownership of Certain Beneficial Owners and Management of Pet Practice...... 97
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS OF PET PRACTICE.................................................. 98
Overview............................................................................ 98
Seasonality......................................................................... 99
Results of Operations............................................................... 100
Results of Operations for the Thirteen Weeks Ended April 3, 1996 Compared to
the Thirteen Weeks Ended March 29, 1995.............................................. 100
Results of Operations for the Year Ended January 3, 1996 Compared to
the Year Ended December 28, 1994..................................................... 101
Results of Operations for the Year Ended December 28, 1994 Compared to
the Period October 27, 1993 (Commencement of Operations)
through December 29, 1993............................................................ 102
Liquidity and Capital Resources..................................................... 103
UNAUDITED PRO FORMA FINANCIAL DATA..................................................... 105
DESCRIPTION OF VCA CAPITAL STOCK....................................................... 126
Common Stock........................................................................ 126
Redeemable Warrants................................................................. 126
VCA Preferred Stock................................................................. 127
VRI Warrants........................................................................ 127
Debentures.......................................................................... 127
Anti-takeover Provisions............................................................ 127
Section 203 of the DGCL............................................................. 128
Transfer Agent...................................................................... 128
COMPARISON OF STOCKHOLDERS' RIGHTS..................................................... 128
ELECTION OF CLASS II DIRECTORS......................................................... 130
Information with Respect to Nominees, Continuing Directors and Executive Officers... 130
PROPOSAL TO APPROVE AN AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF VCA
TO INCREASE THE AUTHORIZED NUMBER OF SHARES OF VCA COMMON STOCK AND
VCA PREFERRED STOCK.................................................................... 131
The Amendment....................................................................... 131
Certain Effects of the Proposed Amendment........................................... 132
Recommendation and Vote............................................................. 132
PROPOSAL TO APPROVE THE ADOPTION OF THE VCA 1996 STOCK INCENTIVE PLAN.................. 132
Introduction........................................................................ 132
Purpose............................................................................. 133
Administration...................................................................... 133
Eligibility and Nondiscretionary Grants............................................. 133
Terms of Options.................................................................... 133
Adjustments upon Changes in Capitalization.......................................... 134
Amendment and Termination of the 1996 Plan.......................................... 134
Effect of Section 16(b) of the Exchange Act......................................... 134
Federal Income Tax Consequences..................................................... 135
Required Vote....................................................................... 136
</TABLE>
6
<PAGE>
<TABLE>
<CAPTION>
PAGE
<S> <C>
PROPOSAL TO APPROVE THE ADOPTION OF THE VCA 1996 EMPLOYEE STOCK PURCHASE PLAN.......... 136
Summary of Plan..................................................................... 136
Required Vote....................................................................... 137
PROPOSALS OF STOCKHOLDERS.............................................................. 137
INDEPENDENT PUBLIC ACCOUNTANTS......................................................... 137
LEGAL OPINION.......................................................................... 137
EXPERTS................................................................................ 137
OTHER MATTERS.......................................................................... 137
ANNUAL REPORT TO STOCKHOLDERS.......................................................... 138
INDEX TO FINANCIAL STATEMENTS.......................................................... F-1
</TABLE>
APPENDICES
Appendix A Agreement and Plan of Reorganization
Appendix B Opinion of National Westminster Bank PLC
Appendix C Opinion of Smith Barney Inc.
Appendix D VCA 1996 Stock Incentive Plan
Appendix E VCA 1996 Employee Stock Purchase Plan
Appendix F Exchange Ratios
7
<PAGE>
SUMMARY OF JOINT PROXY STATEMENT/PROSPECTUS
The following is a summary of certain information contained elsewhere in
this Joint Proxy Statement/Prospectus and is qualified in its entirety by
reference to the more detailed information and financial statements and notes
thereto appearing elsewhere in this Joint Proxy Statement/Prospectus and in the
Appendices hereto. Unless the context otherwise requires, all references herein
to "VCA" refer to Veterinary Centers of America, Inc. and its consolidated
subsidiaries, and all references to "Pet Practice" refer to The Pet Practice,
Inc. and its consolidated subsidiaries. This Joint Proxy Statement/Prospectus
contains forward looking statements, which are inherently uncertain. Actual
results may differ from those discussed in such forward looking statements for
the reasons, among others, discussed in "Risk Factors."
THE COMPANIES
VCA ............ VCA was founded in 1986 and is a leading companion animal
health care company. VCA has established a premier position in
the animal hospital and veterinary diagnostic laboratory
segments and has an emerging presence in the premium pet food
segment. VCA operates the largest network of free-standing,
full service animal hospitals in the country. This network has
grown from one animal hospital in 1988 to 80 full service
animal hospitals located in 16 states at June 20, 1996. As a
leader in the industry, VCA also operates one of the largest
networks of veterinary-exclusive laboratories in the nation
with three full service laboratories and eight STAT (quick
response) laboratories servicing over 8,000 animal hospitals
located in 40 states. VCA also markets both a life-stage and a
therapeutic line of premium pet food through Vet's Choice, a
joint venture with Heinz Pet Products, an affiliate of H.J.
Heinz Company. The mailing address of VCA's principal
executive offices is 3420 Ocean Park Boulevard, Suite 1000,
Santa Monica, California 90405; its telephone number is (310)
392-9599. See "BUSINESS OF VCA."
Pet Practice ... Pet Practice owns and operates veterinary care group
practices. Pet Practice is one of the largest and fastest
growing providers of companion animal veterinary care in the
United States. Pet Practice typically establishes
comprehensive networks that include day clinics and 24-hour
emergency/acute care clinics. In certain markets, Pet Practice
also provides pet boarding and grooming services. Pet Practice
believes it currently is one of the few companies pursuing a
national strategy of consolidating veterinary care group
practices in an effort to create comprehensive veterinary care
networks. Pet Practice currently operates 84 veterinary
clinics in 11 states. Of those 84 clinics, 54 operate in three
established networks, 18 operate in one network in the
integration stage and 12 operate in two networks still in the
development stage. All of Pet Practice's services are provided
on a fee-for-service basis and customers generally remit
payment at the time services are delivered. The mailing
address of Pet Practice's principal executive offices is 1018
West Ninth Avenue, King of Prussia, Pennsylvania 19406; its
telephone number is (610) 992-8800. See "BUSINESS OF PET
PRACTICE."
8
<PAGE>
MEETINGS OF STOCKHOLDERS
VCA ............ The 1996 Annual Meeting of Stockholders of VCA (the "VCA
Annual Meeting") will be held on July 19, 1996 at 10:00 a.m.
(Pacific Daylight Time), at VCA's offices, 3420 Ocean Park
Boulevard, Suite 1000, Santa Monica, California. The purpose
of the VCA Annual Meeting is to consider and vote on the
following proposals: (i) the issuance of shares of VCA Common
Stock in exchange for shares of Pet Practice Common Stock
pursuant to the Merger Agreement, (ii) to elect two Class II
Directors to the VCA Board, (iii) an amendment to VCA's
Certificate of Incorporation to increase the number of
authorized shares of VCA Common Stock from 30,000,000 shares
to 75,000,000 shares and to increase the number of authorized
shares of VCA Preferred Stock from 1,000,000 shares to
2,000,000 shares, (iv) to adopt the VCA 1996 Stock Incentive
Plan, (v) to adopt the VCA 1996 Employee Stock Purchase Plan,
and (vi) such other matters as may properly be brought before
the VCA Annual Meeting.
Holders of record of VCA Common Stock at the close of business
on May 20, 1996 (the "VCA Record Date") will be entitled to
notice of and to vote at the VCA Annual Meeting. On the VCA
Record Date, there were 13,179,882 shares of VCA Common Stock
outstanding and entitled to vote. Each share of VCA Common
Stock is entitled to one vote on each matter that is properly
presented to the stockholders for a vote at the VCA Annual
Meeting. Under the Delaware General Corporation Law (the
"DGCL"), the affirmative vote of the holders of a majority of
the shares of VCA Common Stock present at the VCA Annual
Meeting and entitled to vote is required to approve the
issuance of shares of VCA Common Stock in exchange for shares
of Pet Practice Common Stock pursuant to the Merger Agreement
(the "Merger Proposal"). See "THE MEETINGS OF STOCKHOLDERS --
Record Dates; Voting Rights; Votes Required for Approval."
Proxies (including revocations of previously delivered
proxies) may be delivered (i) by United States mail or courier
service to Continental Stock Transfer & Trust Company, 2
Broadway, 19th Floor, New York, New York 10004, or (ii) by
facsimile to (212) 509-5150.
As of the VCA Record Date, directors and executive officers of
VCA and their affiliates as a group beneficially owned 810,017
shares of VCA Common Stock (excluding shares subject to
exercisable options), or approximately 6.1% of those shares
outstanding as of such date.
Pet Practice ... The Special Meeting of Stockholders of Pet Practice (the "Pet
Practice Special Meeting" and collectively with the VCA Annual
Meeting, the "Stockholder Meetings") will be held on July 19,
1996 at 2:00 p.m. (Eastern Daylight Time) at the Park Ridge
Hotel, 480 North Gulph Road, King of Prussia, Pennsylvania.
The purpose of the Pet Practice Special Meeting is to consider
and vote on (i) a proposal to approve and adopt the Merger
Agreement, and (ii) such other matters as may properly be
brought before the Pet Practice Special Meeting.
9
<PAGE>
Holders of record of Pet Practice Common Stock at the close of
business on May 20, 1996 (the "Pet Practice Record Date") will
be entitled to notice of and to vote at the Pet Practice
Special Meeting. On the Pet Practice Record Date, there were
8,623,720 shares of Pet Practice Common Stock outstanding and
entitled to vote. Each share of Pet Practice Common Stock is
entitled to one vote on each matter that is properly presented
to stockholders for a vote at the Pet Practice Special
Meeting. Under the DGCL, the affirmative vote of the holders
of a majority of the outstanding shares of Pet Practice Common
Stock is required to approve and adopt the Merger Agreement.
See "THE MEETINGS OF STOCKHOLDERS -- Record Dates; Voting
Rights; Votes Required for Approval."
Proxies (including revocations of previously delivered
proxies) may be delivered (i) by United States mail or courier
service to American Stock Transfer & Trust Company, 40 Wall
Street, New York, New York 10005, or (ii) by facsimile to
(718) 921-8331.
As of the Pet Practice Record Date, directors and executive
officers of Pet Practice and their affiliates as a group
beneficially owned 3,901,567 shares of Pet Practice Common
Stock (excluding shares subject to exercisable options), or
approximately 45.2% of those shares outstanding as of such
date.
In connection with the Merger Agreement, a holder of 41.8% of
the outstanding shares of Pet Practice Common Stock has
executed and delivered an irrevocable proxy to VCA to vote its
shares in favor of the Merger. See "THE MEETINGS OF
STOCKHOLDERS -- Record Dates; Voting Rights; Votes Required
for Approval."
THE MERGER
Conversion of
Securities .. Upon consummation of the transactions contemplated by the
Merger Agreement, (a) Pet Practice will be merged with and
into Merger Corp., which will result in Pet Practice becoming
a wholly owned subsidiary of VCA, (b) each issued and
outstanding share of Pet Practice Common Stock will be
converted into the right to receive shares of VCA Common Stock
by reference to an Exchange Ratio, and (c) each outstanding
option of Pet Practice will be assumed by VCA in accordance
with the Merger Agreement and will be exercisable upon the
same terms and conditions as under the applicable agreement or
plan representing such option, except that each option shall
be exercisable for that number of shares of VCA Common Stock
(to the nearest whole share) into which the number of shares
of Pet Practice Common Stock subject to such option
immediately prior to the Effective Time (as defined below)
would be converted under the Merger Agreement and the exercise
price per share of each such option shall be adjusted in the
manner set forth in the Merger Agreement.
10
<PAGE>
Conversion (cont.) .... The Exchange Ratio will be determined by reference to
the average closing price of VCA Common Stock over the
20 trading days ending on the third trading day before
the meetings at which the stockholders of VCA and Pet
Practice consider the merger (the "Average Price"). If
the Average Price of the VCA Common Stock ranges from
$25 to $30 per share, the Exchange Ratio shall be
determined by dividing $10 by the Average Price of the
VCA Common Stock, resulting in a valuation of $10 per
share of Pet Practice Common Stock throughout the range.
If the Average Price of the VCA Common Stock is less
than $24 per share, the Exchange Ratio will be increased
(from 0.395 at $24 per share) by 0.005 for each dollar
of such reduction down to $18.50 per share of VCA Common
Stock, and if the Average Price of VCA Common Stock is
more than $31 per share, the Exchange Ratio shall be
reduced (from 0.3350 at $31 per share) by 0.005 for each
dollar of such increase up to $49.00 per share.
No further adjustment shall be made if the Average Price
of VCA Common Stock shall be less than $18.50. If the
Average Price of the VCA Common Stock is greater than
$49.00, the Exchange Ratio shall be determined by
dividing $12.005 by the Average Price. In all cases, a
proportionate reduction or increase, as the case may be,
shall be made if the price of VCA Common Stock is less
than a round dollar.
Based on the foregoing, the resulting valuation of the
merger consideration per share of Pet Practice Common
Stock will range from $7.82 per share (if the Average
Price is $18.50 per share) to $12.005 per share (if the
Average Price is $49.00 per share).
By way of illustration (i) at $___ per share of VCA
Common Stock (the closing price of the VCA Common Stock
on June ___, 1996, the last practicable date before the
printing of this Joint Proxy Statement/Prospectus), the
Exchange Ratio would be ___, resulting in a valuation of
$___ per share of Pet Practice Common Stock, (ii) at $20
per share of VCA Common Stock, the Exchange Ratio would
be 0.4150, resulting in a valuation of $8.30 per share
of Pet Practice Common Stock, and (iii) at $28.00 per
share of VCA Common Stock, the Exchange Ratio would be
0.3571, resulting in a valuation of $10.00 per share of
Pet Practice Common Stock.
Based upon the number of shares of Pet Practice Common
Stock outstanding at the Pet Practice Record Date and
upon the closing price of VCA Common Stock ($_____) on
the Nasdaq National Market on June __, 1996 (the last
practicable date before the printing of this Joint Proxy
Statement/Prospectus), the former Pet Practice
stockholders will hold, immediately after the Merger,
approximately ___% of the aggregate number of
outstanding shares of VCA Common Stock.
Pet Practice and VCA have established a phone number
which may be called by VCA stockholders and Pet Practice
stockholders to obtain more current estimates of the
Exchange Ratio based upon the foregoing. Please call
(800) 223-2064 for a current estimate of the Exchange
Ratio based upon more recent market closing prices of
the VCA Common Stock. See "THE MERGER AGREEMENT --
Consideration to be Received in the Merger."
11
<PAGE>
Fractional Shares ....... Fractional shares of VCA Common Stock will not be
issued in connection with the Merger. A holder
otherwise entitled to a fractional share will be paid
cash in lieu of such fractional share in an amount
equal to the product of the Average Price (as
defined) of a share of VCA Common Stock multiplied by
the fraction of a share to which such holder would
otherwise be entitled. See "THE MERGER AGREEMENT --
Consideration to be Received in the Merger."
Concurrent Transactions... VCA's growth strategy is dependent principally on its
ability to acquire existing animal hospitals and
veterinary diagnostic laboratories. During the period
from January 1, 1996 to June 20, 1996, VCA acquired
(i) Pets' Rx, the owner and operator of 16 animal
hospitals, (ii) three veterinary diagnostic
laboratories, and (iii) 11 individual animal
hospitals, one of which was consolidated into an
existing facility. VCA continues to evaluate
acquisitions and negotiate with several potential
acquisition candidates. VCA may effect one or more
such acquisitions from the date of this Joint Proxy
Statement/Prospectus through the date of the closing
of the Merger with Pet Practice.
VCA's Reasons for the
Merger; Recommendations
of the VCA Board....... The VCA Board, by unanimous vote, has determined that
the Merger is in the best interests of the
stockholders of VCA and recommends that the
stockholders of VCA vote in favor of the Merger
Proposal. The decision of the VCA Board to enter into
the Merger Agreement and to recommend that
stockholders vote in favor of the Merger Proposal is
based upon its evaluation of a number of factors
including, among others, the opinion of National
Westminster Bank PLC, New York Branch ("NatWest"),
VCA's financial advisor for the Merger, to the effect
that, as of such date and based upon and subject to
certain matters stated therein, the consideration to
be paid by VCA pursuant to the Merger Agreement is
fair to VCA from a financial point of view. See "THE
MERGER -- VCA's Reasons for the Merger;
Recommendations of the VCA Board" and " -- Opinions
of Financial Advisors -- VCA."
Pet Practice's Reasons
for the Merger;
Recommendations of the
Pet Practice Board .... The Pet Practice Board, by unanimous vote, has
determined that the Merger is in the best interests
of the stockholders of Pet Practice and recommends
that the stockholders of Pet Practice vote to approve
the Merger and the Merger Agreement. The decision of
the Pet Practice Board to enter into the Merger
Agreement and to recommend that stockholders vote to
approve the Merger and the Merger Agreement is based
upon its evaluation of a number of factors. See "THE
MERGER -- Pet Practice's Reasons for the Merger;
Recommendations of the Pet Practice Board" and " --
Opinions of Financial Advisors -- Pet Practice."
12
<PAGE>
Opinion of VCA's
Financial Advisor....... On March 21, 1996, prior to the execution of the
Merger Agreement, NatWest rendered to the VCA Board
its written opinion to the effect that, as of such
date and based upon and subject to certain matters
stated therein, the consideration to be paid by VCA
pursuant to the Merger Agreement is fair to VCA from
a financial point of view. A copy of the full text of
the written opinion of NatWest, which sets forth the
assumptions made, procedures followed, matters
considered and limits of its review, is attached to
this Joint Proxy Statement/Prospectus as Appendix B,
and should be read carefully in its entirety.
NatWest's opinion does not address any other aspect
of the Merger or the related transactions and does
not constitute a recommendation to any stockholder as
to how such stockholder should vote at the VCA Annual
Meeting. See "THE MERGER -- Opinions of Financial
Advisors -- VCA."
Opinion of Pet Practice's
Financial Advisor...... Smith Barney Inc. ("Smith Barney") has acted as
financial advisor to Pet Practice in connection with
the Merger and delivered an oral opinion to the Pet
Practice Board on March 21, 1996 (subsequently
confirmed by delivery of a written opinion dated such
date) to the effect that, as of the date of such
opinion and based upon and subject to certain matters
stated therein, the Exchange Ratio was fair, from a
financial point of view, to the holders of Pet
Practice Common Stock. The full text of the written
opinion of Smith Barney dated March 21, 1996, which
sets forth the assumptions made, matters considered
and limitations on the review undertaken, is attached
as Appendix C to this Joint Proxy
Statement/Prospectus and should be read carefully in
its entirety. Smith Barney's opinion is directed only
to the fairness of the Exchange Ratio from a
financial point of view, does not address any other
aspect of the Merger or related transactions and does
not constitute a recommendation to any stockholder as
to how such stockholder should vote at the Pet
Practice Special Meeting. See "THE MERGER -- Opinions
of Financial Advisors -- Pet Practice."
Interests of Certain
Persons in the Merger.. In considering the recommendation of the Pet Practice
Board with respect to the Merger Agreement and the
transactions contemplated thereby, stockholders
should be aware that certain members of the
management of Pet Practice and the Pet Practice Board
have certain interests in the Merger that are in
addition to the interests of stockholders of Pet
Practice generally. See "THE MERGER-- Interests of
Certain Persons in the Merger."
Conditions to the Merger. The obligations of VCA and Pet Practice to consummate
the Merger are subject to the satisfaction of certain
conditions, including, among others, (i) obtaining
requisite stockholder approvals, (ii) the expiration
or termination of the waiting period applicable to
the consummation of the Merger under the Hart-Scott-
Rodino Antitrust Improvements Act of 1976, as amended
(the "HSR Act"), (iii) the effectiveness of the
Registration Statement, and receipt of approvals
under state securities laws, (iv) the absence of any
material adverse change in the financial condition,
business, operations or prospects of the other party,
(v) the absence of any injunction prohibiting
consummation of the Merger, (vi) the receipt of
certain legal opinions with respect to the tax
consequences of the Merger and (vii) the receipt of
accountants' letters with respect to customary "cold
comfort" matters. See "THE MERGER AGREEMENT --
Conditions to the Merger."
13
<PAGE>
Effective Time of the
Merger............. The Merger will become effective (the "Effective
Time") upon the filing of a Certificate of Merger
(the "Certificate of Merger") with the Secretary of
State of the State of Delaware which certificate will
be filed as promptly as practicable after the
requisite stockholder approvals have been obtained
and all other conditions to the Merger have been
satisfied or waived. Subject to the satisfaction (or
waiver) of the other conditions to the obligations of
VCA and Pet Practice to consummate the Merger, it is
presently expected that the Merger will be
consummated on July 19, 1996 or as soon thereafter as
such conditions are satisfied. See "THE MERGER
AGREEMENT -- General."
Exchange of Stock
Certificates........... Upon consummation of the Merger, each holder of a
certificate or certificates representing shares of
Pet Practice Common Stock ("Certificates")
outstanding immediately prior to the Merger will,
upon the surrender thereof (duly endorsed, if
required) to a designated exchange agent (the
"Exchange Agent"), be entitled to receive a
certificate or certificates representing the number
of whole shares of VCA Common Stock into which such
shares of Pet Practice Common Stock will have been
automatically converted as a result of the Merger.
After the consummation of the Merger, the Exchange
Agent will mail a letter of transmittal with
instructions to all holders of record of Pet Practice
Common Stock as of the Effective Time for use in
surrendering their Certificates in exchange for
certificates representing shares of VCA Common Stock.
Certificates should not be surrendered until the
letter of transmittal and instructions are received.
See "THE MERGER AGREEMENT -- Exchange of Shares."
No Dissenters' Rights.... Holders of Pet Practice Common Stock are not entitled
to dissenters' rights in connection with the Merger.
See "THE MEETINGS OF STOCKHOLDERS --No Dissenters'
Rights."
Termination.............. The Merger Agreement may be terminated and the Merger
may be abandoned at any time prior to the Effective
Time, before or after the approval by the
stockholders of VCA and Pet Practice, respectively,
in a number of circumstances, which include, among
others: (a) by the mutual written consent of VCA and
Pet Practice; (b) by either VCA or Pet Practice if
the Average Price of VCA Common Stock is equal to or
less than $18.50; (c) by action of the Board of
Directors of either VCA or Pet Practice if (i) the
Merger shall not have been consummated by September
1, 1996, (ii) the approval of the Merger Proposal by
VCA's stockholders shall not have been obtained at a
stockholders' meeting duly convened for such purpose
(or any adjournment thereof) or (iii) the adoption of
the Merger Agreement and the approval of the
transactions contemplated thereby by Pet Practice's
stockholders shall not have been obtained at a
stockholders' meeting duly convened for such purpose
(or any adjournment thereof); (d) by action of the
Pet Practice Board, if (i) any material condition to
the obligations of Pet Practice is not substantially
satisfied at the times contemplated and the condition
is not waived, or (ii) there has been a breach by VCA
of any representation, warranty, covenant or
agreement contained in the Merger Agreement such that
the conditions to the obligations of Pet Practice
would not be satisfied which is not curable or, if
curable, VCA
14
<PAGE>
does not exercise reasonable efforts to cure; or
(e) by action of the VCA Board, if (i) any material
condition to the obligations of VCA is not
substantially satisfied at the times contemplated and
the condition is not waived, or (ii) there has been a
breach by Pet Practice of any representation,
warranty, covenant or agreement contained in the
Merger Agreement such that the conditions to the
obligations of VCA would not be satisfied which is
not curable or, if curable, Pet Practice does not
exercise reasonable efforts to cure. See "THE MERGER
AGREEMENT -- Termination of the Merger Agreement."
Termination Fee.......... If, following any proposal relating to a merger,
acquisition, consolidation or similar transaction
involving, or any purchase of all or any significant
portion of the assets or any equity securities of,
Pet Practice or any of its subsidiaries, Pet Practice
effects any such transaction, or the Merger Agreement
is terminated, Pet Practice is obligated to pay to
VCA $3.5 million. See "THE MERGER AGREEMENT --
Certain Covenants -- Termination Fee."
Certain Federal Income
Tax Consequences....... The Merger is intended to qualify as a reorganization
within the meaning of Section 368(a) of the Internal
Revenue Code of 1986, as amended (the "Code"), so
that no gain or loss would be recognized by VCA, Pet
Practice or Merger Corp. and no gain or loss would be
recognized by the stockholders of Pet Practice,
except in respect of cash received in lieu of
fractional shares. No ruling from the Internal
Revenue Service will be obtained with respect to the
tax consequences. A condition to the consummation of
the Merger is that VCA and Pet Practice each receive
from their respective counsel a legal opinion to the
effect that the Merger will constitute a tax free
reorganization. See "THE MERGER -- Certain Federal
Income Tax Consequences."
Nasdaq National Market... The VCA Common Stock is traded on the Nasdaq National
Market under the symbol "VCAI." VCA will apply for
listing of the additional shares of VCA Common Stock
issued to the Pet Practice stockholders in connection
with the Merger on the Nasdaq National Market. See
"THE MERGER -- Nasdaq National Market."
Regulatory Matters....... The Merger is subject to the requirements of the HSR
Act, and the rules and regulations thereunder, which
provide that certain transactions may not be
consummated until required information and materials
are furnished to the Antitrust Division of the
Department of Justice (the "Antitrust Division") and
the Federal Trade Commission (the "FTC") and the
requisite waiting period has expired or is
terminated. VCA and Pet Practice filed the required
information and materials with the Antitrust Division
and the FTC effective April 26, 1996 and the
requisite waiting period has expired. See "THE
MERGER -- Regulatory Matters."
Accounting Treatment..... The Merger will be accounted for as a "purchase"
under generally accepted accounting principles. See
"THE MERGER -- Accounting Treatment."
15
<PAGE>
Resale Restrictions...... All shares of VCA Common Stock received by Pet
Practice stockholders in the Merger will be freely
transferable, except that shares of VCA Common Stock
received by persons who are deemed to be "affiliates"
(as such term is defined under the Act) of Pet
Practice and/or VCA will be subject to certain resale
restrictions. Abbingdon Venture Partners Limited
Partnership - II, a Delaware limited partnership
which is the principal stockholder of Pet Practice
(the "Principal Stockholder"), has agreed not to
transfer or otherwise dispose of the Pet Practice
Common Stock owned by it except to its partners who
agree not to transfer or otherwise dispose of the VCA
Common Stock received in the Merger with respect to
such Pet Practice Common Stock for a period ending on
April 30, 1997; provided, that, 33% of such shares
of VCA Common Stock shall no longer be subject to
such restriction on November 1, 1996 and the
remaining shares shall no longer be subject to such
restriction on May 1, 1997. See "THE MERGER -- Resale
Restrictions."
16
<PAGE>
SELECTED HISTORICAL AND UNAUDITED PRO FORMA FINANCIAL DATA
The historical financial data of VCA, Pet Practice and Pets' Rx for the
periods indicated have been derived from their respective historical
consolidated financial statements, and should be read in conjunction with such
consolidated financial statements and the notes thereto, certain of which are
incorporated by reference or included in this Joint Proxy Statement/Prospectus.
The selected unaudited pro forma financial data of VCA and Pet Practice and
the selected unaudited pro forma financial data of VCA, Pet Practice and Pets'
Rx are derived from, or prepared on a basis consistent with, the unaudited pro
forma combined condensed financial statements of VCA and Pet Practice and VCA,
Pet Practice and Pets' Rx, respectively, and should be read in conjunction with
such unaudited pro forma statements and notes thereto which are included in this
Joint Proxy Statement/Prospectus. The unaudited pro forma data are presented for
illustrative purposes only and are not necessarily indicative of the operating
results or financial position that would have existed if the Merger had occurred
on January 1, 1995 (in the case of VCA and Pet Practice) or if the Merger had
occurred on January 1, 1995 and the transaction with Pets' Rx (collectively, the
"Transactions") had been consummated on January 1, 1993 (in the case of VCA, Pet
Practice and Pets' Rx pro forma data), nor are they necessarily indicative of
future operating results or financial position of VCA. No pro forma data
reflecting the combination of VCA and Pets' Rx have been presented because such
information would not be relevant to any transaction involving Pet Practice.
<TABLE>
<CAPTION>
Years Ended December 31, Pro Forma
----------------------------------------------- -------------------------
Three Three
Months Months
VCA: Ended Year Ended Ended
(In thousands, except per March 31, December March 31,
share data) 1991 1992 1993 1994 1995 1996 31, 1995 1996
------- ------- ------- ------- -------- --------- ---------- ---------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Revenues $14,572 $18,476 $25,313 $42,233 $ 92,072 $ 31,004 $143,514 $ 36,390
Operating income (loss) 1,640 1,115 (2,140) 1,796 9,351 3,453 14,447 3,470
Net income (loss) 510 258 (1,858) 589 2,564 1,012 2,479 878
Earnings (loss) per common
share:
Primary $0.14 $0.05 $(0.36) $0.09 $ 0.24 $ 0.07 $ 0.22 $ 0.06
Fully diluted $0.14 $0.05 $(0.29) $0.09 $ 0.23 $ 0.07 $ 0.21 $ 0.06
Weighted average common
shares used
for computing earnings
(loss) per share:
Primary 3,560 5,471 5,165 6,432 10,703 15,110 11,448 15,377
Fully diluted 3,842 5,639 6,238 6,906 11,238 15,492 11,983 15,759
BALANCE SHEET DATA:
Cash and equivalents $13,668 $11,067 $12,419 $ 5,553 $ 46,799 $ 37,615 $115,548
Total assets 30,141 35,596 40,273 52,199 141,465 157,048 245,170
Current portion of long-term
obligations and notes
payable 2,312 1,303 1,542 4,850 6,009 7,563 8,020
Long-term obligations, less
current portion 6,533 9,152 11,285 14,071 27,352 29,588 116,506
Guaranteed purchase price
contingently
payable in cash or common
stock 665 542 542 72 -- -- --
Total stockholders' equity 18,956 22,299 20,590 23,397 91,794 102,145 102,382
</TABLE>
17
<PAGE>
<TABLE>
<CAPTION>
For the Period
October 27, Pro Forma
1993 -----------------------
(Commencement Thirteen Thirteen
of Year Ended Weeks Weeks
PET PRACTICE: Operations) to December Year Ended Ended Year Ended Ended
(In thousands, except per December 29, 28, January April 3, January 3, April 3,
share data) 1993 1994 3, 1996 1996 1996 1996
-------------- ---------- ---------- ---------- ----------- ----------
<S> <C> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Revenues $1,201 $15,111 $40,571 $13,404 $58,828 $13,579
Operating (loss) income (446) (3,101) (1,230) (650) 1,254 (639)
Net loss (629) (4,888) (3,175) (899) (1,727) (910)
Net loss per common share $(0.15) $ (1.20) $ (0.54) $ (0.10) $ (0.29) $ (0.11)
Weighted average common
shares used for computing
loss per share 4,059 4,059 5,863 8,614 6,044 8,626
BALANCE SHEET DATA:
Cash and equivalents $ 74 $ 910 $10,097 $ 4,916
Total assets 11,653 35,417 80,462 79,715
Current portion of long-term
obligations and notes
payable (1) 65 1,609 3,696 3,820
Long-term obligations, less
current portion 9,503 18,885 15,786 16,216
Total stockholders' (deficit)
equity (427) (3,649) 53,220 52,521
<CAPTION>
May 28, 1991
(Commencement
of Three
Operations) Months
PETS' RX: to December Years Ended December 31, Ended
(In thousands, except per 31, ------------------------------------------------ March
share data) 1991 1992 1993 1994 1995 31, 1996
------------- ------- ------- ------- ------- --------
<S> <C> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Revenues $ 346 $3,657 $ 5,785 $ 9,638 $15,622 $ 4,228
Operating loss (282) (726) (1,191) (1,837) (1,017) (116)
Net loss (292) (844) (1,522) (2,805) (1,977) (358)
Net loss per common share $(0.22) $(0.55) $ (0.85) $ (0.46) $ (0.32) $ (0.06)
Average common shares used
for computing loss per share 1,309 1,527 1,793 6,069 6,266 6,267
BALANCE SHEET DATA:
Cash and equivalents $ 2024 $ 889 $ 548 $ 2,254 $ 752 $ 251
Total assets 3,821 6,418 12,316 17,283 15,332 14,581
Current portion of long-term
obligations and notes 67 428 776 702 1,412 1,167
payable
Long-term obligations, less
current portion 477 3,007 9,280 10,986 9,426 9,219
Total stockholders' equity
(deficit) 523 268 (1,315) 606 (1,142) (1,299)
</TABLE>
________________________
(1) Excludes $10,067 of borrowings under line of credit at December 28, 1994.
18
<PAGE>
<TABLE>
<CAPTION>
Year Ended December 31, 1995
-------------------------------------------------------
VCA and Pet
Practice
VCA AND PET PRACTICE PRO FORMA: VCA Pet Practice Pro Forma Pro Forma
(In thousands, except per share data) Pro Forma Pro Forma Adjustments Combined
--------- ------------ ----------- -----------
<S> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Revenues $143,514 $58,828 $202,342
Operating income 14,447 1,254 $(1,612) 14,089
Net income (loss) 2,479 (1,727) (974) (222)
Earnings (loss) per common share:
Primary $ 0.22 $ (0.02)
Fully diluted $ 0.21
Weighted average common shares
used for computing earnings (loss) per share:
Primary 11,448 3,273 14,721
Fully diluted 11,983
<CAPTION>
Three Months Ended March 31, 1996
--------------------------------------------------------
VCA and Pet
Practice
VCA Pet Practice Pro Forma Pro Forma
Pro Forma Pro Forma Adjustments Combined
--------- ------------ ----------- -----------
<S> <C> <C> <C> <C>
Revenues $ 36,390 $13,579 $ 49,969
Operating income 3,470 (639) $ (215) 2,616
Net income (loss) 878 (910) 61 29
Earnings per common share:
Primary $ 0.06 $ 0.00
Fully diluted $ 0.06 $ 0.00
Weighted average common shares
used for computing earnings per share:
Primary 15,377 3,273 18,650
Fully diluted 15,759 3,273 19,032
<CAPTION>
VCA and
Pet
Practice
VCA Pet Practice Pro Forma Pro Forma
BALANCE SHEET DATA: Pro Forma Historical Adjustments Combined
--------- ------------ ----------- ---------
<S> <C> <C> <C> <C>
Cash and equivalents $115,548 $ 4,916 $(3,400) $117,064
Total assets 245,170 79,715 33,804 358,689
Current portion of long-term
obligations and notes payable 8,020 3,820 11,840
Long-term obligations, less
current portion 116,506 16,216 132,722
Total stockholders' equity 102,382 52,521 33,804 188,707
</TABLE>
19
<PAGE>
<TABLE>
<CAPTION>
Year Ended December 31, 1995
------------------------------------------------------------------------
VCA, Pet
Practice and
Pets' Rx
VCA, PET PRACTICE AND PETS' RX: VCA Pro Pet Practice Pets' Rx Pro Forma Pro Forma
(In thousands, except per share data) Forma Pro Forma Historical Adjustments Combined
-------- ------------ ---------- ----------- ------------
<S> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Revenues $143,514 $58,828 $15,622 $217,964
Operating income (loss) 14,447 1,254 (1,017) $(3,413) 11,271
Net income (loss) 2,479 (1,727) (1,977) (2,775) (4,000)
Earnings (loss) per common share:
Primary $ 0.22 $(0.26)
Fully diluted $ 0.21
Weighted average common shares
used for computing earnings (loss) per share:
Primary 11,448 4,074 15,522
Fully diluted 11,983
<CAPTION>
Three Months Ended March 31, 1996
--------------------------------------------------------------------------
VCA, Pet
Practice and
Pets' Rx
VCA Pro Pet Practice Pets' Rx Pro Forma Pro Forma
Forma Pro Forma Historical Adjustments Combined
-------- ------------ ---------- ----------- ------------
<S> <C> <C> <C> <C> <C>
Revenues $ 36,390 $13,579 $ 4,228 $ 54,197
Operating income (loss) 3,470 (639) (116) $ (109) 2,606
Net income (loss) 878 (910) (358) 167 (223)
Earnings (loss) per common share:
Primary $ 0.06 $(0.01)
Fully diluted $ 0.06
Weighted average common shares
used for computing earnings (loss) per share:
Primary 15,377 4,074 19,451
Fully diluted 15,759
<CAPTION>
VCA, Pet
Practice and
Pets' Rx
VCA Pet Practice Pets' Rx Pro Forma Pro Forma
Pro Forma Historical Historical Adjustments Combined
--------- ------------ ---------- ----------- ------------
<S> <C> <C> <C> <C> <C>
BALANCE SHEET DATA:
Cash and equivalents $115,548 $ 4,916 $ 251 $(3,400) $117,315
Total assets 245,170 79,715 14,581 30,529 369,995
Current portion of long-term
obligations and notes payable 8,020 3,820 1,167 13,007
Long-term obligations, less
current portion 116,506 16,216 9,219 141,941
Total stockholders' equity (deficit) 102,382 52,521 (1,299) 33,476 187,080
</TABLE>
20
<PAGE>
MARKET PRICE INFORMATION
The VCA Common Stock and the Pet Practice Common Stock are listed for
quotation on the Nasdaq National Market.
The table below sets forth, for the calendar quarters indicated, the high
and low closing sales prices per share reported on the Nasdaq National Market
for the VCA Common Stock and the Pet Practice Common Stock. Price information
for the Pet Practice Common Stock is supplied since August 1, 1995, the first
business day following Pet Practice's initial public offering.
<TABLE>
<CAPTION>
VCA PET PRACTICE
COMMON STOCK COMMON STOCK
--------------------- ----------------------
HIGH LOW HIGH LOW
--------- ------- -------- -------
<S> <C> <C> <C> <C>
1994:
First Quarter........................... 9 6
Second Quarter.......................... 8 6
Third Quarter........................... 7 1/4 5 7/8
Fourth Quarter.......................... 9 1/2 6 5/8
1995:
First Quarter........................... 11 3/16 8
Second Quarter.......................... 12 1/4 10 3/8
Third Quarter........................... 17 11/16 11 1/2 14 3/4 12 5/8
Fourth Quarter.......................... 16 29/32 12 5/8 14 5/8 9 3/4
1996:
First Quarter............................ 29 3/8 13 5/8 10 3/4 7
Second Quarter (through June 19, 1996)... 32 3/8 23 10 1/8 8 3/4
</TABLE>
The last reported sale prices per share of the VCA Common Stock and the
Pet Practice Common Stock on March 21, 1996, the last trading day preceding
public announcement of the Merger, were $25.75 and $8.875, respectively. On
June ___, 1996, the latest practicable trading day before the printing of this
Joint Proxy Statement/Prospectus, the closing sale price per share of VCA Common
Stock was $_____________ and the closing sale price per share of Pet Practice
Common Stock was $___________.
Because the market price of VCA Common Stock is subject to fluctuation,
and because the number of shares of VCA Common Stock to be received by Pet
Practice stockholders in the Merger fluctuates based upon the market price of
the VCA Common Stock, the market value of the shares of VCA Common Stock that
holders of Pet Practice Common Stock will receive in the Merger may increase or
decrease prior to the Merger. See "THE MERGER -- Consideration to be Received
in the Merger."
As of May 20, 1996, VCA and Pet Practice had approximately 356 and 68
holders of record, respectively. Neither VCA nor Pet Practice has paid any
dividends on their common stock. Each of VCA and Pet Practice currently intends
to retain earnings for use in their respective businesses and does not
anticipate paying cash dividends on their common stock in the foreseeable
future. In addition, the Merger Agreement prohibits the payment of any dividends
by Pet Practice prior to the Effective Time.
21
<PAGE>
COMPARATIVE PER SHARE DATA
The following table contains historical per share data of VCA, Pet
Practice, and Pets' Rx and unaudited pro forma combined per share data after
giving effect to the Merger or the Transactions assuming (x) that .379 of a
share of VCA Common Stock (based upon an assumed Average Price of $26.38) is
issued in exchange for each share of Pet Practice Common Stock, and (y) that
.08592 of a share of VCA Common Stock is issued in exchange for each share of
common stock, par value $.001 per share, of Pets' Rx. This data should be read
in conjunction with the Selected Historical and Unaudited Pro Forma Financial
Data, the pro forma condensed combined financial statements and historical
financial statements of VCA, Pet Practice and Pets' Rx, and the notes thereto,
incorporated in or included elsewhere in this Joint Proxy Statement/Prospectus.
The unaudited pro forma condensed combined financial data are not
necessarily indicative of the operating results that would have been achieved
had the Merger or the Transactions been effected as of the beginning of the
periods presented and should not be construed as representative of future
operations.
<TABLE>
<CAPTION>
Years Ended December 31, Three Months
-------------------------- Ended
1993 1994 1995 March 31, 1996
------ ------ ------ ---------------
<S> <C> <C> <C> <C>
VCA
Primary (Loss) Earnings Per Share (based on VCA
equivalent shares) :
VCA pro forma combined (1)................................ $(0.36) $ 0.09 $ 0.22 $ 0.06
VCA and Pet Practice pro forma (2)........................ (0.36) 0.09 (0.02) 0.00
VCA, Pet Practice and Pets' Rx pro forma (3).............. (0.90) (0.26) (0.26) (0.01)
Book Value
VCA pro forma combined.................................... 7.77
VCA and Pet Practice pro forma............................ 11.47
VCA, Pet Practice and Pets' Rx pro forma.................. 10.84
Pet Practice
Primary (Loss) Earnings Per Share (based on Pet Practice
equivalent shares):
Pet Practice pro forma combined........................... (0.29) (0.11)
Pet Practice and VCA pro forma............................ (0.01) 0.00
Pet Practice, VCA and Pets' Rx pro forma.................. (0.09) 4.35
Book Value
Pet Practice pro forma combined........................... 6.08
Pet Practice and VCA pro forma............................ 4.35
Pet Practice, VCA and Pets' Rx pro forma.................. 4.11
</TABLE>
- --------------------------
(1) For the years ended December 31, 1993 and 1994, the amounts shown represent
the historical net earnings per share of VCA Common Stock. For the year
ended December 31, 1995 and the three months ended March 31, 1996, the
amounts shown represent the pro forma combined net earnings per share of VCA
Common Stock as if each acquisition completed by VCA during fiscal 1995 and
1996 had been effected as of January 1, 1995 and January 1, 1996,
respectively.
(2) For the years ended December 31, 1993 and 1994, the amounts shown represent
the historical net earnings per share of VCA Common Stock. For the year
ended December 31, 1995 and the three months ended March 31, 1996, the
amounts shown represent VCA and Pet Practice pro forma net earnings per
share.
(3) For the years ended December 31, 1993 and 1994, the amounts shown represent
VCA and Pets' Rx pro forma net earnings per share. For the year ended
December 31, 1995 and the three months ended March 31, 1996, the amounts
shown represent VCA, Pet Practice and Pets' Rx pro forma net earnings per
share.
22
<PAGE>
RISK FACTORS
VCA stockholders and Pet Practice stockholders should consider carefully
the following factors, as well as the other information appearing elsewhere or
incorporated in this Joint Proxy Statement/Prospectus in evaluating the Merger.
PENDING TRANSACTIONS
VCA acquired Pets' Rx, the owner and operator of 16 animal hospitals in
California and Nevada, on June 19, 1996.
VCA has entered into the Merger Agreement with Pet Practice and acquired
Pets' Rx with the expectation that the transactions will result in beneficial
synergies for the combined business. These include the potential to realize
improved operating margins at animal hospitals through a strategy of
centralizing various corporate and administrative functions and leveraging fixed
costs while providing customers with improved services.
Achieving these anticipated business benefits will depend in part on
whether the operations of Pet Practice and Pets' Rx, or either of them, can be
integrated with the operations of VCA in an efficient, effective and timely
manner. There can be no assurance that this will occur. The combination of two
or three of the companies will require, among other things, integration of the
companies' management staffs, coordination of the companies' sales and marketing
efforts, integration and coordination of the companies' development teams and
the identification and elimination of redundant and/or unnecessary overhead and
poor-performing hospitals. The success of this process will be significantly
influenced by the ability of the combined business to retain key management and
marketing and development personnel. There is no assurance that this integration
will be accomplished smoothly or successfully or that VCA will be successful in
retaining key members of management. The difficulties of such integration may be
increased by the necessity of coordinating geographically separated
organizations with distinct cultures. The integration of operations of two or
three of the companies following the mergers will require the dedication of
management resources, which may temporarily distract attention from the day-to-
day business of the combined business. The inability of management to integrate
successfully the operations of two or three of the companies could have an
adverse effect on the business and results of the combined business. In
addition, even if the operations of the three companies are ultimately
successfully integrated, it is anticipated that the integration will be
accomplished over time and, in the interim, the combination may have an adverse
effect on the business, results of operations and financial condition of the
combined business.
In addition, there can be no assurance that the present and potential
customers of VCA, Pet Practice and Pets' Rx will continue their current
utilization patterns without regard to the proposed mergers or that the proposed
mergers will not have an adverse impact upon relationships with veterinarians
and other animal health care professionals currently employed by VCA, Pet
Practice and Pets' Rx. Any significant reduction in utilization patterns by VCA,
Pet Practice and Pets' Rx's customers, or any significant adverse impact on
relationships with the veterinarians and other animal health care professionals
currently employed by VCA, Pet Practice or Pets' Rx, could have an adverse
effect on the near-term business and results of operations of the combined
business.
Pet Practice commenced operations in October 1993, although the initial
business Pet Practice acquired has, and most of the veterinary hospitals
acquired since have, operated over a substantial period. Pet Practice had net
losses of $4,888,000 in fiscal 1994, $3,175,000 in fiscal 1995 and $899,000 for
the thirteen weeks ended April 3, 1996 and an accumulated deficit of $9,591,000
as of April 3, 1996 relating to net losses in the period from October 27, 1993
(commencement of operations) through December 29, 1993, fiscal 1994 and 1995 and
the thirteen weeks ended April 3, 1996. In view of Pet Practice's significant
recent growth and the impact of certain charges on Pet Practice's 1994 and 1995
results, Pet Practice's historical financial performance may not be indicative
of its future performance (see "MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF PET PRACTICE"). There can be no
assurance that Pet Practice will achieve profitability or successfully implement
its business strategy. See "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS OF PET PRACTICE."
Pets' Rx commenced operations on May 28, 1991. Pets' Rx had net losses of
approximately $2,805,000 in fiscal 1994, $1,977,000 in fiscal 1995 and $358,000
for the three months ended March 31, 1996 and an accumulated deficit of
$8,505,000 as of March 31, 1996. Further losses are expected to be recorded for
fiscal 1995 if the Pets' Rx merger with VCA is
23
<PAGE>
consummated as a result of anticipated pooling adjustments. In view of Pets'
Rx's recent growth and the impact of nonrecurring charges and certain other
charges on Pets' Rx's 1994 and 1995 results, Pets' Rx's historical financial
performance may not be indicative of its future performance. There can be no
assurance that Pets' Rx will achieve profitability or successfully implement its
business strategy.
ANTICIPATED EFFECTS OF ACQUISITIONS
VCA is currently evaluating the operations of the businesses of Pet
Practice and Pets' Rx for purposes of developing a plan for the integration of
the businesses to be acquired with VCA's existing operations. Although this
plan is not complete at the time of the mailing of this Joint Proxy
Statement/Prospectus, it is anticipated that a significant restructuring of the
combined operations will be required as a result of the mergers. As a
consequence of this restructuring and the consummation of the mergers, VCA
anticipates incurring one-time restructuring and related charges in the second
and/or third quarters of 1996. The magnitude of these charges has not been
quantified at this time.
The Pets' Rx acquisition is intended to be accounted for on a pooling
of interests basis. Under the pooling rules, the historical financial results
of VCA will be restated to reflect the combination, following certain
adjustments. Pets' Rx incurred a loss in each of the three fiscal years ended
December 31, 1995 and in the first quarter ended March 31, 1996. Following the
consummation of the merger, the historical results of VCA will be restated to
reflect the historical losses of Pets' Rx. In addition, Pets' Rx is expected to
continue to incur losses in the second quarter of 1996. Further, under the
pooling rules, the costs incurred by VCA and Pets' Rx in consummating the merger
will be expensed during the second quarter.
The Pet Practice Merger is intended to be accounted for as a purchase.
Under the purchase rules, the Merger is expected to result in a significant
increase in the goodwill and other intangibles recorded on VCA's balance sheet.
This increase in goodwill and other intangibles will be in addition to the
increase resulting from the combination with Pets' Rx, which also has
significant goodwill and other intangibles recorded on its balance sheet. As a
result, VCA expects that its amortization expense will significantly increase
over historical levels.
The combined effect of the restructuring and other charges discussed
above, the pooling treatment in the Pets' Rx acquisition and the increased
amortization expense will have an adverse effect on the results of operations of
VCA in each of the second and third quarters of 1996. Further, the effect of
the increased amortization expense is expected to temper reported earnings of
VCA in the fourth quarter and subsequent periods.
RAPID EXPANSION AND MANAGEMENT OF GROWTH
Due to the number and size of acquisitions completed since January 1,
1994, VCA and Pet Practice have experienced rapid growth. In 1994, VCA
completed six acquisitions (five animal hospitals and one veterinary diagnostic
laboratory) and in 1995, VCA completed 32 acquisitions (25 animal hospitals, six
veterinary diagnostic laboratories and the remaining 30 percent interest in
Professional Animal Laboratory ("PAL")). As a result of these acquisitions,
VCA's revenues have grown from $25.3 million in 1993 to $42.2 million in 1994
and to $92.1 million in 1995. In addition, during this period, VCA entered two
new lines of business, veterinary diagnostic laboratories and premium pet food.
In 1994, Pet Practice acquired 30 veterinary hospitals and in 1995,
Pet Practice acquired 38 veterinary hospitals. As a result of these
acquisitions, Pet Practice's revenues have grown from $1.2 million in the period
from October 27, 1993 to December 29, 1993 to $15.1 million in fiscal 1994 and
to $40.6 million in fiscal 1995.
VCA's and Pet Practice's growth and pace of acquisitions have placed,
and will continue to place, a substantial strain on their respective management,
operational, financial and accounting resources. The successful management of
this growth will require VCA and Pet Practice to continue to implement and
improve their respective financial and management information systems and to
train, motivate and manage their respective employees. There can be no
assurance that the combined business will be able to identify, consummate or
integrate acquisitions without substantial delays, costs or other problems.
Once integrated, acquisitions may not achieve sales, profitability and asset
productivity commensurate with the combined business' other operations. In
addition, acquisitions involve several other risks, including adverse short-term
effects on the combined business' reported operating results, impairments of
goodwill and other intangible assets, the diversion of management's attention,
the dependence on retention, hiring and training of key personnel, the
amortization of intangible assets and risks
24
<PAGE>
associated with unanticipated problems or legal liabilities. The combined
business' failure to manage growth effectively would have a material adverse
effect on the combined business' results of operations and its ability to
execute its business strategy.
In addition, the growth experienced by VCA and Pet Practice, and the
corresponding increased need for timely information, have placed significant
demands on VCA's and Pet Practice's existing accounting and management
information systems. As a result, Pet Practice is in the process of upgrading,
and VCA intends to upgrade, these systems in 1996. No assurance can be given
that these upgrades will be completed successfully or that the new systems can
be successfully integrated or that the new systems will effectively serve the
combined business' future information requirements.
DEPENDENCE ON ACQUISITIONS FOR FUTURE GROWTH
VCA's, Pet Practice's and the combined business' respective growth
strategies are dependent principally on their ability to acquire existing animal
hospitals and (in the case of VCA and the combined business) veterinary
diagnostic laboratories. Successful acquisitions involve a number of factors
which are difficult to control, including the identification of potential
acquisition candidates, the willingness of the owners to sell on reasonable
terms and the satisfactory completion of negotiations. In addition,
acquisitions may be subject to pre-merger or post-merger review by governmental
authorities for antitrust and other legal compliance. Adverse regulatory action
could negatively affect VCA, Pet Practice and the combined business' respective
operations through the assessment of fines or penalties against VCA, Pet
Practice and the combined business or the possible requirement of divestiture of
one or more of VCA's, Pet Practice's and the combined business' operations.
There can be no assurance that the combined business will be able to
identify and acquire acceptable acquisition candidates on terms favorable to the
combined business in a timely manner in the future. Assuming the availability
of capital, VCA's plans include an aggressive acquisition program involving the
acquisition by the combined business of at least 15 to 25 facilities per year.
During the period from January 1, 1996 to June 20, 1996, VCA acquired (i) Pets'
Rx, the owner and operator of 16 animal hospitals, (ii) three veterinary
diagnostic laboratories and (iii) 11 animal hospitals, one of which was
consolidated into an existing facility. During this same period, Pet Practice
has acquired three veterinary hospitals. Each of VCA and Pet Practice continues
to evaluate acquisitions and negotiate with several potential acquisition
candidates (although Pet Practice is precluded by the Merger Agreement from
effecting any acquisition while the Merger is pending without the approval of
VCA). The failure to complete acquisitions and continue expansion could have a
material adverse effect on VCA's, Pet Practice's and the combined business'
financial performance. As the combined business proceeds with its acquisition
strategy, it will continue to encounter the risks associated with the
integration of acquisitions described above.
LEVERAGE
VCA, Pet Practice and Pets' Rx have each incurred substantial
indebtedness to finance the acquisition of their respective animal hospitals and
(in the case of VCA) veterinary diagnostic laboratories. Giving effect to debt
incurred in acquisitions subsequent to March 31, 1996 through June 20, 1996
(excluding the acquisition of Pets' Rx), VCA had at March 31, 1996, consolidated
long-term obligations (including current portion) of approximately $38.8
million. Pet Practice had at April 3, 1996 consolidated long-term obligations
(including current portion) of approximately $20.0 million. At March 31, 1996,
Pets' Rx had consolidated long-term obligations (including current portion) of
$10.4 million. In addition, on April 17, 1996, VCA issued subordinated debt in
an aggregate principal amount of $84.4 million (the "Debentures"). At December
31, 1995 and March 31, 1996, VCA's ratio of long-term debt to total
stockholders' equity was 36.3% and 36.4%, respectively. As of March 31, 1996,
after giving effect to the Transactions and the sale of the Debentures, the
ratio of long-term debt to total stockholders' equity will be 82.8%. VCA
expects to incur additional indebtedness in the future to continue its
acquisition strategy.
RISKS ASSOCIATED WITH INTANGIBLE ASSETS
A substantial portion of the assets of VCA, Pet Practice and Pets' Rx
consists of intangible assets, including goodwill and covenants not to compete
relating to the acquisition of animal hospitals and veterinary diagnostic
laboratories. At March 31, 1996, VCA's balance sheet reflected $85.2 million of
intangible assets of these types, a substantial portion of VCA's $157.0 million
in total assets at such date. At April 3, 1996, Pet Practice's balance sheet
reflected $53.8 million of intangible assets of these types, a significant
portion of Pet Practice's $79.7 million in total assets. At March 31, 1996,
Pets' Rx's balance sheet reflected $9.3 million of intangible assets of these
types, a significant portion of Pets' Rx's $14.6 million in total assets at such
date. VCA expects the aggregate amounts of goodwill and other intangible assets
on its balance sheet to increase in the future
25
<PAGE>
in connection with additional acquisitions. This increase will have an adverse
impact on earnings as goodwill and other intangible assets will be amortized
against earnings. In the event of any sale or liquidation of VCA, there can be
no assurance that the value of these intangible assets will be realized. In
addition, the respective companies continually evaluate whether events and
circumstances have occurred that indicate the remaining balance of intangible
assets may not be recoverable. When factors indicate that these intangible
assets should be evaluated for possible impairment, they may be required to
reduce the carrying value of intangible assets, which could have a material
adverse effect on results of operations during the periods in which such
reduction is recognized. In accordance with this policy, VCA recognized a
writedown of goodwill and related assets in the amount of $2.3 million in 1993
in connection with three of VCA's facilities which were not performing. There
can be no assurance that the combined business will not be required to writedown
assets further in future periods. In connection with an accounting change
related to the pooling of interests of Pets' Rx, the combined company will
recognize a pretax writedown of $2.1 million in each of 1993 and 1995.
GUARANTEED PAYMENTS
In connection with acquisitions in which the purchase price consists,
in part, of VCA Common Stock (the "Guarantee Shares"), VCA often guarantees (the
"Guarantee Right") that the value of such stock (the "Measurement Price") two to
three years following the date of the acquisition (the "Guarantee Period") will
equal or exceed the value of the stock on the date of acquisition (the "Issue
Price"). In the event the Measurement Price does not equal or exceed the Issue
Price, VCA typically is obligated either to (i) pay to the seller in cash, notes
payable or additional shares of VCA Common Stock the difference between the
Issue Price and the Measurement Price multiplied by the number of Guarantee
Shares then held by the seller, or (ii) purchase the Guarantee Shares then held
by the seller. Once the Guarantee Shares are registered for resale under the
Act, which registration VCA covenants to effect generally within six months of
issuance of the Guarantee Shares, the seller's Guarantee Right typically
terminates if the VCA Common Stock trades at 110% to 120% of the Issue Price for
five to 15 consecutive days, depending on the terms of the specific acquisition
at issue. There are 285,444 Guarantee Shares outstanding at March 31, 1996 with
Issue Prices ranging from $11.70 to $17.49 that have not been registered for
resale. If the value of the VCA Common Stock decreases and is less than an
Issue Price at the end of the respective Guarantee Period for these shares, VCA
may be obligated to compensate these sellers.
In connection with the Pet Practice merger, VCA will assume the
Guarantee Rights issued by Pet Practice (which generally operate similarly to
the Guarantee Rights issued by VCA, except that there is no provision for a
release of the Guarantee Right). Giving effect to the terms of the Merger, the
number of Guarantee Shares issued by Pet Practice is not material to the
capitalization of the combined business.
SEASONALITY AND FLUCTUATING QUARTERLY RESULTS
A large portion of the businesses of VCA, Pet Practice and Pets' Rx is
seasonal, with operating results varying substantially from quarter to quarter.
Historically, VCA's revenues have been greater in the second and third quarters
than in the first and fourth quarters. The demand for VCA's veterinary services
are significantly higher during warmer months because pets spend a greater
amount of time outdoors, where they are more likely to be injured and are more
susceptible to disease and parasites. In addition, use of veterinary services
may be affected by levels of infestation of fleas, heartworms and ticks, and the
number of daylight hours, as well as general economic conditions. A substantial
portion of VCA's and the combined business' costs are fixed and do not vary with
the level of demand. Consequently, net income for the second and third quarters
at individual animal hospitals generally has been higher than that experienced
in the first and fourth quarters.
DEPENDENCE ON KEY MANAGEMENT
VCA's and the combined business' success will continue to depend to a
significant extent on VCA's executive officers and other key management,
particularly its Chief Executive Officer, Robert L. Antin. VCA has an
employment contract with Mr. Robert Antin, Mr. Arthur Antin, Chief Operating
Officer of VCA, Mr. Neil Tauber, Senior Vice President of VCA, and Mr. Tomas
Fuller, Chief Financial Officer of VCA, each of which expires in December 1998.
VCA has no other written employment agreements with its executive officers.
None of VCA's officers are parties to noncompetition covenants which extend
beyond the term of their employment with VCA. VCA maintains "key man" life
insurance on Mr. Robert Antin in the amount of $3.0 million, of which VCA is the
sole beneficiary. VCA does not maintain any insurance on the lives of its other
senior management. As VCA continues to grow, it will continue to hire, appoint
or otherwise change senior managers and other
26
<PAGE>
key executives. There can be no assurance that VCA will be able to retain its
executive officers and key personnel or attract additional qualified members to
management in the future. In addition, the success of certain of VCA's
acquisitions may depend on VCA's ability to retain selling veterinarians of the
acquired companies. The loss of services of any key manager or selling
veterinarian could have a material adverse effect upon VCA's business.
JOINT VENTURES
VCA conducts a portion of its veterinary diagnostic laboratory
business through a joint venture with Vet Research, Inc. ("VRI"), and conducts
its pet food business through a joint venture with Heinz Pet Products, an
affiliate of H.J. Heinz Company. VCA has an option (the "VCA Option Agreement")
in January 1997 to acquire the remaining 49 percent interest in the laboratory
joint venture for $18.6 million in cash plus an additional amount based upon the
earnings of the joint venture to be paid over six years. Based on current
information available to it, VCA expects to exercise its purchase option in
January 1997. If for any reason VCA does not exercise the option, VRI has the
option to purchase from VCA its entire 51 percent interest for $3.5 million. On
the earlier of a change in control of VCA or January 1, 2000, Heinz Pet Products
has the option to purchase all of VCA's interest in the Vet's Choice joint
venture at a purchase price equal to the fair market value of such interest.
The proposed acquisition of Pet Practice will not result in a change in control
for purposes of the Vet's Choice joint venture. There can be no assurance that
VCA will not have to sell these joint venture interests.
COMPETITION
The companion animal health care industry is highly competitive and
subject to continual change in the manner in which services are delivered and
providers are selected. VCA believes that the primary competitive factors in
connection with animal hospitals are convenient location, recommendation of
friends, reasonable fees, quality of care and convenient hours. VCA's primary
competitors for its animal hospitals in most markets are individual
practitioners or small, regional multi-clinic practices. In addition, certain
national companies in the pet care industry, including the operators of super-
stores, are developing multi-regional networks of animal hospitals in markets
which include VCA's animal hospitals. Among veterinary diagnostic laboratories,
VCA believes that quality, price and the time required to report results are the
major competitive factors. There are many clinical laboratory companies which
provide a broad range of laboratory testing services in the same markets
serviced by VCA. In addition, several national companies provide on-site
diagnostic equipment that allows veterinarians to perform their own laboratory
tests. VCA's major competitors in the premium pet food industry are Hill's and
Iams, both of which have extensive experience in the manufacture of premium pet
food and possess research and development, marketing and financial resources far
greater than that of Vet's Choice.
GOVERNMENT REGULATION
The laws of some states prohibit veterinarians from splitting fees
with non-veterinarians and prohibit business corporations from providing
veterinary services through the direct employment of veterinarians. These laws
and their interpretations vary from state to state and are enforced by the
courts and by regulatory authorities with broad discretion. Although VCA and
Pet Practice believe their respective operations as currently conducted are in
material compliance with existing applicable laws, there can be no assurance
that VCA's and Pet Practice's existing operational structure will not be
successfully challenged in one or more states as constituting the unlicensed
practice of veterinary medicine. Such a determination in a state could
adversely affect the operations of VCA and the combined business through the
assessment of fines or penalties against VCA or the combined business or the
possible requirement of divestiture of VCA's operations in the state. In
addition, there can be no assurance that state legislation or regulations will
not change so as to restrict VCA's or, in the future, the combined business'
existing operations or the expansion of such operations.
ANTI-TAKEOVER EFFECT
A number of provisions of VCA's Certificate of Incorporation and
bylaws and certain Delaware laws and regulations relating to matters of
corporate governance, certain rights of directors and the issuance of preferred
stock without stockholder approval, may be deemed to have and may have the
effect of making more difficult, and thereby discouraging, a merger, tender
offer, proxy contest or assumption of control and change of incumbent
management, even when stockholders other than VCA's principal stockholders
consider such a transaction to be in their best interest. In addition, H.J.
Heinz Company has an option to purchase VCA's interest in the Vet's Choice joint
venture upon the occurrence of a change in control (as defined in the joint
27
<PAGE>
venture agreement), which may have the same effect. Accordingly, stockholders
may be deprived of an opportunity to sell their shares at a substantial premium
over the market price of the shares.
IMPACT OF SHARES ELIGIBLE FOR FUTURE SALE
Future sales by existing stockholders could adversely affect the
prevailing market price of the VCA Common Stock. As of March 31, 1996, VCA had
12,873,129 shares of common stock outstanding, most of which are either freely
tradeable in the public market without restriction or tradeable in accordance
with Rule 144 under the Act. There are also 159,197 shares which VCA is
obligated to issue in connection with certain acquisitions; 583,333 shares
issuable upon conversion of outstanding preferred stock; 1,505,821 shares of VCA
Common Stock issuable upon exercise of outstanding stock options; 1,607,983
shares of VCA Common Stock issuable upon exercise of outstanding warrants; and
6,635 shares issuable upon conversion of convertible notes. Shares may also be
issued under price guarantees delivered in connection with acquisitions. These
shares will be eligible for immediate sale upon issuance. In addition, if the
Pets' Rx and the Pet Practice transactions are consummated, VCA will be
obligated to issue an aggregate of approximately 801,000 shares (subject to
adjustment) and approximately 3,273,000 shares (assuming the VCA Common Stock
has an average price at that time of $26.375), respectively. In addition, on
April 17, 1996, VCA issued $84.4 million of 5.25% convertible subordinated
debentures which are convertible into 2,457,060 shares of VCA Common Stock at a
rate of $34.35 per share.
POSSIBLE VOLATILITY OF STOCK PRICE
The market price of the VCA Common Stock could be subject to
significant fluctuations caused by variations in quarterly operating results,
litigation involving VCA, announcements by VCA or its competitors, general
conditions in the companion animal health care industry and other factors. The
stock market in recent years has experienced extreme price and volume
fluctuations that have often been unrelated or disproportionate to the operating
performance of publicly traded companies. The broad fluctuations may adversely
affect the market price of the VCA Common Stock. See "MARKET PRICE
INFORMATION."
28
<PAGE>
THE MEETINGS OF STOCKHOLDERS
GENERAL
This Joint Proxy Statement/Prospectus is being furnished to holders of
VCA Common Stock in connection with the solicitation of proxies by the VCA Board
for use at the VCA Annual Meeting to be held on July 19, 1996, at VCA's offices
located at 3420 Ocean Park Boulevard, Suite 1000, Santa Monica, California
90405, commencing at 10:00 a.m., local time, and at any adjournment or
postponement thereof.
This Joint Proxy Statement/Prospectus is also being furnished to
holders of Pet Practice Common Stock in connection with the solicitation of
proxies by the Pet Practice Board for use at the Pet Practice Special Meeting to
be held on July 19, 1996 at the Park Ridge Hotel, 480 North Gulph Road, King of
Prussia, Pennsylvania 19406, commencing at 2:00 p.m., local time, and at any
adjournment or postponement thereof.
This Joint Proxy Statement/Prospectus and the accompanying forms of
proxy are first being mailed to stockholders of VCA and Pet Practice on or about
June __, 1996.
MATTERS TO BE CONSIDERED AT THE MEETINGS
VCA Annual Meeting. At the VCA Annual Meeting, holders of VCA Common
Stock will consider and vote upon:
(i) the issuance of shares of VCA Common Stock in exchange for shares
of Pet Practice Common Stock pursuant to the Merger Agreement (the "Merger
Proposal");
(ii) the election of two Class II Directors to the VCA Board (the
"Director Proposal");
(iii) the amendment to VCA's Certificate of Incorporation to increase
the number of authorized shares of VCA Common Stock from 30,000,000 to
75,000,000 and to increase the number of authorized shares of VCA Preferred
Stock from 1,000,000 to 2,000,000 (the "Certificate Proposal");
(iv) the adoption of the VCA 1996 Stock Incentive Plan;
(v) the adoption of the VCA 1996 Employee Stock Purchase Plan
(collectively with the proposal set forth in clause (iv) above, the "Plan
Proposals"); and
(vi) such other matters as may properly be brought before the VCA
Annual Meeting, or any postponements or adjournments of the VCA Annual Meeting.
Pet Practice Special Meeting. At the Pet Practice Special Meeting,
holders of Pet Practice Common Stock will consider and vote upon a proposal to
approve and adopt the Merger Agreement and such other matters as may properly be
brought before the Pet Practice Special Meeting, or any postponements or
adjournments of the Pet Practice Special Meeting.
Boards of Directors' Recommendations. THE VCA BOARD HAS UNANIMOUSLY
APPROVED THE MERGER PROPOSAL, THE DIRECTOR PROPOSAL, THE CERTIFICATE PROPOSAL
AND THE PLAN PROPOSALS AND RECOMMENDS A VOTE FOR APPROVAL OF SUCH PROPOSALS.
THE PET PRACTICE BOARD HAS UNANIMOUSLY APPROVED THE MERGER AGREEMENT
AND RECOMMENDS A VOTE FOR APPROVAL AND ADOPTION OF THE MERGER AGREEMENT.
29
<PAGE>
RECORD DATES; VOTING RIGHTS; VOTES REQUIRED FOR APPROVAL
VCA. The VCA Board has fixed the close of business on May 20, 1996,
as the VCA Record Date. Only holders of record of shares of VCA Common Stock on
the VCA Record Date are entitled to notice of and to vote at the VCA Annual
Meeting. As of May 20, 1996, there were 13,179,882 shares of VCA Common Stock
outstanding and entitled to vote held by approximately 356 stockholders of
record. Each holder of record as of the VCA Record Date of VCA Common Stock is
entitled to cast one vote per share. The presence, in person or by proxy, of
the holders of a majority of the outstanding shares of VCA Common Stock entitled
to vote is necessary to constitute a quorum at the VCA Annual Meeting.
The approval of the Certificate Proposal will require the affirmative
vote of the holders of a majority of the outstanding shares of VCA Common Stock.
Approval of the Director Proposal will require the affirmative vote of a
plurality of the votes cast for the election of directors at the VCA Annual
Meeting. The approval of the Merger Proposal and the Plan Proposals will
require the affirmative vote of the holders of a majority of the shares of VCA
Common Stock present at the VCA Annual Meeting and entitled to vote. The
approval of the issuance of shares of VCA Common Stock pursuant to the Merger is
required by the rules of the National Association of Securities Dealers, Inc.
governing corporations with securities listed on the Nasdaq National Market.
As of May 20, 1996, directors and executive officers of VCA, and their
affiliates as a group beneficially owned 810,017 shares of VCA Common Stock
(excluding shares subject to exercisable options), or approximately 6.1% of the
shares of VCA Common Stock outstanding as of such date. Each of the directors
and executive officers of VCA has advised VCA that he or she intends to vote or
direct the vote of all shares of VCA Common Stock over which he or she has
voting control for approval of the Merger Proposal, the Certificate Proposal,
the Director Proposal and the Plan Proposals.
As of May 20, 1996, Pet Practice owned no outstanding shares of VCA
Common Stock.
Pet Practice. The Pet Practice Board has fixed the close of business
on May 20, 1996 as the Pet Practice Record Date. Only holders of record of
shares of Pet Practice Common Stock on the Pet Practice Record Date are entitled
to notice of and to vote at the Pet Practice Special Meeting. On May 20, 1996,
there were 8,623,720 shares of Pet Practice Common Stock outstanding and
entitled to vote at the Pet Practice Special Meeting held by approximately 68
stockholders of record. Each holder of record as of the Pet Practice Record
Date of Pet Practice Common Stock is entitled to cast one vote per share. The
presence, in person or by proxy, of the holders of a majority of the outstanding
shares of Pet Practice Common Stock entitled to vote is necessary to constitute
a quorum at the Pet Practice Special Meeting.
Under the DGCL, the affirmative vote, in person or by proxy, of the
holders of a majority of the shares of Pet Practice Common Stock outstanding on
the Pet Practice Record Date and entitled to vote on the Merger and the Merger
Agreement is required to approve and adopt the Merger and the Merger Agreement.
In connection with the Merger Agreement, the Principal Stockholder,
the holder of approximately 41.8% of the outstanding shares of Pet Practice
Common Stock, has executed and delivered an irrevocable proxy (the "Proxy") to
VCA to vote its shares in favor of the Merger.
As of May 20, 1996, directors and executive officers of Pet Practice
and their affiliates as a group beneficially owned approximately 3,901,567
shares of Pet Practice Common Stock (including the 3,600,000 shares beneficially
owned by the Principal Stockholder which are subject to the Proxy, but excluding
shares subject to exercisable options), or approximately 45.2% of the shares of
Pet Practice Common Stock outstanding as of the Pet Practice Record Date. Each
of the directors and executive officers of Pet Practice has advised Pet Practice
that he or she intends to vote or direct the vote of all shares of Pet Practice
Common stock over which he or she has voting control for approval and adoption
of the Merger Agreement.
As of May 20, 1996, VCA owned no outstanding shares of Pet Practice
Common Stock.
Effects of Abstentions and "Broker Non-Votes." At the VCA Annual
Meeting, (i) in determining whether the Certificate Proposal has received the
requisite number of affirmative votes, abstentions and broker non-votes will
have the same effect as a vote against such Proposal; (ii) in determining
whether the Director Proposal has received the requisite number of affirmative
votes, abstentions and broker non-votes will have no effect on the outcome of
the vote on the Director Proposal; and (iii) in
30
<PAGE>
determining whether the Merger Proposal or a particular Plan Proposal has
received the requisite number of affirmative votes, (a) abstentions will be
counted and will have the same effect as a vote against such Proposal and (b)
broker non-votes will have no effect on the outcome of the vote on such
Proposal. At the Pet Practice Special Meeting, in determining whether the
proposal to approve and adopt the Merger Agreement has received the requisite
number of affirmative votes, abstentions and broker non-votes will have the same
effect as a vote against such proposal. At both the VCA Annual Meeting and the
Pet Practice Special Meeting, abstentions and broker non-votes will be counted
for purposes of determining the presence or absence of a quorum.
PROXIES
This Joint Proxy Statement/Prospectus is being furnished to VCA and
Pet Practice stockholders in connection with the solicitation of proxies by and
on behalf of the VCA Board and the Pet Practice Board for use at the VCA Annual
Meeting and the Pet Practice Special Meeting, respectively.
All shares of VCA Common Stock and Pet Practice Common Stock which are
entitled to vote and are represented at the relevant stockholder meeting by
properly executed proxies received prior to or at the relevant stockholder
meeting, and not revoked, will be voted at such stockholder meeting in
accordance with the instructions indicated on such proxies. If no instructions
are indicated (other than in the case of broker non-votes), such proxies will be
voted:
(i) in the case of the VCA Annual Meeting, for approval of the Merger
Proposal, the Certificate Proposal, the Director Proposal and the Plan
Proposals; and
(ii) in the case of the Pet Practice Special Meeting, for approval and
adoption of the Merger Agreement.
Proxies may be delivered by United States mail or courier service, in
the case of VCA stockholders, to Continental Stock Transfer & Trust Company, 2
Broadway, 19th Floor, New York, New York 10004 or by facsimile to (212) 509-5150
and in the case of Pet Practice stockholders, to American Stock Transfer & Trust
Company, 40 Wall Street, New York, New York 10005 or by facsimile to (718) 921-
8331.
If any other matters are properly presented at the stockholder
meetings for consideration, including, among other things, consideration of a
motion to adjourn either stockholder meeting to another time and/or place
(including, without limitation, for the purpose of soliciting additional
proxies), the persons named in the enclosed forms of proxy and acting thereunder
will have discretion to vote on such matters in accordance with their best
judgment.
Any proxy given pursuant to this solicitation may be revoked by the
person giving it at any time before it is voted. Proxies may be revoked by (i)
filing with the Secretary of VCA or Pet Practice, as the case may be, c/o
Continental Stock Transfer & Trust Company, 2 Broadway, 19th Floor, New York,
New York 10004 (or if by facsimile, to (212) 509-5150) or c/o American Stock
Transfer & Trust Company, 40 Wall Street, New York, New York 10005 or by
facsimile to (718) 921-8331, respectively, at or before the taking of the vote
at the relevant stockholder meeting, a written notice of revocation bearing a
later date than the proxy, (ii) duly executing a later dated proxy relating to
the same shares and delivering it to the Secretary of VCA or Pet Practice, as
the case may be, c/o Continental Stock Transfer & Trust Company, 2 Broadway,
19th Floor, New York, New York 10004 (or if by facsimile, to (212) 509-5150) or
c/o American Stock Transfer & Trust Company, 40 Wall Street, New York, New York
10005 (or by facsimile to (718) 921-8331), respectively, before the taking of
the vote at the relevant stockholder meeting or (iii) attending a stockholder
meeting and voting in person (although attendance at a stockholder meeting will
not in and of itself constitute a revocation of a proxy). Any written notice of
revocation or subsequent proxy should be sent so as to be delivered in the case
of VCA stockholders, to Secretary, Veterinary Centers of America, Inc., c/o
Continental Stock Transfer & Trust Company, 2 Broadway, 19th Floor, New York,
New York 10004 (or if by facsimile, to (212) 509-5150), and in the case of Pet
Practice stockholders, to Secretary, The Pet Practice, Inc., c/o American Stock
Transfer & Trust Company, 40 Wall Street, New York, New York 10005 or by
facsimile to (718) 921-8331, at or before the taking of the vote at the relevant
stockholder meeting.
31
<PAGE>
NO DISSENTERS' RIGHTS
No holder of Pet Practice Common Stock will have any dissenters'
rights in connection with, or as a result of, the matters to be acted upon at
the Pet Practice Special Meeting.
PROXY SOLICITATION
All expenses of this solicitation, including the cost of preparing and
mailing this Joint Proxy Statement/Prospectus will be borne by VCA and Pet
Practice. In addition to solicitation by mail, proxies may be solicited in
person by directors, officers and employees of VCA or Pet Practice or by
telephone, telegram, facsimile or other means of communication. Such directors,
officers or employees will not be additionally compensated, but may be
reimbursed for reasonable out-of-pocket expenses incurred in connection with
such solicitation. Arrangements will be made with brokerage houses and other
custodians, nominees and fiduciaries to send proxy material to beneficial
owners; and VCA or Pet Practice, as the case may be, will, upon request,
reimburse them for their reasonable expenses in so doing. VCA and Pet Practice
each have retained Georgeson & Company Inc. to aid in the solicitation of
proxies at a fee in the aggregate of approximately $11,000 plus expenses. To
the extent necessary in order to ensure sufficient representation at the VCA
Annual Meeting or the Pet Practice Special Meeting, VCA or Pet Practice, as the
case may be, may request by telephone or telegram the return of proxies. The
extent to which this will be necessary depends entirely upon how promptly
proxies are returned.
HOLDERS OF PET PRACTICE COMMON STOCK SHOULD NOT SEND ANY CERTIFICATES
REPRESENTING PET PRACTICE COMMON STOCK WITH THE ENCLOSED PROXY CARD. IF THE
TRANSACTION IS APPROVED, A LETTER OF TRANSMITTAL WILL BE MAILED AFTER THE
EFFECTIVE TIME TO EACH PERSON WHO WAS A HOLDER OF OUTSTANDING SHARES OF PET
PRACTICE COMMON STOCK IMMEDIATELY PRIOR TO THE EFFECTIVE TIME. PET PRACTICE
STOCKHOLDERS SHOULD SEND CERTIFICATES REPRESENTING PET PRACTICE COMMON STOCK TO
THE EXCHANGE AGENT ONLY AFTER THEY RECEIVE, AND IN ACCORDANCE WITH THE
INSTRUCTIONS CONTAINED IN, THE LETTER OF TRANSMITTAL.
THE MERGER
This section of the Joint Proxy Statement/Prospectus describes certain
of the more important aspects of the Merger. The following description does not
purport to be complete and the reader is encouraged to review the entire Merger
Agreement, a copy of which is set forth in Appendix A to this Joint Proxy
-------- -
Statement/Prospectus, and the other Appendices to this Joint Proxy
Statement/Prospectus, all of which are incorporated herein by this reference.
BACKGROUND OF THE MERGER
VCA has been one of the premier owners and operators of animal
hospitals in the United States for several years. Pet Practice has also been a
premier owner-operator of animal hospitals in the United States for over two
years. Both companies have been engaged in a business strategy emphasizing
growth by acquisition and consolidation of the industry. The possibility of a
strategic combination was first raised in general terms in several conversations
in January 1996 between senior executives of VCA and Pet Practice at a
professional veterinary conference they were both attending. Following this
conversation, the senior management teams of both companies began exploring the
feasibility of a strategic business combination.
On January 22, 1996, as part of a regularly scheduled VCA board
meeting, the management of VCA made an initial presentation on the
considerations regarding, and received the questions and comments of the VCA
Board with respect to, a possible combination with Pet Practice, including (i) a
preliminary analysis of the strategic factors associated with a possible
strategic business combination, (ii) a preliminary comparative review of VCA's
and Pet Practice's market capitalization, revenues, earnings, and margins, and
(iii) a preliminary presentation regarding each companies' respective
positioning in their respective market places. The VCA Board authorized and
instructed management to explore the possibility of combining VCA with Pet
Practice and to continue discussions with representatives of Pet Practice.
Also, during this period, VCA had been considering a concurrent, but
unrelated, acquisition of Pets' Rx. Discussions between representatives of VCA
and representatives of Pets' Rx continued through February 27, 1996, at which
time an
32
<PAGE>
Agreement and Plan of Reorganization was entered into between VCA and Pets' Rx.
On April 11, 1996, May 23, 1996 and June 7, 1996, the Agreement and Plan of
Reorganization was amended in a writing signed by representatives of both VCA
and Pets' Rx. The closing of the merger between VCA and Pets' Rx is not
conditioned upon the consummation of the Merger with Pet Practice and the
closing of the Merger between VCA and Pet Practice is not conditioned upon the
consummation of the merger between VCA and Pets' Rx.
There were ongoing discussions between Pet Practice management and
members of the Pet Practice Board from time to time in late January 1996 about a
possible business combination with VCA. On January 28, 1996 and during the
following week, Robert L. Antin, Chief Executive Officer of VCA, and Mr. Nagy as
well as Peter J. Cohen, President and Chief Executive Officer of Pet Practice,
had various telephone conversations during which they each expressed their
interest in pursuing exploratory discussions regarding a proposed transaction.
On February 5, 1996, VCA and Pet Practice executed a non-disclosure agreement
providing for the exchange of non-public information.
On February 6, 1996, as part of a regularly scheduled meeting of the
Pet Practice Board which convened telephonically, Mr. Nagy, Chairman of the Pet
Practice Board, made an initial presentation to the Pet Practice Board
regarding, and received the questions and comments of the Pet Practice Board
with respect to, a possible combination with VCA. The Pet Practice Board
authorized Mr. Nagy and other members of Pet Practice's management to pursue
discussions with VCA with respect to a possible combination.
On February 14, 1996, several senior executives of VCA met with senior
executives of Pet Practice in Los Angeles, California. Discussions at this
meeting focused on long-term business and market strategies and possible
synergies that could be realized through a business combination.
From February 14, 1996 through February 28, 1996, representatives of
VCA and Pet Practice and their respective counsel and financial advisors
conducted preliminary business, legal and financial due diligence regarding a
proposed Merger. On February 28, 1996, senior executives of VCA and senior
executives of Pet Practice and their respective counsel and financial advisors,
met in New York City to discuss preliminarily the basis upon which a possible
strategic business combination might be possible and to discuss the
organizational, operational and financial issues attendant thereto.
Between February 28, 1996 and March 21, 1996, VCA's and Pet Practice's
legal counsel and executive officers had further discussions regarding the terms
of a proposed Merger Agreement and related documents, VCA's and Pet Practice's
financial advisors had further discussions regarding valuation issues relevant
to negotiation of a mutually acceptable Exchange Ratio, and VCA and Pet
Practice, and their respective counsel, accountants and financial advisors
conducted business, legal and financial due diligence and exchanged draft Merger
Agreements. The Exchange Ratio was determined by negotiation between the
representatives of VCA and Pet Practice and not by any third party. During this
same period, there were numerous discussions between Mr. Nagy and the members of
the Pet Practice Board on an individual basis concerning the status of the
ongoing negotiations with VCA and the terms of the draft Merger Agreement and
the proposed Exchange Ratio. Throughout this period, the Pet Practice Board
instructed Mr. Nagy that it was reasonable and appropriate for Pet Practice
management to proceed with negotiations.
On March 18, 1996, the VCA Board met and heard presentations from
management and from its financial and legal advisors concerning the ongoing
negotiations with Pet Practice. VCA's financial advisor presented a preliminary
evaluation of the proposed Exchange Ratio and the draft Merger Agreement and the
VCA Board discussed various factors and alternatives to the proposed Merger.
The VCA Board reviewed the terms of the draft Merger Agreement and related
valuation issues. The VCA Board concluded that it was reasonable and
appropriate for the officers to proceed with negotiations.
Negotiations regarding the terms of the proposed Merger Agreement were
held in separate sessions between March 18, 1996 and March 21, 1996. On March
21, 1996, VCA and Pet Practice reached preliminary agreement with one another on
the terms of the proposed Merger Agreement, including the Exchange Ratio,
subject to the approval of the respective boards of directors.
The Merger was unanimously approved at a special meeting of the VCA
Board held on March 21, 1996 at 7:00 p.m., Pacific Standard Time, at the
executive offices of VCA. At that meeting, NatWest reviewed in detail its
financial analysis of the proposed Merger. The VCA Board received a written
opinion from NatWest that, as of March 21, 1996 and based upon
33
<PAGE>
and subject to certain matters stated therein, the consideration to be paid by
VCA pursuant to the Merger Agreement is fair to VCA from a financial point of
view. The VCA Board reviewed and fully discussed the terms of the Merger
Agreement and then unanimously approved the Merger Agreement and the Merger.
On March 21, 1996 at 6:00 p.m., Eastern Standard Time, a special
meeting of the Pet Practice Board was held in New York at the offices of Haythe
& Curley, Pet Practice's legal advisors. At the meeting, Mr. Nagy made a brief
address to the Pet Practice Board in which he reiterated his views of the
strategic advantages and business fit of the proposed combination previously
discussed on an individual basis with the members of the Pet Practice Board.
Smith Barney then made a presentation to the Pet Practice Board of its financial
analysis and rendered to the Pet Practice Board its oral opinion (which opinion
was subsequently confirmed by delivery of a written opinion dated March 21,
1996) to the effect that, as of such date and based upon and subject to certain
matters stated in such opinion, the Exchange Ratio was fair, from a financial
point of view, to the holders of Pet Practice Common Stock. (See "Opinions of
Financial Advisors--Pet Practice.") Pet Practice's legal advisors reviewed
various legal considerations with the Pet Practice Board as well as the
significant provisions of the Merger Agreement. The Pet Practice Board voted
unanimously to approve and adopt the Merger and the Merger Agreement and to
recommend that the Pet Practice stockholders vote in favor of the Merger and
approve and adopt the Merger Agreement.
On the evening of March 21, 1996, VCA and Pet Practice executed and
delivered the Merger Agreement. The Merger Agreement was announced by the
issuance of a joint press release at 7:30 a.m., New York time, on March 22,
1996.
VCA'S REASONS FOR THE MERGER; RECOMMENDATIONS OF THE VCA BOARD
The VCA Board has unanimously approved the Merger and determined that
the Merger is advisable and fair and in the best interests of VCA and its
stockholders. The VCA Board unanimously recommends to the VCA stockholders that
they vote FOR the approval and the adoption of the Merger Proposal. The VCA
Board believes that the Merger will enhance VCA's position as the leading animal
health care company in the United States. Upon consummation of the Merger, the
combined business will have over 145 animal hospitals making it the largest
chain of animal hospitals in the United States. The combined business will be
further enhanced by the consummation of the merger with Pets' Rx, which will
increase the size of the VCA chain to in excess of 160 animal hospitals.
The Merger also will accelerate the expansion of VCA's hospital
operations into several new markets and strengthen VCA's position in the
Chicago, Boston and Florida areas and the mid-Atlantic states. The combined
business' animal hospital operations will extend to 20 states located in each
region of the country.
The VCA Board also considered the positive effect on VCA's
complementary businesses, veterinary laboratory services and the marketing and
distribution of premium pet food. The expanded veterinary hospital operations
provide the combined business new markets for its laboratory services and pet
food and provide a basis for expansion into additional geographic regions. The
Merger also provides the combined business with significant opportunities to
realize the efficiencies and synergies available by operating with one corporate
overhead. VCA believes that it can realize significant cost savings in the
combination of the two companies, particularly in the areas of purchasing (both
medical supplies and office supplies), insurance, communications and other
administrative expense. VCA believes economies can also be realized in such
areas as marketing, advertising, training and continuing education.
The VCA Board also considered negative factors relating to the Merger,
including (i) the risks that the benefits sought in the Merger would not be
fully achieved, (ii) the risk that the Merger would not be consummated, and the
effect of the public announcement of the Merger on VCA's sales and operating
results, (iii) the risks attendant to the integration of the two companies and
possibly a third company, Pets' Rx, and (iv) the other risks described above
under "RISK FACTORS." The VCA Board believes that these risks were outweighed
by the potential benefits to be gained by the Merger.
In the course of its deliberations during board meetings held on
January 22, 1996, March 18, 1996 and March 21, 1996, the VCA Board reviewed with
VCA management a number of factors relevant to the Merger, including the
strategic overview and prospects for VCA. The VCA Board also considered among
other factors (i) information concerning VCA's and Pet Practice's respective
businesses, prospects, financial performance and condition, operations,
management and competitive position; (ii) the financial condition, results of
operations and businesses of VCA and Pet Practice before, and after, giving
effect to the Merger; and (iii) current financial market conditions and
historical market prices, volatility and trading information with
34
<PAGE>
respect to the VCA Common Stock and the Pet Practice Common Stock. In addition,
the directors reviewed the consideration to be issued to Pet Practice's
stockholders in the Merger and the principal terms of the Merger Agreement and
related agreements. The VCA Board considered the financial analyses prepared by
NatWest, including the written opinion of NatWest delivered at the March 21,
1996 meeting of the VCA Board, to the effect that, as of such date and based
upon and subject to certain matters stated therein, the consideration to be paid
by VCA pursuant to the Merger Agreement is fair to VCA from a financial point of
view. The VCA Board also took into account that VCA would be the surviving
corporation and its board of directors and officers would continue as senior
management of the combined business.
In view of the wide variety of factors, both positive and negative,
considered by the VCA Board, the VCA Board did not find it practical to, and did
not, quantify or otherwise assign relative weights to the specific factors
considered.
THE VCA BOARD UNANIMOUSLY RECOMMENDS THAT VCA STOCKHOLDERS VOTE TO
APPROVE THE MERGER PROPOSAL.
35
<PAGE>
PET PRACTICE'S REASONS FOR THE MERGER; RECOMMENDATIONS OF THE PET PRACTICE BOARD
THE PET PRACTICE BOARD HAS UNANIMOUSLY APPROVED AND ADOPTED THE MERGER
AND THE MERGER AGREEMENT AND UNANIMOUSLY RECOMMENDS THAT PET PRACTICE
STOCKHOLDERS VOTE FOR APPROVAL AND ADOPTION OF THE MERGER AND THE MERGER
AGREEMENT.
Prior to taking action on the Merger, the Pet Practice Board reviewed
a draft of the Merger Agreement and received presentations from, and reviewed
the terms and conditions of the transactions contemplated by the Merger
Agreement with, Pet Practice management and Pet Practice's legal and financial
advisors.
The Pet Practice Board considered a number of factors in reaching the
recommendations described above. The factors considered favorably by the Pet
Practice Board include the following:
i) the opportunity for Pet Practice stockholders to receive an
equity interest in a larger, financially stronger, veterinary services
company and the prospects for that combined company;
ii) the financial condition, results of operations and prospects of
Pet Practice as an independent public company, including the dependency of
a portion of Pet Practice's projected future growth on effecting the
acquisition of a substantial number of veterinary hospitals each year and
the constraints on its ability to finance that growth, including the
dilutive impact of additional equity financing;
iii) the similar cultures and strategies of Pet Practice's and VCA's
management;
iv) the financial condition, results of operations and prospects of
VCA;
v) the synergies created by combining the management systems
possessed by each of VCA and Pet Practice, which would create a more highly
developed infrastructure than on a stand-alone basis without having to
incur costs and management time to duplicate, and which could be utilized
without significant additional development expense;
vi) the combined benefits from VCA's and Pet Practice's pooling of
their experienced managers to assist in managing their projected rapid
growth, as well as the significant number of veterinarians in the combined
network, and their recruitment capabilities, which could help service their
recruitment needs;
vii) the ability to provide enhanced levels of care by offering a more
comprehensive range of veterinary services through a combination of the
various operations of the two companies;
viii) recent and historical market prices of Pet Practice Common
Stock and VCA Common Stock;
ix) based upon the market prices of Pet Practice Common Stock and VCA
Common Stock at the close of business on March 21, 1996, Pet Practice
stockholders would receive a premium in excess of 12.67% over the then
closing sale price of Pet Practice Common Stock of $8.875 per share;
x) the oral opinion of Smith Barney (which opinion was subsequently
confirmed by delivery of a written opinion dated March 21, 1996) to the
effect that, as of the date of such opinion and based upon and subject to
certain matters stated in such opinion, the Exchange Ratio was fair, from a
financial point of view, to the holders of Pet Practice Common Stock;
xi) the tax-free nature of the proposed transaction; and
xii) the negotiations regarding the Merger and the Merger Agreement.
In evaluating VCA and its business, the Pet Practice Board also
considered the following factors to be generally negative:
36
<PAGE>
(i) the value placed on the Pet Practice Common Stock implicit in the
proposed Exchange Ratio compared with the initial public offering price of
Pet Practice Common Stock; and
(ii) the risks attendant to the integration of the two companies.
The members of the Pet Practice Board evaluated the factors listed
above in light of their knowledge of the business and operations of Pet Practice
and their business judgment. In view of the variety of factors considered in
connection with their respective evaluations of the transaction, the Pet
Practice Board found it impracticable to, and did not, quantify or otherwise
attempt to assign relative weights to the specific factors considered in its
determination. However, the Pet Practice Board placed special emphasis on the
complementary strengths of the Pet Practice and VCA and the potential for
revenue and profit enhancing synergies to result from a combination, the
prospects for the Pet Practice remaining as an independent public company and
its ability to sustain revenue and earnings growth, and the opportunity provided
by the Merger for Pet Practice stockholders to maintain, on a tax-free basis, an
equity interest in a combined enterprise that has greater assets and financial
resources, a more diversified position in the veterinary services industry and
for which there will be a larger public market with respect to its common stock
than, in each case, currently exists for Pet Practice.
THE PET PRACTICE BOARD UNANIMOUSLY RECOMMENDS THAT PET PRACTICE
STOCKHOLDERS VOTE TO APPROVE AND ADOPT THE MERGER AGREEMENT.
OPINIONS OF FINANCIAL ADVISORS
VCA
VCA engaged NatWest to render financial advisory services and to
render a written opinion (the "Fairness Opinion") as to the fairness, from a
financial point of view, to VCA, of the consideration to be paid in the Merger.
NatWest is an internationally recognized investment banking firm with experience
in the valuation of businesses and their securities in connection with mergers,
acquisitions, sales and distributions of listed and unlisted securities, private
placements and valuations for corporate and other purposes. VCA selected
NatWest to be its financial advisor in this transaction because of NatWest's
significant experience in providing investment banking services to companies in
the health care industry.
NatWest rendered the Fairness Opinion on March 21, 1996 to the effect
that, as of such date and based upon and subject to certain matters set forth
therein, the consideration to be paid by VCA pursuant to the Merger Agreement is
fair to VCA from a financial point of view. NatWest's opinion does not address
any other aspect of the Merger or the related transactions and does not
constitute a recommendation to any stockholder as to how such stockholder should
vote at the VCA Annual Meeting. The scope of NatWest's engagement and NatWest's
review of the transaction was limited as set forth in the Fairness Opinion. The
complete text of the Fairness Opinion is included as Appendix B to this Joint
-------- -
Proxy Statement/Prospectus and is incorporated herein by reference.
Stockholders of VCA are urged to read in its entirety the Fairness Opinion,
which sets forth the assumptions made and matters considered by NatWest.
Upon consummation of the Merger, VCA will pay NatWest a fee (the
"Success Fee") for its services equal to 1.1% of the consideration to be paid by
VCA in the Merger. VCA agreed to pay NatWest a fee of $200,000 (the "Fairness
Opinion Fee") upon delivery of the Fairness Opinion. The Fairness Opinion Fee
shall be credited against the Success Fee. NatWest shall bear the out-of-pocket
expenses incurred by it in connection with its engagement, including all fees
and expenses of its counsel. VCA has agreed to indemnify NatWest against
certain expenses and liabilities in connection with its engagement.
In arriving at the Fairness Opinion, and as the basis therefor,
NatWest, among other things, (i) reviewed the Merger Agreement; (ii) reviewed
historical financial and operating data of VCA and Pet Practice; (iii) reviewed
financial and operating forecasts with respect to Pet Practice provided to
NatWest by management representatives of VCA; (iv) considered public information
of selected comparable companies, and compared Pet Practice, from a financial
point of view, with such companies; (v) considered the terms, to the extent
publicly available, of selected transactions comparable to the Merger and
compared the
37
<PAGE>
consideration to be paid by VCA with the consideration involved in such
transactions; (vi) reviewed market price data and trading activities for VCA's
and Pet Practice's Common Stock; and (vii) conducted such other financial
studies, analysis and investigations as NatWest deemed appropriate. NatWest
also held discussions with management representatives and representatives of the
independent accountants of VCA and Pet Practice concerning the business and
prospects of Pet Practice and the strategic and operating benefits anticipated
by VCA to be derived from the Merger.
NatWest was not engaged to verify independently the accuracy or
completeness of any information which it reviewed in arriving at the Fairness
Opinion, and in rendering such opinion it relied on the accuracy and
completeness of all such information without independent verification. With
respect to the financial and operating forecasts provided to it, NatWest
assumed, with the VCA Board's approval, that they were reasonably prepared on
bases reflecting the best currently available estimates and good faith judgments
of the management of VCA as to the future financial and operating performance of
Pet Practice, consistent with historical data. NatWest also assumed, with the
VCA Board's approval, that a reasonable likelihood exists that the strategic and
operating benefits anticipated by VCA to be derived from the Merger will be
realized. NatWest was not engaged to conduct a physical inspection of any
properties or make an independent valuation or appraisal of the assets or
liabilities, including any contingent liabilities, of Pet Practice, nor were any
such valuations or appraisals furnished to NatWest. NatWest was not engaged to
review any legal, accounting or tax aspects of the Merger. The Fairness Opinion
is based upon economic, monetary, regulatory and market conditions existing on
the date of such opinion. No limitations were imposed by VCA on NatWest with
respect to the investigation made or procedures followed by NatWest.
NatWest calculated the total value of the consideration to be paid by
VCA pursuant to the Merger Agreement to be $86 million, based upon the closing
price of the VCA Common Stock of $25.75 on March 21, 1996.
The following paragraphs summarize the significant qualitative and
quantitative analyses performed by NatWest in arriving at its opinion. In its
analysis, NatWest made numerous assumptions with respect to VCA, Pet Practice,
general business, economic, market and financial conditions, industry
performance and other matters, many of which are beyond the control of the
parties to the Merger. The Fairness Opinion and the financial analyses
performed by NatWest were only one of several factors considered by the VCA
Board in its evaluation of the Merger, and they should not be viewed as
determinative of the VCA Board's or VCA management's views with respect to the
consideration to be paid by VCA in the proposed Merger.
Strategic Considerations. In reaching its opinion as to the fairness
of the consideration to be paid by VCA, NatWest considered the strategic and
operating benefits anticipated by VCA to be realized from the Merger, and
assumed, with the approval of the VCA Board, that a reasonable likelihood exists
that such benefits will be realized. Such anticipated benefits include the
enhancement of VCA's position as the leading animal health care company in the
United States, the combined business having over 145 animal hospitals and being
the largest chain of animal hospitals in the United States; the expansion of
VCA's hospital operations into several new markets and the strengthening of
VCA's position in the Chicago, Boston and Florida areas and the mid-Atlantic
states; the positive effect on VCA's complementary businesses, veterinary
laboratory services and the marketing and distribution of premium pet food; and
the significant opportunities to realize the efficiencies and synergies
available by operating with one corporate overhead. NatWest was unable to, and
did not, quantify the extent of such anticipated benefits.
Comparable Company Trading Multiple Analysis. NatWest used VCA's
adjusted forecasts of Pet Practice's profitability in 1996 and 1997 to derive
implied purchase price multiples and compared those multiples to the trading
multiples of selected publicly traded companies. The selected companies were
divided into two (2) groups: a "Physician Practice Peer Group" of companies,
which consisted of Apogee, Inc., EMCR Holdings, Inc., FPA Medical Management,
Inc., MedCath, Inc., MedPartners, Inc., NovaCare, Inc., Occusystems, Inc.,
Orthodontic Centers of America, Inc., Pediatric Services of America, Inc. and
Physicians Resource Group, Inc.; and a "Pet Products Peer Group" of companies,
which consisted of Petco Animal Supplies, Inc. and PETsMART, Inc. The Physician
Practice Peer Group and the Pet Products Peer Group are referred to herein as,
the "Comparable Companies." NatWest believes that the Comparable Companies are
comparable in certain respects to Pet Practice, although none of them is, of
course, identical to Pet Practice. Accordingly, a complete analysis of the
results of the calculations performed by NatWest cannot be limited to a
quantitative review of such results and involves considerations and judgments
concerning differences in financial and operating characteristics of the
Comparable Companies and other factors that could affect the public trading
value of the Comparable Companies. In addition, the 1996 and 1997 earnings per
share ("EPS") estimates for the Comparable Companies are based on projections
prepared by research analysts using only publicly available information.
Accordingly, such estimates may or may not prove to be accurate.
38
<PAGE>
For the Comparable Companies, NatWest examined certain financial data
that was publicly available, including the last 12 months ("LTM") revenues, LTM
earnings before interest, taxes, depreciation and amortization ("EBITDA"), LTM
earnings before interest and taxes ("EBIT") and LTM EPS. In view of the 1995
net loss sustained by Pet Practice, however, comparable LTM financial data for
Pet Practice did not exist.
NatWest examined calendar year 1996 and 1997 analysts' projections of
EPS for the Comparable Companies published by First Call (an on-line data
service which compiles estimates developed by research analysts) and the per
share closing stock prices of the Comparable Companies on March 20, 1996. Using
this data, NatWest calculated the price/earnings multiples for the respective
Peer Groups based on 1996 and 1997 EPS estimates for each of the Comparable
Companies. NatWest observed that Pet Practice was projected to be only slightly
profitable in 1996 using VCA's adjusted forecast figures.
Using the data for 1997, the Physician Practice Peer Group trading
multiples of projected EPS were as follows: the multiples ranged from 11.7x to
35.5x with a mean of 23.4x and a median of 24.4x. The Pet Products Peer Group
trading multiples ranged from 29.2x to 30.1x with the mean and median both being
29.7x.
NatWest used two scenarios provided by VCA of Pet Practice's adjusted
forecast 1997 financial performance to derive an implied purchase price
multiple. The first case assumed 1997 Pet Practice earnings of approximately
$3.56 million and the more conservative second case assumed 1997 Pet Practice
earnings of $2.72 million. These two cases yielded implied Pet Practice
purchase price multiples of 1997 earnings of 24.2x and 31.6x, respectively.
Comparable Transaction Analysis. NatWest considered the terms, to the
extent publicly available, of selected transactions comparable to the Merger and
sought to compare the consideration to be paid by VCA with the consideration
involved in such transactions. In view of the 1995 net loss sustained by Pet
Practice, there was no basis for the comparison of transaction multiples.
NatWest reviewed and analyzed the premiums paid per share above market
value in selected merger and acquisition transactions in the health care
industry (collectively, the "Comparable Transactions") and compared these
premiums paid to the premium to be paid for Pet Practice implied by an assumed
equity value of $10.00 per share of Pet Practice Common Stock. For purposes of
the following calculations, market value equals the per share closing stock
price as of the relevant measuring date. The Comparable Transactions and the
dates they were announced were as follows: HealthSouth Corporation acquisition
of Advantage Health Corporation (December 1995); MedPartners/Mullikin, Inc.
acquisition of Pacific Physician Services, Inc. (December 1995); Living Centers
of America, Inc. acquisition of Rehability Corporation (April 1995); HealthSouth
Corporation acquisition of ReLife, Inc. (September 1994); NovaCare, Inc.
acquisition of RehabClinics, Inc. (October 1993); NovaCare, Inc. acquisition of
Rehab Systems Company (June 1991). NatWest analyzed the premiums paid in these
transactions at three different times prior to the public announcement of the
transactions. As of the date four (4) weeks prior to announcement of the
acquisitions, the premiums paid above market value ranged from 16.9% to 91.9%
with a mean of 48.2% and a median of 42.8%. As of the date one week prior to
public announcement of the acquisitions, the premiums paid above market value
ranged from 15.4% to 87.6% with a mean of 39.5% and a median of 34.8%. As of
the date one day prior to public announcement of the acquisitions, the premiums
paid above market value ranged from 12.2% to 74.4% with a mean of 33.4% and a
median of 31.1%.
No company, transaction or business used in the "Comparable Company
Trading Multiple Analysis" or the "Comparable Transaction Analysis" as a
comparison is identical to VCA, Pet Practice or the Merger. Accordingly, an
analysis of the foregoing results is not solely mathematical. Rather, it
involves complex considerations and judgments concerning differences in
financial and operating characteristics and other factors that could affect the
acquisition, public trading or other values of the Comparable Companies,
Comparable Transactions or the business segment, company or transactions to
which they are being compared.
Pro Forma Merger Analysis. NatWest analyzed the financial impact
resulting exclusively from the Merger on the pro forma combined company's EPS
for 1996 and 1997 based on forecasts provided by VCA and compared the pro forma
EPS with VCA's EPS as projected by various research analysts. NatWest
considered the pro forma merger analysis to be relevant to its fairness
determination because, among other things, such analysis estimated the extent to
which the transaction could be accretive or dilutive to the existing
stockholders of VCA. This analysis indicated that in 1996 the pro forma impact
of the Merger could be dilutive. The analysis further indicated that in 1997
the pro forma impact of the Merger could be accretive. Using the first
39
<PAGE>
scenario provided by VCA of Pet Practice's adjusted forecast 1997 earnings of
approximately $3.56 million, the impact of the Merger also could be accretive.
Using the more conservative second case provided by VCA of Pet Practice's
adjusted forecast 1997 earnings of approximately $2.72 million, the impact of
the Merger could be accretive. The results of the pro forma merger analysis are
not necessarily indicative of future operating results or financial position and
variations could be material.
Contribution Analysis. NatWest analyzed, among other things, the
respective contributions of VCA and Pet Practice to the estimated revenue,
EBITDA, EBIT and net income of the combined company for the years 1995 through
1997. This analysis indicated that in the years 1995 through 1997, VCA would
contribute approximately 69.4%, 70.8% and 70%, respectively, of revenue, 96%,
84.2% and 79.7%, respectively, of EBITDA, 100%, 89.9% and 82.7%, respectively,
of EBIT and 100%, 96.1% and 85.5%, respectively, of net income, and Pet Practice
would contribute approximately 30.6%, 29.2% and 30%, respectively, of revenue,
4%, 15.8% and 20.3%, respectively, of EBITDA, 0%, 10.1% 17.3%, respectively, of
EBIT and 0%, 3.9% and 14.5%, respectively, of net income of the combined
company. Immediately following consummation of the Merger, stockholders of VCA
and Pet Practice would own approximately 80.1% and 19.9%, respectively, of the
combined company.
The preparation of a fairness opinion involves various determinations
as to the most appropriate and relevant quantitative and qualitative methods of
financial analysis and the application of those methods to the particular
circumstances and, therefore, such an opinion is not readily susceptible to
partial analysis or summary description. In arriving at its opinion, NatWest
did not attribute any particular weight to any analysis or factor considered by
it described above. Subject to the matters set forth in the Fairness Opinion,
the judgments made by NatWest as to its analyses and the factors considered by
it caused NatWest to be of the opinion that the consideration payable by VCA in
the Merger, having a value of $86 million, based on the $25.75 closing price of
the VCA Common Stock on March 21, 1996, is fair, from a financial point of view,
to VCA. NatWest believes that its analyses must be considered as a whole and
that considering any portion of such analyses and of the factors considered,
without considering all analyses and factors, could create a misleading or
incomplete view of the process underlying its opinion. Any estimates contained
in these analyses are not necessarily indicative of actual values or predictive
of future results or values, which may be significantly more or less favorable
than as set forth herein. Estimated values do not purport to be appraisals or
to reflect the prices at which businesses or companies may be sold in the future
and such estimates are inherently subject to uncertainty.
NatWest has performed investment banking and financial advisory
services for VCA from time to time, for which it has received customary
compensation. In the ordinary course of business, NatWest's affiliates actively
trade the securities of VCA and Pet Practice for their own account and the
accounts of their customers and, accordingly, may at any time hold a long or
short position in such securities. NatWest may provide investment banking and
financial advisory services to VCA in the future.
See Appendix B, "Opinion of National Westminster Bank PLC." It is not
-------- -
currently contemplated that such opinion will be updated.
Pet Practice
Smith Barney was retained by Pet Practice to act as its financial
advisor in connection with the Merger. In connection with such engagement, Pet
Practice requested that Smith Barney evaluate the fairness, from a financial
point of view, to the holders of Pet Practice Common Stock of the consideration
to be received by such holders in the Merger. On March 21, 1996, at a meeting
of the Pet Practice Board held to evaluate the proposed Merger, Smith Barney
delivered an oral opinion (subsequently confirmed by delivery of a written
opinion dated such date) to the Pet Practice Board to the effect that, as of the
date of such opinion and based upon and subject to certain matters stated
therein, the Exchange Ratio was fair, from a financial point of view, to the
holders of Pet Practice Common Stock.
In arriving at its opinion, Smith Barney reviewed the Merger Agreement
and held discussions with certain senior officers, directors and other
representatives and advisors of Pet Practice and certain senior officers and
other representatives and advisors of VCA concerning the businesses, operations
and prospects of Pet Practice and VCA. Smith Barney examined certain publicly
available business and financial information relating to Pet Practice and VCA as
well as certain financial forecasts and other data for Pet Practice and VCA
which were provided to Smith Barney by or otherwise discussed with the
respective managements of Pet Practice and VCA, including information relating
to certain strategic implications and operational
40
<PAGE>
benefits anticipated to result from the Merger. Smith Barney reviewed the
financial terms of the Merger as set forth in the Merger Agreement in relation
to, among other things: current and historical market prices and trading volumes
of Pet Practice Common Stock and VCA Common Stock; the respective companies'
historical and projected earnings and operating data; and the capitalization and
financial condition of Pet Practice and VCA. Smith Barney also considered, to
the extent publicly available, the financial terms of certain other similar
transactions recently effected which Smith Barney considered relevant in
evaluating the Merger and analyzed certain financial, stock market and other
publicly available information relating to the businesses of other companies
whose operations Smith Barney considered relevant in evaluating those of Pet
Practice and VCA. Smith Barney also evaluated the potential pro forma financial
impact of the Merger on VCA. In addition to the foregoing, Smith Barney
conducted such other analyses and examinations and considered such other
financial, economic and market criteria as Smith Barney deemed appropriate in
arriving at its opinion. Smith Barney noted that its opinion was necessarily
based upon information available, and financial, stock market and other
conditions and circumstances existing and disclosed, to Smith Barney as of the
date of its opinion.
In rendering its opinion, Smith Barney assumed and relied, without
independent verification, upon the accuracy and completeness of all financial
and other information publicly available or furnished to or otherwise reviewed
by or discussed with Smith Barney. With respect to financial forecasts and
other information and data furnished to or otherwise reviewed by or discussed
with Smith Barney, the respective managements of Pet Practice and VCA advised
Smith Barney that such forecasts and other information and data were reasonably
prepared on bases reflecting the best currently available estimates and
judgments of the respective managements of Pet Practice and VCA as to the future
financial performance of Pet Practice and VCA and the strategic implications and
operational benefits anticipated to result from the Merger. Smith Barney
assumed, with the consent of the Pet Practice Board, that the Merger will be
treated as a tax-free reorganization for federal income tax purposes. Smith
Barney's opinion, as set forth therein, relates to the relative values of Pet
Practice and VCA. Smith Barney did not express any opinion as to what the value
of the VCA Common Stock actually will be when issued to Pet Practice
stockholders pursuant to the Merger or the price at which the VCA Common Stock
will trade subsequent to the Merger. Smith Barney did not make and was not
provided with an independent evaluation or appraisal of the assets or
liabilities (contingent or otherwise) of Pet Practice or VCA nor did Smith
Barney make any physical inspection of the properties or assets of Pet Practice
or VCA. Smith Barney was not asked to consider, and its opinion does not
address, the relative merits of the Merger as compared to any alternative
business strategies that might exist for Pet Practice or the effect of any other
transaction in which Pet Practice might engage. Although Smith Barney evaluated
the Exchange Ratio from a financial point of view, Smith Barney was not asked to
and did not recommend the specific consideration payable in the Merger, which
consideration was determined by Pet Practice and VCA through negotiation. No
other limitations were imposed by Pet Practice on Smith Barney with respect to
the investigations made or procedures followed by Smith Barney in rendering its
opinion. It is not currently contemplated that such opinion will be updated.
THE FULL TEXT OF THE WRITTEN OPINION OF SMITH BARNEY DATED MARCH 21,
1996, WHICH SETS FORTH THE ASSUMPTIONS MADE, MATTERS CONSIDERED AND LIMITATIONS
ON THE REVIEW UNDERTAKEN, IS ATTACHED HERETO AS APPENDIX C AND IS INCORPORATED
-------- -
HEREIN BY REFERENCE. HOLDERS OF PET PRACTICE COMMON STOCK ARE URGED TO READ
THIS OPINION CAREFULLY IN ITS ENTIRETY. SMITH BARNEY'S OPINION IS DIRECTED ONLY
TO THE FAIRNESS OF THE EXCHANGE RATIO FROM A FINANCIAL POINT OF VIEW, DOES NOT
ADDRESS ANY OTHER ASPECT OF THE MERGER OR RELATED TRANSACTIONS AND DOES NOT
CONSTITUTE A RECOMMENDATION TO ANY STOCKHOLDER AS TO HOW SUCH STOCKHOLDER SHOULD
VOTE AT THE PET PRACTICE SPECIAL MEETING.
In preparing its opinion, Smith Barney performed a variety of
financial and comparative analyses, including those described below. The
summary of such analyses does not purport to be a complete description of the
analyses underlying Smith Barney's opinion. The preparation of a fairness
opinion is a complex analytic process involving various determinations as to the
most appropriate and relevant methods of financial analyses and the application
of those methods to the particular circumstances and, therefore, such an opinion
is not readily susceptible to summary description. Accordingly, Smith Barney
believes that its analyses must be considered as a whole and that selecting
portions of its analyses and factors, without considering all analyses and
factors, could create a misleading or incomplete view of the processes
underlying such analyses and its opinion. In its analyses, Smith Barney made
numerous assumptions with respect to Pet Practice, VCA, industry performance,
general business, economic, market and financial conditions and other matters,
many of which are beyond the control of Pet Practice and VCA. The estimates
contained in such analyses and the valuation ranges resulting from any
particular analysis are not necessarily indicative of actual values or
predictive of future results or values, which may be
41
<PAGE>
significantly more or less favorable than those suggested by such analyses. In
addition, analyses relating to the value of businesses or securities do not
purport to be appraisals or to reflect the prices at which businesses or
securities actually may be sold. Accordingly, such analyses and estimates are
inherently subject to substantial uncertainty. Smith Barney's opinion and
financial analyses were only one of many factors considered by the Pet Practice
Board in its evaluation of the Merger and should not be viewed as determinative
of the views of the Pet Practice Board or management with respect to the
Exchange Ratio or the proposed Merger.
Selected Company Analysis. Using publicly available information,
Smith Barney analyzed, among other things, the market values and trading
multiples of Pet Practice and the following selected companies in the pet care
industry: VCA, PETsMART, Inc. and Petco Animal Supplies, Inc. (the "Selected
Companies"), and compared these multiples with the multiples implied for Pet
Practice by the Exchange Ratio. Smith Barney compared market values as multiples
of, among other things, estimated calendar 1996 and 1997 net income, and
adjusted market values (market value, plus total debt, less cash) as multiples
of, among other things, latest 12 months net revenue. Net income projections for
the Selected Companies were based on estimates of selected investment banking
firms and net income projections for Pet Practice and VCA were based on
estimates of selected investment banking firms and internal estimates of the
managements of Pet Practice and VCA. All multiples were based on closing stock
prices as of March 20, 1996 (the last trading day prior to the execution of the
Merger Agreement). Applying representative multiples for the Selected Companies
of estimated calendar 1996 and 1997 net income of 39.4x to 48.3x and 31.0x to
34.3x, respectively, and latest 12 months revenue of 1.6x to 3.1x, this analysis
resulted in an equity reference range for Pet Practice of approximately $8.00 to
$11.50 per share, as compared to the per share value implied by the Exchange
Ratio of approximately $10.00 based on a closing stock price of VCA Common Stock
on March 20, 1996.
Selected Merger and Acquisition Transactions Analysis. Using publicly
available information, Smith Barney analyzed, among other things, the implied
transaction value multiples paid or proposed to be paid in the following
selected merger and acquisition transactions (acquiror/target): PETsMART,
Inc./Petstuff Inc.; and VCA/Pets' Rx, Inc. (the "Selected Transactions"), and
compared these multiples with the multiples implied for Pet Practice by the
Exchange Ratio. Smith Barney compared transaction values as a multiple of, among
other things, latest 12 months revenue. All multiples were based on information
available at the time of announcement of the transaction. Applying
representative multiples for the Selected Transactions of latest 12 months
revenue of 0.8x to 1.6x, this analysis resulted in an equity reference range for
Pet Practice of approximately $2.68 to $6.45 per share, as compared to the per
share value implied by the Exchange Ratio of approximately $10.00 based on a
closing stock price of VCA Common Stock on March 20, 1996.
No company, transaction or business used in the "Selected Company
Analysis" or "Selected Merger and Acquisition Transactions Analysis" as a
comparison is identical to Pet Practice, VCA or the Merger. Accordingly, an
analysis of the results of the foregoing is not entirely mathematical; rather,
it involves complex considerations and judgments concerning differences in
financial and operating characteristics and other factors that could affect the
acquisition, public trading or other values of the Selected Companies, Selected
Transactions or the business segment, company or transaction to which they are
being compared.
Discounted Cash Flow Analysis. Smith Barney performed a discounted
cash flow analysis of the projected free cash flow of Pet Practice for the
fiscal years ending December 31, 1996 through 2000, assuming, among other
things, discount rates of 20.0%, 22.5% and 25.0% and terminal multiples of
unlevered net income of 14.0x to 20.0x. This analysis resulted in an equity
reference range for Pet Practice of approximately $5.52 to $9.96 per share.
Contribution Analysis. Smith Barney analyzed, among other things, the
respective contributions of Pet Practice and VCA to the estimated revenue,
EBITDA, EBIT and net income of the combined company for fiscal years 1995
through 1997. This analysis indicated that in fiscal years 1995 through 1997,
Pet Practice would contribute approximately 30.6%, 34.4% and 38.3%,
respectively, of revenue, 9.2%, 26.2% and 34.6%, respectively, of EBITDA,
(6.9%), 20.3% and 31.5%, respectively, of EBIT and (334.2%), 18.7% and 27.7%,
respectively, of net income, and VCA would contribute approximately 69.4%, 65.6%
and 61.7%, respectively, of revenue, 90.8%, 73.8% and 65.4%, respectively, of
EBITDA, 106.9%, 79.7% and 68.5%, respectively, of EBIT and 434.2%, 81.3% and
72.3%, respectively, of net income, of the combined company. Immediately
following consummation of the Merger, stockholders of Pet Practice and VCA would
own approximately 19.9% and 80.1%, respectively, of the combined company.
Pro Forma Merger Analysis. Smith Barney analyzed certain pro forma
effects resulting from the Merger, including, among other things, the impact of
the Merger on the projected EPS of VCA for fiscal years 1996 and 1997 based on
internal
42
<PAGE>
estimates of the managements of VCA and Pet Practice. The results of the pro
forma merger analysis suggested that the Merger could be accretive to VCA's EPS
in each of the fiscal years analyzed. The actual results achieved by the
combined company may vary from projected results and the variations may be
material.
Other Factors and Comparative Analyses. In rendering its opinion,
Smith Barney considered certain other factors and conducted certain other
comparative analyses, including, among other things: (i) a review of historical
and projected financial results of Pet Practice and VCA; (ii) the history of
trading prices and volume for Pet Practice Common Stock and VCA Common Stock and
the relationship between movements of such Common Stock and movements in the S&P
500 index; (iii) selected analysts' reports on VCA, including analysts'
estimates as to the earnings growth potential of VCA; (iv) the premiums paid in
selected stock-for-stock transactions having transaction values of $75 million
to $150 million; and (v) the pro forma ownership of the combined company.
Pursuant to the terms of Smith Barney's engagement, Pet Practice has
agreed to pay Smith Barney for its services in connection with the Merger an
aggregate financial advisory fee equal to 1.5% of the total consideration
payable in connection with the Merger. Pet Practice has also agreed to
reimburse Smith Barney for reasonable travel and other out-of-pocket expenses
incurred by Smith Barney in performing its services, including reasonable legal
fees and expenses, and to indemnify Smith Barney and related persons against
certain liabilities, including liabilities under the federal securities laws,
arising out of Smith Barney's engagement.
Smith Barney has advised Pet Practice that, in the ordinary course of
business, Smith Barney and its affiliates may actively trade or hold the
securities of Pet Practice and VCA for their own account or for the account of
customers and, accordingly, may at any time hold a long or short position in
such securities. Smith Barney has in the past provided certain investment
banking services to Pet Practice unrelated to the proposed Merger, for which
services Smith Barney has received compensation. In addition, Smith Barney and
its affiliates (including Travelers Group Inc. and its affiliates) may maintain
relationships with Pet Practice, VCA and their respective affiliates.
Smith Barney is a nationally recognized investment banking firm and
was selected by Pet Practice based on Smith Barney's experience, expertise and
familiarity with Pet Practice and its business. Smith Barney regularly engages
in the valuation of businesses and their securities in connection with mergers
and acquisitions, negotiated underwritings, competitive bids, secondary
distributions of listed and unlisted securities, private placements and
valuations for estate, corporate and other purposes.
INTERESTS OF CERTAIN PERSONS IN THE MERGER
As of the VCA Record Date directors and executive officers of VCA and
their affiliates may be deemed to be beneficial owners of approximately 6.1% of
the outstanding shares of VCA Common Stock (excluding shares subject to
exercisable options). Each of the directors and executive officers of VCA has
advised VCA that he or she intends to vote or direct the vote of all of the
outstanding shares of VCA Common Stock over which he or she has voting control
in favor of approval of the Merger Proposal, the Certificate Proposal, the
Director Proposal and the Plan Proposals.
As of the Pet Practice Record Date, directors and executive officers
of Pet Practice and their affiliates may be deemed to be beneficial owners of
approximately 45.2% of the outstanding shares of Pet Practice Common Stock
(excluding shares subject to exercisable options). Each of the directors and
executive officers of Pet Practice has advised Pet Practice that he or she
intends to vote or direct the vote of all of the outstanding shares of Pet
Practice Common Stock over which he or she has voting control in favor of
approval and adoption of the Merger Agreement.
The executive officers of Pet Practice who will continue as officers
and employees of VCA will participate in the VCA 1996 Stock Incentive Plan. See
"PROPOSAL TO APPROVE THE ADOPTION OF THE VCA 1996 STOCK INCENTIVE PLAN."
As provided in the Merger Agreement, by virtue of the Merger, all
options (the "Pet Practice Options") outstanding at the Effective Time under the
Pet Practice 1994 Stock Option Plan, whether or not then exercisable, will be
assumed by VCA and converted into and become a right with respect to VCA Common
Stock. Each Pet Practice Option assumed by VCA will be exercisable upon the
same terms and conditions as under the Pet Practice 1994 Stock Option Plan and
the option agreement
43
<PAGE>
issued thereunder, and VCA will assume the Pet Practice 1994 Stock Option Plan
for such purposes. Pursuant to the Merger Agreement, at and after the Effective
Time, (i) each Pet Practice Option assumed by VCA may be exercised solely for
VCA Common Stock, (ii) the number of shares of VCA Common Stock subject to each
Pet Practice Option will be equal to the number of shares of VCA Common Stock
(rounded to the nearest whole share) into which the number of shares of Pet
Practice Common Stock subject to the Pet Practice Option immediately prior to
the Effective Time, would be converted under the Merger Agreement, (iii) the per
share exercise price for each Pet Practice Option will be equal to (a) the per
share exercise price of the Pet Practice Option in effect immediately prior to
the Effective Time multiplied by the number of shares of Pet Practice Common
Stock subject to such Pet Practice Option immediately prior to the Effective
Time, divided by (b) the number of shares of VCA Common Stock subject to such
Pet Practice Option immediately after the Effective Time. Approval of the
Merger Proposal by the stockholders of VCA will constitute stockholder approval
of the assumption by VCA of the rights and obligations of Pet Practice under the
Pet Practice 1994 Stock Option Plan and of the amendment of such plan to provide
for, among other things, the conversion at the Effective Time of each
outstanding stock option into an option to purchase shares of VCA Common Stock
at the exercise price set forth above.
Pet Practice has agreed, upon the consummation of the Merger at the
Effective Time, to award a bonus (the "Merger Bonuses") to each of the President
and the Chief Financial Officer of Pet Practice in the amounts of $100,000 and
$25,000, respectively, each in recognition of their efforts in effectuating the
Merger. In addition, in connection with the Merger, the vesting provisions with
respect to 5,000 shares of Pet Practice Common Stock held by each of the members
of the Pet Practice Board (other than Messrs. Foster and Nagy) have been waived,
subject to consummation of the Merger.
The Merger Agreement provides that, from and after the Effective Time,
VCA shall cause Merger Corp. to include as part of its Certificate of
Incorporation and bylaws provisions relating to the indemnification of all
current and former directors, officers, employees and agents of Pet Practice
which are substantially similar to the provisions contained in Pet Practice's
Certificate of Incorporation and bylaws. Such provisions shall not be amended,
repealed or otherwise modified after the Effective Time in any manner that would
adversely affect the rights thereunder of individuals who at any time prior to
the Effective Time were directors, officers, employees or agents of Pet Practice
in respect to actions or omissions occurring at or prior to the Effective Time
(including, without limitation, actions or omissions which occur in connection
with the transactions contemplated by the Merger Agreement), unless such
modification is required by law.
ACCOUNTING TREATMENT
The Merger will be accounted for as a "purchase" under generally
accepted accounting principles. Under the purchase method of accounting, the
purchase price of Pet Practice, including direct costs of the Merger, will be
allocated to the assets acquired and liabilities assumed based upon their
estimated relative fair values, with the excess purchase consideration allocated
to goodwill.
The merger between VCA and Pets' Rx is expected to be treated as a
"pooling of interests" for accounting purposes. This accounting method permits
the recorded assets and liabilities of both VCA and Pets' Rx to be carried
forward to the surviving corporation at the recorded historical amounts and no
recognition of goodwill in the combination is required of either company in the
merger.
The Unaudited Pro Forma Condensed Combined Financial Statements
appearing elsewhere in this Joint Proxy Statement/Prospectus are based upon
certain assumptions and allocate the purchase price in the Merger to assets and
liabilities based upon preliminary estimates of their respective fair values.
The unaudited pro forma adjustments and combined amounts are included for
informational purposes only. If the Merger is consummated, VCA's financial
statements will reflect effects of acquisition adjustments only from the
Effective Time. The actual allocation of the purchase price may differ
significantly from the allocation reflected in the Unaudited Pro Forma Condensed
Combined Financial Statements. See "UNAUDITED PRO FORMA FINANCIAL DATA."
CERTAIN FEDERAL INCOME TAX CONSEQUENCES
The following is a summary of the material federal income tax
consequences of the Merger to Pet Practice and the stockholders of Pet Practice
and reflects the opinions of tax counsel attached as Exhibits 8.1 and 8.2 to the
Registration Statement of which this Joint Proxy Statement/Prospectus is a part.
Such opinions are based upon certain assumptions noted
44
<PAGE>
in such opinions. The discussion below is based on current law. This summary
is provided for information purposes only and relates only to Pet Practice
Common Stock held as a capital asset within the meaning of Section 1221 of the
Code by persons who are citizens or residents of the United States. This
discussion does not address aspects of federal taxation other than income
taxation, nor does it address all aspects of federal income taxation, including,
without limitation, aspects of income taxation that may be applicable to
particular stockholders, such as stockholders who are foreign persons, tax-
exempt organizations, insurance companies, financial institutions and dealers in
stocks and securities or persons who acquired all their Pet Practice Common
Stock in a compensation transaction, such as an exercise of an employee option.
No rulings will be sought from the Internal Revenue Service with respect to the
federal income tax consequences of the Merger.
PET PRACTICE STOCKHOLDERS ARE URGED TO CONSULT THEIR OWN TAX ADVISORS
AS TO SPECIFIC TAX CONSEQUENCES TO THEM OF THE MERGER.
Based upon the advice of its legal counsel, VCA and Pet Practice
believe that the Merger will be treated as a reorganization within the meaning
of Section 368 of the Code, and accordingly (i) no gain or loss will be
recognized by Pet Practice as a result of the Merger; (ii) no gain or loss will
be recognized by the Pet Practice stockholders upon the receipt of VCA Common
Stock in exchange for Pet Practice Common Stock in connection with the Merger
(except as discussed below with respect to cash received in lieu of a fractional
interest in VCA Common Stock); (iii) the tax basis of the VCA Common Stock to be
received by the Pet Practice stockholders in connection with the Merger will be
the same as the basis in the Pet Practice Common Stock surrendered in exchange
therefor (reduced by any amount allocable to a fractional share interest for
which cash is received); and (iv) the holding period of the VCA Common Stock to
be received by the Pet Practice stockholders in connection with the Merger will
include the holding period of the Pet Practice Common Stock surrendered in
exchange therefor, provided that the Pet Practice Common Stock is held as a
capital asset at the Effective Time. Pet Practice's obligation to consummate
the Merger is conditioned upon the receipt of a written opinion from its legal
counsel to this effect. Based upon the advice of its legal counsel, VCA
believes that the Merger will result in no gain or loss to VCA on the exchange
of shares of Pet Practice Common Stock. VCA's obligation to consummate the
Merger is conditioned upon the receipt of a written opinion from its legal
counsel to this effect. See "THE MERGER AGREEMENT --- Conditions to the
Merger."
A Pet Practice stockholder who is entitled to receive cash in lieu of
a fractional share interest of VCA Common Stock in connection with the Merger
will recognize gain (or loss) equal to the difference between such cash amount
and the stockholder's basis in the fractional share interest as long as the cash
payment is not essentially equivalent to a dividend. In such event, any gain or
loss recognized will be capital gain (or loss) if the Pet Practice Common Stock
is held by such stockholder as a capital asset at the Effective Time.
THE DISCUSSION SET FORTH ABOVE DOES NOT ADDRESS THE STATE, LOCAL OR
FOREIGN TAX ASPECTS OF THE MERGER. THE DISCUSSION IS BASED ON CURRENTLY
EXISTING PROVISIONS OF THE CODE, EXISTING AND PROPOSED TREASURY REGULATIONS
THEREUNDER AND CURRENT ADMINISTRATIVE RULINGS AND COURT DECISIONS. ALL OF THE
FOREGOING ARE SUBJECT TO CHANGE AND ANY SUCH CHANGES COULD AFFECT THE CONTINUING
VALIDITY OF THIS DISCUSSION. EACH VCA AND PET PRACTICE STOCKHOLDER SHOULD
CONSULT SUCH STOCKHOLDER'S OWN TAX ADVISOR WITH RESPECT TO THE SPECIFIC TAX
CONSEQUENCES OF THE MERGER TO SUCH STOCKHOLDER, INCLUDING THE APPLICATION AND
EFFECT OF STATE, LOCAL AND FOREIGN TAX LAWS AND THE POSSIBLE EFFECTS OF CHANGES
IN FEDERAL LAWS OR OTHER TAX LAWS.
RESALE RESTRICTIONS
All shares of VCA Common Stock received by Pet Practice stockholders
in the Merger will be freely transferable, except that shares of VCA Common
Stock received by persons who are deemed to be "affiliates" (as such term is
defined under the Act) of Pet Practice prior to the Merger may be resold by them
only in transactions permitted by the resale provisions of Rule 145 promulgated
under the Act (or Rule 144 in the case of such persons who become affiliates of
VCA) or as otherwise permitted under the Act. Persons who may be deemed to be
affiliates of Pet Practice or VCA generally include individuals or entities that
control, are controlled by, or are under common control with, such party and may
include certain officers and directors of such party as well as principal
stockholders of such party. The Merger Agreement requires Pet Practice to
exercise its reasonable efforts to cause each of its affiliates to execute a
written agreement to the effect that such person will not offer
45
<PAGE>
to sell, transfer or otherwise dispose of any of the shares of VCA Common Stock
issued to such person in or pursuant to the Merger unless (a) such sale,
transfer or other disposition has been registered under the Act, (b) such sale,
transfer or other disposition is made in conformity with Rule 145 under the Act
or (c) in the opinion of counsel, such sale, transfer or other disposition is
exempt from registration under the Act.
In addition, the Principal Stockholder has agreed not to transfer or
otherwise dispose of the Pet Practice Common Stock owned by it except to its
partners who agree not to transfer or otherwise dispose of the VCA Common Stock
received in the Merger with respect to such Pet Practice Common Stock for a
period ending on April 30, 1997; provided, that, 33% of such shares of VCA
Common Stock shall no longer be subject to such restriction on November 1, 1996
and the remaining shares shall no longer be subject to such restriction on May
1, 1997.
REGULATORY MATTERS
Under the HSR Act and the rules promulgated thereunder by the FTC, the
Merger may not be consummated until notifications have been given and certain
information has been furnished to the Antitrust Division and the FTC and
specified waiting period requirements have been satisfied. VCA and Pet Practice
each filed with the Antitrust Division and the FTC a Notification and Report
Form (the "Notification and Report Form") with respect to the Merger on April
26, 1996. The initial waiting period for each of these filings expired on May
26, 1996.
The Antitrust Division and the FTC frequently scrutinize the legality
under the antitrust laws of transactions such as the Merger. At any time before
or after the Stockholder Meetings, the Antitrust Division or the FTC could take
such action under the antitrust laws as it deems necessary or desirable in the
public interest, including seeking to enjoin the Merger or seeking the
divestiture of substantial assets of Pet Practice or its subsidiaries or VCA or
its subsidiaries.
In addition, state antitrust authorities may also bring legal action
under the antitrust laws. Such action could include seeking to enjoin the
consummation of the Merger or seeking divestiture of certain assets of VCA or
Pet Practice. Private parties may also seek to take legal action under the
antitrust laws under certain circumstances. There can be no assurance that a
challenge to the Merger on antitrust grounds will not be made or, if such a
challenge is made, of the results thereof.
NASDAQ NATIONAL MARKET
VCA expects to apply for the listing of the additional shares of VCA
Common Stock to be issued to the Pet Practice stockholders in connection with
the Merger on the Nasdaq National Market. It is a condition to the Merger that
these shares shall have been approved for listing on the Nasdaq National Market,
subject only to official notice of issuance.
46
<PAGE>
THE MERGER AGREEMENT
The following is a summary of the material provisions of the Merger
Agreement, a copy of which is attached as Appendix A to this Joint Proxy
-------- -
Statement/Prospectus and is incorporated herein by reference. Stockholders of
VCA and Pet Practice are urged to read the Merger Agreement in its entirety for
a more complete description of the Merger.
GENERAL
Pursuant to the Merger Agreement, subject to the terms and conditions
thereof, at the Effective Time, Pet Practice will be merged with and into Merger
Corp. As a result of the Merger, Pet Practice will become a wholly owned
subsidiary of VCA. As part of the Merger, stockholders of Pet Practice will
receive the consideration described below.
Upon the satisfaction or waiver of all conditions to the Merger, and
provided that the Merger Agreement has not been terminated or abandoned, VCA and
Pet Practice will cause the Certificate of Merger to be executed, acknowledged
and filed with the Secretary of State of the State of Delaware as provided in
Section 251 of the DGCL. Such filing is anticipated to take place as soon as
practicable after the last of the conditions precedent to the Merger set forth
in the Merger Agreement have been satisfied or, where permissible, waived, which
is expected to occur shortly after the Stockholder Meetings.
CONSIDERATION TO BE RECEIVED IN THE MERGER
Upon consummation of the Merger, pursuant to the Merger Agreement, (i)
each share of Pet Practice Common Stock issued and outstanding at the Effective
Time, will be converted into a fraction of a share of VCA Common Stock
determined by reference to the Exchange Ratio (defined below), (ii) all shares
of Pet Practice Common Stock will be canceled and cease to exist, and (iii) all
Pet Practice treasury stock, if any, will be canceled and retired without
payment of any consideration therefor. The Exchange Ratio is determined by
reference to the following formula: (a) if the Average Price (defined below) is
between $25.00 and $30.00 (inclusive), the Exchange Ratio shall be determined by
dividing $10.00 by the Average Price, (b) if the Average Price is between $24.00
and $19.00 (inclusive), the Exchange Ratio shall be 0.3950 at $24.00 and
increased 0.005 for each whole dollar by which the Average Price is less than
$24.00, (c) if the Average Price is $18.50 or less, the Exchange Ratio shall be
0.4225, (d) if the Average Price is equal to or greater than $31.00 and less
than $49.00, the Exchange Ratio shall be 0.3350 at $31.00 and reduced 0.005 for
each whole dollar by which the Average Price is greater than $31.00, (e) if the
Average Price is within the ranges described in clause (b) and (d) above, but
the Average Price is not a whole dollar, then the Exchange Ratio shall be
determined as that which would have been computed at the nearest whole dollar
increased or decreased (as applicable) by an amount equal to 0.005 multiplied by
a fraction, the numerator of which shall be the difference between the Average
Price and such nearest whole dollar, and the denominator of which shall be
$1.00, (f) if the Average Price is between $19.00 and $18.50 (exclusive), the
Exchange Ratio shall be 0.4200 increased by an amount equal to 0.0025 multiplied
by a fraction, the numerator of which is the difference between $19.00 and the
Average Price and the denominator of which is $.50, (g) if the Average Price is
between $24.00 and $25.00 (exclusive), the Exchange Ratio shall be 0.3950
increased by an amount equal to 0.005 multiplied by a fraction, the numerator of
which is the difference between the Average Price and $24.00 and the denominator
of which is $1.00, (h) if the Average Price is between $30.00 and $31.00
(exclusive), the Exchange Ratio shall be 0.3333 increased by an amount equal to
0.0017 multiplied by a fraction, the numerator of which is the difference
between the Average Price and $30.00 and the denominator of which is $1.00, and
(i) if the Average Price is equal to or greater than $49.00, the Exchange Ratio
shall be determined by dividing $12.005 by the Average Price. The Average Price
means the average of the closing prices of the VCA Common Stock on the Nasdaq
National Market over the 20 trading day period ending on (and including) the
third trading day immediately preceding the date of the Pet Practice Special
Meeting.
Based on the foregoing, the resulting valuation of the merger
consideration per share of Pet Practice Common Stock will range from $7.82 per
share (if the Average Price is $18.50 per share) to $12.005 per share (if the
Average Price is $49.00 per share).
The following table presents the Exchange Ratios and resulting
valuation of the merger consideration to be received in the Merger for each
share of Pet Practice Common Stock at the Average Prices indicated.
47
<PAGE>
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Average Price $ 18.50 $ 19.00 $ 20.00 $ 21.00 $ 22.00 $ 23.00 $ 24.00 $ 25.00 $ 26.00 $ 27.00 $ 28.00
Exchange Ratio 0.4225 0.4200 0.4150 0.4100 0.4050 0.4000 0.3950 0.4000 0.3846 0.3704 0.3571
Market Value of $ 7.82 $ 7.98 $ 8.30 $ 8.61 $ 8.91 $ 9.20 $ 9.48 $ 10.00 $ 10.00 $ 10.00 $ 10.00
Merger
Consideration
Average Price $ 29.00 $ 30.00 $ 31.00 $32.00 $ 33.00 $ 34.00 $ 35.00 $ 36.00 $ 37.00 $ 38.00 $ 39.00
Exchange Ratio 0.3448 0.3333 0.3350 0.3300 0.3250 0.3200 0.3150 0.3100 0.3050 0.3000 0.2950
Market Value of $ 10.00 $ 10.00 $ 10.39 $ 10.56 $ 10.73 $ 10.88 $ 11.03 $ 11.16 $ 11.29 $ 11.40 $ 11.51
Merger
Consideration
Average Price $ 40.00 $ 41.00 $ 42.00 $ 43.00 $ 44.00 $ 45.00 $ 46.00 $ 47.00 $ 48.00 $ 49.00
Exchange Ratio 0.2900 0.285 0.2800 0.2750 0.2700 0.2650 0.2600 0.2550 0.2500 0.2450
Market Value of $ 11.60 $ 11.69 $ 11.76 $ 11.83 $ 11.88 $ 11.93 $ 11.96 $ 11.99 $ 12.00 $12.005
Merger
Consideration
</TABLE>
For a more complete listing of the Exchange Ratios applicable at
various Average Prices, see Appendix F to this Proxy Statement.
Pet Practice and VCA have established a toll-free phone number which
may be called by VCA stockholders and Pet Practice stockholders to obtain more
current estimates of the Exchange Ratio based upon the foregoing. Please call
(800) 223-2064 for a current estimate of the Exchange Ratio based upon more
recent market closing prices of the VCA Common Stock.
Each outstanding Pet Practice Option will be assumed by VCA in
accordance with the Merger Agreement and will be exercisable upon the same terms
and conditions as under the applicable agreement or plan representing such
option, except that (i) each option shall be exercisable for that number of
shares of VCA Common Stock (to the nearest whole share) into which the number of
shares of Pet Practice Common Stock subject to such option immediately prior to
the Effective Time would be converted under the Merger Agreement and (ii) the
exercise price per share of each such option shall be equal to (x) the per share
exercise price of such option in effect immediately prior to the Effective Time
multiplied by the number of shares of Pet Practice Common Stock subject to such
option immediately prior to the Effective Time, divided by (y) the number of
shares of VCA Common Stock subject to such option immediately after the
Effective Time. Approval of the Merger Agreement by the stockholders of VCA
will constitute stockholder approval of the assumption by VCA of the rights and
obligations of Pet Practice under the Pet Practice 1994 Stock Option Plan and of
the amendment of such plan to provide for, among other things, the conversion at
the Effective Time of each outstanding stock option into an option to purchase
shares of VCA Common Stock.
EXCHANGE OF SHARES
Promptly after the Effective Time, transmittal forms will be mailed to
each holder of record of shares of Pet Practice Common Stock to be used in
forwarding Certificates evidencing such shares for surrender and exchange for
certificates evidencing the shares of VCA Common Stock to which such holder has
become entitled and, if applicable, cash in lieu of a fractional share of VCA
Common Stock. After receipt of such transmittal form, each holder of
Certificates formerly representing Pet Practice Common Stock should surrender
such Certificates, together with a duly completed transmittal form, to the
Exchange Agent, and each such holder will receive in exchange therefor
certificates evidencing the whole number of shares of VCA Common Stock to which
he or she is entitled and any cash which may be payable in lieu of a fractional
share. Such transmittal forms will be accompanied by instructions specifying
other details of the exchange.
48
<PAGE>
PET PRACTICE STOCKHOLDERS SHOULD NOT SEND IN THEIR CERTIFICATES UNTIL
THEY RECEIVE A LETTER OF TRANSMITTAL.
No fractional shares of VCA Common Stock will be issued and any holder
of shares of Pet Practice Common Stock entitled under the Merger Agreement to
receive a fractional share will be entitled to receive only a cash payment in
lieu thereof, which payment will be in an amount equal to the product of the
Average Price (defined above) of a share of VCA Common Stock multiplied by the
fractional percentage of a share of VCA Common Stock to which such holder would
otherwise be entitled.
No dividends or other distributions on shares of VCA Common Stock will
be paid with respect to any shares of Pet Practice Common Stock until the
Certificate representing such shares is surrendered for exchange as provided in
the Merger Agreement. Subject to applicable laws, such dividends and
distributions, if any, will be accumulated and, at the time of such surrender,
all such unpaid dividends and distributions, together with any cash payment in
lieu of a fractional share, will be paid, without interest.
At or after the Effective Time, there will be no transfers on the
transfer books of Pet Practice of shares of Pet Practice Common Stock which were
outstanding immediately prior to the Effective Time.
Any portion of the monies from which cash payments in lieu of
fractional interests in shares of VCA Common Stock will be made (including the
proceeds of any investments thereof) and any shares of VCA Common Stock that are
unclaimed by the former stockholders of Pet Practice one year after the
Effective Time will be delivered to VCA. Any former stockholders of Pet
Practice who have not theretofore complied with the exchange procedures in the
Merger Agreement may thereafter look to VCA only as a general creditor for
payment of their shares of VCA Common Stock, cash in lieu of fractional shares,
and any unpaid dividends and distributions on shares of VCA Common Stock,
deliverable in respect of each share of Pet Practice Common Stock such
stockholder holds. Notwithstanding the foregoing, none of Pet Practice, VCA,
the Exchange Agent or any other person will be liable to any former holder of
shares of Pet Practice Common Stock for any amount properly delivered to a
public official pursuant to applicable abandoned property, escheat or similar
laws.
In the event that any Certificate has been lost, stolen or destroyed,
upon the making of an affidavit of that fact by the person claiming such
Certificate to be lost, stolen or destroyed and, if required by VCA, the posting
by such person of a bond in such reasonable amount as VCA may direct as
indemnity against any claim that may be made against it with respect to such
Certificate, the Exchange Agent will issue in exchange for such lost, stolen or
destroyed Certificate the shares of VCA Common Stock, cash in lieu of fractional
shares, and any unpaid dividends and distributions on shares of VCA Common
Stock, as described above.
REPRESENTATIONS AND WARRANTIES
The Merger Agreement contains various customary representations and
warranties relating to, among other things, (i) due organization, valid
existence and good standing of each of VCA and Pet Practice and each of their
respective subsidiaries and certain corporate matters; (ii) the capital
structure of each of VCA and Pet Practice; (iii) the authorization, execution,
delivery and enforceability of the Merger Agreement, the consummation of the
transactions contemplated by the Merger Agreement and related matters; (iv)
conflicts under charters or bylaws, required consents or approvals and
violations of any instruments or laws; (v) documents and financial statements
filed by each of VCA and Pet Practice with the Commission and the accuracy of
information contained therein; (vi) undisclosed liabilities; (vii) the absence
of certain material adverse events or changes; (viii) taxes, tax returns and
audits; (ix) properties; (x) intellectual properties; (xi) agreements, contracts
and commitments; (xii) litigation; (xiii) environmental matters, hazardous
materials and hazardous material activities; (xiv) employee benefit plans; (xv)
compliance with laws; (xvi) interested party transactions; (xvii) the accuracy
of information supplied by each of VCA and Pet Practice in connection with the
Registration Statement and this Joint Proxy Statement/Prospectus; (xviii) the
absence of existing discussions with other parties; (xix) opinions of financial
advisors; (xx) inapplicability to the Merger of certain provisions of the DGCL;
and (xxi) the interim operations of Merger Corp.
49
<PAGE>
CERTAIN COVENANTS
Conduct of Business Pending the Merger. Pursuant to the Merger
Agreement, VCA and Pet Practice have made various customary covenants relating
to the Merger. Pet Practice has agreed that, prior to the Effective Time, Pet
Practice and its subsidiaries will conduct their operations according to their
usual, regular and ordinary course of business. Specifically, Pet Practice has
agreed, among other things: (i) to preserve intact its business organization,
relationships and goodwill and to keep available the services of its officers
and employees; (ii) not to amend its certificate of incorporation or bylaws;
(iii) not to grant, confer or award any bonuses (other than the Merger Bonuses)
or other forms of cash incentives to any officer, director or key employee
except consistent with past practice or grant or confer any awards (other than
those granted as of the date of the Merger Agreement) under the Pet Practice
1994 Stock Option Plan, not to increase any compensation under any employment
agreement with any of its present or future officers, directors or employees,
except for normal increases consistent with past practice, grant any severance
or termination pay to, or enter into any employment or severance agreement with
any officer or director or amend any such agreement in any material respect
other than severance arrangements which are consistent with past practice with
respect to employees terminated by Pet Practice, and not to adopt any new
employee benefit plan (including any stock option, stock benefit or stock
purchase plan) or amend any existing employee benefit plan in any material
respect; (iv) not to issue new Pet Practice capital stock (except pursuant to
the exercise of contractual rights existing prior to the execution of the Merger
Agreement to acquire any shares of its capital stock), effect a stock split or
change its current capitalization; (v) not to declare any dividends or make any
distributions with respect to its capital stock or redeem any of its capital
stock or stock of its subsidiaries; (vi) not to acquire any corporation,
partnership or any other business organization or division thereof; (vii) not to
incur any indebtedness for borrowed money; (viii) not to sell, pledge, dispose
of or encumber any of its properties or assets except in the ordinary course of
business consistent with past practices; (ix) not to change its accounting
practices; and (x) not to authorize or make capital expenditures in excess of
$500,000 in the aggregate.
VCA has agreed that, prior to the Effective Time, it will, among other
things: (i) conduct its operations in the ordinary course of business and in a
manner consistent with past practices, (ii) preserve intact its business
organization, relationships and goodwill and keep available the services of its
officers and employees, and (iii) not amend any of the material terms of its
securities, except such amendments that affect all shares of VCA Common Stock
equally.
No Solicitation of Transactions. Pursuant to the Merger Agreement,
Pet Practice has agreed that prior to the Effective Time, neither it nor any of
its subsidiaries will permit its officers, directors, employees, agents and
representatives (including, without limitation, any investment banker, attorney
or accountant retained by it or any of its subsidiaries) to initiate, solicit or
encourage, directly or indirectly, any inquiries or make or implement any
proposal or offer (including, without limitation, any proposal or offer to its
stockholders) with respect to a merger, acquisition, consolidation or similar
transaction involving, or any purchase of all or any significant portion of the
assets or any equity securities of, Pet Practice or any of its subsidiaries (any
such proposal or offer being hereinafter referred to as an "Acquisition
Proposal") or engage in any negotiations concerning, or provide any confidential
information or data to, or have any discussions with, any person relating to an
Acquisition Proposal, or otherwise facilitate any effort or attempt to make or
implement an Acquisition Proposal. Pet Practice also agreed to cease and cause
to be terminated any existing activities, discussions or negotiations with any
parties with respect to any of the foregoing and to take the necessary steps to
inform the individuals or entities referred to above of Pet Practice's
obligations with respect to an Acquisition Proposal. Pet Practice has further
agreed that it will notify VCA immediately if any such inquiries or proposals
are received by, any such information is received from, or any such negotiations
or discussions are sought to be initiated or continued with, it. However, the
Pet Practice Board is not prohibited from (i) furnishing information to, or
entering into discussions or negotiations with, any person or entity that makes
an unsolicited bona fide proposal to acquire Pet Practice pursuant to a merger,
consolidation, share exchange, purchase of a substantial portion of the assets,
business combination or other similar transaction, if, and only to the extent
that (A) the Pet Practice Board determines in good faith that such action is
required for the Pet Practice Board to comply with its fiduciary duties to
stockholders imposed by law, (B) the Pet Practice Board has received a legal
opinion from its legal counsel that such action is required for the Pet Practice
Board to comply with its fiduciary duties to stockholders imposed by law, (C)
prior to furnishing such information to, or entering into discussions or
negotiations with, such person or entity, Pet Practice provides written notice
to VCA to the effect that it is furnishing information to, or entering into
discussions or negotiations with, such person or entity, and (D) subject to any
confidentiality agreement with such person or entity (which such party
determined in good faith was required to be executed in order for the Pet
Practice Board to comply with its fiduciary duties to stockholders imposed by
law), Pet Practice keeps VCA informed of the status (not the terms) of any such
discussions or negotiations; and (ii) to the extent applicable, complying with
Rule 14e-2 promulgated under the Exchange Act with regard to an Acquisition
Proposal. Pet Practice may not terminate the Merger
50
<PAGE>
Agreement (except pursuant to the termination provisions contained in the Merger
Agreement), enter into any agreement with respect to, or in any way facilitate,
an Acquisition Proposal while the Merger Agreement remains in effect, or fail to
comply with any of its obligations under the Merger Agreement.
Termination Fee. If, following any Acquisition Proposal, Pet Practice
subsequently effects any merger, acquisition, consolidation or similar
transaction involving, or any purchase of all or any significant portion of the
assets or any equity securities of, Pet Practice or any of its subsidiaries, or
the Merger Agreement is thereafter terminated, Pet Practice shall pay to VCA an
amount equal to $3.5 million.
Meetings of Stockholders. Pursuant to the Merger Agreement, each of
VCA and Pet Practice has agreed to take all necessary action, in accordance with
applicable law and its respective Certificate of Incorporation and bylaws, to
convene promptly the Stockholder Meetings. The VCA Board and the Pet Practice
Board have agreed to recommend such approval and to take all lawful action to
solicit such approvals. However, either the VCA Board or Pet Practice Board, in
the exercise of its good faith judgment and based on the advice of outside
counsel as to its fiduciary duties to its stockholders imposed by law, may
change its recommendation or withdraw its solicitation.
Indemnification and Insurance. The Merger Agreement provides that,
from and after the Effective Time, VCA shall cause Merger Corp. to include as
part of its Certificate of Incorporation and bylaws provisions relating to the
indemnification of all current and former directors, officers, employees and
agents of Pet Practice which are substantially similar to the provisions
contained in Pet Practice's Certificate of Incorporation and bylaws. Such
provisions shall not be amended, repealed or otherwise modified after the
Effective Time in any manner that would adversely affect the rights thereunder
of individuals who at any time prior to the Effective Time were directors,
officers, employees or agents of Pet Practice in respect to actions or omissions
occurring at or prior to the Effective Time (including, without limitation,
actions or omissions which occur in connection with the transactions
contemplated by the Merger Agreement), unless such modification is required by
law.
Other Actions. Pursuant to the Merger Agreement, both VCA and Pet
Practice have agreed to use their best efforts to take, or cause to be taken,
all other action and to do, or cause to be done, all other things necessary,
proper or appropriate to consummate the transactions contemplated by the Merger
Agreement.
Certain Other Covenants. Both VCA and Pet Practice have also agreed:
(i) to make promptly their respective filings, and any other submissions, under
the HSR Act and obtain all other consents, approvals or permits from the
necessary federal and state governments and regulatory agencies (including any
national securities exchange) prior to the Effective Time; (ii) to consult with
each other prior to issuing any press release or public statement; (iii) to
allow all designated officers, attorneys, accountants and representatives of the
other reasonable access to offices, records and files (including information
relating to commitments, contracts, titles and financial position) and to
instruct their respective employees, counsel and financial advisors to cooperate
with each other's investigation; (iv) to cooperate in the filing of the
Registration Statement and obtain all necessary state securities laws permits or
approvals; (v) that Pet Practice will use all reasonable efforts to deliver or
cause to be delivered to VCA an affiliate letter, in a form reasonably
acceptable to VCA, from each of the persons deemed to be "affiliates" of Pet
Practice as such term is defined under the Act at least 20 days prior to the
Effective Time; and (vi) that all costs and expenses incurred in connection with
the Merger shall be paid by the party incurring such costs and expenses except
that the filing fees associated with the HSR filing and the Registration
Statement filing as well as the expenses incurred in connection with the
printing and mailing of the Registration Statement and the Joint Proxy
Statement/Prospectus shall be shared equally by VCA and Pet Practice.
CONDITIONS TO THE MERGER
The obligations of VCA and Pet Practice to consummate the Merger are
conditioned on the fulfillment of the following: (i) the effectiveness of the
Registration Statement and the absence of any stop order suspending the
effectiveness thereof and no proceeding for that purpose having been initiated
by the Commission; (ii) approval, in the manner required by law or the
applicable stock exchange or regulatory body, of the stockholders of VCA and the
stockholders of Pet Practice, of the Merger Agreement and all transactions
contemplated thereby; (iii) expiration or termination of the applicable waiting
period under the HSR Act; (iv) neither VCA nor Pet Practice shall be subject to
any order or injunction of a court of competent jurisdiction which prohibits the
consummation of the transactions contemplated in the Merger Agreement; (v) the
approval for listing of the VCA Common Stock issued to the Pet Practice
stockholders in connection with the Merger on the Nasdaq National Market;
51
<PAGE>
(vi) the receipt by VCA and Pet Practice from their respective counsels of an
opinion to the effect that the Merger will be treated for federal income tax
purposes as a reorganization within the meaning of Section 368 of the Code; and
(vii) for a period of 30 days prior to the Effective Date, there will not have
been a suspension in trading on the Nasdaq National Market, the declaration of a
banking moratorium, any suspension of payments in respect of banks, an outbreak
or major escalation of hostilities between the United States and any foreign
power or any limitation by any governmental authority on credit by financial
institutions.
The obligation of VCA to consummate the Merger is conditioned on the
fulfillment of the following conditions: (i) the performance by Pet Practice,
in all material respects, of its obligations required to be performed on or
prior to the Effective Time and contained in the Merger Agreement; (ii) the
representations and warranties made by Pet Practice in the Merger Agreement
shall be true in all material respects as of the Effective Time; (iii) the
receipt by VCA of an opinion from counsel for Pet Practice customary in merger
transactions; (iv) no material adverse changes in the business, financial
condition or operations of Pet Practice shall have occurred; (v) all material
filings, registrations, covenants, permits, authorizations and regulatory
approvals necessary for the consummation of the Merger shall have been obtained
or made; (vi) VCA shall have received a "comfort" letter from Pet Practice's
independent public accountants; (vii) VCA shall have received an "affiliate"
letter from each affiliate of Pet Practice; (viii) VCA shall have received a
letter from the Principal Stockholder of Pet Practice agreeing not to dispose of
the shares of VCA Common Stock received in the Merger for a period ending on
April 30, 1997; provided, that, 33% of such shares of VCA Common Stock shall no
longer be subject to such restriction on November 1, 1996; and (ix) no law or
order has been enacted or entered which would make the Merger illegal or
materially delay the Effective Time, require VCA or Pet Practice to divest
shares of Pet Practice Common Stock or a material portion of the business,
assets or properties of VCA or Pet Practice or impose any material limitation on
the ability of either of them to conduct their respective businesses and own
their respective assets or properties, or impose limitations on the ability of
VCA to control in any material respect the business operations of Pet Practice.
The obligation of Pet Practice to consummate the Merger is conditioned
on the fulfillment of the following conditions: (i) the performance by VCA, in
all material respects, of its obligations required to be performed on or prior
to the Effective Time and contained in the Merger Agreement; (ii) the
representations and warranties made by VCA in the Merger Agreement shall be true
in all material respects as of the Effective Time ; (iii) the receipt by Pet
Practice of an opinion from counsel for VCA customary in merger transactions;
and (iv) no law or order has been enacted or entered which would make the Merger
illegal or delay the Effective Time beyond September 1, 1996.
TERMINATION OF THE MERGER AGREEMENT
The Merger Agreement is subject to termination at the option of either
VCA or Pet Practice if the Merger is not consummated on or before September 1,
1996. In addition, prior to such time, the Merger Agreement is subject to
termination upon: (i) the disapproval of the Merger Proposal by the VCA
stockholders voting thereon or the disapproval of the Merger Agreement by the
Pet Practice stockholders voting thereon; (ii) the issuance by a court or
governmental, regulatory or administrative agency, of an order, decree or ruling
permanently restraining, enjoining or otherwise prohibiting the consummation of
the Merger; (iii) the Average Price being equal to or less than $18.50; or
(iv) the mutual consent of VCA and Pet Practice.
The Merger Agreement may be terminated by the Pet Practice Board at
any time prior to the Effective Time if (i) there has been a breach by VCA of
any representation, warranty, covenant or agreement in the Merger Agreement such
that the conditions to the obligations of Pet Practice would not be satisfied
and such breach is not curable, or if curable prior to September 1, 1996, VCA is
not exercising reasonable efforts to cure such breach; or (ii) any material
condition to the obligations of Pet Practice is not substantially satisfied at
the time contemplated thereby and such condition is not waived by Pet Practice.
The Merger Agreement may be terminated by the VCA Board at any time
prior to the Effective Time if (i) there has been a breach by Pet Practice of
any representation, warranty, covenant or agreement in the Merger Agreement such
that the conditions to the obligations of VCA would not be satisfied and such
breach is not curable, or if curable prior to September 1, 1996, Pet Practice is
not exercising reasonable efforts to cure such breach; or (ii) any material
condition to the obligations of VCA is not substantially satisfied at the time
contemplated thereby and such condition is not waived by VCA.
52
<PAGE>
AMENDMENT AND WAIVER
The Merger Agreement may be amended at any time by action taken or
authorized by the respective boards of directors of VCA and Pet Practice, but
after approval by the stockholders of VCA and Pet Practice of the matters
presented in connection with the Merger to them, no amendment shall be made
which by law requires further approval by such stockholders, without such
further approval. VCA and Pet Practice by action taken or authorized by their
respective boards of directors, may extend the time for performance of the
obligations or other acts of the other parties to the Merger Agreement, may
waive inaccuracies in the representations or warranties contained in the Merger
Agreement, and may waive compliance with any agreements or conditions contained
in the Merger Agreement.
BUSINESS OF VCA
GENERAL
VCA was founded in 1986 and is a leading companion animal health care
company. VCA has established a premier position in the animal hospital and
veterinary diagnostic laboratory segments and has an emerging presence in the
premium pet food segment. VCA operates one of the largest networks of free-
standing, full service animal hospitals in the country and one of the largest
networks of veterinary-exclusive laboratories in the nation. VCA also markets
both a life-stage and a therapeutic line of premium pet foods through Vet's
Choice, a joint venture with Heinz Pet Products, an affiliate of H.J. Heinz
Company.
Animal hospitals, veterinary diagnostic laboratories and premium pet
foods represented approximately 55%, 40% and 5%, respectively, of VCA's revenues
for the year ended December 31, 1995. VCA's animal hospitals offer a full range
of general medical and surgical services and also perform specialty surgeries
such as orthopedics for small animals, including dogs, cats, birds and other
household pets. In addition to treating disease and injury, VCA's animal
hospitals emphasize pet wellness and offer programs to encourage routine
vaccinations, health examinations, spaying and neutering and dental care. VCA's
veterinary laboratories offer a full range of diagnostic and reference tests.
Laboratory tests are used by veterinarians to diagnose, monitor and treat
diseases through the detection of substances in blood, urine or tissue samples
and other specimens. VCA does not conduct experiments on animals and is not
engaged in animal research. Vet's Choice markets a complete line of life-stage
and therapeutic premium pet foods under the brand names Select Balance and
Select Care, respectively.
RECENT DEVELOPMENTS
Recent Acquisitions
Since January 1, 1996 through June 20, 1996, VCA has acquired (i)
Pets' Rx, Inc., the owner and operator of 16 animal hospitals in California and
Nevada, and (ii) 11 animal hospitals in the states of Maryland, Massachusetts,
Pennsylvania, Florida, Hawaii, Virginia and California. In addition, VCA has
acquired three veterinary laboratories, one of which was Southwest Veterinary
Diagnostics, Inc. ("Southwest"), a veterinary diagnostic laboratory located in
Phoenix, Arizona. The acquisition of Southwest, which services more than 1,900
veterinary hospitals in the states of Arizona, California, New Mexico, Texas,
Kansas, Nebraska and Missouri, and other portions of the Midwest, expands the
customer base of VCA's laboratory division, providing VCA with the opportunity
to serve over 8,000 veterinary hospitals daily. In connection with the
acquisitions which were accounted for as a purchase, VCA paid an aggregate
consideration of $28,718,000 consisting of $13,614,000 in cash, $8,066,000 in
debt, 242,926 shares of VCA Common Stock, with a value of $3,868,000, and the
assumption of liabilities totaling $3,170,000, including acquisition costs. In
connection with the acquisitions which were treated as a pooling of interests,
VCA issued 952,091 shares of VCA Common Stock.
The Pet Practice, Inc.
On March 21, 1996, VCA signed the Merger Agreement with Pet Practice,
pursuant to which VCA will acquire all of the outstanding securities of Pet
Practice. Pet Practice operates 84 veterinary hospitals in 11 states. For a
description of the Merger with Pet Practice, see "THE MERGER."
53
<PAGE>
Debt Offering
On April 17, 1996, VCA issued $84.4 million of 5.25% convertible
subordinated debentures due in 2006. The debentures, non-callable for three
years, will be convertible into approximately 2.5 million shares of VCA Common
Stock at a price of $34.35 per share. The proceeds of this offering are
intended to be used to repay acquisition related debt and for general corporate
purposes.
THE COMPANION ANIMAL HEALTH CARE INDUSTRY
The market segments in which VCA operates had total domestic revenues
in 1994 of approximately $10.0 billion, composed of approximately $8.2 billion
for veterinary care (animal hospitals and veterinary diagnostic laboratories)
and approximately $1.8 billion for premium pet food. Approximately 95% of VCA's
revenues for the year ended December 31, 1995 were derived from the veterinary
care segment of the market with the balance coming from premium pet food sales.
VCA classifies its markets by service or product type into three segments,
Animal Hospital, Laboratory and Premium Pet Food.
Animal Hospitals
Veterinarians diagnose and treat animal illnesses and injuries,
perform surgeries, provide routine medical exams and prescribe medication. Some
veterinarians specialize by type of medicine, such as orthopedics, dentistry,
ophthalmology or dermatology and may specialize by type of animal. The United
States market for veterinary services is highly fragmented with approximately
115 million dogs and cats cared for by an estimated 55,000 veterinarians
practicing at 16,000 animal hospitals. These animal hospitals are primarily
single site, sole practitioner facilities. VCA believes that the principal
factors in a pet owner's decision as to which veterinarian to use include
convenient location, recommendation of friends, reasonable fees and convenient
hours.
The animal hospital industry is consolidating. Factors contributing
to this trend include (i) the desire of some owners of animal hospitals to
diversify their investment portfolio by selling all or a portion of their
investment in the animal hospital, (ii) the buying, marketing and administrative
cost advantages which can be realized by a large, multiple location, multi-
practitioner veterinary provider, (iii) the desire of veterinarians to practice
veterinary medicine rather than spend a large portion of their working time
performing the administrative tasks necessary to operate an animal hospital,
(iv) the cost of financing equipment purchases and upgrading technology
necessary for a successful practice, and (v) the desire of many veterinarians
for more flexible work hours and benefits than are typically available to a sole
practitioner or single site provider.
Veterinary Diagnostic Laboratories
Given the inability of the patient to communicate verbally with the
doctor, laboratory testing is an important part of the diagnostic process in
veterinary medicine. Clinical laboratory tests are used by veterinarians to
diagnose, monitor and treat diseases through the detection of substances in
blood or tissue samples and other specimens.
Veterinary laboratory tests are performed primarily at the animal
hospital, using on-site diagnostic equipment, or at outside veterinary
diagnostic laboratories. On-site diagnostic equipment is sold by a number of
manufacturers. For many types of tests, on-site diagnostic equipment can
provide more timely results than outside laboratories but requires the animal
hospital or veterinarian to purchase the equipment and provide trained personnel
to operate it. Veterinary diagnostic laboratories, such as those operated by
VCA, can provide a wider range of tests than are generally available on-site at
most animal hospitals and do not require any up-front investment on the part of
the animal hospital or veterinarian. Veterinary laboratory services are also
available through universities and several national laboratory companies.
The veterinary laboratory industry is highly fragmented and is
primarily characterized by local and regional competitors. VCA believes that
veterinarians usually prefer to use laboratories that specialize in the
veterinary market and that offer individual attention, rapid test reporting and
response to inquiries by veterinary professionals, a broad spectrum of tests,
convenient sample pick-up times, and customized testing services.
Achieving rapid sample pick-up, diagnostics and reporting, at
competitive prices, is benefited by high throughput volumes. VCA believes that
the industry will continue to consolidate as participants seek to gain a cost
advantage.
54
<PAGE>
Premium Pet Food
Retail sales of pet food in 1994 approximated $8.8 billion, of which
premium pet food accounted for approximately $1.8 billion. Over the past ten
years, the supermarket share of pet food retail sales has decreased from
approximately 95% to approximately 55% as customers have gained increased
product knowledge and sought higher quality products offered by premium pet food
retailers, including super-stores and veterinary professionals. Moreover, a
recommendation from a veterinarian can be instrumental in heightening awareness
and stimulating demand for a particular premium brand.
Premium pet food differentiates itself from pet food typically offered
by supermarkets primarily through its fixed formulas and high quality
ingredients. Within the premium pet food segment, brands distinguish themselves
through superior palatability and digestibility as well as offering product
lines tailored to specific life-stages and health conditions.
BUSINESS STRATEGY
VCA's goal is to become the leading companion animal health care
company serving the animal hospital and veterinary diagnostic laboratory
markets. VCA intends to achieve this goal by continuing to (i) expand its
animal hospital and laboratory businesses through acquisitions and internal
growth, (ii) achieve cost savings by consolidating operations and realizing
economies of scale in purchasing and administrative support functions and by
implementing VCA's standard management programs, (iii) take advantage of its
unique opportunity to deliver its products and services through multiple
channels to its customers, primarily veterinarians and pet owners, and (iv)
capitalize on its leadership position within the companion animal health care
industry to expand into other products and services for veterinarians and pet
owners.
Expand through Acquisitions in New and Existing Markets. Since 1988
VCA has expanded rapidly from a single animal hospital in Los Angeles to a
nationwide network of 80 animal hospitals in 16 states at June 20, 1996. As a
result of these acquisitions and their successful integration into VCA's
operations, VCA has gained a leadership position in the animal hospital
industry, allowing it to expand into the veterinary diagnostic laboratory
business. Since March 1994, VCA has acquired 10 veterinary diagnostic
laboratories, making it the nation's largest network of veterinary-exclusive
diagnostic laboratories serving over 8,000 animal hospitals located in 40
states. Assuming the availability of capital, VCA plans to continue its
aggressive acquisition program. VCA will also consider acquiring multiple
hospital organizations and veterinary diagnostic laboratories, as opportunities
arise.
Consolidate Operations to Enhance Profitability. Upon the acquisition
of an animal hospital or veterinary diagnostic laboratory, VCA immediately
begins to implement management programs to enhance the productivity of
veterinarians and to improve operating results. VCA's business model enables it
to realize improved operating margins at its animal hospitals and veterinary
diagnostic laboratories through a strategy of centralizing various corporate and
administrative functions and leveraging fixed costs while providing its
customers with improved services. This model includes the following objectives:
Centralize Administrative Functions. VCA consolidates most administrative
functions at its corporate office, including purchasing, accounting,
payroll, data processing, personnel, accounts payable, information
services, marketing, planning and budgeting and other administrative
functions.
Consolidate Purchasing. When advantageous, VCA purchases its supplies on a
consolidated basis in order to negotiate better prices and terms from
vendors.
Standardize Training Procedures. VCA implements standardized training
procedures for its administrators and professional personnel. These
programs are developed in conjunction with the Medical Advisory Board and
Client Services Advisory Board, two entities which are staffed by VCA
personnel to recommend medical standards and to establish service and
training standards for local hospitals and laboratories.
Increase Internal Revenues. VCA also seeks to expand through internal
growth. To achieve this, VCA (i) increases veterinarian productivity by freeing
the veterinarian from administrative tasks and providing state-of-the-art
equipment and technical support, (ii) expands the services and operating hours
of certain of its facilities in selected markets, (iii) provides its facilities
with access to medical specialists, (iv) adds VCA's name to the acquired
facilities to enhance customer awareness, and
55
<PAGE>
(v) implements sales programs to attract new customers. By implementing these
strategies, VCA seeks to become the most convenient and most recognized
provider of veterinary services in its markets.
Improve Management Information Systems. As soon as possible, the
acquired company's computer system is replaced with one compatible with VCA's
main computer system. VCA's financial and customer records and laboratory
results are stored in computer databases, most of which may be accessed by VCA's
management. VCA's management information systems provide VCA with efficient
access to financial and operating data to monitor operating data and target
marketing programs to highly specific customer bases.
Continue to Capitalize on Existing Relationships to Leverage Lines of
Business. VCA believes that its three lines of business -- animal hospitals,
veterinary diagnostic laboratories and premium pet food -- are complementary.
As a result of VCA's national presence and name recognition throughout the
veterinary services industry, VCA believes it is building a reputation of
professional integrity and trust among veterinary professionals and brand
identification among pet owners. VCA's strategy is to leverage this
professional reputation and leadership position to expand its operations, both
in other geographic areas and related products and services. An example of the
results of this strategy is VCA's joint venture, Vet's Choice, to market premium
pet food. VCA uses its relationships, as well as its national presence and name
recognition in one line of business to facilitate growth in other lines. Often,
new business opportunities arise in one line of business from contacts made in
connection with and relations developed through VCA's other lines of business.
For example, animal hospital acquisitions may be developed through contacts
initially established in VCA's veterinary diagnostic laboratory business or from
marketing and other promotional efforts in connection with the sale of its
premium pet food.
ACQUISITION STRATEGY
Animal Hospitals. VCA seeks to enter a new market through the
acquisition of one or more relatively large, high quality animal hospitals. It
has been VCA's experience that this initial acquisition in a new market requires
substantially more time to identify, negotiate and consummate than additional
acquisitions in the same market. Following this initial acquisition, VCA seeks
to increase its presence in such market as opportunities arise.
VCA identifies potential candidates for acquisition through its
reputation in the professional community, direct contacts, finder relationships
and advertisements. VCA believes that acquisition opportunities will continue
to increase as it expands the geographic scope of its operations and the
products and services it offers to the companion animal health care community.
The typical acquisition candidate targeted by VCA is located in a 4,000-6,000
square foot, free-standing facility, has annual revenues of between $700,000 and
$1.5 million per year, employs two to six veterinarians, has an operating
history of at least five years and has achieved positive cash flow at an
attractive location with an established reputation in the community.
Veterinary Diagnostic Laboratories. VCA intends to expand its
nationwide network of veterinary-exclusive diagnostic laboratories through
acquisitions and internal growth. VCA seeks acquisition opportunities in the
veterinary diagnostic laboratory industry which will complement its existing
business or which will expand the geographic area which it services. VCA has
been able to realize significant cost savings at its veterinary diagnostic
laboratories by consolidating acquired operations into the existing operations,
reducing fixed overhead, sample collection, analysis and the reporting of
results to veterinarians. By obtaining additional testing volume for the
laboratories and spreading fixed costs over a larger revenue base, the unit
costs of providing laboratory services to clients should decline, producing
improved operating margins. As a result of these economies of scale, VCA has
the ability to reduce or maintain prices for testing services to customers.
Acquisition Consideration. Historically, consideration for
acquisitions has consisted of a combination of cash, the assumption of
liabilities, promissory notes and VCA Common Stock. VCA normally obtains
noncompetition and employment agreements from the selling owners. VCA presently
is evaluating and negotiating a number of potential acquisitions, none of which
are, individually, material to VCA. There can be no assurance, however, that
VCA will be able to identify and acquire animal hospitals or veterinary
diagnostic laboratories on terms favorable to VCA in the future, or in a timely
manner, or convert the acquisitions to the VCA business model as planned. See
"RISK FACTORS--Rapid Expansion and Management of Growth."
56
<PAGE>
OPERATIONS AND MARKETING
Animal Hospitals
VCA believes it operates one of the largest networks of free-standing
full-service animal hospitals in the United States. At June 20, 1996, VCA owned
80 animal hospitals, 19 of which were located in Northern California, 18 in
Southern California, eight in Pennsylvania, six in Massachusetts, five in
Nevada, four in Maryland and three in each of Alaska, Florida and New Mexico,
two in each of Colorado, Utah and Virginia, and one in each of Arizona, Georgia,
Hawaii, Illinois and Delaware.
VCA's animal hospitals offer a full range of general medical and
surgical services for small animals, including dogs, cats, birds and other
household pets. In addition to treating disease and injury, VCA's hospitals
emphasize pet wellness through pet health education and preventative care and
offer programs to encourage routine vaccinations, health examinations, spaying
and neutering and dental care. VCA offers specialized treatment, including
advanced diagnostic services, internal medicine, surgery, oncology,
ophthalmology, dermatology and cardiology. Additional services provided by VCA
at certain locations include grooming, bathing and boarding. VCA also sells
specialty pet products at its hospitals, including pet food, a full range of
pharmaceuticals, vitamins, therapeutic shampoos and conditioners, flea collars
and sprays and other accessory products.
VCA's facilities are open an average of 10 to 15 hours per day, six to
seven days per week. Several of its facilities provide 24-hour emergency care
service.
VCA seeks to provide a uniform and broad range of quality veterinary
services. To accomplish this goal, VCA actively recruits highly qualified
veterinarians and technicians and is committed to supporting continuing
professional education for its professional and lay staff. VCA operates two of
the largest teaching programs maintained at privately owned animal hospitals.
VCA believes that these programs enhance its reputation in the veterinary
profession and provide it with access to qualified recruits among graduating
classes of veterinarians. VCA believes it is an employer of choice for
veterinarians because it offers an increased patient flow and a diverse case
mix, employee benefits not generally available to a sole practitioner,
continuing education, management opportunities, scheduling flexibility to
accommodate personal lifestyles and the ability to relocate to different regions
of the country.
To support VCA's operations, VCA has established a Medical Advisory
Board, whose function is to recommend medical standards, and a Service Advisory
Committee that establishes service and training standards for local hospitals.
The committees are comprised of leading veterinarians and managers representing
different geographic regions and medical specialties served by VCA.
Seeking to provide state-of-the-art medical care in a clean,
attractive environment, VCA renovates facilities and upgrades its equipment on a
periodic basis. In addition, VCA provides, at some of its locations, board
certified or board eligible veterinarians in such specialized fields as internal
medicine, surgery, oncology, ophthalmology, dermatology, orthopedics and
cardiology to expand the range of services available at its facilities.
VCA's animal hospitals generally require a staff of between 10 to 60
full-time equivalent employees, depending upon the facility's size and customer
base. The staff includes administrative and technical support personnel, two or
more veterinarians, an office manager who supervises the day-to-day activities
of the facility and a small office staff. VCA employs a relatively small
corporate staff to provide centralized administrative services to all of its
veterinary hospitals. Financial control is maintained through uniform fiscal
and accounting policies which are established at the corporate level for use at
the hospitals. Financial information is centralized through a computerized data
collection and processing system at the corporate level.
Use of veterinary services has traditionally been seasonal. In
addition, use of veterinary services may be affected by weather conditions,
levels of infestation of fleas, heartworms and ticks, the number of daylight
hours and general economic conditions. The seasonality of the use of veterinary
services may cause operating results to vary significantly from quarter to
quarter. In each of the last five years, demand for VCA's services has been
greater in the second and third quarters than in the first and fourth quarters.
57
<PAGE>
VCA's internal marketing programs rely heavily on its existing client-
base in order to increase the frequency and intensity of the services used by
its clients. Reminder notices are used to increase awareness among VCA's
customers of the advantages of regular, comprehensive veterinary medical care,
including preventive care, such as vaccinations, dental screening and geriatric
care. VCA seeks to obtain referrals from veterinarians by promoting its
specialized diagnostic and treatment capabilities to veterinarians and
veterinary practices which cannot offer their clients such services.
As the number of hospitals in a single regional network grows, media
advertising of VCA's services will become increasingly cost effective. VCA
believes that an effective media advertising program will allow VCA to establish
brand identification as well as expand the revenues derived from the sale of new
and existing services and products. Such programs, services and products, VCA
believes, may increase the opportunities to expand VCA's market share in the
regional markets for veterinary services in which it competes.
Veterinary Diagnostic Laboratories
VCA operates one of the largest networks of veterinary-exclusive
diagnostic laboratories in the United States, servicing approximately 8,000
animal hospitals located in 40 states. VCA operates three full-service
laboratories located in Irvine, California (serving Southern California and the
Southwest), Valparaiso, Indiana (serving the Chicago metropolitan area and other
parts of the Midwest) and Farmingdale, New York (serving the East Coast). These
laboratories also serve as STAT (quick response) laboratories, which are in
addition to VCA's STAT laboratories located in Dallas and Houston, Texas;
Kansas City, Missouri; Phoenix, Arizona; Orlando, Florida; Reno, Nevada; San
Jose, California; and Portland, Oregon.
The veterinary laboratory industry is highly fragmented with many
local and regional competitors, as well as several large independent laboratory
companies. Veterinarians usually prefer to use laboratories that specialize in
the veterinary market and that offer individual attention, rapid test reporting
and response to inquiries by veterinary professionals, a broad spectrum of
tests, convenient sample pick-up times and customized testing services.
Because the patient cannot communicate verbally with the veterinarian,
laboratory testing is an important diagnostic tool. VCA regularly performs
numerous types of diagnostic laboratory tests, including chemistry, hematology,
cytology, anatomical pathology as well as other disease-specific tests.
Clinical tests are performed on animal fluids such as blood or urine and provide
information that is used by veterinarians for medical diagnosis. VCA does not
conduct experiments on animals and is not engaged in animal research. VCA
performs most of its clinical tests with state-of-the-art automated laboratory
testing equipment.
The first step in the testing process is for a veterinarian to take a
specimen from the patient and complete a test request form indicating the tests
to be performed on that specimen. The specimen is then picked up by the
laboratory's driver or by a commercial courier service and delivered to one of
VCA's laboratories for testing. When received at the laboratory, each specimen
and related request form is checked for accuracy and completeness and then given
a unique identification number to ensure that the results are attributed to the
appropriate animal. The test request information is entered into the
laboratory's computer system, where a file of testing and billing information is
established for each specimen. Once this information is entered, the tests are
performed by one of the laboratory technicians or by utilizing VCA's automated
testing equipment. Test results are entered into the computer system through a
computer interface or, in some instances, manually, depending upon the test and
the type of equipment used to conduct the test. Most routine testing is
completed at night and the test results are automatically transmitted via modem
or fax machine to the veterinarian before the start of business the next
morning.
VCA's STAT laboratories perform certain routine tests quickly and
report results to veterinarians within hours of being picked up from the
veterinarian. The turnaround time at VCA's STAT laboratories for reporting test
results is generally three hours or less. The STAT laboratories are located in
geographic areas where there is high concentration of veterinarians and an
airline hub-operation. VCA may establish or close STAT laboratories depending
upon the volume of tests performed and the needs of its veterinarian-clients.
In addition to testing operations, VCA provides a variety of
laboratory services to its veterinarian-clients which VCA believes enhances its
competitive position. These include:
58
<PAGE>
Reporting. Rapid turnaround of test results is critical to the
successful operation of a clinical laboratory. Usually, routine testing is
performed overnight and results are transferred to the veterinarian by
modem or fax machine before 8:00 a.m. the following day.
Specimen Transportation. VCA has developed an extensive network of
drivers and independent couriers which enables VCA to provide timely pickup
and delivery of specimens to its laboratories. Specimens are picked up
from clients and transported to VCA's laboratory facilities on a daily
basis, and in some areas, twice each day.
Client Service. Veterinarians are not obligated to use any particular
laboratory's services and can change laboratory service providers at any
time. Therefore, the services offered by a laboratory are critical to
client satisfaction and retention. In addition to emphasizing client
service through rapid turnaround time and electronic reporting, VCA has
veterinarian specialists on staff to assist the veterinarians to interpret
the lab's results, make diagnoses or treat disease. Accordingly, the
laboratories' staff of professionals includes board certified specialists
in pathology, internal medicine, oncology, cardiology, dermatology,
neurology and endocrinology.
Quality Assurance. VCA's quality assurance programs are intended to
ensure that specimens are collected and transported properly, tests are
performed accurately, and client, patient and test information is reported
and billed correctly. The quality assurance programs include testing
quality control specimens of known concentration or reactivity in order to
ensure accuracy and precision, routine checks and preventive maintenance of
laboratory testing equipment, and personnel standards which ensure that
only qualified personnel perform testing.
VCA has eight full-time sales and marketing staff in its Laboratory
segment. VCA also augments its sales force with field service representatives
whose primary responsibility is maintaining relationships with existing
customers. To support its marketing efforts, VCA, among other activities,
develops marketing literature, attends trade shows, involves itself in trade
associations and provides educational services.
Premium Pet Food
Products
Through its Vet's Choice joint venture with Heinz Pet Products, VCA
markets and distributes two lines of premium pet food. The first line of
products offered by Vet's Choice was a complete line of premium, life-stage pet
foods marketed under the brand name Select Balance. The Select Balance line
consists of dry and canned dog and cat food products nutritionally tailored to
meet the specific dietary needs of dogs and cats in different stages of their
lives. In March 1995, the joint venture commenced to market and distribute a
second product line of premium therapeutic pet foods, marketed under the brand
name Select Care. The Select Care line consists of dry and canned dog and cat
food products, nutritionally tailored to meet the specific dietary needs of dogs
and cats afflicted with illness or disease or other medical conditions requiring
special diets.
Marketing and Distribution
VCA began selling the Select Balance line of pet foods to veterinary
hospitals and clinics in the Spring of 1994. In January 1995, VCA expanded
distribution of the Select Balance line to specialty pet store and pet food
super-store markets. In March 1995, VCA commenced distribution of its Select
Care line of pet foods to veterinary hospitals and clinics. The Select Care
line may be consumed throughout all stages of an animal's life, but because of
its therapeutic attributes, the products should be used only upon the
recommendation of a veterinarian. For this reason, VCA does not intend to
expand distribution of the Select Care pet food line beyond veterinary hospitals
and clinics.
VCA markets its products to veterinary hospitals and clinics
principally through its own direct sales force. VCA's sales force generates
sales by calling on animal hospitals and assisting customers in inventory
planning, arranging and displaying VCA's products and educating the staff about
the product line. VCA intends to market its pet food to retail pet stores
jointly through its sales force and through distributors. VCA is currently
engaged in discussions with several other distributors throughout the United
States. The activities of VCA's direct sales force are supervised by a national
sales manager and three
59
<PAGE>
regional sales managers. VCA's sales force is compensated by a salary plus
commission on net sales made in their respective territories.
Knowledge and acceptance of VCA's brands by veterinarians and other
veterinary professionals is of significant importance to achieving widespread
consumer acceptance of VCA's pet products. VCA believes that its leadership
position in the animal hospital industry can therefore play a significant role
in creating customer awareness and acceptance of the Select Balance and Select
Care products. To assist in marketing its pet food products to the veterinary
community, VCA has formed affiliations with groups of veterinary professionals
in the regional markets in which it competes. These professional affiliations
are established and maintained in conjunction with VCA's Partners In Management
program, which provides discount purchasing programs, training and marketing
programs, continuing education and other professional hospital management
services to veterinary hospital owners. More than 1,300 hospitals and 5,800
animal hospital employees have joined VCA's Partners In Management program. In
addition to the Partners In Management program's promotional efforts, VCA
intends to actively participate in seminars, trade shows and professional
conferences and to contact veterinarians and clinic personnel through direct
mailings, advertising and promotional campaigns.
Manufacturing
VCA's Select Balance product line is manufactured by Heinz Pet
Products pursuant to a manufacturing agreement between Heinz Pet Products and
Vet's Choice. VCA's Select Care product line is manufactured under a contract
with an independent manufacturer located in Canada. If either Heinz Pet
Products or VCA's other manufacturer were to cease supplying VCA with product,
VCA believes it could arrange for manufacture of its product by alternate
sources.
FEES AND SOURCES OF PAYMENT
VCA's fees for provision of veterinary and laboratory services vary
upon the complexity of the required procedure, the relative involvement of the
applicable professionals and local market conditions. VCA does not incur a
significant amount of accounts receivable for the provision of veterinary
services since payment for these services is generally received at the time
services are provided. VCA offers its laboratory services and sells its pet
food on customary commercial terms, requiring payment within 30 days of the date
the service or product is performed or shipped. VCA is not dependent upon third
party payors for collection of its fees.
SYSTEMS
VCA realized the importance of management information systems in the
past and thus has made a significant investment in these systems. Currently,
substantially all of the animal hospitals operate on a common computer system
which is linked to a computer at VCA's headquarters. All of VCA's financial and
customer records and laboratory results are stored in computer databases, most
of which may be accessed by VCA's management.
The computer system provides VCA with efficient access to all
financial and operating data to monitor operating data and target marketing
programs to highly specific customer bases.
VCA intends to further upgrade and integrate its management
information system. When completed, VCA believes that this enhanced management
information system will allow for further cost savings and provide management
with a powerful tool in implementing its marketing and operating strategies.
COMPETITION
The companion animal health care industry is highly competitive. In
its Animal Hospital segment, VCA competes primarily with independent
veterinarians established in private practices or small regional multi-clinic
practices. In addition, certain national companies in the pet care industry,
including the operators of super-stores, are developing multi-regional networks
of animal hospitals in markets which include VCA's markets. The provision of
veterinary services is highly fragmented, with approximately 55,000
veterinarians nationwide practicing in an estimated 16,000 veterinary hospitals
and clinics. VCA believes that convenient location, recommendation of friends,
reasonable fees and convenient hours are the
60
<PAGE>
principal factors in a pet owner's decision as to which veterinarian to use.
VCA believes its facilities are competitive and are designed to respond to the
needs of the pet owner.
Competition in the veterinary diagnostic laboratory industry is
intense. VCA believes that there are many diagnostic laboratory companies which
provide a broad range of laboratory testing services in the same markets
serviced by VCA. Additionally, there are many animal hospitals that provide in-
house laboratory services. Competition is based primarily upon quality, price
and the time required to report results.
Competition among manufacturers of premium pet products is intense
among all segments of the dog and cat food markets. Distribution in the
veterinary practice and specialty pet shops segment is dominated by two
competitors, Hill's, which manufactures Science Diet products, and Iams, which
manufactures Iams and Eukanuba products. These companies have extensive
experience in the manufacture of premium pet food products, use highly
competitive tactics and possess research, development, manufacturing, marketing
and financial resources far greater than that of Vet's Choice. VCA believes
that its ability to penetrate these markets will be significantly enhanced by
its leadership position in the veterinary professional market and by the
experience and resources of its joint venture partner, Heinz Pet Products.
JOINT VENTURE AGREEMENTS
VCA is a party to joint venture agreements relating to the operation
of Vet Research Laboratories, LLC ("Vet Research") and Vet's Choice. The
following is a brief summary of each of these agreements.
Vet Research. In January 1995, VCA significantly expanded its
laboratory services to include coverage on the East Coast with the acquisition
of Cenvet, Inc. ("Cenvet"). VCA then contributed the Cenvet assets to a joint
venture, Vet Research, and its joint venture partner, Vet Research, Inc. ("VRI")
contributed the operations of its full service laboratory. VCA is the managing
partner in the joint venture and has a 51.0% undivided interest in Vet Research.
The operating results of Vet Research are accounted for as part of the
consolidated operations of VCA. Cash is allocated pursuant to a formula during
each contract year, whereby the first $1.5 million is allocated to VRI; the next
$3.0 million is allocated to VCA and the remaining cash is allocated 25 percent
to VCA and 75 percent to VRI. The 1995 results include minority interest
expense of 52.4 percent of Vet Research's income. VCA has the option in January
1997 to acquire the remaining 49.0 percent interest in Vet Research.
Vet's Choice. VCA entered the premium pet foods market in January
1993 when it formed Vet's Choice, a joint venture with Heinz Pet Products, an
affiliate of H.J. Heinz Company, to develop, manufacture, market, distribute and
sell premium pet products. VCA is the managing general partner in the venture,
with a 50.5% equity interest and is responsible for managing the day-to-day
operations of the partnership. Allocation of profits and losses is in
proportion to the respective interests of the partners. On or after the earlier
of a change of control in VCA or January 1, 2000, Heinz Pet Products may
purchase all of VCA's interest in the partnership at a purchase price equal to
the fair market value of such interest. If Heinz Pet Products fails to exercise
its option prior to January 1, 2001, VCA may purchase all of Heinz Pet Products'
interest in the partnership at a purchase price equal to the fair market value
of such interest. The proposed acquisition of Pet Practice will not result in a
change of control for purposes of the Vets' Choice joint venture.
In connection with the formation of Vet's Choice, Heinz Pet Products
invested $3.0 million in VCA through its purchase of 583,333 shares of non-
voting Series A Convertible Preferred Stock which, at the time of the
investment, represented an investment in ten percent of the outstanding equity
of VCA.
Other Joint Venture Arrangements. VCA also operates several of its
animal hospitals through joint ventures or partnerships with one or more of the
veterinarians employed at the facility. In each case, VCA is the majority owner
and managing partner of the joint venture. When appropriate, VCA anticipates
forming similar joint ventures in the future.
GOVERNMENT REGULATION
The operation of veterinary hospitals and laboratories is not subject
to significant government regulation. All of the states in which VCA operates,
however, impose various registration requirements. To fulfill these
requirements, VCA has properly registered each of its facilities with
appropriate governmental agencies and, where required, has appointed a licensed
veterinarian to act on behalf of each facility. All veterinary doctors
practicing in VCA's clinics are required to maintain valid,
61
<PAGE>
unexpired and unrevoked state licenses to practice. VCA believes that some
states, in which it does not currently do business, may limit the ability of a
corporation to operate facilities at which veterinary medicine is practiced. In
addition, although VCA does not anticipate significant additional government
regulation, such developments could significantly limit its business or
expansion.
VCA's growth strategy is dependent principally on its ability to
acquire existing animal hospitals and veterinary diagnostic laboratories.
Acquisitions may be subject to pre-merger or post-merger review by governmental
authorities for anti-trust and other legal compliance. Adverse regulatory
action could negatively affect VCA's operations through the assessment of fines
or penalties against VCA or the possible requirement of divestiture of one or
more of VCA's operations. In October 1995, the staff of the FTC contacted VCA
and requested information for an informal inquiry regarding VCA's formation of
its Vet Research joint venture. The staff has made no allegation of wrongdoing
on the part of VCA and has not initiated a formal investigation. VCA responded
to the staff's request and furnished all of the requested information. VCA is
not aware of the status of the inquiry.
EMPLOYEES
At December 31, 1995, VCA had approximately 1,150 full-time-equivalent
employees, including approximately 250 licensed veterinarians. None of VCA's
employees are covered by a collective bargaining agreement. VCA believes that
its relations with its employees are satisfactory.
PROPERTIES
VCA's corporate headquarters and principal executive offices for VCA
and Vet's Choice are located in Santa Monica, California, in approximately
21,000 square feet of space occupied under a lease which expires on March 3,
1999. The lease currently provides for aggregate minimum monthly rental
payments of approximately $27,000. VCA maintains leased and owned facilities at
63 other locations which house its animal hospitals and laboratories. VCA owns
12 facilities and the remainder are leased from third parties. For the year
ended December 31, 1995, VCA had lease costs of approximately $2,620,000 and VCA
expects to have lease costs at facilities existing at December 31, 1995 of
approximately $3,608,000 in 1996. Lease costs for the hospitals acquired since
December 31, 1995 will amount to approximately $364,000 in 1996. VCA believes
that its real property facilities are adequate for its current needs.
LEGAL PROCEEDINGS
VCA is not a party to any material litigation.
62
<PAGE>
EXECUTIVE OFFICERS AND DIRECTORS OF VCA
Information with respect to the directors and executive officers of
VCA as of March 31, 1996 is as follows:
<TABLE>
<CAPTION>
Name Age Position
- ---- --- --------
<S> <C> <C>
Robert L. Antin........... 46 Chairman of the Board and Chief Executive
Officer
of VCA
Arthur J. Antin........... 49 Chief Operating Officer, Senior Vice President,
Secretary and Director
Neil Tauber............... 45 Senior Vice President
Tomas W. Fuller........... 38 Chief Financial Officer, Vice President and
Assistant Secretary
Deborah W. Moore.......... 31 Chief Accounting Officer, Vice President and
Controller
John B. Chickering, Jr.... 47 Director
Richard Gillespie, M.D.... 62 Director
John A. Heil.............. 42 Director
</TABLE>
Robert L. Antin and Arthur J. Antin are brothers. There are no other
family relationships between any director and/or any executive officer of VCA.
MR. ROBERT L. ANTIN, a founder of VCA, has served as Chief Executive
Officer, President and Chairman of the Board of VCA since its inception. Mr.
Antin is responsible for directing all aspects of VCA's business. From
September 1983 until founding VCA, Mr. Antin was President, Chief Executive
Officer, a director and co-founder of AlternaCare Corp., a publicly held company
which owned, operated and developed free-standing outpatient surgical centers.
AlternaCare Corp. was acquired by Medical Care International in 1988. From July
1978 until September 1983, Mr. Antin was employed as an officer by American
Medical International, Inc. ("AMI"), an owner and operator of health care
facilities. While at AMI, Mr. Antin initially served as Director of Marketing
of Professional Hospital Services, then as Director of New Business Development
responsible for non-hospital related acquisitions and development, and most
recently as a Vice President of AMI and President of AMI Ambulatory Center,
Inc., a subsidiary of AMI operating a chain of ambulatory care centers. Mr.
Antin received his MBA degree with a certification in hospital and health
administration from Cornell University in 1975.
MR. ARTHUR J. ANTIN, a founder of VCA, has served as Chief Operating
Officer, Senior Vice President, Secretary and a Director of VCA since its
inception, and is currently responsible for managing animal hospital and
veterinary laboratory operations for VCA. From October 1983 to September 1986,
Mr. Antin served as Director of Marketing/Investor Relations of AlternaCare
Corp., in which he developed and implemented marketing strategies for a network
of outpatient surgical centers. Mr. Antin received an M.A. degree in Community
Health from New York University and a Post Graduate Certificate in Structured
Programming and Business Application design from Columbia University.
MR. NEIL TAUBER, a founder of VCA, has served as Senior Vice President
and a Director of VCA since its inception and is currently responsible for
identifying and effecting the acquisition of independent animal hospitals and
veterinary diagnostic laboratories. From 1984 to 1986, Mr. Tauber served as the
Director of Corporate Development at AlternaCare Corp., where his
responsibilities included the acquisition of new businesses and syndication to
hospitals and physician groups. From 1981 to 1984, Mr. Tauber served as Chief
Operating Officer of MDM Services, a wholly owned subsidiary of Mediq, a
publicly held health care company, where he was responsible for operating and
developing a network of retail dental centers and industrial medical clinics.
Mr. Tauber holds an MBA from Wagner College.
MR. TOMAS W. FULLER joined VCA in January 1988 and served as Vice
President and Controller until November 1990 when he became Chief Financial
Officer. Prior to joining VCA, from 1980 to 1987, Mr. Fuller served as an audit
manager
63
<PAGE>
for Arthur Andersen LLP. Mr. Fuller holds a BA degree in business/economics
from the University of California at Los Angeles (UCLA).
MS. DEBORAH W. MOORE, a Certified Public Accountant, joined VCA in
September 1992 and served as Controller until becoming Vice President, Chief
Accounting Officer in 1995. Ms. Moore served as a staff accountant at Arthur
Andersen LLP and subsequently as Controller for Chiat/Day/Mojo Inc. prior to
joining VCA. Ms. Moore holds a BA in Economics/Accounting from Claremont
McKenna College.
MR. JOHN B. CHICKERING, JR., a Certified Public Accountant, is
currently the Vice President - Financial Administration for Warner Bros.
International Television Distribution. Prior to his employment at Warner Bros.,
Mr. Chickering served as a staff accountant at KPMG Peat Marwick from August
1975 to June 1977. Mr. Chickering holds an MBA degree with emphasis in
accounting and finance from Cornell University. Mr. Chickering has served as a
Director of VCA since November 1988.
RICHARD GILLESPIE, M.D., was elected to the Board of Directors in June
1995. Dr. Gillespie is a private investor who has investments in several
companies in the United States. From 1983 to 1987, Dr. Gillespie was Vice-
President, a director and co-founder of AlternaCare Corp. Dr. Gillespie also
has served as a director for several other companies, including Lansinoh
Laboratories, Inc. and Geriatric Medical Center, and as the general partner of
Outpatient Diagnostics Center. Dr. Gillespie holds an MD degree from the
University of Tennessee College of Medicine.
MR. JOHN A. HEIL, currently serves as the Vice President-Marketing for
Heinz Pet Products. Since 1978, Mr. Heil has served in various capacities with
other affiliates of the H.J. Heinz Company, including General Manager, Marketing
of Ore-Ida Foods, Inc. and Vice President - Marketing and Sales of Star-Kist
Foods, Inc. Mr. Heil holds a B.A. degree in economics from Lycoming College.
Mr. Heil has served as a Director of VCA since May 1995.
BOARD MEETINGS AND COMMITTEES
The VCA Board held a total of four meetings during the fiscal year
ended December 31, 1995. The VCA Board has an Audit Committee and a
Compensation Committee. The VCA Board does not have a Nominating Committee or a
committee performing similar functions. During the fiscal year ended December
31, 1995, each director attended at least 75% of the meetings of the VCA Board
held while he was a director and of the Committees of the VCA Board on which he
served.
The Audit Committee met one time and the Compensation Committee met
two times during the fiscal year ended December 31, 1995. The Audit Committee's
functions include recommending to the VCA Board the engagement of VCA's
independent auditors, reviewing and approving the services performed by the
independent auditors and reviewing and evaluating VCA's accounting policies and
internal accounting controls. The Compensation Committee reviews and approves
the compensation of officers and key employees and determines and approves the
granting of options under VCA's various stock incentive plans. During the
fiscal year ended December 31, 1995, the members of the Audit Committee were
Messrs. Robert L. Antin and John B. Chickering, Jr.; and the members of the
Compensation Committee were Messrs. John B. Chickering, Jr. and Richard
Gillespie, M.D. Mr. Jean-Charles Lignel also served on the Compensation
Committee during a portion of fiscal 1995. Mr. Lignel is no longer a director
of VCA.
COMPENSATION OF DIRECTORS
Directors of VCA who are not also employees of VCA receive $1,000 for
each meeting of the VCA Board that they attend in person plus reimbursement of
all out-of-pocket expenses incurred in attending such meetings. In addition,
non-employee directors, John B. Chickering, Jr., John Heil, Richard Gillespie
and former non-employee director Jean-Charles Lignel each were granted options
to purchase 10,000 shares of VCA Common Stock upon appointment or election to
the VCA Board. On the respective anniversaries of their joining the VCA Board,
each of the current non-employee directors, if they retain such status, will
receive an additional option to purchase 5,000 shares of VCA Common Stock.
64
<PAGE>
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
During the last fiscal year, executive compensation and the grant of
options under VCA's various stock incentive plans was administered by the
Compensation Committee of the VCA Board. The directors of the Corporation who
served on the Compensation Committee were Robert L. Antin, Jean-Charles Lignel
and John B. Chickering, Jr. Mr. Robert L. Antin is the Chairman of the Board
and Chief Executive Officer of VCA. None of Messrs. Lignel, Chickering or Heil
is, nor has any of them ever been, an officer or employee of VCA. Mr. Lignel is
no longer a director of VCA.
REPORT OF THE COMPENSATION COMMITTEE
The following report of the Compensation Committee to the VCA Board
shall not be deemed to be included in or incorporated by reference into any
filing by VCA under the Act or the Exchange Act including any filing that
incorporates Securities Act or Exchange Act filings in whole or in part by
reference.
GENERAL
The Compensation Committee of the VCA Board (the "Committee") is
responsible for establishing and administering the policies that govern
executive compensation for executive officers and key employees of VCA.
COMPENSATION PHILOSOPHY
VCA's executive compensation program is designed to (1) provide levels
of compensation that integrate pay and incentive plans with VCA's strategic
goals so as to align the interests of executive management with the long-term
interests of VCA's stockholders; (2) attract, motivate and retain executive
talent capable of achieving the strategic business goals of VCA; (3) recognize
outstanding individual contributions; and (4) provide compensation opportunities
which are competitive to those offered by other companies of similar size and
performance. To achieve these goals, VCA's executive compensation program
consists of three main elements: (i) base salary, (ii) annual cash bonus and
(iii) long-term incentives. Each element of compensation has an integral role
in the total executive compensation program.
BASE SALARY
Base salaries for executive officers are determined on an annual basis
by evaluating each executive officer's, including Mr. Robert Antin's, position,
duties, responsibilities, tenure, performance and potential contributions to
VCA. This determination also takes into account the Committee's assessment of
competitive compensation packages for comparable positions in the Southern
California market. The Committee made no formal survey of similarly situated
companies but instead relied upon the general experience of its members and
information supplied by management in assessing the appropriate levels of base
compensation. The financial performance of VCA is also considered. Finally,
factors consistent with VCA's overall compensation policy are taken into
account.
VCA also provides to its employees (including Mr. Robert Antin and the
other officers) medical insurance and other customary employee benefits. VCA
pays term life insurance premiums for the benefit of Messrs. Robert Antin,
Arthur Antin, Neil Tauber and Tomas Fuller, which amounted in fiscal 1995 to
approximately $29,100, $20,640, $17,400 and $11,300, respectively.
ANNUAL CASH BONUSES
Historically, executive officers have been eligible for annual
incentive bonuses in amounts determined at the discretion of the Committee. In
fiscal 1995, the Committee determined to place greater weight on long-term
incentives represented by stock options than on the award of annual cash
bonuses. Consequently, with the concurrence of the executive officers, VCA
awarded no cash bonuses to the executive officers with respect to fiscal 1995
and, in lieu thereof, provided larger individual stock option grants than had
historically been the case. The Committee intends that annual cash bonuses be
part of VCA's long-term executive compensation program and may elect to continue
the practice in fiscal 1996 and subsequent years. Historically, the Committee
has considered an award of an annual bonus subjectively, taking into account
factors such as the financial performance of VCA, increases in stockholder
value, the enhancement of VCA's image and reputation, expansion into new
65
<PAGE>
markets, and the achievement of corporate goals and individual performance. The
Committee has attributed various weights to these factors based upon their
perceived relative importance to VCA at the time compensation determinations
were made.
LONG-TERM INCENTIVES
The Committee provides VCA's executive officers with long-term
incentive compensation through grants of stock options. The Committee is
responsible for selecting the individuals to whom grants should be made, the
timing of grants, the determination of the per share exercise price and the
number of shares subject to each option awarded. The Committee believes that
stock options provide VCA's executive officers with the opportunity to purchase
and maintain an equity interest in VCA and to share in the appreciation of the
value of the VCA Common Stock. The Committee believes that stock options
directly motivate an executive to maximize long-term stockholder value. The
options incorporate vesting periods in order to encourage key employees to
continue in the employ of VCA. All options granted to executive officers during
fiscal 1995 were granted at the fair market value of the VCA Common Stock on the
date of grant. The Committee considers the grant of each option (including
those granted to Mr. Robert Antin) subjectively, considering factors such as the
individual performance of executive officers and competitive compensation
packages in the industry.
CHIEF EXECUTIVE OFFICER
Mr. Robert Antin's base salary ($265,000 for fiscal 1996) and the size
of the stock option grants during fiscal 1995 (options to purchase an aggregate
of 280,000 shares of VCA Common Stock) were determined based upon Mr. Robert
Antin's services to VCA and the financial performance of VCA in the fiscal year
ended December 31, 1995. The most important criteria relied upon by the
Committee was its assessment of the leadership and vision provided by Mr. Antin
in securing substantial progress toward the achievement of VCA's long-term
strategic goals. In particular, the Committee took into account the significant
expansion of VCA's presence in the veterinary laboratory business in 1995 and
the expansion of its premium line of pet food to include therapeutic foods. In
addition, VCA continued its successful acquisition program in the veterinary
hospital industry. Further, VCA achieved significant liquidity with the
completion of a secondary offering of its Common Stock in November 1995.
SUMMARY
The Committee believes that its executive compensation philosophy of
paying VCA's executive officers by means of base salaries, annual cash bonuses
and stock option grants, as described in this report, serves the interests of
VCA and VCA's stockholders.
Compensation Committee: John B. Chickering, Jr.
Richard Gillespie, M.D.
Jean Charles Lignel
66
<PAGE>
SUMMARY COMPENSATION TABLE
The following table shows, as to the Chief Executive Officer and as to
each of the other three most highly compensated executive officers (the "Named
Executive Officers") whose salary plus bonus exceeded $100,000 during the last
fiscal year, information concerning all compensation paid for services to VCA in
all capacities during the last three fiscal years.
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
LONG TERM
ANNUAL COMPENSATION COMPENSATION
------------------------------------------------------------------
NAME AND PRINCIPAL OTHER ANNUAL STOCK OPTION ALL OTHER
POSITION YEAR SALARY BONUS COMPENSATION (1) AWARDS (2) COMPENSATION
- -------------------------- ---- --------- ----------- ---------------- -------------- ------------
<S> <C> <C> <C> <C> <C> <C>
Robert L. Antin 1995 $ 241,091 $ -0- $ 8,800 280,000 -0-
Chairman of the Board 1994 205,730 30,890 (3) 9,600 25,000 -0-
and Chief Executive 1993 196,978 -0- 12,000 90,000 -0-
Officer
Arthur J. Antin 1995 170,915 -0- 7,200 140,000 -0-
Chief Operating 1994 146,953 21,480 (3) 7,200 25,000 -0-
Officer, Senior 1993 139,742 -0- 6,000 50,000 -0-
Vice President
and Secretary
Neil Tauber 1995 144,038 -0- 7,200 120,000 -0-
Senior Vice 1994 120,000 17,592 (3) 7,200 25,000 -0-
President 1993 115,896 -0- 6,000 50,000 -0-
Tomas W. Fuller 1995 101,214 -0- 6,000 110,000 -0-
Chief Financial Officer 1994 92,500 13,090 (3) 6,000 10,000 -0-
and Vice President 1993 88,883 -0- 6,000 50,000 -0-
- ----------
</TABLE>
(1) Includes automobile allowance.
(2) All numbers reflect the number of shares of VCA Common Stock subject to
options granted during the fiscal year.
(3) Reflects bonus awards granted in March 1995 for services rendered during
the fiscal year ended December 31, 1994.
67
<PAGE>
OPTION GRANTS IN LAST FISCAL YEAR
The following table sets forth certain information regarding grants of stock
options made during the fiscal year ended December 31, 1995 to the Named
Executive Officers:
<TABLE>
<CAPTION>
OPTION GRANTS IN LAST FISCAL YEAR
INDIVIDUAL GRANTS
------------------------------------------------------------------
Potential Realizable Value at Assumed
Percent of Total Annual Rates of Stock Price Appreciation for
Number of Options Granted Exercise or Option Term (1)
Options to Employees In Base Price Expiration --------------------------------------------
Name Granted (2) Fiscal Year (3) Per Share (4) Date 5% 10%
- ------------------ ------------- ---------------- ------------- ---------- ------------- --------------
<S> <C> <C> <C> <C> <C> <C>
Robert L. Antin 80,000 9.4% $10.50 3/4/05 $ 528,271 $1,338,744
200,000 23.4% 12.38 11/7/05 1,556,514 3,944,513
Arthur J. Antin 40,000 4.7% 10.50 3/4/05 264,136 669,372
100,000 11.7% 12.38 11/7/05 778,257 1,972,256
Neil Tauber 40,000 4.7% 10.50 3/4/05 264,136 669,372
80,000 9.4% 12.38 11/7/05 622,606 1,577,805
Tomas W. Fuller 40,000 4.7% 10.50 3/4/05 264,136 669,372
70,000 8.2% 12.38 11/7/05 544,780 1,380,579
- ---------------------
</TABLE>
(1) The potential realizable value is based on the assumption that the VCA
Common Stock appreciates at the annual rate shown (compounded annually)
from the date of grant until the expiration of the option term. These
amounts are calculated pursuant to applicable requirements of the
Commission and do not represent a forecast of the future appreciation of
VCA Common Stock.
(2) The option grants set forth on this chart which expire on March 4, 2005 and
November 7, 2005 are exercisable in thirty-six (36) and twenty-four (24)
equal monthly installments, respectively, commencing on the date of grant.
The options may, at the discretion of the administrator of the stock option
plan pursuant to which such options were granted, become immediately
exercisable upon certain change of control events. The options set forth
above were each granted for a term of 10 years.
(3) Options covering an aggregate of 854,750 shares were granted to eligible
optionees during the fiscal year ended December 31, 1995.
(4) The exercise price and tax withholding obligations related to exercise may
be paid by delivery of already owned shares, subject to certain conditions.
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR END OPTION
VALUES
The following table sets forth, for each of the Named Executive Officers,
certain information regarding the exercise of stock options during the fiscal
year ended December 31, 1995 and the value of unexercised options at December
31, 1995 based upon the closing price of the VCA Common Stock on the Nasdaq
National Market on December 29, 1995 ($16.875 per share).
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR
AND FISCAL YEAR-END OPTION VALUES
<TABLE>
<CAPTION>
NUMBER OF SECURITIES VALUE OF ALL UNEXERCISED
SHARES ACQUIRED UNDERLYING UNEXERCISED IN-THE-MONEY OPTIONS AT FISCAL
ON VALUE OPTIONS AT FISCAL YEAR-END YEAR END(1)
NAME EXERCISE REALIZED EXERCISABLE/UNEXERCISABLE EXERCISABLE/UNEXERCISABLE
- ----------------- ---------------- -------- -------------------------- --------------------------------
<S> <C> <C> <C> <C>
Robert L. Antin -0- -0- 165,750/274,584 $1,992,407/$1,448,193
Arthur J. Antin -0- -0- 130,111/147,889 1,669,647/840,128
Neil Tauber -0- -0- 117,027/127,639 1,464,306/745,464
Tomas W. Fuller -0- -0- 116,361/104,306 1,480,689/615,042
</TABLE>
68
<PAGE>
EMPLOYMENT AGREEMENTS
On January 1, 1994, VCA entered into employment agreements with each of Robert
L. Antin, Arthur J. Antin, and Neil Tauber, which currently expire on December
31, 1998. Pursuant to the terms of these agreements, during the fiscal year
ended December 31, 1996, Messrs. Robert L. Antin, Arthur J. Antin and Neil
Tauber will receive an annual base salary of $265,000, $189,000 and $162,000,
respectively. This base salary is subject to annual upward adjustment at the
discretion of the VCA Board, with a mandatory annual increase by a percentage
amount at least equal to the cost of living increase. In addition, the VCA
Board has determined that executive officers of VCA may earn bonuses during each
calendar year based upon management achieving performance goals established by
the Compensation Committee of the VCA Board on an annual basis. VCA may
terminate each of the employment agreements for cause or upon mutual agreement.
In each of these employment agreements, events constituting "termination by the
employee for cause" include (i) the willful breach of any of the material
obligations of VCA to the employee under his employment agreement; (ii) the
relocation of the chief executive offices of VCA outside of Los Angeles County,
California; or (iii) in the case of employees who also serve as members of the
VCA Board, the failure of the employee to be reelected to, or the removal of the
employee from, the VCA Board. Events constituting "termination by VCA for
cause" include (i) conviction of the employee of any felony involving the
embezzlement, theft or misappropriation of monies or other property or moral
turpitude, or the employee's commission of any fraud or embezzlement against VCA
or any of its subsidiaries; or (ii) the willful and continued neglect by the
employee of his duties under the employment agreement which continues for 60
days following receipt by the employee of written notice. Both the employee and
VCA have the right immediately to terminate the employment agreement without
cause by delivery of written notice of the termination to the other.
If employment is terminated due to death, the agreements provide that VCA will
pay the affected employee severance pay equal to two years' salary. If
employment is terminated due to the disability of the employee, without cause or
if VCA's principal executive office is moved from Los Angeles, the affected
employee is entitled to severance pay in an amount equal to three years' base
salary. If employment is terminated due to a change in control of VCA, the
affected employee is entitled to severance pay in an amount equal to the greater
of (a) three years' base salary and (b) the base salary such employee would have
received during the period between the date of such employee's termination and
the scheduled expiration date of his employment agreement. If employment is
terminated due to the scheduled expiration of an employment agreement, the
affected employee is entitled to severance pay in an amount equal to one year's
base salary. "Change of control" is defined in each of these agreements to
include (a) a consolidation or merger of VCA into another entity in which VCA is
not the continuing or surviving corporation or pursuant to which shares of VCA
Common Stock would be converted into cash, securities or other property, other
than a merger of VCA in which the VCA stockholders immediately prior to the
merger have the same proportionate ownership of common stock of the surviving
corporation immediately after the merger, (b) any sale, lease or other transfer
of all or a significant portion of the assets of VCA, (c) the approval by the
VCA stockholders of any plan or proposal for the liquidation or dissolution of
VCA, (d) the ownership by any person, who at the effective date of the
employment agreement owned less than 10% of the VCA Common Stock, of 20% or more
of the VCA Common Stock or (e) during any consecutive two year periods,
individuals who at the beginning of such period constitute the entire VCA Board
shall cease for any reason to constitute a majority thereof unless the election,
or the nomination for election by the VCA stockholders, of each new director was
approved by a vote of at least two-thirds of the directors then still in office
who were directors at the beginning of the period.
In April 1992, VCA entered into an agreement with Tomas W. Fuller, Chief
Financial Officer, Vice President and Assistant Secretary of VCA, pursuant to
which it agreed that if Mr. Fuller's employment is terminated without cause (as
defined above), VCA will pay to Mr. Fuller severance pay equal to six months'
salary.
COMPLIANCE WITH SECTION 16(A) OF THE SECURITIES EXCHANGE ACT
Section 16(a) of the Exchange Act requires VCA's executive officers, directors
and persons who own more than ten percent of a registered class of VCA's equity
securities to file reports of ownership and changes in ownership with the
Commission. Executive officers, directors, and greater-than-ten percent
stockholders are required by the regulations of the Commission to furnish VCA
with copies of all Section 16(a) forms they file. Based solely on its review of
the copies of such forms received by it, VCA believes that, during the year
ended December 31, 1995, all relevant Section 16(a) filing requirements were
complied with, except as follows: Ms. Moore, an executive officer, filed one
report late relating to her position as an executive officer; Mr. Gillespie, a
director, filed one report late relating to his position as a director; Mr.
Fuller,
69
<PAGE>
an executive officer, filed one report late for a transaction involving the sale
of 1,500 warrants and a transaction involving the grant of an option to purchase
40,000 shares of VCA Common Stock; Mr. Robert L. Antin, an executive officer and
director, filed one report late involving nine separate transactions relating to
the sale, in the aggregate, of 25,500 warrants and the grant of an option to
purchase 80,000 shares of VCA Common Stock and one report late involving three
separate transactions relating to the sale, in the aggregate, of 30,000
warrants. VCA is aware of no other failures to file required forms.
STOCK PERFORMANCE GRAPH
COMPARISON OF 50 MONTH CUMULATIVE TOTAL RETURN*
AMONG VETERINARY CENTERS OF AMERICA, INC., THE NASDAQ STOCK
MARKET - US INDEX AND THE RUSSELL 2000 INDEX
[PERFORMANCE GRAPH APPEARS HERE]
* $100 INVESTED ON 10/10/91 IN STOCK OR ON 09/30/91 IN INDEX -INCLUDING
REINVESTMENT OF DIVIDENDS FISCAL YEAR ENDING DECEMBER 31.
<TABLE>
<CAPTION>
Cumulative Total Return
------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C>
10/91 12/91 12/92 12/93 12/94 12/95
Veterinary Ctrs. Amer. Inc. VCAI 100 69 116 116 149 300
NASDAQ STOCK MARKET - US INAS 100 112 130 150 146 207
RUSSELL 2000 IR20 100 106 126 149 146 188
</TABLE>
70
<PAGE>
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF VCA
The following table sets forth certain information provided by VCA regarding
beneficial ownership of VCA Common Stock as of May 20, 1996 and as adjusted to
reflect the issuance of 3,272,993 shares of VCA Common Stock in connection with
the Merger by (i) each director and Named Executive Officer of VCA; (ii) each
person known to VCA to be the beneficial owner of more than 5% of the
outstanding VCA Common Stock, and (iii) all directors and executive officers of
VCA as a group. Except as may be indicated in the footnotes to the table, each
of such persons has the sole voting and investment power with respect to the
shares owned, subject to applicable community property laws. The address of each
person listed is in care of VCA, 3420 Ocean Park Boulevard, Suite 1000, Santa
Monica, California 90405, unless otherwise set forth below such person's name.
<TABLE>
<CAPTION>
PERCENT OF CLASS PERCENT OF CLASS
OWNED OWNED
NAME AND ADDRESS NUMBER OF SHARES(1) PRIOR TO MERGER AFTER MERGER(2)
- ------------------------------ --------------------- ------------------- ----------------
<S> <C> <C> <C>
Savannah Investments Limited 950,000 7.2% 5.7%
Kirk House, 4th Floor
Grand Cayman
British West Indies
The TCW Group, Inc. 730,500 5.5% 4.4%
865 South Figueroa Street
Los Angeles, California 90017
Robert L. Antin (3) 854,563 6.4% 5.0%
Arthur J. Antin (4) 339,398 2.5% 2.0%
Neil Tauber (5) 191,472 1.4% 1.1%
Tomas W. Fuller (6) 120,390 * *
John B. Chickering, Jr. (7) 13,333 * *
Richard Gillespie, M.D. (8) 20,000 * *
John A. Heil -- -- --
All of VCA's executive officers and 1,541,156 11.1% 8.8%
directors as a group (8 persons)
(3)(4)(5)(6)(7)(8)(9)
- ------------------------------------
</TABLE>
* Less than one percent.
(1) Under Rule 13d-3 of the Exchange Act, certain shares may be deemed to be
beneficially owned by more than one person (if, for example, persons share
the power to vote or the power to dispose of the shares). In addition,
shares are deemed to be beneficially owned by a person if the person has the
right to acquire the shares (for example upon exercise of an option) within
60 days of the date as of which the information is provided. In computing
the percentage ownership of any person, the amount of shares outstanding is
deemed to include the amount of shares beneficially owned by such person
(and only such person) by reason of these acquisition rights. As a result,
the percentage of outstanding shares of any person as shown in this table
does not necessarily reflect the person's actual ownership or voting power
with respect to the number of shares of VCA Common Stock actually
outstanding at May 20, 1996.
(2) Assumes the issuance of 3,272,993 shares of VCA Common Stock in the Merger
in exchange for 8,632,520 shares of Pet Practice Common Stock, including
8,800 shares of Pet Practice Common Stock underlying options which were
exercisable on, or which will become exercisable within, 60 days of May 20,
1996.
(3) Includes (i) 101,866 shares held by Mr. Robert Antin's minor children and
(ii) 248,805 shares of VCA Common Stock reserved for issuance upon exercise
of stock options which are or will become exercisable on or prior to July
19, 1996.
71
<PAGE>
(4) Includes (i) 50,000 shares which Mr. Arthur J. Antin holds as custodian for
Mr. Robert L. Antin's minor children under the California Uniform Gifts to
Minor's Act, (ii) 43,666 shares held by Mr. Arthur J. Antin's minor
children; and (iii) 175,139 shares of VCA Common Stock reserved for issuance
upon exercise of stock options which are or will become exercisable on or
prior to July 19, 1996.
(5) Includes 156,472 shares of VCA Common Stock reserved for issuance upon
exercise of stock options which are or will become exercisable on or prior
to July 19, 1996.
(6) Consists of 120,390 shares of VCA Common Stock reserved for issuance upon
exercise of stock options which are or will become exercisable on or prior
to July 19, 1996.
(7) Consists of 13,333 shares of VCA Common Stock reserved for issuance upon
exercise of stock options which are or will become exercisable on or prior
to July 19, 1996.
(8) Includes (i) 5,000 shares of VCA Common Stock underlying warrants, and (ii)
10,000 shares of VCA Common Stock reserved for issuance upon exercise of
stock options which are or will become exercisable on or prior to July 19,
1996.
(9) Includes, with respect to other executive officers, 2,000 shares of VCA
Common Stock reserved for issuance upon exercise of stock options which are
or will become exercisable on or prior to July 19, 1996.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
GENERAL
Founded in 1986, VCA is a leading companion animal health care company
operating in the markets for veterinary care, veterinary diagnostic laboratories
and premium pet food. VCA made its first animal hospital acquisition in
December 1986, when it acquired West Los Angeles Animal Hospital, one of the
largest privately-owned teaching animal hospitals in the United States. Between
1987 and 1992, VCA's operations were directed primarily at establishing a
corporate infrastructure and building a network of animal hospitals in selected
regional markets. During this period, VCA grew with the acquisition of 17
additional animal hospitals and one veterinary diagnostic laboratory.
In 1993, VCA implemented its current business strategy and began to expand
the scope of its operations in order to realize its goals of integrating the
markets for veterinary care, veterinary diagnostic laboratories and premium pet
food. The integration of these three markets is the foundation of VCA's
business strategy to leverage its access to its primary customers, veterinarians
and pet owners. From January 1, 1993 through December 31, 1995, VCA acquired
and integrated into its operations 36 animal hospitals. Also in 1993, VCA
entered into a joint venture called Vet's Choice, with Heinz Pet Products, an
affiliate of H.J. Heinz Company to develop, manufacture and market a full-line
of premium pet food. In March 1994, VCA expanded its veterinary diagnostic
laboratory operations by acquiring a 70 percent interest in Professional Animal
Laboratory ("PAL"). In January 1995, VCA acquired an additional veterinary
diagnostic laboratory, Cenvet, Inc. ("Cenvet"), which it then contributed in
March 1995 for a 51 percent interest in a joint venture, Vet Research
Laboratories, LLC ("Vet Research"), which combined the operations of Cenvet with
that of a full-service veterinary laboratory known as Vet Research, Inc.
("VRI"). In 1995, VCA further expanded its veterinary diagnostic laboratory
operations by acquiring three smaller, regional veterinary diagnostic
laboratories and by purchasing the remaining 30 percent interest in PAL and four
smaller laboratories.
RECENT DEVELOPMENTS
For a discussion of recent developments see "Business of VCA--Recent
Developments."
ANTICIPATED EFFECTS OF ACQUISITIONS
VCA is currently evaluating the operations of the businesses of Pet
Practice and Pets' Rx for purposes of developing a plan for the integration of
the businesses to be acquired with VCA's existing operations. Although this
plan is not complete
72
<PAGE>
at the time of the mailing of this Joint Proxy Statement/Prospectus, it is
anticipated that a significant restructuring of the combined operations will be
required as a result of the mergers. As a consequence of this restructuring and
the consummation of the mergers, VCA anticipates incurring one-time
restructuring and related charges in the second and/or third quarters of 1996.
The magnitude of these charges has not been quantified at this time.
The Pets' Rx acquisition is intended to be accounted for on a pooling of
interests basis. Under the pooling rules, the historical financial results of
VCA will be restated to reflect the combination, following certain adjustments.
Pets' Rx incurred a loss in each of the three fiscal years ended December 31,
1995 and in the first quarter ended March 31, 1996. Following the consummation
of the merger, the historical results of VCA will be restated to reflect the
historical losses of Pets' Rx. In addition, Pets' Rx is expected to continue to
incur losses in the second quarter of 1996. Further, under the pooling rules,
the costs incurred by VCA and Pets' Rx in consummating the merger will be
expensed during the second quarter.
The Pet Practice Merger is intended to be accounted for as a purchase.
Under the purchase rules, the Merger is expected to result in a significant
increase in the goodwill and other intangibles recorded on VCA's balance sheet.
This increase in goodwill and other intangibles will be in addition to the
increase resulting from the combination with Pets' Rx, which also has
significant goodwill and other intangibles recorded on its balance sheet. As a
result, VCA expects that its amortization expense will significantly increase
over historical levels.
The combined effect of the restructuring and other charges discussed above,
the pooling treatment in the Pets' Rx acquisition and the increased amortization
expense will have an adverse effect on the results of operations of VCA in each
of the second and third quarters of 1996. Further, the effect of the increased
amortization expense is expected to temper reported earnings of VCA in the
fourth quarter and subsequent periods.
BASIS OF REPORTING
VCA reports its operations in three business lines--Animal Hospital,
Laboratory and Premium Pet Food. Animal Hospital operations include the
operations of VCA's animal hospitals. Laboratory operations include the
operations of VCA Lab (merged into PAL in March 1994), PAL (acquired in March
1994), Cenvet (from the date acquired, January 1, 1995 through the formation of
Vet Research in March 1995), Vet Research and five smaller veterinary
laboratories since the date of acquisition. VCA acquired the remaining 30
percent interest in PAL from its minority interest partner effective July 1,
1995. VCA currently owns a 51 percent interest in Vet Research. Premium Pet
Food includes the operations of the Vet's Choice joint venture of which VCA owns
a 50.5 percent interest. During 1993, Vet's Choice was primarily engaged in
developing and testing the formulas for its first product line, Select Balance,
and building a marketing infrastructure in anticipation of commencing
distribution in 1994. Vet's Choice began to generate revenue in March 1994 with
the launch of Select Balance. In 1995, Vet's Choice began selling its second
product line, Select Care. VCA's operating results include the results of
operations of the joint ventures on a consolidated basis.
VCA's animal hospitals use VCA's veterinary diagnostic laboratory services
and purchase and resell the pet food products of Vet's Choice. Revenue and the
corresponding expense from intercompany sales totaling $1,727,000, $759,000,
$344,000 in 1995, 1994, 1993, respectively, and $278,000 and $733,000 in the
three months ended March 31, 1995 and 1996, respectively, have been eliminated
from VCA's operating results.
73
<PAGE>
RESULTS OF OPERATIONS
Three months ended March 31, 1996 compared to three months ended March 31, 1995.
Revenues
The following table summarizes VCA's revenues for each of the three month
periods ended March 31:
<TABLE>
<CAPTION>
1996 1995
------------ -----------
<S> <C> <C>
Animal Hospital $17,831,000 $ 9,150,000
Laboratory 12,056,000 5,817,000
Premium Pet Food 1,850,000 541,000
Intercompany Sales (733,000) (278,000)
----------- -----------
$31,004,000 $15,230,000
=========== ===========
</TABLE>
Revenues for the Animal Hospital operations increased 94.9% from 1995
to 1996. This growth was primarily the result of growth in the number of
facilities owned and operated by VCA. The results for 1996 include the results
of 20 veterinary hospitals acquired from April 1, 1995 to December 31, 1995, and
the results, from the date of acquisition, for an additional seven veterinary
hospitals acquired during the first quarter of 1996. The increase in revenues
resulting from changes in volume or prices at existing facilities was
approximately 9.1%.
Revenues of the Laboratory operations increased 107.3% from 1995 to
1996 due to the inclusion of a full quarter of Vet Research operations and the
acquisition of six other veterinary diagnostic laboratories since March 31,
1995.
Vet's Choice began generating revenues in March 1994 when it commenced
commercial distribution of Select Balance through VCA's network of owned animal
hospitals. Distribution was expanded nationally to independent veterinary
hospitals in selected regional markets beginning in the second quarter of 1994.
In April 1995, Vet's Choice commenced distributing its second product line,
Select Care, a complete line of therapeutic diets.
Gross Profit
Gross profit for each of the three month periods ended March 31, is
comprised of the following:
<TABLE>
<CAPTION>
1996 1995
---------- ---------
<S> <C> <C>
Animal Hospital $2,441,000 $1,488,000
Laboratory 4,670,000 1,747,000
Premium Pet Food 690,000 186,000
---------- ----------
$7,801,000 $3,421,000
========== ==========
</TABLE>
Gross profit of the Animal Hospital operations represents the
contribution from the hospital operations and is comprised of revenues less all
costs of services and products at the hospitals, including salaries of
veterinarians, technicians and all other hospital-based personnel, facilities
rent and occupancy costs and medical supply costs and costs of goods sold
associated with the retail sales of pet food and pet supplies. Animal Hospital
gross profit increased 64.0% from 1995 to 1996, representing 16.3% and 13.7% of
Animal Hospital revenues in 1995 and 1996 respectively. The decrease in gross
profit as a percentage of revenues from 1995 to 1996 was primarily attributable
to increased supply costs.
Gross profit of the Laboratory operations is comprised of revenues
less all direct costs of services at the laboratory, including salaries of
veterinarians, technicians and other non-administrative laboratory-based
personnel, facilities rent and occupancy costs and supply costs. As a
percentage of revenues, laboratory gross profit was 30.0% and 38.7% of revenues
in
74
<PAGE>
1995 and 1996, respectively. The increase in gross profit as a percentage of
revenue from 1995 to 1996 was primarily attributable to the inclusion of a full
quarter of Vet Research operations in 1996.
Gross profit of Premium Pet Food is comprised of revenues less cost of
goods sold, including warehousing, freight and distribution costs. Gross profit
as a percentage of revenues in 1995 and 1996 was 34.4% and 37.2%, respectively.
The Laboratory and Premium Pet Food operations are expected to
continue to carry gross profit margins that are higher than the Animal Hospital
operations. Consequently, historical gross profit margins for VCA as a whole
may not be indicative of those to be expected in the future.
Selling, General and Administrative Expenses
VCA Corporate selling, general and administrative expense consists of
administrative expense at VCA's headquarters, including the salaries of
corporate officers and other personnel, accounting, legal and other professional
expense and rent and occupancy.
Selling, general and administrative expense for each of the three
month periods ended March 31, is comprised of the following:
<TABLE>
<CAPTION>
1996 1995
---------- ----------
<S> <C> <C>
VCA Corporate $1,279,000 $ 827,000
Laboratory 915,000 500,000
Premium Pet Food 1,120,000 935,000
---------- ----------
$3,314,000 $2,262,000
========== ==========
</TABLE>
VCA Corporate and Laboratory selling, general and administrative
expense, as a percentage of Animal Hospital and Laboratory revenues, was 8.9%
and 7.3% in 1995 and 1996, respectively. The decrease from 1995 to 1996 was
primarily attributable to spreading the expenses over a larger revenue base.
Premium Pet Food selling, general and administrative expense as a
percentage of Premium Pet Food revenues was 172.8% and 60.5% in 1995 and 1996,
respectively. The decrease as a percentage of revenue was primarily
attributable to spreading the expenses over a larger revenue base.
Depreciation and Amortization
Depreciation and amortization expense primarily relates to the
depreciation of capital assets and the amortization of excess cost over the fair
value of net assets acquired (goodwill) and certain other intangibles.
Depreciation and amortization expense increased from $548,000 in 1995 to
$1,034,000 in 1996. VCA's policy is to amortize goodwill over the expected
period to be benefited, not exceeding forty years. The increase in depreciation
and amortization expense is primarily due to the acquisition of hospitals and
laboratories.
Restructuring Charge
The operations of Cenvet (acquired January 1, 1995) were merged into
Vet Research Inc.'s operations to form Vet Research Laboratories. The combined
operations were restructured to eliminate duplicate operating and overhead
costs. In connection with the restructuring, VCA recorded a charge of
$1,086,000 in the first quarter of 1995 to accrue the estimated costs associated
with the restructuring, consisting primarily of lease termination and severance
costs.
75
<PAGE>
Year ended December 31, 1996 compared to year ended December 31, 1995.
The following table sets forth, for the periods indicated, the
percentage of certain items in relation to revenues.
<TABLE>
<CAPTION>
Percentage of Revenues
For the Years Ended December 31,
--------------------------------
1995 1994 1993
------ ----- -----
<S> <C> <C> <C>
Revenues.................................. 100.0% 100.0% 100.0%
Direct costs.............................. 73.3 75.9 80.3
----- ----- -----
Gross profit.............................. 26.7 24.1 19.7
Selling, general and administrative....... 11.8 16.4 15.2
Depreciation and amortization............. 3.5 3.5 3.8
Restructuring charge...................... 1.2 -- --
Writedown of assets....................... -- -- 9.1
----- ----- -----
Operating income (loss)................... 10.2 4.2 (8.4)
Interest income........................... 0.8 0.9 1.7
Interest expense.......................... 2.6 3.3 3.4
----- ----- -----
Income (loss) before minority interest,
income taxes and cumulative effect of
accounting change......................... 8.4 1.8 (10.1)
Minority interest in income (loss)
of subsidiaries........................... 3.2 (1.3) (1.3)
----- ----- -----
Income (loss) before income taxes and
cumulative effect of accounting change..... 5.2 3.1 (8.8)
Provision (benefit) for income taxes...... 2.4 1.7 (0.6)
----- ----- -----
Income (loss) before cumulative effect
of accounting change...................... 2.8 1.4 (8.2)
Cumulative effect of accounting change.... -- -- 0.9
----- ----- -----
Net income (loss)......................... 2.8% 1.4% (7.3)%
===== ===== =====
</TABLE>
Revenues
Revenues in 1993 were derived primarily from VCA's Animal Hospital
operations. Laboratory revenues increased significantly with the acquisition of
PAL in March 1994 and Cenvet in January 1995 and the subsequent formation of the
Vet Research joint venture in March 1995. Also in March 1994, Premium Pet Food
began to generate revenues from the sale of Vet's Choice's first product line,
Select Balance.
Animal Hospital operations represented approximately 54.8%, 74.1% and 95.2%
of total Company revenues in 1995, 1994 and 1993, respectively. Laboratory
operations represented 40.1%, 23.6% and 4.8% of total Company revenues in 1995,
1994 and 1993, respectively. Premium Pet Food operations represented 5.1% and
2.3% of total Company revenues in 1995 and 1994, respectively. VCA anticipates
that Animal Hospital revenues as a percentage of total revenues will continue to
decline in future periods as a result of the expansion of VCA's Laboratory
operations in 1994 and 1995 and the anticipated growth in sales of Select
Balance and Select Care.
The following table summarizes VCA's revenues for each of the three years
in the period ended December 31, 1995:
76
<PAGE>
<TABLE>
<CAPTION>
1995 1994 1993
----------- ----------- -----------
<S> <C> <C> <C>
Animal Hospital $51,437,000 $31,846,000 $24,423,000
Laboratory 37,606,000 10,150,000 1,234,000
Premium Pet Food 4,756,000 996,000 --
Intercompany Sales (1,727,000) (759,000) (344,000)
----------- ----------- -----------
$92,072,000 $42,233,000 $25,313,000
=========== =========== ===========
</TABLE>
Revenues of the Animal Hospital operations increased 30.4% from 1993 to
1994 and 61.5% from 1994 to 1995. This growth was primarily the result of
growth in the number of facilities owned and operated by VCA. The increase in
revenues resulting from changes in volume or prices at facilities operated
during all of 1994 and 1995 was 6.0%.
Revenues of the laboratory operations increased from 1993 to 1994 due to
the acquisition of PAL in March 1994. Revenues increased 270.5% in 1995 due
primarily to the acquisition of Cenvet and to the formation of the Vet Research
joint venture in March 1995.
Prior to 1994, the Vet's Choice Premium Pet Food operations was primarily
engaged in developing and testing the formulas for its first product line and
building a marketing infrastructure in anticipation of commencing distribution
in 1994. Vet's Choice began generating revenues in March 1994 when it commenced
commercial distribution of Select Balance through VCA's network of animal
hospitals in March 1994. Distribution was expanded nationally to independent
veterinary hospitals in selected regional markets beginning in the second
quarter of 1994. Vet's Choice revenue increased further in 1995 with the
introduction of Select Care in the beginning of 1995.
Gross Profit
The following table summarizes VCA's gross profit for each of the three
years in the period ended December 31, 1995:
<TABLE>
<CAPTION>
1995 1994 1993
----------- ----------- ----------
<S> <C> <C> <C>
Animal Hospital $ 9,381,000 $ 6,252,000 $4,946,000
Laboratory 13,629,000 3,577,000 42,000
Premium Pet Food 1,551,000 349,000 --
----------- ----------- ----------
$24,561,000 $10,178,000 $4,988,000
=========== =========== ==========
</TABLE>
Animal Hospital gross profit represents the contribution from the Animal
Hospital operations and is comprised of revenues less all costs of services and
products at the animal hospitals, including salaries of veterinarians,
technicians and all other hospital-based personnel, facilities rent and
occupancy costs and medical supply costs. Animal Hospital gross profit increased
from $4,946,000 in 1993 to $6,252,000 in 1994 and to $9,381,000 in 1995,
increases of $1,306,000 or 26.4% and $3,129,000 or 50.0%, respectively. As a
percentage of Animal Hospital revenues, gross profit decreased from 20.3% in
1993 to 19.6% in 1994 and 18.2% in 1995. The decrease in gross profit
contributed by Animal Hospitals as a percentage of Animal Hospital revenues from
1993 to 1994 and to 1995 was attributable primarily to the lower gross profit
margins at the newly acquired facilities and, additionally in 1995, to the
effect of a promotional campaign designed to expand the customer base.
Laboratory gross profit is comprised of revenues less all direct costs of
services at the veterinary diagnostic laboratories, including salaries of
veterinarians, technicians and other non-administrative laboratory-based
personnel, facilities rent and occupancy costs and supply costs. Laboratory
gross profit increased from $42,000 in 1993 to $3,577,000 in 1994 and to
$13,629,000 in 1995, an increase of $3,535,000 and $10,052,000, respectively.
As a percentage of Laboratory revenues, gross profit contributed by Laboratory
operations increased from 3.4% in 1993 to 35.2% in 1994 and to 36.2% in 1995.
The increase in the gross profit contributed by Laboratory operations as a
percentage of revenues in 1994 over 1993 was attributable to the acquisition of
PAL in March 1994 and the positive effects of combining the operations of VCA
Lab into the PAL operations and, for 1995, the acquisition of Cenvet and the
formation of Vet Research in January and March 1995, respectively.
77
<PAGE>
Premium Pet Food gross profit is comprised of revenues less cost of goods
sold, including freight and distribution costs. Premium Pet Food gross profit
totaled $349,000 in 1994 and $1,551,000 in 1995. As a percentage of revenues,
gross profit was 35.0% in 1994 and 32.6% in 1995. The decrease in gross profit
as a percent of revenue was attributable to the release of Select Care in 1995,
which has lower gross profit margins than Select Balance. Gross profit also
decreased in 1995 due to increased sales to distributors which have lower gross
profit margins than sales to veterinary hospitals, which were VCA's primary
source of sales in 1994.
Laboratory and Premium Pet Food are expected to continue to realize gross
profit margins that are higher than that of the Animal Hospital line of
business. Consequently, as these businesses represent an increasing percentage
of VCA's revenues, historical gross profit margins for VCA as a whole may not be
indicative of those to be expected in the future.
Selling, General and Administrative Expenses
The following table sets forth VCA's selling, general and administrative
expense for each of the three years in the period ended December 31, 1995:
<TABLE>
<CAPTION>
1995 1994 1993
----------- ---------- ----------
<S> <C> <C> <C>
VCA Corporate $ 3,826,000 $2,762,000 $2,248,000
Laboratory 2,921,000 737,000 --
Premium Pet Food 4,086,000 3,428,000 1,614,000
----------- ---------- ----------
$10,833,000 $6,927,000 $3,862,000
=========== ========== ==========
</TABLE>
VCA Corporate selling, general and administrative expense consists of
administrative expense at VCA's headquarters, including the salaries of
corporate officers and other personnel, accounting, legal and other
professional expense, and rent and occupancy costs. VCA Corporate selling,
general and administrative expense increased from $2,248,000 in 1993 to
$2,762,000 in 1994, and to $3,826,000 in 1995, increases of $514,000 or 22.9%,
and $1,064,000 or 38.5% respectively. As a percentage of revenues, VCA
Corporate general and administrative expense decreased from 9.2% in 1993 to 8.7%
in 1994 and 7.4% in 1995. The decreases from 1993 to 1995 are primarily
attributable to spreading the expenses over a larger revenue base.
Laboratory selling, general and administrative expense consists primarily
of sales and administrative personnel and selling, marketing and promotional
expense. Laboratory selling, general and administrative expense increased to
$2,921,000 for the year ended December 31, 1995 from $737,000 for the comparable
period in 1994, an increase of $2,184,000. As a percentage of Laboratory
revenues, Laboratory selling, general and administrative expense increased to
7.8% for the year ended December 31, 1995 from 7.3% for the comparable period
in 1994. The increase in selling, general and administrative expense is
primarily attributable to the addition of Cenvet in January 1995 and the
formation of Vet Research in March 1995.
Premium Pet Food selling, general and administrative expense consists
primarily of sales and administrative personnel and selling, marketing and
promotional expense. Premium Pet Food general and administrative expense
increased from $3,428,000 in 1994 to $4,086,000 in 1995, an increase of $658,000
or 19.2%. The increases from 1994 to 1995 were primarily attributable to
additional sales and administrative personnel and increases in marketing and
promotional expenses associated with the launch of Select Balance in March 1994
and the launch of Select Care in April 1995. The general and administrative
expense in 1993 included $709,000 of general, administrative and start-up costs
and $905,000 of research and product development costs associated with the
development of Select Balance.
Depreciation and Amortization
Depreciation and amortization expense primarily relates to the depreciation
of capital assets and the amortization of excess cost over the fair value of net
assets acquired (goodwill) and certain other intangibles. Depreciation and
amortization expense increased from $956,000 in 1993 to $1,455,000 in 1994 and
to $3,291,000 in 1995, representing 3.8%, 3.5% and 3.5% of revenue in 1993, 1994
and 1995, respectively. VCA's policy is to amortize goodwill over the expected
period to be benefited, not exceeding forty years. The increase in depreciation
and amortization expense is primarily due to the acquisition of animal hospitals
and veterinary diagnostic laboratories.
78
<PAGE>
Restructuring Charge
The operations of Cenvet were merged into VRI's operations to form Vet
Research in March 1995. The combined operations were restructured to eliminate
duplicate operating and overhead costs. The restructuring included the
consolidation of facilities, staff reductions and the consolidation of ancillary
operations. In connection with the restructuring, VCA recorded a charge of
$1,086,000 in the first quarter of 1995 to accrue the estimated costs associated
with the restructuring, consisting primarily of lease termination and severance
costs.
Writedown of Assets
During 1993, VCA charged $2,310,000 to operations related to a writedown of
goodwill and certain intangible assets at three of VCA's facilities. The three
facilities that were written down in 1993 will collectively have a net loss in
1996 of approximately $100,000. VCA's goal in 1996 and 1997 is to minimize the
facilities' cash flow requirements and ultimately bring the facilities to a
breakeven status. Management of VCA believes that VCA's strategy of building a
network of animal hospitals is served by continuing to operate these animal
hospitals even though the facilities themselves may not generate profits.
Operating Income
Operating income increased from a loss of $2,140,000 in 1993 to income of
$1,796,000 in 1994 and to $9,351,000 in 1995, an increase of $3,936,000 in
1994 and $7,555,000 in 1995. The increases primarily reflect higher operating
income at most of VCA's animal hospitals and veterinary diagnostic laboratories,
increased pet food sales and an increase in the number of animal hospitals and
veterinary diagnostic laboratories owned and operated by VCA. As a percentage of
revenues, operating income increased from a loss of 8.4% in 1993 to income of
4.2% in 1994 and to 10.2% in 1995.
The operating loss in 1993 resulted from a $2,310,000 writedown of goodwill
and certain other intangible assets at three of VCA's facilities (see Notes 2
and 13 of Notes to Consolidated Financial Statements). Operating income in 1995
includes the restructuring charge of $1,086,000 (see Note 14 of Notes to
Consolidated Financial Statements). Operating income (loss) in 1993, 1994 and
1995 also includes the operating losses of Vet's Choice amounting to $1,614,000,
$3,094,000 and $2,573,000, respectively. Excluding these items, operating
income would have increased from $1,784,000 in 1993 to $4,890,000 in 1994 and to
$13,010,000 in 1995, an increase of $3,106,000 and $8,120,000 in 1994 and 1995,
respectively. As a percentage of revenue, operating income would have been 7.0%
in 1993, 11.6% in 1994 and 14.6% in 1995.
Interest Income
Interest income decreased from $448,000 in 1993 to $366,000 in 1994 and
increased to $729,000 in 1995, a decrease of $82,000 or 18.3% and an increase of
$363,000 or 99.2%, respectively. These changes are primarily due to changes in
VCA's average daily cash balances. As a percentage of revenues, interest income
decreased from 1.7% in 1993 to 0.9% in 1994 and to 0.8% in 1995.
Interest Expense
Interest expense increased from $873,000 in 1993 to $1,382,000 in 1994 and
$2,368,000 in 1995, increases of $509,000 or 58.3% and $986,000 or 71.3%,
respectively. These increases are primarily due to increases in VCA's
outstanding indebtedness incurred for acquisitions. As a percentage of
revenues, interest expense decreased from 3.4% in 1993 to 3.3% in 1994 and 2.6%
in 1995.
Income Taxes
Income taxes were $2,238,000, $731,000 and ($152,000) in 1995, 1994 and
1993, respectively. A reconciliation of the provision for income taxes for 1994
and 1995 to the amount computed at the Federal statutory rate is included in
Note 11 of Notes to Consolidated Financial Statements. VCA's effective income
tax rate for 1995 was higher than the statutory rate and VCA expects that its
effective income tax rate may be higher than the statutory rate in the future
primarily due to the nondeductibility for income tax purposes of the
amortization of goodwill at certain of VCA's facilities. In addition, VCA's
effective tax rate was higher than the statutory rate for 1993 due to the
nondeductibility of the writedown of assets.
79
<PAGE>
Minority Interest
Minority interest in income (loss) of the consolidated subsidiaries was
$2,910,000, ($540,000) and ($334,000) in 1995, 1994 and 1993, respectively. The
increase is primarily due to the earnings of the Vet Research joint venture and
the reduced losses of Vet's Choice.
LIQUIDITY AND CAPITAL RESOURCES
VCA's operations require continued access to cash, primarily to fund
acquisitions, reduce long-term debt obligations and to fund property and
equipment additions.
Cash provided by operations during the years ended December 31, 1995, 1994
and 1993 and the three months ended March 31, 1996 and 1995 was $4,056,000,
$1,472,000, $1,592,000, $1,332,000 and $41,000 respectively. VCA's operating and
the three months ended March 31, 1996 and 1995 cash flow was adversely impacted
by the Vet's Choice joint venture, which had a net cash outflow of $3,043,000,
$2,878,000, $133,000, $717,000 and $1,087,000 in the same periods. Excluding the
Vet's Choice operations, cash provided by operations in the years ended December
31, 1995, 1994 and 1993 and the three months ended March 31, 1996 and 1995 was
$7,099,000, $4,350,000, $1,725,000, $2,049,000 and $1,128,000 respectively.
During 1995, 1994, 1993 and the three months ended March 31, 1996 in
connection with acquisitions, VCA used cash in the amounts of $9,107,000
(acquisition of 25 hospitals, six veterinary diagnostic laboratories and the
remaining 30 percent interest in PAL), $5,948,000 (acquisition of five animal
hospitals and one veterinary diagnostic laboratory), $1,021,000 (acquisition
of six animal hospitals) and $9,875,000 (acquisition of seven animal hospitals
and one veterinary diagnostic laboratory). Additionally, in 1995, 1994 and 1993,
VCA paid $250,000, $60,000 and $250,000 to acquire options to purchase the land
and building of five facilities. From April 1, 1996 through June 19, 1996, VCA
used $3,739,000 in connection with the acquisition of four animal hospitals and
two veterinary diagnostic laboratories.
During these same periods VCA used $2,067,000, $1,052,000, $649,000 and
$948,000 to purchase additions to property and equipment and $4,971,000,
$2,494,000, $1,553,000 and $3,000,000 to reduce long-term obligations.
In January 1995, Star-Kist Foods, Inc. through its Heinz Pet Products
division, purchased 1,159,420 shares of VCA Common Stock at $8.625 per share,
resulting in net proceeds to VCA of $9,980,000. In November 1995, VCA completed
a secondary public offering of 2,965,026 shares of VCA Common Stock for net
proceeds of approximately $33,932,000. Also in 1995, VCA received net proceeds
of $8,896,000 in connection with the exercise of 1,271,508 of its redeemable
warrants. In connection with the formation of Vet Research in March 1995, VCA
issued warrants to purchase 363,636 shares of VCA Common Stock at $11.00 per
share (the "Vet Research warrants"). The warrants were purchased at $0.001 per
warrant and are exercisable until the fifth day following the last date upon
which VCA is permitted to close the purchase of the remaining 49% interest.
During 1995, VCA received $550,000 in connection with the exercise of 50,000 of
these warrants. In the three months ended March 31, 1996, VCA received net
proceeds of $5,330,000 in connection with the exercise of its warrants.
In April 1996, VCA received net proceeds of $82,697,000 related to the
sale, in an offshore offering and concurrent private placement in the United
States, of $84,385,000 of 5.25% convertible subordinated debentures due in 2006.
The debentures, non-callable for three years, will be convertible into
approximately 2.5 million shares of VCA's common stock at a rate of $34.35 per
share.
VCA has a $3.1 million unsecured line of credit. The line of credit is at
the bank prime rate and converts to a 36-month term loan at December 18, 1996,
is not removed. At March 31, 1996, VCA had $3.1 million available under the
line.
Of its cash and equivalents on hand at December 31, 1995 and 1994, and
March 31, 1996 approximately $1,907,000, $2,982,000 and $1,134,000 respectively,
was restricted for use by Vet's Choice. In 1996, Vet's Choice used $773,000 of
cash, primarily for increases in inventory and cost of sales. During the year
ended December 31, 1995, Vet's Choice used $3,075,000 of cash to fund its
operating losses, the opening of three regional warehouses, marketing and
promotional expenses and an increase in its sales force. In 1994, Vet's Choice
used $2,839,000 of cash primarily for start-up and operational costs. As
provided for in the Joint Venture Agreement, VCA and Heinz Pet Products each
contributed $1.0 million to Vet's Choice in the third quarter of 1995. In May
1996, VCA and Heinz Pet Products contributed $1,010,000 and $990,000,
respectively to Vets' Choice. As sales of Premium Pet Food grow, Vet's Choice
will require additional cash to fund its working capital requirements (primarily
inventory and accounts receivable). Heinz Pet Products has agreed to lend Vet's
Choice up to $1.0 million at its bank prime rate plus one-half percent to assist
in meeting these working capital needs. Vet's Choice, however, may require
additional equity or debt financing. If Vet's Choice is unable to obtain debt
financing on favorable terms, it may be necessary for VCA to make additional
capital contributions to the venture.
80
<PAGE>
VCA, Pet Practice and Pets' Rx have each incurred substantial indebtedness
to finance the acquisition of their respective animal hospitals and (in the case
of VCA) veterinary diagnostic laboratories. Giving effect to debt incurred in
acquisitions subsequent to March 31, 1996 through June 20, 1996 (excluding the
acquisition of Pets' Rx), VCA had at March 31, 1996, consolidated long-term
obligations (including current portion) of approximately $38.8 million. Pet
Practice had at April 3, 1996 consolidated long-term obligations (including
current portion) of approximately $20.0 million. At March 31, 1996, Pets' Rx had
consolidated long-term obligations (including current portion) of $10.4 million.
In addition, on April 17, 1996, VCA issued subordinated debt in an aggregate
principal amount of $84.4 million (the "Debentures"). At December 31, 1995 and
March 31, 1996, VCA's ratio of long-term debt to total stockholders' equity was
36.3% and 36.4%, respectively. As of March 31, 1996, after giving effect to the
Transactions and the sale of the Debentures, the ratio of long-term debt to
total stockholders' equity will be 82.8%. VCA expects to incur additional
indebtedness in the future to continue its acquisition strategy.
VCA has achieved its growth in the past, and anticipates it will continue
its growth in the future, through the acquisition of animal hospitals and
veterinary diagnostic laboratories for cash, stock and notes payable.
VCA intends to fund its future cash requirements primarily from cash on
hand, internally generated funds, the net proceeds from the exercise of its
warrants (which, if all were exercised, would generate approximately $9.9
million of cash), and borrowings on VCA's $3.1 million unsecured line of credit.
VCA believes these sources of funds will be sufficient to continue VCA's
operations and planned capital expenditures for at least the next 12 months. A
significant portion of VCA's cash requirements is determined by the pace and
size of its acquisitions. Consequently, VCA may need to obtain additional debt
or equity financings. The type, timing and cash needs, the availability of
other financing sources and prevailing conditions in the financial markets.
81
<PAGE>
NEW ACCOUNTING PRONOUNCEMENTS
In March 1995, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 121 "Accounting for the Impairment of Long-
Lived Assets and for Long-Lived Assets to be Disposed Of." The Statement
requires that long-lived assets and certain identifiable intangibles held and
used by an entity be reviewed for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be
recoverable. The Statement has been adopted by VCA effective January 1996. VCA
does not expect implementation of this statement to have a material effect on
its financial position or its results of operations.
In November 1995, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standards No. 123 "Accounting for Stock-Based
Compensation." The Statement recommends changes in accounting for employee
stock-based compensation plans, and requires certain disclosures with respect to
these plans. The Statement's disclosures have been adopted by VCA effective
January 1, 1996.
SEASONALITY AND QUARTERLY FLUCTUATIONS
Although not readily detectable because of the impact of acquisitions,
VCA's operations are somewhat seasonal. In particular, revenues at VCA's animal
hospitals historically have been greater in the second and third quarters than
in the first and fourth quarters. The demand for VCA's veterinary services are
significantly higher during warmer months because pets spend a greater amount of
time outdoors, where they are more likely to be injured and are more susceptible
to disease and parasites. In addition, use of veterinary services may be
affected by levels of infestation of fleas, heartworms and ticks, the number of
daylight hours, as well as general economic conditions. VCA expects its
veterinary laboratory operations to experience the same seasonality as its
animal hospitals. A substantial portion of VCA's costs are fixed and do not
vary with the level of demand. Consequently, net income for the second and
third quarters, at individual animal hospitals, generally has been higher than
that experienced in the first and fourth quarters. However, should Premium Pet
Food sales increase and become a larger percentage of VCA's total revenue, VCA
expects these seasonality factors will be reduced.
The following table sets forth revenues, gross profit and operating income
for each of the quarters since January 1, 1994:
<TABLE>
<CAPTION>
QUARTER ENDED
----------------------------------------------------
DECEMBER 31, SEPTEMBER 30, JUNE 30, MARCH 31,
1995 1995 1995 1995
------------ ------------ -------- ---------
<S> <C> <C> <C> <C>
1995
Revenues........... $26,646 $26,917 $23,279 $15,230
Gross profit....... 6,798 7,632 6,710 3,421
Operating income... 2,850 2,781 3,109 611(1)
<CAPTION>
QUARTER ENDED
-------------------------------------------------------
DECEMBER 31, SEPTEMBER 30, JUNE 30, MARCH 31,
1994 1994 1994 1994
--------------- ------------- --------- ---------
<S> <C> <C> <C> <C>
1994
Revenues........... $11,108 $11,842 $11,370 $ 7,913
Gross profit....... 2,878 3,282 2,642 1,376
Operating income... 538 1,330 220 (292)
</TABLE>
__________
(1) Before a restructuring charge of $1,086,000. Including the effect of this
charge, the operating loss would have been $475,000.
INFLATION
Historically, VCA's operations have not been materially affected by
inflation. However, if Premium Pet Food sales increase and become a larger
percentage of VCA's total revenue, VCA expects inflation to have a minimal
impact on its
82
<PAGE>
operations in the event that raw material prices and other market conditions
change. VCA intends to pass increased costs on to its customers through price
increases, although VCA may not be able to adjust its prices immediately. There
can be no assurance that VCA's operations will not be affected by inflation in
the future.
83
<PAGE>
BUSINESS OF PET PRACTICE
GENERAL
Pet Practice owns and operates veterinary care group practices. Pet
Practice is one of the largest and fastest growing providers of companion animal
veterinary care in the United States. Pet Practice typically establishes
comprehensive networks that include day clinics and 24-hour emergency/acute care
clinics. In certain markets, Pet Practice also provides pet boarding and
grooming services. Pet Practice believes it is currently one of the few
companies pursuing a national strategy of consolidating veterinary care group
practices in an effort to create comprehensive veterinary care networks. Pet
Practice currently operates 84 veterinary clinics in 11 states. Of those 84
clinics, 54 operate in three established networks, 18 operate in one network in
the integration stage and 12 operate in two networks still in the development
stage. All of Pet Practice's services are provided on a fee-for-service basis
and customers generally remit payment at the time services are delivered.
Pet Practice was founded in October 1993 through the acquisition of 15
clinics in Detroit, Michigan. Since that time, Pet Practice has refined its
operating model, put in place the existing management team and, as of April 3,
1996, completed the acquisition of 71 additional clinics and opened one newly
built clinic. The majority of Pet Practice's management team and the Pet
Practice Board have had extensive experience in the strategic development of
public companies in fragmented service industries, including the development and
implementation of acquisition and integration strategies. In addition, members
of Pet Practice's management team have had substantial experience in marketing
and brand name development.
THE VETERINARY SERVICES INDUSTRY
Veterinary care in the U.S. is provided by veterinarians, generally
assisted by veterinary technicians. Veterinarians are graduates of four-year
accredited veterinary schools and, in most states, become licensed to practice
veterinary medicine upon passing national board examinations. They diagnose and
treat animal illnesses and injuries, perform surgeries, provide check-ups and
prescribe medication. Some veterinarians specialize by type of medicine, such as
orthopedics, dentistry, ophthalmology and dermatology, and many specialize by
type of animal.
There are approximately 115 million dogs and cats in the United States with
over 50% of American households owning at least one dog or cat. According to
industry studies, Americans spent over $7 billion on veterinary services for
companion animals and $2 billion on boarding and grooming services in 1993 out
of approximately $20 billion spent on pet care. Industry studies also indicate
that over the past decade, the veterinary services market has grown at a
compound annual rate of approximately 9%.
84
<PAGE>
STRATEGY
Pet Practice's strategy is to develop extensive veterinary care delivery
networks in selected geographic markets. Pet Practice believes that by
developing a comprehensive care delivery network in a market, it can improve
convenience to the customer, generate significant cost advantages, deliver
higher quality care and increase its attractiveness to customers and employees.
Each of Pet Practice's established networks includes a number of "spoke"
day clinics that serve as referral locations to one or more strategically
located 24 hour emergency/acute care "hub" clinics. In some markets, Pet
Practice also provides related services such as boarding and grooming. Pet
Practice's 24 hour "hub" clinics typically are larger than "spoke" clinics,
utilize sophisticated medical equipment and employ specialists as well as
primary care veterinarians. "Spoke" day clinics typically are open from 7 a.m.
to 7 p.m. and are designed to provide routine wellness and sick care services.
Pet Practice believes that its comprehensive networks provide significant
opportunities to cross-refer customers between "hub" and "spoke" clinics as well
as to Pet Practice's boarding and grooming programs.
Pet Practice typically establishes a "pedestal" position in a market
through the acquisition of a quality-oriented veterinary group practice with a
significant market presence, an experienced team of veterinarians, a strong
local reputation and future growth potential. Pet Practice then densifies the
region around the pedestal through complementary acquisitions of practices
sharing many of the qualities of the pedestal.
Once Pet Practice has established a network of sufficient size in a
particular geographic market, it seeks to grow internally in that market. Pet
Practice promotes internal growth through (i) implementing sales and marketing
programs designed to attract new customers, (ii) creating a consumer recognized
brand name image for its veterinary services, (iii) expanding services to
existing customers, (iv) enhancing convenience to customers by offering seven-
day, extended and 24-hour service, (v) increasing productivity of veterinarians
through improved support by technicians, and by freeing them from certain
administrative tasks, (vi) enhancing the medical sophistication of services
through the addition of specialists, and (vii) selective start-ups of new
veterinary clinics. By establishing substantial networks and marketing
aggressively, Pet Practice seeks to become the most convenient and most
recognized provider of veterinary services in each of its markets.
PATIENT SERVICES
Pet Practice provides a full range of veterinary and ancillary services
through six networks in 11 states, which encompass 84 clinics. The following
table illustrates the locations where Pet Practice is providing services:
<TABLE>
<CAPTION>
Number
of
Network Location Clinics Network Status
- ---------------- ------- --------------
<S> <C> <C>
Metropolitan Detroit (Michigan, Northern Ohio)................. 24 Established
Metropolitan Indianapolis (Indiana, Southern Ohio)............. 10 Established
Metropolitan Chicago (Illinois, Northern Indiana).............. 20 Established
Florida........................................................ 18 Integration Stage
Mid-Atlantic (Delaware, Maryland, West Virginia, New Jersey, 9 Development Stage
Eastern Ohio)...............................................
Massachusetts.................................................. 3 Development Stage
--
Total.......................................................... 84
==
</TABLE>
Veterinarians are the principal provider of veterinary services, often
assisted by technicians. Pet Practice seeks to optimize the balance between
veterinarians and technicians in the performance of veterinary services.
Veterinary specialists are utilized in each network on an internal and external
referral basis.
Pet Practice provides a broad range of services including wellness care,
puppy and kitten starter services encompassing spaying or neutering, vaccination
series and exams, and adult pet well care for routine health care and parasite
prevention. Sick care is Pet Practice's primary service and ranges from single
visits to complicated treatment regimens and surgeries, sometimes involving
veterinary specialists. Emergency 24 hour care at selected facilities is another
of Pet Practice's important services,
85
<PAGE>
often involving intensive care, complex orthopedic and other procedures. Many of
Pet Practice's clinics also provide important ancillary services, particularly
boarding and grooming.
Considerable seasonality of demand for veterinary services exists in the
northern half of the United States, where a majority of Pet Practice's
facilities are located. Pet Practice has significantly higher revenues during
warmer months because pets spend more time outdoors, where they are more likely
to be injured and are susceptible to diseases and parasites, which are more
prevalent during that time of the year. In the future, to the extent that Pet
Practice develops more southern networks and installs programs to diminish the
effects of seasonality in the northern states, Pet Practice believes that
seasonality of demand will have less of an impact on revenues.
NETWORK DEVELOPMENT
To date, Pet Practice is developing networks in markets where it
believes there are attractive veterinary service demographics and has targeted
those markets based on concentration of pet ownership, population density and
number of veterinarians. Based on these demographics, Pet Practice's initial
network development has focused on the Upper Midwest, the Mid-Atlantic region
and Florida. However, as Pet Practice becomes larger, it may pursue selectively
the acquisition of large regional pedestal group practices throughout the United
States.
As Pet Practice completes acquisitions in a target market it begins the
process of integrating them into comprehensive pet health care delivery networks
of "hub and spoke" clinics. The initial pedestal acquisition in a target market
generally provides one or more major clinics that can be transformed into
network "hub" clinics, while densification acquisitions generally provide
"spoke" clinics. Efforts are made to improve services and business performance
through such initial activities as modifying hours of service, changing the mix
of services, providing customer service training and improving facilities and
equipment. Attention also is given to personnel matters including introduction
of Pet Practice's benefit programs, Pet Practice corporate culture and
productivity enhancements such as balancing veterinarian/technician ratios and
payroll as a function of seasonality.
Pet Practice's established networks have "hub" clinics and "spoke"
clinics, and sometimes ancillary services such as boarding and grooming.
Following is a summary of the types of services provided by clinics in
established networks.
. "Hub" Clinics. "Hub" clinics are strategically located throughout
a region and are open 24-hours per day year round. These clinics are
typically larger than "spoke" clinics and offer a full range of
services including wellness, sick animal care, surgery, specialties
such as orthopedics, dentistry, and oncology, emergency care, and in
some instances boarding and grooming. Accordingly, each "hub" clinic
also serves as a "center of excellence" on clinical matters. Cross-
referrals and consultations among the clinics are encouraged. The
"hub" clinic generally offers convenience and services greater in
scope than the individual veterinarian practitioner can offer.
. "Spoke" Clinics. Four or more "spoke" day clinics typically surround
the "hub" clinic and are generally located within 15 miles of the
"hub". "Spokes" are approximately one-half the size of "hubs" and are
open typically from 7 a.m. to 7 p.m. "Spokes" provide routine wellness
and sick care and refer special emergency and after-hours cases to the
"hub" clinics. In some instances, "spoke" clinics also offer boarding
and grooming.
. Ancillary Services. Each network may be further enhanced by ancillary
services such as kennels (of which Pet Practice currently operates
one) and grooming. In a pet services network, kennels, which provide
boarding of pets for short or extended stays, enhance Pet Practice's
overall services in concert with the clinics. In addition, kennels and
certain clinics offer grooming services, including bathing, hair
clipping and nail clipping. Some clinics in the network are unable to
provide boarding and grooming due to local ordinances or space
limitations. Other clinics offer limited service in cages without the
benefits of exercise room or luxury services. For more comprehensive
services, the clinics will be able to refer to the network kennels
(which may be located at a clinic site) as these are developed. These
ancillary services, in turn, are expected to increase the loyalty of
network service users through continuum of care.
86
<PAGE>
MARKETING
Marketing is an important method of attracting customers through various
advertising and sales promotion programs and maintaining their loyalty through
Pet Practice's customer service culture.
Advertising and Sales Promotions
Marketing and advertising programs for the majority of independent
veterinary practices are generally unsophisticated. Independent veterinary
practices have traditionally relied on location, tenure, word-of-mouth and
limited advertising (e.g. Yellow Pages) as the primary means of attracting new
customers. While Pet Practice will also depend on these techniques to develop
and maintain its customer base, management intends to use more sophisticated
marketing and advertising to attract new customers and maximize service to
existing customers. Therefore, considerable investment has been made in brand
name, logo and signage development.
A focus of Pet Practice's advertising is women between the ages of 25
and 54, who tend to be the predominant customers for pet care services. Pet
Practice targets two types of customers: (i) the relationship customer who
visits a veterinary clinic for all veterinary care one or two times per year and
(ii) the emergency customer who visits a veterinary clinic (particularly a 24-
hour "hub" clinic) because a pet is suddenly ill or injured.
Pet Practice utilizes television advertising to attract new customers,
increase 24-hour emergency service awareness and to build its brand name
recognition within a metropolitan community. Television advertising has been
shown to be effective in creating brand name awareness and in building image.
Pet Practice's television advertising reinforces Pet Practice's image as a
provider of convenient, friendly and caring, high-quality and comprehensive
veterinary services.
Radio advertising focuses the potential customer's attention on
specific, important, seasonal care issues (e.g. heartworm prevention in dogs).
Such advertisements remind listeners to check the Yellow Pages for the nearest
Pet Practice location. Furthermore, the Yellow Pages are generally effective as
a means of attracting emergency customers.
For customer convenience, Pet Practice seeks high-traffic locations with
attractive signage for its clinics. Pet Practice has invested heavily in highly
visible free standing signage with a common clinic sign and logo which
reinforces its brand name image. This same sign and logo are reinforced through
in-clinic signage and print and television advertising. Each city with multiple
practice/clinic locations benefits from the exposure potential customers gain by
driving past Pet Practice's other clinic locations.
Because most customers choose a veterinarian located within five miles
of their homes, geographically targeted direct mail programs can be effective in
building market share. Additionally, promotional coupons are occasionally used
to encourage return visits for regular veterinary care and increase trial use
among those who have not used Pet Practice's services. Reminder cards are mailed
to existing customers recommending preventive or routine care. Boarding and
grooming services and related wellness services (such as vaccinations) in a
convenient choice of settings within the network may further bond relationships
with the customer.
In each network, Pet Practice also establishes relationships with pet
referral sources, such as breeders, retailers and humane societies.
Customer Service Culture
While Pet Practice's marketing programs seek to attract new customers
through consumer awareness, its customer service culture focuses on customer
satisfaction and retention. Employees undergo formal customer service training
to learn the key elements of assuring customer satisfaction and retention.
Company management and employees have jointly developed and monitored a number
of customer service standards, policies and programs relating to customer
relations and efficient delivery of service.
87
<PAGE>
Pet Practice surveys customers on a regular basis to determine
satisfaction and evaluate their visits to Pet Practice's clinics. These surveys
are used to adapt continually Pet Practice's services to satisfy its customers'
desire for convenient, compassionate and informative veterinary care.
CLINICAL LEADERSHIP
Pet Practice's corporate culture mandates giving the highest priority to
assuring state-of-the-art veterinary medical practices, successful outcomes and
clinical learning opportunities. Pet Practice encourages clinical learning
through continuing education, internal forums, vendor supported events and
participation in industry professional societies and meetings.
The position of Chief Veterinary Officer ("CVO") was established to
provide Pet Practice with a formal advocate for clinical excellence who not only
acts as an administrator for this function but who also serves as a clearing
house for the expertise that comes with each practice acquired by Pet Practice.
The CVO develops relationships with prominent veterinary specialists and
selected universities. Detailed interactions take place at the regional level
with Veterinary Medical Policy and Procedures Committees ("VMPPCs") established
for individual or contiguous areas with rotating representatives from local
clinics affiliated with Pet Practice. Area VMPPCs have been instituted in the
Detroit, Indianapolis, Chicago, Mid-Atlantic and Florida networks with
significant results in protocol development, technology and drug selection and
quality assurance.
As part of many acquisitions, Pet Practice will have the opportunity to
hire various specialists, some board certified by the various colleges of the
American Veterinary Medical Association ("AVMA"). These highly skilled
veterinarians are expected to apply their expertise in each network, or
sometimes nationally in various networks. Management plans to emphasize raising
the acuity of services available in the overall mix provided by Pet Practice
with the aid of the specialists.
Pet Practice management recognizes that pet health is controlled by pet
owners. Accordingly, Pet Practice develops educational materials and training
programs to support owner education, thus better enabling pet owners to make
informed health care choices for their pets. Community involvement by the
veterinarians as teachers of good health care practices is stressed. Media
advertising is designed generally to share valuable pet care information with
the public.
EMPLOYER OF CHOICE PROGRAMS
Pet Practice's goal is to be considered the employer of choice in the
veterinary services industry. To achieve this goal, Pet Practice attempts to
create a positive culture and to provide human resource programs seldom
available at the individual veterinarian practitioner level.
To achieve human resource program goals, Pet Practice offers an employee
benefit package not generally available to independent veterinarian
practitioners, job security in a changing veterinary care environment,
continuing education, management opportunities and an ability to relocate within
Pet Practice to different regions of the country. In addition, Pet Practice will
offer the benefit of national networking of veterinary professionals which,
through formal and informal sharing of resources, experience and expertise, will
help ensure that Pet Practice develops and employs some of the best veterinarian
practitioners in the veterinary services industry.
Employee benefit programs provide health, disability and life insurance
and stock option and retirement plans to Pet Practice's employees. In addition,
Pet Practice offers many of its employees the opportunity to work either on a
full-time or part-time basis to accommodate the personal needs of its
practitioners.
MANAGEMENT INFORMATION SYSTEMS
Management recognizes the importance of systems in driving productivity
and supporting Pet Practice's growth plans, and has made and continues to make
significant investments in both practice management and financial information
systems. Pet Practice is currently in the process of installing a common
practice management system in all of its clinics. This practice management
system will link point-of-sale terminals in each clinic with the headquarters
office, allowing Pet Practice to monitor key operating data on a daily basis,
including revenues and number of transactions by type of procedure, inventory
activity, clinic labor hours and customer demographic data. In addition, Pet
Practice plans to utilize its practice management system to
88
<PAGE>
maintain certain of its patient medical records in electronic form, providing
efficient and effective access to key clinical patient data.
As of June 5, 1996, Pet Practice has substantially completed the
installation of this common practice management system in 63 of its clinics.
Pet Practice intends to convert the remainder of its existing clinics and
clinics acquired through future acquisitions to this practice management system.
To maximize administrative efficiency, Pet Practice has substantially
centralized its financial information systems.
COMPETITION
The veterinary services industry is highly fragmented with approximately
16,000 individual small animal private practices competing for clients. Larger
practices typically have two or more veterinarians in a group practice
configuration. This type of practice represents the preferred source of
acquisitions for Pet Practice. Several of these group practices are growing in
various metropolitan markets by start-ups or absorption of smaller, weaker
practices or the practices of retiring veterinarians.
The local veterinarian's principal strengths tend to be strong client
relationships and personal service. However, many local veterinarians are
limited in their ability to practice state-of-the-art medicine due to lack of
time to keep pace with medical advances, limited capital for updating equipment
and facilities and recruiting, purchasing and marketing issues. Although
customers show increasing preference for convenient hours, only the largest
practices are able to schedule 24-hour or extended hour service. Accordingly,
Pet Practice as consolidator can gain competitive advantage by nurturing client
relationships and overcoming the above limitations of the smaller private
practices. By extending the hours of acquired practices, Pet Practice is
expected to provide early differentiation as networks are developed by Pet
Practice.
Furthermore, Pet Practice believes that in recent years, newly graduated
veterinarians (approximately 2,050 in 1993) are less inclined to purchase or
start private practices due to growing capital requirements and a desire for a
less demanding lifestyle. Pet Practice believes that this trend will tend to
make it an attractive place for employment and experience gathering for newly
graduated veterinarians.
Pet Practice is aware of at least three significant efforts to
consolidate veterinary services. VCA, which operates approximately 64 clinics,
is pursuing a multidirectional strategy encompassing clinic ownership, practice
management, pet food development and laboratory services. In addition, Pet
Practice is aware of at least two additional significant efforts to consolidate
veterinary services, but has experienced no direct competition as a result of
these consolidations.
There are a growing number of retail chains selling pet foods and other
products from large, well-stocked "superstores" in important retail locations,
which are within Pet Practice's markets. Two of the leading superstore chains
compete with Pet Practice in that they have initiated veterinary clinics in
their stores. One of the superstore chains has plans with a veterinarian
entrepreneur both to accelerate the installation of veterinary practices in its
stores and increase the medical acuity of its offered services. Pet Practice
believes that it can successfully compete with the leading superstore chains in
that the superstore chains do not offer, for example, the number of locations,
convenience and extensive range of services provided by Pet Practice's pet care
delivery networks. To date, other superstore chains have chosen not to initiate
such programs in an effort to align themselves with the independent veterinarian
practitioner community. Accordingly, Pet Practice does not view these superstore
chains as competitors and, in fact, has a co-operative referral relationship
with one such superstore chain. However, there can be no assurance that, in the
future, such superstore chains will not compete with Pet Practice.
LICENSING AND CERTIFICATION; PROFESSIONAL ASSOCIATIONS; REGULATION
Veterinary care in the U.S. is provided by veterinarians, generally
assisted by veterinary technicians and assistants. Veterinarians are graduates
of four-year accredited veterinary schools and, in most states, become licensed
to practice veterinary medicine upon passing the National Board Examination
("NBE") and the Clinical Competency Test ("CCT") administered by the National
Board of the Examination Committee. State licensure of a veterinarian is
granted, in most instances, based on each state's criteria established by
reference to the national passing scores on the NBE and the CCT. Veterinary
technicians and assistants are regulated under most states' veterinary practice
acts. Standard testing and licensing throughout the U.S. is being
89
<PAGE>
promoted by veterinary educators with some support by the American Veterinary
Medical Association ("AVMA"). The Veterinary Technician National Examination is
currently being offered in 40 states. Most veterinary clinics employ on-the-job
trained veterinary assistants.
The AVMA is the largest organization in the veterinary services industry
with more than 56,000 veterinarian members (representing about 80% of the
veterinary profession), of whom more than 42,000 are engaged in clinical
practice. Of that number, approximately 30,000 are engaged exclusively in small
animal practice and about 5,000 are in mixed (both large animal and small
animal) practices focusing predominantly on small animals. The AVMA sets policy
and influences the veterinary profession's direction and coordinates activities
of subordinate bodies and specialty groups, but it does not act as a regulatory
body.
The American Animal Hospital Association, with approximately 16,000
members, is an organization dedicated to enhancing the abilities of
veterinarians to provide quality medical care to companion animals, conduct
successful practices, maintain their facilities with high standards of
excellence and meet the public's needs for veterinary care.
Each state has an association that varies in influence and size. Some of
these state associations are involved in regulatory activity in conjunction with
state veterinary boards, including investigations with regard to disciplinary
actions or facility inspections and/or licensing. In addition, there are
numerous local county and community organizations which usually serve as social
and educational organizations.
The laws of some states prohibit veterinarians from splitting fees with
non-veterinarians and prohibit business corporations from providing veterinary
services through the direct employment of veterinarians. These laws and their
interpretations vary from state to state and are enforced by the courts and by
regulatory authorities with broad discretion. The states in which Pet Practice
operates which have laws prohibiting business corporations from providing
veterinary services through the direct employment of veterinarians are,
Delaware, Illinois, Indiana, Ohio, New Hampshire, New Jersey and West Virginia.
Pet Practice believes that its operations as currently conducted are in material
compliance with laws concerning corporate practice of veterinary medicine based
upon discussions with the appropriate governmental regulatory agency in each of
the states in which it operates.
TRADEMARKS
Pet Practice owns a number of registered trademarks and has filed
applications to register additional trademarks and service marks with the United
States Patent and Trademark Office, including "The Pet Practice" and related
logos. Pet Practice believes Pet Practice trademarks and logos will be important
components in its merchandising and marketing strategy and that it will have all
service and trademark rights necessary to conduct business under the Pet
Practice name.
EMPLOYEES
At April 1, 1996, Pet Practice had approximately 1,125 employees. Of
these, approximately 10 are corporate management, 190 are veterinarians, 875 are
other clinic personnel including veterinary technicians, receptionists,
veterinary assistants and groomers, 20 are field management and 30 are
administrative and clerical. None of Pet Practice's employees is represented by
a labor union and Pet Practice is not aware of any current activity to organize
any of its employees. Management considers relations between Pet Practice and
its employees to be good.
INSURANCE
Pet Practice believes that it maintains the types and amounts of
insurance customary in the veterinary services industry, including coverage for
general liability, product liability, property damage, workers' compensation and
malpractice liability. In most states, pets are considered property and are
covered by the owner's homeowners' insurance. The liability of a veterinarian
practice for malpractice is generally limited to the cost of the pet or the
medical service performed. Pet Practice considers its insurance coverage to be
adequate both as to risks and amounts.
90
<PAGE>
PROPERTIES
Pet Practice's principal executive offices are located at 1018 West
Ninth Avenue, King of Prussia Pennsylvania. In addition, Pet Practice leases
other office space and clinical facilities and owns 10 clinics, eight of which
are subject to mortgages, in various cities in the United States. See Note 5 of
Notes to Pet Practice's Consolidated Financial Statements for information
concerning Pet Practice's mortgages and leases for its facilities. Pet Practice
does not anticipate that it will experience any difficulty in renewing any such
leases upon their expiration or obtaining different space on comparable terms if
such leases are not renewed. Pet Practice believes that these facilities are
well maintained and are of adequate size for present needs and planned expansion
in the near future. In general, Pet Practice intends to lease rather than
purchase facilities.
LEGAL PROCEEDINGS
From time to time, Pet Practice is party to certain claims, suits and
complaints which arise in the ordinary course of business. Currently, there are
no such claims, suits or complaints which, in the opinion of management, would
have a material adverse effect on Pet Practice's financial position, liquidity
or results of operations.
EXECUTIVE OFFICERS OF PET PRACTICE
Certain information with respect to the executive officers of Pet
Practice is set forth below:
<TABLE>
<CAPTION>
Age at
Name December 31, 1995 Position
---- ------------------ --------
<S> <C> <C>
Stephen F. Nagy............. 51 Chairman of the Board and Director
Peter J. Cohen.............. 41 President, Chief Executive Officer and Director
Andrew S. Dworkis, D.V.M.... 52 Senior Vice President -- Development, Chief
Veterinary Officer and Director
Warren D. Barratt........... 36 Vice President, Chief Financial Officer and
Secretary
Mark G. Hardin.............. 45 Controller
Lori Stokes-Powers.......... 40 Vice President -- Human Resources
Donna Yokich Schlitt........ 33 Director of Marketing
Linda Larson................ 48 Director of Information Systems
</TABLE>
STEPHEN F. NAGY has been Chairman of the Board of Pet Practice since
March 1995 and a director of Pet Practice since October 1993. Mr. Nagy was Vice
President of Pet Practice from October 1993 to March 1995. He also acted as
President of Pet Practice from October 1993 to February 1994. Mr. Nagy has been
Executive Vice President of Foster Management Company, an investment advisor,
and general partner of investment funds managed by it since 1989.
PETER J. COHEN has been President and a director of Pet Practice since
February 1994 and Chief Executive Officer of Pet Practice since March 1995. Mr.
Cohen was Chief Operating Officer of Pet Practice from February 1994 to March
1995. He previously served as Vice President of Sales at National Media
Corporation, a leading television direct response and marketing company, from
1992 until joining Pet Practice. He was Senior Vice President of Corporate
Operations at Nutri/Systems, Inc., a 1,700 clinic national weight loss
management company, from 1989 until 1992; Executive Vice President of Operations
and Marketing for The Circle K Corporation, a 4,600 location convenience store
chain, from 1986 to 1989; and held various management positions with The
Southland Corporation, the nation's largest convenience store operator, from
1977 to 1985.
ANDREW S. DWORKIS, D.V.M. has been Senior Vice President--Development of
Pet Practice since February 1994 and Chief Veterinary Officer and a director of
Pet Practice since October 1993. Dr. Dworkis was the founder of Pet Practice's
initial acquisition, Professional Veterinary Hospitals of America, Inc. ("PVH"),
where he was a veterinary practitioner and served in various executive
capacities, including President and Chief Veterinary Officer, from that
company's inception in 1983 through February 1994. Prior to 1983, Dr. Dworkis
was in private practice in the Detroit area.
91
<PAGE>
WARREN D. BARRATT has been Vice President and Chief Financial Officer of
Pet Practice since June 1994. From 1982 until joining Pet Practice, Mr. Barratt
held various management positions with Price Waterhouse LLP, most recently as
Senior Manager.
MARK G. HARDIN has been the Controller of Pet Practice since December
1994. He previously served as Controller of Everfast, Inc., a retailer and
wholesaler of decorative fabrics, from February 1991 to June 1994. From December
1986 until February 1991, Mr. Hardin served as Assistant Controller for McCrory
Stores, Inc., a variety retailer.
LORI STOKES-POWERS has been Vice President--Human Resources of Pet
Practice since June 1994. She previously served as Employee Relations Manager
for the Dairy Division of Kraft General Foods, Inc. from 1989 until joining Pet
Practice.
DONNA YOKICH SCHLITT has been National Director of Marketing for Pet
Practice since June 1994. From August 1990 until June 1994, she was the Director
of Marketing for PVH. She has 15 years of marketing experience, including her
positions as Associate Brand Manager at the Stroh Brewery Company from 1986
until joining Pet Practice, Advertising Coordinator for Merrill Lynch, Pierce,
Fenner and Smith Incorporated from 1985 to 1986, and in various marketing
capacities for two architectural firms from 1980 to 1985.
LINDA LARSON has been Director of Information Systems of Pet Practice
since February 1995. Prior to joining Pet Practice, Ms. Larson was Director of
Information Systems at NovaCare, Inc.'s Medical Rehabilitation Hospital
Division. From 1987 to 1991, she was Manager of Information Systems at the
Specialty Hospital Group of National Medical Enterprises, Inc.
No family relationship exists between any directors or executive
officers of Pet Practice. Executive officers serve at the discretion of the Pet
Practice Board.
Compensation Information
The following table sets forth information concerning the compensation
of Pet Practice's Chief Executive Officer and each of the other most highly
compensated executive officers of Pet Practice whose total annual salary and
bonus exceeded $100,000 for fiscal 1994 and 1995.
Summary Compensation Table
--------------------------
<TABLE>
<CAPTION>
Annual Compensation Long Term
Compensation
---------------------------------------------------------------------------
Other
Name and Principal Annual Awards
Position Year(3) Salary($) Bonus($) Compensation($) Options(#)
- --------------------------------------- ------- ------------ ---------- --------------- -------------
<S> <C> <C> <C> <C> <C>
John H. Foster 1995 17,500(2) 0 0 0
Director (1) 1994 30,000(2) 0 0 0
Peter J. Cohen 1995 157,269 38,448 528(6) 10,000
President (1) 1994(4) 132,115 39,000(5) 0 0
Andrew S. Dworkis, D.V.M. 1995 115,492 5,291 15,128(7) 5,000
Senior Vice President--Development 1994 110,000 0 15,160(8) 0
and Chief Veterinary Officer
Warren D. Barratt 1995 89,544 17,860 346(6) 7,500
Vice President and Chief Financial 1994(9) 45,500 6,951 0 0
Officer
</TABLE>
_________________________________
(1) Effective March 13, 1995, Mr. Foster relinquished his positions as Chairman
and Chief Executive Officer and Stephen F. Nagy was appointed Chairman of
the Board and Peter J. Cohen was appointed Chief Executive Officer of Pet
Practice. Mr. Foster is currently a director of Pet Practice.
92
<PAGE>
(2) Represents a management fee of $2,500 per month paid to Foster Management
Company, of which Mr. Foster is the sole stockholder. The agreement to pay
a monthly management fee was terminated as of August 1995.
(3) Pet Practice commenced operations on October 27, 1993. As a result, no
executive officer of Pet Practice had an annual salary and bonus in excess
of $100,000 in 1993 and therefore, no information is set forth herein with
respect to 1993.
(4) Mr. Cohen's employment with Pet Practice commenced on February 1, 1994.
(5) Includes $7,500 paid to Mr. Cohen in 1993 as a bonus with respect to the
commencement of his employment with Pet Practice.
(6) Consists of contributions made by Pet Practice to The Pet Practice, Inc.
401(k) Retirement Plan (f/k/a the Professional Veterinary Hospitals of
America, Inc. 401(k) Retirement Plan) (the "Retirement Plan") on behalf of
such executive officer. The dollar value of other perquisites and personal
benefits was less than the lesser of $50,000 or 10% of the total annual
salary and bonus for such named executive officer, and, accordingly, has
been omitted.
(7) Consists of a $15,000 allowance for automobile and other reimbursed
expenses and a $63 contribution made by Pet Practice to its Retirement Plan
on behalf of Dr. Dworkis. The balance of such compensation relates to
miscellaneous items.
(8) Consists of a $15,000 allowance for automobile and other reimbursed
expenses and a $95 contribution made by Pet Practice to its Retirement Plan
on behalf of Dr. Dworkis. The balance of such compensation relates to
miscellaneous items.
(9) Mr. Barratt's employment with Pet Practice commenced on June 2, 1994.
The following table sets forth the grants of stock options to the
executive officers named in the Summary Compensation Table during the fiscal
year ended January 3, 1996. The amounts shown for each of the named executive
officers as potential realizable values are based on arbitrarily assumed
annualized rates of stock price appreciation of five percent and ten percent
over the exercise price of the options during the full terms of the options,
which would result in stock prices of approximately $20.78 and $33.02,
respectively. The amounts shown as potential realizable values for all
stockholders represent the corresponding increases in the market value of
8,492,100 outstanding shares of the Pet Practice Common Stock held by all
stockholders as of January 3, 1996, which would total approximately $176,465,838
and $280,409,142, respectively. No gain to the optionees is possible without an
increase in stock price which will benefit all stockholders proportionately.
These potential realizable values are based solely on arbitrarily assumed rates
of appreciation required by applicable Commission regulations. Actual gains, if
any, on option exercises and holdings of Pet Practice Common Stock are dependent
on the future performance of the Pet Practice Common Stock and overall market
conditions. There can be no assurance that the potential realizable values
shown in this table will be achieved.
<TABLE>
<CAPTION>
OPTION GRANTS IN LAST FISCAL YEAR
INDIVIDUAL GRANTS
------------------------------------------------------------
Potential Realizable Value at Assumed
Percent of Annual Rates of Stock Price
Total Options Appreciation for Option Term
Number of Granted to Exercise ----------------------------------------
Options Employees Price Per
Name Granted Fiscal Year Share Expiration Date 5% 10%
- --------------------------- ---------- -------------- ----------- ----------------- ----------------- -------------------
<S> <C> <C> <C> <C> <C> <C>
All Stockholders' Stock
Appreciation N/A N/A N/A N/A $176,465,838 $280,409,142
John H. Foster............... 0 0 N/A N/A N/A N/A
Peter J. Cohen............... 10,000 11.5% $12.75 09/19/05 80,300 202,700
</TABLE>
93
<PAGE>
<TABLE>
<S> <C> <C> <C> <C> <C> <C>
Andrew S. Dworkis, D.V.M..... 5,000 5.8% $12.75 09/19/05 40,150 101,350
Warren D. Barratt............ 7,500 6.8% $12.75 09/19/05 60,244 152,025
</TABLE>
The following table sets forth the number and value of options held by
the executive officers of Pet Practice named in the Summary Compensation Table.
During the fiscal year ended January 3, 1996, none of the executive officers
named in the Summary Compensation Table exercised any options to purchase Pet
Practice Common Stock.
FISCAL YEAR-END OPTION VALUES
<TABLE>
<CAPTION>
Value of Unexercised
Number of Unexercised In-The-Money
Options at January 3, 1996 Options at January 3, 1996(1)
-------------------------------- ---------------------------------
Name Exercisable/Unexercisable Exercisable/Unexercisable
- ---- -------------------------------- ---------------------------------
<S> <C> <C>
John H. Foster.............. N/A N/A
Peter J. Cohen.............. 0/10,000 $0/0
Andrew S. Dworkis, D.V.M.... 0/5,000 $0/0
Warren D. Barratt........... 0/7,500 $0/0
</TABLE>
__________________________
(1) In-the-money options are those for which the fair market value of the
underlying Pet Practice Common Stock exceeds the exercise price of the
option. The value of in-the-money options is determined in accordance with
regulations of the Commission by subtracting the aggregate exercise price
of the option from the aggregate year-end value of the underlying Pet
Practice Common Stock.
Director Compensation
Directors of Pet Practice do not receive fees for service as directors
but are reimbursed for out-of-pocket expenses. During 1994 and 1995, Pet
Practice paid Foster Management Company (an investment advisor of which John H.
Foster, a director of Pet Practice, is the Chairman of the Board and sole
stockholder), an aggregate of $47,500 in management fees (at the rate of $2,500
per month) and approximately $48,000 as reimbursement of out-of-pocket expenses.
The agreement to pay a monthly management fee terminated upon completion of Pet
Practice's initial public offering. In August 1995, Pet Practice paid Foster
Management Company a fee of $500,000 for its assistance in effectuating Pet
Practice's initial public offering.
Employment Arrangements
Pet Practice has entered into an agreement, which is terminable at
will, with Peter J. Cohen. The agreement provides that Mr. Cohen will receive a
base salary of $150,000 per year with a possible bonus, at the discretion of the
Chairman of the Board of Pet Practice, of up to 30% of such base salary each
year. The agreement also sets forth other employee benefit arrangements.
In connection with the acquisition by Pet Practice of PVH, Dr. Dworkis
entered into a five-year employment agreement. The agreement provides for Dr.
Dworkis to receive an annual base salary of $110,000, subject to merit increases
as determined by the Pet Practice Board, and, during the fourth and fifth years
of his employment, to earn bonuses, payable in cash and Pet Practice Common
Stock, on terms approved by the Pet Practice Board. The agreement also provides
that in the event that Dr. Dworkis' employment with Pet Practice is terminated
other than voluntarily, by death or disability or for due cause (as defined in
the agreement), Pet Practice shall pay Dr. Dworkis 70% of his base salary for a
period of three years. In addition, Dr. Dworkis purchased 20,000 shares of Pet
Practice Common Stock at $.055 per share. Such shares are subject to
94
<PAGE>
repurchase by Pet Practice for $.055 per share in the event of the termination
of Dr. Dworkis' employment with Pet Practice prior to January 1998.
In addition, Pet Practice has entered into agreements, which are
terminable at will, with each of Warren D. Barratt, Lori Stokes-Powers, Mark G.
Hardin, Donna Yokich Schlitt and Linda Larson which set forth, among other
things, the base salary, bonus, equity participation, and other employee benefit
arrangements for each of them.
Compensation Committee Interlocks and Insider Participation
The members of the Compensation Committee of the Pet Practice Board for
fiscal 1995 were R. Bruce Mosbacher, John H. Foster, Stephen F. Nagy and Charles
Velge. Mr. Foster, Chairman of the Board and Chief Executive Officer of Pet
Practice during fiscal 1995 and a director of Pet Practice, was also Chairman of
the Board, Chief Executive Officer, a director and a member of the Compensation
Committee of each of NovaCare, Inc. and Apogee, Inc. during fiscal 1995. Mr.
Nagy, a director of Pet Practice and since March 1995, Chairman of the Board of
Pet Practice, was also a director of Hearing Health Services, Inc. (a company of
which Mr. Foster is Chairman of the Board and Chief Executive Officer) and
Chairman of the Board of Valley Forge Dental Associates, Inc. (a company of
which Mr. Foster is a director).
As discussed below, Pet Practice has engaged in a variety of
transactions with a limited partnership of which John H. Foster and Stephen F.
Nagy are general partners of the general partner and Foster Management Company,
an investment advisor of which Mr. Foster is the Chairman of the Board and sole
stockholder and Mr. Nagy is an Executive Vice President.
In connection with Pet Practice's initial capitalization, the Principal
Stockholder, an investment partnership operated by Foster Management Company (an
investment advisor of which John H. Foster is the Chairman of the Board and sole
stockholder), purchased 3,600,000 shares of Pet Practice Common Stock for
$198,000, and 8,000 shares of mandatory redeemable preferred stock ("Redeemable
Preferred Stock") for $800,000. In August 1995, Pet Practice redeemed the
Redeemable Preferred Stock, which was mandatorily redeemable upon the completion
of Pet Practice's initial public offering, for an aggregate redemption price of
$800,000, plus $117,128.77 in accrued dividends. John H. Foster and Stephen F.
Nagy are general partners of the general partner of the Principal Stockholder.
In October 1993, Pet Practice entered into agreements with the
Principal Stockholder whereby the Principal Stockholder lent Pet Practice up to
$20,000,000 pursuant to 8% Promissory Notes the ("8% Promissory Notes") due
August 30, 1998. Pet Practice borrowed $12,391,000 from the Principal
Stockholder pursuant to the 8% Promissory Notes. In addition, the Principal
Stockholder guaranteed certain loan obligations of Pet Practice. In August
1995, Pet Practice repaid the principal amount of the 8% Promissory Notes
together with $1,618,265.54 in accrued interest from the net proceeds of Pet
Practice's initial public offering. Finally, in August 1995, Pet Practice paid
off all outstanding loan obligations which were guaranteed by the Principal
Stockholder.
During 1994 and 1995, Pet Practice paid Foster Management Company an
aggregate of $47,500 in management fees (at the rate of $2,500 per month) and
approximately $48,000 as reimbursement of out-of-pocket expenses. The agreement
to pay a monthly management fee terminated upon completion of Pet Practice's
initial public offering. In August 1995, Pet Practice paid Foster Management
Company a fee of $500,000 for its assistance in effectuating Pet Practice's
initial public offering. Pet Practice believes that the terms of such
transactions with Foster Management Company are no less favorable to Pet
Practice than the terms Pet Practice could have obtained from non-affiliated
parties. However, since such transactions were not the result of third-party
negotiations, there can be no assurance that Pet Practice could not have
obtained more favorable terms from a non-affiliated party.
Certain Transactions
Pet Practice has engaged in a variety of transactions with the
Principal Stockholder, an investment partnership of which John H. Foster and
Stephen F. Nagy are general partners of the general partner, and Foster
Management Company, an investment advisor of which Mr. Foster is the Chairman of
the Board and sole stockholder and Mr. Nagy is the Executive Vice President.
See "Compensation Committee Interlocks and Insider Participation."
95
<PAGE>
Pet Practice sold to each of the directors and executive officers of
Pet Practice the following shares of Pet Practice Common Stock in the following
months for $.08 per share, which shares of Pet Practice Common Stock vest over a
five-year period contingent upon continued service: in February 1994, 120,000
shares of Pet Practice Common Stock to Peter J. Cohen, President, Chief
Executive Officer and a director of Pet Practice; in March 1994, 5,000 shares of
Pet Practice Common Stock each to R. Bruce Mosbacher, Foster Bam, Carlo Grosso,
James C. New and Charles Velge, directors of Pet Practice; and in June 1994,
10,000 shares of Pet Practice Common Stock to Warren D. Barratt, Vice President
and Chief Financial Officer of Pet Practice, and 5,000 shares of Pet Practice
Common Stock to Lori Stokes-Powers, Vice President--Human Resources of Pet
Practice. In connection with the proposed Merger with VCA, the vesting
provisions with respect to 5,000 shares of Pet Practice Common Stock have been
waived for each of Messrs. Cohen, Mosbacher, Bam, Grosso, New and Velge, subject
to consummation of the Merger.
Pet Practice has entered into stock purchase agreements with each of
its directors and executive officers (except John H. Foster and Stephen F. Nagy)
(the "Stock Purchase Agreements") pursuant to which such individuals purchased
their respective shares of Pet Practice Common Stock. The Stock Purchase
Agreements provide for restrictions on the sale of such shares and further
provide that Pet Practice has the option to repurchase any such shares which
have not become vested through the passage of time at $.08 per share upon the
termination, for any reason whatsoever, of such individual's directorship or
employment, as the case may be, with Pet Practice. Except as provided in the
immediately preceding paragraph, such restrictions and repurchase rights shall
continue to be applicable on the same basis to the VCA Common Stock received by
such individuals in the Merger in exchange for such shares of Pet Practice
Common Stock. Pet Practice and each of Messrs. Bam, Barratt, Cohen, Grosso,
Mosbacher, New and Velge and Ms. Stokes-Powers agreed that, in the event of a
proposed sale of control of Pet Practice, each of such individuals will be
permitted, or may be required, to sell a number of those shares of Pet Practice
Common Stock covered by his or her respective Stock Purchase Agreement as shall
be proportionate to the number of shares of Pet Practice Common Stock that the
controlling stockholders shall sell of the shares owned by them, for the same
consideration per share and on the same terms and conditions received by such
controlling stockholders in such sale of control.
Dr. Andrew S. Dworkis was a stockholder of PVH, which Pet Practice
acquired in October 1993. In consideration for his stock in PVH, Pet Practice
paid Dr. Dworkis $483,500 in cash and a contingent, non-interest bearing note in
the principal amount of approximately $233,000, and agreed to pay Dr. Dworkis
certain additional cash payments if the value of PVH is validated as evidenced
by its achievement of certain financial and operational goals. In June 1995,
Pet Practice renegotiated certain of such additional cash payments to eliminate
certain performance criteria in exchange for a non-interest bearing note in the
principal amount of approximately $311,000. In connection with the acquisition
of PVH, Dr. Dworkis purchased 57,067 shares of Pet Practice Common Stock for
$.055 per share.
Dr. Dworkis is a partner in a partnership which leases six veterinary
clinics to Pet Practice. The lease agreements provide for annual base rental
rates currently ranging from $1,634 to $7,117 per month. All of the leases are
"triple net" leases. Four of the leases expire in October 2003 with, in each
case, an option to renew for five additional years. One of the leases expires
in October 1998 with one five-year renewal option and one of the leases expires
in February 1997 with two one-year renewal options. During the period from
October 27, 1993 to December 29, 1993, and the fiscal years ended December 28,
1994 and January 3, 1996, Pet Practice paid $44,800, $268,800 and $268,800,
respectively, to the partnership pursuant to the leases.
In connection with the acquisition of PVH, Dr. Dworkis entered into a
five-year employment agreement with Pet Practice. In addition, Dr. Dworkis
purchased 20,000 shares of Pet Practice Common Stock at $.055 per share. Such
shares are subject to repurchase by Pet Practice for $.055 per share in the
event of the termination of Dr. Dworkis' employment with Pet Practice prior to
January 1998. In connection with the proposed Merger with VCA, the vesting
provisions with respect to 5,000 of such shares of Pet Practice Common Stock
have been waived, subject to consummation of the Merger. See "Employment
Arrangements."
On August 9, 1994, Pet Practice executed a demand promissory note
payable to United States Trust Company of New York ("U.S. Trust") (the "First
U.S. Trust Note") in the principal amount of the lesser of the amount borrowed
or $7,000,000, with an interest rate equal to U.S. Trust's prime rate. On
September 28, 1994, the First U.S. Trust Note was amended and restated and the
maximum principal amount thereof was increased from $7,000,000 to $8,000,000,
payable on demand together with interest thereon at U.S. Trust's prime rate.
Additionally, on December 5, 1994, Pet Practice executed a demand
96
<PAGE>
promissory note payable to U.S. Trust (the "Second U.S. Trust Note") in the
principal amount of the lesser of the amount borrowed or $5,000,000, with an
interest rate equal to U.S. Trust's prime rate.
On February 27, 1995, Pet Practice executed a demand promissory note
payable to PNC Bank, National Association ("PNC Bank") (the "PNC Note") in the
principal amount of the lesser of the amount borrowed or $5,000,000, with an
interest rate, at Pet Practice's option, equal to (a) the greater of (i) PNC
Bank's prime rate or (ii) the federal funds rate plus 0.5% or (b) the eurodollar
rate plus 2%. On July 6, 1995, the PNC Note was amended and restated and the
maximum principal amount thereof was increased from $5,000,000 to $6,000,000.
The Principal Stockholder unconditionally guaranteed the payment of Pet
Practice's obligations to U.S. Trust and PNC Bank under all such notes, and
secured the guarantee to U.S. Trust by a pledge of cash deposits. In August
1995, Pet Practice repaid the $13,000,000 aggregate principal amount outstanding
under the First U.S. Trust Note and the Second U.S. Trust Note, together with
accrued interest thereon in the aggregate amount of $154,611.11, from the net
proceeds of Pet Practice's initial public offering. In August 1995, Pet
Practice repaid the $5,926,692 principal amount outstanding under the PNC Note,
together with accrued interest thereon of $46,822, from the net proceeds of Pet
Practice's initial public offering.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF PET PRACTICE
The stockholders (including any "group" as that term is used in Section
13(d)(3) of the Exchange Act) who, to the knowledge of the Pet Practice Board,
owned beneficially more than five percent of Pet Practice's one class of
outstanding voting securities as of April 1, 1996, each director and each
executive officer named in the Summary Compensation Table of Pet Practice and
all directors and officers of Pet Practice as a group, and their respective
share holdings as of such date (according to information furnished by them to
Pet Practice), are set forth in the following table. Except as indicated in the
footnotes to the table, all of such shares are owned with sole voting and
investment power. The address of each person listed is in care of Pet Practice,
1018 West Ninth Avenue, King of Prussia, Pennsylvania 19406, unless otherwise
set forth below such person's name.
<TABLE>
<CAPTION>
PERCENT OF CLASS PERCENT OF CLASS
OWNED PRIOR TO OWNED AFTER
NAME AND ADDRESS NUMBER OF SHARES MERGER MERGER(1)
- ------------------------------------------ ------------------------- -------------------- ----------------
<S> <C> <C> <C>
Abbingdon Venture Partners 3,600,000 41.8% 8.6%
Limited Partnership-II(9)
1018 West Ninth Avenue
King of Prussia, Pennsylvania 19406
John H. Foster 3,614,000(2) 41.9% 8.6%
Foster Management Company
1018 West Ninth Avenue
King of Prussia, Pennsylvania 19406
Stephen F. Nagy 3,601,000(3) 41.8% 8.6%
Foster Management Company
1018 West Ninth Avenue
King of Prussia, Pennsylvania 19406
Weiss, Peck & Greer, L.L.C. 581,500(4) 6.7% 1.4%
One New York Plaza
New York, New York 10004
The Kaufmann Fund Inc. 500,000(5) 5.8% 1.2%
140 E. 46th Street, 43rd Floor
New York, New York 10017
Peter J. Cohen 120,000 1.4% *
Andrew S. Dworkis, D.V.M. 77,067 * *
Foster Bam 54,500(6) * *
Warren D. Barratt 10,000 * *
</TABLE>
97
<PAGE>
<TABLE>
<CAPTION>
PERCENT OF CLASS PERCENT OF CLASS
OWNED PRIOR TO OWNED AFTER
NAME AND ADDRESS NUMBER OF SHARES MERGER MERGER(1)
- ------------------------------------------- ------------------- -------------------- ----------------
<S> <C> <C> <C>
Carlo Grosso 5,000 * *
R. Bruce Mosbacher 5,000(7) * *
James C. New 5,000 * *
Charles Velge 5,000 * *
Directors and officers as a 3,904,067(2)(3)(6)(7) 45.3% 9.3%
group (14 persons) (8)
- ----------------------------
</TABLE>
* Less than one percent.
(1) Assumes the issuance of 3,272,993 shares of VCA Common Stock in the Merger
in exchange for 8,632,520 shares of Pet Practice Common Stock, including
8,800 shares of Pet Practice Common Stock underlying options which were
exercisable on, or which will become exercisable within, 60 days of April
1, 1996.
(2) Includes 3,600,000 shares of Pet Practice Common Stock owned by the
Principal Stockholder, a limited partnership of which Mr. Foster is a
general partner of the general partner.
(3) Includes 3,600,000 shares of Pet Practice Common Stock owned by the
Principal Stockholder, a limited partnership of which Mr. Nagy is a general
partner of the general partner.
(4) Information as to the holdings of Weiss, Peck & Greer, L.L.C. ("WPG") is as
of December 31, 1995 and is based upon a report on Schedule 13G filed with
the Commission. Such report indicates that 581,500 shares were
beneficially owned by WPG with shared voting power and shared dispositive
power.
(5) Information as to the holdings of The Kaufmann Fund Inc. (the "Kaufmann
Fund") is as of December 31, 1995 and is based upon a report on Schedule
13G filed with the Commission. Such report indicates that 500,000 shares
were beneficially owned by the Kaufmann Fund with sole voting power and
sole dispositive power.
(6) Includes 45,500 shares of Pet Practice Common Stock owned by Foster &
Foster, an investment partnership of which Mr. Bam is the Managing Partner.
(7) Represents shares of Pet Practice Common Stock owned by the Mosbacher/Ditz
Living Trust, of which Mr. Mosbacher is the trustee and is a beneficiary.
(8) Includes 2,500 shares of Pet Practice Common Stock presently issuable to
executive officers of Pet Practice upon the exercise of stock options.
(9) Investment decisions with respect to the shares of Pet Practice Common
Stock owned by the Principal Stockholder are made by its general partner,
Abbingdon-II Partners, a New York general partnership ("Abbingdon-II").
The general partners of Abbingdon-II are John H. Foster, Stephen F. Nagy,
trusts for the benefit of the children of Messrs. Foster and Nagy, and
Caroline H. Fleming.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS OF PET PRACTICE
OVERVIEW
Pet Practice owns and operates veterinary care group practices. Pet
Practice is one of the largest and fastest growing providers of companion animal
veterinary care in the United States. Pet Practice typically establishes
comprehensive networks
98
<PAGE>
that include day clinics and 24-hour emergency/acute care clinics. In certain
markets, Pet Practice also provides pet boarding and grooming services. Pet
Practice believes it is currently one of the few companies pursuing a national
strategy of consolidating veterinary care group practices in an effort to create
comprehensive veterinary care networks. Pet Practice currently operates 84
veterinary clinics in 11 states. All of Pet Practice's services are provided on
a fee-for-service basis and customers generally remit payment at the time
services are delivered.
Pet Practice believes that by developing comprehensive care delivery networks in
selected geographic markets, it can improve convenience to the customer,
generate significant cost advantages, deliver higher quality care and increase
its attractiveness to customers and employees. For instance, as a result of its
scale, Pet Practice can employ a full range of veterinary specialists, support
the operation of 24-hour emergency "hub" clinics and finance sophisticated
marketing programs including television, radio and print advertising designed to
build brand name awareness and educate customers. Pet Practice believes, based
on market studies conducted by independent consultants, that convenience and
brand name awareness are two of the most important factors affecting a
customer's choice of veterinarian. In addition, Pet Practice's larger size
relative to traditional providers of veterinary care enables it to leverage
corporate overhead, achieve economies of scale in purchasing and support the
development of management information systems. Finally, Pet Practice is able to
leverage labor costs, employing part-time and full-time practitioners and
offering a full complement of employee benefits.
Pet Practice has a short operating history and has grown rapidly through
acquisitions. Pet Practice was founded in October 1993 through the acquisition
of 15 clinics in Detroit, Michigan. From October 1993 through June 1994, Pet
Practice refined its operating model, put in place the existing management team
and began to put in place the infrastructure to execute its growth and
acquisition strategies. In July 1994, Pet Practice initiated its growth plan and
through April 3, 1996, completed the acquisition of 71 additional clinics and
opened one newly-built clinic. Of the additional acquired clinics, Pet Practice
added 25 during the fiscal quarter ended September 28, 1994, five during the
fiscal quarter ended December 28, 1994, 11 during the fiscal quarter ended March
29, 1995, five during the fiscal quarter ended September 27, 1995, 22 during the
fiscal quarter ended January 3, 1996 and three during the fiscal quarter ended
April 3, 1996. During the period April 4 to June 5, 1996, Pet Practice closed
two of its lower volume clinics, the impact of which is not material to Pet
Practice's results of operations. The following table sets forth the growth in
the number of clinics operated by Pet Practice since commencement of its
operations in October 1993 through June 5, 1996.
<TABLE>
<CAPTION>
Fiscal Quarter Ended
---------------------------------------------------------
October 27
to Year Ended March June September April 4 to
December 29, December 28, 29, 28, 27, January 3, April 3, June 5,
1993 1994 1995 1995 1995 1996 1996 1996
------------ ------------- -------- ------- ------------ ---------- -------- ----------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Number of clinics at
beginning of period........ - 15 44 55 55 60 83 86
Number of clinics acquired
during period.............. 15 30 11 - 5 22 3 -
Number of new clinics
opened during period....... - - - - - 1 - -
Number of clinics consolidated
during period. - (1) - - - - - (2)
Number of clinics at end of ---- ---- ---- ---- ---- ---- ---- --
period..................... 15 44 55 55 60 83 86 84
==== ==== ==== ==== ==== ==== ==== ==
</TABLE>
SEASONALITY
Considerable seasonality of demand for veterinary services exists in the
northern half of the United States, where a majority of Pet Practice's current
clinics are located. Pet Practice has significantly higher revenues during
warmer months because pets spend more time outdoors, where they are more likely
to be injured and are susceptible to diseases and parasites, which are more
prevalent during that time of year. Demand for veterinary services is less
seasonal in the southern states.
99
<PAGE>
While Pet Practice's revenues are highly seasonal, with peak demand for
veterinary services occurring in the second and third quarters of Pet Practice's
fiscal year and significantly reduced demand in the first and fourth fiscal
quarters, a majority of Pet Practice's cost of revenues, including labor and
occupancy costs, are fixed or semi-fixed and, thus, are not generally subject to
significant seasonal variation. As a result, gross profit both on an absolute
dollar basis and as a percentage of revenues is significantly higher in the
second and third fiscal quarters as compared to the first and fourth fiscal
quarters.
RESULTS OF OPERATIONS
Pet Practice's fiscal year is a 52-53 week year which ends on the
Wednesday nearest to December 31.
Cost of revenues includes clinic labor and labor-related costs, clinic
occupancy costs, clinic materials and supplies and clinic marketing costs.
Clinic marketing costs comprise substantially all of Pet Practice's marketing
costs and include costs of clinic-specific direct mail and localized media
marketing programs. Pet Practice uses such marketing programs primarily to
attract new customers and maximize service to existing customers and, thus,
classifies the costs of these programs as a cost of revenues.
General and administrative expenses include all costs related to corporate
and field management and administrative support operations, including labor and
labor-related costs, occupancy costs, professional fees (primarily legal and
accounting) and non-clinic related insurance.
The following table sets forth, for the periods indicated, the relative
percentages which certain items in Pet Practice's Consolidated Statement of
Operations bear to net revenues:
<TABLE>
<CAPTION>
Period from October 27, Year Ended Thirteen Weeks Ended
1993 (commencement of --------------------------- ----------------------
operations) to December 28, January 3, March 29, April 3,
December 29, 1993 1994 1996 1995 1996
----------------------- ---------------------------- ----------------------
<S> <C> <C> <C> <C> <C>
Net revenues............................... 100.0% 100.0% 100.0% 100.0% 100.0%
Cost of revenues........................... 105.0% 92.2% 85.7% 93.6% 90.3%
----- ----- ----- ----- -----
Gross profit............................... (5.0%) 7.8% 14.3% 6.4% 9.7%
General and administrative expenses........ 29.0% 25.6% 14.3% 16.1% 11.1%
Amortization of excess of cost over fair
value of net assets acquired and other
intangible assets......................... 3.2% 2.7% 3.0% 3.3% 3.4%
----- ----- ----- ----- -----
Loss from operations....................... (37.2%) (20.5%) (3.0%) (13.0%) (4.8%)
Interest expense........................... 15.2% 10.5% 5.8% 9.1% 2.4%
Interest income............................ - - (1.2%) (0.1%) (0.7%)
----- ----- ----- ----- -----
Loss before income taxes................... (52.4%) (31.0%) (7.6%) (22.0%) (6.5%)
Provision for income taxes................. - 1.3% 0.2% (0.3%) (0.2%)
----- ----- ----- ----- -----
Net loss................................... (52.4%) (32.3%) (7.8%) (22.3%) (6.7%)
===== ===== ===== ===== =====
</TABLE>
RESULTS OF OPERATIONS FOR THE THIRTEEN WEEKS ENDED APRIL 3, 1996 COMPARED TO THE
THIRTEEN WEEKS ENDED MARCH 29, 1995
Net revenues increased from $7,607 for the thirteen weeks ended March 29,
1995 to $13,404 for the thirteen weeks ended April 3, 1996, representing an
increase of $5,797, or 76%. Of this increase approximately $1,144 was
attributable to the inclusion in the first fiscal quarter of 1996 of a full
quarter's results of operations of 11 clinics acquired during the first fiscal
100
<PAGE>
quarter of 1995, approximately $4,074 was attributable to the acquisition of a
total of 31 additional clinics during the third and fourth fiscal quarters of
1995 and the first fiscal quarter of 1996, and approximately $579 was
attributable to internal growth of Pet Practice's clinics owned for all or a
part of the first fiscal quarter of 1995.
Gross profit increased to $1,300 in the first fiscal quarter of 1996 from
$487 in the first fiscal quarter of 1995. Gross profit as a percentage of net
revenues increased to 9.7% in the first fiscal quarter of 1996 from 6.4% in the
first fiscal quarter of 1995. This increase was primarily attributable to
internal growth of Pet Practice's clinics owned for all or a part of the first
fiscal quarter of 1995, and the acquisition of clinics during the first, third
and fourth fiscal quarters of 1995 and the first fiscal quarter of 1996, with
relatively higher aggregate, average gross profit margins than the aggregate,
average gross profit margins of Pet Practice's clinics owned for all of the
first fiscal quarter of 1995.
General and administrative expenses increased from $1,223 in the first fiscal
quarter of 1995 to $1,490 in the first fiscal quarter of 1996. This increase in
costs relating to corporate and field management and administrative support
functions was primarily attributable to the rapid expansion of Pet Practice's
operations subsequent to the first fiscal quarter of 1995. General and
administrative expenses as a percentage of net revenues decreased from 16.1% in
the first fiscal quarter of 1995 to 11.1% in the first fiscal quarter of 1996.
This decrease was primarily the result of the leveraging of general and
administrative costs over a significantly increased revenue base.
Amortization of excess of cost over fair value of the net assets acquired and
other intangible assets increased to $460 for the first fiscal quarter of 1996
from $248 for the same period in 1995. This increase was attributable to
inclusion of a full quarter of amortization of intangible assets relating to the
additional 31 clinics acquired by Pet Practice during the third and fourth
fiscal quarters of 1995 and the first fiscal quarter of 1996.
Interest expense decreased to $321 for the thirteen weeks ended April 3, 1996
as compared to $697 for the thirteen weeks ended March 29, 1995. This net
decrease was primarily due to the fact that Pet Practice repaid all of its
borrowings from banks and approximately $12,391 of indebtedness to related
parties outstanding during the first fiscal quarter of 1995 with a portion of
the net proceeds of its initial public offering consummated in August 1995.
Interest income increased to $93 in the first fiscal quarter of 1996 as
compared to $6 in the first fiscal quarter of 1995. This increase was primarily
attributable to interest income earned on the remaining net cash proceeds from
Pet Practice's August 1995 initial public offering.
RESULTS OF OPERATIONS FOR THE YEAR ENDED JANUARY 3, 1996 COMPARED TO THE YEAR
ENDED DECEMBER 28, 1994
Net revenues increased from $15,111 for the year ended December 28, 1994 to
$40,571 for the year ended January 3, 1996, representing an increase of $25,460,
or 168%. Of this increase approximately $13,625 was attributable to the
inclusion of a full year's results of operations for clinics acquired during
1994, approximately $8,753 was attributable to the acquisition of 38 clinics
during the year ended January 3, 1996 and approximately $3,082 was attributable
to internal growth of Pet Practice's clinics owned for all or a part of the
year.
Gross profit increased to $5,795 for the year ended January 3, 1996 from
$1,175 for the year ended December 28, 1994. Gross profit as a percentage of
net revenues increased to 14.3% for the year ended January 3, 1996 from 7.8% for
the year ended December 28, 1994. This increase was primarily attributable to
internal revenue growth of Pet Practice's clinics owned for all or a part of the
year ended January 3, 1996 and the acquisition of clinics during the fourth
fiscal quarter of 1994 and the first three fiscal quarters of 1995 with
relatively higher aggregate gross profit margins than the aggregate gross profit
margins of Pet Practice's clinics owned for all or a part of the first nine
months of 1994.
General and administrative expenses increased from $3,867 for the year ended
December 28, 1994 to $5,796 for the year ended January 3, 1996. This increase
in costs relating to corporate and field management and administrative support
functions was primarily attributable to the rapid expansion of Pet Practice's
operations during 1995. General and administrative expenses as a percentage of
net revenues decreased from 25.6% for the year ended December 28, 1994 to 14.3%
for the year ended January 3, 1996. This decrease was primarily the result of
the leveraging of general and administrative costs over a significantly
increased revenue base.
101
<PAGE>
Amortization of excess of cost over fair value of net assets acquired and
other intangible assets increased to $1,229 for the year ended January 3, 1996
from $409 for the year ended December 28, 1994. This increase was attributable
to the acquisition of clinics as outlined above.
Interest expense increased to $2,336 for the year ended January 3, 1996 as
compared to $1,594 for the year ended December 28, 1994. This increase was
primarily due to an increase in borrowings from banks under line of credit
agreements and indebtedness to related parties during the first half of the year
ended January 3, 1996 as compared to the same period in the prior year, and an
increase in the amount of outstanding indebtedness to sellers in connection with
acquisitions. These increases were partially offset by the repayment of all of
Pet Practice's borrowings from banks under line of credit agreements and
approximately $12,391 of indebtedness to related parties with a portion of the
proceeds of its initial public offering consummated in August 1995. See Notes 5
and 10 of Notes to Pet Practice's Consolidated Financial Statements.
Interest income increased from approximately $7 for the year ended December
28, 1994 to approximately $475 for the year ended January 3, 1996. This
increase was primarily attributable to interest income earned on the net cash
proceeds from Pet Practice's August 1995 initial public offering.
RESULTS OF OPERATIONS FOR THE YEAR ENDED DECEMBER 28, 1994 COMPARED TO THE
PERIOD OCTOBER 27, 1993 (COMMENCEMENT OF OPERATIONS) THROUGH DECEMBER 29, 1993
Results of operations for these periods are generally not comparable because
the results of operations for the period October 27, 1993 through December 29,
1993 represent only approximately two months of operations.
Net revenues increased from $1,201 for the period October 27, 1993 through
December 29, 1993 to $15,111 for the year ended December 28, 1994, representing
an increase of $13,910, or 1,158%. Of this increase approximately $7,213 was
attributable to the inclusion for the year ended December 28, 1994 of a full
year's results of operations of the 15 clinics acquired during the period
October 27, 1993 through December 29, 1993, approximately $5,488 was
attributable to the acquisition of 30 additional clinics during the year ended
December 28, 1994 and approximately $1,209 was attributable to internal growth
of Pet Practice's clinics owned for all or a part of the year ended December 28,
1994.
Gross profit increased to $1,175 for the year ended December 28, 1994 from a
loss of $60 for the period October 27, 1993 through December 29, 1993. Gross
profit as a percentage of net revenues increased to 7.8% for the year ended
December 28, 1994 from a negative 5.0% for the period October 27, 1993 through
December 29, 1993. This increase was primarily attributable to internal revenue
growth, the acquisition of clinics during 1994 with relatively higher aggregate,
average gross profit margins than the aggregate, average gross profit margins of
Pet Practice's clinics owned for all or a part of the period October 27, 1993
through December 29, 1993, and the negative impact of late fall/early winter
seasonality during the period October 27, 1993 through December 29, 1993.
General and administrative expenses increased from $348 for the period
October 27, 1993 through December 29, 1993 to $3,867 for the year ended December
28, 1994. This increase in costs relating to corporate and field management and
administrative support functions was primarily attributable to the rapid
expansion of Pet Practice's operations during 1994 and the inclusion of a full
year's results of operations in 1994. General and administrative expenses as a
percentage of net revenues decreased from 29.0% in the period October 27, 1993
through December 29, 1993 to 25.6% for the year ended December 28, 1994. This
decrease was primarily the result of the leveraging of the general and
administrative costs over a significantly increased revenue base.
Amortization of excess of cost over fair value of net assets acquired and
other intangible assets increased to $409 for the year ended December 28, 1994
from $38 for the period October 27, 1993 through December 29, 1993. This
increase was attributable to inclusion of a full year of amortization of
intangible assets relating to the acquisition made in 1993 and amortization of
intangible assets relating to the additional 30 clinics acquired by Pet Practice
during 1994.
Interest expense increased to $1,594 for the year ended December 28, 1994 as
compared to $183 for the period October 27, 1993 through December 29, 1993.
This increase was primarily due to the inclusion of a full year of interest
expense on debt incurred during the period October 27, 1993 through December 29,
1993 and additional debt incurred to finance acquisitions and operations in
1994.
102
<PAGE>
LIQUIDITY AND CAPITAL RESOURCES
Pet Practice's operations require continued access to cash, primarily to fund
acquisitions, purchases of property and equipment, debt repayments, payments
pursuant to earn-out arrangements and working capital requirements.
Pet Practice's operations and acquisitions through July 1995 were financed
primarily through debt provided by Pet Practice's major stockholder and
borrowings under an aggregate of $19,000 in demand credit facilities with banks,
which were unconditionally guaranteed by Pet Practice's major stockholder. All
of such debt was repaid in August 1995 using a portion of the net proceeds of
Pet Practice's initial public offering of 4,300,000 shares of Pet Practice
Common Stock, which was consummated on August 4, 1995. Pet Practice's demand
credit facilities with banks were terminated effective with the public offering.
Net proceeds of Pet Practice's initial public offering, after repayment of
approximately $34,000 of certain debt and mandatorily redeemable preferred stock
and related interest and dividends thereon, were approximately $23,000. Such
net proceeds were added to Pet Practice's working capital and have been used
primarily to finance acquisitions and capital expenditures and for general
corporate purposes.
Pet Practice had a working capital deficit of approximately $186 and cash and
cash equivalents of approximately $4,916 at April 3, 1996, working capital of
approximately $4,161 and cash and cash equivalents of approximately $10,097 at
January 3, 1996, and a working capital deficit of approximately $16,168 and cash
and cash equivalents of approximately $910 at December 28, 1994. The increases
in both working capital and cash and cash equivalents from December 28, 1994
were primarily attributable to the net proceeds of Pet Practice's initial public
offering, less cash used for acquisitions, purchases of property and equipment
and working capital during the period from August 1995 through April 3, 1996.
Cash used by operating activities was $1,239 for the thirteen weeks ended
April 3, 1996, and $4,486 and $2,117 for the years ended January 3, 1996 and
December 28, 1994, respectively.
During the thirteen weeks ended April 3, 1996 and the years ended January 3,
1996 and December 28, 1994, Pet Practice used cash totalling approximately
$2,116, $13,082 and $9,557, respectively, for acquisitions. Pet Practice has
achieved a substantial portion of its growth in the past, and anticipates it
will derive a substantial part of its growth in the future, through acquisitions
of veterinary clinics for a combination of cash, notes payable and stock.
Subject to available capital, Pet Practice anticipates it will complete the
acquisition of a significant number of additional clinics in 1996.
Pet Practice has issued cash, notes and shares of Pet Practice Common Stock
to sellers in connection with acquisitions of practices to date. Pet Practice
is obligated to pay additional consideration to sellers of businesses primarily
contingent upon achievement of certain financial criteria over periods of one to
five years from the dates of acquisition. Although the amount of additional
consideration to be issued cannot be determined until the earn-out periods
expire and the attainment of criteria is established, Pet Practice expects that
the additional consideration issued to sellers pursuant to these arrangements
will constitute a significant portion of the total consideration for certain
acquisitions. If such criteria are attained, but not exceeded, Pet Practice
will be obligated to make cash payments of approximately $2,881 and issue
approximately 90,000 shares of Pet Practice Common Stock over the next five
years. A lesser amount of cash would be paid and a lesser number of shares of
Pet Practice Common Stock would be issuable under certain acquisition agreements
if the financial criteria are not met and a greater amount of cash would be paid
and a greater number of shares of Pet Practice Common Stock would be issuable
under certain acquisition agreements if the financial criteria are exceeded.
For example, if the financial criteria with respect to certain of the
acquisitions were to be exceeded by 20%, Pet Practice would be obligated to make
cash payments of approximately $3,167 and issue approximately 109,000 shares of
Pet Practice Common Stock over the next five years.
During the thirteen weeks ended April 3, 1996 and the years ended January 3,
1996 and December 28, 1994, Pet Practice used approximately $905, $4,662 and
$206, respectively, for purchases of property and equipment. Pet Practice
anticipates that it will use between $2,000 and $4,000 for purchases of property
and equipment in 1996.
Pet Practice intends to fund its future cash requirements primarily from cash
on hand, internally generated funds and other sources of financing currently
being explored by Pet Practice. Pet Practice's cash requirements for 1996
exceed the aggregate of cash currently on hand and cash expected to be generated
internally. As a result, Pet Practice is currently
103
<PAGE>
exploring potential sources for additional financing. There can be no
assurances that such suitable financing can be obtained. If Pet Practice is
unable to obtain such additional financing, management may need to modify the
pace of acquisitions and/or the planned level of capital expenditures.
As discussed further in "THE MERGER" and Note 12 of Notes to Pet Practice's
Consolidated Financial Statements, on March 22, 1996 Pet Practice announced that
it had signed a definitive agreement (the "Merger Agreement") providing for the
merger of Pet Practice with VCA. If completed, the Merger will result in Pet
Practice becoming a wholly owned subsidiary of VCA. Consummation of the merger
is expected in the second or third quarter of 1996 and is subject to certain
conditions.
Pursuant to the terms of the Merger Agreement, Pet Practice is subject to
certain restrictions on actions it can take between the date of the Merger
Agreement and the closing of the Merger of Pet Practice and VCA. In particular,
there are restrictions on capital expenditures and on Pet Practice's ability to
make acquisitions. The restrictions set forth in the Merger Agreement may
impact Pet Practice's plans with respect to acquisitions and capital
expenditures.
Recently Issued Accounting Standards
In October 1995, the FASB issued Statement of Financial Accounting Standards
No. 123, "Accounting for Stock Based Compensation" ("SFAS 123"). SFAS 123, the
disclosure provisions of which must be implemented for fiscal years beginning
subsequent to December 15, 1995, establishes a fair value based method of
accounting for stock based compensation plans, the effect of which can either be
disclosed or recorded. Pet Practice will adopt the disclosure provisions of
SFAS 123 in 1996. Pet Practice intends to retain the intrinsic value method of
accounting for stock based compensation which it currently follows.
104
<PAGE>
UNAUDITED PRO FORMA FINANCIAL DATA
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
The following unaudited pro forma financial data and explanatory notes
give effect to all acquisitions (36 animal hospitals and nine veterinary
diagnostic laboratories) completed by VCA during 1995 and 1996 (through June 7,
1996) (the "VCA Acquired Companies"), VCA's issuance on April 17, 1996 of the
Debentures and the pending acquisition of four animal hospitals (the "Pending
VCA Acquisitions").
The unaudited pro forma financial data have been prepared utilizing the
historical consolidated financial statements of VCA and the historical financial
statements of the VCA Acquired Companies and the Pending VCA Acquisitions. The
acquisitions have been accounted for under purchase accounting except for the
acquisition of two animal hospitals which have been accounted for as a pooling
of interests. The unaudited pro forma financial data are based on the estimates
and assumptions set forth in the notes thereto.
The unaudited pro forma condensed consolidated statements of operations
for VCA represent the historical results of operations of VCA for the year ended
December 31, 1995 and the three months ended March 31, 1996 adjusted to reflect
the acquisitions of the VCA Acquired Companies and the Pending VCA Acquisitions
as if they had occurred at the beginning of the period. The unaudited pro forma
condensed consolidated balance sheet represents the balance sheet of VCA at
March 31, 1996 adjusted to reflect the issuance of the Debentures and the
acquisitions of the VCA Acquired Companies acquired after March 31, 1996 and the
Pending VCA Acquisitions as if such acquisitions had occurred on March 31, 1996.
Unaudited pro forma financial data are provided for illustrative
purposes only and are not necessarily indicative of the results of operations or
financial position that would have occurred if the issuance of the Debentures
and the acquisitions of the VCA Acquired Companies and the Pending VCA
Acquisitions had been consummated at the beginning of the period presented and
March 31, 1996 respectively, nor are they necessarily indicative of future
operating results or financial position.
105
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
FOR THE YEAR ENDED DECEMBER 31, 1995
(In thousands, except per share data)
<TABLE>
<CAPTION>
VCA PRO PRO VCA VCA
ACQUIRED FORMA FORMA PENDING PRO FORMA PRO FORMA
VCA COMPANIES(1) ADJUSTMENTS COMBINED ACQUISITIONS(25) ADJUSTMENTS COMBINED
--------- --------- ----------- --------- ---------------- ---------- -----------
<S> <C> <C> <C> <C> <C> <C> <C>
Revenues
Animal hospital............. $51,437 $30,458 $ 81,895 $3,310 $ 85,205
Laboratory.................. 37,606 17,674 $ 125 (2) 55,405 55,405
Pet food.................... 4,756 4,756 4,756
Intercompany sales.......... (1,727) (125)(3) (1,852) (1,852)
------- ------- ------- -------- ------ -------- --------
92,072 48,132 140,204 3,310 143,514
------- ------- ------- -------- ------ -------- --------
Direct costs
Animal hospital............. 42,056 28,015 (1,308)(4) 68,763 3,076 $ 76(4) 71,915
Laboratory.................. 23,977 10,155 (5)(5) 34,127 34,127
Pet food.................... 3,205 3,205 3,205
Intercompany sales.......... (1,727) (125)(3) (1,852) (1,852)
------- ------- ------- -------- ------ -------- --------
67,511 38,170 (1,438) 104,243 3,076 76 107,395
------- ------- ------- -------- ------ -------- --------
Gross profit
Animal hospital............. 9,381 2,443 1,308 13,132 234 (76) 13,290
Laboratory.................. 13,629 7,519 130 21,278 21,278
Pet food.................... 1,551 1,551 1,551
------- ------- ------- -------- ------ -------- --------
24,561 9,962 1,438 35,961 234 (76) 36,119
Selling, general and
administrative.............. 10,833 5,411 (993)(6) 15,251 15,251
Depreciation and
amortization................ 3,291 977 937(7) 5,205 24 106(7) 5,335
Royalty fees................. 118 (118)(8)
Restructuring charge......... 1,086 1,086 1,086
------- ------- ------- -------- ------ -------- --------
Operating income............. 9,351 3,456 1,612 14,419 210 (182) 14,447
Interest expense, net........ 1,639 318 1,593(9) 3,550 37 139(9) 3,726
------- ------- ------- -------- ------ -------- --------
Income before minority
interest and provision for
income taxes................ 7,712 3,138 19 10,869 173 (321) 10,721
Minority interest in income
of subsidiaries............. 2,910 7 346(10) 3,263 3,263
------- ------- ------- -------- ------ -------- --------
Income before provision for
income taxes................ 4,802 3,131 (327) 7,606 173 (321) 7,458
Provision for income taxes... 2,238 102 2,698(11) 5,038 (59)(11) 4,979
------- ------- ------- -------- ------ -------- --------
Net income................... $ 2,564 $ 3,029 $(3,025) $ 2,568 $ 173 $ (262) $ 2,479
======= ======= ======= ======== ====== ======== ========
Primary earnings per share... $ 0.24 $ 0.22 $ 0.22
======= ======== ========
Weighted average common
shares used for computing
primary earnings per share.. 10,703 745(12) 11,448 11,448
======= ======= ======== ========
Fully diluted earnings per
share....................... $ 0.23 $ 0.21 $ 0.21
======= ======== ========
Weighted average common
shares used for computing
fully diluted earnings per
share...................... 11,238 745(12) 11,983 11,983
======= ======= ======== ========
</TABLE>
106
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 1996
(In thousands, except per share data)
<TABLE>
<CAPTION>
VCA PRO PRO VCA VCA
ACQUIRED FORMA FORMA PENDING PRO FORMA PRO FORMA
VCA COMPANIES(28) ADJUSTMENTS COMBINED ACQUISITIONS(27) ADJUSTMENTS COMBINED
--------- ------------- ----------- --------- ---------------- ----------- -----------
<S> <C> <C> <C> <C> <C> <C> <C>
Revenues
Animal hospital............. $17,831 $2,049 $19,880 $790 $20,670
Laboratory.................. 12,056 2,547 14,603 14,603
Pet food.................... 1,850 1,850 1,850
Intercompany sales.......... (733) (733) (733)
------- ------ ------ ------- ---- ---- -------
31,004 4,596 35,600 790 36,390
------- ------ ------ ------- ---- ---- -------
Direct costs
Animal hospital............. 15,390 1,929 $(150)(4) 17,169 723 $ 32(4) 17,924
Laboratory.................. 7,386 1,618 (21)(5) 8,983 8,983
Pet food.................... 1,160 1,160 1,160
Intercompany sales.......... (733) (733) (733)
------- ------ ------ ------- ---- ---- -------
23,203 3,547 (171) 26,579 723 32 27,334
------- ------ ------ ------- ---- ---- -------
Gross profit
Animal hospital............. 2,441 120 150 2,711 67 (32) 2,746
Laboratory.................. 4,670 929 21 5,620 5,620
Pet food.................... 690 690 690
------- ------ ------ ------- ---- ---- -------
7,801 1,049 171 9,021 67 (32) 9,056
Selling, general and
administrative.............. 3,314 1,147 (78)(6) 4,383 4,383
Depreciation and amortization 1,034 37 100 (7) 1,171 5 27 (7) 1,203
------- ------ ------ ------- ---- ---- -------
Operating income............. 3,453 (135) 149 3,467 62 (59) 3,470
Interest expense, net........ 296 16 176 (9) 488 36 (9) 524
------- ------ ------ ------- ---- ---- -------
Income before minority
interest and provision for
income taxes................ 3,157 (151) (27) 2,979 62 (95) 2,946
Minority interest in income
of subsidiaries............. 1,346 1,346 1,346
------- ------ ------ ------- ---- ---- -------
Income before provision for
income taxes................ 1,811 (151) (27) 1,633 62 (95) 1,600
Provision for income taxes... 799 (64)(11) 735 (13)(11) 722
------- ------ ------ ------- ---- ---- -------
Net income................... $ 1,012 $ (151) $ 37 $ 898 $ 62 $(82) $ 878
======= ====== ====== ======= ==== ==== =======
Primary earnings per share... $ 0.07 $ 0.06 $ 0.06
======= ======= =======
Weighted average common
shares used for computing
primary earnings per share. 15,110 267 (12) 15,377 15,377
======= ====== ======= =======
Fully diluted earnings per
share....................... $ 0.07 $ 0.06 $ 0.06
======= ======= =======
Weighted average common
shares used for computing
fully diluted earnings per
share....................... 15,492 267 (12) 15,759 15,759
======= ====== ======= =======
</TABLE>
107
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET
AT MARCH 31, 1996
(In thousands)
<TABLE>
<CAPTION>
SECOND PRO PRO VCA VCA
QUARTER FORMA FORMA PENDING PRO FORMA PRO FORMA
VCA ACQUISITIONS(13) ADJUSTMENTS COMBINED ACQUISITIONS(26) ADJUSTMENTS COMBINED
-------- ---------------- ----------- -------- --------------- ------------ ---------
<S> <C> <C> <C> <C> <C> <C> <C>
ASSETS
Current assets:
Cash and
equivalents $ 37,615 $78,958 (14) $116,573 $(1,025)(14) $115,548
Accounts
receivable, net 8,816 $ 3 (1)(15) 8,818 $260 (235)(15) 8,843
Other current assets 5,497 51 (10)(16) 5,538 113 (63)(16) 5,588
-------- ---- ------- -------- ---- ----- -------
51,928 54 78,947 130,929 373 (1,323) 129,979
Property and
equipment, net 15,981 654 1,053 (17) 17,688 379 (254)(17) 17,813
Other assets:
Notes receivable 1,183 1,183 1,183
Goodwill 79,637 3,829 (18) 83,466 37 2,026 (18) 85,529
Covenants 5,573 407 (19) 5,980 252 (19) 6,232
Other 2,746 1,688 (20) 4,434 4 (4)(21) 4,434
-------- ---- ------- -------- ---- ------- --------
$157,048 $708 $85,924 $243,680 $793 $ 697 $245,170
======== ==== ======= ======== ==== ======= ========
LIABILITIES AND
STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of
long-term debt $ 7,563 $ 232 (22) $ 7,795 $167 $ 58 (22) $ 8,020
Accounts payable 5,794 $ 21 5,815 146 (146)(23) 5,815
Other accrued
liabilities 5,577 174 150 (22) 5,901 31 134 (22) 6,066
-------- ---- ------- -------- ---- ----- -------
18,934 195 382 19,511 344 46 19,901
Long-term obligations,
less current
portion 29,588 322 85,496 (24) 115,406 210 890 (24) 116,506
Deferred income taxes 1,538 1,538 1,538
Minority interest 4,843 4,843 4,843
Stockholders' equity 102,145 191 46 (25) 102,382 239 (25) (239)(25) 102,382
-------- ---- ------- -------- ---- ----- --------
$157,048 $708 $85,924 $243,680 $793 $ 697 $245,170
======== ==== ======= ======== ==== ===== ========
</TABLE>
108
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(1) Reflects the historical statement of operations data of the VCA Acquired
Companies for the period from January 1, 1995 to the earlier of the
respective dates of acquisition of such companies or December 31, 1995.
Each of the acquisitions has been accounted for as a purchase. Accordingly,
the results of operations of each such VCA Acquired Company is included in
the results of operations of VCA from the date of acquisition.
The following are the VCA Acquired Companies: Cenvet, Inc. ("Cenvet"),
January 1995; Animal Reference Lab, January 1995; BerLa, Inc. (d/b/a Animal
and Avian Clinic of Golden Cove), January 1995; Silver Spur Animal
Hospital, Inc., January 1995; Stephen A. LaDue D.V.M., P.A. (d/b/a Tampa
Animal Medical Center), January 1995; Lewis Veterinary Hospital, Inc.,
February 1995; Animal Hospital of Sinking Spring, March 1995; Vet Research,
Inc., March 1995; Lewelling Veterinary Hospital, Inc., April 1995;
Northwest Veterinary Diagnostics, Inc., May 1995; South County Veterinary
Clinic, Inc., May 1995; Alpine Veterinary Clinic, Inc., May 1995; Eagle
River Veterinary Hospital, Inc., June 1995; Clinipath Diagnostics, Inc.,
July 1995; Florida Veterinary Laboratories, Inc. (composed of four
hospitals), July 1995; Miller Animal Hospital, Inc., July 1995; Marina
Veterinary Clinic, July 1995; South Shore Veterinary Associates, Inc., July
1995 (includes four animal hospitals); Pet Complex, P.A. (d/b/a All Pets
Animal Complex-Sandy), July 1995; Brett T. Neville, D.V.M., Inc., P.C.
(d/b/a All Pets Animal Complex-Taylorsville), July 1995; Castle Shannon
Veterinary Hospital, Inc., August 1995; Fox Chapel Animal Hospital, Inc.,
September 1995 (includes two animal hospitals); East Anchorage Veterinary
Hospital, Inc., September 1995; Greater Savannah Hospital for Animals,
Inc., September 1995; Kaneohe Pet Health Center, November 1995; Elkton
Veterinary Center, Inc. (composed of two hospitals), November 1995;
Conawago Veterinary Practice, January 1996; Animal Hospital of St.
Petersburg, Inc., January 1996; Kaneohe Veterinary Clinic, January 1996;
Veterinary Referral Associates, Inc., February 1996; Lammers Veterinary
Hospital, Inc., February 1996; Southwest Veterinary Diagnostics Inc., March
1996; Clarmar Animal Hospital, Inc., March 1996; Rotherwood Animal Clinic,
Inc., March 1996; Northboro Veterinary Clinic, Inc., April 1996; Diagnostic
Veterinary Services, Inc., May 1996; the assets pertaining to the
veterinary business of APL Healthcare Group Inc., May 1996; Beacon Hill Cat
Hospital, Inc., May 1996; Old Town Veterinary Hospital, Inc., May 1996;
North Rockville Veterinary Hospital Inc., June 1996.
(2) Represents the revenue for laboratory services previously rendered by
laboratories not owned by VCA. Such services are to be rendered by
laboratories owned by VCA following the respective dates of acquisition.
(3) Represents the elimination of intercompany revenue and the corresponding
expense.
(4) Represents principally an adjustment of $597,000 and $107,000 for the
twelve months ended December 31, 1995 and the three months ended March 31,
1996, respectively, related to rental expense for the difference between
such historical amounts and that to be paid following the acquisitions as a
result of modifications to lease terms or the purchase of the hospital land
and buildings previously leased, and an adjustment of $685,000 and $74,000
for the twelve months ended December 31, 1995 and the three months ended
March 31, 1996, respectively, related to compensation for services provided
by owner/veterinarians and other key employees for the difference between
such historical amounts and employment terms existing following the
acquisition.
(5) Represents principally an adjustment of $86,000 and $21,000 for the twelve
months ended December 31, 1995 and the three months ended March 31, 1996,
respectively, related to (i) rental expense for the difference between such
historical amounts and that to be paid following the acquisitions as a
result of modifications to lease terms or the purchase of the laboratory
land and buildings previously leased, and (ii) increases reflecting the
incremental costs associated with the laboratory revenue which was
previously rendered by laboratories not owned by VCA. Such services are to
be rendered by laboratories owned by VCA following the respective dates of
acquisition.
(6) Adjustments to selling, general and administrative expenses consist
primarily of adjustments to certain VCA Acquired Companies' historical
amounts relating to (i) compensation for services provided by
owner/veterinarians and other key employees for the difference between such
historical amounts and employment terms existing following the acquisition,
and (ii) administrative services eliminated following certain acquisitions.
109
<PAGE>
(7) Reflects additional depreciation of assets acquired and amortization of
goodwill and other intangibles resulting from the acquisition of the VCA
Acquired Companies. Goodwill acquired in 1995 and 1996 amounted to
$55,247,000. Other intangibles acquired in 1995 and 1996 amounted to
$6,412,000. Goodwill is amortized over forty years. Other intangibles
consist primarily of covenants not to compete and are amortized over the term
of the agreement (principally 5 to 10 years).
(8) Reflects the elimination of royalty fee expense under an agreement that was
not assumed by VCA.
(9) Reflects the additional interest expense that would have been incurred on
the indebtedness of $27,558,000 issued by VCA in connection with the
acquisitions of the VCA Acquired Companies ($1,325,000 related to the VCA
Pending Acquisitions). Annual interest rates on such indebtedness range
from approximately 5.0 percent to 9.0 percent.
(10) Represents the minority interest in certain of the VCA Acquired Companies
net of an adjustment of $219,000, to eliminate a minority interest in
another VCA Acquired Company acquired in 1995.
(11) Represents an adjustment to provide income taxes at the effective rate.
(12) To reflect the issuance of approximately 1,469,200 and 393,940 shares of
VCA Common Stock for the twelve months ended December 31, 1995 and the
three months ended March 31, 1996, respectively, in connection with the
acquisition of the VCA Acquired Companies.
(13) Reflects the combined financial position of the VCA Acquired Companies
acquired after March 31, 1996 (the "Second Quarter Acquisitions"). See
Note 1.
(14) Represents (i) the net proceeds received in connection with the issuance of
the Debentures ($82,697,000) net of cash consideration paid in connection
with the Second Quarter Acquisitions ($3,739,000) and (ii) cash
consideration ($1,025,000) to be paid in connection with the VCA Pending
Acquisitions.
(15) Reflects an adjustment to net realizable value of accounts receivable
acquired from certain companies.
(16) Reflects an adjustment to reflect other current assets, principally
inventory, at fair market value.
(17) Reflects an adjustment to fair market value of property and equipment, net,
acquired.
(18) Reflects the excess of cost over the fair value of the net tangible assets
acquired in connection with the acquisitions.
(19) Represents the value of consideration given in connection with non-compete
agreements obtained in connection with the acquisitions.
(20) Represents the deferred financing costs related to the issuance of the
Debentures.
(21) Reflects the exclusion of certain assets not acquired in connection with
certain acquisitions.
(22) Represents the indebtedness incurred or assumed in connection with the
acquisitions, net of indebtedness of the acquired entities which was not
assumed.
(23) Reflects the elimination of certain current liabilities not assumed in
connection with the acquisition of certain of the Second Quarter
Acquisitions.
(24) Reflects long-term indebtedness incurred in connection with the acquisition
of certain Second Quarter Acquisitions and VCA Pending Acquisitions at
annual interest rates ranging from 5.0 percent to 8.0 percent.
(25) Reflects the elimination of the stockholders' equity of the Second Quarter
Acquisitions and VCA Pending Acquisitions.
(26) Reflects the pending acquisition of four animal hospitals scheduled to be
consummated before July 15, 1996.
110
<PAGE>
(27) Reflects the acquisition of animal hospitals and laboratories which
occurred in 1996. See Note 1. The operations of Conawago Veterinary
Practice, Animal Hospital of St. Petersburg, Inc. and Kaneohe Veterinary
Clinic which were acquired on January 2, 1996 are included in "VCA Acquired
Companies."
111
<PAGE>
PET PRACTICE
The following unaudited pro forma financial data and explanatory notes
give effect to all acquisitions (41 animal hospitals during 1995 and through
June 7, 1996) completed by Pet Practice (collectively, the "Pet Practice
Acquired Companies"). The unaudited pro forma financial data should be read in
conjunction with Pet Practice's historical consolidated financial statements and
notes thereto appearing elsewhere in this Joint Proxy Statement/Prospectus.
The unaudited pro forma financial data have been prepared utilizing the
historical financial statements of Pet Practice and the historical financial
statements of the Pet Practice Acquired Companies. The unaudited pro forma
financial data are based on the estimates and assumptions set forth in the notes
to the unaudited pro forma financial data.
The unaudited pro forma condensed consolidated statements of operations
represent the historical results of operations of Pet Practice for the period
ended January 3, 1996 and the thirteen weeks ended April 3, 1996 adjusted to
reflect acquisitions of the Pet Practice Acquired Companies as if they had
occurred at the beginning of the periods presented. Each of the acquisitions
has been accounted for as a purchase.
The unaudited pro forma financial data are provided for illustrative
purposes only and are not necessarily indicative of the results of operations or
financial position that would have occurred if the acquisitions of the Pet
Practice Acquired Companies had been consummated at the beginning of the periods
presented, nor are they necessarily indicative of future operating results or
financial position.
112
<PAGE>
THE PET PRACTICE, INC.
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
FOR THE YEAR ENDED JANUARY 3, 1996
(In thousands, except per share data)
<TABLE>
<CAPTION>
PET PRACTICE PET PRACTICE
ACQUIRED PRO FORMA PRO FORMA
PET PRACTICE COMPANIES (1) ADJUSTMENTS COMBINED
--------------- ---------------- ------------ -------------
<S> <C> <C> <C> <C>
Revenues $40,571 $18,257 $58,828
Costs of revenues 34,776 15,914 $(761)(2) 49,929
------- ------- ----- -------
Gross profit 5,795 2,343 761 8,899
General and administrative 5,796 410 (410)(3) 5,796
Amortization of excess of cost over fair
value of net assets acquired and other
intangible assets 1,229 620 (4) 1,849
------- ------- ----- -------
Operating income (loss) (1,230) 1,933 551 1,254
Interest expense, net 1,861 290 746 (5) 2,897
------- ------- ----- -------
Income (loss) before provision for (3,091) 1,643 (195) (1,643)
income taxes
Provision for income taxes 84 84
------- ------- ----- -------
Net income (loss) $(3,175) $ 1,643 $(195) $(1,727)
======= ======= ===== =======
Loss per share $ (0.54) $ (0.29)
======= ===== =======
Weighted average common shares used
for computing loss per share 5,863 181 (6) 6,044
======= ===== =======
</TABLE>
113
<PAGE>
THE PET PRACTICE, INC.
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
FOR THE THIRTEEN WEEKS ENDED APRIL 3, 1996
(In thousands, except per share data)
<TABLE>
<CAPTION>
PET PRACTICE PET PRACTICE
ACQUIRED PRO FORMA PRO FORMA
PET PRACTICE COMPANIES (1) ADJUSTMENTS COMBINED
------------ ------------- ----------- ------------
<S> <C> <C> <C> <C>
Revenues $13,404 $175 $13,579
Costs of revenues 12,104 172 $(18)(2) 12,258
------- ---- ---- -------
Gross profit 1,300 3 18 1,321
General and administrative 1,490 1,490
Amortization of excess of cost over fair
value of net assets acquired and other
intangible assets 460 10 (4) 470
------- ---- ---- -------
Operating income (loss) (650) 3 8 (639)
Interest expense, net 228 12 10 (5) 250
------- ---- ---- -------
Loss before provision for
income taxes (878) (9) (2) (889)
Provision for income taxes 21 21
------- ---- ---- -------
Net Loss $ (899) $ (9) $ (2) $ (910)
======= ==== ==== =======
Loss per share $ (0.10) $ (0.11)
======= =======
Weighted average common shares used
for computing loss per share 8,614 12 (6) 8,626
======= ==== =======
</TABLE>
114
<PAGE>
THE PET PRACTICE, INC.
NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(1) Reflects the historical statement of operations data for the Pet Practice
Acquired Companies for the period from December 29, 1994 to the earlier
of the respective dates of the acquisition of such companies or January
3, 1996. Each of the acquisitions has been accounted for as a purchase.
Accordingly, the results of operations of each of the Pet Practice
Acquired Companies is included in the results of operations of Pet
Practice from the date of acquisition.
The following animal hospitals represent the Pet Practice Acquired
Companies:
Marietta Animal Hospital, Inc.; W. Harold Davis, D.V.M. (d/b/a Zionsville
Animal Clinic); S.V. Rowell D.V.M., Ltd. (d/b/a La Grange Park Pet
Hospital); Salvatore M. Zeitlin, V.M.D.; P.A. (d/b/a Palm Beach County
Animal Medical Clinic); Forrest D. Hayes, P.A. (d/b/a Atlantic Animal
Clinic); Glen R. Redeker, D.V.M. (d/b/a Oakton Animal Clinic); Charles R.
McCune, D.V.M. (d/b/a 46th Street Pet Clinic); Mary L. Jutte, D.V.M.
(d/b/a Southland Hospital for Animals and Taylor Veterinary Clinic);
Academy Animal Hospital of Hillsboro, Inc.; Robert S. Legg, D.V.M., P.A.
(d/b/a Colonial Animal Hospital); Riviera Animal Hospital, Inc.; Academy
Animal Inc.; Andreas Wurzer, D.V.M. (d/b/a Chicago Heights Animal
Hospital); Richard R. Brown, D.V.M. (d/b/a Golfview Animal Clinic);
Westboro Animal Hospital, P.C.; Andrew M. Payson, D.V.M., P.A. (d/b/a
Boca Grove Animal Hospital & Pet Supplies); Edward A. Jones, D.V.M.
(d/b/a Companion Animal Hospital and Oldsmar Animal Hospital); Edgebrook
Veterinary Hospital P.C.; George D. Brodsky, D.V.M. (d/b/a Bourbonnais
Animal Clinic); Bowie Hospital, Inc. and Crofton Animal Hospital, Inc.;
Peter E. Coakley, V.M.D. (d/b/a Animal Extra Care); Academy Animal
Hospital of Boca, Inc.; Academy Animal Hospital of Cooper City, Inc.;
Academy Animal Hospital of Coral Springs, Inc.; Peticare Animal Medical
Center, P.C.; Peter V. Birzon, D.V.M., Animal Hospital of North Miami
Beach, P.A.; Jon J. Rappaport, D.V.M. and Craig Horowitz, D.V.M. and
Miami Shores Animal Hospital, P.A.; Edward D. Lukuch, D.V.M. (d/b/a
Midpark Animal Hospital); Joanne Nelson (d/b/a Collins & South Pompano
Animal Hospital); Dr. Jenifer Preston, Inc. (d/b/a Westerville East
Animal Hospital); Donald Denoff, D.V.M., P.A. (d/b/a Wellington Animal
Hospital); and Neshaminy Animal Medical Center, P.C.
(2) The adjustments to costs of revenues consist primarily of reductions or
increases to certain of the Pet Practice Acquired Companies' historical
amounts of compensation for services provided by owner/veterinarians for
the difference between such historical amounts and amounts specified in
employment contracts for comparable positions in Pet Practice, net of
certain general and administrative expenses of the Pet Practice Acquired
Companies which have been reclassified as costs of revenues.
(3) The adjustments to general and administrative expenses consist primarily
of (i) reductions or increases to certain of the Pet Practice Acquired
Companies' historical amounts of compensation for certain owners and
administrative personnel between such historical amounts and amounts
specified in employment contracts for such individuals, (ii) elimination
of certain non-recurring charges and credits attributable to the
acquisitions of the Pet Practice Acquired Companies and (iii)
reclassifications of certain amounts to cost of revenues.
(4) The adjustment to amortization of excess of cost over fair value of net
assets acquired and other intangible assets relates to the additional
amortization over periods of three to 40 years of the excess of cost over
fair value of net assets acquired and other intangible assets of the Pet
Practice Acquired Companies.
(5) The adjustment reflects the additional interest expense that would have
been incurred and the reduction of interest income had the consideration
in the form of cash and notes for the acquisitions of the Pet Practice
Acquired Companies been paid on December 29, 1994, net of the elimination
of approximately $290,000 of interest expense relating to outstanding
debt of certain of the Pet Practice Acquired Companies that was not
assumed by Pet Practice. The notes relating to the acquisition of the
Pet Practice Acquired Companies bear interest at annual rates of 6.0% to
8.0%.
(6) Reflects the issuance of an aggregate of approximately 221,000 shares of
Pet Practice Common Stock in connection with the Pet Practice Acquired
Companies.
115
<PAGE>
VCA AND PET PRACTICE
The unaudited pro forma financial data and explanatory notes set forth below
give effect to VCA's acquisition of the VCA Acquired Companies, the VCA Pending
Acquisitions, the issuance of the Debentures and the Merger with Pet Practice,
including the acquisition by Pet Practice of the Pet Practice Acquired
Companies. The unaudited pro forma financial data should be read in conjunction
with the historical consolidated financial statements and notes thereto of Pet
Practice appearing elsewhere in this Joint Proxy Statement/Prospectus. The
Merger is to be accounted for as a purchase.
The unaudited pro forma financial data have been prepared utilizing VCA's
unaudited pro forma financial data and Pet Practice's unaudited pro forma
financial data. The unaudited pro forma financial data are based on estimates
and assumptions set forth in the notes to the unaudited pro forma financial
data.
The unaudited pro forma condensed combined statements of operations
represent the unaudited pro forma results of operations of VCA and Pet Practice
for the year ended December 31, 1995 and January 3, 1996, respectively, and the
period ended March 31, 1996 and April 3, 1996, respectively, giving effect to
the Merger as if it had occurred at the beginning of the period. The unaudited
pro forma condensed combined balance sheet was prepared to reflect the Merger as
if it had occurred on March 31, 1996.
Unaudited pro forma financial data are provided for illustrative purposes
only and are not necessarily indicative of the results of operations or
financial position that would have occurred if the Merger had been consummated
at the beginning of the periods presented nor are they necessarily indicative of
future operating results or financial position.
116
<PAGE>
VCA AND PET PRACTICE
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
FOR THE YEAR ENDED DECEMBER 31, 1995
(In thousands, except per share data)
<TABLE>
<CAPTION>
VCA AND
VCA PET PRACTICE PET PRACTICE
PRO FORMA PRO FORMA PRO FORMA PRO FORMA
COMBINED COMBINED ADJUSTMENTS COMBINED
-------- ------------ ----------- ------------
<S> <C> <C> <C> <C>
Revenues
Animal hospital........................... $ 85,205 $ 58,828 $144,033
Laboratory................................ 55,405 55,405
Pet food.................................. 4,756 4,756
Intercompany sales........................ (1,852) (1,852)
-------- -------- ------- --------
143,514 58,828 202,342
Direct costs
Animal hospital........................... 71,915 49,929 $ (636)(1) 121,208
Laboratory................................ 34,127 34,127
Pet food.................................. 3,205 3,205
Intercompany sales........................ (1,852) (1,852)
-------- -------- ------- --------
107,395 49,929 (636) 156,688
Gross profit
Animal hospital........................... 13,290 8,899 636 22,825
Laboratory................................ 21,278 21,278
Pet food.................................. 1,551 1,551
-------- -------- ------- --------
36,119 8,899 636 45,654
Selling, general and administrative........ 15,251 5,796 (152)(1) 20,895
Amortization of excess of cost over fair
value of net assets acquired and other
intangible assets......................... 1,849 (1,849)(1)
Depreciation and amortization.............. 5,335 4,249 (1)(2) 9,584
Restructuring charge....................... 1,086 1,086
-------- -------- ------- --------
Operating income........................... 14,447 1,254 (1,612) 14,089
Interest expense, net...................... 3,726 2,897 6,623
-------- -------- ------- --------
Income (loss) before minority interest
and provision for income taxes............ 10,721 (1,643) (1,612) 7,466
Minority interest in income of
subsidiaries.............................. 3,263 3,263
-------- -------- ------- --------
Income (loss) before provision for 7,458 (1,643) (1,612) 4,203
income taxes..............................
Provision for income taxes................. 4,979 84 (638)(3) 4,425
-------- -------- ------- --------
Net income (loss).......................... $ 2,479 $ (1,727) $ (974) $ (222)
========= ======== ======= ========
Primary earnings (loss) per share.......... $ 0.22 $ (0.02)
========= ========
Weighted average common shares used
for computing primary earnings (loss)
per share................................. 11,448 3,273 (8) 14,721
========= ======= ========
Fully diluted earnings (loss) per share.... $ 0.21
=========
Weighted average common shares used
for computing fully diluted earnings
per share................................. 11,983
=========
</TABLE>
117
<PAGE>
VCA AND PET PRACTICE
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 1996
(In thousands, except per share data)
<TABLE>
<CAPTION>
VCA AND
VCA PET PRACTICE PET PRACTICE
PRO FORMA PRO FORMA PRO FORMA PRO FORMA
COMBINED COMBINED ADJUSTMENTS COMBINED
-------- ------------ ----------- ------------
<S> <C> <C> <C> <C>
Revenues
Animal hospital........................... $20,670 $13,579 $34,249
Laboratory................................ 14,603 14,603
Pet food.................................. 1,850 1,850
Intercompany sales........................ (733) (733)
------- ------- ------ -------
36,390 13,579 49,969
Direct costs
Animal hospital........................... 17,924 12,258 $ (343)(1) 29,839
Laboratory................................ 8,983 8,983
Pet food.................................. 1,160 1,160
Intercompany sales........................ (733) (733)
------- ------- ------ -------
27,334 12,258 (343) 39,249
Gross profit
Animal hospital........................... 2,746 1,321 343 4,410
Laboratory................................ 5,620 5,620
Pet food.................................. 690 690
------- ------- ------ -------
9,056 1,321 343 10,720
Selling, general and administrative........ 4,383 1,490 (42)(1) 5,831
Amortization of excess of cost over fair
value of net assets acquired and other
intangible assets......................... 470 (470)(1)
Depreciation and amortization.............. 1,203 1,070 (1)(2) 2,273
------- ------- ------ -------
Operating income (loss).................... 3,470 (639) (215) 2,616
Interest expense, net...................... 524 250 774
------- ------- ------ -------
Income (loss) before minority interest
and provision for income taxes............ 2,946 (889) (215) 1,842
Minority interest in income of
subsidiaries.............................. 1,346 1,346
------- ------- ------ -------
Income (loss) before provision for
income taxes.............................. 1,600 (889) (215) 496
Provision for income taxes................. 722 21 (276)(3) 467
------- ------- ------ -------
Net income (loss).......................... $ 878 $ (910) $ 61 $ 29
======= ======= ====== =======
Primary earnings per share................. $ 0.06 $ 0.00
======= =======
Weighted average common shares used
for computing primary earnings per
share..................................... 15,377 3,273 (8) 18,650
======= ====== =======
Fully diluted earnings per share........... $ 0.06 $ 0.00
======= =======
Weighted average common shares used
for computing fully diluted earnings
per share................................. 15,759 3,273 (8) 19,032
======= ====== =======
</TABLE>
118
<PAGE>
VCA AND PET PRACTICE
UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET
AT MARCH 31, 1996
(IN THOUSANDS)
<TABLE>
<CAPTION>
VCA AND
VCA PET PRACTICE
PRO FORMA PRO FORMA PRO FORMA
COMBINED PET PRACTICE ADJUSTMENTS COMBINED
-------- ------------ ----------- ------------
<S> <C> <C> <C> <C>
ASSETS
Current assets:
Cash and equivalents $115,548 $ 4,916 $ (3,400)(4) $117,064
Accounts receivable, net 8,843 836 9,679
Other current assets 5,588 5,010 10,598
-------- ------- -------- --------
129,979 10,762 (3,400) 137,341
Property and equipment, net 17,813 15,029 (857)(5) 31,985
Other assets:
Notes receivable 1,183 1,183
Goodwill 85,529 90,309 (6)(9) 175,838
Covenants 6,232 96 (9) 6,328
Excess of cost over fair value of
net assets acquired and other
intangible assets 53,775 (53,775)(9)
Other 4,434 149 1,431 (9) 6,014
-------- ------- -------- --------
$245,170 $79,715 $ 33,804 $358,689
======== ======= ======== ========
LIABILITIES AND
STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt $ 8,020 $ 3,820 $ 11,840
Accounts payable 5,815 2,169 7,984
Other accrued liabilities 6,066 4,989 11,055
-------- ------- -------- --------
19,901 10,978 30,879
Long-term obligations, less current 116,506 16,216 132,722
portion
Other liabilities
Deferred income taxes 1,538 1,538
Minority interest 4,843 4,843
Stockholders' equity 102,382 52,521 $ 33,804 (7)(8) 188,707
-------- ------- -------- --------
$245,170 $79,715 $ 33,804 $358,689
======== ======= ======== ========
</TABLE>
119
<PAGE>
VCA AND PET PRACTICE
NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
(1) To reclassify depreciation expense and amortization of excess of cost over
fair value of net assets acquired and other intangible assets to conform
with VCA's presentation.
(2) Represents depreciation of assets acquired and amortization of goodwill
and other intangibles.
(3) Represents an adjustment to provide income taxes at the effective rate.
(4) Represents transaction costs including financial advisor, legal and
accounting fees.
(5) Represents an adjustment to fair market value of the property and
equipment acquired.
(6) Represents the excess of cost over the fair value of the net tangible
assets acquired in connection with the acquisition of Pet Practice.
(7) Adjustment to reflect the elimination of Pet Practice's stockholders'
equity in connection with the acquisition.
(8) Represents the issuance of approximately 3,273,000 shares of VCA Common
Stock in connection with the acquisition assuming the average closing
price of VCA Common Stock, for purposes of computing the exchange ratio,
is $26.375 per share.
(9) To reclassify Pet Practice balances to conform with VCA's presentation.
120
<PAGE>
VCA, PET PRACTICE AND PETS' RX
The following unaudited pro forma financial data and explanatory notes
give effect to the combination of VCA (as adjusted for the acquisitions of the
VCA Acquired Companies, the VCA Pending Acquisitions and the issuance of the
Debentures), Pet Practice (as adjusted for the acquisitions of the Pet Practice
Acquired Companies) and Pets' Rx. The combination with Pet Practice is
reflected as a purchase and the combination with Pets' Rx is reflected as a
pooling of interests. The unaudited pro forma combined financial data should
be read in conjunction with the historical Consolidated Financial Statements
and Notes thereto of VCA, Pet Practice and Pets' Rx and the unaudited pro forma
financial data of VCA and Pet Practice which are included elsewhere in this
Joint Proxy Statement/Prospectus.
This unaudited pro forma data have been prepared utilizing VCA's unaudited
pro forma financial data, Pet Practice's financial data and the historical
financial statements of Pets' Rx. The unaudited pro forma financial data are
based on the estimates and assumptions set forth in the notes to the unaudited
pro forma financial data.
The unaudited pro forma condensed combined statements of operations
reflecting the combination of VCA, Pet Practice and Pets' Rx represent the
historical results of operations of VCA for the three years ended December 31,
1995 and the three months ended March 31, 1996 adjusted to reflect (i) the
acquisitions of the VCA Acquired Companies, the VCA Pending Acquisitions and
the Merger with Pet Practice as if such transactions had occurred on January 1,
1995, and (ii) the acquisition of Pets' Rx as if it had occurred on January 1,
1993. The unaudited pro forma condensed combined balance sheet was prepared to
reflect certain of the transactions as if they had occurred at March 31, 1996.
Unaudited pro forma financial data are provided for illustrative purposes
only and are not necessarily indicative of the results of operations or
financial position that would have occurred if the Merger with Pet Practice and
the merger with Pets' Rx had been consummated at the beginning of the period,
nor are they necessarily indicative of future operating results or financial
position.
121
<PAGE>
VCA, PET PRACTICE AND PETS' RX
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED DECEMBER 31, 1993, 1994, 1995
AND THE THREE MONTHS ENDED MARCH 31, 1996
(In thousands, except per share data)
<TABLE>
<CAPTION>
1993 1994 1995 MARCH 31, 1996
-------- -------- --------- --------------
<S> <C> <C> <C> <C>
Revenues
Animal hospital............................................ $30,208 $41,484 $159,655 $38,477
Laboratory................................................. 1,234 10,150 55,405 14,603
Pet food................................................... 996 4,756 1,850
Intercompany sales......................................... (344) (759) (1,852) (733)
------- ------- -------- -------
31,098 51,871 217,964 54,197
Direct costs
Animal hospital............................................ 24,714 34,373 134,444 33,346
Laboratory................................................. 1,192 6,573 34,127 8,983
Pet food................................................... 647 3,205 1,160
Intercompany sales......................................... (344) (759) (1,852) (733)
------- ------- -------- -------
25,562 40,834 169,924 42,756
Gross profit
Animal Hospital............................................ 5,494 7,111 25,211 5,131
Laboratory................................................. 42 3,577 21,278 5,620
Pet food................................................... 349 1,551 690
------- ------- -------- -------
5,536 11,037 48,040 11,441
Selling, general and administrative......................... 4,916 8,704 23,098 6,361
Depreciation and amortization............................... 1,410 2,065 10,437 2,474
Restructuring charge........................................ 1,086
Writedown of assets......................................... 4,506 2,148
------- ------- -------- -------
Operating (loss) income..................................... (5,296) 268 11,271 2,606
Interest expense, net....................................... 756 1,984 7,533 991
------- ------- -------- -------
(Loss) income provision before minority interest (6,052) (1,716) 3,738 1,615
and (benefit) for income taxes.............................
Minority interest in (loss) income of subsidiaries.......... (334) (540) 3,313 1,371
------- ------- -------- -------
(Loss) income before (benefit) provision for income taxes (5,718) (1,176) 425 244
and cumulative effect of accounting change.................
(Benefit) provision for income taxes........................ (152) 731 4,425 467
------- ------- -------- -------
Loss before cumulative effect of accounting change.......... (5,566) (1,907) (4,000) (223)
Cumulative effect of accounting change...................... 221
------- ------- -------- -------
Net loss.................................................... $(5,345) $(1,907) $ (4,000) $ (223)
======= ======= ======== =======
Loss per share.............................................. $ (0.90) $ (0.26) $ (0.26) $ (0.01)
======= ======= ======== =======
Weighted average common shares used
for computing loss per share.............................. 5,966 7,233 15,522 19,451
======= ======= ======== =======
</TABLE>
122
<PAGE>
VCA, PET PRACTICE AND PETS' RX
UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET
AT MARCH 31, 1996
(In thousands)
<TABLE>
<CAPTION>
VCA, PET
VCA AND PET PRACTICE AND PETS'
PRACTICE PRO FORMA POOLING RX PRO FORMAT
COMBINED (1) PETS' RX (2) ADJUSTMENTS COMBINED
------------------ ------------ ---------------- -----------------
<S> <C> <C> <C> <C>
ASSETS
Current Assets
Cash and equivalents......................... $117,064 $ 251 $117,315
Accounts receivable, net..................... 9,679 178 9,857
Other current assets......................... 10,598 480 11,078
-------- ------- ------- --------
137,341 909 138,250
Property and equipment, net................... 31,985 3,993 35,978
Other assets:
Notes receivable............................. 1,183 100 1,283
Goodwill..................................... 175,838 8,872 (3,116)(3) 181,594
Covenants.................................... 6,328 438 (159)(3) 6,607
Other........................................ 6,014 269 6,283
-------- ------- ------- --------
$358,689 $14,581 $(3,275) $369,995
======== ======= ======= ========
LIABILITIES AND STOCKHOLDERS'
EQUITY (DEFICIT)
Current liabilities:
Current portion of long-term debt............ $ 11,840 $ 1,167 $ 13,007
Accounts payable............................. 7,984 1,061 9,045
Other accrued liabilities.................... 11,055 1,217 12,272
-------- ------- ------- --------
30,879 3,445 34,324
Long-term obligations, less current portion... 132,722 9,219 141,941
Deferred income taxes......................... 1,538 1,538
Minority interest............................. 4,843 269 5,112
Redeemable convertible preferred stock........ 2,947 $(2,947)(4)
Stockholders' equity (deficit)................ 188,707 (1,299) (328)(3)(4) 187,080
-------- ------- ------- --------
$358,689 $14,581 $(3,275) $369,995
======== ======= ======= ========
</TABLE>
123
<PAGE>
PETS' RX, INC.
CONDENSED COMBINED STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED DECEMBER 31, 1993, 1994, 1995
AND THE THREE MONTHS ENDED MARCH 31, 1996 (UNAUDITED)
(In thousands, except per share data)
<TABLE>
<CAPTION>
1993 1994 1995 MARCH 31, 1996
----------- -------- -------- --------------
<S> <C> <C> <C> <C>
Revenues...................................... $ 5,785 $ 9,638 $15,622 $4,228
Direct costs.................................. 5,237 8,779 13,236 3,507
------- ------- ------- ------
Gross profit.................................. 548 859 2,386 721
Selling, general and administrative........... 1,054 1,777 2,203 530
Depreciation and amortization................. 562 919 1,200 307
Writedown of assets........................... 123
------- ------- ------- ------
Operating loss................................ (1,191) (1,837) (1,017) (116)
Interest expense, net......................... 331 968 910 217
------- ------- ------- ------
Loss before minority interest................. (1,522) (2,805) (1,927) (333)
Minority interest in income of subsidiaries... 50 25
------- ------- ------- ------
Net loss...................................... $(1,522) $(2,805) $(1,977) $ (358)
======= ======= ======= ======
Loss per share................................ $ (0.85) $ (0.46) $ (0.32) $(0.06)
======= ======= ======= ======
Weighted average common shares used
for computing loss per share................ 1,793 6,069 6,266 6,267
======= ======= ======= ======
</TABLE>
124
<PAGE>
VCA, PET PRACTICE AND PETS' RX
NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
STATEMENTS
(1) Represents the historical financial position of VCA and the Pet Practice
combined as if the purchase of Pet Practice took place on March 31, 1996.
(2) Represents the historical financial position of Pets' Rx at March 31, 1996.
(3) To reflect the write down of assets, amounting to $3.9 million, related to
conforming the Pets' Rx method for evaluating the impairment of long lived
assets to VCA's method net of an adjustment of $632,000 to reflect the
reclassification of certain intangibles to conform to VCA policy. VCA uses
an estimate of the related facility's undiscounted net income over the
remaining life of the goodwill and other intangibles in measuring whether
the goodwill is recoverable.
(4) Represents the exchange of the redeemable convertible preferred stock as
part of the Pets' Rx merger.
125
<PAGE>
DESCRIPTION OF VCA CAPITAL STOCK
The total number of shares that VCA is authorized to issue is
31,000,000, consisting of 30,000,000 shares of VCA Common Stock, par value
$0.001 per share, and 1,000,000 shares of Preferred Stock, par value $0.001 per
share ("VCA Preferred Stock"). The following statements are brief summaries of
certain provisions relating to VCA's capital stock.
COMMON STOCK
The holders of VCA Common Stock are entitled to one vote for each
share held of record on all matters to be voted on by the VCA stockholders. The
holders of VCA Common Stock are entitled to receive ratably dividends when, as
and if declared by the VCA Board out of funds legally available therefor. In
the event of a liquidation, dissolution or winding up of VCA, the holders of
VCA Common Stock are entitled to share ratably in all assets remaining
available for distribution to them after payment of liabilities and after
provision is made for each class of stock, if any, having preference over the
VCA Common Stock.
The holders of VCA Common Stock, as such, have no conversion,
preemptive or other subscription rights and there are no redemption provisions
applicable to the VCA Common Stock. All the outstanding shares of VCA Common
Stock are validly issued, fully paid and nonassessable.
VCA distributes periodic reports and other information, including
notices of annual meetings and special meetings of the stockholders of VCA, to
recordholders of VCA Common Stock at the addresses indicated on VCA's stock
records.
REDEEMABLE WARRANTS
At May 20, 1996 there were 1,129,011 shares of VCA Common Stock
issuable upon exercise of outstanding warrants (the "Redeemable Warrants"). The
Redeemable Warrants were issued in registered form pursuant to an agreement,
dated October 10, 1991 (the "Warrant Agreement"), between VCA and Continental
Stock Transfer & Trust Company (the "Warrant Agent"). The following discussion
of certain terms and provisions of the Redeemable Warrants is qualified in its
entirety by reference to the detailed provisions of the Warrant Agreement.
One Redeemable Warrant represents the right of the registered holder
to purchase one share of VCA Common Stock at an exercise price of 120% of the
initial offering price of VCA Common Stock per share, subject to adjustment
(the "Purchase Price"). The Redeemable Warrants are entitled to the benefit of
adjustments in the Purchase Price and in the number of shares of VCA Common
Stock and/or other securities deliverable upon the exercise thereof in the
event of a stock dividend, stock split, reclassification, reorganization,
consolidation or merger. VCA has the right to reduce the Purchase Price or
increase the number of shares of VCA Common Stock issuable upon the exercise of
the Redeemable Warrants.
Unless previously redeemed, the Redeemable Warrants may be exercised
at any time commencing April 10, 1992 and prior to the close of business on
October 10, 1996 (the "Expiration Date"). On and after the Expiration Date,
the Redeemable Warrants become wholly void and of no value. VCA may at any
time extend the Expiration Date of all outstanding Redeemable Warrants for such
increased period of time as it may determine. The Redeemable Warrants may be
exercised at the office of the Warrant Agent.
VCA has the right at any time after April 10, 1992 to redeem the
Redeemable Warrants in whole for cancellation at a price of $0.20 each, by
written notice mailed 30 days prior to the redemption date to each Redeemable
Warrant holder at his address as it appears on the books of the Warrant Agent.
Such notice may be given within ten days following any period of 20 consecutive
trading days during which the high closing bid of the shares of VCA Common
Stock on the Nasdaq National Market exceeds a per share price equal to $9.00
(150% of the initial public offering price of the VCA Common Stock), subject to
adjustments for stock dividends, stock splits and the like. If the Redeemable
Warrants are called for redemption, they must be exercised prior to the close
of business on the date of any such redemption or the right to purchase the
applicable shares of VCA Common Stock is forfeited.
126
<PAGE>
No holder, as such, of Redeemable Warrants is entitled to vote or
receive dividends or be deemed the holder of shares of VCA Common Stock for any
purpose whatsoever until such Redeemable Warrants have been duly exercised and
the Purchase Price has been paid in full.
If required, VCA will file a new registration statement with the
Commission with respect to the securities underlying the Redeemable Warrants
prior to the exercise of the Redeemable Warrants and deliver a prospectus with
respect to such securities to all Redeemable Warrant holders as required by
Section 10(a)(3) of the Act.
VCA PREFERRED STOCK
The VCA Board has the authority to issue the authorized and unissued
VCA Preferred Stock in one or more series with such designations, rights and
preferences as may be determined from time to time by the VCA Board.
Accordingly, the VCA Board is empowered, without stockholder approval, to issue
VCA Preferred Stock with dividend, liquidation, conversion, voting or other
rights which could adversely affect the voting power or other rights of the
holders of VCA Common Stock.
On December 22, 1992, VCA completed the sale of 583,333 shares of
Series A Convertible Preferred Stock, par value $0.001 per share (the "Series A
Shares"), for net proceeds of $2,985,000. The Series A Shares are convertible
into 583,333 shares of VCA Common Stock commencing December 22, 1997. The
Series A Shares participate in any dividend payments on VCA Common Stock on an
as converted basis. The Series A Shares have a liquidation preference of $5.14
per share and are callable by VCA any time after March 22, 1998 at a price of
$5.14 per share. The Series A Shares have no voting rights, other than certain
protective rights in the event of an adverse change in the rights, preferences
or privileges of the Series A Shares as provided by the DGCL.
As a result of the issuance of the Series A Shares, 416,667 shares of
VCA Preferred Stock remain authorized and unissued and may be issued in one or
more series with such designations, rights and preferences as may be determined
from time to time by the VCA Board. In the event of issuance, the VCA
Preferred Stock could be utilized under certain circumstances as a way of
discouraging, delaying or preventing an acquisition or change in control of
VCA. VCA does not currently intend to issue any shares of VCA Preferred Stock.
VRI WARRANTS
In connection with the formation of Vet Research, VCA issued warrants
to purchase 363,636 shares of VCA Common Stock at $11.00 per share (the "VRI
Warrants"). At May 20, 1996, there were 179,636 shares of VCA Common Stock
issuable upon exercise of outstanding VRI Warrants. The warrants were
purchased at $0.001 per share and are exercisable until the fifth day following
the last day upon which VCA is permitted to close the purchase of VRI's
interest in Vet Research pursuant to the VCA Option Agreement. On April 26,
1995, VCA filed a Registration Statement on Form S-3 with respect to the shares
of VCA Common Stock issuable upon exercise of the VRI Warrants. Holders of the
VRI Warrants agreed to a restriction upon the sale of any shares issuable upon
exercise of the VRI Warrants which will lapse with respect to 50,000 shares
issuable to each of the two holders upon exercise of the VRI Warrants at the
time of exercise and with respect to an additional 50,000 shares every 90 days
thereafter, but which in any event will lapse entirely on April 30, 1997.
DEBENTURES
On April 17, 1996, VCA issued the Debentures which mature on May 1,
2006. The Debentures become convertible into shares of VCA Common Stock on
July 27, 1996 initially at a conversion price of $34.35 per share (equivalent
to approximately 29.11 shares of VCA Common Stock for each $1,000 principal
amount of Debentures). VCA has agreed to file a registration statement
relating to the resale of the Debentures and the shares of VCA Common Stock
issuable on conversion of the Debentures no later than August 15, 1996.
ANTI-TAKEOVER PROVISIONS
VCA's Certificate of Incorporation and bylaws include a number of
provisions which may have the effect of discouraging persons from pursuing non-
negotiated takeover attempts. These provisions include a classified board of
directors, the inability of stockholders to take action by written consent
without a meeting, the inability of stockholders to call for a special
127
<PAGE>
meeting of stockholders under certain circumstances without the approval of the
board and the inability of stockholders to remove directors without cause. The
Certificate of Incorporation also contains a provision that requires a 66 2/3
percent vote to amend any of the previously discussed provisions. In addition,
the availability of a large number of shares of VCA Common Stock and VCA
Preferred Stock for issuance by the VCA Board without further stockholder
approval could have the effect of making it more difficult, and thereby
discouraging, a merger, tender offer, proxy contest or assumption of control
and change of incumbent management. Further, H.J. Heinz Company has an option
to purchase VCA's interest in the Vet's Choice joint venture upon the
occurrence of a change in control (as defined in the joint venture agreement).
SECTION 203 OF THE DGCL
VCA is a Delaware corporation and is subject to Section 203 of the
DGCL. Section 203 of the DGCL prevents an "interested stockholder" (defined
generally as a person owning 15% or more of a corporation's outstanding voting
stock or an affiliate of such person) from engaging in a "business combination"
(as defined) with a Delaware corporation for three years following the date
such person became an interested stockholder unless (i) before such person
became an interested stockholder, the board of directors of the corporation
approved the transaction in which the interested stockholder became an
interested stockholder or approved the business combination; (ii) upon
consummation of the transaction that resulted in the interested stockholder
becoming an interested stockholder, the interested stockholder owns at least
85% of the voting stock of the corporation outstanding at the time the
transaction commenced (excluding stock held by directors who are also officers
of the corporation and employee stock plans that do not provide employees with
the right to determine confidentially whether shares held subject to the plan
will be tendered in a tender or exchange offer); or (iii) following the
transaction in which such person became an interested stockholder, the business
combination is approved by the board of directors of the corporation and
authorized at a meeting of stockholders by vote of the holders of two-thirds of
the outstanding voting stock of the corporation not owned by the interested
stockholder. Under Section 203 of the DGCL, the restrictions described above
also do not apply to certain business combinations proposed by an interested
stockholder following the announcement or notification of one of certain
extraordinary transactions involving the corporation and a person who had not
been an interested stockholder during the previous three years or became an
interested stockholder with the approval of a majority of the corporation's
directors. The provisions of Section 203 of the DGCL requiring a super majority
vote of disinterested shares to approve certain corporate transactions could
enable a minority of VCA's stockholders to exercise veto power over such
transactions.
TRANSFER AGENT
VCA's transfer and warrant agent is Continental Stock Transfer & Trust
Company, 2 Broadway, New York, New York 10004.
COMPARISON OF STOCKHOLDERS' RIGHTS
At the Effective Time, the stockholders of Pet Practice will become
stockholders of VCA, and their rights will be governed by the DGCL and VCA's
Certificate of Incorporation (the "VCA Certificate") and bylaws (the "VCA
Bylaws"). The following discussion is not intended to be complete and is
qualified in its entirety by reference to the DGCL, the VCA Certificate, the
VCA Bylaws, Pet Practice's Certificate of Incorporation (the "Pet Practice
Certificate") and bylaws (the "Pet Practice Bylaws"). The VCA Certificate and
VCA Bylaws are incorporated by reference herein and will be sent to holders of
shares of Pet Practice Common Stock upon request. See "INCORPORATION OF
CERTAIN DOCUMENTS BY REFERENCE."
Since both VCA and Pet Practice are organized under the laws of the
State of Delaware, any differences in the rights of holders of VCA Common Stock
and Pet Practice Common Stock will arise solely from differences in their
respective Certificates and Bylaws. The VCA Certificate and VCA Bylaws are
substantially similar to the Pet Practice Certificate and Bylaws, respectively,
except for certain matters as described herein.
Authorized Capital. The total number of authorized shares of capital
stock of VCA is 31,000,000 shares, consisting of 30,000,000 shares of VCA
Common Stock and 1,000,000 shares of VCA Preferred Stock. If the Certificate
Proposal is approved at the VCA Annual Meeting, the number of authorized shares
of VCA Common Stock will increase to 75,000,000 shares. The total number of
authorized shares of capital stock of Pet Practice is 21,000,000 shares,
consisting of 20,000,000 shares of Pet Practice Common Stock and 1,000,000
shares of preferred stock, $.01 par value per share.
128
<PAGE>
Directors. The VCA Bylaws provide that the number of directors shall
not be less than three and no more than nine persons. The Pet Practice Bylaws
provide that the number of directors shall be no fewer than one and no more
than 12 persons.
The VCA Certificate establishes three classes of directors, as nearly
equal in number of directors as possible, with each director elected for a term
expiring at the third succeeding annual meeting of stockholders after his or
her election. The Pet Practice Board is not divided into separate classes.
Each Pet Practice director serves until the next annual meeting of stockholders
after his or her election.
The VCA Bylaws provide for a quorum of a majority of the total number
of its directors. The Pet Practice Bylaws provide for a quorum of one-third of
the Pet Practice Board.
Removal of Directors. The VCA Bylaws provide that any director may be
removed, for cause only, by a vote of the majority of the outstanding shares
entitled to vote in connection with the election of such director, regardless
of class, voting together as a class. The Pet Practice Bylaws provide that any
director may be removed by the affirmative vote of a majority of the shares of
stock entitled to vote at the meeting to remove such director.
Filling Vacancies on the Board of Directors. The VCA Bylaws provide
that any vacancy on the VCA Board, however resulting, shall be filled only by a
majority of the directors then in office, although less than a quorum, or by a
sole remaining director, and not by the stockholders. The Pet Practice Bylaws
provide that any vacancy in the office of a director occurring for any reason
other than removal by the stockholders may be filled by a majority of the
directors then in office or by a sole remaining director. With respect to a
vacancy created by the removal of a director by the stockholders, such vacancy
shall be filled by the stockholders at a meeting of stockholders called for
that purpose.
Stockholder Action Without a Meeting. Under the VCA Certificate, no
action may be taken by the stockholders except at a meeting. Under the Pet
Practice Bylaws, the stockholders may act by written consent executed by
holders of outstanding capital stock having not less than the minimum number of
votes that would be necessary to authorize or take such action at a meeting at
which all shares entitled to vote thereon were present and voted.
Business Combinations. Under Section 203 of the DGCL ("Section 203"),
certain "business combinations" with "interested stockholders" (as each term is
defined in Section 203) of Delaware corporations are subject to a three- year
moratorium unless specified conditions are met. The provisions of Section 203
apply to VCA but do not apply to Pet Practice because in the Pet Practice
Certificate, Pet Practice elected not to be subject to the provisions of
Section 203.
Anti-takeover Provisions. The VCA Certificate and Bylaws include a
number of provisions which may have the effect of discouraging persons from
pursuing non-negotiated takeover attempts. These provisions include a
classified board of directors, the inability of stockholders to take action by
written consent without a meeting, the inability of stockholders to call for a
special meeting of stockholders under certain circumstances without the
approval of the board and the inability of stockholders to remove directors
without cause. The VCA Certificate also contains a provision that requires a
66 2/3 percent vote to amend any of the previously discussed provisions. In
addition, the availability of a large number of shares of VCA Common Stock and
VCA Preferred Stock for issuance by the VCA Board without further stockholder
approval could have the effect of making it more difficult, and thereby
discouraging, a merger, tender offer, proxy contest or assumption of control
and change of incumbent management. Further, H.J. Heinz Company has an option
to purchase VCA's interest in the Vet's Choice joint venture upon the
occurrence of a change in control (as defined in the joint venture agreement).
129
<PAGE>
ELECTION OF CLASS II DIRECTORS
In accordance with the VCA Certificate and the VCA Bylaws, the VCA
Board is divided into three classes. At each Annual Meeting of Stockholders of
VCA, directors constituting one class are elected for three-year terms. The
VCA Bylaws provide that the VCA Board shall consist of not less than three and
no more than nine members as determined from time to time by the VCA Board.
The VCA Board currently consists of two Class I Directors, with terms expiring
in 1997, two Class II Directors, with terms expiring in 1996, and two Class III
Directors, with terms expiring in 1998. At the VCA Annual Meeting, two Class
II Directors will be elected for terms expiring at the 1999 VCA Annual Meeting.
If the number of directors is changed, any increase or decrease is to be
apportioned among the classes so as to maintain the number of directors in each
class as nearly equal as possible. Directors may be removed only with cause by
the vote of a majority of the stockholders then entitled to vote.
Unless otherwise instructed, the proxy holders will vote the proxies
received by them for the nominees named below. If either nominee is unable or
unwilling to serve as a director at the time of the VCA Annual Meeting or any
postponements or adjournments thereof, the proxies will be voted for such
nominee as shall be designated by the current VCA Board to fill the vacancy.
VCA has no reason to believe that either nominee will be unwilling or unable to
serve if elected as a director.
THE VCA BOARD UNANIMOUSLY RECOMMENDS A VOTE "FOR" THE ELECTION OF THE NOMINEES
LISTED BELOW
The VCA Board proposes the election of the following nominees as Class
II Directors:
Neil Tauber
John B. Chickering, Jr.
If elected, each nominee is expected to serve until the 1999 VCA
Annual Meeting of Stockholders. The affirmative vote of a plurality of the
shares present in person or represented by proxy at the VCA Annual Meeting and
voting on the election of the Class II Directors, is required for the election
of the above named nominees.
INFORMATION WITH RESPECT TO NOMINEES, CONTINUING DIRECTORS AND EXECUTIVE
OFFICERS
The following table sets forth certain information with respect to the
nominees, continuing directors and executive officers of VCA as of March 31,
1996. See "BUSINESS OF VCA -- Executive Officers and Directors."
<TABLE>
<CAPTION>
Year Term
Name Age Principal Occupation Expires
---- --- -------------------- -------
<S> <C> <C> <C>
NOMINEES:
Neil Tauber 45 Senior Vice President of VCA 1996
John B. Chickering, Jr. 47 Private Investor 1996
CONTINUING
DIRECTORS:
Robert L. Antin 46 Chairman of the Board and Chief Executive Officer of VCA 1997
Richard Gillespie 62 Private Investor 1997
Arthur J. Antin 49 Chief Operating Officer, Senior Vice President, and Secretary of 1998
VCA
John A. Heil 42 Vice President - Marketing for Heinz Pet Products 1998
OTHER EXECUTIVE
OFFICERS:
Tomas W. Fuller 38 Chief Financial Officer and Vice President and Assistant Secretary
Deborah W. Moore 31 Chief Accounting Officer, Vice President and Controller
</TABLE>
130
<PAGE>
The executive officers of VCA are appointed by and serve at the discretion
of the VCA Board. Robert L. Antin and Arthur J. Antin are brothers. There are no
other family relationships between any director and/or any executive officer of
VCA.
PROPOSAL TO APPROVE AN AMENDMENT TO THE CERTIFICATE OF
INCORPORATION OF VCA
TO INCREASE THE AUTHORIZED NUMBER OF SHARES OF VCA COMMON STOCK
AND VCA PREFERRED STOCK
THE AMENDMENT
On January 22, 1996, the VCA Board adopted resolutions approving and
recommending that the stockholders adopt an amendment to Article Fourth of the
VCA Certificate to increase the authorized VCA Common Stock from 30,000,000
shares to 75,000,000 shares, and to increase the authorized VCA Preferred Stock
from 1,000,000 shares to 2,000,000 shares. The relative rights and limitations
of the VCA Common and VCA Preferred Stock would remain unchanged under the
amendment. The VCA Common and VCA Preferred Stock do not have preemptive
rights.
At May 20, 1996, VCA had 13,179,882 shares of VCA Common Stock issued and
outstanding and 583,333 shares of VCA Preferred Stock issued and outstanding.
In addition, VCA has reserved: (i) 1,498,404 shares of VCA Common Stock for
issuance to employees, officers, directors, and consultants of VCA pursuant to
options, (ii) 1,308,647 shares of VCA Common Stock for issuance upon exercise of
outstanding warrants, (iii) 6,635 shares of VCA Common Stock for issuance upon
conversion of convertible notes, (iv) 583,333 shares of VCA Common Stock for
issuance upon conversion of VCA Preferred Stock, (v) 2,457,060 shares of VCA
Common Stock for issuance upon conversion of the Debentures, and (vi) 159,197
shares of VCA Common Stock for certain acquisitions. Thus, at May 20, 1996,
there were 10,966,039 authorized shares of VCA Common Stock unissued and not
reserved for issuance. If the proposed mergers with Pets' Rx and Pet Practice
are consummated, there will be approximately 6,892,000 authorized shares of VCA
Common Stock unissued and not reserved for issuance.
The proposed increase in the authorized VCA Common Stock has been recommended
by the VCA Board to assure that an adequate supply of authorized unissued shares
is available for general corporate needs, such as future stock dividends or
stock splits or the issuance of shares under VCA's stock incentive plans. The
additional authorized shares of VCA Common Stock could also be used for such
purposes as raising additional capital for the operations of VCA or financing
the acquisition of other animal hospitals and veterinary diagnostic laboratories
or related businesses. In addition, the availability of a large number of
shares of VCA Common Stock and VCA Preferred Stock for issuance by the VCA Board
without further stockholder approval could have the effect of making it more
difficult, and thereby discouraging, a merger, tender offer, proxy contest or
assumption of control and change of incumbent management. See "DESCRIPTION OF
VCA CAPITAL STOCK--Anti-takeover Provisions" for a discussion of other
antitakeover provisions applicable to VCA. There currently are no plans or
arrangements relating to the issuance of any of the additional shares of VCA
Common Stock proposed to be authorized.
If the Proposal is adopted, the amended portion of Article Fourth of the VCA
Certificate will read as follows:
FOURTH: The total number of shares which the Corporation shall have
-------
authority to issue is 77,000,000, consisting of 75,000,000 shares of
common stock, par value $0.001 per share (the "Common Stock") and
2,000,000 shares of preferred stock, par value $0.001 per share (the
"Preferred Stock").
The only changes in Article Fourth which will be effected if the
Proposal is approved are changes to the three numbers set forth in bold face
type above. Presently, Article Fourth provides that the shares of all classes
of stock which VCA may issue is 31,000,000, 30,000,000 of which are shares of
VCA Common Stock and 1,000,000 of which are shares of VCA Preferred Stock. All
other provisions of Article Fourth will remain unchanged.
131
<PAGE>
CERTAIN EFFECTS OF THE PROPOSED AMENDMENT
The VCA Board believes that approval of the Proposal is essential for
the growth and development of VCA. However, the following should be considered
by a stockholder in deciding how to vote upon this Proposal.
The Proposal, if approved, would strengthen the position of the VCA
Board and might make the removal of the VCA Board more difficult, even if such
removal would be generally beneficial to VCA's stockholders. The authorization
to issue the additional shares of VCA Common Stock would provide the VCA Board
with a capacity to negate the efforts of unfriendly tender offerors through the
issuance of securities to others who are friendly or desirable to the VCA
Board.
The Proposal is not the result of the VCA Board's knowledge of any
specific effort to accumulate VCA's securities or to obtain control of VCA by
means of a merger, tender offer, proxy solicitation in opposition to management
or otherwise. VCA is not submitting the Proposal to enable it to frustrate any
efforts by another party to acquire a controlling interest or to seek
representation on the VCA Board. The submission of the Proposal is not a part
of any plan by VCA's management to adopt a series of amendments to the VCA
Certificate or Bylaws so as to render the takeover of VCA more difficult.
The additional shares which the VCA Board would be authorized to issue
upon approval of the Proposal, if so issued, would have a dilutive effect upon
the percentage of equity of VCA owned by present stockholders. The issuance of
such additional shares might be disadvantageous to current stockholders in that
any additional issuances would potentially reduce per share dividends, if any.
Stockholders should consider, however, that the possible impact upon dividends
is likely to be minimal in view of the fact that VCA has never paid dividends,
has never adopted any policy with respect to the payment of dividends and does
not intend to pay any cash dividends in the foreseeable future. VCA instead
intends to retain earnings, if any, for use in financing growth and additional
business opportunities.
RECOMMENDATION AND VOTE.
The VCA Board has unanimously approved the amendment of the VCA
Certificate to increase the authorized number of shares of VCA Common Stock and
VCA Preferred Stock. The affirmative vote of a majority of the outstanding
shares of VCA Common Stock is required for the approval of the adoption of such
amendment to the VCA Certificate. Unless marked otherwise, proxies received
will be voted for the adoption of such amendment to the VCA Certificate.
THE VCA BOARD UNANIMOUSLY RECOMMENDS A VOTE "FOR" THE ADOPTION OF THE AMENDMENT
TO THE VCA CERTIFICATE TO INCREASE THE AUTHORIZED NUMBER OF SHARES OF VCA
COMMON STOCK AND VCA PREFERRED STOCK.
PROPOSAL TO APPROVE THE ADOPTION OF THE
VCA 1996 STOCK INCENTIVE PLAN
INTRODUCTION
The proposed VCA 1996 Stock Incentive Plan (the "1996 Plan") was
adopted by the VCA Board effective as of November 7, 1995, subject to the
approval of the 1996 Plan by the stockholders. The 1996 Plan supplements VCA's
1987, 1991 and 1995 stock incentive plans and provides for the issuance of
options to purchase shares of the VCA Common Stock ("Shares") to selected
directors, officers, employees and consultants of VCA and its subsidiaries.
Subject to adjustment for stock splits, stock dividends and other similar
events, the total number of Shares reserved for issuance under the 1996 Plan
shall be 1,500,000 Shares. As of the VCA Record Date, options to purchase
57,888 Shares had been granted to eligible employees (none of whom were
officers) of VCA pursuant to the terms of the 1996 Plan, subject to the
approval of the 1996 Plan by the stockholders, at an exercise price of $12.375
per Share.
The following sections summarize the principal features of the 1996
Plan, a copy of which is attached as Appendix D to this Joint Proxy
-------- -
Statement/Prospectus. Although this Joint Proxy Statement/Prospectus contains
a summary of the principal
132
<PAGE>
features of the 1996 Plan, this summary is not intended to be complete and
reference should be made to Appendix D to this Joint Proxy Statement/Prospectus
-------- -
for the complete text of the 1996 Plan.
PURPOSE
The purpose of the 1996 Plan is to advance the interests of VCA and its
stockholders by strengthening VCA's and its subsidiaries' ability to obtain and
retain the services of the types of employees, consultants, officers and
directors who will contribute to VCA's long term success and to provide
incentives which are linked directly to increases in stock value which will
inure to the benefit of all stockholders of VCA.
ADMINISTRATION
The 1996 Plan will be administered by a committee of the VCA Board (the
"Committee"), each member of which is a non-employee member of the VCA Board, a
Disinterested Person (as defined in Rule 16b-3 promulgated under the Exchange
Act), and an Outside Director (as defined in Section 162(m) of the Code.)
ELIGIBILITY AND NONDISCRETIONARY GRANTS
The 1996 Plan provides that options may be granted to non-employee
directors who are designated as eligible persons by the VCA Board, other non-
employee directors (subject to the limitations described below), officers
(including officers who are directors), employees and consultants of VCA and
its subsidiaries. The Committee will determine the persons to be selected as
optionees, the terms of vesting of options and the number of Shares to be
subject to each option. Non-employee directors shall be entitled to receive
the following: (i) the nondiscretionary grant of a non-statutory option to
purchase 10,000 Shares upon the non-employee director's election or appointment
to the VCA Board, and (ii) for so long as the non-employee director remains on
the VCA Board, an annual nondiscretionary grant on the date of VCA's annual
meeting of stockholders of non-statutory options to purchase 5,000 Shares.
Unless designated "eligible persons," non-employee directors are not eligible
for additional grants. All options granted to the non-employee directors shall
have an exercise price equal to 100% of the fair market value of the Shares on
the date of grant and shall vest in 12 equal monthly installments.
If the VCA stockholders approve the 1996 Plan, the group identified
below will receive the number of shares set forth opposite its name.
<TABLE>
<CAPTION>
NAME AND POSITION NUMBER OF SHARES
----------------- ----------------
<S> <C>
Chief Executive Officer 0
Current Executive Officers 0
Current Directors who are not Executive
Officers 0
All employees, excluding executive officers 57,888
</TABLE>
TERMS OF OPTIONS
The terms of options granted under the 1996 Plan are determined by the
Committee. In the sole and absolute discretion of the Committee, such options
may be either "incentive stock options" within the meaning of Section 422 of the
Code ("ISOs"), or non-statutory options. However, to the extent that the
aggregate market value of the Shares with respect to which ISOs are exercisable
for the first time by any individual under the 1996 Plan and all other incentive
plans of VCA and any parent or subsidiary of VCA during any calendar year
exceeds $100,000, such options shall not be treated as ISOs. In addition, no
participant shall be granted options with respect to more than 500,000 Shares
during any one year period. Each option will be evidenced by an option agreement
between VCA and the optionee to whom such option is granted on such terms and
conditions as shall be determined by the Committee from time to time. The terms
of the option agreements need not be identical. Each option is, however, subject
to the following terms and conditions:
133
<PAGE>
Exercise of the Option. The Committee determines when options granted under
the 1996 Plan may be exercisable. An option is exercised by giving written
notice of exercise to VCA, specifying the number of full Shares to be purchased,
and tendering payment of the purchase price. Payment for Shares issued upon
exercise of an option may be made by cash, by cashier's check or certified
check, by surrender of previously owned Shares (if the Committee authorizes
payment in Shares and such Shares have been held for at least six months), by
surrender of the number of Shares issuable upon exercise of the stock option
having a fair market value on the date of exercise equal to the option exercise
price (if the Committee authorizes such method of payment), or by any
combination thereof or any other form of legal consideration acceptable to the
Committee. The 1996 Plan provides that, upon the recommendation of the
Committee, VCA may loan optionees the funds necessary to exercise their options.
Option Price. The ISO exercise price shall equal or exceed the fair market
value of the Shares on the date the option is granted. The exercise price for
ISOs granted to individuals beneficially holding at least 10% of the outstanding
securities of VCA shall equal or exceed 110% of the fair market value of Shares
on the date the option is granted.
Termination of Options. All options granted under the 1996 Plan expire ten
years from the date of grant, or such shorter period as is determined by the
Committee. No option is exercisable by any person after such expiration. If an
option expires, terminates or is canceled in full, the Shares not purchased
thereunder may again be available for option.
Non-transferability of Options. An option is not transferable by the
optionee otherwise than by will or the laws of descent and distribution and is
exercisable during the optionee's lifetime only by the optionee, his or her
guardian or legal representative.
Other Provisions. The option agreement may contain such other terms,
provisions and conditions not inconsistent with the 1996 Plan as may be
determined by the Committee.
ADJUSTMENTS UPON CHANGES IN CAPITALIZATION
The 1996 Plan and each option granted thereunder contain provisions for
appropriate adjustments in the exercise price per Share (but not the total
price) and the number of Shares subject to the option in the event of any change
in the number of issued Shares which results from a split-up or consolidation of
Shares, payment of a Share dividend, a recapitalization or other like capital
adjustment. Options may provide for acceleration of vesting upon a change of
control. Alternatively, the Committee has the right, in its sole discretion, to
accelerate the vesting of options granted pursuant to the 1996 Plan in the event
of such a change in control.
AMENDMENT AND TERMINATION OF THE 1996 PLAN
The VCA Board may amend the 1996 Plan at any time, may suspend it from time
to time or may terminate it without approval of the stockholders; provided,
however, that stockholder approval is required for any amendment which
materially increases the number of Shares for which options may be granted,
materially modifies the requirements of eligibility or materially increases the
benefits which may accrue to optionees under the 1996 Plan. However, no such
action by the VCA Board or stockholders may unilaterally alter or impair any
option previously granted under the 1996 Plan without the consent of the
optionee. In any event, the 1996 Plan shall terminate ten years from the date of
stockholder approval unless sooner terminated by action of the VCA Board.
EFFECT OF SECTION 16(B) OF THE EXCHANGE ACT.
The acquisition and disposition of VCA Common Stock by officers, directors
and more than 10% stockholders of VCA ("Insiders") pursuant to awards granted to
them under the 1996 Plan may be subject to Section 16(b) of the Exchange Act.
Pursuant to Section 16(b), a purchase of VCA Common Stock by an Insider within
six months before or after a sale of VCA Common Stock by the Insider could
result in recovery by VCA of all or a portion of any amount by which the sale
proceeds exceeds the purchase price. Insiders are required to file reports of
changes in beneficial ownership under Section 16(a) of the Exchange Act upon
acquisitions and dispositions of shares. Rule 16b-3 provides an exemption from
Section 16(b) liability for certain transactions pursuant to certain employee
benefit plans. The 1996 Plan is designed to comply with Rule 16b-3.
134
<PAGE>
FEDERAL INCOME TAX CONSEQUENCES
The following general discussion of the principal tax considerations is
based upon the tax laws and regulations of the United States existing as of the
date hereof, all of which are subject to modification at any time. The 1996 Plan
does not constitute a qualified retirement plan under Section 401(a) of the Code
(which generally covers trusts forming part of a stock bonus, pension or profit-
sharing plan funded by the employer and/or employee contributions which are
designed to provide retirement benefits to participants under certain
circumstances) and is not subject to the Employee Retirement Income Security Act
of 1974 (the pension reform law which regulates most types of privately funded
pension, profit-sharing and other employee benefit plans).
Pursuant to Section 162(m) of the Code ("Section 162(m)"), non-performance-
based compensation in excess of $1 million to certain senior executives of
public companies is not deductible by such public companies. Performance-based
compensation is excluded from applicable employee remuneration for Section
162(m) limitation purposes. The 1996 Plan is intended to qualify as performance-
based compensation which is not subject to the $1 million limitation. In order
for the 1996 Plan to qualify as performance-based compensation under Section
162(m) and therefore be exempt from the $1 million limitation, the 1996 Plan
must be approved by the stockholders of VCA.
Consequences to Employees: Incentive Stock Options. No income is recognized
for federal income tax purposes by an optionee at the time an ISO is granted,
and, except as discussed below, no income is recognized by an optionee upon his
or her exercise of an ISO. If the optionee makes no disposition of the Shares
received upon exercise within two years from the date such option is granted or
one year from the date such option is exercised, the optionee will recognize
long-term capital gain or loss when he or she disposes of his or her Shares.
Such gain or loss will be measured by the difference between the exercise price
of the option and the amount received for the Shares at the time of disposition.
If the optionee disposes of Shares acquired upon exercise of an ISO within
two years after being granted the option or within one year after acquiring the
Shares, any amount realized from such disqualifying disposition will be taxable
as ordinary income in the year of disposition to the extent that the lesser of
(A) the fair market value of the Shares on the date the ISO was exercised or (B)
the fair market value at the time of such disposition, exceeds the ISO exercise
price. Any amount realized upon disposition in excess of the fair market value
of the Shares on the date of exercise will be treated as long-term or short-term
capital gain, depending upon whether the shares have been held for more than one
year.
The use of stock acquired through exercise of an ISO to exercise an ISO
will constitute a disqualifying disposition if the applicable holding period
requirement has not been satisfied.
For alternative minimum tax purposes, the excess of the fair market value
of the stock as of the date of exercise over the exercise price of the ISO is
included in computing alternative minimum taxable income.
Consequences to Employees: Non-statutory Options. No income is recognized
by a holder of non-statutory options at the time non-statutory options are
granted under the 1996 Plan. In general, at the time Shares are issued to a
holder pursuant to exercise of non-statutory options, the holder will recognize
ordinary income equal to the excess of the sum of cash and the fair market value
of the Shares on the date of exercise over the exercise price.
A holder will recognize gain or loss on the subsequent sale of Shares
acquired upon exercise of non-statutory options in an amount equal to the
difference between the selling price and the tax basis of the Shares, which will
include the price paid plus the amount included in the holder's income by reason
of the exercise of the non-statutory options. Provided the Shares are held as a
capital asset, any gain or loss resulting from a subsequent sale will be long-
term or short-term capital gain or loss depending upon whether the Shares have
been held for more than one year.
Consequences to VCA: Incentive Stock Options. VCA will not be allowed a
deduction for federal income tax purposes at the time of the grant or exercise
of an ISO. There are also no federal income tax consequences to VCA as a result
of the disposition of Shares acquired upon exercise of an ISO if the disposition
is not a disqualifying disposition. At the time of a disqualifying disposition
by an optionee, VCA will be entitled to a deduction for the amount received by
the optionee to the extent that such amount is taxable to the optionee as
ordinary income.
135
<PAGE>
Consequences to VCA: Non-statutory Options. VCA will be entitled to a
deduction for federal income tax purposes in the year and in the same amount as
the optionee is considered to have realized ordinary income in connection with
the exercise of non-statutory options if provision is made for withholding of
federal income taxes, where applicable.
Cash Payments. The Committee may authorize VCA to provide cash payments to
holders of non-statutory options to reimburse such persons for the tax they
incur with respect to the exercise of non-statutory options.
REQUIRED VOTE
The VCA Board has unanimously approved the adoption of the 1996 Plan. The
affirmative vote of a majority of the Shares present in person or represented by
proxy at the VCA Annual Meeting and voting on the approval of the adoption of
the 1996 Plan is required for the approval of the adoption of the 1996 Plan.
Unless marked otherwise, proxies received will be voted for the adoption of the
1996 Plan.
THE VCA BOARD UNANIMOUSLY RECOMMENDS A VOTE "FOR" THE ADOPTION OF THE APPROVAL
OF THE VCA 1996 STOCK INCENTIVE PLAN
PROPOSAL TO APPROVE THE ADOPTION OF THE VCA
1996 EMPLOYEE STOCK PURCHASE PLAN
SUMMARY OF PLAN
The proposed VCA 1996 Employee Stock Purchase Plan (the "Stock Purchase
Plan") was adopted by the VCA Board on January 20, 1996. The Stock Purchase Plan
supplements VCA's stock option plans and provides selected officers, employees
and consultants of VCA and its subsidiaries with an opportunity to purchase
Shares through regular payroll deductions. Subject to adjustment for stock
splits, stock dividends and other similar events, the total number of Shares
reserved for issuance under the Stock Purchase Plan shall be 250,000 Shares.
The following sections summarize the principal features of the Stock
Purchase Plan, a copy of which is attached as Appendix E to this Joint Proxy
-------- -
Statement/Prospectus. Although this Joint Proxy Statement/Prospectus
contains a summary of the principal features of the Stock Purchase Plan, this
summary is not intended to be complete and reference should be made to
Appendix E to this Joint Proxy Statement/Prospectus for the complete text of
- -------- -
the Stock Purchase Plan.
The purpose of the Stock Purchase Plan is to provide incentives to the
employees by encouraging their ownership of shares of VCA Common Stock. All
officers and employees of VCA and its subsidiaries who are currently employed by
VCA or any of its subsidiaries who work at least 20 hours per week and who have
been regularly and continuously employed by VCA or its subsidiaries for at least
90 days are eligible to participate in the Stock Purchase Plan. Executive
officers of VCA are not eligible to participate in the Stock Purchase Plan.
Each eligible participant may contribute to the Stock Purchase Plan a
percentage of his or her base compensation ranging from 5% to 15%. VCA will
contribute to the Stock Purchase Plan for each employee who is a participant, an
amount up to 20% of the employee's contribution, as determined in the discretion
of the VCA Board, on the first anniversary of such contribution.
Up to 250,000 shares of VCA Common Stock may be issued under the Stock
Purchase Plan. This number will be appropriately adjusted for stock dividends,
stock splits, reclassifications and other changes affecting VCA's stock.
The VCA Board may, at its discretion, terminate the Stock Purchase Plan or
amend it in any respect, except that no such termination or amendment shall
affect the right of a participant to receive his or her proportionate interest
in shares or contributions which have vested under the Stock Purchase Plan.
Approval of the Stock Purchase Plan will require the affirmative vote of the
holders of a majority of the Shares present in person or by proxy at the VCA
Annual Meeting. Failure of the stockholders to approve the Stock Purchase Plan
will not terminate the Plan, but will merely have the effect of precluding
exemption under Rule 16b-3 under the Exchange Act for purchases by officers of
VCA.
136
<PAGE>
REQUIRED VOTE
The VCA Board has unanimously approved the adoption of the Stock Purchase
Plan. The affirmative vote of a majority of the Shares present in person or
represented by proxy at the VCA Annual Meeting and voting on the proposed Stock
Purchase Plan is required for the approval of the adoption of the Stock Purchase
Plan. Unless marked otherwise, proxies received will be voted for the adoption
of the Stock Purchase Plan.
THE VCA BOARD UNANIMOUSLY RECOMMENDS A VOTE "FOR" THE ADOPTION OF THE PROPOSED
1996 EMPLOYEE STOCK PURCHASE PLAN.
PROPOSALS OF STOCKHOLDERS
A proper proposal submitted by a stockholder for presentation at VCA's 1997
Annual Meeting and received at VCA's executive offices no later than February
__, 1997, will be included in VCA's Proxy Statement and form of proxy relating
to the 1997 VCA Annual Meeting.
Under the VCA Bylaws, to bring business before an annual meeting, a
stockholder must give written notice thereof to the Secretary of VCA not less
than 60 nor more than 90 days before such meeting. The notice must set forth the
name, address and number of shares owned by the stockholder making the proposal,
a brief description of the business desired to be brought before the meeting and
the reasons for conducting it at such meeting, as well as such other information
as would be required to be disclosed in the solicitation of proxies under
Regulation 14(a) under the Exchange Act. Nomination for the VCA Board must also
include the written consent of the nominee to be elected and serve.
INDEPENDENT PUBLIC ACCOUNTANTS
Arthur Andersen LLP, independent certified public accountants, were
selected by the VCA Board to serve as independent auditors of VCA for the fiscal
year ended December 31, 1995, and have been selected by the VCA Board to serve
as independent auditors for the fiscal year ending December 31, 1996.
Representatives of Arthur Andersen LLP are expected to be present at the VCA
Annual Meeting, will have an opportunity to make a statement if they desire to
do so and will respond to appropriate questions from stockholders.
LEGAL OPINION
The validity of VCA Common Stock issuable in the Merger has been passed
upon by Troop Meisinger Steuber & Pasich, LLP, 10940 Wilshire Blvd., Los
Angeles, California 90024, as counsel to VCA.
EXPERTS
The audited consolidated financial statements of VCA, the audited financial
statements of Southwest Veterinary Diagnostic, Inc., the audited supplemental
combined financial statements of VCA and the audited financial statements of
Pets' Rx, Inc. included in this Joint Proxy Statement/Prospectus and elsewhere
in the Registration Statement, to the extent and for the periods indicted, have
been audited by Arthur Andersen LLP, independent public accountants, as
indicated in their reports with respect thereto, and are included herein in
reliance upon the authority of said firm as experts in giving said reports.
The financial statements of Pet Practice included in this Joint Proxy
Statement/Prospectus have been audited by Price Waterhouse LLP, independent
accountants, as set forth in its report thereon appearing elsewhere herein. Such
financial statements have been so included in reliance on such report, given on
the authority of said firm as experts in auditing and accounting.
OTHER MATTERS
The VCA Board is not aware of any matter to be acted upon at the VCA Annual
Meeting and the Pet Practice Board is not aware of any matter to be acted upon
at the Pet Practice Special Meeting other than described in this Joint Proxy
Statement/Prospectus. Unless otherwise directed, all shares represented by the
persons named in the accompanying proxy will
137
<PAGE>
be voted in favor of the proposals described in this Joint Proxy
Statement/Prospectus. If any other matter properly comes before the meeting,
however, the proxy holders will vote thereon in accordance with their best
judgment.
ANNUAL REPORT TO STOCKHOLDERS
The VCA Annual Report for the fiscal year ended December 31, 1995 is being
mailed to VCA's stockholders along with this Joint Proxy Statement/Prospectus.
The VCA Annual Report is not to be considered part of the soliciting material.
138
<PAGE>
INDEX TO FINANCIAL STATEMENTS
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
VETERINARY CENTERS OF AMERICA, INC.
Consolidated Balance Sheets as of March 31, 1996 and
December 31, 1995.................................................... F-4
Consolidated Statements of Operations for the Three Months
Ended March 31, 1996 and 1995........................................ F-5
Consolidated Statements of Cash Flows for the Three
Months Ended March 31, 1996 and 1995................................. F-6
Notes to Financial Statements............................................. F-8
Report of Independent Public Accountants.................................. F-9
Consolidated Balance Sheets at December 31, 1995 and 1994................. F-10
Consolidated Statements of Operations for the Years Ended
December 31, 1995, 1994, and 1993.................................... F-11
Consolidated Statements of Stockholders' Equity for the
Years Ended December 31, 1995, 1994 and 1993......................... F-12
Consolidated Statements of Cash Flows for the Years Ended
December 31, 1995, 1994 and 1993..................................... F-13
Notes to Consolidated Financial Statements................................ F-15
Report of Independent Public Accountants.................................. F-28
Supplemental Combined Balance Sheets at December 31, 1995
and 1994 and March 31, 1996.......................................... F-29
Supplemental Combined Statements of Operations for the
Years Ended December 31, 1995, 1994 and 1993
and the Three Months Ended March 31, 1996 and 1995................... F-30
Supplemental Combined Statements of Stockholders'
Equity for the Years Ended December 31, 1995, 1994
and 1993 and the Three Months Ended March 31, 1996................... F-31
Supplemental Combined Statements of Cash Flows for
the Years Ended December 31, 1995, 1994 and 1993
and the Three Months Ended March 31, 1996 and 1995................... F-32
Notes to Supplemental Combined Financial Statements....................... F-34
THE PET PRACTICE, INC.
Consolidated Balance Sheet as of April 3, 1996 and
January 3, 1996...................................................... F-50
Consolidated Statement of Operations for the Thirteen Weeks Ended
April 3, 1996 and March 29, 1995..................................... F-52
Consolidated Statement of Changes in Stockholders' Equity
for the Thirteen Weeks Ended April 3, 1996........................... F-53
Consolidated Statement of Cash Flows for the Thirteen Weeks Ended
April 3, 1996 and March 29, 1995..................................... F-54
Notes to Consolidated Financial Statements................................ F-55
Report of Independent Accountants......................................... F-58
</TABLE>
F-1
<PAGE>
<TABLE>
<CAPTION>
PAGE
-----
<S> <C>
Consolidated Balance Sheet as of December 28, 1994, and
January 3, 1996...................................................... F-59
Consolidated Statement of Operations for the Period October
27, 1993 to December 29, 1993 and for the Fiscal
Years Ended December 28, 1994 and January 3, 1996.................... F-60
Consolidated Statement of Changes in Stockholders' Equity
(Deficit) for the Period October 27, 1993 to December
29, 1993 and for the Fiscal Years Ended December 28,
1994 and January 3, 1996............................................. F-61
Consolidated Statement of Cash Flows for the Period October
27, 1993 to December 29, 1993 and for the Fiscal
Years Ended December 28, 1994 and January 3, 1996.................... F-62
Notes to Consolidated Financial Statements................................ F-63
PROFESSIONAL VETERINARY HOSPITALS OF AMERICA, INC.
Report of Independent Accountants......................................... F-73
Statement of Operations for the Year Ended January 27, 1993
and the Period January 28, 1993 to October 26, 1993.................. F-74
Statement of Stockholders' Deficit for the Year
Ended January 27, 1993 and the Period
January 28, 1993 to October 26, 1993................................. F-75
Statement of Cash Flows for the Year Ended January 27, 1993
and the Period January 28, 1993 to October 26, 1993.................. F-76
Notes to Financial Statements............................................. F-77
PETS' RX, INC.
Consolidated Balance Sheets as of March 31, 1996
and December 31, 1995................................................ F-80
Consolidated Statements of Operations for the Three
Months Ended March 31, 1996 and 1995................................. F-81
Consolidated Statements of Cash Flows for the Three Months
Ended March 31, 1996 and 1995........................................ F-82
Notes to Consolidated Financial Statements................................ F-83
Report of Independent Public Accountants.................................. F-84
Report of Independent Public Accountants.................................. F-85
Consolidated Balance Sheets as of December 31, 1995
and 1994............................................................. F-86
</TABLE>
F-2
<PAGE>
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
Consolidated Statements of Operations for the Years
Ended December 31, 1995, 1994 and 1993............................... F-87
Consolidated Statements of Redeemable Preferred Stock
and Stockholders' Equity (Deficit) for the Years
Ended December 31, 1995, 1994 and 1993............................... F-88
Consolidated Statements of Cash Flows for the Years
Ended December 31, 1995, 1994 and 1993............................... F-89
Notes to Consolidated Financial Statements................................ F-90
SOUTHWEST VETERINARY DIAGNOSTICS, INC.
Report of Independent Public Accountants.................................. F-102
Balance Sheet at December 31, 1995........................................ F-103
Statement of Operations for the Year
Ended December 31, 1995.............................................. F-105
Statement of Stockholders' Equity for the Year
Ended December 31, 1995.............................................. F-106
Statement of Cash Flows for the Year
Ended December 31, 1995.............................................. F-107
Notes to Financial Statements............................................. F-108
</TABLE>
APPENDICES
Appendix A Agreement and Plan of Reorganization
Appendix B Opinion of National Westminster Bank PLC
Appendix C Opinion of Smith Barney Inc.
Appendix D VCA 1996 Stock Incentive Plan
Appendix E VCA 1996 Employee Stock Purchase Plan
Appendix F Exchange Ratios
F-3
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
ASSETS
<TABLE>
<CAPTION>
March 31, December 31,
1996 1995
------------ ------------
<S> <C> <C>
Current assets:
Cash and equivalents............................................. $ 37,615,000 $ 46,799,000
Accounts receivable, less allowance for uncollectible accounts... 8,816,000 6,303,000
Inventory, prepaid expenses and other............................ 4,121,000 3,518,000
Deferred income taxes............................................ 1,126,000 1,175,000
Prepaid income taxes............................................. 250,000 494,000
------------ ------------
Total current assets.......................................... 51,928,000 58,289,000
Property, plant and equipment, net................................. 15,981,000 13,641,000
Other assets:
Goodwill, net.................................................... 79,637,000 61,359,000
Covenants not to compete, net.................................... 5,573,000 4,885,000
Building purchase options........................................ 887,000 887,000
Notes receivable................................................. 1,183,000 878,000
Deferred costs and other......................................... 1,859,000 1,526,000
------------ ------------
$157,048,000 $141,465,000
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of long-term obligations......................... $ 7,563,000 $ 6,009,000
Accounts payable................................................. 5,794,000 4,850,000
Accrued payroll and taxes........................................ 2,238,000 1,961,000
Other accrued liabilities........................................ 3,339,000 3,593,000
------------ ------------
Total current liabilities..................................... 18,934,000 16,413,000
Long-term obligations, less current portion........................ 29,588,000 27,352,000
Deferred income taxes.............................................. 1,538,000 1,301,000
Minority interest.................................................. 4,843,000 4,605,000
Stockholders' equity:
Preferred stock, par value $0.001................................ 1,000 1,000
Common stock, par value $0.001................................... 13,000 12,000
Additional paid-in capital....................................... 99,072,000 89,734,000
Accumulated earnings............................................. 3,059,000 2,047,000
------------ ------------
Total stockholders' equity.................................... 102,145,000 91,794,000
------------ ------------
$157,048,000 $141,465,000
============ ============
</TABLE>
The accompanying notes are an integral part of these consolidated balance
sheets.
F-4
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED
MARCH 31, 1996 AND 1995
(UNAUDITED)
<TABLE>
<CAPTION>
1996 1995
----------- -------------
<S> <C> <C>
Revenues.............................................................................. $31,004,000 $15,230,000
Direct costs.......................................................................... 23,203,000 11,809,000
----------- -----------
Gross profit.......................................................................... 7,801,000 3,421,000
Selling, general and administrative................................................... 3,314,000 2,262,000
Depreciation and amortization......................................................... 1,034,000 548,000
Restructuring charge.................................................................. -- 1,086,000
----------- -----------
Operating income (loss)............................................................... 3,453,000 (475,000)
Interest and other investment income.................................................. 376,000 120,000
Interest expense...................................................................... 672,000 479,000
----------- -----------
Income (loss) before minority interest and provision (benefit) for income taxes....... 3,157,000 (834,000)
Minority interest in income of subsidiaries........................................... 1,346,000 21,000
----------- -----------
Income (loss) before provision (benefit) for income taxes............................. 1,811,000 (855,000)
Provision (benefit) for income taxes.................................................. 799,000 (263,000)
----------- -----------
Net income (loss)..................................................................... $ 1,012,000 $ (592,000)
=========== ===========
Earnings (loss) per share............................................................. $0.07 $(0.09)
=========== ===========
Weighted average common equivalent shares used for computing earnings (loss) per share 15,110,000 6,865,000
=========== ===========
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
F-5
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED
MARCH 31, 1996 AND 1995
(UNAUDITED)
<TABLE>
<CAPTION>
1996 1995
------------- ------------
<S> <C> <C>
Cash flows from operating activities:
Net income (loss).................................................... $ 1,012,000 $ (592,000)
Adjustments to reconcile net income (loss) to net cash provided by
operating activities:
Depreciation and amortization.................................... 1,034,000 548,000
Amortization of debt discount.................................... 72,000 3,000
Minority interest in income of subsidiaries...................... 1,346,000 21,000
(Increase) decrease in other assets, net......................... (325,000) 59,000
Decrease in deferred income taxes................................ 286,000 65,000
Increase in accounts receivable, net............................. (1,289,000) (1,507,000)
Increase in inventory, prepaid expenses and other................ (387,000) (885,000)
Decrease (increase) in prepaid income taxes...................... 244,000 (332,000)
Increase in accounts payable and accrued liabilities............. 300,000 2,704,000
Payments to minority interest partners........................... (961,000) (43,000)
----------- -----------
Net cash provided by operating activities..................... 1,332,000 41,000
----------- -----------
Cash flows from investing activities:
Property and equipment additions, net................................ (948,000) (78,000)
Business acquisitions, net of cash acquired.......................... (12,051,000) (2,028,000)
------------ -----------
Net cash used in investing activities......................... (12,999,000) (2,106,000)
------------ -----------
Cash flows from financing activities:
Reduction of long-term obligations................................... (3,000,000) (1,471,000)
Payments received on notes receivable................................ 12,000 32,000
Net proceeds from exercise of warrants............................... 5,330,000 2,108,000
Proceeds from issuance of common stock under stock option plans...... 141,000 4,000
Proceeds from issuance of common stock............................... -- 9,980,000
Repayment of line of credit.......................................... -- (1,100,000)
------------ -----------
Net cash provided by financing activities..................... 2,483,000 9,553,000
------------ -----------
(Decrease) increase in cash and equivalents............................ (9,184,000) 7,488,000
Cash and equivalents at beginning of period............................ 46,799,000 5,553,000
------------ -----------
Cash and equivalents at end of period.................................. $ 37,615,000 $13,041,000
============ ===========
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
F-6
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED
MARCH 31, 1996 AND 1995
(UNAUDITED)
(continued)
<TABLE>
<CAPTION>
1996 1995
----------- -----------
<S> <C> <C>
Supplemental disclosures of cash flow information:
Interest paid................................................................... $ 550,000 $ 457,000
Taxes paid...................................................................... 269,000 4,000
Supplemental schedule of non-cash investing and financing activities:
In connection with acquisitions, assets acquired and liabilities assumed
were as follows:
Fair value of assets acquired............................................... $23,304,000 $11,571,000
Less: Consideration given
Cash paid to sellers, net of cash acquired............................... 9,875,000 2,028,000
Cash paid in settlement of assumed liabilities........................... 2,176,000 --
Common stock issued...................................................... 3,868,000 2,300,000
----------- -----------
Liabilities assumed including notes payable issued, net of payments......... $ 7,385,000 $ 7,243,000
=========== ===========
In connection with the formation of the joint venture and partnerships, assets and
liabilities contributed by the partners were as follows:
Assets..................................................................... $ 317,000 $ 2,876,000
Liabilities................................................................ -- 1,063,000
----------- -----------
Non-cash capital contribution of minority interest partners................ $ 317,000 $ 1,813,000
=========== ===========
Non-cash increase in long-term obligations due to purchase of property..... $ -- $ 163,000
=========== ===========
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
F-7
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
MARCH 31, 1996
(UNAUDITED)
(1) GENERAL
The accompanying unaudited consolidated financial statements of Veterinary
Centers of America, Inc. and subsidiaries (the "Company" or "VCA") have been
prepared in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-Q. Accordingly, they
do not include all of the information and footnotes required by generally
accepted accounting principles for complete financial statements. In the
opinion of management, all adjustments considered necessary for a fair
presentation have been included. The results of operations for the three months
ended March 31, 1996 and 1995 are not necessarily indicative of the results to
be expected for the full year. For further information, refer to the financial
statements and footnotes thereto for the year ended December 31, 1995 included
in the Company's Annual Report on Form 10-K as filed with the Securities and
Exchange Commission on March 25, 1996.
(2) RECLASSIFICATIONS
Certain 1995 balances have been reclassified to conform with the 1996
financial statement presentation.
(3) ACQUISITIONS
During the first quarter of 1996, the Company purchased seven veterinary
hospitals and a veterinary diagnostic laboratory in separate transactions for a
total consideration (including acquisition costs) of $23,304,000 consisting of
$9,875,000 in cash, $6,551,000 in long-term obligations, 242,926 shares of VCA
common stock, with a value of $3,868,000, and the assumption of liabilities
totaling $3,010,000.
On February 27, 1996, the Company signed a definitive merger agreement with
Pets' Rx, Inc. ("Pets' Rx") which agreement was amended on April 11, 1996,
pursuant to which the Company may acquire all of the outstanding securities of
Pets' Rx for 850,000 shares of VCA common stock. Pets' Rx owns and operates 16
veterinary hospitals in the San Jose and Sacramento, California and the Las
Vegas, Nevada markets. The Company expects that the Pets' Rx merger will be
consummated in the second quarter of 1996.
On March 21, 1996, the Company signed a definitive merger agreement with The
Pet Practice, Inc. ("The Pet Practice") pursuant to which the Company may
acquire all of the outstanding securities of The Pet Practice for approximately
3.2 million shares of VCA common stock. The Pet Practice currently operates 86
veterinary hospitals in 11 states. The Company expects that The Pet Practice
merger will be consummated in the third quarter of 1996.
(4) INCOME TAXES
The provision for income taxes is greater than the amount computed using the
statutory rate due primarily to nondeductible amortization of intangible assets.
(5) SUBSEQUENT EVENTS
On April 17, 1996, the Company received net proceeds of $82,697,000 from an
offshore offering and concurrent private placement in the United States, of
$84,385,000 of 5.25% convertible subordinated debentures due in 2006. The
debentures, non-callable for three years, will be convertible into approximately
2.5 million shares of the Company's common stock at a rate of $34.35 per share.
Under the terms of the agreement the debentures and common stock issuable upon
conversion will be registered under the United States Securities Act of 1933 by
October 12, 1996.
F-8
<PAGE>
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To Veterinary Centers of America, Inc.:
We have audited the accompanying consolidated balance sheets of VETERINARY
CENTERS OF AMERICA, INC. (a Delaware corporation) and subsidiaries as of
December 31, 1995 and 1994, and the related consolidated statements of
operations, stockholders' equity and cash flows for each of the three years in
the period ended December 31, 1995. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of Veterinary Centers of
America, Inc. and subsidiaries as of December 31, 1995 and 1994, and the results
of their operations and their cash flows for each of the three years in the
period ended December 31, 1995 in conformity with generally accepted accounting
principles.
As discussed in Notes 2 and 11 to the consolidated financial statements,
effective January 1, 1993, the Company changed its method of accounting for
income taxes.
Our audits were made for the purpose of forming an opinion on the basic
financial statements taken as a whole. The schedule listed in the index of
financial statements is presented for purposes of complying with the Securities
and Exchange Commission's rules and is not part of the basic financial
statements. This schedule has been subjected to the auditing procedures
applied in the audit of the basic financial statements and, in our opinion,
fairly states in all material respects the financial data required to be set
forth therein in relation to the basic financial statements taken as a whole.
/s/ Arthur Andersen LLP
ARTHUR ANDERSEN LLP
Los Angeles, California
February 23, 1996
F-9
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
AT DECEMBER 31, 1995 AND 1994
A S S E T S
<TABLE>
<CAPTION>
1995 1994
------------ -----------
<S> <C> <C>
CURRENT ASSETS:
Cash and equivalents.................................................... $ 46,799,000 $ 5,553,000
Accounts receivable, less allowance for uncollectible accounts of
$1,648,000 and $797,000 at December 31, 1995 and 1994, respectively... 6,303,000 1,745,000
Inventory, prepaid expenses and other................................... 3,518,000 965,000
Deferred income taxes................................................... 1,175,000 438,000
Prepaid income taxes.................................................... 494,000 172,000
------------ -----------
Total current assets.............................................. 58,289,000 8,873,000
PROPERTY, PLANT AND EQUIPMENT, NET....................................... 13,641,000 8,554,000
OTHER ASSETS:
Goodwill, net........................................................... 61,159,000 30,635,000
Covenants not to compete, net........................................... 4,885,000 1,946,000
Building purchase options............................................... 1,087,000 837,000
Notes receivable........................................................ 878,000 787,000
Deferred costs and other................................................ 1,526,000 567,000
------------ -----------
$141,465,000 $52,199,000
============ ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Current portion of long-term obligations................................ $ 6,009,000 $ 4,850,000
Accounts payable........................................................ 4,850,000 2,126,000
Accrued payroll and taxes............................................... 1,961,000 984,000
Other accrued liabilities............................................... 3,593,000 1,517,000
------------ -----------
Total current liabilities......................................... 16,413,000 9,477,000
LONG-TERM OBLIGATIONS, less current portion.............................. 27,352,000 14,071,000
GUARANTEED PURCHASE PRICE CONTINGENTLY
PAYABLE IN CASH OR COMMON STOCK........................................ -- 72,000
DEFERRED INCOME TAXES.................................................... 1,301,000 148,000
MINORITY INTEREST........................................................ 4,605,000 5,034,000
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Preferred stock; $.001 par value; Authorized -- 1,000,000 shares:
Issued and outstanding -- 583,333 at December 31, 1995 and 1994... 1,000 1,000
Common stock; $.001 par value; Authorized -- 30,000,000 shares:
Issued and outstanding -- 12,056,607 and 5,480,998 at
December 31, 1995 and 1994, respectively.......................... 12,000 5,000
Additional paid-in capital............................................. 89,734,000 23,908,000
Accumulated earnings (deficit)......................................... 2,047,000 (517,000)
------------ -----------
Total stockholders' equity..................................... 91,794,000 23,397,000
------------ -----------
$141,465,000 $52,199,000
============ ===========
</TABLE>
The accompanying notes are an integral part of these consolidated balance
sheets.
F-10
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
<TABLE>
<CAPTION>
1995 1994 1993
----------- ------------ ------------
<S> <C> <C> <C>
Revenues...................................................... $92,072,000 $42,233,000 $25,313,000
Direct costs.................................................. 67,511,000 32,055,000 20,325,000
----------- ----------- -----------
Gross profit.................................................. 24,561,000 10,178,000 4,988,000
Selling, general and administrative........................... 10,833,000 6,927,000 3,862,000
Depreciation and amortization................................. 3,291,000 1,455,000 956,000
Restructuring charge.......................................... 1,086,000 -- --
Writedown of assets........................................... -- -- 2,310,000
----------- ----------- -----------
Operating income (loss)....................................... 9,351,000 1,796,000 (2,140,000)
Interest income............................................... 729,000 366,000 448,000
Interest expense.............................................. 2,368,000 1,382,000 873,000
----------- ----------- -----------
Income (loss) before minority interest, income taxes and
cumulative effect of accounting change....................... 7,712,000 780,000 (2,565,000)
Minority interest in income (loss) of subsidiaries............ 2,910,000 (540,000) (334,000)
----------- ----------- -----------
Income (loss) before income taxes and
cumulative effect of accounting change....................... 4,802,000 1,320,000 (2,231,000)
Provision (benefit) for income taxes.......................... 2,238,000 731,000 (152,000)
----------- ----------- -----------
Income (loss) before cumulative effect of accounting change... 2,564,000 589,000 (2,079,000)
Cumulative effect of accounting change........................ -- -- 221,000
----------- ----------- -----------
Net income (loss)............................................. $ 2,564,000 $ 589,000 $(1,858,000)
=========== =========== ===========
PRIMARY EARNINGS (LOSS) PER SHARE:
Earnings (loss) before cumulative
effect of accounting change............................ $ 0.24 $ 0.09 $ (0.40)
Cumulative effect of accounting change................... -- -- 0.04
----------- ----------- -----------
Net earnings (loss) per common share..................... $ 0.24 $ 0.09 $ (0.36)
=========== =========== ===========
Average common shares used for computing
primary earnings (loss) per share..................... 10,703,000 6,432,000 5,165,000
=========== =========== ===========
FULLY DILUTED EARNINGS (LOSS) PER SHARE:
Earnings (loss) before cumulative
effect of accounting change............................ $ 0.23 $ 0.09 $ (0.33)
Cumulative effect of accounting change................... -- -- 0.04
----------- ----------- -----------
Net earnings (loss) per common share..................... $ 0.23 $ 0.09 $ (0.29)
=========== =========== ===========
Average common shares used for computing
fully diluted earnings (loss) per share................ 11,238,000 6,906,000 6,238,000
=========== =========== ===========
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
F-11
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
<TABLE>
<CAPTION>
Common Stock Preferred Stock Additional Accumulated
------------------------------------------------------ Paid-In Earnings
Shares Amount Shares Amount Capital (Deficit)
--------------- -------- --------------- ------- ------------ ------------
<S> <C> <C> <C> <C> <C> <C>
BALANCES, December 31, 1992............ 5,133,785 $ 5,000 583,333 $1,000 $21,541,000 $ 752,000
Issued under stock option plans........ 39,171 -- -- -- 149,000 --
Net loss............................... -- -- -- -- -- (1,858,000)
--------- ------- -------- ------ ----------- -----------
BALANCES, December 31, 1993............ 5,172,956 5,000 583,333 1,000 21,690,000 (1,106,000)
Issued under stock option plans........ 9,499 -- -- -- 31,000 --
Business acquisitions.................. 235,329 -- -- -- 1,717,000 --
Settlement of guaranteed purchase 63,214 -- -- -- 470,000 --
price contingently payable in cash or
common stock.........................
Net income............................. -- -- -- -- -- 589,000
--------- ------- -------- ------ ----------- -----------
BALANCES, December 31, 1994............ 5,480,998 5,000 583,333 1,000 23,908,000 (517,000)
Sale of common stock................... 4,124,446 4,000 -- -- 43,908,000 --
Sale of redeemable warrants............ -- -- -- -- 58,000 --
Exercise of redeemable warrants........ 1,271,508 2,000 -- -- 8,894,000 --
Exercise of warrants issued in
connection with the Vet Research
joint venture......................... 50,000 -- -- -- 550,000 --
Issued under stock option plans........ 29,367 -- -- -- 209,000 --
Business acquisitions.................. 1,075,288 1,000 -- -- 11,979,000 --
Conversion of convertible debt......... 25,000 -- -- -- 175,000 --
Settlement of guaranteed purchase
price contingently
payable in cash or common stock....... -- -- -- -- 53,000 --
Net income............................. -- -- -- -- -- 2,564,000
---------- ------- -------- ------ ----------- -----------
BALANCES, December 31, 1995............ 12,056,607 $12,000 583,333 $1,000 $89,734,000 $ 2,047,000
========== ======= ======== ====== =========== ===========
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
F-12
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
<TABLE>
<CAPTION>
1995 1994 1993
------------- ------------ ------------
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)................................................. $ 2,564,000 $ 589,000 $(1,858,000)
Adjustments to reconcile net income (loss) to net cash provided
by operating activities:
Depreciation and amortization.................................. 3,291,000 1,455,000 956,000
Amortization of debt discount.................................. 454,000 15,000 13,000
Equity contribution for product development costs.............. -- -- 806,000
Utilization of acquired NOL carryforwards...................... 69,000 -- 40,000
Writedown of assets............................................ -- -- 2,310,000
Minority interest in income (loss) of subsidiary............... 2,910,000 (540,000) (600,000)
Distributions to minority interest partners.................... (4,015,000) (904,000) (122,000)
(Increase) decrease in accounts receivable, net................ (2,140,000) (124,000) 24,000
(Increase) decrease in inventory and other..................... (1,787,000) (319,000) 152,000
(Increase) decrease in prepaid income taxes.................... (322,000) (172,000) 99,000
Increase in other assets, net.................................. (227,000) (71,000) (235,000)
(Increase) decrease in deferred income tax asset............... (737,000) 408,000 (872,000)
Increase in accounts payable and accrued liabilities........... 3,559,000 1,399,000 467,000
(Decrease) increase in income taxes payable.................... -- (337,000) 412,000
Increase in deferred income tax liability...................... 437,000 73,000 --
------------ ----------- -----------
Net cash provided by operating activities................... 4,056,000 1,472,000 1,592,000
------------ ----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Business acquisitions, net of cash acquired....................... (9,107,000) (5,948,000) (1,021,000)
Property and equipment additions, net............................. (2,067,000) (1,052,000) (649,000)
Payments for building purchase options............................ (250,000) (60,000) (250,000)
------------ ----------- -----------
Net cash used in investing activities....................... (11,424,000) (7,060,000) (1,920,000)
------------ ----------- -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
(Repayment of) proceeds from line of credit and
addition of long-term obligations.............................. (1,100,000) 1,100,000 85,000
Reduction of long-term obligations and notes payable.............. (4,971,000) (2,494,000) (1,553,000)
Payments received on notes receivable............................. 79,000 55,000 29,000
Payments on guaranteed purchase price
contingently payable in cash or common stock.................... (19,000) -- --
Net proceeds from sale of common stock............................ 43,912,000 -- --
Net proceeds from exercise of redeemable warrants................. 8,896,000 -- --
Proceeds from exercise of warrants issued
in connection with Vet Research joint venture.................. 550,000 -- --
Proceeds from sale of redeemable warrants......................... 58,000 -- --
Proceeds from issuance of common stock under stock option plans... 209,000 31,000 149,000
Capital contribution of minority interest partners................ 1,000,000 30,000 2,970,000
------------ ----------- -----------
Net cash provided by (used in) financing activities......... 48,614,000 (1,278,000) 1,680,000
------------ ----------- -----------
INCREASE (DECREASE) IN CASH AND EQUIVALENTS......................... 41,246,000 (6,866,000) 1,352,000
CASH AND EQUIVALENTS AT BEGINNING OF YEAR........................... 5,553,000 12,419,000 11,067,000
------------ ----------- -----------
CASH AND EQUIVALENTS AT END OF YEAR................................. $ 46,799,000 $ 5,553,000 $12,419,000
============ =========== ===========
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
F-13
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
(CONTINUED)
<TABLE>
<CAPTION>
1995 1994 1993
------------- ------------ ------------
<S> <C> <C> <C>
SUPPLEMENTAL DISCLOSURES OF CASH FLOW
INFORMATION:
Interest paid................................................ $ 1,906,000 $ 1,295,000 $ 822,000
Taxes paid................................................... 2,688,000 759,000 193,000
SUPPLEMENTAL SCHEDULE OF NONCASH
INVESTING AND FINANCING ACTIVITIES:
In connection with acquisitions, assets acquired
and liabilities assumed were as follows:
Fair value of assets acquired............................... $ 43,005,000 $15,553,000 $ 4,363,000
Less: Consideration given
Cash paid................................................. (9,107,000) (5,948,000) (1,271,000)
Common stock issued....................................... (11,980,000) (1,717,000) --
------------ ----------- -----------
Liabilities assumed including notes payable issued.......... $ 21,918,000 $ 7,888,000 $ 3,092,000
============ =========== ===========
In connection with the formation of the joint venture and
partnerships, assets and liabilities contributed
by the partners were as follows:
Assets...................................................... $ 3,224,000 $ 330,000 $ --
Liabilities................................................. 1,063,000 -- --
------------ ----------- -----------
Non-cash capital contribution of minority
interest partners......................................... $ 2,161,000 $ 330,000 $ --
============ =========== ===========
Issuance of common stock in exchange
for convertible debt...................................... $ 175,000 $ -- $ --
============ =========== ===========
Settlement of guaranteed purchase price
through issuance of common stock.......................... $ 53,000 $ 470,000 $ --
============ =========== ===========
Non-cash increase in long-term obligations due to
purchase of equipment and building........................ $ 184,000 $ 164,000 $ 860,000
============ =========== ===========
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
F-14
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1995
1. THE COMPANY
Veterinary Centers of America, Inc. (VCA or the Company), a Delaware
corporation, was founded in 1986 and is a leading companion animal health care
company. The Company operates one of the largest networks of free-standing,
full service animal hospitals in the country and one of the largest networks of
veterinary-exclusive diagnostic laboratories in the nation. The Company also
markets both a life-stage and a therapeutic line of premium pet foods through
Vet's Choice, a joint venture with Heinz Pet Products, an affiliate of H.J.
Heinz Company.
At December 31, 1995, the Company owned 54 animal hospitals, 17 of which were
located in Southern California, seven in each of Northern California and
Pennsylvania, four in Massachusetts, three in each of Alaska and New Mexico, two
in each of Colorado, Florida, Maryland and Utah, and one in each of Arizona,
Georgia, Hawaii, Illinois and Delaware. The Company's animal hospitals provide
primary care, diagnostic, surgical and boarding services for animals.
In March 1994, the Company expanded its presence in the laboratory business with
the acquisition of a 70 percent interest in Professional Animal Laboratory
("PAL"). During 1995, the Company further expanded its laboratory business with
the acquisition of Cenvet, Inc. ("Cenvet") and its subsequent contribution to
Vet Research Laboratories, LLC. ("Vet Research"). Also in 1995, the Company
acquired four other veterinary diagnostic laboratories, as well as the remaining
30 percent interest in PAL. The Company's laboratories serve over 6,500 animal
hospitals located in 25 states.
In January 1993, the Company formed a joint venture, Vet's Choice, to develop,
manufacture, market and distribute new pet products and services. The joint
venture was in the development stage during all of 1993 and consequently
generated no revenues or gross profit in 1993 (Note 4). The joint venture
distributes two lines of premium pet food, Select Balance, a life-stage diet and
Select Care, a therapeutic line. Select Balance is sold to veterinary hospitals
and clinics, as well as pet stores. Select Care is sold only to veterinary
hospitals.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
a. Principles of Consolidation
The accompanying consolidated financial statements include the accounts of the
Company and all majority owned subsidiaries. All significant intercompany
transactions and balances have been eliminated.
b. Cash Equivalents
For purposes of the balance sheets and statements of cash flows, the Company
considers only highly liquid investments to be cash equivalents. Of its cash on
hand at December 31, 1995 and 1994, $1,907,000 and $2,982,000, respectively, was
restricted for use in the conduct of the Vet's Choice joint venture.
c. Inventory
Inventory is valued at the lower of cost or market using the first-in, first-out
method.
d. Property, Plant and Equipment
Property, plant and equipment is recorded at cost. Capitalized equipment leases
are recorded at the lower of the present value of the minimum lease payments or
the fair value of the equipment at the beginning of the lease term.
F-15
<PAGE>
Depreciation is recorded using the straight-line method over the estimated
useful lives of property and equipment (principally five to seven years) and
capitalized equipment leases (principally five years). Leasehold improvements
are amortized over the lives of the leases (principally 10 years). Costs of
normal repairs and maintenance are expensed as incurred.
<TABLE>
<CAPTION>
Property, plant and equipment consisted of:
1995 1994
------------ ------------
<S> <C> <C>
Land..................................... $ 2,647,000 $ 2,065,000
Building and improvements................ 4,542,000 2,891,000
Leasehold improvements................... 1,728,000 1,204,000
Furniture and equipment.................. 6,531,000 3,238,000
Capitalized equipment leases............. 1,275,000 532,000
----------- -----------
16,723,000 9,930,000
Less -- Accumulated depreciation......... (3,082,000) (1,376,000)
----------- -----------
$13,641,000 $ 8,554,000
=========== ===========
</TABLE>
Accumulated depreciation on equipment held under capital leases amounted to
$293,000 and $170,000 at December 31, 1995 and 1994, respectively.
e. Goodwill and Other Intangible Assets
Goodwill relating to acquisitions represents the purchase price paid and
liabilities incurred in excess of the fair market value of net assets acquired.
Goodwill is amortized over the expected period to be benefited, not exceeding 40
years, on a straight-line basis.
Subsequent to its acquisitions, the Company continually evaluates whether events
and circumstances have occurred that indicate the remaining estimated useful
life of goodwill may warrant revision or that the remaining balance of goodwill
may not be recoverable. When factors indicate that goodwill should be evaluated
for possible impairment, the Company uses an estimate of the related facility's
undiscounted net income over the remaining life of the goodwill in measuring
whether the goodwill is recoverable (Note 13).
Other intangible assets principally include covenants not to compete. The value
assigned to the covenants not to compete is amortized on a straight-line basis
over the term of the agreements (principally 5 to 10 years).
Accumulated amortization of goodwill and covenants not to compete and other at
December 31, 1995 is $5,808,000 and $1,939,000, respectively. Accumulated
amortization of goodwill and covenants not to compete and other at December 31,
1994 is $4,406,000 and $821,000, respectively.
In March 1995, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 121 "Accounting for the Impairment of Long-
Lived Assets and for Long-Lived Assets to be Disposed Of." The Statement
requires that long-lived assets and certain identifiable intangibles held and
used by an entity be reviewed for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be
recoverable. The Statement must be adopted by the Company no later than January
1, 1996. The Company does not expect implementation of this statement to have a
material effect on its financial position or its results of operations.
f. Investments
Effective January 1, 1994, the Company adopted Statement of Financial Accounting
Standards No. 115, "Accounting For Certain Investments in Debt and Equity
Securities," which establishes standards of financial accounting and reporting
for investments in equity securities that have readily determinable fair values
and for all investments in debt securities. The adoption of this Statement did
not have a material effect on the financial position or results of operations of
the Company.
F-16
<PAGE>
g. Accounting Change
Effective January 1, 1993, the Company adopted Statement of Financial Accounting
Standards No. 109, "Accounting For Income Taxes," which requires recognition of
deferred tax liabilities and assets for the expected future tax consequences of
events that have been included in the financial statements or tax returns.
Under this method, deferred tax liabilities and assets are determined based on
the difference between the financial statement and tax basis of assets and
liabilities using enacted tax rates in effect for the year in which the
differences are expected to reverse (Note 11).
The cumulative effect of this accounting change, which resulted in recognizing
previously unrecognized tax benefits for years prior to January 1, 1993,
decreased the net loss for 1993 by $221,000.
h. Reclassifications
Certain 1994 balances have been reclassified to conform with the 1995 financial
statement presentation.
3. ACQUISITIONS AND DISPOSITIONS
During 1995, the Company purchased 25 animal hospitals for an aggregate
consideration (including acquisition costs) of $29,019,000, consisting of
$6,436,000 in cash, $10,859,000 in debt, 836,576 shares of common stock of the
Company, with a value of $9,780,000, and the assumption of liabilities totaling
$1,944,000. In addition, the Company paid $250,000 to acquire an option to
purchase the land and building of two of the hospitals.
Also during 1995, the Company purchased substantially all of the assets of
Cenvet, a full-service veterinary diagnostic laboratory, four other veterinary
diagnostic laboratories and the remaining 30 percent interest in PAL, for an
aggregate consideration of $13,986,000, including acquisition costs, consisting
of $2,671,000 in cash, $8,633,000 in long-term obligations, 238,712 shares of
VCA common stock, with a value of $2,200,000 and the assumption of liabilities
totaling $482,000.
On March 20,1995, the Company and Vet Research, Inc., ("VRI"), formed Vet
Research Laboratories, LLC ("Vet Research"). In connection with the formation
of Vet Research, VRI contributed all of the assets and certain of the
liabilities of VRI's full-service veterinary diagnostic laboratory located in
Farmingdale, New York. The Company contributed substantially all of the assets
and certain of the liabilities of Cenvet for a 51 percent controlling interest
in the joint venture (Note 4).
In connection with the formation of Vet Research, the Company issued warrants to
purchase 363,636 shares of the common stock of the Company at $11.00 per share.
The warrants were purchased at $0.001 per warrant and are exercisable until the
fifth day following the last day upon which the Company is permitted to close
the purchase of VRI's interest in Vet Research pursuant to the VCA Option
Agreement.
In 1994, VCA purchased four veterinary hospitals for a total consideration
(including acquisition costs) of $5,754,000 consisting of $1,329,000 in cash,
$3,663,000 in non-recourse promissory notes payable, 91,996 shares of VCA common
stock with a value of $680,000, and the assumption of liabilities totaling
$82,000. In addition, the Company paid $60,000 to acquire an option to purchase
the land and building of one of the hospitals.
In 1994, the Company acquired substantially all of the assets and assumed
certain of the liabilities of PAL, a full-service veterinary laboratory, located
in Irvine, California. In connection with the purchase, the Company also
acquired from a principal shareholder of PAL, the real property and building
occupied by the business of PAL. The business is operated by a partnership to
which the Company contributed the veterinary laboratory that it previously
owned. The net consideration (including acquisition costs) paid by the Company
in connection with these transactions, totaling $9,799,000, consisted of
$4,619,000 in cash, $3,446,000 in notes payable, 143,333 shares of VCA common
stock with a value of $1,037,000, and the assumption of liabilities totaling
$697,000.
F-17
<PAGE>
The non-recourse notes payable, with a principal amount of $3,663,000, to the
previous owners of the hospitals are secured by the assets of the acquired
hospitals. The fair market value of the tangible assets acquired, including
accounts receivable, supplies, inventory and hospital equipment, totals
approximately $360,000.
In 1993, VCA purchased six veterinary hospitals for a total consideration of
$4,113,000 consisting of $1,021,000 in cash, $2,967,000 in non-recourse notes
payable and the assumption of liabilities totaling $125,000. In addition, the
Company paid $250,000 to acquire options to purchase the land and building of
two of the hospitals. The obligations of the Company to the previous owners
pursuant to the non-recourse notes are secured by the assets of the companies
acquired. The fair market value of the tangible assets acquired including
accounts receivable, supplies, inventory and hospital equipment, totals
approximately $295,000. During 1993, the Company exercised its option to
purchase the land and building of one of its animal hospitals for total
consideration of approximately $1,296,000 consisting of a $436,000 option
payment made in 1992 and the assumption of a mortgage payable in the amount of
$860,000.
All acquisitions have been accounted for using the purchase method of
accounting. The operations of the acquired companies are included in the
accompanying consolidated financial statements from the date of acquisition.
The pro forma results listed below are unaudited and reflect purchase price
accounting adjustments assuming 1994 and 1995 acquisitions occurred at January
1, 1994. The pro forma results are not necessarily indicative of what actually
would have occurred if the acquisitions had been in effect for the entire
periods presented. In addition, they are not intended to be a projection of
future results and do not reflect any efficiencies that might be achieved from
the combined operation.
<TABLE>
<CAPTION>
(Unaudited)
1995 1994
------------ ------------
<S> <C> <C>
Revenue...................................... $112,070,000 $100,229,000
Net income................................... $ 4,811,000 $ 4,018,000
Primary earnings per share................... $ 0.40 $ 0.43
Fully diluted earnings per share............. $ 0.39 $ 0.41
Weighted average shares used for computing
earnings per share:
Primary.................................... 11,959,000 9,420,000
Fully diluted.............................. 12,494,000 9,894,000
</TABLE>
4. JOINT VENTURES
In January 1993, the Company entered into a joint venture with Heinz Pet
Products, Vet's Choice, to develop, manufacture and market new pet products and
services. The Company obtained a 50.5 percent controlling interest in the joint
venture for a capital contribution of $3,030,000 in cash and is the managing
general partner. Heinz Pet Products ("HPP"), contributed $2,970,000 in cash
for a 49.5 percent minority interest in the joint venture. Under the terms of
the partnership agreement, HPP also agreed to make an additional capital
contribution of their product development costs of up to $1 million. The actual
costs incurred during 1993 were $806,000. Such costs were expensed and credited
to the minority interest partner's equity account. Commencing January 1, 1996
the joint venture will make preferential distributions to HPP of any
distributable cash in excess of $3 million in any fiscal year until such time as
HPP has received preferential distributions amounting to the total development
costs that it contributed. As provided by the partnership agreement, the
Company and Heinz Pet Products each contributed $1 million to the joint venture
in the third quarter of 1995. The joint venture agreement between the Company
and HPP provides for restrictions on the transfer of each partner's respective
interest in the joint venture and for reciprocal buy-sell provisions. Heinz Pet
Products has agreed to lend Vet's Choice up to $1.0 million at its bank prime
rate plus one-half percent for working capital.
The Company operates Vet Research in a joint venture with VRI. Vet Research's
operating results have been accounted for as part of the consolidated
operations of the Company. Distributions of distributable cash will be made
F-18
<PAGE>
pursuant to a formula contained in the operating agreement between the Company
and VRI. Pursuant to that formula, during each contract year, the first $1.5
million of distributable cash is distributed to VRI; the next $3 million of
distributable cash is distributed to the Company; and the remaining
distributable cash is distributed 25 percent to the Company and 75 percent to
VRI. The Company has recorded minority interest expense related to the joint
venture based on the estimated percentage of annual income which will be
distributed to the minority interest partner pursuant to the operating
agreement. The estimate is reviewed and adjusted on a quarterly basis. The
1995 results include minority interest expense of 52.4 percent of Vet Research's
income.
The Company has an option pursuant to an agreement with VRI to acquire VRI's
entire interest in Vet Research for a purchase price as computed in accordance
with the operating agreement. The Company's option is exercisable January 1,
1997 through January 31, 1997. If the Company does not exercise its option, VRI
has an option to acquire the Company's interest in Vet Research.
5. LONG-TERM OBLIGATIONS
Long-term obligations consisted of the following at December 31, 1995 and 1994:
<TABLE>
<CAPTION>
1995 1994
----------- ----------
<S> <C> <C>
8 percent note payable, convertible into VCA common stock at $12.50 per
share, due through 1997, secured by certain fixed and intangible assets........... $ 57,000 $ 86,000
5 percent note payable, convertible into VCA common stock at $15.00 per
share due through 1997, secured by stock of certain subsidiaries.................. 196,000 391,000
11.2 percent note payable due through 1997, secured by assets
of a certain subsidiary........................................................... 408,000 483,000
Adjustable rate note payable, interest at the treasury bill rate (6.3 percent
at December 31, 1995) adjusted annually, due through June 2000 (discounted
at 6.5 percent)................................................................... 300,000 355,000
Obligation due monthly through May 2000, secured by assets of certain
subsidiary (discounted at 6.5 percent)............................................ 230,000 273,000
Obligation due quarterly through 1997, (discounted at 8.75 percent)................. 361,000 --
Obligation due quarterly through 2002, secured by assets of certain
subsidiary (discounted at 8.75 percent)........................................... 2,580,000 --
Adjustable rate note payable, interest at the bank prime rate plus 0.5 percent,
(capped at 8.5 percent at December 31, 1995), adjusted annually, due through
2000, secured by stock of a certain subsidiary................................... 592,000 698,000
3 percent note payable, converted into VCA common stock in June 1995
at $7.00 per share................................................................ -- 175,000
Adjustable rate notes payable, interest at the bank prime rate, adjusted annually
(capped at 8.0 percent at December 31, 1995), various maturities through 2000,
secured by assets and stock of certain subsidiaries............................... 2,516,000 2,899,000
Adjustable rate notes payable, interest at the bank prime rate plus 1 percent
(8.0 percent to 9.5 percent at December 31, 1995), various maturities through
2002, secured by assets and stock of certain subsidiaries......................... 510,000 589,000
6 percent notes payable, due through 2002, secured by stock of certain subsidiary... 641,000 760,000
7 percent and 7.5 percent notes payable, due through 2007, secured by
assets and stock of certain subsidiaries.......................................... 10,953,000 3,034,000
8 percent notes payable, various maturities through 2006, secured by stock of
certain subsidiaries.............................................................. 6,915,000 339,000
9 percent and 9.8 percent notes payable, various maturities through 2005,
secured by assets of certain subsidiary and building.............................. 898,000 --
Notes payable and other obligations, various maturities through 1997, secured
by land, building and stock of certain subsidiaries (discounted at 10 to
12 percent)....................................................................... 299,000 471,000
10 percent notes payable, various maturities through 2005, secured by stock
and assets of certain subsidiaries and land and building.......................... 2,627,000 2,867,000
</TABLE>
F-19
<PAGE>
<TABLE>
<CAPTION>
1995 1994
------------ ------------
<S> <C> <C>
Revolving line of credit at the bank prime rate (8.5 percent at December 31, 1995)
matures December 1996, convertible into a 36 month term loan....................... -- $ 1,100,000
10.5 percent note payable, due through 1997, secured by land and
building of a certain subsidiary................................................... $ 1,016,000 1,025,000
Adjustable rate notes payable, interest at bank prime rate, plus 1.5 percent
(capped at 9.0 percent at December 31, 1995), due through 2001, secured
by assets and stock of certain subsidiaries........................................ 707,000 803,000
11 percent note payable due through 2001, secured by assets
of certain subsidiary.............................................................. 383,000 449,000
Adjustable rate notes payable at the bank prime rate, plus 1 percent
(9.75 percent at December 31, 1995)................................................ 420,000 1,688,000
Notes payable, secured by assets and stock of certain subsidiaries, various
maturities through 2001, interest at an average rate of 11 to 12 percent........... 123,000 152,000
----------- -----------
Total debt obligations............................................................... 32,732,000 18,637,000
Capital lease obligations, due through 2000 (Note 9)................................. 862,000 358,000
Less -- Unamortized discount......................................................... (233,000) (74,000)
----------- -----------
33,361,000 18,921,000
Less -- Current portion.............................................................. (6,009,000) (4,850,000)
----------- -----------
$27,352,000 $14,071,000
=========== ===========
</TABLE>
The annual aggregate scheduled maturities of debt obligations for the five years
subsequent to December 31, 1995 are presented below:
<TABLE>
<S> <C>
1996.......... $6,009,000
1997.......... 6,321,000
1998.......... 4,260,000
1999.......... 3,839,000
2000.......... 4,246,000
Thereafter.... 8,686,000
-----------
$33,361,000
===========
</TABLE>
Certain acquisition debt of the Company included above and amounting to
$23,102,000 and $14,608,000 at December 31, 1995 and 1994, respectively, is
non-recourse debt secured solely by the assets or the stock of the veterinary
hospital acquired under security arrangements whereby the creditor's sole remedy
in the event of default is the contractual right to take possession of the
entire veterinary hospital regardless of the outstanding indebtedness at the
time of default.
The Company has an unsecured line of credit of $3.1 million. The line of credit
is at the bank prime rate (8.5 percent at December 31, 1995) and expires in
December 1996, at which time the outstanding balance on the line can, at the
Company's option, convert to a 36-month term loan. At December 31, 1995, the
Company had $3.1 million available under the line.
The following disclosure of the estimated fair value of the Company's debt is
made in accordance with the requirements of Statement of Financial Accounting
Standards No. 107 "Disclosures about Fair Value of Financial Instruments." The
estimated fair value amounts have been determined by the Company using available
market information and appropriate valuation methodologies. Considerable
judgment is required to develop the estimates of fair value, thus the estimates
provided therein are not necessarily indicative of the amounts that could be
realized in a current market exchange.
F-20
<PAGE>
<TABLE>
<CAPTION>
December 31, 1995
-----------------------
Carrying Fair
Amount Value
---------- -----------
<S> <C> <C>
Fixed-rate long-term debt................. $23,229,000 $19,677,000
Variable-rate long-term debt.............. 4,123,000 4,123,000
</TABLE>
The carrying values of variable-rate long-term debt is a reasonable estimate of
their fair value. The estimated fair value of the Company's fixed-rate long-
term debt is based on prime plus an estimated spread at December 31, 1995 for
similar securities with similar remaining maturities.
6. PREFERRED STOCK
On December 22, 1992, the Company completed the sale of 583,333 shares of
convertible preferred stock for net proceeds of $2,985,000. The shares are
convertible into 583,333 shares of the Company's common stock commencing
December 22, 1997. The preferred stock participates in any dividend payments on
the Company's common stock on an as converted basis. The preferred stock has a
liquidation preference of $5.14 per share and it is callable by the Company any
time after March 22, 1998 at a price of $5.14 per share. The preferred stock
has no voting rights.
Under the Company's certificate of incorporation, the Company is authorized to
issue additional series of preferred stock. The rights, preferences and
privileges of the preferred stock are to be determined by the board of directors
and do not require stockholder approval.
7. COMMON STOCK
In January 1995, Star-Kist Foods, Inc. through its Heinz Pet Products division
purchased 1,159,420 shares of the Company's common stock at $8.625 per share,
resulting in net proceeds to the Company of $9,980,000.
In November 1995, the Company completed a secondary public offering of 2,965,026
shares of common stock for net proceeds of $33,932,000.
During 1995, the Company issued 1,075,226 shares of the Company's common stock
valued at $11,980,000, the fair market value at the date of commitment, as a
portion of the consideration for 15 animal hospitals and three veterinary
diagnostic laboratories. Of this amount, 156,303 shares of common stock valued
at $1,970,000 had not been issued as of December 31, 1995. Such shares are
reflected as though they are outstanding in the accompanying consolidated
financial statements.
In conjunction with the acquisition of two hospitals and PAL in 1994, the
Company issued 235,329 shares of common stock with a market value at the date of
issue of $1,717,000. Also in 1994, the Company issued 63,214 shares of common
stock in settlement of a guaranteed purchase price contingently payable in cash
or common stock (Note 8).
On October 6, 1991, the Company completed a public offering of 2,400,000 shares
of common stock and 3,240,000 redeemable warrants for $12,598,000. Each
redeemable warrant entitles the holder to purchase one share of common stock for
$7.20 commencing April 10, 1992 until October 10, 1996, and is redeemable at the
option of the Company at any time after April 10, 1992 on 30 days prior written
notice, provided that the market price of the common stock equals or exceeds
$9.00 per share for 20 consecutive trading days ending within 10 days prior to
notice of redemption. Such market price exceeded $9.00 per share for 20
consecutive days on March 10,1995. During 1995, redeemable warrants were
exercised for 1,271,508 shares of common stock. Cash proceeds from the exercise
of redeemable warrants amounted to $8,896,000.
Under the provisions of the Company's non-qualified and incentive stock option
plans for officers and key employees, 750,000 shares of common stock were
reserved for issuance at December 31, 1992. On May 5, 1995, the stockholders of
the Company approved the adoption of the Veterinary Centers of America, Inc.
1995 Stock Incentive Plan, and authorized the reservation of 750,000 shares of
common stock for issuance under the Plan. The options become exercisable over a
two to five year period, commencing at the date of grant or one year from the
F-21
<PAGE>
date of grant depending on the option. All options expire 10 years from the
date of grant. The prices of all options granted were greater than or equal to
the fair market value at the date of the grant.
The table below summarizes the transactions in the Company's stock option plans
during 1995, 1994 and 1993:
<TABLE>
<CAPTION>
1995 1994 1993
---------- -------- --------
<S> <C> <C> <C>
Options outstanding at beginning of year... 705,001 598,650 342,700
Granted.................................... 820,750 132,800 275,500
Exercised.................................. (21,034) (9,499) (5,838)
Canceled................................... (13,200) (16,950) (13,712)
--------- ------- -------
Options outstanding at end of year
($.75 to $12.38 per share)............... 1,491,517 705,001 598,650
========= ======= =======
Exercisable at end of year................. 640,824 419,708 285,338
========= ======= =======
</TABLE>
In addition to the options granted under VCA's stock option plans, the Company
had 45,667 and 54,000 options outstanding at December 31, 1995 and 1994,
respectively, to certain members of the board of directors and to the previous
owners of certain acquired companies. During 1995, 8,333 of these options were
exercised. The options are exercisable at $.75 to $6.00 per share. At December
31, 1995, 45,667 of the options are exercisable.
In November 1995, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 123 "Accounting for Stock-Based
Compensation." The statement recommends changes in accounting for employee
stock-based compensation plans, and requires certain disclosures with respect to
these plans. The Statement's disclosures will be adopted by the Company
effective January 1, 1996.
8. GUARANTEED PURCHASE PRICE CONTINGENTLY PAYABLE IN CASH OR COMMON STOCK
The Company has guaranteed the value of certain shares of its common stock
issued in connection with the acquisition of certain animal hospitals in 1995.
If the aggregate market value of the stock (as quoted by a nationally recognized
stock exchange) at various specified valuation dates is below the value of the
stock on the acquisition date, the Company has agreed to pay the difference in
additional shares of stock, cash or notes payable. The Company's guarantee of
the value, however, terminates if the common stock is registered for resale and
trades at 110% to 120% of the issue price of the stock for five to twenty
consecutive days. At December 31, 1995, there were 404,495 shares of stock
outstanding with such guarantees, with issue prices ranging from $11.26 to
$14.95.
In connection with certain acquisitions completed prior to 1995, the Company
guaranteed the price of certain shares of its common stock issued in connection
with the acquisitions. If the aggregate market value of the stock (as quoted by
a nationally recognized stock exchange) had not reached the guaranteed value,
which exceeded the value of the stock at the acquisition date, by the various
specified valuation dates, the Company agreed to pay the difference in
additional shares of stock, cash, or notes payable. The guaranteed purchase
price contingently payable in cash or common stock represents the liability for
the difference between the aggregate guaranteed value of the common stock net of
the Company's estimate of the fair market value of the stock at the date of the
acquisition, discounted at 10 percent.
In 1995, pursuant to two of these stock guarantee arrangements pertaining to a
total of 13,494 shares, the Company paid $19,000 in cash for the difference
between the guaranteed value of the stock held and the market value of the
stock, as defined. The difference between the $19,000 and the $72,000 liability
for the guaranteed purchase price contingently payable in cash or common stock,
amounting to $53,000 was credited to additional paid-in-capital.
In 1994, pursuant to a stock guarantee arrangement for 80,000 shares, the
Company issued 63,214 shares of common stock for the difference between the
guaranteed value of the stock held and the market value of the stock, as
defined. The market value of the additional shares issued, totaling $470,000,
was charged to the liability for the guaranteed purchase price contingently
payable in cash or common stock.
F-22
<PAGE>
9. COMMITMENTS
The Company operates many of its hospitals from premises that are leased from
the hospitals' previous owners under operating leases with terms, including
renewal options, ranging from one to 35 years.
The annual lease payments under the lease agreements have provisions for annual
increases based on the Consumer Price Index. The Company also leases certain
medical and computer equipment under capital leases.
The future minimum lease payments at December 31, 1995 are as follows:
<TABLE>
<CAPTION>
Capital Operating
Leases Leases
----------- ------------
<S> <C> <C>
1996.......................................... $ 401,000 $ 3,145,000
1997.......................................... 317,000 3,153,000
1998.......................................... 227,000 2,948,000
1999.......................................... 46,000 2,449,000
2000.......................................... 12,000 2,288,000
Thereafter.................................... -- 30,242,000
---------- -----------
1,003,000 $44,225,000
===========
Less -- Amount representing interest.......... (141,000)
----------
Present value of net minimum lease payments... $ 862,000
==========
</TABLE>
Rent expense totaled $2,936,000, $1,574,000 and $1,170,000 for the years ended
December 31, 1995, 1994 and 1993, respectively. Rental income totaled $246,000,
$96,000 and $96,000 for the years ended December 31, 1995, 1994 and 1993,
respectively.
The Company has employment agreements with three officers of the Company which
currently expire on December 31, 1998. Each of the agreements provide for
annual compensation (subject to upward adjustment) which aggregated $559,000 for
the year ended December 31, 1995.
10. CALCULATION OF PER SHARE AMOUNTS
Earnings per share calculations are based on the weighted average common shares
outstanding including obligated shares (Note 7) plus common shares subject to
dilutive stock options, common shares contingently issuable pursuant to the
guaranteed purchase price contingently payable in cash or common stock as
discussed in Note 8, convertible debt and shares issuable upon redemption of
redeemable warrants and conversion of preferred stock. Stock options, common
shares contingently issuable and shares issuable upon conversion of preferred
stock are not included in the weighted average common shares in 1993 as they
have an anti-dilutive effect.
F-23
<PAGE>
11. Income Taxes
The provision for income taxes is comprised of the following:
<TABLE>
<CAPTION>
1995 1994 1993
----------- --------- ----------
<S> <C> <C> <C>
Federal:
Current.... $1,888,000 $183,000 $ 490,000
Deferred... (192,000) 296,000 (595,000)
---------- -------- ---------
1,696,000 479,000 (105,000)
---------- -------- ---------
State:
Current.... 560,000 239,000 141,000
Deferred... (18,000) 13,000 (188,000)
---------- -------- ---------
542,000 252,000 (47,000)
---------- -------- ---------
$2,238,000 $731,000 $(152,000)
========== ======== =========
</TABLE>
Effective January 1, 1993, the Company adopted the provisions of Statement of
Financial Accounting Standards No. 109, "Accounting for Income Taxes" ("SFAS
109"). SFAS 109 requires recognition of deferred tax liabilities and assets for
the expected future tax consequences of events that have been included in the
financial statements or tax returns. Under this method, deferred tax
liabilities and assets are determined based on the difference between the
financial statement and tax bases of assets and liabilities using enacted tax
rates in effect for the year in which the differences are expected to reverse.
The Company reflected the impact as a cumulative adjustment in the 1993 first
quarter and did not restate prior periods. The cumulative adjustment had a
favorable impact of $221,000 on the net loss.
The net deferred tax asset (liability) is comprised of the following:
<TABLE>
<CAPTION>
1995 1994
------------ ----------
<S> <C> <C>
Current deferred tax assets (liabilities):
Accounts receivable................................ $ 301,000 $ 165,000
State taxes........................................ 156,000 34,000
Other liabilities and reserves..................... 223,000 156,000
Start-up costs..................................... 59,000 120,000
Property, plant and equipment...................... 95,000 (33,000)
Restructuring...................................... 345,000 --
Other assets....................................... (4,000) (4,000)
----------- ---------
Total current deferred tax asset, net... $ 1,175,000 $ 438,000
=========== =========
<CAPTION>
1995 1994
----------- ---------
<S> <C> <C>
Non-current deferred tax (liabilities) assets:
Net operating loss carryforwards................... $ 76,000 $ 145,000
Start-up costs..................................... 288,000 151,000
Miscellaneous...................................... -- 25,000
Other assets....................................... (119,000) (124,000)
Intangible assets.................................. (1,805,000) (66,000)
Valuation allowance................................ (76,000) (145,000)
Property, plant and equipment...................... 335,000 (134,000)
----------- ---------
Total non-current deferred tax liability, net........ $(1,301,000) $(148,000)
=========== =========
</TABLE>
F-24
<PAGE>
A reconciliation of the provision for income taxes to the amount computed at the
Federal statutory rate is as follows:
<TABLE>
<CAPTION>
1995 1994 1993
----- ----- -------
<S> <C> <C> <C>
Federal income tax at statutory rate... 34.0% 34.0% (34.0)%
Effect of amortization of goodwill..... 5.0 9.0 5.0
State taxes, net of Federal benefit.... 8.0 12.0 2.0
Cumulative impact of tax law change.... -- -- (3.0)
Writedown of assets.................... -- -- 24.0
---- ---- ------
47.0% 55.0% (6.0)%
==== ==== ======
</TABLE>
For financial reporting purposes, the benefit arising from the utilization of
operating loss carryforwards generated by companies prior to their acquisition
by VCA is accounted for as a reduction of goodwill of the acquired companies.
Such benefit amounted to $40,000 and $69,000 for the years ended December 31,
1993 and 1995, respectively. No benefit was realized for the year ended
December 31, 1994. For tax reporting purposes, the acquired companies have
Federal net operating loss carryforwards at December 31, 1995 of approximately
$260,000 expiring through 2003.
12. 401(K) PLAN
During 1992, the Company established a voluntary retirement plan under Section
401(k) of the Internal Revenue Code. The plan covers all eligible employees and
provides for annual matching contributions by the Company at the discretion of
the Company's board of directors. In 1995, 1994 and 1993, the Company provided
a matching contribution of 20 percent, 20 percent and 15 percent, respectively
of the first five percent of the employees' contributions, as defined. Such
matching contributions approximated $87,000, $46,000 and $24,000 in 1995, 1994
and 1993, respectively.
13. WRITEDOWN OF ASSETS
During 1993, the Company charged $2,310,000 to operations related to the
writedown of goodwill and certain intangible assets at three of the Company's
facilities. The determination to writedown these assets was based on the
Company's estimate that forecasted losses at each facility indicated that the
intangible assets would not be realized.
The first of the three hospitals was purchased in March 1989, with goodwill on
the acquisition of $920,000. In the five years subsequent to the acquisition,
the hospital generated losses aggregating $84,000 through December 31, 1993, due
primarily to severe competition in the area from the veterinarian from whom the
Company acquired the hospital. In January 1994, the economy in the area where
the hospital operates was adversely impacted by the "Northridge Earthquake,"
further impacting the hospital's revenues and operating results.
The second hospital was purchased in December 1989, at a price of approximately
$1 million, with goodwill on the acquisition of $997,000. Since the
acquisition, the hospital generated aggregate net income of $250,000 through
December 31, 1993, including a loss of $44,000 in 1992 and income of $17,000 in
1993. Included in the operating results is income of $73,000 in 1992 and
$39,000 in 1993 from the rental of space at the facility to a veterinary surgery
referral practice. The rental agreement was terminated in July 1993 and, due to
the specialization of the services provided by the referral practice, the
hospital was unable to find a suitable replacement. In addition to the impact
of the loss of rental income, the hospital's revenue and income were adversely
impacted by the loss of referral business from the referral practice. The
departure of the group had a permanent negative impact on the hospital's net
income and the recoverability of goodwill.
The third hospital was purchased in December 1991 at a price of approximately
$800,000, with goodwill and other intangible assets on the acquisition of
$778,000. The hospital generated net income in 1992 of $52,000 and a net loss
in 1993 of $59,000. The hospital provided 24-hour emergency service under an
arrangement whereby a veterinary emergency group used the hospital space during
the hours that the regular hospital was closed. The emergency clinic's
presence in the hospital provided substantial indirect benefits to the
hospital's operating results. In September 1993, the emergency group terminated
its arrangement with the hospital, and the operating results were adversely
impacted. The Company has determined that emergency services cannot be replaced
and the impact on the hospital will be permanent.
F-25
<PAGE>
The Company's goal over the next two years is to minimize the facilities' cash
flow requirements and ultimately bring the facilities to a breakeven status.
The Company's strategy of building a network of hospitals in the markets they
serve will be benefited by the hospitals' ability to provide services to
customers in their vicinity, even though the facilities will not generate
profits.
14. RESTRUCTURING CHARGE
The operations of Cenvet were merged into VRI's operations to form Vet Research
in March 1995. The combined operations were restructured to eliminate
duplicate operating and overhead costs. The restructuring included the
consolidation of facilities, staff reductions and the consolidation of ancillary
operations. In connection with the restructuring, the Company recorded a charge
of $1,086,000 in the first quarter of 1995 to accrue the estimated costs
associated with the restructuring, consisting primarily of lease termination and
severance costs.
The following is a summary of the restructuring costs:
<TABLE>
<CAPTION>
1995
----------
<S> <C>
Employee severance costs... $ 468,000
Lease commitments.......... 433,000
Other...................... 185,000
----------
$1,086,000
==========
</TABLE>
During 1995, the Company utilized $237,000 of the reserve for restructuring. At
December 31, 1995, $849,000 of the restructuring reserves remained on the
Company's balance sheet.
15. LINES OF BUSINESS
The Company classifies its business operations into three segments: Animal
Hospital, Premium Pet Food and Laboratory. Prior to January 1993, the Company's
principal line of business was owning and operating animal hospitals. On
January 1, 1993, the Company formed a joint venture, Vet's Choice, to develop,
market and distribute new pet products and services (Note 4). Vet's Choice
began generating revenue in March 1994 when it commenced distribution of its
first product line. In March 1994, the Company acquired Professional Animal
Laboratory and combined its existing laboratory to form the Laboratory segment.
<TABLE>
<CAPTION>
Animal Premium Corporate &
(In thousands) Hospital Pet Food Laboratory Eliminations Total
-------- --------- ---------- ------------- --------
<S> <C> <C> <C> <C> <C>
1995
Revenues.................. $51,437 $ 4,756 $37,606 $(1,727) $ 92,072
Gross profit.............. 9,381 1,551 13,629 -- 24,561
Restructuring cost........ -- -- 1,086 -- 1,086
Operating income (loss)... 7,455 (2,573) 8,359 (3,890) 9,351
Identifiable assets....... 62,152 3,854 29,798 45,661 141,465
1994
Revenues.................. $31,846 $ 996 $10,150 $ (759) $ 42,233
Gross profit.............. 6,252 349 3,577 -- 10,178
Operating income (loss)... 5,123 (3,094) 2,563 (2,796) 1,796
Identifiable assets....... 31,995 3,599 13,532 3,073 52,199
</TABLE>
F-26
<PAGE>
16. SUBSEQUENT EVENTS
During the first quarter of 1996 through March 19, 1996, the Company purchased
six veterinary hospitals and a veterinary diagnostic laboratory in separate
transactions for a total consideration (including acquisition costs) of
$22,224,000, consisting of $9,650,000 in cash, $6,151,000 in notes payable,
242,926 shares of VCA common stock with a value of $3,868,000 and the assumption
of liabilities totaling $2,555,000.
On February 27, 1996, the Company signed a definitive merger agreement with
Pets' Rx, Inc. ("Pets' Rx"), pursuant to which the Company will acquire all of
the outstanding securities of Pets' Rx. Pets' Rx owns and operates 16
veterinary hospitals in the San Jose and Sacramento, California and the Las
Vegas, Nevada markets. Under the terms of the merger, the stockholders of Pets'
Rx will receive approximately 970,000 shares of the Company's common stock
(subject to adjustment). The Company expects that the merger will be
consummated in the second quarter of 1996. The merger will be accounted for as
a pooling of interests. If consummated, the merger will provide the Company
with entry into the Las Vegas, Nevada market and will strengthen the Company's
presence in Northern California.
Consummation of the merger with Pets' Rx is subject to certain significant
conditions. Consequently, the merger of Pets' Rx and the Company may never be
consummated.
On March 21, 1996, the Company signed a definitive merger agreement with The Pet
Practice, Inc. ("TPP"), pursuant to which the Company will acquire all of the
outstanding securities of TPP. TPP operates 86 veterinary hospitals in 11
states.
Under the terms of the agreement, each share of TPP common stock will be
converted into a fraction of a share of VCA common stock determined by a
reference to the average closing price of VCA common stock over the twenty
trading days ending on the third day before the shareholder meetings at which
the stockholders of VCA and TPP will consider the merger. If the average price
of the VCA common stock ranges from $25 to $30 per share, the exchange ratio
shall be determined by dividing $10 by the average price of the VCA common
stock, resulting in a valuation of $10 per share of TPP common stock throughout
the range. If the average closing price of the VCA common stock is less than
$24 per share, the exchange ratio will be increased (from 0.395 shares at $24
per share) by 0.005 for each dollar of such reduction down to $18.50 of VCA
common stock, and if the average price of VCA common stock is more than $31 per
share, the exchange ratio shall be reduced (from 0.3350 at $31 per share) by
0.005 for each dollar of such increase, up to $49.00 per share. No further
adjustment shall be made if the price of VCA stock shall be less than $18.50.
In each case, a proportionate reduction or increase, as the case may be, shall
be made if the price of VCA common stock is less than a round dollar. If the
average price of the VCA common stock is greater than $49.00, the exchange ratio
should be determined by dividing $12.005 by the average price. By way of
illustration, at $23 per share of VCA common stock, the exchange ratio shall be
0.400, resulting in a valuation of $9.20 per share of TPP common stock. At
$32.00 per share of VCA common stock, the exchange ratio shall be 0.330,
resulting in a valuation of $10.56 per share of TPP common stock. The Company
expects that the merger will be consummated in the second quarter of 1996. The
merger will be accounted for as a purchase. Each party has the right to
terminate the definitive agreement if the average price of VCA common shares is
$18.50 or less.
Consummation of the merger is subject to certain significant conditions.
Consequently, the merger of VCA and TPP may never be consummated.
F-27
<PAGE>
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To Veterinary Centers of America, Inc.:
We have audited the accompanying supplemental combined balance sheets of
Veterinary Centers of America, Inc. (a Delaware corporation), and subsidiaries,
as of December 31, 1995 and 1994, and the related supplemental combined
statements of operations, changes in stockholders' equity and cash flows for
each of the three years in the period ended December 31, 1995 and the balance
sheet of Pets' Rx, Inc. as of December 31, 1995, and the related statements of
operations, changes in stockholders' equity and cash flows for the year then
ended included in the supplemental combined financial statements of Veterinary
Centers of America, Inc. The supplemental combined historical statements give
retroactive effect to the merger with Pets' Rx, Inc., on June 19, 1996, which
subsequently will be accounted for as a pooling of interests as described in
Note 1. These supplemental financial statements are the responsibility of the
Companies' management. Our responsibility is to express an opinion on these
supplemental financial statements based on our audits.
We did not audit the 1994 and 1993 financial statements of Pets' Rx, Inc.,
included in the supplemental combined financial statements of Veterinary Centers
of America, Inc., which statements reflect total assets and revenues
constituting 25 percent and 19 percent, respectively, in 1994 and 19 percent of
revenue in 1993, of the related supplemental combined totals. These statements
were audited by other auditors whose reports thereon has been furnished to us,
and our opinion expressed herein, insofar as it relates to the amounts included
for Pets' Rx, Inc., in 1994 and 1993 is based solely upon the reports of the
other auditors.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits and the reports of the other auditors provide a
reasonable basis for our opinion.
In our opinion, based upon our audits and the reports of the other
auditors, the supplemental combined financial statements referred to above
present fairly, in all material respects, the combined financial position of
Veterinary Centers of America, Inc. and Pets' Rx, Inc. as of December 31, 1995
and 1994, and the results of their operations and their cash flows for each of
the three years in the period ended December 31, 1995, after giving retroactive
effect to the merger with Pets' Rx, Inc. as described in Note 1, in conformity
with generally accepted accounting principles.
/s/ Arthur Andersen LLP
ARTHUR ANDERSEN LLP
Los Angeles, California
June 19, 1996
F-28
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
SUPPLEMENTAL COMBINED BALANCE SHEETS
AT DECEMBER 31, 1995 AND 1994
AND MARCH 31, 1996 (UNAUDITED)
ASSETS
<TABLE>
<CAPTION>
DECEMBER 31,
----------------------------- MARCH 31,
1995 1994 1996
------------- ------------ -------------
CURRENT ASSETS: (Unaudited)
<S> <C> <C> <C>
Cash and equivalents........................................................... $ 47,551,000 $ 7,807,000 $ 37,866,000
Accounts receivable, less allowance for uncollectible accounts of $1,671,000
and $797,000 at December 31, 1995 and 1994, respectively, and
$1,881,000 at March 31, 1996 (unaudited)...................................... 6,508,000 1,955,000 8,994,000
Inventory, prepaid expenses and other.......................................... 3,984,000 1,326,000 4,121,000
Deferred income taxes.......................................................... 1,175,000 438,000 1,126,000
Prepaid income taxes........................................................... 494,000 172,000 730,000
------------ ----------- ------------
Total current assets.......................................................... 59,712,000 11,698,000 52,837,000
PROPERTY, PLANT AND EQUIPMENT, NET............................................. 17,695,000 12,692,000 19,974,000
OTHER ASSETS:
Goodwill, net................................................................. 66,943,000 38,264,000 85,392,000
Covenants not to compete, net................................................. 5,210,000 2,646,000 5,852,000
Building purchase options..................................................... 1,087,000 837,000 887,000
Notes receivable.............................................................. 978,000 1,080,000 1,283,000
Deferred costs and other...................................................... 1,791,000 685,000 2,129,000
------------ ----------- ------------
$153,416,000 $67,902,000 $168,354,000
============ =========== ============
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Current portion of long-term obligations....................................... $ 7,421,000 $ 5,552,000 $ 8,730,000
Accounts payable............................................................... 5,930,000 2,980,000 6,855,000
Accrued payroll and taxes...................................................... 2,207,000 1,191,000 2,531,000
Other accrued liabilities...................................................... 4,705,000 2,498,000 4,264,000
------------ ----------- ------------
Total current liabilities..................................................... 20,263,000 12,221,000 22,380,000
LONG TERM OBLIGATIONS, less current portion.................................... 36,778,000 25,057,000 38,807,000
GUARANTEED PURCHASE PRICE CONTINGENTLY PAYABLE IN
CASH OR COMMON STOCK.......................................................... 72,000
DEFERRED INCOME TAXES.......................................................... 1,301,000 148,000 1,538,000
MINORITY INTEREST.............................................................. 4,856,000 5,034,000 5,112,000
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Preferred stock; $.001 par value; Authorized -- 1,000,000 shares:
Issued and outstanding -- 583,333 at December 31, 1995 and 1994.............. 1,000 1,000 1,000
Common stock; $.001 par value; Authorized -- 30,000,000 shares:
Issued and outstanding -- 12,845,831 and 6,248,126 at
December 31, 1995 and 1994 respectively, and 13,828,444
at March 31, 1996 (unaudited)................................................ 13,000 6,000 14,000
Additional paid-in capital.................................................... 99,685,000 33,630,000 109,223,000
Accumulated deficit........................................................... (9,481,000) (8,267,000) (8,721,000)
------------ ----------- ------------
Total stockholders' equity................................................... 90,218,000 25,370,000 100,517,000
------------ ----------- ------------
$153,416,000 $67,902,000 $168,354,000
</TABLE>
The accompanying notes are an integral part of these supplemental combined
balance sheets.
F-29
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
SUPPLEMENTAL COMBINED STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
AND THE THREE MONTHS ENDED MARCH 31, 1996 AND 1995 (UNAUDITED)
<TABLE>
<CAPTION>
Years Ended December 31, Three Months Ended March 31,
------------------------------------------------ -----------------------------
1995 1994 1993 1996 1995
-------------- ------------- ------------- ------------- ------------
(Unaudited)
<S> <C> <C> <C> <C> <C>
Revenues....................................... $107,694,000 $51,871,000 $31,098,000 $35,232,000 $18,652,000
Direct costs................................... 80,747,000 40,834,000 25,562,000 26,710,000 14,741,000
------------ ----------- ----------- ----------- -----------
Gross profit................................... 26,947,000 11,037,000 5,536,000 8,522,000 3,911,000
Selling, general and administrative............ 13,036,000 8,704,000 4,916,000 3,844,000 2,761,000
Depreciation and amortization.................. 4,144,000 2,065,000 1,410,000 1,235,000 740,000
Restructuring charge........................... 1,086,000 1,086,000
Writedown of assets............................ 2,148,000 4,506,000
------------ ----------- ----------- ----------- -----------
Operating income (loss)........................ 6,533,000 268,000 (5,296,000) 3,443,000 (676,000)
Interest income................................ 828,000 404,000 469,000 388,000 145,000
Interest expense............................... 3,377,000 2,388,000 1,225,000 901,000 737,000
------------ ----------- ----------- ----------- -----------
Income (loss) before minority interest, income
taxes and cumulative effect of accounting
change........................................ 3,984,000 (1,716,000) (6,052,000) 2,930,000 (1,268,000)
Minority interest in income (loss) of
subsidiaries.................................. 2,960,000 (540,000) (334,000) 1,371,000 31,000
------------ ----------- ----------- ----------- -----------
Income (loss) before income taxes and
cumulative effect of accounting change........ 1,024,000 (1,176,000) (5,718,000) 1,559,000 (1,299,000)
Provision (benefit) for income taxes........... 2,238,000 731,000 (152,000) 799,000 (263,000)
------------ ----------- ----------- ----------- -----------
(Loss) income before cumulative effect of
accounting change............................. (1,214,000) (1,907,000) (5,566,000) 760,000 (1,036,000)
Cumulative effect of accounting change......... 221,000
------------ ----------- ----------- ----------- -----------
Net (loss) income.............................. $ (1,214,000) $(1,907,000) $(5,345,000) $ 760,000 $(1,036,000)
============ =========== =========== =========== ===========
(LOSS) EARNINGS PER SHARE:
(Loss) earnings before cumulative effect of
accounting change............................. $(0.11) $(0.26) $(0.93) $0.05 $(0.14)
Cumulative effect of accounting change......... 0.03
------------ ----------- ----------- ----------- -----------
Net (loss) earnings per common share........... $(0.11) $(0.26) $(0.90) $0.05 $(0.14)
============ =========== =========== =========== ===========
Average common shares used for computing
(loss) earnings per share..................... 11,504,000 7,233,000 5,966,000 15,911,000 7,666,000
============ =========== =========== =========== ===========
</TABLE>
The accompanying notes are an integral part of these supplemental combined
financial statements.
F-30
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
SUPPLEMENTAL COMBINED STATEMENTS OF STOCKHOLDERS' EQUITY
FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
AND THE THREE MONTHS ENDED MARCH 31, 1996 (UNAUDITED)
<TABLE>
<CAPTION>
Common Stock Preferred Stock Additional Accumulated
------------------------ ------------------ Paid-In Earnings
Shares Amount Shares Amount Capital (Deficit)
------------- --------- -------- -------- ------------ -------------
<S> <C> <C> <C> <C> <C> <C>
BALANCES, December 31, 1992
As previously stated.......................... 5,133,785 $ 5,000 583,000 $1,000 $ 21,541,000 $ 752,000
Pooling with Pets' Rx, Inc.................... 256,853 3,919,000 (1,335,000)
----------- ------- -------- ------ ------------ -----------
Balances, as restated......................... 5,390,638 5,000 583,000 1,000 25,460,000 (583,000)
Sale of common stock.......................... 46,317 200,000
Sale of warrants.............................. 221,000
Issued under stock option plans............... 39,171 149,000
Stock dividend................................ 7,680 208,000 (208,000)
Net loss...................................... (5,345,000)
----------- ------- -------- ------ ------------ -----------
BALANCES, December 31, 1993................... 5,483,806 5,000 583,000 1,000 26,238,000 (6,136,000)
Sale of common stock.......................... 125,808 3,245,000
Sale of warrants.............................. 13,000
Exercise of warrants.......................... 55,580 55,000
Stock dividend................................ 8,256 224,000 (224,000)
Stock issued for payment of interest.......... 30,841 223,000
Issued under stock option plans............... 32,765 198,000
Business acquisitions......................... 237,483 1,732,000
Conversion of convertible debt................ 210,373 1,000 1,232,000
Settlement of guaranteed purchase price
contingently payable in cash or common
stock.................................... 63,214 470,000
Net loss...................................... (1,907,000)
----------- ------- -------- ------ ------------ -----------
BALANCES, December 31, 1994................... 6,248,126 6,000 583,000 1,000 33,630,000 (8,267,000)
Sale of common stock.......................... 4,129,616 4,000 44,058,000
Sale of redeemable warrants................... 4,607 58,000
Exercise of redeemable warrants............. 1,271,508 2,000 8,894,000
Exercise of warrants issued in connection
with the Vet Research joint venture.......... 50,000 550,000
Issued under stock plans...................... 29,367 209,000
Business acquisitions......................... 1,075,288 1,000 11,979,000
Conversion of convertible debt................ 37,319 254,000
Settlement of guaranteed purchase price
contingently payable in cash or common
stock.................................... 53,000
Net loss...................................... (1,214,000)
----------- ------- -------- ------ ------------ -----------
BALANCES, December 31, 1995................... 12,845,831 13,000 583,000 1,000 99,685,000 (9,481,000)
Sale of common stock (unaudited).............. 6,894 200,000
Exercise of redeemable warrants
(unaudited).................................. 542,431 1,000 3,855,000
Exercise of warrants issued in connection
with the Vet Research joint venture
(unaudited)................................. 134,000 1,474,000
Issued under stock plans (unaudited).......... 56,363 141,000
Business acquisitions (unaudited)............. 242,925 3,868,000
Net income (unaudited)........................ 760,000
----------- ------- -------- ------ ------------ -----------
BALANCES, March 31, 1996 (Unaudited).......... 13,828,444 $14,000 583,000 $1,000 $109,223,000 $(8,721,000)
=========== ======= ======== ====== ============ ===========
</TABLE>
The accompanying notes are an integral part of these supplemental combined
financial statements.
F-31
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
SUPPLEMENTAL COMBINED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
AND THE THREE MONTHS ENDED MARCH 31, 1996 AND 1995 (UNAUDITED)
<TABLE>
<CAPTION>
Three Months Ended
March 31,
------------------------------
1995 1994 1993 1996 1995
------------ ------------- ------------- -------------- --------------
(Unaudited)
<S> <C> <C> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income............................. $ (1,214,000) $(1,907,000) $(5,345,000) $ 760,000 $(1,036,000)
Adjustments to reconcile net (loss) income to
net cash provided by operating activities:
Depreciation and amortization................ 4,144,000 2,065,000 1,410,000 1,235,000 740,000
Gain on sale of land and building............ (19,000) (18,000)
Amortization of debt discount................ 454,000 15,000 13,000 72,000 3,000
Equity contribution for product development
costs....................................... 806,000
Utilization of acquired NOL carryforwards.... 69,000 40,000
Writedown of assets.......................... 2,148,000 4,506,000
Minority interest in income (loss) of
subsidiary.................................. 2,960,000 (540,000) (600,000) 1,371,000 31,000
Distributions to minority interest partners.. (4,058,000) (904,000) (122,000) (961,000) (43,000)
(Increase) decrease in accounts receivable,
net......................................... (2,140,000) (124,000) 24,000 (1,289,000) (1,507,000)
(Increase) decrease in inventory and other... (1,875,000) (203,000) 16,000 (374,000) (925,000)
(Increase) decrease in prepaid income taxes.. (322,000) (172,000) 99,000 244,000 (332,000)
(Increase) decrease in other assets, net..... (208,000) (122,000) (271,000) (330,000) 7,000
(Increase) decrease in deferred income tax
asset....................................... (737,000) 408,000 (872,000) 286,000 65,000
Increase in accounts payable and accrued
liabilities................................. 4,198,000 2,829,000 801,000 208,000 3,026,000
(Decrease) increase in income taxes payable.. (337,000) 412,000
Increase in deferred income tax liability.... 437,000 73,000
----------- ----------- ---------- ----------- ------------
Net cash provided by operating activities... 3,837,000 1,081,000 917,000 1,222,000 11,000
----------- ----------- ---------- ----------- ------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Business acquisitions, net of cash acquired... (9,147,000) (6,810,000) (2,161,000) (12,051,000) (2,028,000)
Property, plant and equipment additions, net.. (2,983,000) (1,166,000) (809,000) (1,012,000) (156,000)
Sale of marketable securities................. 140,000
Proceeds from sale of land and building....... 600,000 600,000
Payments for building purchase options........ (250,000) (60,000) (250,000)
----------- ----------- ---------- ----------- ------------
Net cash used in investing activities........ (11,780,000) (8,036,000) (3,080,000) (13,063,000) (1,584,000)
----------- ----------- ---------- ----------- ------------
CASH FLOWS FROM FINANCING ACTIVITIES:
(Repayment of) proceeds from line of credit
and addition of long-term obligations........ (1,100,000) 1,394,000 1,511,000 (1,100,000)
Reduction of long-term obligations and notes
payable...................................... (6,241,000) (3,097,000) (1,908,000) (3,526,000) (2,269,000)
Payments received (advances made) on notes
receivable................................... 272,000 (43,000) 31,000 12,000 225,000
Payments on guaranteed purchase price
contingently payable in cash or common stock. (19,000)
Net proceeds from sale of common stock........ 44,062,000 3,245,000 200,000 200,000 10,080,000
Net proceeds from exercise of warrants........ 55,000
Net proceeds from exercise of redeemable
warrants..................................... 8,896,000 3,855,000 2,108,000
Proceeds from exercise of warrants issued in
connection with Vet Research joint venture... 550,000 1,474,000
Proceeds from sale of warrants................ 13,000 221,000
Proceeds from sale of redeemable warrants..... 58,000
Proceeds from issuance of common stock under
stock option plans........................... 209,000 198,000 149,000 141,000 4,000
Capital contribution of minority interest
partners..................................... 1,000,000 30,000 2,970,000
----------- ----------- ---------- ----------- ------------
Net cash provided by financing activities... 47,687,000 1,795,000 3,174,000 2,156,000 9,048,000
----------- ----------- ---------- ----------- ------------
INCREASE (DECREASE) IN CASH AND EQUIVALENTS.... 39,744,000 (5,160,000) 1,011,000 (9,685,000) 7,475,000
CASH AND EQUIVALENTS AT BEGINNING OF YEAR...... 7,807,000 12,967,000 11,956,000 47,551,000 7,807,000
------------ ----------- ----------- ------------ ------------
CASH AND EQUIVALENTS AT END OF YEAR............ $ 47,551,000 $ 7,807,000 $12,967,000 $ 37,866,000 $15,282,000
============ =========== =========== ============ ============
</TABLE>
The accompanying notes are an integral part of these supplemental combined
financial statements.
F-32
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
SUPPLEMENTAL COMBINED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
AND THE THREE MONTHS ENDED MARCH 31, 1996 AND 1995 (UNAUDITED)
(CONTINUED)
<TABLE>
<CAPTION>
Three Months
Years Ended December 31, Ended March 31,
----------------------------------------- --------------------------------
1995 1994 1993 1996 1995
------------ ---------- ---------- --------------- -------------
(Unaudited)
<S> <C> <C> <C> <C> <C>
SUPPLEMENTAL DISCLOSURES OF CASH
FLOW INFORMATION:
Interest paid...................................... $ 2,878,000 $ 2,277,000 $ 1,146,000 $ 832,000 $ 701,000
Taxes paid......................................... 2,688,000 759,000 193,000 269,000 4,000
SUPPLEMENTAL SCHEDULE OF
NONCASH INVESTING AND FINANCING
ACTIVITIES:
In connection with acquisitions, assets
acquired and liabilities assumed were as
follows:
Fair value of assets acquired...................... $ 43,223,000 $19,584,000 $10,846,000 $23,304,000 $11,571,000
Less: Consideration given
Cash paid to sellers, net of cash acquired........ (9,147,000) (6,810,000) (2,161,000) (9,875,000) (2,028,000)
Cash paid in settlement of
assumed liabilities.............................. (2,176,000)
Common stock issued............................... (11,980,000) (1,732,000) (3,868,000) (2,300,000)
------------ ----------- ----------- ----------- -----------
Liabilities assumed including
notes payable issued.............................. $ 22,096,000 $11,042,000 $ 8,685,000 $ 7,385,000 $ 7,243,000
============ =========== =========== =========== ===========
In connection with the formation of the joint
venture and partnerships, assets and liabilities
contributed by the partners were as follows:
Assets............................................. $ 3,467,000 $ 330,000 $ -- $ 317,000 $ 3,119,000
Liabilities........................................ 1,063,000 1,063,000
------------ ----------- ----------- ----------- -----------
Non-cash capital contribution of minority
interest partners................................. $ 2,404,000 $ 330,000 $ -- $ 317,000 $ 2,056,000
============ =========== =========== =========== ===========
Issuance of common stock in exchange for
convertible debt.................................. $ 254,000 $ 1,233,000 $ -- $ -- $ --
============ =========== =========== =========== ===========
Settlement of guaranteed purchase price
through issuance of common stock.................. $ 53,000 $ 470,000 $ -- $ -- $ --
============ =========== =========== =========== ===========
Non-cash increase in long-term obligations due
to purchase of equipment and building............. $ 262,000 $ 164,000 $ 860,000 $ -- $ 466,000
============ =========== =========== =========== ===========
Conversion of accounts payable to notes
payable........................................... $ 381,000 $ -- $ -- $ -- $ --
============ =========== =========== =========== ===========
Payment of accrued interest on notes by
issuance of common stock.......................... $ -- $ 223,000 $ -- $ -- $ --
============ =========== =========== =========== ===========
</TABLE>
The accompanying notes are an integral part of these supplemental combined
financial statements.
F-33
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO SUPPLEMENTAL COMBINED FINANCIAL STATEMENTS
DECEMBER 31, 1995
(Information with respect to the unaudited three months ended
March 31, 1996 and 1995 is not covered by report of independent public
accountants)
1. BASIS OF PRESENTATION, BUSINESS AND ORGANIZATION
The Merger
In June 1996, Veterinary Centers of America, Inc. ("VCA" or the "Company")
merged with Pets' Rx, Inc. (Pets' Rx), in a transaction to be accounted for as a
pooling of interests (the "Merger"). On or about August 15, 1996, VCA will
restate its historical financial statements to reflect the pooling of interests
transaction. Those restated financials will resemble these supplemental
combined consolidated financial statements in all material aspects. These
supplemental financial statements are presented to provide the reader with an
understanding of the combined historical results of VCA.
Pursuant to the Merger, each share of Pets' Rx common stock was converted into
.08617 shares of VCA common stock. In aggregate, 6,323,294 million shares of
Pets' Rx common stock were converted into 544,880 shares of VCA common stock.
Each share of Pets' Rx redeemable convertible preferred stock outstanding
immediately prior to the merger was converted into 118,329 shares of VCA common
stock. Each share of convertible preferred stock outstanding immediately prior
to the Merger was converted into 137,872 shares of VCA common stock. Previously
reported financial information for VCA and Pets' Rx for each of the three years
in the period ended December 31, 1995, is shown in the table below. To conform
to consistent methods of accounting, adjustments of historical data were made.
Among these were the adjustments related to the allocation of intangible assets
in connection with purchase transactions and the related amortization and the
writedown of intangible assets resulting from conforming to VCA's method of
analyzing the realization of goodwill utilizing the undiscounted net income
method.
<TABLE>
<CAPTION>
(In thousands) Years Ended December 31,
-----------------------------------
1995 1994 1993
----------- --------- --------
<S> <C> <C> <C>
Historical VCA net income (loss) $ 2,564 $ 589 $(1,858)
Historical Pets' Rx net loss (1,977) (2,805) (1,522)
------- ------- -------
Historical combined net income (loss) 587 (2,216) (3,380)
Amortization of assets 347 309 108
Writedown of assets (2,148) -- (2,073)
------- ------- -------
Restated combined net loss $(1,214) $(1,907) $(5,345)
======= ======= =======
</TABLE>
Veterinary Centers of America, Inc. Formation
Veterinary Centers of America, Inc. ("VCA" or the "Company"), a Delaware
corporation, was founded in 1986 and is a leading companion animal health care
company. The Company operates one of the largest networks of free-standing,
full service animal hospitals in the country and one of the largest networks of
veterinary-exclusive diagnostic laboratories in the nation. The Company also
markets both a life-stage and a therapeutic line of premium pet foods through
Vet's Choice, a joint venture with Heinz Pet Products, an affiliate of H.J.
Heinz Company.
At June 19, 1996, the Company owned 80 animal hospitals, 19 of which were
located in Northern California, 18 in Southern California, eight in
Pennsylvania, six in Massachusetts, five in Nevada, four in Maryland, three in
each of Alaska, Florida and New Mexico, two in each of Colorado, Utah and
Virginia, and one in each of Arizona, Georgia, Hawaii, Illinois and Delaware.
The Company's animal hospitals provide primary care, diagnostic, surgical and
boarding services for animals.
F-34
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO SUPPLEMENTAL COMBINED FINANCIAL STATEMENTS
(Information with respect to the unaudited three months ended
March 31, 1996 and 1995 is not covered by report of independent public
accountants)
In March 1994, the Company expanded its presence in the laboratory business
with the acquisition of a 70 percent interest in Professional Animal Laboratory
("PAL"). During 1995, the Company further expanded its laboratory business with
the acquisition of Cenvet, Inc. ("Cenvet") and its subsequent contribution to
Vet Research Laboratories, LLC. ("Vet Research"). Also in 1995, the Company
acquired four other veterinary diagnostic laboratories, as well as the remaining
30 percent interest in PAL. The Company's laboratories serve over 8,000 animal
hospitals located in 40 states.
In January 1993, the Company formed a joint venture, Vet's Choice, to develop,
manufacture, market and distribute new pet products and services. The joint
venture was in the development stage during all of 1993 and consequently
generated no revenues or gross profit in 1993 (Note 4). The joint venture
distributes two lines of premium pet food, Select Balance, a life-stage diet and
Select Care, a therapeutic line. Select Balance is sold to veterinary hospitals
and clinics, as well as pet stores. Select Care is sold only to veterinary
hospitals.
Pets' Rx Formation
Pets' Rx was incorporated in Delaware on May 28, 1991. The Company is engaged
in the acquisition and operation of veterinary clinics. As of December 31,
1995, the Company operates 16 clinics in the San Jose and Sacramento,
California, and Las Vegas, Nevada, markets.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
a. Principles of Consolidation
The supplemental combined financial statements include the financial position
and results of operations of VCA and all of its subsidiaries combined with the
financial position and results of operations of Pets' Rx and all of its
subsidiaries. As previously discussed, these supplemental combined financial
statements reflect how VCA's consolidated financial statements will look
following the June 19, 1996 restatement for the merger with Pets' Rx.
b. Interim Accounting Policy
The accompanying unaudited supplemental combined financial statements have not
been audited by independent public accountants, but in the opinion of VCA and
Pets' Rx management, such unaudited statements include all adjustments
(consisting only of normal recurring accruals) necessary for a fair presentation
of the combined financial positions of VCA and Pets' Rx as of March 31, 1996 and
the results of their operations and cash flows for the three months ended March
31, 1995 and 1996. Although the management of VCA and Pets' Rx believes that
the disclosures in these supplemental combined financial statements are adequate
to make the information presented not misleading, certain information normally
included in financial statements prepared in accordance with generally accepted
accounting principles has been condensed or omitted pursuant to the rules and
regulations of the Securities and Exchange Commission. The results of
operations for the three months ended March 31, 1995 and 1996 are not
necessarily indicative of the results to be expected for the full year.
c. Cash Equivalents
For purposes of the balance sheets and statements of cash flows, the Company
considers only highly liquid investments to be cash equivalents. Of its cash on
hand at December 31, 1995 and 1994, $1,907,000 and $2,982,000, respectively, was
restricted for use in the conduct of the Vet's Choice joint venture.
d. Inventory
Inventory is valued at the lower of cost or market using the first-in, first-
out method.
F-35
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO SUPPLEMENTAL COMBINED FINANCIAL STATEMENTS
(Information with respect to the unaudited three months ended
March 31, 1996 and 1995 is not covered by report of independent public
accountants)
e. Property, Plant and Equipment
Property, plant and equipment is recorded at cost. Capitalized equipment
leases are recorded at the lower of the present value of the minimum lease
payments or the fair value of the equipment at the beginning of the lease term.
Depreciation is recorded using the straight-line method over the estimated
useful lives of property and equipment (principally five to seven years) and
capitalized equipment leases (principally five years). Leasehold improvements
are amortized over the lives of the leases (principally 10 years). Costs of
normal repairs and maintenance are expensed as incurred.
Property, plant and equipment consisted of:
<TABLE>
<CAPTION>
1995 1994
------------ -------------
<S> <C> <C>
Land............................... $ 2,795,000 $ 2,328,000
Building and improvements.......... 6,544,000 5,378,000
Leasehold improvements............. 2,410,000 1,458,000
Furniture and equipment............ 8,633,000 4,909,000
Capitalized equipment leases....... 1,334,000 532,000
----------- -----------
21,716,000 14,605,000
Less -- Accumulated depreciation... (4,021,000) (1,913,000)
----------- -----------
$17,695,000 $12,692,000
=========== ===========
</TABLE>
Accumulated depreciation on equipment held under capital leases amounted to
$303,000 and $170,000 at December 31, 1995 and 1994, respectively.
f. Goodwill and Other Intangible Assets
Goodwill relating to acquisitions represents the purchase price paid and
liabilities incurred in excess of the fair market value of net assets acquired.
Goodwill is amortized over the expected period to be benefited, not exceeding 40
years, on a straight-line basis.
Subsequent to its acquisitions, the Company continually evaluates whether
events and circumstances have occurred that indicate the remaining estimated
useful life of goodwill may warrant revision or that the remaining balance of
goodwill may not be recoverable. When factors indicate that goodwill should be
evaluated for possible impairment, the Company uses an estimate of the related
facility's undiscounted net income over the remaining life of the goodwill in
measuring whether the goodwill is recoverable (Note 13).
Other intangible assets principally include covenants not to compete. The
value assigned to the covenants not to compete is amortized on a straight-line
basis over the term of the agreements (principally 5 to 10 years).
Accumulated amortization of goodwill and covenants not to compete and other at
December 31, 1995 is $3,563,000 and $2,986,000, respectively. Accumulated
amortization of goodwill and covenants not to compete and other at December 31,
1994 is $3,792,000 and $1,259,000, respectively.
In March 1995, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 121 "Accounting for the Impairment of Long-
Lived Assets and for Long-Lived Assets to be Disposed Of." The Statement
requires that long-lived assets and certain identifiable intangibles held and
used by an entity be reviewed for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be
recoverable. The Statement was adopted by the Company
F-36
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO SUPPLEMENTAL COMBINED FINANCIAL STATEMENTS
(Information with respect to the unaudited three months ended
March 31, 1996 and 1995 is not covered by report of independent public
accountants)
on January 1, 1996. The Company does not expect implementation of this
statement to have a material effect on its financial position or its results of
operations.
g. Investments
Effective January 1, 1994, the Company adopted Statement of Financial
Accounting Standards No. 115, "Accounting For Certain Investments in Debt and
Equity Securities," which establishes standards of financial accounting and
reporting for investments in equity securities that have readily determinable
fair values and for all investments in debt securities. The adoption of this
Statement did not have a material effect on the financial position or results
of operations of the Company.
h. Accounting Change
Effective January 1, 1993, the Company adopted Statement of Financial
Accounting Standards No. 109, "Accounting For Income Taxes," which requires
recognition of deferred tax liabilities and assets for the expected future tax
consequences of events that have been included in the financial statements or
tax returns. Under this method, deferred tax liabilities and assets are
determined based on the difference between the financial statement and tax basis
of assets and liabilities using enacted tax rates in effect for the year in
which the differences are expected to reverse (Note 11).
The cumulative effect of this accounting change, which resulted in recognizing
previously unrecognized tax benefits for years prior to January 1, 1993,
decreased the net loss for 1993 by $221,000.
i. Reclassifications
Certain 1994 balances have been reclassified to conform with the 1995 financial
statement presentation.
3. ACQUISITIONS AND DISPOSITIONS
During 1996, through June 19, 1996, the Company purchased 11 veterinary
hospitals and three veterinary diagnostic laboratories in separate transactions.
In connection with the acquisitions which were accounted for as a purchase, the
aggregate consideration (including acquisition costs) was $28,718,000 consisting
of $13,614,000 in cash, $8,066,000 in long-term obligations, 242,926 shares of
VCA common stock with a value of $3,868,000 and the assumption of liabilities
totalling $3,170,000. In connection with the two acquisitions which were
treated as a pooling of interests, VCA issued 151,010 shares of VCA common
stock. Additionally, on June 19, 1996 the Company consummated a merger with
Pets' Rx for 801,081 shares of VCA common stock. The merger with Pets' Rx will
be accounted for as a pooling of interests.
During 1995, the Company purchased 25 animal hospitals for an aggregate
consideration (including acquisition costs) of $29,019,000, consisting of
$6,436,000 in cash, $10,859,000 in debt, 836,576 shares of common stock of the
Company, with a value of $9,780,000, and the assumption of liabilities totaling
$1,944,000. In addition, the Company paid $250,000 to acquire an option to
purchase the land and building of two of the hospitals.
Also during 1995, the Company purchased substantially all of the assets of
Cenvet, a full-service veterinary diagnostic laboratory, four other veterinary
diagnostic laboratories and the remaining 30 percent interest in PAL, for an
aggregate consideration of $13,986,000, including acquisition costs, consisting
of $2,671,000 in cash, $8,633,000 in long-term obligations, 238,712 shares of
VCA common stock, with a value of $2,200,000 and the assumption of liabilities
totaling $482,000.
On March 20,1995, the Company and Vet Research, Inc., ("VRI"), formed Vet
Research Laboratories, LLC ("Vet Research"). In connection with the formation
of Vet Research, VRI contributed all of the assets and certain of the
liabilities of VRI's full-service veterinary diagnostic laboratory located in
Farmingdale, New York. The Company contributed substantially all of the assets
and certain of the liabilities of Cenvet for a 51 percent controlling interest
in the joint venture (Note 4).
In connection with the formation of Vet Research, the Company issued warrants
to purchase 363,636 shares of the common stock of the Company at $11.00 per
share. The warrants were purchased at $0.001 per warrant and are exercisable
until the fifth day
F-37
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO SUPPLEMENTAL COMBINED FINANCIAL STATEMENTS
(Information with respect to the unaudited three months ended
March 31, 1996 and 1995 is not covered by report of independent public
accountants)
following the last day upon which the Company is permitted to close the purchase
of VRI's interest in Vet Research pursuant to the VCA Option Agreement.
In 1994, VCA purchased four veterinary hospitals for a total consideration
(including acquisition costs) of $5,754,000 consisting of $1,329,000 in cash,
$3,663,000 in non-recourse promissory notes payable, 91,996 shares of VCA common
stock with a value of $680,000, and the assumption of liabilities totaling
$82,000. In addition, the Company paid $60,000 to acquire an option to purchase
the land and building of one of the hospitals.
In 1994, the Company acquired substantially all of the assets and assumed
certain of the liabilities of PAL, a full-service veterinary laboratory, located
in Irvine, California. In connection with the purchase, the Company also
acquired from a principal shareholder of PAL, the real property and building
occupied by the business of PAL. The net consideration (including acquisition
costs) paid by the Company in connection with these transactions, totaling
$9,799,000, consisted of $4,619,000 in cash, $3,446,000 in notes payable,
143,333 shares of VCA common stock with a value of $1,037,000, and the
assumption of liabilities totaling $697,000.
The non-recourse notes payable, with a principal amount of $3,663,000, to the
previous owners of the hospitals are secured by the assets of the acquired
hospitals. The fair market value of the tangible assets acquired, including
accounts receivable, supplies, inventory and hospital equipment, totals
approximately $360,000.
In 1993, VCA purchased six veterinary hospitals for a total consideration of
$4,113,000 consisting of $1,021,000 in cash, $2,967,000 in non-recourse notes
payable and the assumption of liabilities totaling $125,000. In addition, the
Company paid $250,000 to acquire options to purchase the land and building of
two of the hospitals. The obligations of the Company to the previous owners
pursuant to the non-recourse notes are secured by the assets of the companies
acquired. The fair market value of the tangible assets acquired including
accounts receivable, supplies, inventory and hospital equipment, totals
approximately $295,000. During 1993, the Company exercised its option to
purchase the land and building of one of its animal hospitals for total
consideration of approximately $1,296,000 consisting of a $436,000 option
payment made in 1992 and the assumption of a mortgage payable in the amount of
$860,000.
All 1993 and 1994 acquisitions have been accounted for using the purchase
method of accounting. The operations of the acquired companies are included in
the accompanying consolidated financial statements from the date of acquisition.
Since its inception, Pets' Rx has completed the acquisition of 19 veterinary
clinics (of which three have been merged into other clinics). All of the
acquisitions were accounted for using the purchase method of accounting;
accordingly, the costs of these acquisitions have been allocated to assets
acquired based on their fair value at date of acquisition. The results of the
acquired clinics are included in Pets' Rx results commencing from the date of
acquisition.
During 1995, Pets' Rx acquired a veterinary hospital for a total consideration
of $218,000 consisting of $40,000 in cash, $25,000 in a secured promissory note
payable, $15,000 payable under covenants not to compete, $31,000 payable under
an assumed lease obligation, and $107,000 in other liabilities.
During 1995, a limited liability company (LLC) was formed by combining a
veterinary clinic owned by Pets' Rx with the practice of another veterinary
clinic owned by an unrelated party. Certain assets were contributed by each
party to form the new entity, which is not liable for any contracts or for any
indebtedness relating to the predecessor clinics. The Company has an 80%
interest in the LLC.
During 1994, Pets' Rx completed the acquisition of six veterinary hospitals for
total consideration of $4,031,000, consisting of $862,000 in cash, $2,529,000 in
secured promissory notes payable, $325,000 payable under covenants not to
compete, 2,154 shares of common stock valued at $15,000 and the assumption of
$300,000 of notes payable.
During 1993, Pets' Rx completed the acquisition of four veterinary clinics for
total consideration of $6,733,000 consisting of $1,140,000 in cash, $5,350,000
in secured promissory notes payable, $200,000 payable under covenants not to
compete, and the assumption of $43,000 in trade and payroll liabilities.
F-38
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO SUPPLEMENTAL COMBINED FINANCIAL STATEMENTS
(Information with respect to the unaudited three months ended
March 31, 1996 and 1995 is not covered by report of independent public
accountants)
The unaudited pro forma results listed below reflect purchase price accounting
adjustments assuming 1994, 1995 and 1996 acquisitions (through June 19, 1996)
occurred at January 1, 1994. The pro forma results are not necessarily
indicative of what actually would have occurred if the acquisitions had been in
effect for the entire periods presented. In addition, they are not intended to
be a projection of future results and do not reflect any efficiencies that might
be achieved from the combined operations.
<TABLE>
<CAPTION>
UNAUDITED PRO FORMA INFORMATION
-------------------------------
YEARS ENDED DECEMBER 31,
1995 1994
-------------- ------------
<S> <C> <C>
Revenue......................... $127,933,000 $113,655,000
Net income (loss)............... 1,048,000 (4,000)
Net earnings (loss) per share... $ 0.08 $ (0.00)
</TABLE>
4. JOINT VENTURES
In January 1993, the Company entered into a joint venture with Heinz Pet
Products, Vet's Choice, to develop, manufacture and market new pet products and
services. The Company obtained a 50.5 percent controlling interest in the joint
venture for a capital contribution of $3,030,000 in cash and is the managing
general partner. Heinz Pet Products ("HPP"), contributed $2,970,000 in cash
for a 49.5 percent minority interest in the joint venture. Under the terms of
the partnership agreement, HPP also agreed to make an additional capital
contribution of their product development costs of up to $1 million. The actual
costs incurred during 1993 were $806,000. Such costs were expensed and credited
to the minority interest partner's equity account. Commencing January 1, 1996
the joint venture will make preferential distributions to HPP of any
distributable cash in excess of $3 million in any fiscal year until such time as
HPP has received preferential distributions amounting to the total development
costs that it contributed. As provided by the partnership agreement, the
Company and Heinz Pet Products each contributed $1 million to the joint venture
in the third quarter of 1995. The joint venture agreement between the Company
and HPP provides for restrictions on the transfer of each partner's respective
interest in the joint venture and for reciprocal buy-sell provisions. Heinz Pet
Products has agreed to lend Vet's Choice up to $1.0 million at its bank prime
rate plus one-half percent for working capital.
The Company operates Vet Research in a joint venture with VRI. Vet Research's
operating results have been accounted for as part of the consolidated operations
of the Company. Distributions of distributable cash will be made pursuant to a
formula contained in the operating agreement between the Company and VRI.
Pursuant to that formula, during each contract year, the first $1.5 million of
distributable cash is distributed to VRI; the next $3 million of distributable
cash is distributed to the Company; and the remaining distributable cash is
distributed 25 percent to the Company and 75 percent to VRI. The Company has
recorded minority interest expense related to the joint venture based on the
estimated percentage of annual income which will be distributed to the minority
interest partner pursuant to the operating agreement. The estimate is reviewed
and adjusted on a quarterly basis. The 1995 results include minority interest
expense of 52.4 percent of Vet Research's income.
The Company has an option pursuant to an agreement with VRI to acquire VRI's
entire interest in Vet Research for a purchase price as computed in accordance
with the operating agreement. The Company's option is exercisable January 1,
1997 through January 31, 1997. If the Company does not exercise its option, VRI
has an option to acquire the Company's interest in Vet Research.
F-39
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO SUPPLEMENTAL COMBINED FINANCIAL STATEMENTS
(Information with respect to the unaudited three months ended
March 31, 1996 and 1995 is not covered by report of independent public
accountants)
5. LONG-TERM OBLIGATIONS
Long-term obligations consisted of the following at December 31, 1995 and 1994:
<TABLE>
<CAPTION>
1995 1994
----------- ----------
<S> <C> <C>
8 percent note payable, convertible into VCA common stock at $12.50 per
share, due through 1997, secured by certain fixed and intangible assets............ $ 57,000 $ 86,000
5 percent note payable, convertible into VCA common stock at $15.00 per
share due through 1997, secured by stock of certain subsidiaries................... 196,000 391,000
11.2 percent note payable due through 1997, secured by assets
of a certain subsidiary............................................................ 408,000 483,000
Adjustable rate note payable, interest at the treasury bill rate (6.3 percent
at December 31, 1995) adjusted annually, due through June 2000 (discounted
at 6.5 percent).................................................................... 300,000 355,000
Obligation due monthly through May 2000, secured by assets of certain
subsidiary (discounted at 6.5 percent)............................................. 230,000 273,000
Obligation due quarterly through 1997, (discounted at 8.75 percent).................. 361,000 --
Obligation due quarterly through 2002, secured by assets of certain
subsidiary (discounted at 8.75 percent)............................................ 2,580,000 --
Adjustable rate note payable, interest at the bank prime rate plus 0.5 percent,
(capped at 8.5 percent at December 31, 1995), adjusted annually, due through
2000, secured by stock of a certain subsidiary.................................... 592,000 698,000
3 percent note payable, converted into VCA common stock in June 1995
at $7.00 per share................................................................. -- 175,000
Adjustable rate notes payable, interest at the bank prime rate, adjusted annually
(capped at 8.0 percent at December 31, 1995), various maturities through 2000,
secured by assets and stock of certain subsidiaries................................ 2,516,000 2,899,000
Adjustable rate notes payable, interest at the bank prime rate plus 1 percent
(8.0 percent to 9.5 percent at December 31, 1995), various maturities through
2002, secured by assets and stock of certain subsidiaries.......................... 510,000 589,000
6 percent notes payable, due through 2002, secured by stock of certain subsidiary.... 641,000 760,000
7 percent and 7.5 percent notes payable, due through 2007, secured by
assets and stock of certain subsidiaries........................................... 10,953,000 3,034,000
8 percent notes payable, various maturities through 2006, secured by stock of
certain subsidiaries............................................................... 6,915,000 339,000
9 percent and 9.8 percent notes payable, various maturities through 2005,
secured by assets of certain subsidiary and building............................... 898,000 --
Notes payable and other obligations, various maturities through 1997, secured
by land, building and stock of certain subsidiaries (discounted at 10 to
12 percent)........................................................................ 299,000 471,000
10 percent notes payable, various maturities through 2005, secured by stock
and assets of certain subsidiaries and land and building........................... 2,627,000 2,867,000
Revolving line of credit at the bank prime rate (8.5 percent at December 31, 1995)
matures December 1996, convertible into a 36 month term loan....................... -- 1,100,000
10.5 percent note payable, due through 1997, secured by land and
building of a certain subsidiary................................................... 1,016,000 1,025,000
Adjustable rate notes payable, interest at bank prime rate, plus 1.5 percent
(capped at 9.0 percent at December 31, 1995), due through 2001, secured
by assets and stock of certain subsidiaries........................................ 707,000 803,000
11 percent note payable due through 2001, secured by assets
of certain subsidiary.............................................................. 383,000 449,000
Adjustable rate notes payable at the bank prime rate, plus 1 percent
(9.75 percent at December 31, 1995)................................................ 420,000 1,688,000
Notes payable, secured by assets and stock of certain subsidiaries, various
maturities through 2001, interest at an average rate of 11 to 12 percent........... 123,000 152,000
Promissory notes, secured by assets of certain subsidiaries, bearing interest
at interest rates between 7% and 10% payable monthly, principal is generally
due in monthly installments through July 2014...................................... 7,517,000 8,285,000
Promissory note, interest at prime plus 3% (11.75% at December 31, 1995),
principal and interest payable in monthly installments through July 2000 133,000 154,000
</TABLE>
F-40
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO SUPPLEMENTAL COMBINED FINANCIAL STATEMENTS
(Information with respect to the unaudited three months ended
March 31, 1996 and 1995 is not covered by report of independent public
accountants)
<TABLE>
<CAPTION>
1995 1994
------------ ------------
<S> <C> <C>
Convertible promissory note payable to a shareholder, officer and director,
secured by assets of certain subsidiaries, interest at 9% per annum payable
semi-annually, principal due July 1996, convertible into 6,463 shares of
common stock............................................................................. $ 250,000 $ 250,000
Convertible promissory notes, secured by assets of certain subsidiaries,
interest at 7% per annum payable monthly, principal due through December 2003,
convertible into 7,637 shares of common stock............................................ 649,000 649,000
Convertible promissory note payable to an employee, secured by assets of certain
subsidiaries, interest at 8.5% per annum, interest and principal payable in
monthly installments from January 1994 through December 1998, convertible into
8,617 shares of common stock............................................................. 671,000 686,000
Convertible promissory notes payable primarily to directors and stockholders,
secured by common stock and key man life insurance, interest at 12% per annum
payable annually, principal due December 1998 and January 1996, convertible
into shares of common stock at an initial conversion rate of $7.23 and $8.70............. 490,000 579,000
Obligations under covenants not to compete, payable in installments through 2003........... 782,000 1,005,000
Installment obligations bearing interest at 8% to 10.25%, due through 2005................. 295,000 --
Installment obligations, variable interest rates, periodic installments due through 1996... -- 131,000
----------- -----------
Total debt obligations..................................................................... 43,519,000 30,376,000
Capital lease obligations, due through 2000 (Note 9)....................................... 931,000 358,000
Less -- Unamortized discount............................................................... (251,000) (125,000)
----------- -----------
44,199,000 30,609,000
Less -- Current portion.................................................................... (7,421,000) (5,552,000)
----------- -----------
$36,778,000 $25,057,000
=========== ===========
</TABLE>
The annual aggregate scheduled maturities of debt obligations for the five
years subsequent to December 31, 1995 are presented below:
<TABLE>
<S> <C>
1996........................................ $ 7,421,000
1997........................................ 7,971,000
1998........................................ 5,815,000
1999........................................ 4,315,000
2000........................................ 4,675,000
Thereafter.................................. 14,002,000
-----------
$44,199,000
===========
</TABLE>
Certain acquisition debt of the Company included above and amounting to
$33,889,000 and $26,347,000 at December 31, 1995 and 1994, respectively, is
non-recourse debt secured solely by the assets or the stock of the veterinary
hospital acquired under security arrangements whereby the creditor's sole remedy
in the event of default is the contractual right to take possession of the
entire veterinary hospital regardless of the outstanding indebtedness at the
time of default.
The Company has an unsecured line of credit of $3.1 million. The line of
credit is at the bank prime rate (8.5 percent at December 31, 1995) and expires
in December 1996, at which time the outstanding balance on the line can, at the
Company's option, convert to a 36-month term loan. At December 31, 1995, the
Company had $3.1 million available under the line.
In April 1996, the Company received net proceeds of $82,697,000 related to the
sale, in an offshore offering and concurrent private placement in the United
States, of $84,385,000 of 5.25% convertible subordinated debentures due in 2006.
The debentures, non-callable for three years, are convertible into approximately
2.5 million shares of the Company's common stock at a rate of $34.35 per share.
The following disclosure of the estimated fair value of the Company's debt is
made in accordance with the requirements of Statement of Financial Accounting
Standards No. 107 "Disclosures about Fair Value of Financial Instruments." The
estimated fair value amounts have been determined by the Company using available
market information and appropriate valuation methodologies.
F-41
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO SUPPLEMENTAL COMBINED FINANCIAL STATEMENTS
(Information with respect to the unaudited three months ended
March 31, 1996 and 1995 is not covered by report of independent public
accountants)
Considerable judgment is required to develop the estimates of fair value, thus
the estimates provided therein are not necessarily indicative of the amounts
that could be realized in a current market exchange.
<TABLE>
<CAPTION>
December 31, 1995
------------------------
Carrying Fair
Amount Value
----------- -----------
<S> <C> <C>
Fixed-rate long-term debt................. $33,952,000 $30,104,000
Variable-rate long-term debt.............. 4,256,000 4,256,000
</TABLE>
The carrying values of variable-rate long-term debt is a reasonable estimate of
their fair value. The estimated fair value of the Company's fixed-rate long-
term debt is based on prime plus an estimated spread at December 31, 1995 for
similar securities with similar remaining maturities.
6. PREFERRED STOCK
On December 22, 1992, the Company completed the sale of 583,333 shares of
convertible preferred stock for net proceeds of $2,985,000. The shares are
convertible into 583,333 shares of the Company's common stock commencing
December 22, 1997. The preferred stock participates in any dividend payments on
the Company's common stock on an as converted basis. The preferred stock has a
liquidation preference of $5.14 per share and it is callable by the Company any
time after March 22, 1998 at a price of $5.14 per share. The preferred stock
has no voting rights.
Under the Company's certificate of incorporation, the Company is authorized to
issue additional series of preferred stock. The rights, preferences and
privileges of the preferred stock are to be determined by the board of directors
and do not require stockholder approval.
7. COMMON STOCK
In January 1995, Star-Kist Foods, Inc. through its Heinz Pet Products division
purchased 1,159,420 shares of the Company's common stock at $8.625 per share,
resulting in net proceeds to the Company of $9,980,000.
In November 1995, the Company completed a secondary public offering of
2,965,026 shares of common stock for net proceeds of $33,932,000.
During 1995, the Company issued 1,075,226 shares of the Company's common stock
valued at $11,980,000, the fair market value at the date of commitment, as a
portion of the consideration for 15 animal hospitals and three veterinary
diagnostic laboratories. Of this amount, 156,303 shares of common stock valued
at $1,970,000 had not been issued as of December 31, 1995. Such shares are
reflected as though they are outstanding in the accompanying consolidated
financial statements.
In conjunction with the acquisition of two hospitals and PAL in 1994, the
Company issued 237,483 shares of common stock with a market value at the date of
issue of $1,732,000. Also in 1994, the Company issued 63,214 shares of common
stock in settlement of a guaranteed purchase price contingently payable in cash
or common stock (Note 8) and 30,841 shares of common stock for repayment of
promissory note interest.
On October 6, 1991, the Company completed a public offering of 2,400,000 shares
of common stock and 3,240,000 redeemable warrants for $12,598,000. Each
redeemable warrant entitles the holder to purchase one share of common stock for
$7.20 commencing April 10, 1992 until October 10, 1996, and is redeemable at the
option of the Company at any time after April 10, 1992 on 30 days prior written
notice, provided that the market price of the common stock equals or exceeds
$9.00 per share for 20 consecutive trading days ending within 10 days prior to
notice of redemption. Such market price exceeded $9.00 per share for 20
consecutive days on March 10,1995. During 1995, redeemable warrants were
exercised for 1,271,508 shares of common stock. Cash proceeds from the exercise
of redeemable warrants amounted to $8,896,000. At December 31, 1995, there are
1,968,492 redeemable warrants outstanding.
F-42
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO SUPPLEMENTAL COMBINED FINANCIAL STATEMENTS
(Information with respect to the unaudited three months ended
March 31, 1996 and 1995 is not covered by report of independent public
accountants)
Under the provisions of the Company's non-qualified and incentive stock option
plans for officers and key employees, 750,000 shares of common stock were
reserved for issuance at December 31, 1992. On May 5, 1995, the stockholders of
the Company approved the adoption of the Veterinary Centers of America, Inc.
1995 Stock Incentive Plan, and authorized the reservation of 750,000 shares of
common stock for issuance under the Plan. The options become exercisable over a
two to five year period, commencing at the date of grant or one year from the
date of grant depending on the option. All options expire 10 years from the
date of grant. The prices of all options granted were greater than or equal to
the fair market value at the date of the grant.
The table below summarizes the transactions in the Company's stock option plans
during 1995, 1994 and 1993:
<TABLE>
<CAPTION>
1995 1994 1993
---------- -------- --------
<S> <C> <C> <C>
Options outstanding at beginning of year... 748,172 652,894 379,021
Granted.................................... 820,965 144,993 293,423
Exercised.................................. (21,034) (32,765) (5,838)
Canceled................................... (13,200) (16,950) (13,712)
---------- -------- --------
Options outstanding at end of year
($.75 to $31.91 per share).............. 1,534,903 748,172 652,894
========== ======== ========
Exercisable at end of year................. 684,210 462,879 339,582
========== ======== ========
</TABLE>
In addition to the options granted under VCA's stock option plans, the Company
had 45,667 and 54,000 options outstanding at December 31, 1995 and 1994,
respectively, to certain members of the board of directors and to the previous
owners of certain acquired companies. During 1995, 8,333 of these options were
exercised. The options are exercisable at $.75 to $6.00 per share. At December
31, 1995, 45,667 of the options are exercisable.
In November 1995, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 123 "Accounting for Stock-Based
Compensation." The statement recommends changes in accounting for employee
stock-based compensation plans, and requires certain disclosures with respect to
these plans. The Statement's disclosures were adopted by the Company effective
January 1, 1996.
8. GUARANTEED PURCHASE PRICE CONTINGENTLY PAYABLE IN CASH OR COMMON STOCK
The Company has guaranteed the value of certain shares of its common stock
issued in connection with the acquisition of certain animal hospitals in 1995.
If the aggregate market value of the stock (as quoted by a nationally recognized
stock exchange) at various specified valuation dates is below the value of the
stock on the acquisition date, the Company has agreed to pay the difference in
additional shares of stock, cash or notes payable. The Company's guarantee of
the value, however, terminates if the common stock is registered for resale and
trades at 110% to 120% of the issue price of the stock for five to twenty
consecutive days. At December 31, 1995, there were 404,495 shares of stock
outstanding with such guarantees, with issue prices ranging from $11.26 to
$14.95.
In connection with certain acquisitions completed prior to 1995, the Company
guaranteed the price of certain shares of its common stock issued in connection
with the acquisitions. If the aggregate market value of the stock (as quoted by
a nationally recognized stock exchange) had not reached the guaranteed value,
which exceeded the value of the stock at the acquisition date, by the various
specified valuation dates, the Company agreed to pay the difference in
additional shares of stock, cash, or notes payable. The guaranteed purchase
price contingently payable in cash or common stock represents the liability for
the difference between the aggregate guaranteed value of the common stock net of
the Company's estimate of the fair market value of the stock at the date of the
acquisition, discounted at 10 percent.
F-43
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO SUPPLEMENTAL COMBINED FINANCIAL STATEMENTS
(Information with respect to the unaudited three months ended
March 31, 1996 and 1995 is not covered by report of independent public
accountants)
In 1995, pursuant to two of these stock guarantee arrangements pertaining to a
total of 13,494 shares, the Company paid $19,000 in cash for the difference
between the guaranteed value of the stock held and the market value of the
stock, as defined. The difference between the $19,000 and the $72,000 liability
for the guaranteed purchase price contingently payable in cash or common stock,
amounting to $53,000 was credited to additional paid-in-capital.
In 1994, pursuant to a stock guarantee arrangement for 80,000 shares, the
Company issued 63,214 shares of common stock for the difference between the
guaranteed value of the stock held and the market value of the stock, as
defined. The market value of the additional shares issued, totaling $470,000,
was charged to the liability for the guaranteed purchase price contingently
payable in cash or common stock.
9. COMMITMENTS
The Company operates many of its hospitals from premises that are leased from
the hospitals' previous owners under operating leases with terms, including
renewal options, ranging from one to 35 years.
The annual lease payments under the lease agreements have provisions for annual
increases based on the Consumer Price Index. The Company also leases certain
medical and computer equipment under capital leases.
The future minimum lease payments at December 31, 1995 are as follows:
<TABLE>
<CAPTION>
Capital Operating
Leases Leases
---------- -----------
<S> <C> <C>
1996.......................................... $ 425,000 $ 4,004,000
1997.......................................... 341,000 3,970,000
1998.......................................... 251,000 3,772,000
1999.......................................... 67,000 3,211,000
2000.......................................... 16,000 3,041,000
Thereafter.................................... -- 36,672,000
---------- -----------
1,100,000 $54,670,000
===========
Less -- Amount representing interest.......... (169,000)
----------
Present value of net minimum lease payments... $ 931,000
==========
</TABLE>
Rent expense totaled $3,880,000, $2,158,000 and $1,606,000 for the years ended
December 31, 1995, 1994 and 1993, respectively. Rental income totaled $246,000,
$96,000 and $96,000 for the years ended December 31, 1995, 1994 and 1993,
respectively.
The Company has employment agreements with three officers of the Company which
currently expire on December 31, 1998. Each of the agreements provide for
annual compensation (subject to upward adjustment) which aggregated $559,000 for
the year ended December 31, 1995.
10. CALCULATION OF PER SHARE AMOUNTS
Earnings per share calculations are based on the weighted average common shares
outstanding including obligated shares (Note 7) plus common shares subject to
dilutive stock options, common shares contingently issuable pursuant to the
guaranteed purchase price contingently payable in cash or common stock as
discussed in Note 8, convertible debt and shares issuable upon redemption of
redeemable warrants and conversion of preferred stock. Stock options, common
shares contingently issuable and shares issuable upon conversion of preferred
stock are not included in the weighted average common shares in 1995, 1994 and
1993 as they have an anti-dilutive effect.
F-44
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO SUPPLEMENTAL COMBINED FINANCIAL STATEMENTS
(Information with respect to the unaudited three months ended
March 31, 1996 and 1995 is not covered by report of independent public
accountants)
11. INCOME TAXES
The provision for income taxes is comprised of the following:
<TABLE>
<CAPTION>
1995 1994 1993
----------- --------- ----------
<S> <C> <C> <C>
Federal:
Current.... $1,888,000 $183,000 $ 490,000
Deferred... (192,000) 296,000 (595,000)
---------- -------- ---------
1,696,000 479,000 (105,000)
---------- -------- ---------
State:
Current.... 560,000 239,000 141,000
Deferred... (18,000) 13,000 (188,000)
---------- -------- ---------
542,000 252,000 (47,000)
---------- -------- ---------
$2,238,000 $731,000 $(152,000)
========== ======== =========
</TABLE>
Effective January 1, 1993, the Company adopted the provisions of Statement of
Financial Accounting Standards No. 109, "Accounting for Income Taxes" ("SFAS
109"). SFAS 109 requires recognition of deferred tax liabilities and assets for
the expected future tax consequences of events that have been included in the
financial statements or tax returns. Under this method, deferred tax
liabilities and assets are determined based on the difference between the
financial statement and tax bases of assets and liabilities using enacted tax
rates in effect for the year in which the differences are expected to reverse.
The Company reflected the impact as a cumulative adjustment in the 1993 first
quarter and did not restate prior periods. The cumulative adjustment had a
favorable impact of $221,000 on the net loss.
The net deferred tax asset (liability) is comprised of the following:
<TABLE>
<CAPTION>
1995 1994
---------- ---------
<S> <C> <C>
Current deferred tax assets (liabilities):
Accounts receivable........................ $ 301,000 $ 165,000
State taxes................................ 156,000 34,000
Other liabilities and reserves............. 588,000 430,000
Start-up costs............................. 59,000 120,000
Property, plant and equipment.............. 95,000 (33,000)
Restructuring.............................. 345,000 --
Other assets............................... (4,000) (4,000)
Valuation allowance........................ (365,000) (274,000)
---------- ---------
Total current deferred tax asset, net.... $1,175,000 $ 438,000
========== =========
</TABLE>
F-45
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO SUPPLEMENTAL COMBINED FINANCIAL STATEMENTS
(Information with respect to the unaudited three months ended
March 31, 1996 and 1995 is not covered by report of independent public
accountants)
<TABLE>
<CAPTION>
1995 1994
----------- -----------
<S> <C> <C>
Non-current deferred tax (liabilities) assets:
Net operating loss carryforwards...................................... $ 2,482,000 $ 1,824,000
Writedown of assets................................................... 1,587,000 779,000
Start-up costs........................................................ 288,000 151,000
Miscellaneous......................................................... -- 25,000
Other assets.......................................................... (119,000) (124,000)
Intangible assets..................................................... (2,037,000) (211,000)
Valuation allowance................................................... (3,760,000) (2,389,000)
Property, plant and equipment......................................... 258,000 (203,000)
----------- -----------
Total non-current deferred tax liability, net....................... $(1,301,000) $ (148,000)
=========== ===========
</TABLE>
A reconciliation of the provision for income taxes to the amount computed at
the Federal statutory rate is as follows:
<TABLE>
<CAPTION>
1995 1994 1993
------- ------- ------
<S> <C> <C> <C>
Federal income tax at statutory rate.................................... 34.0% (34.0)% (34.0)%
Effect of amortization of goodwill...................................... 5.0 9.0 5.0
State taxes, net of Federal benefit..................................... 8.0 12.0 2.0
Cumulative impact of tax law change..................................... -- -- (3.0)
Increase in valuation allowance
associated with writedown of assets
and operating losses................................................. 172.0 75.0 27.0
------ ----- -----
219.0% 62.0% (3.0)%
====== ===== =====
</TABLE>
For financial reporting purposes, the benefit arising from the utilization of
operating loss carryforwards generated by companies prior to their acquisition
by VCA is accounted for as a reduction of goodwill of the acquired companies.
Such benefit amounted to $40,000 and $69,000 for the years ended December 31,
1993 and 1995, respectively. No benefit was realized for the year ended
December 31, 1994. For tax reporting purposes, the acquired companies have
Federal net operating loss carryforwards at December 31, 1995 of approximately
$260,000 expiring through 2003.
At December 31, 1995, Pets' Rx has federal and state net operating loss ("NOL")
carryforwards of approximately $6.5 million and $3.2 million, respectively.
These NOL carryforwards expire at various dates through 2010 and 2000,
respectively.
Under the Tax Reform Act of 1986, the utilization of NOL carryforwards to
reduce taxable income will be restricted in certain circumstances. Events which
cause such a limitation include, but are not limited to, a cumulative ownership
change of more than 50% over a three year period. Management believes that the
issuance of convertible preferred stock during 1994 and the merger with VCA
caused such a change in ownership and, accordingly, utilization of the Pets' Rx
NOL carryforwards may be limited in future years.
12. 401(K) PLAN
During 1992, the Company established a voluntary retirement plan under Section
401(k) of the Internal Revenue Code. The plan covers all eligible employees and
provides for annual matching contributions by the Company at the discretion of
the Company's board of directors. In 1995, 1994 and 1993, the Company provided
a matching contribution of 20 percent, 20 percent and 15 percent, respectively
of the first five percent of the employees' contributions, as defined. Such
matching contributions approximated $87,000, $46,000 and $24,000 in 1995, 1994
and 1993, respectively.
F-46
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO SUPPLEMENTAL COMBINED FINANCIAL STATEMENTS
(Information with respect to the unaudited three months ended
March 31, 1996 and 1995 is not covered by report of independent public
accountants)
13. WRITEDOWN OF ASSETS
During 1993, the Company charged $4,506,000 to operations related to the
writedown of goodwill and certain intangible assets at three VCA facilities and
five Pets' Rx facilities. The determination to writedown these assets was based
on the Company's estimate that forecasted losses at each facility indicated that
the intangible assets would not be realized.
The first of the three hospitals was purchased in March 1989, with goodwill on
the acquisition of $920,000. In the five years subsequent to the acquisition,
the hospital generated losses aggregating $84,000 through December 31, 1993, due
primarily to severe competition in the area from the veterinarian from whom the
Company acquired the hospital. In January 1994, the economy in the area where
the hospital operates was adversely impacted by the "Northridge Earthquake,"
further impacting the hospital's revenues and operating results.
The second hospital was purchased in December 1989, at a price of approximately
$1 million, with goodwill on the acquisition of $997,000. Since the
acquisition, the hospital generated aggregate net income of $250,000 through
December 31, 1993, including a loss of $44,000 in 1992 and income of $17,000 in
1993. Included in the operating results is income of $73,000 in 1992 and
$39,000 in 1993 from the rental of space at the facility to a veterinary surgery
referral practice. The rental agreement was terminated in July 1993 and, due to
the specialization of the services provided by the referral practice, the
hospital was unable to find a suitable replacement. In addition to the impact
of the loss of rental income, the hospital's revenue and income were adversely
impacted by the loss of referral business from the referral practice. The
departure of the group had a permanent negative impact on the hospital's net
income and the recoverability of goodwill.
The third hospital was purchased in December 1991 at a price of approximately
$800,000, with goodwill and other intangible assets on the acquisition of
$778,000. The hospital generated net income in 1992 of $52,000 and a net loss
in 1993 of $59,000. The hospital provided 24-hour emergency service under an
arrangement whereby a veterinary emergency group used the hospital space during
the hours that the regular hospital was closed. The emergency clinic's
presence in the hospital provided substantial indirect benefits to the
hospital's operating results. In September 1993, the emergency group terminated
its arrangement with the hospital, and the operating results were adversely
impacted. The Company has determined that emergency services cannot be replaced
and the impact on the hospital will be permanent.
In 1993, Pets' Rx recognized a writedown of goodwill of $123,000 related to a
hospital that was closed in early 1994.
As a result of conforming to consistent methods of accounting, four hospitals
acquired by Pets' Rx in early to mid-1992 became impaired in 1993. Three of the
four hospitals are located in the Sacramento area, a market which had not
matured as anticipated. These three hospitals had losses excluding amortization
of intangible costs totaling $91,000 for 1993. The fourth hospital located in
the San Jose market had also not matured as anticipated and recorded a loss
excluding amortization of $76,000 in 1993 resulting in a writedown for the four
hospitals of $2,073,000.
As of late 1995, it was further determined that three hospitals acquired by
Pets' Rx in late 1993 and 1994 were impaired. One hospital acquired in late
1994 is also located in the depressed Sacramento market and its addition failed
to improve the overall Sacramento region performance. The remaining hospitals'
performance reflect factors specific to their operations and location and are
not indicative of the San Jose and Las Vegas markets. These three hospitals
recorded losses totaling $206,000 in 1995 and resulted in a writedown of
$2,148,000.
The Company's goal over the next two years is to minimize the facilities' cash
flow requirements and ultimately bring the facilities to a breakeven status.
The Company's strategy of building a network of hospitals in the markets they
serve will be benefited by the hospitals' ability to provide services to
customers in their vicinity, even though the facilities will not generate
profits.
14. RESTRUCTURING CHARGE
The operations of Cenvet were merged into VRI's operations to form Vet Research
in March 1995. The combined operations were restructured to eliminate
duplicate operating and overhead costs. The restructuring included the
consolidation of facilities, staff reductions and the consolidation of ancillary
operations. In connection with the restructuring, the Company recorded a charge
of
F-47
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO SUPPLEMENTAL COMBINED FINANCIAL STATEMENTS
(Information with respect to the unaudited three months ended
March 31, 1996 and 1995 is not covered by report of independent public
accountants)
$1,086,000 in the first quarter of 1995 to accrue the estimated costs associated
with the restructuring, consisting primarily of lease termination and severance
costs.
The following is a summary of the restructuring costs:
<TABLE>
<CAPTION>
1995
----------
<S> <C>
Employee severance costs... $ 468,000
Lease commitments.......... 433,000
Other...................... 185,000
----------
$1,086,000
==========
</TABLE>
During 1995, the Company utilized $237,000 of the reserve for restructuring.
At December 31, 1995, $849,000 of the restructuring reserves remained on the
Company's balance sheet.
15. LINES OF BUSINESS
The Company classifies its business operations into three segments: Animal
Hospital, Premium Pet Food and Laboratory. Prior to January 1993, the Company's
principal line of business was owning and operating animal hospitals. On
January 1, 1993, the Company formed a joint venture, Vet's Choice, to develop,
market and distribute new pet products and services (Note 4). Vet's Choice
began generating revenue in March 1994 when it commenced distribution of its
first product line. In March 1994, the Company acquired Professional Animal
Laboratory and combined its existing laboratory to form the Laboratory segment.
<TABLE>
<CAPTION>
ANIMAL PREMIUM CORPORATE &
(IN THOUSANDS) HOSPITAL PET FOOD LABORATORY ELIMINATIONS TOTAL
- -------------- -------- -------- ---------- ------------ --------
<S> <C> <C> <C> <C> <C>
1995
Revenues.................. $67,059 $ 4,756 $37,606 $(1,727) $107,694
Gross profit.............. 11,767 1,551 13,629 -- 26,947
Restructuring cost........ -- -- 1,086 -- 1,086
Operating income (loss)... 4,637 (2,573) 8,359 (3,890) 6,533
Identifiable assets....... 74,073 3,854 29,798 45,661 153,416
1994
Revenues.................. $41,484 $ 996 $10,150 $ (759) $ 51,871
Gross profit.............. 7,111 349 3,577 -- 11,037
Operating income(loss).... 3,595 (3,094) 2,563 (2,796) 268
Identifiable assets....... 47,698 3,599 13,532 3,073 67,902
</TABLE>
16. SUBSEQUENT EVENTS
During 1996 through June 18, 1996, the Company purchased eleven veterinary
hospitals and three veterinary diagnostic laboratories (See Note 3).
On March 21, 1996, the Company signed a definitive merger agreement with The
Pet Practice, Inc. ("TPP"), pursuant to which the Company will acquire all of
the outstanding securities of TPP. TPP operates 86 veterinary hospitals in 11
states.
Under the terms of the agreement, each share of TPP common stock will be
converted into a fraction of a share of VCA common stock determined by a
reference to the average closing price of VCA common stock over the twenty
trading days ending on the third day before the shareholder meetings at which
the stockholders of VCA and TPP will consider the merger. If the average price
of the VCA common stock ranges from $25 to $30 per share, the exchange ratio
shall be determined by dividing $10 by the average price of the VCA common
stock, resulting in a valuation of $10 per share of TPP common stock throughout
the range. If the average closing price of the VCA common stock is less than
$24 per share, the exchange ratio will be increased (from 0.395 shares at $24
per share) by 0.005 for each dollar of such reduction down to $18.50 of VCA
common stock, and if the average price of VCA common stock is more than $31 per
share, the exchange ratio shall be reduced (from 0.3350 at $31 per share) by
0.005 for each dollar of such increase, up to $49.00 per share. No further
adjustment shall be made if the price of VCA stock shall be less than
F-48
<PAGE>
VETERINARY CENTERS OF AMERICA, INC. AND SUBSIDIARIES
NOTES TO SUPPLEMENTAL COMBINED FINANCIAL STATEMENTS
(Information with respect to the unaudited three months ended
March 31, 1996 and 1995 is not covered by report of independent public
accountants)
$18.50. In each case, a proportionate reduction or increase, as the case may
be, shall be made if the price of VCA common stock is less than a round dollar.
If the average price of the VCA common stock is greater than $49.00, the
exchange ratio should be determined by dividing $12.005 by the average price.
By way of illustration, at $23 per share of VCA common stock, the exchange ratio
shall be 0.400, resulting in a valuation of $9.20 per share of TPP common stock.
At $32.00 per share of VCA common stock, the exchange ratio shall be 0.330,
resulting in a valuation of $10.56 per share of TPP common stock. The Company
expects that the merger will be consummated in the second quarter of 1996. The
merger will be accounted for as a purchase. Each party has the right to
terminate the definitive agreement if the average price of VCA common shares is
$18.50 or less.
Consummation of the merger is subject to certain significant conditions.
Consequently, the merger of VCA and TPP may never be consummated.
F-49
<PAGE>
THE PET PRACTICE, INC.
CONSOLIDATED BALANCE SHEET
(IN THOUSANDS)
<TABLE>
<CAPTION>
APRIL 3, 1996 JANUARY 3,
(UNAUDITED) 1996
------------- ---------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents........................... $ 4,916 $10,097
Accounts receivable, net of allowance
for doubtful accounts of $258 at
April 3, 1996 and $363 at January 3, 1996.......... 836 809
Other receivables................................... 264 534
Inventories......................................... 3,154 3,175
Other current assets, including
deferred merger costs of $625 in 1996............. 1,592 966
------- -------
Total current assets.............................. 10,762 15,581
Property and equipment, net........................... 15,029 13,465
Excess of cost over fair value of net
assets acquired and other intangible assets,
net................................................. 53,775 51,271
Other assets.......................................... 149 145
------- -------
$79,715 $80,462
======= =======
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-50
<PAGE>
THE PET PRACTICE, INC.
CONSOLIDATED BALANCE SHEET
(IN THOUSANDS)
<TABLE>
<CAPTION>
LIABILITIES, MANDATORILY APRIL 3,
REDEEMABLE PREFERRED STOCK, 1996 JANUARY 3,
AND STOCKHOLDERS' EQUITY (UNAUDITED) 1996
----------- ----------
<S> <C> <C>
Current liabilities:
Current portion of long-term debt, including
due to related parties of $1,741 at
April 3, 1996 and $1,649 at January 3, 1996.......... $ 3,820 $ 3,696
Accounts payable..................................... 2,169 2,540
Accrued expenses and other current liabilities....... 4,959 5,184
------- -------
Total current liabilities........................... 10,948 11,420
Long-term debt, including amounts due to
related parties of $7,872 at April 3, 1996
and $7,848 at January 3, 1996........................ 16,216 15,786
Other liabilities..................................... 30 36
------- -------
Total liabilities................................... 27,194 27,242
------- -------
Commitments and contingencies......................... - -
Mandatorily redeemable preferred stock, $0.01
par value, 10 shares authorized...................... - -
------- -------
- -
Stockholders' equity:
Preferred stock, $0.01 par value, 1,000
shares authorized....................................
Common stock, $0.01 par value, 20,000
shares authorized; 8,632 shares issued
and outstanding at April 3, 1996 and
8,607 at January 3, 1996............................. 86 86
Capital in excess of par value....................... 62,026 61,826
Accumulated deficit.................................. (9,591) (8,692)
------- -------
Total stockholders' equity........................... 52,521 53,220
------- -------
$79,715 $80,462
======= =======
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-51
<PAGE>
THE PET PRACTICE, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(UNAUDITED)
<TABLE>
<CAPTION>
THIRTEEN WEEKS ENDED
--------------------------
APRIL 3, MARCH 29,
1996 1995*
---------- ---------
<S> <C> <C>
Net revenues................................................ $13,404 $ 7,607
Cost of revenues............................................ 12,104 7,120
------- -------
Gross profit................................................ 1,300 487
General and administrative expenses......................... 1,490 1,223
Amortization of excess of cost over fair value
of net assets acquired and other intangible assets......... 460 248
Loss from operations........................................ (650) (984)
Non-operating expenses (income):
Interest expense - related parties......................... 167 328
Interest expense - other................................... 154 369
Interest income............................................ (93) (6)
------- -------
228 691
------- -------
Loss before income taxes.................................... (878) (1,675)
Provision for income tax expense............................ 21 19
------- -------
Net loss.................................................... $ (899) $(1,694)
======= =======
Net loss per common share................................... $(0.10) $(0.42)
======= =======
Shares used in net loss per common
share computation.......................................... 8,614 4,059
======= =======
</TABLE>
*Certain reclassifications have been made for comparative purposes.
The accompanying notes are an integral part of these financial statements.
F-52
<PAGE>
THE PET PRACTICE, INC.
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
(IN THOUSANDS)
(UNAUDITED)
<TABLE>
<CAPTION>
COMMON STOCK
--------------------
CAPITAL IN ACCUM-
NUMBER PAR EXCESS OF ULATED
OF SHARES VALUE PAR VALUE DEFICIT TOTAL
--------- ----- --------- ------- -----
<S> <C> <C> <C> <C> <C>
Balance at January 3, 1996...... 8,607 $86 $61,826 $(8,692) $53,220
Common stock issued in
connection with acquisitions... 25 - 200 - 200
Net loss........................ - - - (800) (899)
----- --- ------- ------- -------
Balance at April 3, 1996........ 8,632 $86 $62,026 $(9,591) $52,521
===== === ======= ======= =======
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-53
<PAGE>
THE PET PRACTICE, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
(IN THOUSANDS)
(UNAUDITED)
<TABLE>
<CAPTION>
Thirteen Weeks Ended
---------------------------
April 3, March 29,
1996 1995
-------- ---------
<S> <C> <C>
Cash flows from operating activities:
Net loss........................................................ $ (899) $(1,694)
Adjustments to reconcile net loss to net cash
provided (used) by operations:
Depreciation and amortization................................. 845 448
Provision for doubtful accounts............................... (26) 28
Finance charges on mandatorily
redeemable preferred stock................................... 16
Other non-cash charges........................................ 36
Changes in assets and liabilities, net of
effects of businesses acquired:
Increase in accounts receivable............................... (8) (90)
Decrease (increase) in inventories............................ 57 (223)
Decrease (increase) in other current assets................... 274 (482)
Decrease in accounts payable.................................. (370) (461)
Increase (decrease) in other accrued expenses
and in other current liabilities.............................. (1,107) 517
Other assets and other liabilities............................ (5) 13
------- -------
Net cash used in operating activities......................... (1,239) (1,892)
------- -------
Cash flows from investing activities:
Payments for purchases of businesses,
net of cash acquired of $6 in 1996
and $7 in 1995................................................ (2,116) (4,139)
Purchases of property and equipment............................ (905) (850)
------- -------
Net cash used in investing activities......................... (3,021) (4,989)
------- -------
Cash flows from financing activities:
Borrowings under line of credit agreements..................... - 7,194
Principal payments on long-term obligations.................... (921) (169)
------- -------
Net cash provided by (used in) financing activities........... (921) 7,025
------- -------
Net increase (decrease) in cash and cash equivalents............ (5,181) 144
Cash and cash equivalents at beginning of period................ 10,097 910
------- -------
Cash and cash equivalents at end of period...................... $ 4,916 $ 1,054
======= =======
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-54
<PAGE>
PET PRACTICE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
APRIL 3, 1996
(Dollar amounts in thousands, except per share data)
(Unaudited)
NOTE 1 - BASIS OF PRESENTATION
The accompanying consolidated financial statements are unaudited, except for the
Consolidated Balance Sheet as of January 3, 1996. The statements have been
prepared in accordance with the rules and regulations of the Securities and
Exchange Commission and should be read in conjunction with the Company's
consolidated financial statements and notes thereto for the year ended January
3, 1996, included in its Annual Report on Form 1O-K, as filed with the
Securities and Exchange Commission. Certain information and note disclosures
normally included in financial statements prepared in accordance with generally
accepted accounting principles have been condensed or omitted pursuant to such
rules and regulations. In the opinion of Company management, the consolidated
financial data for the unaudited interim periods presented include all
adjustments, consisting only of normal recurring adjustments, necessary to
present a fair statement of the results of such interim periods.
Operating results for the thirteen-week period ended April 3, 1996 are not
necessarily indicative of the results that may be expected for a full year or
any portion thereof.
NOTE 2 - DEFINITIVE MERGER AGREEMENT
On March 21, 1996, the Company signed a definitive agreement (the "Merger
Agreement") with Veterinary Centers of America, Inc. ("VCA"), pursuant to which
VCA will acquire all ...... outstanding securities of the Company.
Under the terms of the Merger Agreement, each share of the Company's common
stock will be converted into a fraction of a share of VCA common stock
determined by reference to the average closing price of VCA common stock over
the 20 trading days ending on the third day before the stockholder meetings, at
which the stockholders of VCA and the Company will consider the merger. If the
average price of the VCA common stock ranges from $25 to $30 per share, the
exchange ratio shall be determined by dividing $10 by the average price of VCA
common stock, resulting in a valuation of $10 per share of the Company's Common
Stock throughout the range. If the average closing price of VCA common stock is
less than $24 per share, the exchange ratio will be increased (from 0.395 shares
at $24 per share) by 0.005 for each dollar of such reduction down to $18.50 of
VCA common stock, and if the average price of VCA common stock is more than $31
per share, the exchange ratio shall be reduced (from 0.3350 at $31 per share) by
0.005 for each dollar of such increase, up to $49 per share. No further
adjustment shall be made if the price of VCA common stock
F-55
<PAGE>
PET PRACTICE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
APRIL 3, 1996
(Dollar amounts in thousands, except per share data)
(Unaudited)
shall be less than $18.50. In each case, a proportionate reduction or increase,
as the case may be, shall be made if the price of VCA common stock is less than
a round dollar. By way of illustration, at $23 per share of VCA common stock,
the exchange ratio shall be 0.400, resulting in a valuation of $9.20 per share
of the Company's Common Stock. At $32 per share of VCA common stock, the
exchange ratio shall be 0.330, resulting in a valuation of $10.56 per share of
the Company's Common Stock. The merger will be accounted for as a purchase. If
the average price of VCA common stock is greater than $49, the exchange ratio
shall be determined by dividing $12.005 by the average price. Each party has the
right to terminate the definitive agreement if the average price of VCA common
stock is $18.50 or less. The Company expects that the merger will be consummated
in the third quarter of 1996.
Consummation of the merger is subject to certain significant conditions. The
Merger Agreement with VCA may be terminated by either VCA or the Company at any
time prior to the closing (i) if any material condition to the obligations of
the Company or VCA set forth in the Merger Agreement is not substantially
satisfied at the time or times contemplated thereby, (ii) there is a material
breach of any representation, warranty, condition, or agreement contained in the
Merger Agreement (that is not cured within 30 days of the tune that written
notice of such breach is received by the breaching party), (iii) if the merger
shall not have been consummated on or before September 1, 1996, or (iv) upon
their mutual consent.
For all of the foregoing reasons, the merger of VCA and the Company may never be
consummated.
The Company filed a copy of the Merger Agreement with the Securities and
Exchange Commission in its Current Report on Form 8-K dated March 21, 1996.
NOTE 3 - BUSINESS ACQUISITIONS
The Company acquired three clinics during the thirteen weeks ended April 3,
1996.
These acquisitions have been accounted for using the purchase method of
accounting. Accordingly, the purchase price was allocated to assets and
liabilities acquired based upon their estimated fair values at the dates of
acquisition. The results of operations of the acquired companies are included in
the consolidated financial statements from the respective dates of acquisition.
F-56
<PAGE>
PET PRACTICE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
APRIL 3, 1996
(Dollar amounts in thousands, except per share data)
(Unaudited)
Information with respect to these acquisitions is presented below:
Cash paid (net of cash acquired)................ $1,177
Common stock issued............................. 200
Notes and mortgages issued...................... 1,475
Transaction and other costs..................... 1,126
------
Fair value of tangible assets acquired,
principally accounts receivable, inventory,
and property and equipment.................... 1,014
------
Cost in excess of fair value of assets
acquired and other intangible assets.......... $2,964
======
The following unaudited pro forma consolidated results of operations of the
Company and its. . subsidiaries for the thirteen weeks ended April 3, 1996 give
effect on a pro forma basis to the practices acquired during the period from
January 4, 1996 through May 15, 1996, as if such practices had been acquired as
of January 4, 1996.
Net revenues $13,579
Loss from operations (639)
Net loss (910)
Net loss per common share (0.11)
The pro forma results of operations are not necessarily indicative of the actual
results of operations that would have occurred had the acquisitions been made on
January 4, 1996, or the Company's results of operations which may occur in the
future.
NOTE 4 - INCOME TAXES
Due to the Company's operating losses, there is no provision for federal income
taxes.
NOTE 5 - SUPPLEMENTAL STATEMENT OF CASH FLOWS INFORMATION
Cash paid during the thirteen weeks ended April 3, 1996 for interest and income
taxes was $344 and $36, respectively.
F-57
<PAGE>
REPORT OF INDEPENDENT ACCOUNTANTS
To the Board of Directors and Stockholders of
The Pet Practice, Inc.
In our opinion, the accompanying consolidated balance sheet and the related
consolidated statements of operations, of changes in stockholders' equity
(deficit) and of cash flows present fairly, in all material respects, the
financial position of The Pet Practice, Inc. and its subsidiaries at January 3,
1996 and December 28, 1994 and the results of their operations and their cash
flows for the period October 27, 1993 (commencement of operations) to December
29, 1993, the year ended December 28, 1994 and the year ended January 3, 1996 in
conformity with generally accepted accounting principles. These financial
statements are the responsibility of the Company's management; our
responsibility is to express an opinion on these financial statements based on
our audits. We conducted our audits of these statements in accordance with
generally accepted auditing standards which require that we plan and perform the
audit to obtain reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements,
assessing the accounting principles used and significant estimates made by
management and evaluating the overall financial statement presentation. We
believe that our audits provide reasonable basis for the opinion expressed
above.
/s/ Price Waterhouse LLP
PRICE WATERHOUSE LLP
Philadelphia, PA
March 22, 1996
F-58
<PAGE>
THE PET PRACTICE, INC.
CONSOLIDATED BALANCE SHEET
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<TABLE>
<CAPTION>
DECEMBER 28, JANUARY 3,
1994 1996
------------ ----------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents........................................... $ 910 $10,097
Accounts receivable, net of allowance for doubtful
accounts of $103 at December 28, 1994 and
$363 at January 3, 1996............................................ 205 809
Other receivables................................................... 34 534
Inventories......................................................... 1,077 3,175
Other current assets................................................ 845 966
------- -------
Total current assets.............................................. 3,071 15,581
Property and equipment, net.......................................... 6,148 13,465
Excess of cost over fair value of net assets acquired and
other intangible assets............................................. 25,941 51,271
Other assets......................................................... 257 145
------- -------
$35,417 $80,462
======= =======
LIABILITIES, MANDATORILY REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Borrowings under line of credit..................................... $10,067 $ -
Current portion of long-term debt, including due to
related parties of $758 at December 28, 1994
and $1,649 at January 3, 1996..................................... 1,609 3,696
Accounts payable.................................................... 1,786 2,540
Accrued expenses and other current liabilities...................... 5,777 5,184
------- ------
Total current liabilities....................................... 19,239 11,420
Long-term debt, including amounts due to related parties of
$14,921 at December 28, 1994 and $7,848
at January 3, 1996.................................................. 18,885 15,786
Other liabilities.................................................... 67 36
------- ------
38,191 27,242
------- -------
Commitments and contingencies
Mandatorily redeemable preferred stock, $.01 par value,
10 shares authorized, 8 shares issued at
December 28, 1994, at redemption value 875 -
------- ------
Stockholders' equity (deficit):
Preferred stock, $.01 par value, 1,000 shares authorized............
Common stock, $.01 par value, 20,000 shares authorized;
3,978 and 8,607 shares issued at December 28, 1994
and January 3, 1996, respectively................................. 40 86
Capital in excess of par value...................................... 1,828 61,826
Accumulated deficit................................................. (5,517) (8,692)
------- ------
Total stockholders' equity (deficit)............................ (3,649) 53,220
------- ------
$35,417 $80,462
======= =======
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-59
<PAGE>
THE PET PRACTICE, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<TABLE>
<CAPTION>
YEAR ENDED
OCTOBER 27 TO ---------------------------
DECEMBER 29, DECEMBER 28, JANUARY 3,
1993* 1994* 1996*
-------------- ------------- -----------
<S> <C> <C> <C>
Net revenues $1,201 $15,111 $40,571
Cost of revenues (including related party lease
expense of $45, $437, and $841 for the period
October 27, 1993 to December 29, 1993; the year
ended December 28, 1994; and the year ended
January 3, 1996, respectively)................................ 1,261 13,936 34,776
------ ------- -------
Gross profit (loss)............................................ (60) 1,175 5,795
General and administrative expenses............................ 348 3,867 5,796
Amortization of excess of cost over fair value of net assets
acquired and other intangible assets.......................... 38 409 1,229
------ ------- -------
Loss from operations........................................... (446) (3,101) (1,230)
------ ------- -------
Non-operating (income) expenses:
Interest expense--related parties............................. 145 889 991
Interest expense--other....................................... 38 705 1,345
Interest income............................................... - (7) (475)
------ ------- -------
183 1,587 1,861
------ ------- -------
Loss before income taxes....................................... (629) (4,688) (3,091)
Provision for income tax expense............................... - 200 84
------ ------- -------
Net loss....................................................... $ (629) $(4,888) $(3,175)
====== ======= =======
Net loss per common share...................................... $(0.15) $ (1.20) $ (0.54)
====== ======= =======
Shares used in net loss per common share computation........... 4,059 4,059 5,863
====== ======= =======
</TABLE>
*Certain reclassifications have been made for comparative purposes.
The accompanying notes are an integral part of these financial statements.
F-60
<PAGE>
THE PET PRACTICE, INC.
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)
(IN THOUSANDS)
<TABLE>
<CAPTION>
CAPITAL STOCK
------------------ CAPITAL IN
PAR EXCESS OF ACCUMULATED
SHARES VALUE PAR VALUE DEFICIT TOTAL
------ ----- ---------- ------------ --------
<S> <C> <C> <C> <C> <C>
Common stock issued,
October 27, 1993............... 3,600 $36 $ 162 $ - $ 198
Common stock issued............. 77 1 3 - 4
Net loss for the period ended
December 29, 1993.............. - - - (629) (629)
----- --- ------- ------- -------
Balance, December 29, 1993...... 3,677 37 165 (629) (427)
Common stock issued in
connection with acquisitions... 141 1 1,652 - 1,653
Common stock issued............. 160 2 11 - 13
Net loss for the year ended
December 28, 1994.............. - - - (4,888) (4,888)
----- --- ------- ------- -------
Balance, December 28, 1994...... 3,978 40 1,828 (5,517) (3,649)
Common stock issued in
connection with acquisitions... 329 3 3,463 - 3,466
Common stock issued through
public offering................ 4,300 43 56,535 - 56,578
Net loss for the year ended
January 3, 1996................ - - - (3,175) (3,175)
----- --- ------- ------- -------
Balance, January 3, 1996........ 8,607 $86 $61,826 $(8,692) $53,220
===== === ======= ======= =======
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-61
<PAGE>
THE PET PRACTICE, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
(IN THOUSANDS)
<TABLE>
<CAPTION>
YEAR ENDED
OCTOBER 27 TO ---------------------------
DECEMBER 29, DECEMBER 28, JANUARY 3,
1993 1994 1996
------------- ------------- -----------
<S> <C> <C> <C>
Cash flows from operating activities:
Net loss.................................................. $ (629) $ (4,888) $ (3,175)
Adjustments to reconcile net loss to net cash
provided (used) by operations:
Depreciation and amortization........................... 96 760 2,017
Provision for doubtful accounts......................... - 16 65
Finance charges on mandatorily redeemable
preferred stock....................................... 10 64 42
Other non-cash charges.................................. - 143 -
Changes in assets and liabilities, net of
effects from businesses acquired:
Decrease (increase) in accounts receivable............. 1 (168) (456)
Increase in inventories................................ (55) (225) (1,263)
Increase in other current assets....................... (23) (665) (584)
Increase in accounts payable........................... 51 793 726
Increase (decrease) in accrued expenses and
current liabilities................................... 224 2,079 (1,891)
Other assets and other liabilities..................... - (26) 33
------- -------- --------
Net cash used by operating activities................ (325) (2,117) (4,486)
------- -------- --------
Cash flows from investing activities:
Payments for purchases of businesses, net of
cash acquired of $73 for the period ended
December 29, 1993, $156 for the year
ended December 28, 1994, and $41 for the
year ended January 3, 1996.............................. (7,430) (9,557) (13,082)
Purchases of property and equipment....................... (48) (206) (4,662)
------- -------- --------
Net cash used by investing activities.................. (7,478) (9,763) (17,744)
------- -------- --------
Cash flows from financing activities:
Proceeds from issuance of common stock.................... 202 12 56,578
Proceeds from issuance of mandatorily
redeemable preferred stock.............................. 800 - -
Proceeds from issuance of long-term debt.................. 9,324 3,067 -
Borrowings under line of credit agreements................ - 10,067 8,859
Redemption of mandatorily redeemable
preferred stock......................................... - - (800)
Payments of line of credit agreements..................... - - (18,926)
Principal payments on long-term obligations............... (2,449) (430) (14,294)
------- -------- --------
Net cash provided by financing activities.............. 7,877 12,716 31,417
------- -------- --------
Net increase in cash and cash equivalents.................. 74 836 9,187
Cash at beginning of period................................ - 74 910
------- -------- --------
Cash at end of period...................................... $ 74 $ 910 $ 10,097
======= ======== ========
Supplemental disclosure of cash flow information:
Interest paid............................................. $ 38 $ 276 $ 3,601
======= ======== ========
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-62
<PAGE>
THE PET PRACTICE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
NOTE 1 -- ORGANIZATION AND OPERATION:
The Pet Practice, Inc. (the "Company") was formed to provide companion
animal veterinary care services. The Company's operations commenced on October
27, 1993 with the acquisition of Professional Veterinary Hospitals of America,
Inc. (a Michigan corporation). Since this initial acquisition, the Company has
acquired additional practices (see Note 3) such that as of January 3, 1996, the
Company operates 83 veterinary clinics in 10 states, all in the Eastern half of
the United States.
NOTE 2 -- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:
Fiscal year:
The Company's accounting year is a 52-53 week fiscal year which ends on the
Wednesday nearest to December 31.
Principles of consolidation:
The consolidated financial statements include the accounts of the Company
and its wholly and beneficially owned subsidiaries ("Subsidiaries"). In response
to certain regulations in certain states in which the Company operates, several
Subsidiaries operate as professional corporations which, in turn, have executed
management agreements with the Company. Through the terms of the management
agreements, the Company has complete unilateral control over the professional
corporations. The management agreements entered into with the professional
corporations substantially restrict the business activities of these
professional corporations and the rights of their shareholders. Under related
agreements, the Company has the option to purchase, or to designate a purchaser
for, the stock of the professional corporations. These professional corporations
are consolidated because the Company (as opposed to affiliates of the Company)
has unilateral and perpetual control over the assets and operations of the
professional corporations and because, notwithstanding the lack of technical
majority ownership, consolidation of the professional corporations is necessary
to present fairly the financial position and results of operations of the
Company due to the existence of a parent-subsidiary relationship by means other
than majority ownership of the professional corporations' voting stock. The
Company has perpetual control over the professional corporations because the
Company does not intend to terminate any of its management agreements with the
professional corporations and, upon termination of any such agreement by the
veterinarian, the Company intends to exercise its option to purchase the stock
of the professional corporation for $100. Fees paid to the Company under these
agreements approximate the operating income, as defined, of the Subsidiaries.
All significant intercompany accounts and transactions have been eliminated.
Use of estimates in the preparation of financial statements:
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Statement of cash flows:
For purposes of reporting cash flows, cash and cash equivalents include
cash on hand and short-term investments with original maturities of 90 days or
less.
F-63
<PAGE>
THE PET PRACTICE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
Net revenues:
Net revenues are reported at the estimated amounts to be realized through
payments from customers and are recognized when the services are performed.
Inventories:
Inventories consist of pharmaceuticals, retail pet products and other
veterinary care products and are valued at the lower of first-in, first-out
cost, or market.
Property and equipment:
Property and equipment are stated at cost less accumulated depreciation and
amortization. Additions and betterments are capitalized and maintenance and
repairs are charged to current operations. The cost of assets retired or
otherwise disposed of and the related accumulated depreciation and amortization
are removed from the accounts and the gain or loss on such dispositions is
reflected in current operations. Depreciation is provided using the straight-
line method. Estimated useful lives of the assets are:
Buildings....................... 20-40 years
Medical equipment............... 7 years
Furniture and fixtures.......... 7 years
Leasehold improvements.......... Shorter of life of lease or 10 years
Office equipment................ 5 years
Vehicles........................ 5 years
Long-lived and intangible assets:
Assets and liabilities acquired in connection with business combinations
accounted for under the purchase method are recorded at their respective fair
values. Deferred taxes have been recorded to the extent of differences between
the fair value of the tax basis of the assets acquired and liabilities assumed.
The excess of the purchase price over the fair value of the net assets acquired
is amortized on a straight-line basis over 40 years. Other intangible assets
include client lists, assembled work force, and non-competition agreements,
which are amortized on a straight-line basis over periods ranging from three to
six years.
The Company adopted Statement of Financial Accounting Standards No. 121,
"Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to
Be Disposed Of" (SFAS No. 121), effective December 29, 1994. The carrying value
of long-lived assets and certain identifiable intangible assets will be
evaluated whenever changes in circumstances indicate the carrying amount of such
assets may not be recoverable. In performing such review for recoverability,
the Company compares the expected future cash flows to the carrying value of
long-lived assets and identifiable intangibles. If the expected undiscounted
future cash flows are less than the carrying amount of such assets, the Company
recognizes an impairment loss for the difference between the carrying amount of
the assets and their estimated fair value. If an asset being tested for
recoverability was acquired in a business combination accounted for using the
purchase method, the excess of cost over fair value of net assets that arose in
that transaction is allocated to the assets being tested for recoverability on a
pro rata basis using the relative fair values of the long-lived assets and
identifiable intangibles acquired at the acquisition date. In estimating future
cash flows for determining whether an asset is impaired, and if expected future
cash flows are used in measuring assets that are impaired, assets are grouped by
operating unit.
F-64
<PAGE>
THE PET PRACTICE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
In addition, the carrying value of the excess of cost over fair value of
net assets acquired is subject to a separate evaluation by estimating the
expected future undiscounted net cash flows from operating activities. If these
estimated net cash flows are less than the carrying amount of the excess of cost
over fair value of net assets acquired, the Company recognizes an impairment
loss in an amount necessary to write down the excess of cost over fair value of
net assets acquired to fair value, as determined from expected future cash
flows.
Income taxes:
The Company has applied the asset and liability approach of Statement of
Financial Accounting Standards No. 109, Accounting for Income Taxes, for
financial accounting and reporting purposes. The Company accounts for certain
items of income and expense in different time periods for financial reporting
and income tax purposes. Provisions for deferred income taxes are made in
recognition of such temporary differences, where applicable. A valuation
allowance is established against deferred tax assets unless the Company believes
it more likely than not that the benefit will be realized.
Net loss per common share:
Net loss per common share for the period ended December 29, 1993 and the
year ended December 28, 1994 has been computed by dividing the net loss
applicable to common stock by the number of shares of common stock outstanding
at August 4, 1995 (the date of consummation of the Company's initial public
offering of its common stock), as all shares issued prior to that date were
issued at prices significantly below the offering price in the Company's initial
public offering of its common stock.
Net loss per common share for the year ended January 3, 1996 has been
computed by dividing the net loss applicable to common stock by the weighted
average number of common shares outstanding during the year. For purposes of
computing such weighted average, the number of shares of common stock
outstanding at August 4, 1995 was treated as outstanding for the entire period
from December 29, 1994 to August 4, 1995.
NOTE 3 -- BUSINESS ACQUISITIONS:
On October 27, 1993, the Company acquired all of the issued and outstanding
common stock of Professional Veterinary Hospitals of America, Inc. (a Michigan
corporation). During 1994, the Company purchased all of the issued and
outstanding common stock of three practices and certain assets of an additional
10 practices. During 1995, the Company purchased all of the issued and
outstanding common stock of three practices and certain assets of an additional
38 practices.
The acquisitions have been accounted for using the purchase method of
accounting. Accordingly, the purchase price was allocated to assets and
liabilities acquired based upon their estimated fair values at the dates of
acquisition. The results of operations of the acquired companies are included
in the consolidated financial statements from the respective dates of
acquisition.
F-65
<PAGE>
THE PET PRACTICE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
Information with respect to these acquisitions is presented below:
<TABLE>
<CAPTION>
YEAR ENDED
OCTOBER 27 TO -------------------------
DECEMBER 29, DECEMBER 28, JANUARY 3,
1993 1994 1996
------------- ------------ ----------
<S> <C> <C> <C>
Cash paid (net of cash acquired)........................ $7, 430 $ 9,908 $11,249
Common stock issued..................................... - 1,510 3,239
Notes issued............................................ 233 3,200 10,644
Deferred cash payments.................................. - - 500
Transaction and other costs............................. 78 2,056 2,753
------- ------- -------
7,741 16,674 28,385
Liabilities assumed..................................... 3,882 5,641 2,378
------- ------- -------
11,623 22,315 30,763
Fair value of tangible assets acquired, principally
accounts receivable, inventory, and property
and equipment.......................................... 2,579 4,678 4,204
------- ------- -------
Cost in excess of fair value of assets acquired and
other intangible assets.............................. $ 9,044 $17,637 $26,559
======= ======= =======
</TABLE>
Acquisitions made subsequent to January 3, 1996 were made for an aggregate
amount of $2,135, consisting of $485 in cash, $550 in notes, and 23,000 shares
of the Company's common stock.
The unaudited results of operations for the year ended January 3, 1996 on a
pro forma basis as if the practices acquired in fiscal 1995 and fiscal 1996 to
date had been acquired as of the beginning of fiscal 1995 are as follows:
<TABLE>
<S> <C>
Net revenues........................................... $58,828
Income from operations................................. 1,107
Net loss............................................... (1,728)
Net loss per common share.............................. (0.29)
</TABLE>
Excess of cost over fair value of net assets acquired and other intangible
assets comprise the following:
<TABLE>
<CAPTION>
DECEMBER 28, JANUARY 3,
1994 1996
------------ -----------
<S> <C> <C>
Excess of cost over fair value of net assets acquired............ $25,149 $50,877
Client lists..................................................... 591 946
Assembled work force............................................. 635 1,008
Non-competition agreements....................................... 12 115
------- -------
26,387 52,946
Accumulated amortization....................................... (446) (1,675)
------- -------
$25,941 $51,271
======= =======
</TABLE>
F-66
<PAGE>
THE PET PRACTICE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
NOTE 4 -- PROPERTY AND EQUIPMENT:
<TABLE>
<CAPTION>
DECEMBER 28, JANUARY 3,
1994 1996
------------- -----------
<S> <C> <C>
Land.................................. $ 358 $ 1,582
Buildings............................. 2,571 3,939
Building and leasehold improvements... 1,374 1,459
Furniture and equipment............... 2,255 7,683
------ -------
6,558 14,663
Less: Accumulated depreciation...... (410) (1,198)
------ -------
$6,148 $13,465
====== =======
</TABLE>
Depreciation expense was $59 for the period October 27, 1993 to December
29, 1993, $351 for the year ended December 28, 1994, and $788 for the year ended
January 3, 1996.
NOTE 5 -- NOTES PAYABLE AND LONG-TERM DEBT:
Notes payable and long-term debt are comprised of the following:
<TABLE>
<CAPTION>
DECEMBER 28, JANUARY 3,
1994 1996
------------- -----------
<S> <C> <C>
Subordinated notes payable to stockholder, interest at 8% due
quarterly, principal due 1998.................................. $ 12,391 $ -
Borrowings under lines of credit with banks (weighted average
rate of 8.5% at December 28, 1994)............................. 10,067 -
Notes payable (6%-13% interest) payable through 2006............ 6,002 15,529
Mortgages payable (6%-11%), payable through 2010............... 973 2,500
Capital lease obligations (9.6% - 10.4%)........................ 1,128 1,453
-------- -------
30,561 19,482
Less: Current portion........................................ (11,676) (3,696)
-------- -------
Long-term debt.................................................. $ 18,885 $15,786
======== =======
</TABLE>
Scheduled maturities of long-term debt outstanding excluding capital lease
obligations as of January 3, 1996 were as follows:
<TABLE>
<S> <C>
1996.............................................. $3,633
1997.............................................. 3,787
1998.............................................. 3,427
1999.............................................. 2,558
2000.............................................. 2,647
</TABLE>
The subordinated notes payable to stockholder at December 28, 1994
represented borrowings pursuant to a $20,000 note between the Company and one of
its stockholders which permited it to borrow funds for acquisitions and general
corporate purposes.
F-67
<PAGE>
THE PET PRACTICE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
Notes and mortgages payable arose principally from acquisitions and include
certain amounts due to related parties. Certain of the Company's acquisition
notes payable are secured by the assets of the veterinary practice acquired.
The borrowings under lines of credit with a bank at December 28, 1994
represented borrowings pursuant to a $13,000 credit facility and were made at
the bank's prime rate. Such notes were secured by the guarantee of a
stockholder. In February 1995, the Company entered into a $5,000 line of credit
facility with another financial institution. Borrowings under this facility
were made at market interest rates and were secured by a guarantee of a
stockholder as well as certain of the Company's operating subsidiaries. Both of
these credit facilities with banks were terminated effective with the Company's
initial public offering.
The book value of notes and long-term debt approximates their fair value.
NOTE 6 -- INCOME TAXES:
Due to the Company's operating losses, no provision for federal income
taxes was recorded during any period. A provision for current state income taxes
was recorded during the years ended December 28, 1994 and January 3, 1996.
The reconciliation of the federal statutory tax rate to the effective tax
rate is as follows:
<TABLE>
<CAPTION>
YEAR ENDED
OCTOBER 27 TO --------------------------
DECEMBER 29, DECEMBER 28, JANUARY 3,
1993 1994 1996
------------- ----------- -----------
<S> <C> <C> <C>
Federal statutory tax rate............................. (34)% (34)% (34)%
State income taxes, less related federal tax benefit... - 4 3
Amortization not deductible for tax purposes........... 1 2 6
Losses for which no tax benefit was recognized......... 33 32 28
--- --- ---
Effective tax rate................................... -% 4% 3%
=== === ===
</TABLE>
The components of net deferred taxes are as follows:
<TABLE>
<CAPTION>
DECEMBER 29, DECEMBER 28, JANUARY 3,
1993 1994 1996
----------- ------------ ----------
<S> <C> <C> <C>
Net operating loss carryforwards....................... $ 1,563 $ 3,113 $ 4,138
Accruals and reserves not currently deductible
for tax purposes...................................... 39 226 276
------- ------- -------
Gross deferred tax assets.............................. 1,602 3,339 4,414
Valuation allowance.................................... (1,279) (3,033) (3,730)
------- ------- -------
Net deferred tax assets................................ 323 306 684
------- ------- -------
Depreciable assets..................................... (323) (203) (454)
Intangible assets...................................... - (103) (230)
------- ------- -------
Gross deferred tax liabilities......................... (323) (306) (684)
------- ------- -------
Net deferred taxes................................... $ - $ - $ -
======= ======= =======
</TABLE>
At January 3, 1996, the Company had net operating loss carryforwards for
federal income tax purposes of approximately $12,200 (the estimated tax benefit
of which is approximately $4,138). Their use is limited to future taxable
earnings of the Company and, as specified in the Internal Revenue Code, use of
certain of the net operating loss carryforwards is limited as they were acquired
by the Company in a purchase of the stock of another company. The carryforwards
expire in varying amounts through 2010. A valuation reserve has been
established against the benefit of the net operating loss carryforwards.
F-68
<PAGE>
THE PET PRACTICE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
NOTE 7 -- COMMITMENTS AND CONTINGENCIES:
Operating leases:
The Company leases certain office and veterinary care facilities as well as
vehicles and equipment under noncancellable operating leases which require
future minimum annual rentals as follows:
<TABLE>
<CAPTION>
CAPITAL OPERATING
LEASES LEASES
------- ----------
<S> <C> <C>
1996...................................... $ 198 $2,679
1997...................................... 198 2,509
1998...................................... 198 2,294
1999...................................... 180 2,105
2000...................................... 160 1,648
Thereafter................................ 1,758 7,019
------
2,692
Amounts representing interest............. 1,239
------
Present value of minimum lease payments 1,453
Less current portion.................... (63)
------
Long-term obligation...................... $1,390
======
</TABLE>
Certain of the leases contain renewal options and escalation clauses which
require payments of additional rent to the extent of increases in related
operating costs. Included in future rental commitments are payments totaling
$10,178 which will be made to related parties. Six of these leases are with
partnerships in which a director of the Company is a partner, and these leases
expire at various dates from 1997 through 2003, although the Company has renewal
options. Rent expense was $118 for the period October 27 to December 29, 1993,
$971 for the year ended December 28, 1994, and $1,865 for the year ended January
3, 1996.
Contingent payments related to business acquisitions:
In connection with certain acquisitions (see Note 3), the Company has
entered into contractual arrangements whereby additional shares of the Company's
common stock and cash may be issued to former owners of acquired practices upon
attainment of specified financial and non-financial criteria over periods of
three to five years as set forth in the respective agreements. The number of
shares of common stock and cash to be issued can not be determined until the
earnout periods expire and the attainment of criteria is established. If such
criteria are attained, but not exceeded, the Company will be obligated to make
cash payments of approximately $2,881 and issue approximately 90,000 shares of
common stock over the next five years.
A lesser amount of cash would be paid and a lesser number of shares of
common stock would be issuable under certain acquisition agreements if the
financial criteria are not met and a greater amount of cash would be paid and a
greater number of shares of common stock would be issuable under certain
acquisition agreements if the financial criteria are exceeded. For example, if
the financial criteria with respect to each of the acquisitions were to be
exceeded by 20%, the Company would be obligated to make cash payments of $3,167
and issue approximately 109,000 shares of common stock over the next five years.
Since, by the terms of the related agreements, these payments are considered
contingent consideration for the acquired business, amounts payable pursuant to
these provisions, if earned, will be recorded as additional purchase price in
the period the criteria are attained.
F-69
<PAGE>
THE PET PRACTICE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
In addition, in certain circumstances, the Company is required to issue
additional shares of common stock if, on the second anniversary of the
acquisition closing, the market price of the common stock falls below specified
levels ranging from $10.00 to $16.00 per share. Based on the market price of
the common stock at January 3, 1996, an aggregate of approximately 19,000 shares
would be issuable. Additionally, the number of shares of common stock delivered
in connection with one acquisition as part of the purchase price was subject to
adjustment, such that the value of such shares was equal to $320 as of the date
of the Company's initial public offering. The Company issued an additional 1,334
shares of common stock in connection with such acquisition. Additional shares
issued were recorded as an adjustment to the previously issued consideration.
In connection with two acquisitions, the Company entered into arrangements
with the former owners, who are now employees, that provided for amounts to be
payable upon attainment of a number of specified financial and non-financial
criteria. Since, by the terms of the related agreements these payments are
considered compensatory, amounts payable pursuant to these provisions, if
earned, are recorded as compensation expense. In June 1995, the Company
renegotiated these arrangements to eliminate future payments based on
performance criteria in exchange for non-interest bearing notes payable by the
Company. The settlement of these arrangements resulted in one-time, non-cash
charges to general and administrative expenses of approximately $383 and $705 in
the years ended December 28, 1994 and January 3, 1996, respectively.
One arrangement for contingent compensation payments remains in place,
which calls for estimated aggregate payments of approximately $260 over the next
five years if specified criteria are attained.
NOTE 8 -- ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES:
Accrued expenses and other current liabilities are comprised of the
following:
<TABLE>
<CAPTION>
DECEMBER 28, JANUARY 3,
1994 1996
------------- ----------
<S> <C> <C>
Accrued salaries, wages, and vacation... $ 507 $1,634
Accrued interest........................ 1,431 166
Other................................... 3,839 3,384
------ ------
$5,777 $5,184
====== ======
</TABLE>
NOTE 9 -- EMPLOYEE BENEFITS:
401(k) Plan:
Beginning in April 1994, the Company sponsored a 401(k) plan for employees
with more than one year of service. Contributions to the plan totaled $10 for
the period from inception of the Plan to December 28, 1994, and $14 for the year
ended January 3, 1996.
1994 Stock Option Plan:
The Company sponsors a stock option plan for key employees and directors.
There are available for options under the Plan a total of 400,000 shares of
common stock. As of January 3, 1996, total options to purchase 100,250 shares
have been granted. Such options are exercisable at prices ranging between $4.00
and $15.00 per share over the next 10 years. All options are subject to a five-
year vesting period. At January 3, 1996, 2,700 options were vested. No options
have been exercised.
F-70
<PAGE>
THE PET PRACTICE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
Options are granted at the market value of the underlying shares as of the
grant date, therefore no compensation expense is recorded relative to the plan.
NOTE 10 -- STOCKHOLDERS' EQUITY (DEFICIT)
On August 4, 1995, the Company consummated its initial public offering of
4,300,000 shares of common stock at $15.00 per share. The net proceeds of the
offering of approximately $56,600 were used (i) to repay $12,391 principal
amount of related-party debt, together with accrued interest; (ii) to redeem
$800 of the Company's Redeemable Preferred Stock, together with accrued
dividends; (iii) to repay approximately $13,000 borrowed from United States
Trust Company of New York pursuant to a demand line of credit facility, together
with accrued interest; (iv) to repay approximately $6,000 borrowed from PNC
Bank, National Association, pursuant to a demand line of credit facility,
together with accrued interest; and (v) to pay a fee of $500 to Foster
Management Company, of which a director of the Company is the Chairman and sole
stockholder, for services in connection with the consummation of the public
offering. The remaining net proceeds of approximately $23,000 were added to
working capital and will be used primarily to finance future acquisitions and
capital expenditures and for general corporate purposes.
In October 1993, the Company sold 3,600,000 shares of common stock to an
investment partnership managed by Foster Management Company at a price of $.055
per share. During 1993, the Company sold 77,067 shares of common stock to an
officer of the company at a price of $.055 per share.
During 1994, the Company also sold 160,000 shares of common stock to
officers, directors and employees of the Company for $.08 per share. The
Company has entered into stock purchase agreements with certain of its directors
and certain of its executive officers pursuant to which such individuals
purchased their respective shares of common stock. The stock purchase
agreements provide for restrictions on the sale of such shares and for the
ownership of such shares to vest ratably over a five-year period. Unvested
shares may be repurchased by the Company at their original issued price in
certain circumstances.
NOTE 11 -- MANDATORILY REDEEMABLE PREFERRED STOCK:
The Company is authorized to issue 1,000,000 shares of preferred stock,
$.01 par value. The powers, designations, preferences and relative,
participating, optional or other special rights are established by the Board of
Directors.
During 1993, the Board of Directors authorized 10,000 shares of mandatorily
redeemable preferred stock, par value $.01 per share (the "Redeemable Preferred
Stock"), and the Company sold 8,000 shares of such Redeemable Preferred Stock to
an investment partnership managed by Foster Management Company for $100 per
share. The Redeemable Preferred Stock is redeemable at $100 per share plus
cumulative unpaid dividends at a rate of 8% per annum at the Company's option.
Holders of the Redeemable Preferred Stock are entitled to preference payments in
the event of any liquidation, dissolution or winding-up of the Company. The
Redeemable Preferred Stock was mandatorily redeemed at the closing of the
Company's initial public offering.
Dividends on the Redeemable Preferred Stock of $10 for the period October
27, 1993 to December 29, 1993, $64 for the year ended December 28, 1994, and $42
for the year ended January 3, 1996 have been recorded as interest expense.
F-71
<PAGE>
THE PET PRACTICE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
NOTE 12 -- SUBSEQUENT EVENT:
On March 22, 1996, the Company announced that it signed a definitive
agreement providing for the merger of the Company with Veterinary Centers of
America, Inc. ("VCA"). If completed, this merger will result in the Company
becoming a wholly-owned subsidiary of VCA. Consummation of the merger is
expected in the second quarter of 1996 and is subject to certain conditions.
F-72
<PAGE>
REPORT OF INDEPENDENT ACCOUNTANTS
To the Board of Directors and Stockholders of
Professional Veterinary Hospitals of America, Inc.
In our opinion, the accompanying statements of operations, of stockholders'
deficit and of cash flows present fairly, in all material respects, the results
of operations and cash flows of Professional Veterinary Hospitals of America,
Inc. for the year ended January 27, 1993 and for the period January 28, 1993
through October 26, 1993 in conformity with generally accepted accounting
principles. These financial statements are the responsibility of the Company's
management; our responsibility is to express an opinion on these financial
statements based on our audit. We conducted our audit of these statements in
accordance with generally accepted auditing standards which require that we
plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements, assessing the accounting principles used and
significant estimates made by management, and evaluating the overall financial
statement presentation. We believe that our audit provides a reasonable basis
for the opinion expressed above.
/s/ Price Waterhouse LLP
PRICE WATERHOUSE LLP
Philadelphia, PA
March 29, 1995
F-73
<PAGE>
PROFESSIONAL VETERINARY HOSPITALS OF AMERICA, INC.
STATEMENT OF OPERATIONS
<TABLE>
<CAPTION>
Year ended January 28 to
January 27, 1993 October 26, 1993
---------------- ----------------
<S> <C> <C>
Revenues................................ $8,198,609 $6,713,526
Direct costs of services................ 7,087,949 5,334,202
---------- ----------
Gross profit 1,110,660 1,379,324
General and administrative expenses..... 1,234,988 1,282,267
---------- ----------
Income (loss) from operations (124,328) 97,057
Other expenses, net..................... 572,120 346,500
---------- ----------
Net loss.............................. $ (696,448) $ (249,443)
========== ==========
</TABLE>
The accompanying notes are an integral part of these financial statements
F-74
<PAGE>
PROFESSIONAL VETERINARY HOSPITALS OF AMERICA, INC.
STATEMENT OF STOCKHOLDERS' DEFICIT
For the Year Ended January 27, 1993 and
the Period January 28, 1993 to October 26, 1993
<TABLE>
<CAPTION>
Common stock
------------------------------------------------
Class A Class B Capital in Total
shares shares excess of Accumulated stockholders'
issued Amount issued Amount par value deficit deficit
--------- ------- ------- ------- ---------- ------------ ------------
<S> <C> <C> <C> <C> <C> <C> <C>
Balance, January 29, 1992... 3,130,000 $31,300 25,000 $25,000 $2,652,020 $(3,207,672) $ (499,352)
Repurchase and retirement of
Class A common stock from
former officer............ (280,000) (2,800) (53,200) (56,000)
Net loss.................... (696,448) (696,448)
--------- ------- ------ ------- ---------- ----------- -----------
Balance, January 27, 1993... 2,850,000 28,500 25,000 25,000 2,598,820 (3,904,120) (1,251,800)
Net loss.................... (249,443) (249,443)
--------- ------- ------ ------- ---------- ----------- -----------
Balance, October 26, 1993... 2,850,000 $28,500 25,000 $25,000 $2,598,820 $(4,153,563) $(1,501,243)
========= ======= ====== ======= ========== =========== ===========
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-75
<PAGE>
PROFESSIONAL VETERINARY HOSPITALS OF AMERICA, INC.
STATEMENT OF CASH FLOWS
<TABLE>
<CAPTION>
Year ended January 28 to
January 27, 1993 October 26, 1993
---------------- ----------------
<S> <C> <C>
Cash flows from operating activities:
Net loss ............................................. $(696,448) $(249,443)
Adjustments to reconcile net loss to net cash
provided by operating activities:
Depreciation and amortization....................... 347,579 268,224
Rent concession..................................... (19,934) 6,189
Gain (loss) on disposal of property and equipment... (1,418) 9,063
Warrant redemption finance charge................... 264,000 196,000
Changes in:
Accounts receivable............................... 4,389 (11,023)
Other assets...................................... (8,856) 5,212
Inventory......................................... 19,100 25,500
Prepaid expenses.................................. (17,365) 11,049
Accounts payable.................................. (17,427) (9,026)
Accrued and other liabilities..................... 263,269 61,310
--------- ---------
Net cash provided by operating activities....... 136,889 313,055
--------- ---------
Cash flows from financing activities:
Payments on long-term debt............................ (376,248) (120,332)
Stock repurchase from former officer.................. (56,000)
--------- ---------
Net cash (used for) financing activities............ (432,248) (120,332)
--------- ---------
Cash flows from investing activities:
Proceeds from sale of property and equipment.......... 67,220
Capital expenditures.................................. (48,660) (216,181)
--------- ---------
Net cash provided by (used for) investing
activities......................................... 18,560 (216,181)
--------- ---------
Net decrease in cash.................................... (276,799) (23,458)
Cash, beginning of period............................... 373,188 96,389
--------- ---------
Cash, end of period..................................... $ 96,389 $ 72,931
========= =========
Supplemental disclosure of cash flow information:
Cash paid during the period for interest.............. $ 380,476 $ 21,182
========= =========
Noncash financing and investing activities:
Debt relieved in disposal of property and
equipment............................................ $ 126,272 $ -
========= =========
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-76
<PAGE>
PROFESSIONAL VETERINARY HOSPITALS OF AMERICA, INC.
NOTES TO FINANCIAL STATEMENTS
NOTE 1 - ACCOUNTING POLICIES:
Basis of presentation:
Professional Veterinary Hospitals of America, Inc. ("PVH" or the "Company")
provides on-site veterinary services and related activities in southeastern
Michigan.
PVH's accounting year was a 52-53 week fiscal year which ended on the last
Wednesday in January. The results of operations and changes in stockholders'
equity (deficit) and cash flows presented herein are for the year ended January
27, 1993 and the period from January 28, 1993 through October 26, 1993 (see
Note 9).
Net revenues:
Net revenues are reported at the estimated amounts to be realized through
payments from customers and are recognized when the service is performed.
Inventory:
Inventory consists of pharmaceuticals, retail pet products and other
veterinary care products and is valued at lower of market or cost determined on
a first-in, first-out basis.
Property and equipment:
Property and equipment are stated at cost less accumulated depreciation.
Additions and improvements to property and equipment are capitalized and
maintenance and repairs are charged to current operations. Adjustments of the
assets and the related accumulated depreciation accounts are made for
retirement and disposal of property and equipment with the resulting gain or
loss included in the results of operations.
Depreciation is provided substantially using the straight-line method.
Estimated useful lives of the assets are:
<TABLE>
<S> <C>
Building and building improvements.. Shorter of the life of the lease or 31.5 years
Leasehold improvements.............. Shorter of the life of the lease or 10 years
Furniture and equipment............. 5 to 10 years
</TABLE>
Goodwill:
The excess of cost over acquired net assets (goodwill) is being amortized
on a straight-line basis over its estimated useful life of 40 years.
Cash equivalents:
For purposes of the statement of cash flows, all highly liquid investments
with a maturity of three months or less are considered cash equivalents.
Income taxes:
The Company has adopted Statement of Financial Accounting Standards No.
109, "Accounting for Income Taxes" (FAS 109). The asset and liability approach
requires the recognition of deferred tax liabilities and assets for the expected
future tax consequences of temporary differences between the carrying amounts
and the tax bases of assets and liabilities.
F-77
<PAGE>
PROFESSIONAL VETERINARY HOSPITALS OF AMERICA, INC.
NOTES TO FINANCIAL STATEMENTS - (Continued)
NOTE 2 - LEASES:
PVH's facility leases are classified as operating leases and expire on
various dates through January 21, 2002. Most leases contain renewal options.
Additionally, PVH leases certain office and medical equipment under leases
classified as capital with an initial or remaining term in excess of one year.
Amounts charged to operations for rental expense were $606,960 and $424,328 for
the fiscal year ended January 27, 1993 and the period ended October 26, 1993,
respectively.
NOTE 3 - FINANCING ARRANGEMENT:
On January 29, 1992, the Company entered into a sale and leaseback agreement
in connection with two of its hospital facilities including land, building,
furniture and equipment with Mack/Inkster Properties Limited Partnership, a
Michigan limited partnership. Under the sale agreement, the Company sold the
facilities for $600,000. In addition, the Company entered into an agreement to
leaseback the facilities for a ten-year period with varying monthly rental
charges of $5,800 to $15,000 over the life of the lease. The Company made lease
payments totaling $69,600 and $52,200 during the year ended January 27, 1993 and
during the period from January 28 to October 26, 1993, respectively. Because the
agreement provides the Company with an option to repurchase the assets, the
sale-leaseback is accounted for as a financing from the partnership. The net
book value of the facilities is amortized over the life of the lease agreement.
Concurrent with the purchase of the Company by The Pet Practice, Inc. (see
Note 9), the Company purchased all of the property owned by Mack/Inkster
Properties Limited Partnership for $700,000.
NOTE 4 - SUBORDINATED NOTES:
On May 14, 1991, PVH issued subordinated notes with a face value of
$1,400,000 and warrants to purchase 250,000 shares of Class A common stock to
stockholders of the Company with interest at 11% payable in varying amounts
through July 1, 1994. At October 26, 1993, $1,310,000 of the notes were
outstanding.
From July 1, 1994 through December 31, 1994, the holders of the warrants may
purchase up to 250,000 shares of Class A common stock at $2.50 per share or
require PVH to redeem each warrant for $3.00. If PVH defaults on principal
payments under the subordinated notes, additional warrants may be issued.
The Company provides for the estimated cost associated with redemption of the
warrants by recording charges to interest expense. Such charges were $452,000
for the year ended January 27, 1993, and $196,000 for the period ended October
26, 1993.
Concurrent with the purchase of the Company by The Pet Practice, Inc. (see
Note 9), the Company repaid the subordinated debt and related accrued interest
and repurchased the warrants for a total of $1,600,000.
NOTE 5 - LONG-TERM DEBT:
Other long-term debt arrangements consisted of the following at
October 26, 1993:
Note payable, bank, with monthly payments of $14,919 plus
interest at 1% above prime due through October 1, 1994. This
loan was repaid concurrent with the transaction described in
Note 9 ........................................................ $356,725
Obligations under capitalized leases (Note 3) .................. 8,235
Note payable, bank, with interest at 12.75%, monthly payments of
$387 including interest, due through April 30, 1995 ........... 6,970
--------
Total debt (all current) ....................................... $371,930
========
F-78
<PAGE>
PROFESSIONAL VETERINARY HOSPITALS OF AMERICA, INC.
NOTES TO FINANCIAL STATEMENTS - (Continued)
NOTE 6 - RELATED PARTY TRANSACTIONS:
PVH Property Management Co., a partnership owned by two of the stockholders
of PVH, leases office and clinic space to PVH. During the periods ended January
27, 1993 and October 26, 1993, PVH paid $231,600 and $173,700, respectively, in
lease payments to PVH Property Management Company.
Two of the stockholders of PVH are partners in the Mack/Inkster Properties
Limited Partnership (see Note 3).
NOTE 7 - INCOME TAXES:
No current or deferred provision for federal income taxes has been recorded
by the Company for the year ended January 27, 1993 or for the period January 28
to October 26, 1993 due to net operating losses incurred by the Company during
these periods. At October 26, 1993, PVH had net operating loss carryforwards of
approximately $3,957,000, which may be used to reduce future taxable income and
expires beginning in 1997. Their use is limited to future taxable earnings of
the Company and, as specified in the Internal Revenue Code, certain ownership
changes would result in limitations on the Company's ability to utilize its net
operating loss carryforwards.
The provision for income taxes differs from the amount of income tax
determined by applying statutory tax rates to pretax income primarily due to the
net operating losses for which no benefit is recorded.
NOTE 8 - COMMON STOCK:
Class B common stock is entitled to such votes and dividends that it would be
entitled to had it been converted into Class A common stock. Upon liquidation,
Class B common stock ranks senior to the rights of Class A common stock. In
addition, Class B common stock is convertible, only in its entirety, to Class A
common stock on a 100 to 1 basis.
NOTE 9 - SUBSEQUENT EVENT:
On October 26, 1993, The Pet Practice, Inc., a Delaware corporation, acquired
100% of the stock of the Company.
F-79
<PAGE>
PETS' RX, INC.
--------------
CONSOLIDATED BALANCE SHEETS
---------------------------
(In thousands)
<TABLE>
<CAPTION>
ASSETS
March 31, December 31,
1996 1995
----------- ------------
(Unaudited) (Audited)
<S> <C> <C>
CURRENT ASSETS:
Cash and cash equivalents $ 251 $ 752
Other current assets 658 671
------- -------
Total current assets 909 1,423
PROPERTY AND EQUIPMENT, net 3,993 4,054
INTANGIBLE ASSETS, net 9,309 9,490
NOTES RECEIVABLE 100 100
OTHER ASSETS 270 265
------- -------
$14,581 $15,332
======= =======
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable $ 1,061 $ 1,080
Current portion of long-term obligations 1,167 1,412
Accrued expenses and other current liabilities 1,218 1,358
------- -------
Total current liabilities 3,446 3,850
------- -------
LONG-TERM OBLIGATIONS, net of current portion 9,219 9,426
------- -------
MINORITY INTEREST 269 251
------- -------
COMMITMENTS AND CONTINGENCIES
REDEEMABLE CONVERTIBLE PREFERRED STOCK 2,947 2,947
------- -------
STOCKHOLDERS' DEFICIT
Preferred stock, $0.01 par value 3,395 3,395
Convertible preferred stock (Series A) subscribed 200 --
Common stock, $0.01 par value 63 63
Additional paid-in capital 3,547 3,547
Accumulated deficit (8,505) (8,147)
------- -------
Total stockholders' deficit (1,300) (1,142)
------- -------
$14,581 $15,332
======= =======
</TABLE>
The accompanying notes are an integral part of these consolidated balance
sheets.
F-80
<PAGE>
PETS' RX, INC.
--------------
CONSOLIDATED STATEMENTS OF OPERATIONS
-------------------------------------
FOR THE THREE MONTHS ENDED MARCH 31, 1996 AND 1995
--------------------------------------------------
(In thousands)
(Unaudited)
<TABLE>
<CAPTION>
1996 1995
-------- -------
<S> <C> <C>
REVENUES
$4,228 $3,422
------ ------
COST OF SERVICES:
Cost of revenues 803 623
Salaries and wages of clinic operations 1,661 1,359
Other operating expenses of clinics 1,043 950
------ ------
Gross profit 721 490
------ ------
GENERAL AND ADMINISTRATIVE 530 499
DEPRECIATION AND AMORTIZATION 307 280
------ ------
Operating loss (116) (289)
INTEREST EXPENSE (229) (258)
INTEREST INCOME 12 25
------ ------
Loss before minority interest in income of subsidiary (333) (522)
MINORITY INTEREST IN INCOME OF SUBSIDIARY 25 10
------ ------
Net loss $ (358) $ (532)
====== ======
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
F-81
<PAGE>
PETS' RX, INC.
--------------
CONSOLIDATED STATEMENTS OF CASH FLOWS
-------------------------------------
FOR THE MONTHS ENDED MARCH 31, 1996 AND 1995
--------------------------------------------
(In thousands)
(Unaudited)
<TABLE>
<CAPTION>
1996 1995
------- -------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $(358) $ (532)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 307 280
Gain on sale of land and building -- (18)
Minority interest in income of subsidiary in excess of distribution 25 10
Changes in assets and liabilities
Other current assets 13 (40)
Other assets (5) (52)
Accounts payable (20) 196
Accrued expenses and other current liabilities (72) 126
----- ------
Net cash used in operating activities (110) (30)
----- ------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment (64) 78
Proceeds from sale of land and building -- 600
Payments received under note receivable -- 193
----- ------
Net cash (used in) provided by investing activities (64) 715
----- ------
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of convertible preferred stock, preferred
stock subscribed, and common stock 200 100
Principal payments under long-term obligations (527) (798)
----- ------
Net cash used in financing activities (327) (698)
----- ------
Net decrease in cash and cash equivalents (501) (13)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 752 2,254
----- ------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 251 $2,241
===== ======
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid during the year $ 282 $ 243
Non-cash financing activities -- Capital leases -- $ 60
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
F-82
<PAGE>
PETS' RX, INC.
--------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
------------------------------------------
MARCH 31, 1996
--------------
1. GENERAL:
-------
The Company
- -----------
Pets' Rx, Inc. (the "Company") was incorporated in Delaware on May 28, 1991. The
Company is engaged in the acquisition and operation of veterinary clinics. As of
March 31, 1996, the Company operates 16 clinics in the San Jose and Sacramento,
California, and Las Vegas, Nevada, markets.
The Company has substantial operating and debt service obligations as a result
of the significant acquisition activity. The Company will require additional
capital in 1996 if the merger discussed in Note 3 is not consummated.
Principles of Consolidation
- ---------------------------
The accompanying consolidated financial statements include the accounts of the
Company and its majority-owned subsidiary and have been prepared in accordance
with generally accepted accounting principles for interim financial information.
Accordingly, they do not include all of the information and footnotes required
by generally accepted accounting principles for complete financial statements.
All significant intercompany transactions and balances have been eliminated. The
results of operations for the three months ended March 31, 1996 and 1995 are not
necessarily indicative of the results to be expected for the full year. Minority
interest on the accompanying balance sheet represents the initial contribution
of assets to the subsidiary by the minority member increased by the member's
share of income less distributions made.
2. RECLASSIFICATIONS:
-----------------
Certain prior year amounts have been reclassified to conform to their 1995
classifications.
3. MERGER AGREEMENT:
----------------
In February, 1996 the Company entered into a merger agreement (the
"Agreement")with Veterinary Centers of America, Inc. ("VCA"). Under the terms of
the Agreement as amended, which is intended to qualify for pooling-of-interests
accounting, stockholders and rights holders, as defined, are to receive shares
of VCA common stock, par value $0.001 with a market value on June 14,1996 of
approximately $22.4 million. The stockholders of the Company voted to approve
the merger on June 14, 1996 and the merger is expected to be consummated on June
18, 1996.
4. SUBSEQUENT EVENT:
----------------
During the second quarter of 1996, the Company received additional working
capital through the issuance of notes payable to existing shareholders and to
Veterinary Centers of America, Inc. in the amount of $200,000 and $210,000,
respectively.
F-83
<PAGE>
Report of Independent Public Accountants
To the Board of Directors and
Stockholders of Pets' Rx, Inc.:
We have audited the accompanying consolidated balance sheet of Pets' Rx, Inc. (a
Delaware corporation) and subsidiary as of December 31, 1995, and the related
consolidated statements of operations, redeemable preferred stock and
stockholders' equity (deficit), and cash flows for the year then ended. These
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audit.
We conducted our audit in accordance with generally accepted auditing standards
which require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement. An
audit includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements. An audit includes assessing the
accounting principles used and significant estimates made by management, as well
as evaluating the overall financial statement presentation. We believe that our
audit provides a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Pets' Rx, Inc. and subsidiary
as of December 31, 1995, and the results of their operations and their cash
flows for the year then ended in conformity with generally accepted accounting
principles.
/s/ Arthur Andersen LLP
San Jose, California
March 20, 1996
F-84
<PAGE>
REPORT OF INDEPENDENT ACCOUNTANTS
To The Board of Directors and
Stockholders of Pets' Rx, Inc.
In our opinion, the accompanying balance sheet and the related statements of
operations, of redeemable preferred stock and stockholders' equity (deficit) and
of cash flows present fairly, in all material respects, the financial position
of Pets' Rx, Inc at December 31, 1994 and the results of its operations and its
cash flows for the years ended December 31, 1994 and 1993 in conformity with
generally accepted accounting principles. These financial statements are the
responsibility of the Company's management; our responsibility is to express an
opinion on these financial statements based on our audits. We conducted our
audits of these statements in accordance with generally accepted auditing
standards which require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatement. An audit includes examining on a test basis, evidence supporting
the amounts and disclosures in the financial statements, assessing the
accounting principles used and significant estimates made by management, and
evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for the opinion expressed above.
/s/ Price Waterhouse LLP
PRICE WATERHOUSE LLP
San Jose, California
September 12, 1995
F-85
<PAGE>
PETS' RX, INC.
--------------
CONSOLIDATED BALANCE SHEETS
---------------------------
AS OF DECEMBER 31, 1995 AND 1994
--------------------------------
(In thousands, except share and per share data)
ASSETS
------
<TABLE>
<CAPTION>
1995 1994
------- -------
<S> <C> <C>
CURRENT ASSETS:
Cash and cash equivalents $ 752 $ 2,254
Other current assets (Note 2) 671 571
------- -------
Total current assets 1,423 2,825
PROPERTY AND EQUIPMENT, net (Note 2) 4,054 4,138
INTANGIBLE ASSETS, net (Note 2) 9,490 9,909
NOTE RECEIVABLE (Note 3) 100 293
OTHER ASSETS 265 118
------- -------
$15,332 $17,283
======= =======
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
----------------------------------------------
CURRENT LIABILITIES:
Accounts payable $ 1,080 $ 854
Current portion of long-term obligations (Note 4) 1,412 702
Accrued expenses and other current liabilities (Note 2) 1,358 1,188
------- -------
Total current liabilities 3,850 2,744
------- -------
LONG-TERM OBLIGATIONS, net of current portion (Note 4) 9,426 10,986
------- -------
MINORITY INTEREST (Note 3) 251 -
------- -------
COMMITMENTS AND CONTINGENCIES (Note 3 and 9)
REDEEMABLE CONVERTIBLE PREFERRED STOCK:
2,000,000 shares designated; 915,464 shares issued and outstanding in 1995
and 1994 (Note 5) 2,947 2,947
------- -------
STOCKHOLDERS' EQUITY (DEFICIT) (Notes 6 and 7):
Preferred stock, $0.01 par value; 5,000,000 shares authorized
Convertible preferred stock, 100,000 shares designated Series A; 38,000
and 35,000 shares issued and outstanding in 1995 and 1994 3,395 3,095
Convertible preferred stock (Series A) 5,000 shares
subscribed - 150
Common stock, $0.01 par value; 20,000,000 shares authorized; 6,265,685 and
6,069,261 shares issued and outstanding in 1995 and 1994 63 61
Additional paid-in capital 3,547 3,470
Accumulated deficit (8,147) (6,170)
------- -------
Total stockholders' equity (deficit) (1,142) 606
------- -------
$15,332 $17,283
======= =======
</TABLE>
F-86
<PAGE>
PETS' RX, INC.
--------------
CONSOLIDATED STATEMENTS OF OPERATIONS
-------------------------------------
FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
----------------------------------------------------
(In thousands)
<TABLE>
<CAPTION>
1995 1994 1993
------- ------- -------
<S> <C> <C> <C>
REVENUES $15,622 $ 9,638 $ 5,785
------- ------- -------
COSTS OF SERVICES:
Cost of revenues 3,045 2,055 1,214
Salaries and wages of clinic operations 6,136 4,162 2,429
Other operating expenses of clinics 4,055 2,562 1,594
------- ------- -------
13,236 8,779 5,237
------- ------- -------
Gross profit 2,386 859 548
GENERAL AND ADMINISTRATIVE 2,203 1,777 1,054
DEPRECIATION AND AMORTIZATION 1,200 919 562
WRITE-OFF OF GOODWILL - - 123
------- ------- -------
Operating loss (1,017) (1,837) (1,191)
INTEREST EXPENSE (1,009) (1,006) (352)
INTEREST INCOME 99 38 21
------- ------- -------
Loss before minority interest in
income of subsidiary (1,927) (2,805) (1,522)
MINORITY INTEREST IN INCOME OF SUBSIDIARY 50 - -
------- ------- -------
Net loss $(1,977) $(2,805) $(1,522)
======= ======= =======
</TABLE>
The accompanying notes are an integral part
of these consolidated financial statements.
F-87
<PAGE>
PETS' RX, INC.
--------------
CONSOLIDATED STATEMENTS OF REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY
------------------------------------------------------------------------------
(DEFICIT)
---------
FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
----------------------------------------------------
(In thousands, except share data)
<TABLE>
<CAPTION>
Stockholders' Equity (Deficit)
-----------------------------------------
Redeemable Series A
Preferred Stock Preferred Stock Common Stock
--------------- ---------------- --------------------
Shares Amount Shares Amount Shares Amount
------- ------ ------ -------- --------- ------
<S> <C> <C> <C> <C> <C> <C>
BALANCE AT DECEMBER 31, 1992 792,170 $2,515 - $ - 1,792,500 $18
Issuance of common stock warrants - - - - - -
Issuance of redeemable preferred stock warrants - - - - - -
Redeemable preferred stock dividend 59,424 208 - - - -
Subscription of Series C preferred stock - - - - - -
Net loss - - - - - -
------- ------ ------ ------ --------- ---
BALANCE AT DECEMBER 31, 1993 851,594 2,723 - - 1,792,500 18
Redeemable preferred stock dividend 63,870 224 - - - -
Issuance of common stock for surrender of Series C
preferred stock subscription - - - - 537,500 5
Issuance of Series A convertible preferred
stock, net of issuance cost of $238 - - 35,000 3,262 - -
Issuance of common stock to directors in conjunction
with sale of Series A preferred stock - - - (167) 270,000 3
Subscription of Series A convertible preferred stock - - - - - -
Issuance of common stock for exercise and surrender
of warrants - - - - 645,000 6
Issuance of common stock for payment of note interest - - - - 357,903 4
Issuance of common stock for note conversion - - - - 2,441,358 25
Issuance of common stock for acquisition - - - - 25,000 -
Issuance of common stock warrants - - - - - -
Net loss - - - - - -
------- ------ ------ ------ --------- ---
BALANCE AT DECEMBER 31, 1994 915,464 2,947 35,000 3,095 6,069,261 61
Issuance of Series A convertible preferred stock - - 3,000 300 - -
Issuance of common stock for bridge note conversion - - - - 142,960 2
Issuance of common stock for exercise and surrender of
warrants - - - - 53,464 -
Net loss - - - - - -
------- ------ ------ ------ --------- ---
BALANCE AT DECEMBER 31, 1995 915,464 $2,947 38,000 $3,395 6,265,685 $63
======= ====== ====== ====== ========= ===
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
<TABLE>
<CAPTION>
Stockholders' Equity (Deficit)
-------------------------------------------------------
Additional
Paid-in Stock Accumulated
Capital Subscribed Deficit Total
---------- ----------- ----------- --------
<S> <C> <C> <C> <C>
BALANCE AT DECEMBER 31, 1992 $1,386 $ - $(1,411) $ (7)
Issuance of common stock warrants 101 - - 101
Issuance of redeemable preferred stock warrants 121 - - 121
Redeemable preferred stock dividend - - (208) (208)
Subscription of Series C preferred stock - 200 - 200
Net loss - - (1,522) (1,522)
----- ------- ------- -------
BALANCE AT DECEMBER 31, 1993 1,608 200 (3,141) (1,315)
Redeemable preferred stock dividend - - (224) (224)
Issuance of common stock for surrender of Series C
preferred stock subscription 195 (200) - -
Issuance of Series A convertible preferred
stock, net of issuance cost of $238 - - - 3,262
Issuance of common stock to directors in conjunction
with sale of Series A preferred stock 164 - - -
Subscription of Series A convertible preferred stock - 150 - 150
Issuance of common stock for exercise and surrender
of warrants 49 - - 55
Issuance of common stock for payment of note interest 219 - - 223
Issuance of common stock for note conversion 1,207 - - 1,232
Issuance of common stock for acquisition 15 - - 15
Issuance of common stock warrants 13 - - 13
Net loss - - (2,805) (2,805)
----- ------- ------- -------
BALANCE AT DECEMBER 31, 1994 3,470 150 (6,170) 606
Issuance of Series A convertible preferred stock - (150) - 150
Issuance of common stock for bridge note conversion 77 - - 79
Issuance of common stock for exercise and surrender of
warrants - - - -
Net loss - - (1,977) (1,977)
----- ------- ------- -------
BALANCE AT DECEMBER 31, 1995 3,547 $ - $(8,147) $(1,142)
===== ======= ======= =======
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
F-88
<PAGE>
PETS' RX, INC.
--------------
CONSOLIDATED STATEMENTS OF CASH FLOWS
-------------------------------------
FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
----------------------------------------------------
(In thousands)
<TABLE>
<CAPTION>
1995 1994 1993
-------- -------- --------
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $(1,977) $(2,805) $(1,522)
Adjustments to reconcile net loss to net cash used in operating activities-
Depreciation and amortization 1,200 919 562
Gain on sale of land and building (19) - -
Write-off of goodwill - - 123
Minority interest in income of subsidiary in excess of distributions 7 - -
Changes in assets and liabilities, net of effect of acquired clinics-
Other current assets (88) 116 (136)
Other assets 19 (51) (36)
Accounts payable 607 476 115
Accrued expenses and other current liabilities 32 954 219
------- ------- -------
Net cash used in operating activities (219) (391) (675)
------- ------- -------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment (916) (114) (160)
Purchases of veterinary clinics (40) (862) (1,140)
Sale of marketable securities - - 140
Proceeds from sale of land and building 600 - -
Payments received (advances made) under note receivable 193 (98) 2
------- ------- -------
Net cash used in investing activities (163) (1,074) (1,158)
------- ------- -------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of long-term obligations - 294 1,426
Proceeds from issuance of redeemable preferred stock warrants and
common stock warrants - 13 222
Net proceeds from issuance of convertible preferred stock, preferred
stock subscribed, and common stock 150 3,467 200
Principal payments under long-term obligations (1,270) (603) (356)
------- ------- -------
Net cash provided by (used in) financing activities (1,120) 3,171 1,492
------- ------- -------
Net increase (decrease) in cash and cash equivalents (1,502) 1,706 (341)
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR 2,254 548 889
------- ------- -------
CASH AND CASH EQUIVALENTS AT END OF YEAR $ 752 $ 2,254 $ 548
======= ======= =======
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid during the year $ 972 $ 982 $ 324
Non-cash financing activities-
Payment of accrued interest on notes by issuance of common stock $ - $ 223 $ -
Conversion of notes payable to common stock $ 79 $ 1,232 $ -
Capital leases $ 78 $ - $ -
Conversion of accounts payable to note payable $ 381 $ - $ -
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
F-89
<PAGE>
PETS' RX, INC.
--------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
------------------------------------------
DECEMBER 31, 1995
-----------------
1. THE COMPANY AND ITS SIGNIFICANT ACCOUNTING POLICIES:
---------------------------------------------------
The Company
- -----------
Pets' Rx, Inc. (the "Company") was incorporated in Delaware on May 28, 1991. The
Company is engaged in the acquisition and operation of veterinary clinics. As of
December 31, 1995, the Company operates 16 clinics in the San Jose and
Sacramento, California, and Las Vegas, Nevada, markets.
The Company has substantial operating and debt service obligations as a result
of the significant acquisition activity (see Note 3). The Company will require
additional capital in 1996 if the merger discussed in Note 11 is not
consummated.
Use of Estimates in the Preparation of Financial Statements
- -----------------------------------------------------------
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from the estimates.
Principles of Consolidation
- ---------------------------
The accompanying consolidated financial statements include the accounts of the
Company and its majority-owned subsidiary. All significant intercompany
transactions and balances have been eliminated. Minority interest on the
accompanying balance sheet represents the initial contribution of assets to the
subsidiary by the minority member increased by the member's share of income less
distributions made.
Revenue Recognition
- -------------------
Revenues are recognized upon performance of veterinary services or sale of
related veterinary products.
Cash Equivalents
- ----------------
All highly liquid investments purchased with an original maturity of three
months or less are considered to be cash equivalents.
Inventories
- -----------
Inventories consist of veterinary supplies, pharmaceuticals, and retail
veterinary products and are stated at the lower of cost, determined using the
first-in, first-out basis, or market.
F-90
<PAGE>
Property and Equipment
- ----------------------
Property and equipment are stated at cost. Property and equipment, other than
leasehold improvements, are depreciated using the straight-line method over the
estimated useful lives of the assets, generally thirty-seven years for buildings
and three to seven years for equipment. Amortization of leasehold improvements
is computed using the straight-line method over the shorter of the remaining
lease term or the estimated useful lives of the improvements.
Intangible Assets
- -----------------
Acquired animal records are valued based on their expected future contribution
and are amortized using the straight-line method over the estimated lives of the
records, generally seven years. Payments due under covenants not to compete are
capitalized and amortized over the life of the covenants, generally five years,
using the straight-line method. The excess of the Company's investment in
veterinary clinics over the fair value of the net assets acquired (goodwill) is
amortized using the straight-line method over its estimated useful life of 40
years. Intangible assets relating to discontinued clinics are charged to expense
upon approval of the decision to close the clinic.
Income Taxes
- ------------
Income taxes are determined using an asset and liability approach that
recognizes deferred tax assets and liabilities for the expected future tax
consequences of events that have been recognized in the Company's financial
statements or tax returns.
New Accounting Standards
- ------------------------
In October 1995, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards (SFAS) No. 123, "Accounting for Stock-Based
Compensation," which will be effective for the Company's 1996 fiscal year. SFAS
No. 123 allows companies which have stock-based compensation arrangements with
employees to adopt a new fair-value basis of accounting for stock options and
other equity instruments, or to continue to apply the existing accounting rules
under Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock
Issued to Employees" but with additional financial statement disclosure. The
Company plans to continue to account for stock-based compensation arrangements
under APB Opinion No. 25 and, therefore, does not anticipate SFAS No. 123 will
have a material impact on its financial position, results of operations or cash
flows.
In March 1995, the Financial Accounting Standards Board issued SFAS No. 121,
"Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to
Be Disposed of." This pronouncement requires that long-lived assets and certain
identifiable intangible assets be reviewed for impairment whenever events or
changes in circumstances indicate that the carrying amount of an asset may not
be recoverable. An impairment loss is to be recognized when the sum of
undiscounted cash flows is less than the carrying amount of the asset.
Measurement of the loss for assets that the entity expects to hold and use is to
be based on the fair value of the asset. Although this pronouncement did not
have a material impact on the Company's financial condition or results of
operations at adoption in 1996, its provisions will be applicable to any future
assessments of its long-lived assets. Goodwill not associated with long-lived
assets will continue to be assessed under APB Opinion No. 17.
F-91
<PAGE>
Reclassifications
- -----------------
Certain prior year amounts have been reclassified to conform to their 1995
classifications.
2. BALANCE SHEET COMPONENTS (in thousands):
---------------------------------------
<TABLE>
<CAPTION>
December 31,
-----------------
1995 1994
------- -------
<S> <C> <C>
Other current assets:
Accounts receivable, net $ 205 $ 210
Inventories 429 346
Prepaid expenses 37 15
------- -------
$ 671 $ 571
======= =======
Property and equipment:
Buildings $ 2,002 $ 2,487
Clinic equipment 1,534 1,381
Leasehold improvements 682 254
Computer and office equipment 627 290
------- -------
4,845 4,412
Less- Accumulated depreciation and
amortization (939) (537)
------- -------
3,906 3,875
Land 148 263
------- -------
$ 4,054 $ 4,138
======= =======
Intangible Assets:
Covenants not to compete and animal records $ 3,314 $ 3,351
Goodwill 8,359 7,960
------- -------
11,673 11,311
Less- Accumulated amortization (2,183) (1,402)
------- -------
$ 9,490 $ 9,909
======= =======
Accrued Expenses and Other Current Liabilities:
Payroll $ 246 $ 207
Professional services 252 139
Vacation 183 145
Settlement 200 350
Other 477 347
------- -------
$ 1,358 $ 1,188
======= =======
</TABLE>
F-92
<PAGE>
3. ACQUISITIONS:
------------
Since its inception, the Company has completed the acquisition of 19 veterinary
clinics (of which three have been merged into other clinics). All of the
acquisitions were accounted for using the purchase method of accounting;
accordingly, the costs of these acquisitions have been allocated to assets
acquired based on their fair value at date of acquisition. The results of the
acquired clinics are included in the Company's results commencing from the date
of acquisition.
During 1993, the Company completed the acquisition of four veterinary clinics
for total consideration of $6,733,000 consisting of $1,140,000 in cash,
$5,350,000 in secured promissory notes payable, $200,000 payable under covenants
not to compete, and the assumption of $43,000 in trade and payroll liabilities.
During 1994, the Company completed the acquisition of six veterinary clinics for
total consideration of $4,031,000 consisting of $862,000 in cash, $2,529,000 in
secured promissory notes payable, $325,000 payable under convenants not to
compete, 25,000 shares of newly issued common stock of the Company valued at
$15,000 and the assumption of $300,000 of notes payable.
In conjunction with one of the 1994 acquisitions, the Company advanced cash of
$100,000 to the seller in exchange for an unsecured note receivable. Under the
terms of the note, the Company will receive quarterly installments of interest
at a rate of 7.5% per annum, with the entire principal balance and all accrued
and unpaid interest due on November 1, 2004.
The Company is contingently obligated for additional purchase price
consideration related to one of its 1994 acquisitions. The amount to be paid
equals 50 percent of the amount by which the revenues for the twelve-month
period ending September 1997 exceed a base revenue amount. This additional
consideration will be recorded as additional purchase price when and if earned.
During 1995, the Company completed the acquisition of two veterinary clinics. In
April 1995, the Company acquired a veterinary hospital for a total consideration
of $218,000 consisting of $40,000 in cash, $25,000 in secured promissory note
payable, $15,000 payable under covenants not to compete, $31,000 payable under
an assumed lease obligation, and $32,000 in other assumed liabilities. The
agreement also requires an additional payment based on revenues derived from
pre-acquisition clients during the eighteen month period after the acquisition.
As such, the Company recorded additional purchase price and a liability of
$75,000 for the amounts expected to be paid in 1996. The purchase price will be
adjusted in 1996 to reflect the actual payment.
During 1995, a limited liability company (LLC) was formed by combining a
veterinary clinic owned by the Company (Spring Mountain Clinic) with the
practice of another veterinary clinic owned by an unrelated party. Certain
assets were contributed by each party to form the new entity, which is not
liable for any contracts or for any indebtedness relating to the predecessor
clinics. The Company has an 80% interest in the LLC. The Company has certain
obligations under an operating lease for the real property of the facility used
by the other member prior to the consolidation of the operations of the LLC into
the Spring Mountain clinic. Upon the occurrence of certain events, including an
initial public offering or merger with a public company (see Note 11), the
minority owner's interest may be converted into shares of the public entity.
F-93
<PAGE>
The pro forma results listed below are unaudited and reflect purchase price
accounting adjustments assuming the 1994 and 1995 acquisitions occurred at
January 1, 1994. The pro forma results are not necessarily indicative of what
actually would have occurred if the acquisitions had been in effect for the
entire periods presented. In addition, they are not intended to be a projection
of future results and do not reflect any efficiencies that might be achieved
from the combined operations.
<TABLE>
<CAPTION>
1995 1994
---------- --------
<S> <C> <C>
Revenues $15,863 $13,426
Net loss (1,962) (3,004)
</TABLE>
4. LONG-TERM OBLIGATIONS:
----------------------
Long-term obligations consisted of the following (in thousands, except share
data):
<TABLE>
<CAPTION>
December 31,
---------------------------
1995 1994
---------- ---------
<S> <C> <C>
Promissory notes, secured by clinics, bearing
interest at interest rates between 7% and 10%
payable monthly, principal is generally due in
monthly installments through July 2014 $ 7,517 $ 8,285
Promissory note, interest at prime plus 3%
(11.75% at December 31, 1995), principal and
interest payable in monthly installments through 133 154
July 2000
Convertible promissory note payable to a
shareholder, officer and director, secured by a
clinic, interest at 9% per annum payable
semi-annually, principal due July 1996,
convertible into 75,000 shares of common stock 250 250
Convertible promissory notes, secured by clinics,
interest at 7% per annum payable monthly,
principal due through December 2003, convertible
into 88,625 shares of common stock 649 649
Convertible promissory note payable to an
employee, secured by a clinic, interest at 8.5%
per annum, interest and principal payable in
monthly installments from January 1994 through
December 1998, convertible into 100,000 shares of
common stock 671 686
Convertible promissory notes payable primarily to
directors and stockholders, secured by common
stock and key man life insurance, interest at 12%
per annum payable annually, principal due
December 1998, convertible into shares of common
stock at a conversion rate of $0.6233 183 272
Convertible promissory notes payable primarily
to stockholders, interest at 12%, repaid at
maturity on January 1, 1996 307 307
</TABLE>
F-94
<PAGE>
<TABLE>
<CAPTION>
December 31,
--------------------
1995 1994
-------- --------
<S> <C> <C>
Obligations under covenants not to compete,
payable in installments through 2003 782 1,005
Installment obligations bearing interest at 8% to
10.25%, due through 2005 295 -
Installment obligations, variable interest rates,
periodic installments due through 1996 - 131
Capital lease obligations (see Note 9) 69 -
------- -------
Total obligations 10,856 11,739
Less- Unamortized portion of discount on notes
payable (18) (51)
Less- Current portion (1,412) (702)
------- -------
Total long-term obligations $ 9,426 $10,986
======= =======
</TABLE>
Future principal payments, excluding capital lease obligations (see Note 9), are
as follows (in thousands):
<TABLE>
<CAPTION>
Year Ending
December 31,
------------
<S> <C>
1996 $ 1,398
1997 1,650
1998 1,555
1999 476
2000 429
Thereafter 5,279
-------
$10,787
=======
</TABLE>
In 1995, the Company restructured a $50,000 payment under a covenant not to
compete to extend the payment date to 1997. In consideration of the extension,
the Company committed to issue 2,500 shares of the Company's common stock and
granted an option to convert the $50,000 into the Company's common stock at
$2.50 per share. No shares have been issued under this agreement as of December
31, 1995.
Convertible Promissory Notes Issued with Stock Warrants
- -------------------------------------------------------
Under the terms of a financing agreement the Company entered into during 1993,
the Company issued convertible promissory notes with a face value of $1,348,000,
warrants to purchase 404,250 shares of common stock at an exercise price of
$0.50 per share and warrants to purchase 404,250 shares of Series B Convertible
Preferred Stock at an exercise price of $0.50 per share. The common warrants may
be exercised at any time until their expiration in December 1998. The preferred
warrants allowed for exercise until December 1998 or upon repayment or
conversion of the promissory notes. The estimated fair value of the warrants has
been recorded as discount on notes payable and is being amortized over the term
of the notes. In 1994 and 1995, 645,000 and 53,464 shares of common stock were
issued
F-95
<PAGE>
upon exercise and surrender of warrants, respectively. All shares were issued at
a reduced exercise price under the terms of the agreement for the issuance of
Series A Preferred Stock.
In December 1993, the Company received $500,000 in cash for a $500,000
convertible promissory note and a subscription for 500,000 shares of Series C
Preferred stock valued at $0.40 per share. These proceeds have been allocated
among the note payable and the stock subscription, with the difference between
the face value and the proceeds being recorded as discount on notes payable and
amortized over the term of the note. The face value of the note was $500,000 and
bears interest at 12%.
During 1994, notes payable with a face value of $1,575,000 were converted into
2,441,358 shares of common stock including shares for interest thereon. The
Company also issued convertible promissory notes with a face value of $307,000
together with warrants to purchase 127,813 shares of common stock at an exercise
price of $2.40 per share. The common warrants expire in December 1998.
5. REDEEMABLE CONVERTIBLE PREFERRED STOCK:
--------------------------------------
The Company's articles of incorporation authorize the issuance of up to
5,000,000 shares of Preferred Stock, 2,000,000 of which have been designated
redeemable convertible preferred stock.
The Redeemable Preferred Stock has certain rights, preferences and restrictions.
Each share of Redeemable Preferred Stock is convertible into one and one-half
shares of common stock, subject to adjustment for dilution, at the option of the
holder. The Redeemable Preferred Stock automatically converts to common stock
upon the sale of common stock by the Company pursuant to an effective
registration statement under the Securities Act of 1933 at a price per share of
at least $5.25.
The Company's articles of incorporation cannot be amended to alter in an adverse
manner the designations, preferences or other rights of the Redeemable Preferred
Stock without the consent of the holders of a majority of the outstanding shares
of Redeemable Preferred Stock, voting together as a class. Similar consent is
required for a change to the Company's articles of incorporation that
establishes, authorizes or enlarges a series of any class of capital stock
ranking senior to the Redeemable Preferred Stock. The Redeemable Preferred Stock
shareholders have no additional voting rights.
At its option, the Company may redeem the then outstanding shares of Redeemable
Preferred Stock at any time after October 15, 1994 at a redemption price of
$3.50 per share plus all declared but unpaid dividends. On October 15, 2001, any
shares of Redeemable Preferred Stock remaining outstanding must be redeemed at a
redemption price of $3.50 per share plus all declared but unpaid dividends.
In the event of liquidation, the holders of the Redeemable Preferred Stock are
entitled to receive, prior to and in preference to any distribution to the
holders of common stock, the amount of $3.50 plus any accrued but unpaid
dividends. After such distribution, holders of the Redeemable Preferred Stock
are entitled to no further participation in the remaining assets of the Company.
The holders of Preferred stock are entitled to receive, when and as declared by
the Board of Directors, cash dividends per share in the amounts determined by
the Board of Directors.
F-96
<PAGE>
The Redeemable Preferred Stock is on parity with all other preferred stock.
6. CONVERTIBLE PREFERRED STOCK
---------------------------
Series A Preferred Stock
- ------------------------
In October 1994, the Company entered into an agreement whereby the Company sold
35,000 shares of Series A Preferred Stock to an investor at a price of $100 per
share (par value $0.01 per share). Also pursuant to the agreement, approximately
$1,575,000 of the Company's 12% Convertible Promissory Notes was converted into
Common Stock. The agreement also limits the number of preferred stock purchase
warrants which may be issued.
The agreement also required a reduction in the number of directors. In
conjunction with this reduction, the Company issued certain directors 270,000
shares of common stock for no consideration (see Note 7). The fair value of
these shares has been recorded as issuance costs of the Series A Preferred
Stock.
Concurrent with the closing, a director and shareholder agreed to purchase 5,000
shares of the Series A Preferred Stock for an aggregate consideration of
$500,000. Through December 31, 1995, the Company had received payments totaling
$300,000 pursuant to which 3,000 shares were issued. The remaining $200,000 was
received in 1996, at which time the remaining subscribed shares were issued. The
Series A Preferred Stock has certain rights, preferences and restrictions.
The Series A Preferred Stock is on a parity with all other "Convertible
Preferred Stock" and "Series B Convertible Preferred Stock," when issued. The
Series A is senior to Common Stock.
Holders of the Series A Preferred Stock are entitled to receive, when and if
declared by the Board of Directors, cumulative dividends at the annual rate of
7.5% times the stated value ($100 per share); provided, however, that dividends
must also have been declared on the "Convertible Preferred Stock" and the
"Series B Convertible Preferred Stock."
In the event of any voluntary or involuntary liquidation or dissolution, the
holders of Series A Preferred Stock are entitled to an amount equal to $125 per
share, plus accrued and unpaid dividends.
Series A shareholders may convert such shares into shares of Common Stock at a
rate equal to the stated value plus accrued and unpaid dividends, divided by the
conversion price. The initial conversion price is $2.50 per share. Shares of
Series A will be converted into shares of Common Stock at the conversion rate
should the Company file a registration statement for a common share offering
with aggregate gross proceeds of at least $7,500,000.
Series A holders and the Common Stock class will vote together as a class on
transactions and each share of Series A is entitled to the number of votes per
share equal to the number of shares of Common Stock issuable upon conversion of
the Series A. However, as long as at least 10,000 shares of Series A are issued
and outstanding, the Board of Directors shall not exceed five members and the
holders of Series A are entitled (voting as a class) to elect in person or by
proxy one director. If less than 10,000 shares are issued and outstanding, the
term of the director elected by the Series A shall end and the remaining
directors shall fill the vacancy. In addition, there are voting rights to
prevent the establishment of new capital stock classes and enlargement of
existing classes.
F-97
<PAGE>
Series B Preferred Stock Warrants
- ---------------------------------
During 1994 and 1995, outstanding warrants for Series B Preferred Stock were
surrendered to the Company for the direct issuance of shares of common stock
into which the Series B Preferred Stock were convertible. As of December 31,
1995, warrants to purchase 55,018 shares of Series B Preferred Stock at an
exercise price of $0.50 were outstanding.
7. COMMON STOCK:
------------
During 1994, the Company issued 25,000 shares of common stock as part of the
consideration for acquisition of a clinic and 357,903 shares of common stock for
repayment of promissory note interest.
During 1993 and 1994 the Company issued certain equity securities to investors.
In early 1996 the Company determined that such issuances were technically
invalid due to the lack of filing legal documents in some states on a timely
basis. Effective 1994, the Company's board of directors has resolved to issue
537,500 shares of common stock in exchange for the surrender of one class of
such equity securities and to issue 322,500 shares of common stock in exchange
for the surrender of the other class of such equity securities. Such shares of
common stock represent the number of shares into which the invalidly issued
securities were originally converted in 1994.
Common Stock Warrants
- ---------------------
In addition to the common stock warrants discussed in Note 4, the Company, as of
December 31, 1995, has warrants outstanding to purchase 108,544 common shares at
exercise prices ranging from $0.50 to $2.66 per share. These warrants are
exercisable at the option of the holder and expire on December 31, 1998. A
nominal value was assigned to the warrants.
Common Stock Options
- --------------------
In July 1991, the Company granted an officer and director options to purchase
162,000 shares of the Company's common stock at a price of $0.50 per share. The
options, which are currently exercisable, expire in July 2001.
In 1992 and 1993, the Board of Directors authorized the grant of options to
officers of the Company to purchase 197,500 shares of common stock at a price of
$2.33 per share. The options, which are currently exercisable, expire in
December 2002.
In January 1992, the Board of Directors adopted a resolution which provides for
the grant of common stock options to directors who are not employees of the
Company (the "Outside Directors"). Under the resolution, each of the Outside
Directors received options to purchase 54,000 shares of Common Stock at an
exercise price per share of $1.67. Such options vest ratably over a four year
period. In 1994, certain directors were required to resign, pursuant to the
Stock Purchase Agreement for the issuance of Series A Preferred Stock. In
consideration for the reconstitution of the Board of Directors, the Outside
Directors' options became fully vested and the exercise price was reduced to
zero. The fair value of the options were recorded as an issuance cost of the
Series A Preferred Stock.
F-98
<PAGE>
In 1994, the Board of Directors granted options to purchase 141,500 shares of
Common Stock at a price of $2.75 per share to employees. These options, which
are currently exercisable, expire in 2004 .
A summary of the stock option activity follows:
<TABLE>
<CAPTION>
Number Price
of Shares Per Share
---------- ---------
<S> <C> <C>
Balance at December 31, 1992 421,500 $0.50 - $2.33
Granted 208,000 $2.33
Exercised - -
Canceled - -
--------
Balance at December 31 ,1993 629,500 $0.50 - $2.33
Granted 141,500 $2.75
Exercised (270,000) -
Canceled - -
--------
Balance at December 31, 1994 501,000 $0.50 - $2.75
Granted 2,500 $2.75
Exercised - -
Canceled - -
--------
Balance at December 31, 1995 503,500 $0.50 - $2.75
========
Exercisable at December 31, 1995 503,500 $0.50 - $2.75
========
</TABLE>
8. INCOME TAXES:
------------
No provision for income taxes has been recorded as the Company has incurred
losses since its inception.
At December 31, 1995, the Company has federal and state net operating loss
("NOL") carryforwards of approximately $6.5 million and $3.2 million,
respectively. These NOL carryforwards expire at various dates through 2010 and
2000, respectively.
Deferred tax assets of approximately $2.6 million and $1.9 million, resulting
primarily from NOL carryforwards, were fully offset by a valuation allowances as
of December 31, 1995 and 1994 due to the uncertainty of realization.
Under the Tax Reform Act of 1986, the utilization of NOL carryforwards to reduce
taxable income will be restricted in certain circumstances. Events which cause
such a limitation include, but are not limited to, a cumulative ownership change
of more than 50% over a three year period. Management believes that the issuance
of Convertible Preferred Stock during 1994 caused such a change in ownership
and, accordingly, utilization of NOL carryforwards may be limited in future
years.
F-99
<PAGE>
9. COMMITMENTS AND CONTINGENCIES:
-----------------------------
The Company leases clinic and office facilities under noncancelable operating
lease agreements. The leases require the Company to pay property taxes,
maintenance and certain insurance expenses. Total rent expense under the
operating leases was $944,000, $584,000 and $436,000 for the years ended
December 31, 1995, 1994 and 1993, respectively.
Minimum future lease payments under non-cancelable operating and capital leases
are as follows (in thousands):
<TABLE>
<CAPTION>
Year Ending Operating Capital
December 31, Leases Leases
------------ --------- --------
<S> <C> <C>
1996 $ 859 $ 24
1997 817 24
1998 824 24
1999 762 21
2000 753 4
Thereafter 6,430 -
------- ---
$10,445 97
======= ---
Less- Amounts representing
interest (28)
----
Present value of net minimum
lease payments $ 69
====
</TABLE>
The cost of equipment under capital lease included in the balance sheet as
property and equipment as of December 31, 1995 was approximately $78,000.
Accumulated amortization of the leased equipment as of December 31, 1995 was
approximately $13,000.
In February 1996, the Company settled a wrongful termination claim in which it
was the defendant. The settlement amount of approximately $200,000 approximated
the accrued amount as of December 31, 1995 related to this matter.
Various claims arising in the course of business, seeking monetary damages, are
pending. The amount of liability, if any, from such claims cannot be determined
with certainty; however, in the opinion of management, the ultimate outcome of
such claims will not have a material adverse effect on the Company's financial
position, results of operations or cash flows.
F-100
<PAGE>
10. DISCLOSURES ABOUT FAIR VALUE OF FINANCIAL INSTRUMENTS:
-----------------------------------------------------
The following disclosure of the estimated fair value of the Company's debt is
made in accordance with the requirements of SFAS No. 107, "Disclosures about
Fair Value of Financial Instruments." The estimated fair value amounts have been
determined by the Company using available market information and appropriate
valuation methodologies. Considerable judgment is required to develop the
estimates of fair value, thus the estimates provided therein are not necessarily
indicative of the amounts that could be realized in a current market exchange.
<TABLE>
<CAPTION>
December 31, 1995
-----------------
Carrying Fair
Amount Value
-------- -------
<S> <C> <C>
Fixed-rate long-term debt $10,723 $10,427
Variable rate long-term debt 133 139
------- ------
$10,856 $10,566
======= ======
</TABLE>
The estimated fair value of the Company's fixed-rate long-term debt is based on
prime plus an estimated spread at December 31, 1995 for similar securities with
similar remaining maturities.
11. SUBSEQUENT EVENTS:
-----------------
In February, 1996 the Company entered into a merger agreement with Veterinary
Centers of America, Inc. (VCA). Under terms of the agreement, which is intended
to qualify for pooling-of-interests accounting, stockholders and rights holders,
as defined, are to receive shares with a market value on March 20, 1996 of
approximately $25 million.
F-101
<PAGE>
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
----------------------------------------
To the Board of Directors and Stockholders of
Veterinary Centers of America, Inc.:
We have audited the accompanying balance sheet of SOUTHWEST VETERINARY
DIAGNOSTICS, INC. (an Arizona corporation) as of December 31, 1995, and the
related statements of operations, stockholder's equity and cash flows for the
year then ended. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
financial statements based on our audit.
We conducted our audit in accordance with generally accepted auditing standards.
Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audit provides a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Southwest Veterinary
Diagnostics, Inc. as of December 31, 1995, and the results of its operations and
its cash flows for the year then ended in conformity with generally accepted
accounting principles.
/s/ ARTHUR ANDERSEN LLP
-----------------------
ARTHUR ANDERSEN LLP
Los Angeles, California
March 22, 1996
F-102
<PAGE>
SOUTHWEST VETERINARY DIAGNOSITICS, INC.
---------------------------------------
BALANCE SHEET - DECEMBER 31, 1995
---------------------------------
ASSETS
------
<TABLE>
<S> <C>
CURRENT ASSETS:
Cash $ 293,800
Accounts receivable, net of allowance
for doubtful accounts of $260,000 998,600
Supplies inventory 109,400
Prepaid expenses 29,900
Note receivable 75,000
----------
Total current assets 1,506,700
PROPERTY, PLANT AND EQUIPMENT, net 1,393,000
OTHER ASSETS 8,400
----------
$2,908,100
==========
</TABLE>
The accompanying notes are an integral part of this balance sheet.
F-103
<PAGE>
SOUTHWEST VETERINARY DIAGNOSTICS, INC.
--------------------------------------
BALANCE SHEET - DECEMBER 31, 1995
---------------------------------
LIABILITIES AND STOCKHOLDERS' EQUITY
------------------------------------
<TABLE>
<S> <C>
CURRENT LIABILITIES:
Accounts payable $ 108,500
Current portion of long-term debt 146,400
Current portion of bank line of credit 26,700
Accrued payroll 186,500
Accrued expenses 27,600
----------
Total current liabilities 495,700
LONG-TERM DEBT, less current portion 386,800
BANK LINE OF CREDIT, less current portion 173,300
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Common stock, $1 par value:
Authorized--100,000 shares
Issued and outstanding--15,000 shares 15,000
Accumulated earnings 1,837,300
----------
Total stockholders' equity 1,852,300
----------
$2,908,100
==========
</TABLE>
The accompanying notes are an integral part of this balance sheet.
F-104
<PAGE>
SOUTHWEST VETERINARY DIAGNOSTICS, INC.
--------------------------------------
STATEMENT OF OPERATIONS
-----------------------
FOR THE YEAR ENDED DECEMBER 31, 1995
------------------------------------
<TABLE>
<S> <C>
REVENUES $10,604,800
DIRECT COST OF SERVICES 6,094,300
-----------
GROSS PROFIT 4,510,500
OPERATING EXPENSES:
Selling, general and administrative expenses 3,363,700
Officers' salaries 500,800
Depreciation and amortization 332,000
-----------
OPERATING INCOME 314,000
OTHER INCOME (EXPENSE):
Other income 175,300
Interest expense (88,400)
-----------
NET INCOME $ 400,900
===========
</TABLE>
The accompanying notes are an integral part of this financial statement.
F-105
<PAGE>
SOUTHWEST VETERINARY DIAGNOSTICS, INC.
--------------------------------------
STATEMENT OF STOCKHOLDERS' EQUITY
---------------------------------
FOR THE YEAR ENDED DECEMBER 31, 1995
------------------------------------
<TABLE>
<CAPTION>
Common Stock
------------ Accumulated
Shares Amount Earnings
------ ------ -----------
<S> <C> <C> <C>
BALANCE, December 31, 1994 15,000 $15,000 $1,465,400
Net income -- -- 400,900
Cash distributions to stockholders -- -- (29,000)
------ ------- ----------
BALANCE, December 31, 1995 15,000 $15,000 $1,837,300
====== ======= ==========
</TABLE>
The accompanying notes are an integral part of this financial statement.
F-106
<PAGE>
SOUTHWEST VETERINARY DIAGNOSTICS, INC.
--------------------------------------
STATEMENT OF CASH FLOWS
-----------------------
FOR THE YEAR ENDED DECEMBER 31, 1995
------------------------------------
<TABLE>
<S> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $ 400,900
Adjustment to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization 332,000
Provision for doubtful accounts 221,000
Changes in operating assets and liabilities:
Increase in accounts receivable (85,400)
Decrease in supplies inventory 9,300
Decrease in prepaid expenses 4,700
Decrease in note receivable 100,000
Decrease in other assets 92,200
Decrease in accounts payable (13,800)
Increase in accrued payroll 41,600
Increase in accrued expenses 13,300
Decrease in deferred revenue (175,000)
---------
Net cash provided by operating activities 940,800
---------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment (342,300)
Proceeds from disposal of fixed assets 4,700
---------
Net cash used in investing activities (337,600)
---------
CASH FLOWS FROM FINANCIAL ACTIVITIES:
Principal payments on long-term debt and bank line of credit (313,600)
Proceeds of long-term debt and bank line of credit 31,800
Principal payments on capital leases (49,700)
Cash distributions to stockholders (29,000)
---------
Net cash used in financing activities (360,500)
---------
NET INCREASE IN CASH 242,700
CASH, beginning of year 51,100
---------
CASH, end of year $ 293,800
=========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid $ 88,400
=========
</TABLE>
The accompanying notes are an integral part of this financial statement.
F-107
<PAGE>
SOUTHWEST VETERINARY DIAGNOSTICS, INC.
--------------------------------------
NOTES TO FINANCIAL STATEMENT
----------------------------
DECEMBER 31, 1995
-----------------
1. THE COMPANY
-----------
Southwest Veterinary Diagnostics, Inc. ("the Company") was incorporated in
Arizona in January 1, 1978. The Company operates veterinary medical
laboratories in Phoenix, Arizona; Kansas City, Missouri; and Dallas, Texas.
These operating facilities serve veterinary clinics throughout 15 states. Of
the customer base, 55 percent is attributable to California.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
------------------------------------------
a. Supplies Inventory
------------------
Supplies inventory consists of laboratory reagents and supplies used for
test analysis and is stated at the lower of cost or market value using the
first-in, first-out method.
b. Property and Equipment
----------------------
Property and equipment is stated at cost. Depreciation is computed
principally using the straight-line method over the estimated useful lives
of the assets which range from 5 to 40 years.
Expenditures for additions and improvements are capitalized, and costs of
normal repairs and maintenance are expensed as incurred. The cost and
accumulated depreciation of property and equipment retired or otherwise
disposed of are eliminated and any resulting gain or loss is recognized at
the time of disposal.
c. Financial Instruments
---------------------
The fair value of the Company's financial instruments, including cash and
the installment note receivable, approximate their carrying value.
F-108
<PAGE>
3. PROPERTY, PLANT AND EQUIPMENT
-----------------------------
Property, plant and equipment at December 31, 1995 consist of the following:
<TABLE>
<S> <C>
Land $ 325,200
Furniture and equipment 1,879,200
Building improvements 209,500
Transportation equipment 149,200
Capitalized equipment leases 856,300
----------
3,419,400
Less--Accumulated depreciation
and amortization (2,026,400)
----------
Property, plant and equipment,
net $1,393,000
==========
</TABLE>
Accumulated depreciation on equipment held under capital leases amounted to
$319,626 at December 31, 1995.
4. BANK LINES OF CREDIT
--------------------
The Company has a revolving line of credit providing for borrowings up to
$600,000, interest payable monthly at prime, plus 1.5 percent. Unpaid principal
and interest are due May, 1996. There was no balance outstanding on the line as
of December 31, 1995. The line of credit is collateralized by accounts
receivable and inventory and is guaranteed by stockholders. The note contains
restrictive covenants limiting fixed asset purchases and requiring that certain
financial ratios be maintained. At December 31, 1995, all covenants have been
met. The interest rate in effect at December 31, 1995 was 10 percent.
The Company has a line of credit providing for borrowings up to $400,000, due in
monthly payments at 1.5 percent over prime. Borrowings on the line totaled
$200,000 at December 31, 1995. The remaining principal and interest are due
April, 2001. The line of credit is collateralized by laboratory equipment and is
guaranteed by stockholders. The note contains restrictive covenants limiting
fixed asset purchases and requiring that certain financial ratios be maintained.
At December 31, 1995, the Company was in compliance with these covenants. The
interest rate in effect at December 31, 1995 was 10 percent.
F-109
<PAGE>
5. LONG TERM DEBT
--------------
Long-term debt consists of the following:
Note payable, due in monthly installments of approximately
$10,900 interest at bank prime rate plus 1.5 percent
(currently at 10 percent), collateralized by equipment,
receivables and a second deed of trust on a building owned
by a related partnership (see Note 9) and guaranteed by
the stockholders of the Company, due through
September, 1999. $487,500
Note payable, due in monthly installments of approximately
$1,000 including interest at 10 percent, maturing
December, 1998, collateralized by a vehicle. 31,800
Capital lease obligations, due through 1998 13,900
--------
533,200
Less--Current portion (146,400)
--------
$386,800
========
The lending agreements contain various restrictive covenants limiting the amount
of fixed asset purchases and the requirement to maintain specified financial
ratios. As of December 31, 1995 the Company was not in compliance with certain
restrictive covenants. The Company obtained a waiver from the bank related to
these covenants.
At December 31, 1995, long-term debt maturing in the next five years consists
of the following:
1996 $146,400
1997 145,200
1998 144,100
1999 97,500
Thereafter -
--------
533,200
========
6. EMPLOYEE BENEFIT PLANS
----------------------
Effective October 1, 1991, the Company adopted a qualified 401(k) employee
savings and profit sharing plan for the benefit of substantially all employees.
Under the plan, employees can defer a portion of their compensation and
contribute it to the plan. Matching contributions are made at the sole
discretion of the Board of Directors. The plan's trustees are officers of the
Company. The Company's policy is to fund profit sharing costs as incurred.
Profit sharing expense was $4,800 for the year ended December 31, 1995.
F-110
<PAGE>
7. COMMITMENTS AND CONTINGENCIES
-----------------------------
Leasing Arrangements
- --------------------
The Company entered into a lease in September, 1991, for Kansas City, Missouri
operating facilities. This lease requires future minimum rentals of
approximately $1,460 a month through March, 1996. Rent on this facility was
approximately $19,000 for the year ended December 31, 1995.
The Company entered into a lease in March, 1993 for Dallas, Texas operating
facilities. This lease requires future minimum rentals of approximately $1,700
a month through March, 1998. Rent on this facility was approximately $21,000 for
the year ended December 31, 1995.
The Company is obligated under operating leases for various equipment and
automobiles. These leases require monthly payments ranging from approximately
$1,000 to $1,800, expiring November, 1996 through October, 1998. Payments under
these leases were approximately $44,000 for the year ended December 31, 1995.
The Company leases certain equipment under capital leases with noncancellable
terms through 1998.
Future minimum payments at December 31, 1995 are as follows:
Capital Operating
Leases Leases
-------- ---------
1996 $ 8,100 $ 88,000
1997 5,000 76,000
1998 2,500 42,000
1999 - -
2000 - -
------- --------
15,600 $206,000
Less-Amount representing interest (1,700) ========
-------
Present value of net minimum
lease payments $13,900
=======
PENDING OR THREATENED LITIGATION
- --------------------------------
The Company from time to time is a party to various legal proceedings which are
incidental to its business. In the opinion of management, the ultimate
resolution of these proceedings will not have a material adverse effect on the
Company's financial position or results of operations.
F-111
<PAGE>
8. INCOME TAXES
------------
The Company is taxed as a Subchapter-S corporation under Section 1362 of the
Internal Revenue Code and related state statutes. Under this provision, all
income is taxed directly to the stockholders of the Company.
9. RELATED PARTY TRANSACTIONS
--------------------------
The Company rents, on a month-to-month basis, certain operating facilities and
equipment from a partnership in which the officers of the Company are partners.
The amount of rent is subject to change based upon fluctuations in the prime
interest rate and changes in operating expenses. Rent expense pursuant to this
arrangement was approximately $65,000 for the year ended December 31, 1995.
In December, 1994 the Company entered into a joint venture with Veterinary
Diagnostics Services, Inc. (VDS) to operate a Portland laboratory. The Company
obtained a 50 percent interest as one of two general partners in the
joint venture for nominal consideration. During 1995 the Company sold a customer
list valued at $175,000 to the joint venture. As of December 31, 1995 the
balance due on the related note receivable was $75,000.
In August 1995, the Company entered into a six month consulting agreement with
VDS providing for payment of $10,000 per month. Additionally, in August 1995,
the Company sold its 50 percent interest in the joint venture to VDS for
nominal consideration.
10. SUBSEQUENT EVENT
----------------
On March 4, 1996 Veterinary Centers of America, Inc. ("VCA"), acquired
substantially all of the assets and assumed certain of the liabilities of the
Company. Under the terms of the acquisition agreement, liabilities not assumed
by VCA were assumed by the former stockholders of the Company.
F-112
<PAGE>
APPENDIX A
AGREEMENT AND PLAN OF REORGANIZATION
BY AND AMONG
VETERINARY CENTERS OF AMERICA, INC.
GOLDEN MERGER CORPORATION
AND
THE PET PRACTICE, INC.
MARCH 21, 1996
<PAGE>
TABLE OF CONTENTS
-----------------
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
AGREEMENT AND PLAN OF REORGANIZATION........................ 2
RECITALS.................................................... 2
AGREEMENT................................................... 2
1. Definitions............................................ 2
2. The Merger............................................. 7
2.1. Execution, Filing, Effective Time............... 7
2.2. Constituent and Surviving Corporations.......... 7
2.3. Certificate of Incorporation and Bylaws......... 8
2.4. Board of Directors and Officers................. 8
2.5. Conversion of the Company Common Stock.......... 8
2.6. Company Purchase Rights......................... 10
2.7. Closing of Transfer Books....................... 11
2.8. Related Agreement............................... 11
3. Closing Date........................................... 11
4. Representations and Warranties of the Company.......... 12
4.1. Organization and Standing; Articles and By-
Laws............................................ 12
4.2. Authorization................................... 12
4.3. No Consents..................................... 13
4.4. Capital Stock................................... 13
4.5. Subsidiaries.................................... 14
4.6. SEC Reports and Financial Statement............. 14
4.7. Absence of Certain Changes or Events............ 15
4.8. Litigation...................................... 16
4.9. Tax Returns..................................... 16
4.10. Properties, Encumbrances........................ 17
4.11. Personal Property............................... 18
4.12. Employee Benefit Plans.......................... 18
4.13. Certain Agreements.............................. 18
4.14. Compliance With Applicable Law.................. 19
4.15. Environmental Compliance Matters................ 19
4.16. No Brokers...................................... 20
4.17. Registration Statement; Proxy Statement/Pros-
pectus.......................................... 20
4.18. Information..................................... 21
4.19. Tax Free Merger................................. 21
4.20. Related Party Indebtedness and Obligations...... 21
4.21. No Dissenters Rights............................ 21
4.22. Stockholder Intention to Sell................... 21
5. Representations and Warranties of the Parent........... 21
5.1. Organization and Standing; Articles and By-
Laws............................................ 22
5.2. Authorization................................... 22
5.3. No Consents..................................... 22
</TABLE>
i
<PAGE>
<TABLE>
<S> <C>
5.4. Capitalization.................................. 23
5.5. Authorization of Parent Common Stock............ 24
5.6. SEC Reports..................................... 24
5.7. Absence of Certain Changes or Events............ 25
5.8. Litigation...................................... 25
5.9. Compliance With Applicable Law.................. 25
5.10. No Brokers...................................... 26
5.11. Registration Statement; Proxy
Statement/Prospectus............................ 26
5.12. Information..................................... 26
5.13. Tax Free Merger................................. 26
6. Pre-Merger Covenants of Parent and the Company......... 27
6.1. Conduct of Business by the Company.............. 27
6.2. Conduct of Business by Parent................... 29
6.3. Inspection of Records........................... 30
6.4. Stockholder Approval............................ 30
6.5. Registration Statement; Proxy Statement......... 30
6.6. Agreements by Affiliated Stockholders of the
Company......................................... 31
6.7. Expenses........................................ 31
6.8. Reorganization.................................. 31
6.9. Filings; Other Action........................... 31
6.10. Publicity....................................... 32
6.11. Acquisition Proposals........................... 32
6.12. Indemnification................................. 33
7. Conditions to Each Party's Obligation to Effect the
Merger................................................. 34
7.1. Stockholder Approval............................ 34
7.2. Hart Scott Act.................................. 34
7.3. No Legal Action................................. 34
7.4. Registration Statement Effective................ 34
7.5. Listing of Additional Shares on NMS............. 34
7.6. Tax Opinion..................................... 34
7.7. Trading Activity................................ 34
8. Additional Conditions to Obligations of the Parent..... 35
8.1. Representations, Covenants, Certificate......... 35
8.2. Permits and Approvals........................... 35
8.3. No Adverse Change............................... 35
8.4. Certain Legal Matters........................... 35
8.5. Certificate..................................... 36
8.6. Opinion of Counsel for the Company.............. 36
8.7. Comfort Letter.................................. 36
8.8. Rule 145 Affiliates............................. 36
8.9. Agreements with Certain Stockholders............ 36
9. Additional Conditions to the Obligations of the
Company................................................ 37
9.1. Representations, Covenants, Certificate......... 37
</TABLE>
ii
<PAGE>
<TABLE>
<S> <C>
9.2. Certain Legal Matters........................... 37
9.3. Certificate..................................... 37
9.4. Opinion of Counsel for Parent and Sub........... 37
10. Termination............................................ 37
10.1. Termination..................................... 37
10.2. Effect of Termination........................... 38
11. Miscellaneous Provisions............................... 39
11.1. Notices......................................... 39
11.2. Severability.................................... 40
11.3. Exhibits and Schedules.......................... 40
11.4. Governing Law................................... 40
11.5. No Adverse Construction......................... 40
11.6. Counterparts.................................... 40
11.7. Costs and Attorneys' Fees....................... 40
11.8. Successors and Assigns.......................... 40
11.9. Amendment....................................... 40
11.10. Waiver.......................................... 41
11.11. Entire Agreement................................ 41
11.12. Best Efforts.................................... 41
11.13. Survival of Representations and Warranties...... 41
</TABLE>
iii
<PAGE>
AGREEMENT AND PLAN OF REORGANIZATION
This Agreement and Plan of Reorganization (the "Agreement") is made and
entered into as of March 21, 1996, by and among THE PET PRACTICE, INC., a
Delaware corporation (the "Company"), GOLDEN MERGER CORPORATION, a Delaware
corporation ("Sub"), and VETERINARY CENTERS OF AMERICA, INC., a Delaware
corporation ("Parent"), with respect to the following:
R E C I T A L S
---------------
A. The Board of Directors of Parent, the Company and Sub each has
determined that a business combination among Parent, the Company and Sub is in
the best interest of their respective companies and shareholders and presents an
opportunity for their respective companies to achieve long-term strategic and
financial benefits, and accordingly the parties have agreed to effect the merger
provided for herein (the "Merger") upon the terms and subject to the conditions
set forth herein.
B. For federal income tax purposes, it is intended that the Merger shall
qualify as a tax-free reorganization within the meaning of Section 368(a) of the
Internal Revenue Code of 1986, as amended (the "Code"), and for financial
accounting purposes shall be accounted for as a purchase.
C. Parent, Sub and the Company desire to make certain representations,
warranties and agreements in connection with the Merger.
D. Parent and the Company jointly desire that Parent acquire all of the
issued and outstanding stock of the Company.
E. The parties have determined that the most expeditious manner of
accomplishing such acquisition would be the merger of the Company with and into
Sub (the "Merger").
F. The parties hereto desire to adopt a Plan of Reorganization within the
meaning of Section 368(a) of the Code.
A G R E E M E N T
-----------------
NOW, THEREFORE, in consideration of the foregoing and of the
representations, warranties, covenants and agreements contained herein, the
parties to this Agreement hereby agree as follows:
1. DEFINITIONS. As used in this Agreement, terms defined in the preamble
-----------
and recitals hereto shall have the respective meanings specified therein and the
following terms shall have the meanings set forth below:
2
<PAGE>
(a) "AFFILIATE" means, when used with reference to a specified
Person, any Person that directly or indirectly through one or more
intermediaries controls or is controlled by, or is under common control with,
the specified Person.
(b) "AGREEMENT" shall mean this Agreement and Plan of
Reorganization.
(c) "AVERAGE PRICE" shall mean the average of the closing prices
of the Parent Common Stock on the NMS (as reported by the Wall Street Journal,
or if not so reported as reported by another authoritative source) over the 20
trading day period ending on (and including) the third trading day immediately
preceding the date of the meeting of the Stockholders contemplated in Section
6.4. For purposes of the preceding sentence, a "trading day" means a day on
which trading generally takes place on the NMS and on which trading in shares of
Parent Common Stock occurred.
(d) "CODE" shall mean the Internal Revenue Code of 1986, as
amended.
(e) "COMPANY" shall mean The Pet Practice, Inc., a Delaware
corporation.
(f) "COMPANY COMMON STOCK" shall mean the Common Stock, par
value $0.01 per share, of the Company.
(g) "COMPANY PURCHASE RIGHTS" shall mean each outstanding option,
purchase right, subscription or other right or agreement or commitment of any
character relating to the issuance of shares of Company Common Stock (including,
without limitation, options or rights that may be issued and outstanding under
the Company Stock Option Plan or pursuant to any contingent payment provision
contained in any agreement pursuant to which the Company acquired any of its
Veterinary Hospitals).
(h) "COMPANY SECURITIES" shall mean the Company Common Stock
and the Company Purchase Rights.
(i) "CONTROL" (including as used in the terms "controlling,"
"controlled by" and "under common control with") of a Person means the
possession, direct or indirect, of the power to direct or cause the direction of
the management and policies of a Person, whether through the ownership of voting
securities, by contract, or otherwise.
(j) "DELAWARE LAW" shall mean the General Corporation Law of the
State of Delaware.
(k) "EXCHANGE ACT" shall mean the Securities Exchange Act of
1934, as amended.
3
<PAGE>
(l) "EXCHANGE FACTOR" shall be determined by reference to the
following formula: (i) if the Average Price is between $25.00 and $30.00
(inclusive), the Exchange Factor shall be determined by dividing $10.00 by the
Average Price, (ii) if the Average Price is between $24.00 and $19.00
(inclusive), the Exchange Factor shall be 0.3950 at $24.00 and increased 0.005
for each whole dollar by which the Average Price is less than $24.00, (iii) if
the Average Price is $18.50 or less, the Exchange Factor shall be 0.4225, (iv)
if the Average Price is equal to or greater than $31.00 and less than $49.00 the
Exchange Factor shall be 0.3350 at $31.00 and reduced 0.005 for each whole
dollar by which the Average Price is greater than $31.00, (v) if the Average
Price is within the ranges described in clause (ii) and (iv) above, but the
Average Price is not a whole dollar, then the Exchange Factor shall be
determined as that which would have been computed at the nearest whole dollar
increased or decreased (as applicable) by an amount equal to 0.005 multiplied by
a fraction, the numerator of which shall be the difference between the Average
Price and such nearest whole dollar, and the denominator of which shall be
$1.00, (vi) if the Average Price is between $19.00 and $18.50 (exclusive) the
Exchange Factor shall be .4200 increased by an amount equal to .0025 multiplied
by a fraction, the numerator of which is the difference between $19.00 and the
Average Price and the denominator of which is $.50, (vii) if the Average Price
is between $24.00 and $25.00 (exclusive) the Exchange Factor shall be 0.3950
increased by an amount equal to 0.005 multiplied by a fraction, the numerator of
which is the difference between the Average Price and $24.00 and the denominator
of which is $1.00, (viii) if the Average Price is between $30.00 and $31.00
(exclusive) the Exchange Factor shall be 0.3333 increased by an amount equal to
0.0017 multiplied by a fraction, the numerator of which is the difference
between the Average Price and $30.00 and the denominator of which is $1.00, and
(ix) if the Average Price is greater than $49.00 the Exchange Factor shall be
determined by dividing $12.005 by the Average Price. An illustration of the
application of the foregoing is attached hereto as Exhibit "A."
(m) "GAAP" shall mean generally accepted accounting principles.
(n) "HART SCOTT ACT" shall mean the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, as amended.
(o) "MATERIAL ADVERSE EFFECT" means when used in connection with
the Company or any of its Subsidiaries, or Parent or any of its Subsidiaries, as
the case may be, any condition, change or effect that, individually or when
taken together with all other such conditions, changes or effects that existed
or occurred prior to the date of determination of the existence or occurrence of
the Material Adverse Effect, is or is reasonably likely to be materially adverse
to the business, assets (including intangible assets), financial condition or
results of operations of the
4
<PAGE>
Company and its Subsidiaries or Parent and its Subsidiaries, in each case taken
as a whole.
(p) "MERGER" shall have the meaning provided in recital B to this
Agreement.
(q) "NMS" shall mean the NASDAQ National Market System.
(r) "PARENT" means Veterinary Centers of America, Inc., a
Delaware corporation.
(s) "PARENT PURCHASE RIGHTS" shall mean each outstanding option,
purchase right, subscription or other right or agreement or commitment of any
character relating to the issuance of shares of Parent Common Stock (including,
without limitation, options or rights that may be issued and outstanding under
any stock option plan or pursuant to any stock guarantee provision contained in
any agreement pursuant to which Parent acquired any of its Veterinary
Hospitals).
(t) "PARENT COMMON STOCK" shall mean the Common Stock, par value
$0.001 per share, of Parent.
(u) "PERSON" includes an individual, partnership, limited
liability company, limited liability partnership, trust, estate, corporation,
joint venture, unincorporated association, government bureau or agency or other
entity of whatsoever kind or nature.
(v) "PRINCIPAL STOCKHOLDERS" shall mean the holder or holders of
the Restricted Shares.
(w) "RESTRICTED SHARES" shall mean the 3,600,000 shares of
Company Common Stock held as of the date hereof by Abbingdon Venture Partners
Limited Partnership - II.
(x) "SECURITIES ACT" means the Securities Act of 1933, as
amended.
(y) "SEC" means the Securities and Exchange Commission.
(z) "STOCKHOLDERS" shall mean the stockholders of the Company.
(aa) "SUB" shall mean Golden Merger Corporation, a Delaware
corporation.
(ab) "SUB COMMON STOCK" shall mean the Common Stock, par value
$0.001 per share, of Sub.
(ac) "SUBSIDIARY" of a corporation means (i) any corporation of
which equity securities possessing a majority of the
5
<PAGE>
ordinary voting power in electing the board of directors are, at the time as of
which such determination is being made, owned by such corporation either
directly or indirectly through one or more Subsidiaries, and (ii) any Person
(other than a corporation) in which such corporation or any Subsidiary, directly
or indirectly, has more than a 10% ownership interest or over which it exercises
control.
(ad) "VETERINARY HOSPITALS" shall mean the veterinary hospitals
and clinics owned and operated by the Company or its Subsidiaries or Parent or
its Subsidiaries, as the case may be.
<TABLE>
<CAPTION>
Section
Defined Term Where Found
------------ -----------
<S> <C>
Acquisition Proposal 6.11
AICPA Statement 8.7
Certificate of Merger 2.1
Closing 3
Closing Date 3
Company Financial Statements 4.6
Company Reports 4.6
Constituent Corporations 2.2
Company Disclosure Letter 4
Effective Time 2.1
ERISA Affiliate 4.12
Exchange Agent 2.5.(c)
Exchange Fund 2.5.(c)
Form S-4 6.5
Hazardous Substances, Hazardous Wastes,
Hazardous Materials and Toxic Substances 4.15
Parent Financial Statements 5.6
Parent Reports 5.6
Proxy Statement/Prospectus 6.5
Remedies Exception 4.2
Rule 145 Affiliates 8.8
Surviving Corporation 2.2
Treasury Shares 2.5.(a)
</TABLE>
6
<PAGE>
2. THE MERGER.
----------
2.1. EXECUTION, FILING, EFFECTIVE TIME. On the date of the Closing
of the Merger referred to in Section 3, and subject to the terms and conditions
hereinafter set forth, the Company and Sub agree to cause the Merger to be
consummated by executing, delivering and filing with the office of the Delaware
Secretary of State a Certificate of Merger (the "Certificate of Merger") in a
form approved by the Company and Parent, which approval shall not be
unreasonably withheld or delayed, and such other documents as may be required by
the provisions of the Delaware Law and as are necessary to cause the Merger to
become effective. The Merger shall become effective when such Certificate of
Merger and such other necessary documents are so filed with the Secretary of
State of the State of Delaware. The time at which the Merger becomes effective
is herein referred to as the "Effective Time."
2.2. CONSTITUENT AND SURVIVING CORPORATIONS. The Company and Sub
shall be the constituent corporations in the Merger (collectively, the
"Constituent Corporations"). At the Effective Time, the Company shall be merged
into Sub in accordance with the Delaware Law and Sub shall be the surviving
corporation in the Merger (in such capacity, Sub is sometimes hereinafter
referred to as the "Surviving Corporation"). At the Effective Time, the identity
and separate existence of the Company shall cease. Upon the effectiveness of the
Merger, the Surviving Corporation shall possess all of the rights, privileges,
immunities, powers, franchises and authority, whether of a public or private
nature, and be subject to all restrictions, disabilities and duties, of each of
the Constituent Corporations, and all the rights, privileges, immunities,
powers, franchises and authority of each of the Constituent Corporations, and
all assets and properties of every description, real, personal and mixed, and
every interest therein, wherever located, and all debts and other obligations
belonging or due to either of the Constituent Corporations on whatever account,
as well as stock subscriptions and all other things in action belonging or due
to each of the Constituent Corporations, shall be vested in the Surviving
Corporation, and all property rights, privileges, immunities, powers, franchises
and authority, and all and every other interest, shall be thereafter as
effectually the property of the Surviving Corporation as they were of the
Constituent Corporations, and the title to any real estate or interest therein
vested in either Constituent Corporation shall not revert or be in any way
impaired by reason of the Merger but all rights of creditors and all liens upon
any property of either of the Constituent Corporations shall be preserved
unimpaired, and the Surviving Corporation shall be liable for the debts and
other obligations of each of the Constituent Corporations, and any claims
existing or action or proceeding pending, by or against either of the
Constituent Corporations may be prosecuted to judgment with right of appeal, as
if the Merger had not taken place.
7
<PAGE>
2.3. CERTIFICATE OF INCORPORATION AND BYLAWS. The Certificate of
Incorporation and Bylaws of the Sub in effect immediately prior to the Effective
Time shall be in the Certificate of Incorporation and Bylaws of the Surviving
Corporation.
2.4. BOARD OF DIRECTORS AND OFFICERS. The directors and officers of
Sub in office immediately prior to the Effective Time shall continue as the
directors and officers of the Surviving Corporation upon the effectiveness of
the Merger.
2.5. CONVERSION OF THE COMPANY COMMON STOCK.
(a) Conversion of Company Common Stock. At the Effective
----------------------------------
Time, each share of Company Common Stock issued and outstanding immediately
prior to the Effective Time (excluding any treasury shares of the Company Common
Stock then owned by the Company or any of its Subsidiaries and any shares of the
Company Common Stock then held by Parent or any of its Subsidiaries) shall, by
virtue of the Merger and without any action on the part of the Parent, Sub, the
Company or the holder thereof, be cancelled and converted into that number of
shares of fully paid and nonassessable shares of Parent Common Stock equal to
the Exchange Factor. No fractional shares of Parent Common Stock will be issued,
but in lieu thereof, any holder of shares of Company Common Stock entitled to
receive a fractional share of Parent Common Stock shall be paid cash (rounded to
the nearest whole cent) equal to the product of multiplying such fraction by the
Average Price. If more than one certificate representing shares of Company
Common Stock shall be surrendered at one time for the account of the same
stockholder of record, the number of full shares of Parent Common Stock for
which certificates shall be delivered shall be computed on the basis of the
aggregate number of shares of the Company Common Stock represented by the
certificates so surrendered. All shares of Company Common Stock held by the
Company at the Effective Time as treasury shares or held by any of the Company's
Subsidiaries or by Parent or any of its Subsidiaries (collectively, "Treasury
Shares") shall cease to exist and the certificates for such shares shall, as
promptly as practicable thereafter, be cancelled and no shares of capital stock
of Parent or Sub shall be issued in exchange therefor.
(b) Adjustment to the Exchange Factor. The Exchange Factor
---------------------------------
shall be adjusted to reflect fully the effect of any stock split, reverse stock
split, stock dividend including any dividend or distribution of securities
convertible into shares of Parent Common Stock or shares of Company Common
Stock), reorganization, recapitalization or other like change in the number of
shares of Parent Common Stock or shares of Company Common Stock occurring after
the date hereof and prior to the Effective Time; provided, however, that no such
-----------------
changes to the capital stock of Parent, the Surviving Corporation or the Company
shall be effected except as permitted by this Agreement.
8
<PAGE>
(c) Payment for Company Common Stock. Parent shall authorize
--------------------------------
one or more persons reasonably acceptable to the Company to act as exchange
agents (the "Exchange Agent") hereunder. As of the Effective Time, Parent shall
deposit, or cause to be deposited, with the Exchange Agent, for the benefit of
the holders of the Company Common Stock, certificates representing the number of
whole shares of Parent Common Stock and cash in lieu of fractional shares (such
cash and certificates, together with any dividends or distributions thereon,
being hereinafter referred to as the "Exchange Fund") into which the shares of
the Company Common Stock outstanding at the Effective Time are converted in
accordance with Section 2.5.(a) hereof. The Exchange Fund shall include
sufficient cash as is reasonably determined by Parent to be necessary to account
for additional fractional shares as the result of shares which are held in
depositary, nominee or book entry form.
(d) Delivery of New Certificates. Promptly after the
----------------------------
Effective Time, Parent shall cause the Exchange Agent to mail to each holder of
record of a certificate or certificates representing shares of Company Common
Stock (a "Certificate" and collectively the "Certificates") (i) a letter of
transmittal which shall specify that delivery shall be effected, and risk of
loss and title to the Certificates shall pass, only upon delivery of the
Certificates to the Exchange Agent and shall be in such form and have such other
provisions as Parent may reasonably specify and (ii) instructions for use in
effecting the surrender of the Certificates in exchange for certificates
representing shares of Parent Common Stock and cash in lieu of fractional
shares. Upon surrender of a Certificate for cancellation to the Exchange Agent
together with such letter of transmittal, duly executed and completed in
accordance with the instructions thereto, the holder of such Certificate shall
be entitled to receive in exchange therefor (x) a certificate representing that
number of whole shares of Parent Common Stock and (y) a check representing the
amount of cash in lieu of fractional shares, if any, and unpaid dividends and
distributions, if any, which such holder has the right to receive in respect of
the Certificate surrendered pursuant to the provisions of this Section 2.5.(d),
after giving effect to any required withholding tax, and the Certificate so
surrendered shall forthwith be cancelled. No interest will be paid or accrued on
the cash included within the Exchange Fund, payable to holders of Certificates.
Certificates surrendered for exchange by any Person constituting a Rule 145
Affiliate shall not be exchanged until Parent has received a written agreement
from such Person as provided in Section 8.8 of this Agreement. Certificates for
Restricted Shares surrendered for exchange by a Principal Stockholder shall not
be exchanged until Parent has received a written agreement from such Person as
provided in Section 8.9 hereof. If any certificate for shares of Parent Common
Stock is to be issued in a name other than that in which a certificate for
shares of the Company Common Stock so surrendered is then registered, such
surrender shall be accompanied by payment of any applicable transfer taxes and
documents required for a valid
9
<PAGE>
transfer. From and after the Effective Time, until so surrendered, each
Certificate theretofore representing shares of issued and outstanding Company
Common Stock shall be deemed for all corporate purposes, except as provided in
Section 2.5.(a) with respect to fractional shares and Treasury Shares, and
except as set forth below, to evidence the number of whole shares of Parent
Common Stock into which such shares of Company Common Stock shall have been
converted. Unless and until any such Certificates shall be so surrendered, the
holder of such Certificate shall not have any right to receive any cash amounts
included in the Exchange Fund. Upon surrender of a Certificate representing the
Company Common Stock, the holder of record thereof shall receive a certificate
representing the whole shares of Parent Common Stock, cash in lieu of fractional
shares to which he shall be entitled, and all dividends and other distributions
which shall have been paid or made to holders of record of Parent Common Stock
after the Effective Time with respect to such shares of Parent Common Stock,
without interest thereon. All such cash amounts unclaimed at the end of one year
from the Effective Time shall be released or repaid by the Exchange Agent to
Parent, after which the holders of the shares not receiving such payment shall
look, subject to applicable escheat or other laws, only to Parent as general
creditors for payment thereof.
(e) No Liability. None of Parent, the Company, the Exchange
------------
Agent or any other person shall be liable to any former holder of shares of
Company Common Stock for any amount properly delivered to a public official
pursuant to applicable abandoned property, escheat or similar laws.
(f) Lost, Stolen or Destroyed Certificates. In the event any
--------------------------------------
Certificate shall have been lost, stolen or destroyed, upon the making of an
affidavit of that fact by the person claiming such Certificate to be lost,
stolen or destroyed and, if required by the Surviving Corporation, the posting
by such person of a bond in such reasonable amount as the Surviving Corporation
may direct as indemnity against any claim that may be made against it with
respect to such Certificate, the Exchange Agent will issue in exchange for such
lost, stolen or destroyed Certificate the shares of Parent Common Stock, cash in
lieu of fractional shares, and unpaid dividends and distributions on shares of
Parent Common Stock as provided in Section 2.5.(d), deliverable in respect
thereof pursuant to this Agreement.
2.6. COMPANY PURCHASE RIGHTS. Each of the Company Purchase Rights,
whether vested or unvested, shall, subject to the terms of any applicable stock
option, warrant agreement or other applicable agreement evidencing the same,
remain outstanding following the Effective Time. At the Effective Time, such
Company Purchase Rights shall, by virtue of the Merger and without any further
action on the part of the Company, Parent, Sub or the holder of any Company
Purchase Right, be assumed by Parent in such manner that Parent (x) is a
corporation "assuming a stock option in
10
<PAGE>
a transaction to which Section 424 applied" within the meaning of Section 422A
of the Code or (y) to the extent Section 424 of the Code does not apply to any
such Company Purchase Rights, would be such a corporation were Section 424
applicable to such option. Each Company Purchase Right assumed by Parent shall
be exercisable upon the same terms and conditions as under the applicable stock
option, warrant agreement or other applicable agreement evidencing the same,
except that (i) each such Company Purchase Right shall be exercisable for that
number of shares of Parent Common Stock (to the nearest whole share) into which
the number of shares of Company Common Stock subject to such Company Purchase
Right immediately prior to the Effective Time would be converted under Section
2.5.(a) of this Agreement, and (ii) the option price per share of Parent Common
Stock shall be equal to (x) the per share exercise price of such Company
Purchase Right in effect immediately prior to the Effective Time multiplied by
the number of shares of Company Common Stock subject to such Company Purchase
Right immediately prior to the Effective Time, divided by (y) the number of
----------
shares of Parent Common Stock subject to such Company Purchase Right immediately
after the Effective Time. No payment shall be made for fractional interests.
In connection with the assumption of the Company Purchase Rights, Parent shall
effect such assumption in such manner as not to affect the "incentive" status of
those options which are "incentive" stock options within the meaning of the Code
at the Effective Time. From and after the date hereof, no additional Company
Purchase Rights shall be granted by the Company and no "vesting" or exercise
schedule of Company Purchase Rights shall be modified or accelerated (other than
pursuant to the express terms of such Company Purchase Right) and no exercise
price of any Company Purchase Right shall be modified without the prior written
consent of Parent.
2.7. CLOSING OF TRANSFER BOOKS. At and after the Effective Time,
transfers of the shares of Company Common Stock outstanding immediately prior to
the Effective Time shall not be made on the stock transfer books of the Company.
2.8. RELATED AGREEMENT. Each of the Principal Stockholders have
executed and delivered to the Parent a separate agreement pursuant to which they
(i) agree to vote the shares of Company Common Stock held by them in favor of
this Agreement and the Merger at the Stockholders Meeting called for that
purpose and have granted a proxy to Parent to do the same in their place and
stead, and (ii) agree not to sell, transfer, hypothecate or otherwise dispose of
any of their shares of Company Common Stock or Company Purchase Rights held by
them as of the date hereof until the earlier to occur of termination of this
Agreement or the Effective Time, except as expressly provided for therein.
3. CLOSING DATE. The Closing of the Merger (the "Closing") shall, unless
------------
another date or place is agreed to in writing by the parties, take place at the
offices of Troop Meisinger Steuber & Pasich, 10940 Wilshire Boulevard, Los
Angeles, California 90024
11
<PAGE>
(except for the filing of the Certificate of Merger, which shall take place in
the office of the Secretary of State of the State of Delaware) on the second
business day following the satisfaction or waiver of all conditions precedent to
the Merger, including those set forth in Sections 7, 8 and 9 of this
Agreement, but in no event later than 60 days after the Form S-4 becomes
effective. The date of the Closing is referred to in this Agreement as the
"Closing Date."
4. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. Except as set forth in
----------------------------------------------
the disclosure letter delivered at or prior to the execution of this Agreement
by the Company, which shall refer to the relevant Sections of this Agreement
(the "Company Disclosure Letter"), the Company represents and warrants to and
agrees with Parent and Sub as follows:
4.1. ORGANIZATION AND STANDING; ARTICLES AND BY-LAWS. The Company
is a corporation duly organized, validly existing and in good standing under the
laws of the State of Delaware. The Company is qualified, licensed or
domesticated as a foreign corporation and is in good standing in all
jurisdictions where the character of its properties owned or held under lease or
the nature of its activities make such qualification necessary, except where the
failure to be so qualified, licensed or domesticated would not have a Material
Adverse Effect on the Company. The Company has all requisite power and
authority and all requisite licenses, permits and franchises necessary to own,
lease and operate its properties and assets and to carry on its business in the
manner and in the locations as presently conducted, except where the failure to
do so would not have a Material Adverse Effect on the Company. Copies of the
Certificate of Incorporation (as certified by the Delaware Secretary of State)
and Bylaws of the Company have been delivered to Parent and are accurate and
complete as of the date hereof.
4.2. AUTHORIZATION. The Company has the requisite corporate power
and authority to enter into and carry out the terms and conditions of this
Agreement and all the transactions contemplated hereunder. The execution and
delivery of this Agreement and the consummation of the transactions contemplated
hereby have been duly authorized by the Company's Board of Directors and, other
than the Stockholder approval required pursuant to Section 6.4 hereof, all
corporate proceedings have been taken and no other corporate proceedings on the
part of the Company are necessary to authorize the execution, delivery and
performance by the Company of this Agreement. This Agreement has been duly
executed and delivered by the Company and constitutes the valid and binding
obligations of the Company, enforceable in accordance with its terms, except as
enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium or similar laws relating to or affecting creditors'
rights generally from time to time in effect and except that equitable remedies
may not in all cases be available (regardless of whether enforceability is
considered in a proceeding at law or in equity) (collectively, the
12
<PAGE>
"Remedies Exception"). The execution, delivery and performance of this
Agreement by the Company will not conflict with or constitute a breach,
violation or default under the Company's Certificate of Incorporation or By-
Laws, any statute, law or administrative regulation, or under any judgment,
decree, order, writ, governmental permit or license, any material contract,
agreement, lease, indenture or instrument to which the Company or any of its
Subsidiaries is a party or by which the Company or any of its Subsidiaries is
bound, which breach, violation or default would have a Material Adverse Effect
on the Company.
4.3. NO CONSENTS. No consent, authorization, order or approval of,
or filing with or registration with, any governmental authority, commission,
board or other regulatory body of the United States or any state or political
subdivision thereof, or any other Person, is required to be made or obtained by
the Company for or in connection with the execution and delivery by the Company
of this Agreement and the consummation by the Company of the transactions
contemplated hereby, the absence of which would have a Material Adverse Effect
on the Company, other than the filing of the Certificate of Merger with the
Delaware Secretary of State and filings made pursuant to the Hart Scott Act.
4.4. CAPITAL STOCK. The authorized capital stock of the Company
consists of 20,000,000 shares of Company Common Stock, par value $0.01 per
share, and 1,000,000 shares of Preferred Stock, $0.01 par value per share. As
of the date hereof, (i) there are 8,595,544 shares of Company Common Stock
issued and outstanding, all of which are duly authorized, validly issued, fully
paid and non-assessable and were not issued in violation of any preemptive
rights or any Federal or State securities laws, (ii) no shares of Company Common
Stock are held by Subsidiaries of the Company, and (iii) 237,564 shares of
Company Common Stock are reserved for future issuance under outstanding Company
Purchase Rights (assuming that the financial criteria for the achievement of
contingent payment provisions in agreements pursuant to which the Company
acquired its Veterinary Hospitals were to be met, but not exceeded). As of the
date hereof, there are no shares of Company Preferred Stock issued and
outstanding. As of the date hereof, there are (i) no options, warrants, calls,
subscriptions, convertible securities or other rights, (including preemptive
rights), agreements, understandings, arrangements or commitments of any
character obligating the Company now or at any time in the future to issue or
sell any of its capital stock or other equity interests of the Company or any of
its Subsidiaries, (ii) there are no obligations, contingent or otherwise, of the
Company or any of its Subsidiaries, to repurchase, redeem or otherwise acquire
any shares of capital stock or other equity interests of the Company or any of
its Subsidiaries or to provide funds or to make any investment (in the form of a
loan, capital contribution or otherwise) in any Subsidiary or another entity,
other than guarantees of bank obligations of Subsidiaries entered into in the
ordinary course of business, (iii) there are no outstanding bonds,
13
<PAGE>
debentures, notes or other obligations of the Company the holders of which have
the right to vote (or which are convertible into or exercisable for securities
having the right to vote) with the Company shareholders on any matter, (iv)
there are no obligations, contingent or otherwise, guaranteeing the value of any
of the shares of the Common Stock of the Company or any of its Subsidiaries
either now or at any time in the future, and (v) there are no voting trusts,
proxies or other agreements or understandings to which the Company is a party or
is bound with respect to the voting of any capital stock or other equity
interests of the Company or any of its Subsidiaries.
4.5. SUBSIDIARIES. The Company Disclosure Letter sets forth a true
and correct list of each Subsidiary of the Company as of the date hereof. All
of the outstanding capital stock of each such Subsidiary is owned entirely by
the Company or by a Subsidiary of the Company, as the case may be, as of the
date hereof, free and clear of all liens, charges, pledges, security interests
or other encumbrances, except for restrictions on transfer imposed by applicable
securities laws. All such shares of capital stock have been duly authorized and
validly issued and are fully paid and nonassessable. There are no agreements,
understandings or undertakings governing the rights and duties of the Company or
any Subsidiary of the Company as a stockholder of any Subsidiary, including,
without limitation, any agreement, arrangement or understanding under which the
Company is or may become obligated, directly or indirectly, to acquire or
dispose of any equity interest in, make any capital contribution or extend
credit to, or act as guarantor, surety or indemnitor for any liability of any
Subsidiary. Each such Subsidiary is duly organized, validly existing and in
good standing under the laws of its jurisdiction of organization, has the
corporate power and authority to carry on its business as it is now being
conducted and is duly qualified to do business and is in good standing in all
jurisdictions where the failure to be so qualified would have a Material Adverse
Effect on the Company. Other than its Subsidiaries, the Company has no interest
in any corporation, joint venture, partnerships or other business enterprise.
4.6. SEC REPORTS AND FINANCIAL STATEMENT. The Company has filed
with the SEC all forms, reports, registration statements, proxy statements and
other documents (collectively, the "Company Reports") required to be filed by
the Company under the Securities Act, the Exchange Act, and the rules and
regulations promulgated thereunder (collectively, the "Securities Laws"), except
failures to file which, individually or collectively, do not have a Material
Adverse Effect on the Company. The Company has heretofore furnished Parent with
true and complete copies of all Company Reports filed as of the date hereof. As
of their respective dates, or, in the case of registration statements, as of
their effective dates, all of the Company Reports, including all exhibits and
schedules thereto and all documents incorporated by reference therein, (i)
complied as to form in all material respects with the
14
<PAGE>
requirements of the Securities Laws applicable thereto, and (ii) did not contain
any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements, in light of
the circumstances under which they were made, not misleading. The Company has
filed with the SEC all documents and agreements which were required to be filed
as exhibits to the Company Reports, except failures to file, if any, which,
individually or collectively, do not have a Material Adverse Effect on the
Company. The audited consolidated financial statements and unaudited interim
consolidated financial statements of the Company included or incorporated by
reference in the Company Reports (collectively, the "Company Financial
Statements") have been prepared in accordance with GAAP applied on a consistent
basis (except as may be indicated therein or in the notes thereto) and fairly
present the financial position of the Company as of and at the dates thereof and
the results of operations and cash flows for the periods then ended, subject in
the case of the unaudited interim financial statements, to normal, recurring
year-end adjustments and any other adjustments described therein, which were not
and are not expected to be material in amount or effect. Except as set forth or
reflected in the Company Financial Statement at December 28, 1994, or as set
forth in the unaudited balance sheets included in the Company Reports since that
date, neither the Company nor any of its Subsidiaries, has any liabilities or
obligations of any kind or nature (whether accrued, absolute, contingent or
otherwise) which would be required to be reflected or reserved against in any
balance sheet of the Company or any of its Subsidiaries, or in the notes
thereto, prepared in accordance with GAAP consistently applied, except
liabilities arising since September 27, 1995 either (i) in the ordinary course
of business; or (ii) which, individually or collectively, would not have a
Material Adverse Effect on the Company.
4.7. ABSENCE OF CERTAIN CHANGES OR EVENTS. Except as disclosed in
the Company Reports filed with the SEC prior to the date hereof, since December
28, 1994, the Company and its Subsidiaries has conducted its business in all
material respects in the ordinary and usual course consistent with past
practice, and there has not been (a) any event or occurrence which could result
in a Material Adverse Effect on the Company, (b) any material change in
accounting methods, principles and practices by the Company and its Subsidiaries
(except for any such changes required by reason of a concurrent change in GAAP
or to conform a Subsidiary's accounting methods, principles or practices to
those of the Company), (c) any damage, destruction or loss, whether covered by
insurance or not, having a Material Adverse Effect on the Company, (d) any entry
by the Company or any of its Subsidiaries into any commitment or transaction
material to the Company which is not in the ordinary course of business
consistent with past practice, (e) any declaration, payment or setting aside for
payment of any dividends, or (f) any grant to any officer or director of any
increase in compensation (other than periodic salary increases not in excess of
10% made in the ordinary course
15
<PAGE>
of business consistent with past practice or increases resulting from job
promotions or expansions of employment responsibilities), or any loan to any
officer or director, or any adoption, amendment in any material respect or
termination of any bonus, profit sharing, stock option, employee stock
ownership, pension, retirement, deferred compensation, employment or consulting
or other plan, agreement or arrangement for the benefit of employees of the
Company.
4.8. LITIGATION. The Company has disclosed in the Company
Disclosure Letter all information in its possession or custody or under its
control with respect to litigation pending as of the date hereof. Except as set
forth in the Company Disclosure Letter, the Company has no litigation pending as
of the date hereof. To the best of the Company's knowledge, the ultimate
liability for damages arising from such litigation (based upon assumptions that
the Company believes in good faith to be reasonable under the circumstances) is
either adequately reserved against in the Company Financial Statement at
December 28, 1994 or in the unaudited balance sheets included in the Company
Reports since that date or will not have a Material Adverse Effect on the
Company. Except as set forth in the Company Disclosure Letter, there are no
actions, suits or proceedings of any nature pending, or, to the knowledge of the
Company, threatened, against or by the Company or any of its properties, assets
or business, nor is the Company or any of its properties, assets or business,
subject to any order, judgment, ruling, or decree of any competent authority,
which would have, or is reasonably like to have, a Material Adverse Effect on
the Company. The Company has not received notice of violation of any applicable
statute, regulation, code, ordinance, rule, order, judgment, decree or
requirement relating to its operations or its owned or leased properties and to
the Company's knowledge, no such violation exists, in each case, other than a
violation which would not have a Material Adverse Effect on the Company.
4.9. TAX RETURNS. The Company and each of its Subsidiaries (i) has
accurately prepared and duly and timely filed all federal and state and all
other material income, property, sales and use and other applicable tax reports
and returns ("Tax Returns") required to be filed (subject to any extensions
applicable to any such filing) except where the failure to do so would not have
a Material Adverse Effect on the Company, and all such returns are true and
complete in all material respects, (ii) has paid all Taxes shown to be due and
payable on such Tax Returns or which have become due and payable pursuant to any
assessment, deficiency notice, 30-day letter, or other notice received by it,
and (iii) has properly accrued all Taxes for such periods subsequent to the
periods covered by the Tax Returns, except for any Taxes which would not have a
Material Adverse Effect on the Company. The Tax Returns of the Company and each
of its Subsidiaries have not been examined by the appropriate taxing authority.
Neither the Company nor any of its Subsidiaries has
16
<PAGE>
executed or filed with the Internal Revenue Service ("IRS") or any other taxing
authority any agreement now in effect extending the period for assessment or
collection of any income or other Taxes. Neither the Company nor any of its
Subsidiaries is a party to any pending action or proceeding by any governmental
authority for assessment or collection of Taxes, and to the knowledge of the
Company, no claim for assessment or collection of Taxes has been asserted
against it. True, correct and complete copies of all Tax Returns filed by the
Company and each of its Subsidiaries and all communications relating thereto
have been delivered to Parent or made available to the representatives of
Parent. All Taxes which the Company is required to withhold or collect,
including without limitation, sales and use taxes, have been duly withheld or
collected and, to the extent required, have been paid over to the proper
governmental authorities or are held in separate bank accounts for such
purposes, except where the failure to do so would not have a Material Adverse
Effect on the Company. For purposes hereof, the term, "Taxes" shall mean and
include all taxes, charges, fees, levies or other assessments, including,
without limitation, income, gross receipts, excise, property, sales,
withholding, social security, occupation, use, service, license, payroll,
franchise, transfer and recording taxes, fees and charges imposed by the United
States, or any state, local or foreign government or subdivision or agency
thereof, whether computed on a separate, consolidated, unitary, combined or any
other basis; and such term shall include any interest, fines, penalties or
additional amounts attributable or imposed on or with respect to any such taxes,
charges, fees, levies or other assessments.
4.10. PROPERTIES, ENCUMBRANCES. The Company and its Subsidiaries
have good and marketable title in fee simple to, or a valid leasehold interest
in, each of the real properties reflected on the Company Financial Statements or
which have been acquired after the date thereof or used by them as of the date
hereof (collectively, the "Company Properties"), in each case, free and clear of
all liens, mortgages or deeds of trust, claims against title, security interests
or other encumbrances on title ("Liens") or any rights of way, written
agreements, laws, ordinances or regulations affecting the use or occupancy of
such properties, or any reservations of an interest in title ("Restrictions")
except (a) Liens and Restrictions included in the Company Disclosure Letter, (b)
the rights of the landlords under applicable leases, and (c) Liens and
Restrictions which do not have a Material Adverse Effect on the Company. All
rental payments due under any lease pursuant to which the Company uses any
Company Property has been paid and neither the Company nor any of its
Subsidiaries is in default, and to the knowledge of the Company, the landlord
under the lease is not in default, and no condition or event exists which with
the giving of notice or the passage of time, or both, would constitute a
material default by any party under any such leases other than any such non-
payment or default which could not have a Material Adverse Effect on the
Company.
17
<PAGE>
4.11. PERSONAL PROPERTY. The Company and its Subsidiaries own good
and marketable title to or a valid right to use all items of personal property
owned or used by them which are material to their business, free and clear of
all Liens other than those which would not, individually or in the aggregate,
have a Material Adverse Effect on the Company.
4.12. EMPLOYEE BENEFIT PLANS. The Company Disclosure Letter sets
forth a list of all plans and other arrangements involving direct or indirect
compensation or benefits to officers, directors or consultants or providing
employee benefits to employees of the Company or its Subsidiaries, including,
without limitation, all "employee benefit plans" as defined in Section 3(3) of
the Employee Retirement Income Security Act of 1974, as amended ("ERISA"), and
all bonus, stock option, stock purchase, incentive, deferred compensation,
supplemental retirement, severance and other similar fringe or employee benefit
plans, and all employment or executive compensation agreements (collectively,
the "Company Plans"). All Company Plans comply with and are and have been
operated in material compliance with each applicable provision of ERISA, the
Code, other federal statutes, state law (including, without limitation, state
insurance law) and the regulations and rules promulgated pursuant thereto or in
connection therewith, except for any such failure to comply which would not have
a Material Adverse Effect on the Company. No Company Plan is covered by Title
IV of ERISA or Section 412 of the Code. Neither the Company, any of its
Subsidiaries, nor any affiliate of the Company as determined under Section
414(b), (c), (m) or (o) of the Code ("ERISA Affiliate") has failed to make any
contributions or to pay any amounts due and owing as required by the terms of
any Company Plan, which failure would have a Material Adverse Effect on the
Company. True and complete copies of each Company Plan have been made available
to Parent or its representatives. Except as required by Section 4980B of the
Code, neither the Company, any of its Subsidiaries nor any ERISA Affiliate has
promised any former employee or other individual not employed by the Company,
any of its Subsidiaries or any ERISA Affiliate, medical or other benefit
coverage, and neither the Company, any of its Subsidiaries nor any ERISA
Affiliate maintains or contributes to any plan or arrangement providing medical
benefits, life insurance or other welfare benefits to former employees, their
spouses or dependents or any other individual not employed by the Company, any
of its Subsidiaries or any ERISA Affiliate except to the extent required by
applicable law.
4.13. CERTAIN AGREEMENTS. Except as set forth in the Company
Disclosure Letter, neither the Company nor any of its Subsidiaries is a party to
any oral or written (i) material agreement (including, without limitation, any
employment, management, severance or consulting contract) with any current or
former officer, director, or holder of more than 10% of the outstanding shares
of the Company Common Stock or with any entity
18
<PAGE>
in which any of the foregoing is a more than 10% equity owner, officer,
director, employee or consultant, (ii) any agreement the benefits of which are
contingent, or the terms of which are materially altered, upon the occurrence of
a transaction involving the Company or any of its Subsidiaries of the nature
contemplated by this Agreement, (iii) agreement or plan, including any stock
option plan, stock appreciation rights plan, restricted stock plan or stock
purchase plan, any of the benefits of which will be increased, or the vesting of
benefits of which will be accelerated, by the occurrence of the transactions
contemplated by this Agreement or the value of any of the benefits of which will
be calculated on the basis of the transactions contemplated by this Agreement or
(iv) agreement involving the acquisition of any interest or investment in a
veterinary hospital or any other business.
4.14. COMPLIANCE WITH APPLICABLE LAW. The businesses of the Company
and its Subsidiaries are not being conducted in violation of any applicable law,
ordinance, regulation, decree or order of any governmental entity, except for
violations which either singly or in the aggregate do not and are not expected
to have a Material Adverse Effect on the Company. Neither the Company nor any
Company Subsidiary is a party to or subject to any judgment, decree, or order
entered in any suit or proceeding brought by any governmental agency or by any
other person, enjoining the Company or any Company Subsidiary with respect to
any business practice, the acquisition of any property, or the conduct of
business in any area.
4.15. ENVIRONMENTAL COMPLIANCE MATTERS. The businesses of the
Company and its Subsidiaries as conducted in the past were not and as currently
being conducted are not in violation of any applicable law, ordinance, rule,
prohibition or regulation relating to air, water or noise pollution, or the
production, storage, labeling or disposition of wastes or hazardous or toxic
substances, or the health, safety or environmental conditions on, beneath or
about any of the properties owned, used or leased by the Company or any of its
Subsidiaries or relating to the business of the Company or any of its
Subsidiaries (such laws, ordinances, rules, prohibitions and regulations being
herein referred to as "Environmental Laws"), except for any such violation which
would not have a Material Adverse Effect on the Company. The Company and its
Subsidiaries have timely filed all material reports, obtained all material
approvals and permits and generated and maintained all material data,
documentation and records required under any applicable Environmental Laws,
except where the failure to do so would not have a Material Adverse Effect on
the Company. Neither the Company, its Subsidiaries nor, to the knowledge of the
Company or its Subsidiaries, any other Person has placed, stored, buried,
spilled or released, used, generated, manufactured, refined, processed, treated,
dumped or disposed of any materials produced by, or resulting from, any
business, commercial or industrial activities, operations or processes,
including without limitation
19
<PAGE>
any materials which are "Hazardous Wastes", "Hazardous Substances", "Hazardous
Materials", "Pollutants", "Toxic Substances", "Solid Wastes" or "Contaminants"
(as such terms are defined in any applicable Environmental Law, including
without limitation the Comprehensive Environmental Response, Compensation and
Liability Act of 1980, as amended, the Hazardous Materials Transportation Act,
the Resource Conservation and Recovery Act and the Toxic Substances Control
Act), on, beneath or about, or transported any such materials to or from, any of
the properties owned, used or leased by the Company or its Subsidiaries in each
case other than in material compliance with applicable Environmental Laws and in
the ordinary course of the Company's or its Subsidiaries' business or where the
failure to comply would not have a Material Adverse Effect on the Company.
Neither the Company nor its Subsidiaries has received any notice from any
governmental agency or private or public entity advising it that it is or may be
responsible, or potentially responsible, for costs with respect to a release, a
threatened release or clean up of materials located in any property owned by the
Company or its Subsidiaries or produced by, or resulting from, any business,
commercial or industrial activities, operations or processes of the Company or
its Subsidiaries, including without limitation, materials which are Hazardous
Wastes, Hazardous Substances, Hazardous Materials, Pollutants, Toxic Substances,
Solid Wastes or Contaminants.
4.16. NO BROKERS. Other than with respect to the services of Smith
Barney Inc., the Company's financial advisor, (the arrangements with which have
been disclosed in writing to Parent), neither the Company nor any Company
Subsidiary has entered into any contract, arrangement or understanding with any
Person or firm which may result in the obligation of the Company, the Surviving
Corporation or the Parent to pay any finder's fee, brokerage or agent's
commissions or other like payments in connection with the negotiation, execution
or performance of this Agreement and the Company is not aware of any claim for
any such payment.
4.17. REGISTRATION STATEMENT; PROXY STATEMENT/PROSPECTUS. None of
the information supplied by the Company for inclusion or incorporation by
reference in (a) the Form S-4, or (b) the Proxy Statement/Prospectus will, in
the case of the Form S-4, at the time it becomes effective and at the time of
the respective meetings of the Company's and Parent's stockholders to vote on
this Agreement and the transactions contemplated hereby, and in the case of the
Proxy Statement/Prospectus, at the time of the mailing thereof to the
stockholders of the Company and Parent and at the time of the stockholders
meetings, contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not
misleading.
20
<PAGE>
4.18. INFORMATION. All written information provided to Parent, Sub
or their respective agents by or on behalf of the Company or any of its
representatives (including, without limitation, each representation and warranty
of the Company set forth in this Agreement) is, and the Company covenants that
any such information provided hereafter shall be, true and correct in all
material respects and does not, or shall not, omit any material fact required to
be included therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading.
4.19. TAX FREE MERGER. At the Effective Time, the Surviving
Corporation will acquire at least 90 percent of the fair market value of the net
assets, and at least 70 percent of the fair market value of the gross assets,
held by the Company prior to the Merger. For purposes of this representation,
amounts used by the Company to pay reorganization expenses and all redemptions,
distributions and payments, in cash or property, made by the Company in
connection with the Merger shall be included as assets of the Company prior to
the Merger.
4.20. RELATED PARTY INDEBTEDNESS AND OBLIGATIONS. Any and all
indebtedness from any current or former officer or director of the Company or
shareholder of 10% or more of Company Common Stock and any affiliate thereof,
other than indebtedness incurred in connection with the acquisition of any
Veterinary Hospital, has been repaid in full, and all contractual obligations,
other than those incurred in connection with the acquisition of any Veterinary
Hospital, to all such persons other than those expressly provided for herein and
other than as set forth in the Company Disclosure Letter have been terminated
without payment of any severance or termination fee.
4.21. NO DISSENTERS RIGHTS. Pursuant to Section 262(b)(i) of the
Delaware Law, there are no dissenters rights available to the Company
Stockholders.
4.22. STOCKHOLDER INTENTION TO SELL. To the knowledge of the
Company, no stockholder of the Company has a present plan or intention to sell,
exchange, or otherwise dispose of the shares of Parent Common Stock such
stockholder will receive in connection with the Merger.
5. REPRESENTATIONS AND WARRANTIES OF THE PARENT. Except as set forth in
--------------------------------------------
the disclosure letter delivered at or prior to the execution of this Agreement
by the Parent, which shall refer to the relevant Sections of this Agreement (the
"Parent Disclosure Letter"), the Parent and Sub jointly and severally represent,
warrant, covenant and agree with the Company as follows:
21
<PAGE>
5.1. ORGANIZATION AND STANDING; ARTICLES AND BY-LAWS. Each of
Parent and Sub is a corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware. Parent is qualified, licensed
or domesticated as a foreign corporation and is in good standing in all
jurisdictions where the character of its properties owned or held under lease or
the nature of its activities make such qualification necessary, except where the
failure to be so qualified, licensed or domesticated would not have a Material
Adverse Effect on Parent. Sub has not conducted any business prior to the date
hereof and has no material assets and liabilities other than those incident to
its formation. The Parent has all requisite power and authority and all
requisite licenses, permits and franchises necessary to own, lease and operate
its properties and assets and to carry on its business in the manner and in the
locations as presently conducted, except where the failure to do so would not
have a Material Adverse Effect on Parent. Copies of the Certificate of
Incorporation (as certified by the Delaware Secretary of State) and Bylaws of
each of Parent and Sub have been delivered to the Company and are accurate and
complete as of the date hereof.
5.2. AUTHORIZATION. Each of the Parent and Sub has the requisite
corporate power and authority to enter into and carry out the terms and
conditions of this Agreement and all the transactions contemplated hereunder.
The execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby have been duly authorized by Parent's and Sub's
Boards of Directors and, other than the stockholder approval required pursuant
to Section 6.4 hereof, all corporate proceedings have been taken and no other
corporate proceedings on the part of Parent or Sub are necessary to authorize
the execution, delivery and performance by Parent and Sub of this Agreement.
This Agreement has been duly executed and delivered by each of Parent and Sub
and constitutes the legal, valid and binding obligations of Parent and Sub,
enforceable against each in accordance with its terms, subject to the Remedies
Exception. The execution, delivery and performance of this Agreement by the
Parent and Sub will not conflict with or constitute a breach, violation or
default under the Parent's or Sub's Certificate of Incorporation or By-Laws, any
statute, law or administrative regulation, or under any judgment, decree, order,
writ, governmental permit or license, any material contract, agreement, lease,
indenture or instrument to which the Parent or Sub or any of the Subsidiaries of
Parent is a party or by which the Parent or any of the Subsidiaries of Parent is
bound, which breach, violation or default would have a Material Adverse Effect
on the Parent.
5.3. NO CONSENTS. No consent, authorization, order or approval of,
or filing with or registration with, any governmental authority, commission,
board or other regulatory body of the United States or any state or political
subdivision thereof, or any other Person, is required to be made or obtained by
Parent or Sub for or in connection with the execution and delivery by Parent and
Sub of
22
<PAGE>
this Agreement and the consummation by Parent and Sub of the transactions
contemplated hereby, the absence of which would have a Material Adverse Effect
on Parent, other than the filing of the Certificate of Merger with the Delaware
Secretary of State, filings made pursuant to the Hart Scott Act, compliance with
the Securities Laws and compliance with any applicable state securities or "blue
sky" laws.
5.4. CAPITALIZATION. The authorized capital stock of Parent consists
of 30,000,000 shares of Parent Common Stock, par value $0.001 per share, and
1,000,000 shares of Preferred Stock, $0.001 par value per share. As of the date
hereof, (i) there are 12,496,666 shares of Parent Common Stock issued and
outstanding, all of which are duly authorized, validly issued, fully paid and
non-assessable and were not issued in violation of any preemptive rights or any
Federal or State securities laws, (ii) there are 583,333 shares of Parent
Preferred Stock issued and outstanding, all of which are duly authorized,
validly issued, fully paid and nonassessable and were not issued in violation of
any preemptive rights or any Federal or State securities laws, (iii) no shares
of Parent Common Stock are held by Subsidiaries of the Parent, (iv) 3,483,932
shares of Parent Common Stock are reserved for future issuance under outstanding
Parent Purchase Rights, and (v) 970,000 shares of Parent Common Stock (subject
to adjustment) are reserved for future issuance in connection with the
acquisition of a Veterinary Hospital. As of the date hereof, there are (i) no
options, warrants, calls, subscriptions, convertible securities or other rights,
(including preemptive rights), agreements, understandings, arrangements or
commitments of any character obligating the Parent now or at any time in the
future to issue or sell any of its capital stock or other equity interests of
the Parent or any of its Subsidiaries, (ii) there are no obligations, contingent
or otherwise, of the Parent or any of its Subsidiaries, to repurchase, redeem or
otherwise acquire any shares of capital stock or other equity interests of the
Parent or any of its Subsidiaries or to provide funds or to make any investment
(in the form of a loan, capital contribution or otherwise) in any Subsidiary or
another entity, other than guarantees of bank obligations of Subsidiaries
entered into in the ordinary course of business, (iii) there are no outstanding
bonds, debentures, notes or other obligations of Parent the holders of which
have the right to vote (or which are convertible into or exercisable for
securities having the right to vote) with the Parent shareholders on any matter,
(iii) there are no obligations, contingent or otherwise, guaranteeing the value
of any of the shares of the Common Stock of the Parent or any of its
Subsidiaries either now or at any time in the future, and (iv) there are no
voting trusts, proxies or other agreements or understandings to which the Parent
is a party or is bound with respect to the voting of any capital stock or other
equity interests of the Parent or any of its Subsidiaries.
23
<PAGE>
5.5. AUTHORIZATION OF PARENT COMMON STOCK. The issuance of shares of
Parent Common Stock at the Closing will have been duly authorized by all
necessary corporate action prior to the Effective Time and, when issued as
contemplated by this Agreement, all such shares of Parent Common Stock will be
validly issued, fully paid and non-assessable.
5.6. SEC REPORTS. The Parent has filed with the SEC all forms,
reports, registration statements, proxy statements and other documents
(collectively, the "Parent Reports") required to be filed by the Parent under
the Securities Laws, except failures to file which, individually or
collectively, do not have a Material Adverse Effect on Parent. The Parent has
heretofore furnished the Company with true and complete copies of all Parent
Reports filed as of the date hereof. As of their respective dates, or, in the
case of registration statements, as of their effective dates, all of the Parent
Reports, including all exhibits and schedules thereto and all documents
incorporated by reference therein, (i) complied as to form in all material
respects with the requirements of the Securities Laws applicable thereto, and
(ii) did not contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not
misleading. The Parent has filed with the SEC all documents and agreements
which were required to be filed as exhibits to the Parent Reports, except
failures to file, if any, which, individually or collectively, do not have a
Material Adverse Effect on Parent. The audited consolidated financial
statements and unaudited interim consolidated financial statements of the Parent
included or incorporated by reference in the Parent Reports (collectively, the
"Parent Financial Statements") have been prepared in accordance with GAAP
applied on a consistent basis (except as may be indicated therein or in the
notes thereto) and fairly present the financial position of the Parent as of and
at the dates thereof and the results of operations and cash flows for the
periods then ended, subject in the case of the unaudited interim financial
statements, to normal, recurring year-end adjustments and any other adjustments
described therein, which were not and are not expected to be material in amount
or effect. Except as set forth or reflected in the Parent Financial Statement
at December 31, 1995, or as set forth in the unaudited balance sheets included
in the Parent Reports since that date, neither the Parent nor any of its
Subsidiaries, has any liabilities or obligations of any kind or nature (whether
accrued, absolute, contingent or otherwise) which would be required to be
reflected or reserved against in any balance sheet of the Parent or any of its
Subsidiaries, or in the notes thereto, prepared in accordance with GAAP
consistently applied, except liabilities since December 31, 1995 either (i) in
the ordinary course of business or (ii) which, individually or collectively,
would not have a Material Adverse Effect on Parent.
24
<PAGE>
5.7. ABSENCE OF CERTAIN CHANGES OR EVENTS. Except as disclosed in
the Parent Reports filed with the SEC prior to the date hereof, since December
31, 1995, the Parent and its Subsidiaries have conducted their business in all
material respects in the ordinary and usual course consistent with past
practice, and there has not been (a) any event or occurrence which could result
in a Material Adverse Effect on Parent, (b) any material change in accounting
methods, principles and practices by the Parent and its Subsidiaries (except for
any such changes required by reason of a concurrent change in GAAP or to conform
a Subsidiary's accounting methods, principles or practices to those of Parent),
(c) any damage, destruction or loss, whether covered by insurance or not, having
a Material Adverse Effect on the Parent, (d) any entry by the Parent or any of
its Subsidiaries into any commitment or transaction material to the Parent which
is not in the ordinary course of business consistent with past practice, or (e)
any declaration, payment or setting aside for payment of any dividends.
5.8. LITIGATION. The Parent has disclosed in the Parent Disclosure
Letter all information in its possession or custody or under its control with
respect to litigation pending as of the date hereof. Except as set forth in the
Parent Disclosure Letter, the Parent has no litigation pending as of the date
hereof. To the best of the Parent's knowledge, the ultimate liability for
damages arising from such litigation (based upon assumptions that the Parent
believes in good faith to be reasonable under the circumstances) is either
adequately reserved against in the Parent Financial Statement at December 31,
1995 or in the unaudited balance sheets included in the Parent Reports since
that date or will not have a Material Adverse Effect on the Parent. Except as
set forth in the Parent Disclosure Letter, there are no actions, suits or
proceedings of any nature pending, or, to the knowledge of the Parent,
threatened, against or by the Parent or any of its properties, assets or
business, nor is the Parent or any of its properties, assets or business,
subject to any order, judgment, ruling, or decree of any competent authority,
which would have, or is reasonably likely to have, a Material Adverse Effect on
Parent. The Parent has not received notice of violation of any applicable
statute, regulation, code, ordinance, rule, order, judgment, decree or
requirement relating to its operations or its owned or leased properties and to
the Parent's knowledge, no such violation exists, in each case, other than a
violation which would not have a Material Adverse Effect on the Parent.
5.9. COMPLIANCE WITH APPLICABLE LAW. The businesses of the Parent
and its Subsidiaries are not being conducted in violation of any applicable law,
ordinance, regulation, decree or order of any governmental entity, except for
violations which either singly or in the aggregate do not and are not expected
to have a Material Adverse Effect on the Parent. Neither the Parent nor any
Parent Subsidiary is a party to or subject to any judgment, decree, or order
entered in any suit or proceeding brought by any governmental agency or by any
other person, enjoining the Parent or
25
<PAGE>
any Parent Subsidiary with respect to any business practice, the acquisition of
any property, or the conduct of business in any area.
5.10. NO BROKERS. Other than with respect to the services of NatWest
Securities, Limited, the Parent's financial advisor, (the arrangements with
which have been disclosed in writing to the Company), neither the Parent nor any
Subsidiary has entered into any contract, arrangement or understanding with any
Person or firm which may result in the obligation of the Parent, the Surviving
Corporation or the Company to pay any finder's fee, brokerage or agent's
commissions or other like payments in connection with the negotiation, execution
or performance of this Agreement and the Parent is not aware of any claim for
any such payment.
5.11. REGISTRATION STATEMENT; PROXY STATEMENT/PROSPEC-TUS. None of
the information supplied by the Parent for inclusion or incorporation by
reference in (a) the Form S-4, or (b) the Proxy Statement/Prospectus will, in
the case of the Form S-4, at the time it becomes effective and at the time of
the respective meetings of the Company's and the Parent's stockholders to vote
on this Agreement and the transactions contemplated hereby, and in the case of
the Proxy Statement/Prospectus, at the time of the mailing thereof to the
stockholders of the Company and Parent and at the time of such stockholders
meetings, contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not
misleading.
5.12. INFORMATION. All written information provided to Company or
its agents by or on behalf of the Parent or any of its representatives
(including, without limitation, each representation and warranty of the Parent
set forth in this Agreement) is, and the Parent covenants that any such
information provided hereafter shall be, true and correct in all material
respects and does not, or shall not, omit any material fact required to be
included therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading.
5.13. TAX FREE MERGER.
(a) At the Effective Time, by reason of the Merger, the
Surviving Corporation will acquire at least 90 percent of the fair market value
of the net assets and at least 70 percent of the fair market value of the gross
assets, held by the Company immediately prior to the Merger. For purposes of
this representation, amounts used by the Company to pay reorganization expenses
and all redemptions, distributions, and payments, in cash or property, made by
the Company to its stockholders in connection with the Merger shall be included
as assets of the Company prior to the Merger.
26
<PAGE>
(b) Prior to the Merger, Parent will be in control of Sub
within the meaning of Section 368(c) of the Code.
(c) Parent has no plan or intention as part of the plan of the
Merger to cause the Surviving Corporation to issue after the Effective Time
additional shares of stock that would result in Parent losing control of the
Surviving Corporation within the meaning of Section 368(c) of the Code or any
warrants, options, convertible securities, or any other type of right pursuant
to which any person could acquire stock in the Surviving Corporation that, if
exercised or converted, would affect Parent's acquisition or retention of
control of the Surviving Corporation, as defined in Section 368(c) of the Code.
(d) Parent has no plan or intention to reacquire any of its
Parent Common Stock issued in the Merger.
(e) Parent has no plan or intention to liquidate the Surviving
Corporation, to merge the Surviving Corporation with or into another corporation
or to sell or otherwise dispose of the Surviving Corporation stock except for
transfers of stock to a corporation controlled by Parent.
(f) Following the Merger, the Surviving Corporation will
continue the Company's historic business or use a significant portion of its
historic business assets in a business.
(g) Following the Effective Time, Parent shall use its best
efforts, and shall cause the Surviving Corporation to use its best efforts, to
conduct its business and the Surviving Corporation's business in a manner which
would not jeopardize the characterization of the Merger as a reorganization
within the meaning of Section 368(a)(2)(D) of the Code.
6. PRE-MERGER COVENANTS OF PARENT AND THE COMPANY. Each of Parent and
----------------------------------------------
the Company covenants and agrees with the other that:
6.1. CONDUCT OF BUSINESS BY THE COMPANY. During the period from the
date of this Agreement until the earlier to occur of the termination of this
Agreement or the Effective Time, except as contemplated by this Agreement,
unless the Parent has consented in writing thereto, the Company (i) shall, and
shall cause each of its Subsidiaries to, conduct its operations only in, and the
Company and its Subsidiaries shall not take any action except in, the ordinary
course of business and in a manner consistent with past practice, and (ii) shall
use its reasonable commercial efforts, and shall cause each of its Subsidiaries
to use its reasonable commercial efforts, to preserve intact its respective
business organizations and goodwill, keep available the services of its
respective officers and employees and maintain satisfactory relationships with
those persons having business relationships with it, and (iii) shall confer on a
regular basis with one or more representatives of the Parent to report
operational matters of
27
<PAGE>
materiality and any proposals to engage in any material transactions. By way of
amplification and not limitation, and except as noted above, neither the Company
nor any of its Subsidiaries shall, during the period from the date of this
Agreement and continuing until the earlier of the termination of this Agreement
or the Effective Time, directly or indirectly, do, or propose to do, any of the
following without the prior written consent of Parent:
(a) amend or otherwise change its Certificate of Incorporation
or Bylaws;
(b) split, combine, reclassify or amend the terms of any of
its capital stock;
(c) declare, set aside or pay any dividend or distribution
payable in cash, stock or property or any combination thereof with respect to
shares of its capital stock;
(d) except pursuant to Company Purchase Rights outstanding on
the date hereof, authorize, issue, sell, pledge, encumber or agree to authorize,
issue, sell, pledge or encumber any additional shares of its capital stock of
any class or any other securities in respect of, in lieu of or in substitution
of Company Common Stock outstanding as of the date hereof or any options,
warrants, conversion rights or other rights to acquire capital stock of the
Company or any of its Subsidiaries;
(e) redeem or otherwise acquire any of its outstanding equity
securities or any outstanding options or rights to purchase any such equity
securities or make any commitment to take such action;
(f) accelerate, amend or change (or permit any acceleration,
amendment or change of) the period of exercisability of any Company Purchase
Right or authorize cash payments in exchange for any Company Purchase Right
(other than pursuant to the express terms of such Company Purchase Right);
(g) sell, pledge, dispose of or encumber any material assets of
the Company or any of its Subsidiaries, except in the ordinary course of
business consistent with past practice;
(h) acquire (by merger, consolidation or acquisition of stock
or assets) any corporation, partnership or any other business organization or
division thereof;
(i) incur any indebtedness for borrowed money, or assume,
guarantee or otherwise as an accommodation become responsible for, the
obligations of any other person or entity (in the case of any such indebtedness,
Parent's consent shall not be unreasonably withheld or delayed);
28
<PAGE>
(j) authorize any capital expenditures or purchase of fixed
assets for the Company and its Subsidiaries which are in the aggregate more than
$500,000;
(k) increase the compensation or benefits payable or to become
payable to its officers or employees, except in amounts consistent with past
practices; or grant any severance or termination pay to, or enter into any
employment or severance agreement with, any director, officer or other employee
of the Company or any of its Subsidiaries; or establish any collective
bargaining, bonus, profit sharing, compensation, stock option, pension,
retirement, deferred compensation, employment or consulting or other plan,
agreement, trust, fund, plan, policy or arrangement for the benefit of any
current or former directors, officers or employees;
(l) take any action to change accounting policies or
procedures;
(m) make any material tax election inconsistent with past
practices or settle or compromise any material federal, state, local or foreign
tax liability;
(n) pay, discharge or satisfy any material claims, liabilities
or obligations other than in the ordinary course of business and consistent with
past practices;
(o) take or agree to take, any action which would cause a
material breach of any of the representations or warranties of the Company
contained in this Agreement or prevent the Company from performing or cause the
Company not to perform its covenants hereunder in any material respect; or
(p) submit any matters to the shareholders of the Company for a
vote prior to the Closing other than the Merger.
6.2. CONDUCT OF BUSINESS BY PARENT. During the period from the date
of this Agreement until the earlier to occur of the termination of this
Agreement or the Effective Time, except as contemplated by this Agreement,
unless the Company has consented in writing thereto, which consent shall not be
unreasonably withheld, Parent (i) shall, and shall cause each of its
Subsidiaries to, conduct its operations only in, and Parent and its Subsidiaries
shall not take any action except in, the ordinary course of business and in a
manner consistent with past practice, (ii) shall use its reasonable commercial
efforts, and shall cause each of its Subsidiaries to use its reasonable
commercial efforts, to preserve intact its respective business organizations and
goodwill, keep available the services of its respective officers and employees
and maintain satisfactory relationships with those persons having business
relationships with it, and (iii) shall not amend any of the material terms or
provisions of Parent's securities, except for any such amendments which affect
equally all shares of Parent
29
<PAGE>
Common Stock. Notwithstanding the foregoing, nothing contained in this Section
6.2 shall serve to preclude Parent from effecting (i) any and all acquisitions
which have been or are approved by its Board of Directors or (ii) any debt or
equity financing which has been or is approved by its Board of Directors.
6.3. INSPECTION OF RECORDS. From the date hereof to the earlier to
occur of the termination of this Agreement and the Effective Time, each of the
Company and Parent shall allow the duly authorized and appropriate officers,
attorneys, accountants and other representatives of the other access at all
reasonable times to the records and files, correspondence, audits and
properties, as well as to all information relating to commitments, contracts,
titles and financial position, or otherwise pertaining to, the business and
affairs of the Company and Parent and their respective Subsidiaries. Parent and
the Company acknowledge that they are parties to that certain Confidentiality
Agreement, dated February 5, 1996 (the "Confidentiality Agreement") the terms
and conditions of which shall survive the execution of this Agreement and shall
continue to be binding on the parties with respect to the inspections referred
to in this Section 6.3 of this Agreement.
6.4. STOCKHOLDER APPROVAL. Each of the Company and Parent will take
all necessary or appropriate action under the Exchange Act, Delaware Law and
their respective Certificates of Incorporation and Bylaws to call a meeting of
its stockholders, to be held at the earliest practicable date, to consider and
vote on a proposal to approve this Agreement, the Merger and the transactions
contemplated hereby and thereby, will submit the same to its stockholders with a
recommendation for approval by the Board of Directors of the Company or Parent,
as the case may be, and will solicit the approval thereof by such stockholders
by mailing or delivering to each of the stockholders a Proxy
Statement/Prospectus as provided for below.
6.5. REGISTRATION STATEMENT; PROXY STATEMENT. Parent and the
Company shall cooperate and promptly prepare, and Parent shall file with the SEC
as soon as practicable, a Registration Statement on Form S-4 ("Form S-4") under
the Securities Act, with respect to the Parent Common Stock issuable in the
Merger, a portion of which shall serve as the proxy statement with respect to
the meetings of stockholders of the Company and Parent (the "Proxy
Statement/Prospectus"). The respective parties will cause the Proxy
Statement/Prospectus and the Form S-4 to comply as to form in all material
respects with the applicable provisions of the Securities Act, the Exchange Act
and the rules and regulations thereunder. If at any time prior to the
stockholders' meetings referred to in Section 6.4 of this Agreement, any event
should occur relating to Parent or the Company which should be set forth in an
amendment of, or a supplement to, the Form S-4, the affected party will inform
the other and the Company and Parent shall promptly prepare, file and mail such
amendment or supplement; provided, no such amendment or supplement shall be
filed or mailed
30
<PAGE>
until approved by Parent and the Company and their respective counsel. Parent
shall use all reasonable efforts, and the Company will cooperate with Parent, to
have the Form S-4 declared effective by the SEC as promptly as practicable.
Parent shall use its best efforts to obtain, prior to the effective date of the
Form S-4 all necessary state securities law or "Blue Sky" permits or approvals
required to carry out the transactions contemplated by this Agreement and will
pay all expenses incident thereto.
6.6. AGREEMENTS BY AFFILIATED STOCKHOLDERS OF THE COMPANY. The
Company shall use all reasonable efforts to deliver or cause to be delivered to
Parent, at least 20 days prior to the Closing Date, from each of the Rule 145
Affiliates of the Company, an Affiliate Letter in a form reasonably acceptable
to the Company to the effect that such person will not offer to sell, sell or
otherwise dispose of any shares of the Parent Common Stock issued in the Merger
except pursuant to an effective registration statement or in compliance with
Rule 145, as amended from time to time, or in a transaction which, in the
opinion of legal counsel reasonably satisfactory to Parent, is exempt from the
registration requirements of the Securities Act. Parent shall be entitled to
place legends as specified in such Rule 145 Affiliate Letters on the certificate
evidencing any Parent Common Stock to be received by such Rule 145 Affiliates
pursuant to the terms of this Agreement, and to issue appropriate stop transfer
instructions to the transfer agent for the Parent Common Stock, consistent with
the terms of such Affiliate Letters.
6.7. EXPENSES. Whether or not the Merger is consummated, all costs
and expenses incurred in connection with this Agreement and the transactions
contemplated hereby shall be paid by the party incurring such expenses except as
expressly provided herein and except that (a) the filing fee in connection with
the Hart Scott Act filing (if applicable), (b) the filing fee in connection with
the filing of the Form S-4 or Proxy Statement/Prospectus with the SEC and (c)
the expenses incurred in connection with printing and mailing the Form S-4 and
the Proxy Statement/Prospectus, shall be shared equally by the Company and
Parent.
6.8. REORGANIZATION. From and after the date hereof and until the
Effective Time, neither Parent nor the Company nor any of their respective
Subsidiaries or other Affiliates shall (i) knowingly take any action, or
knowingly fail to take any action, that would jeopardize qualification of the
Merger as a reorganization with the meaning of Section 368(a) of the Code; or
(ii) enter into any contract, agreement, commitment or arrangement with respect
to the foregoing.
6.9. FILINGS; OTHER ACTION. Subject to the terms and conditions
herein provided, the Company and Parent shall (a) promptly make their respective
filing and thereafter make any other required submissions under the Hart Scott
Act with respect to the Merger; (b) use all reasonable efforts to cooperate with
one
31
<PAGE>
another in (i) determining which filings are required to be made prior to the
Effective Time with, and which consents, approvals, permits or authorizations
are required to be obtained prior to the Effective Time from states and foreign
jurisdictions in connection with the execution and delivery of this Agreement
and the consummation of the transactions contemplated hereby and (ii) timely
making all such filings and timely seeking all such consents, approvals, permits
or authorizations; and (c) use all reasonable efforts to take, or cause to be
taken, all other action and do, or cause to be done, all other things necessary,
proper or appropriate to consummate and make effective the transactions
contemplated by this Agreement. If, at any time after the Effective Time, any
further action is necessary or desirable to carry out the purpose of this
Agreement, the proper officers and directors of Parent and the Company shall
take all such necessary action.
6.10. PUBLICITY. The initial press release relating to this
Agreement shall be a joint press release in a form mutually agreeable to Parent
and the Company and the Parent and the Company shall, subject to their
respective legal obligations of public companies, use reasonable efforts to
agree upon the text of any other press release before issuing any such press
release or otherwise making public statements with respect to the transactions
contemplated hereby and in making any filings with any federal or state
governmental or regulatory agency or with any national securities exchange with
respect thereto.
6.11. ACQUISITION PROPOSALS. Prior to the Effective Time, the
Company agrees (a) that neither it nor any of its Subsidiaries shall, and it
shall direct and use its best efforts to cause its officers, directors,
employees, agents and representatives (including, without limitation, any
investment banker, attorney or accountant retained by it or any of its
Subsidiaries) not to, initiate, solicit or encourage, directly or indirectly,
any inquiries or the making or implementation of any proposal or offer
(including, without limitation, any proposal or offer to its Stockholders) with
respect to a merger, acquisition, consolidation or similar transaction
involving, or any purchase of all or any significant portion of the assets or
any equity securities of, the Company or any of its Subsidiaries (any such
proposal or offer being hereinafter referred to as an "Acquisition Proposal") or
engage in any negotiations concerning, or provide any confidential information
or data to, or have any discussions with, any person relating to an Acquisition
Proposal, or otherwise facilitate any effort or attempt to make or implement an
Acquisition Proposal; (b) that it will immediately cease and cause to be
terminated any existing activities, discussions or negotiations with any parties
conducted heretofore with respect to any of the foregoing and will take the
necessary steps to inform the individuals or entities referred to above of the
obligations undertaken in this Section 6.11; and (c) that it will notify Parent
immediately if any such inquiries or proposals are received by, any
32
<PAGE>
such information is received from, or any such negotiations or discussions are
sought to be initiated or continued with, it; provided, however, that nothing
-------- -------
contained in this Section 6.11 shall prohibit the Board of Directors of the
Company from (i) furnishing information to or entering into discussions or
negotiations with, any person or entity that makes an unsolicited bona fide
proposal to acquire the Company pursuant to a merger, consolidation, share
exchange, purchase of a substantial portion of the assets, business combination
or other similar transaction, if, and only to the extent that (A) the Board of
Directors determines in good faith that such action is required for the Board of
Directors to comply with its fiduciary duties to stockholders imposed by law,
(B) the Board of Directors has received a legal opinion from Haythe & Curley
that such action is required for the Board of Directors to comply with its
fiduciary duties to stockholders imposed by law, (C) prior to furnishing such
information to, or entering into discussions or negotiations with, such person
or entity, the Company provides written notice to Parent to the effect that it
is furnishing information to, or entering into discussions or negotiations with,
such person or entity, and (D) subject to any confidentiality agreement with
such person or entity (which such party determined in good faith was required to
be executed in order for the Board of Directors to comply with its fiduciary
duties to stockholders imposed by law), the Company keeps Parent informed of the
status (not the terms) of any such discussions or negotiations; and (ii) to the
extent applicable, complying with Rule 14e-2 promulgated under the Exchange Act
with regard to an Acquisition Proposal. Nothing in this Section 6.11 shall (x)
permit any party to terminate this Agreement (except as specifically provided in
Section 6.11 hereof), (y) permit any party to enter into any agreement with
respect to an Acquisition Proposal during the term of this Agreement (it being
agreed that during the term of this Agreement, no party shall enter into any
agreement with any person that provides for, or in any way facilitates, an
Acquisition Proposal (other than a confidentiality agreement in customary
form)), or (z) affect any other obligation of any party under this Agreement.
If, following any Acquisition Proposal, the Company subsequently effects any
merger, acquisition, consolidation or similar transaction involving, or any
purchase of all or any significant portion of the assets or any equity
securities of, the Company or any of its Subsidiaries, or this Agreement is
thereafter terminated, the Company shall pay Parent an amount equal to $3.5
million.
6.12. INDEMNIFICATION. From and after the Effective Time, Parent
shall cause the Surviving Corporation to, and the Surviving Corporation shall,
include as part of its Certificate of Incorporation and Bylaws provisions
relating to the indemnification of all current and former directors, officers,
employees and agents of the Company which are substantially similar to the
provisions contained in the Company's Certificate of Incorporation and Bylaws.
Such provisions shall not be amended, repealed or otherwise modified after the
Effective Time in any manner that would
33
<PAGE>
adversely affect the rights thereunder of individuals who at any time prior to
the Effective Time were directors, officers, employees or agents of the Company
in respect to actions or omissions occurring at or prior to the Effective Time
(including, without limitation, actions or omissions which occur in connection
with the transactions contemplated by this Agreement), unless such modification
is required by law.
7. CONDITIONS TO EACH PARTY'S OBLIGATION TO EFFECT THE MERGER. The
----------------------------------------------------------
respective obligations of each party to effect the Merger shall be subject to
the fulfillment at or prior to the Effective Time of the following conditions:
7.1. STOCKHOLDER APPROVAL. This Agreement shall have been approved
and adopted by the requisite vote or written consent of the stockholders of
Parent and the Company.
7.2. HART SCOTT ACT. The waiting period (and any extension
thereof), if any, applicable to the consummation of the Merger under the Hart
Scott Act shall have expired or have been terminated.
7.3. NO LEGAL ACTION. No preliminary or permanent injunction or
other order, decree or ruling issued by any court of competent jurisdiction, or
by any governmental, administrative or regulatory agency or commission, in the
United States preventing the consummation of the Merger shall be in effect.
7.4. REGISTRATION STATEMENT EFFECTIVE. The Registration Statement
on Form S-4 shall have become effective and shall not be subject to a "stop
order," and no action, suit, proceeding or investigation by the SEC to suspend
the effectiveness thereof shall have been initiated and be continuing, or shall
have been threatened and be unresolved.
7.5. LISTING OF ADDITIONAL SHARES ON NMS. The shares of Parent
Common Stock issued in connection with the Merger shall have been approved for
listing on NMS.
7.6. TAX OPINION. The Company and Parent shall have each received
an opinion from their respective counsel, dated the Effective Date, to the
effect that the Merger will be treated for Federal income tax purposes as a
reorganization within the meaning of Section 368(a) of the Code, and that the
Company will be a party to that reorganization within the meaning of Section
368(b) of the Code.
7.7. TRADING ACTIVITY. There shall not have occurred and be
continuing at any time within 30 days prior to the proposed Effective Date (i)
any suspension in trading on Nasdaq, any fixing of minimum or maximum prices for
trading, or maximum ranges for prices for securities on Nasdaq by the NASD or by
the SEC or any other governmental authority having jurisdiction, (ii) the
34
<PAGE>
declaration of a banking moratorium by federal or California authorities, (iii)
any suspension of payments in respect of banks in the United States, (iv) an
outbreak or major escalation of hostilities between the United States and any
foreign power or of any other insurrection or armed conflict involving the
United States, (v) any limitation, whether or not mandatory, by any governmental
authority on, or any event which might affect the extension of, credit by banks
or other financial institutions, or (vi) in the case of any of the foregoing
existing on the date hereof a material acceleration or worsening thereof.
8. ADDITIONAL CONDITIONS TO OBLIGATIONS OF THE PARENT. All obligations
--------------------------------------------------
of Parent under this Agreement are subject to the fulfillment at or prior to the
Closing of the following additional conditions, any of which may be waived in
writing in whole or in part by Parent:
8.1. REPRESENTATIONS, COVENANTS, CERTIFICATE. The Company shall
have performed in all material respects its agreements contained in this
Agreement required to be performed on or prior to the Effective Time, and the
representations and warranties of the Company herein contained shall be true in
all material respects as of the date of this Agreement and the Effective Time.
8.2. PERMITS AND APPROVALS. All material filings, registrations,
covenants, permits, authorizations and regulatory approvals of governmental
authorities necessary for the consummation of the Merger shall have been duly
obtained or made and shall be in full force and effect.
8.3. NO ADVERSE CHANGE. There shall not have occurred any change in
the financial condition, business or operations of the Company and its
subsidiaries that would have or would be reasonably likely to have a Material
Adverse Effect on the Company.
8.4. CERTAIN LEGAL MATTERS. There shall not have been any statute,
rule, regulation or order promulgated, enacted, entered, enforced or deemed
applicable to the Merger by any United States federal or state government or
governmental authority, nor shall there be in effect an order or judgment
entered by any United States federal or state court, which (i) would make the
consummation of the Merger illegal or would materially delay the Effective Time,
(ii) would require the divestiture by Parent, the Company or any of their
respective Subsidiaries of any of the shares of Company Common Stock or of a
material portion of the business, assets, or property of either Parent or any of
its Subsidiaries, or of the Company or any of its Subsidiaries, or impose any
material limitation on the ability of any of them to conduct their respective
businesses and own their respective assets or property, or (iii) impose any
limitations on the ability of
35
<PAGE>
Parent, directly or indirectly, to control in any material respect the business
or operations of the Company, or any of its Subsidiaries.
8.5. CERTIFICATE. Parent shall have received a certificate of the
Company dated the Effective Time, signed by a senior officer of the Company,
certifying that (i) all representations and warranties of the Company were true
and correct in all material respects when made and are true and correct in all
material respects on the Effective Time as if made on the Effective Time, and
(ii) the Company has performed and complied in all material respects with all
covenants and agreements required in this Agreement to be performed or complied
with by it on or prior to the Effective Time.
8.6. OPINION OF COUNSEL FOR THE COMPANY. Parent shall have received
from Messrs. Haythe & Curley, counsel for the Company herein, an opinion, dated
the Effective Time, in form and substance customary in transactions of the type
contemplated by this Agreement.
8.7. COMFORT LETTER. Parent shall have received a "comfort" letter
from Price Waterhouse LLP, independent public accountants for the Company, of
the kind contemplated by the Statement of Auditing Standards with respect to
Letters to Underwriters promulgated by the American Institute of Certified
Public Accountants (the "AICPA Statement"), dated the Effective Time, in form
and substance reasonably satisfactory to Parent in connection with the
procedures undertaken by it with respect to the financial statements and other
financial information of the Company and its Subsidiaries contained in the Proxy
Statement/Prospectus and Form S-4 and the other matters contemplated by the
AICPA Statement and customarily included in comfort letters relating to
transactions similar to the Merger.
8.8. RULE 145 AFFILIATES. Parent shall have received from each
"affiliate" of the Company, as such term is defined and used in SEC Rule 145
("Rule 145 Affiliates"), a written undertaking signed by such Rule 145 Affiliate
contemplated by Section 6.6 hereof.
8.9. AGREEMENTS WITH CERTAIN STOCKHOLDERS. Prior to the Closing
Date, Parent shall have received an agreement in a form reasonably satisfactory
to it executed by the Principal Stockholders to the effect that each such Person
shall not sell, transfer or otherwise dispose of the shares of Parent Common
Stock received in the Merger with respect to the Restricted Shares for a period
ending on April 30, 1997; provided, that, 33% of such shares of Parent Common
Stock issued to each Principal Stockholder shall be free of such restriction on
November 1, 1996 and the remaining shares shall be free of such restriction on
May 1, 1997, and (ii) each such Person shall grant a proxy to Parent to vote
such shares of Parent Common Stock for those Persons from time to time
36
<PAGE>
nominated for election by the Board of Directors (which proxy shall terminate
upon transfer of such shares to the public).
9. ADDITIONAL CONDITIONS TO THE OBLIGATIONS OF THE COMPANY. All
-------------------------------------------------------
obligations of the Company under this Agreement are subject to the fulfillment
at or prior to the Closing of the following additional conditions, any of which
may be waived in writing, in whole or in part, by the Company:
9.1. REPRESENTATIONS, COVENANTS, CERTIFICATE. Parent and Sub shall
have performed in all material respects their respective agreements contained in
this Agreement required to be performed on or prior to the Effective Time, and
the representations and warranties of Parent and Sub herein contained shall be
true and correct in all material respects as of the date of this Agreement and
the Effective Time with the same effect as though made at the Effective Time.
9.2. CERTAIN LEGAL MATTERS. There shall not have been any statute,
rule, regulation or order promulgated, enacted, entered, enforced or deemed
applicable to the Merger by any United States federal or state government or
governmental authority, nor shall there be in effect an order or judgment
entered by any United States federal or state court, which would make the
consummation of the Merger illegal or would delay the Effective Time beyond the
period set forth in Section 10.1.(d).
9.3. CERTIFICATE. The Company shall have received a certificate of
Parent dated the Effective Time, signed by a senior officer of Parent,
certifying that (i) all representations and warranties of Parent were true and
correct in all material respects when made and are true and correct in all
material respects on the Effective Time as if made on the Effective Time, and
(ii) Parent has performed and complied in all material respects with all
covenants and agreements required in this Agreement to be performed or complied
with by it on or prior to the Effective Time.
9.4. OPINION OF COUNSEL FOR PARENT AND SUB. The Company shall have
received from Messrs. Troop Meisinger Steuber & Pasich, LLP, counsel for Parent
and Sub, an opinion dated the Effective Time, in form and substance as is
customary in transactions of the type contemplated by this Agreement.
10. TERMINATION.
-----------
10.1. TERMINATION. This Agreement may be terminated at any time
prior to the Effective Time, notwithstanding the approval thereof by the
stockholders of Company or Parent:
(a) By the Parent, if any material condition to the obligations
of Parent set forth in Section 7 or 8 is not substantially satisfied at the
time or times contemplated thereby and such condition is not waived by Parent
or, by the Company, if
37
<PAGE>
any material condition to the obligations of the Company set forth in Section 7
or 9 is not substantially satisfied at the time or times contemplated thereby
and such condition is not waived by the Company. Each party's right to terminate
under this Section 10.1.(a) shall relate only to conditions to that party's
obligations;
(b) By the Company, upon a breach of any representation,
warranty, covenant or agreement on the part of Parent or Sub set forth in this
Agreement such that the conditions to the obligations of the Company set forth
herein would not be satisfied; provided, however, if such breach is curable
prior to September 1, 1996 by Parent or Sub through the exercise of reasonable
efforts, then so long as Parent or Sub, as the case may be, is exercising such
reasonable efforts, the Company may not terminate this Agreement pursuant to
this Section;
(c) By the Parent, upon a breach of any representation,
warranty, covenant or agreement on the part of the Company set forth in this
Agreement such that the conditions to the obligations of Parent set forth herein
would not be satisfied; provided, however, if such breach is curable prior to
September 1, 1996 by the Company through the exercise of reasonable efforts,
then so long as the Company is exercising such reasonable efforts, Parent may
not terminate this Agreement pursuant to this Section;
(d) By either Parent or the Company if the Merger shall not
have been consummated on or before September 1, 1996;
(e) By either Parent or the Company if a court of competent
jurisdiction or governmental, regulatory or administra-tive agency or commission
shall have issued a non-appealable final order, degree or ruling or taken any
other action, in each case having the effect of permanently restraining,
enjoining or otherwise prohibiting the Merger;
(f) By either Parent or the Company if, at either of their
respective stockholders' meetings, the requisite vote of the stockholders of the
Company or Parent, respectively, is not obtained;
(g) By either Parent or the Company if the Average Price is
equal to or less than $18.50; or
(h) By mutual written consent of the Company and Parent
authorized by their respective Boards of Directors.
10.2. EFFECT OF TERMINATION. If this Agreement is terminated
pursuant to Section 10.1, this Agreement shall become void and of no effect with
no liability on the part of any party hereto, except that (a) the agreements
contained in Section 6.7 and the last sentence of Section 6.3 shall survive the
termination hereof and (b) if termination of this Agreement shall be judicially
38
<PAGE>
determined to have been caused by willful breach of this Agreement, then, in
addition to other remedies at law or equity for breach of this Agreement, the
party so found to have willfully breached this Agreement shall indemnify the
other parties for their respective costs, fees and expenses of their counsel,
accountants and other experts and advisors as well as fees and expenses incident
to negotiation, preparation and execution of this Agreement and related
documentation and their stockholders' meetings and consents.
11. MISCELLANEOUS PROVISIONS.
------------------------
11.1. NOTICES. All notices, demands or other communications
hereunder shall be in writing and shall be deemed to have been duly given if (i)
delivered in person, on the date actually given, (ii) by United States mail,
certified or registered, with return receipt requested, on the date which is two
business days after the date of mailing, or (iii) if sent by telex or facsimile
transmission, with a copy mailed on the same day in the manner provided in (ii)
above, on the date transmitted provided receipt is confirmed by telephone:
(a) if to the Parent to:
Veterinary Centers of America, Inc.
3420 Ocean Park Boulevard
Santa Monica, California 90405
Attention: Robert L. Antin
Telecopy No.: (310) 392-7464
With copies to:
Troop Meisinger Steuber & Pasich, LLP
10940 Wilshire Boulevard
Suite 800
Los Angeles, California 90024
Attention: C.N. Franklin Reddick III, Esq.
Telecopy No.: (310) 443-8512
(b) if to the Company to:
The Pet Practice, Inc.
1018 West Ninth Avenue
King of Prussia, Pennsylvania 19406
Attention: Peter J. Cohen
Telecopy No.: (610) 992-0492
With copies to:
Haythe & Curley
237 Park Avenue
New York, New York 10017
Attention: Andrew J. Beck, Esq.
Telecopy No.: (212) 682-0200
or at such other address as may have been furnished by such Person in writing to
the other parties.
39
<PAGE>
11.2. SEVERABILITY. Should any Section or any part of a Section
within this Agreement be rendered void, invalid or unenforceable by any court of
law for any reason, such invalidity or unenforceability shall not void or render
invalid or unenforceable any other Section or part of a Section in this
Agreement.
11.3. EXHIBITS AND SCHEDULES. Each Exhibit and Schedule delivered
pursuant to the terms of this Agreement and each document, instrument and
certificate delivered by the parties in connection with the transactions
contemplated hereby constitutes an integral part of this Agreement.
11.4. GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND
CONSTRUED BOTH AS TO VALIDITY AND PERFORMANCE AND ENFORCED IN ACCORDANCE WITH
THE LAWS OF THE STATE OF DELAWARE, WITHOUT GIVING EFFECT TO THE CHOICE OF LAW
PRINCIPLES THEREOF.
11.5. NO ADVERSE CONSTRUCTION. The rule that a contract is to be
construed against the party drafting the contract is hereby waived, and shall
have no applicability in construing this Agreement or any provisions hereof.
11.6. COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original but all of which
together shall constitute one and the same instrument.
11.7. COSTS AND ATTORNEYS' FEES. In the event that any action, suit,
or other proceeding is instituted concerning or arising out of this Agreement,
the prevailing party shall recover all of such party's costs, and reasonable
attorneys' fees incurred in each and every such action, suit, or other
proceeding, including any and all appeals or petitions therefrom.
11.8. SUCCESSORS AND ASSIGNS. All rights, covenants and agreements
of the parties contained in this Agreement shall, except as otherwise provided
herein, be binding upon and inure to the benefit of their respective successors
and assigns.
11.9. AMENDMENT. This Agreement may be amended by the parties
hereto, by action taken by their respective Boards of Directors at any time
before or after approval hereof by the Stockholders, but after any such
approval, no amendment shall be made which changes the Exchange Factor, or which
is otherwise not permitted by the Delaware Law, without the further approval of
the Stockholders. This Agreement may not be amended except by an instrument in
writing signed on behalf of each of the parties hereto.
40
<PAGE>
11.10. WAIVER. At any time prior to the Effective Time, any party
hereto, by action taken by its Board of Directors, at any time before or after
approval hereof by the Stockholders of the Company, may (i) extend the time for
the performance of any of the obligations or other acts of the other parties
hereto, (ii) waive any inaccuracies in the representations and warranties of the
other parties contained herein or in any document delivered pursuant hereto, and
(iii) waive compliance with any of the agreements or conditions contained
herein. Any agreement on the part of a party hereto shall be valid if set forth
in an instrument in writing signed on behalf of such party by a duly authorized
officer.
11.11. ENTIRE AGREEMENT. This Agreement, the attached Exhibits and
Schedules, the other schedules referred to in this Agreement and the
Confidentiality Agreement contain the entire understanding of the parties and
there are no further or other agreements or understandings, written or oral, in
effect between the parties relating to the subject matter hereof unless
expressly referred to herein.
11.12. BEST EFFORTS. Subject to the terms and conditions of this
Agreement, each party will use its best efforts to take, or cause to be taken,
all actions and do, or cause to be done, all things necessary, proper or
advisable under applicable laws and regulations to consummate the transactions
contemplated by this Agreement.
11.13. SURVIVAL OF REPRESENTATIONS AND WARRANTIES. The
representations, warranties, covenants and agreements contained herein and in
any certificate or other writing delivered pursuant hereto shall not survive the
Effective Time, except Sections 2 and 6.12
41
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed and delivered
this Agreement as of the date first above written.
VETERINARY CENTERS OF AMERICA, INC.
A DELAWARE CORPORATION
By:______________________________
Name:
Title:
THE PET PRACTICE, INC.
A DELAWARE CORPORATION
By:______________________________
Name:
Title:
GOLDEN MERGER CORPORATION
A DELAWARE CORPORATION
By:______________________________
Name:
Title:
42
<PAGE>
PROJECT MILKBONE
<TABLE>
<S> <C> <C> <C> <C> <C> <C> <C>
Golden Stock Price $ 18.50 $ 19.00 $ 20.00 $ 21.00 $ 22.00 $ 23.00 $ 24.00
Lab Stock Price $ 7.816 $ 7.980 $ 8.300 $ 8.610 $ 8.910 $ 9.200 $ 9.480
Exchange Ratio 0.4225 0.4200 0.4150 0.4100 0.4050 0.4000 0.3950
Lab Shares 8.6 8.6 8.6 8.6 8.6 8.6 8.6
Golden Shares Issued 3.63 3.61 3.57 3.53 3.48 3.44 3.40
Transaction Value $ 67.2 $ 68.6 $ 71.4 $ 74.0 $ 76.6 $ 79.1 $ 81.5
Golden Stock Price $ 25.00 $ 26.00 $ 27.00 $ 28.00 $ 29.00 $ 30.00
Lab Stock Price $10.000 $10.000 $10.000 $10.000 $10.000 $10.000
Exchange Ratio 0.4000 0.3846 0.3704 0.3571 0.3448 0.3333
Lab Shares 8.6 8.6 8.6 8.6 8.6 8.6
Golden Shares Issued 3.44 3.31 3.19 3.07 2.97 2.87
Transaction Value $ 86.0 $ 86.0 $ 86.0 $ 86.0 $ 86.0 $ 86.0
Golden Stock Price $ 31.00 $ 32.00 $ 33.00 $ 34.00 $ 35.00
Lab Stock Price $10.385 $10.560 $10.725 $10.880 $11.025
Exchange Ratio 0.3350 0.3300 0.3250 0.3200 0.3150
Lab Shares 8.6 8.6 8.6 8.6 8.6
Golden Shares Issued 2.86 2.84 2.80 2.75 2.71
Transaction Value $ 89.3 $ 90.8 $ 92.2 $ 93.6 $ 94.8
</TABLE>
- ----------------------------
(i) Mutual out at a Golden price per share of $18.50
(ii) Below Golden price per share of $18.50, the exchange ratio is fixed at
0.4225.
(iii) Between price points the exchange ratio will be interpolated
proportionately.
(iv) Over Golden price per share of $49.00, the exchange ratio is equal to
$12.005 and the Average Price.
43
<PAGE>
APPENDIX B
[LETTERHEAD OF NATWEST MARKETS]
March 21, 1996
Board of Directors
Veterinary Centers of America, Inc.
3420 Ocean Park Boulevard, Suite 1000
Santa Monica, CA 90405
Gentlemen:
You have requested our opinion as to the fairness, to Veterinary Centers
of America, Inc. (the "Company"), from a financial point of view, of the
consideration to be paid by the Company pursuant to the Agreement and Plan of
Merger among the Company, Golden Merger Corporation, a wholly-owned subsidiary
of the Company (the "Subsidiary"), and The Pet Practice, Inc. ("Pet Practice"),
dated as of March 21, 1996 (the "Merger Agreement"), pursuant to which Pet
Practice is to be merged into the Subsidiary. The terms and conditions of the
foregoing transaction (the "Merger") are more fully set forth in the Merger
Agreement.
In arriving at our opinion, we have: (1) reviewed the Merger Agreement; (2)
reviewed historical financial and operating data of the Company and Pet
Practice; (3) reviewed financial and operating forecasts with respect to Pet
Practice provided to us by management representatives of the Company; (4)
considered public information of selected comparable companies, and compared Pet
Practice, from a financial point of view, with such companies; (5) considered
the terms, to the extent publicly available, of selected transactions comparable
to the Merger and compared the consideration to be paid by the Company with the
consideration involved in such transactions; (6) reviewed market price data and
trading activities for Pet Practice common stock; and (7) conducted such other
financial studies, analyses and investigations as we deemed appropriate. We also
held discussions with management representatives and representatives of the
independent accountants of the Company and Pet Practice concerning the business
and prospects of Pet Practice and the strategic and operating benefits
anticipated by the Company to be derived from the Merger.
We were not engaged to independently verify the accuracy or completeness of
any information which, we reviewed in arriving at our opinion. We relied upon
the accuracy and completeness of all such information, without independent
verification.
<PAGE>
With respect to the financial and operating forecasts provided to us, we
assumed, with your approval, that such forecasts were reasonably prepared on
bases reflecting the best currently available estimates and good faith judgments
of the management of the Company as to the future financial and operating
performance of Pet Practice, consistent with historical data. We also assumed,
with your approval, that a reasonable likelihood exists that the strategic and
operating benefits anticipated by the Company to be derived from the Merger will
be realized.
We were not engaged to conduct a physical inspection of any properties or
make an independent valuation or appraisal of any assets or liabilities of Pet
Practice and we were not furnished with any such valuations or appraisals. We
were not engaged to review any legal, accounting or tax aspects of the Merger.
Our opinion herein is based on our assessment of economic, market,
regulatory and other conditions as they exist and can be evaluated on the date
of this letter. Our opinion herein is provided solely for your use in your
evaluation of the Merger and is not intended to confer rights or remedies upon
any stockholders of the Company or any other persons.
National Westminster Bank Plc, New York Branch ("NatWest Markets"), and its
affiliates, as part of their investment banking services, are regularly engaged
in the valuation of businesses and securities in connection with mergers,
acquisitions, sales and distributions of listed and unlisted securities, private
placements and valuations for corporate and other purposes. NatWest Markets
will receive a fee for rendering this opinion. In the ordinary course of
business, our affiliates actively trade the securities of the Company and Pet
Practice for their own account and the accounts of their customers and,
accordingly, may at any time hold a long or short position in such securities.
We may provide investment banking and financial advisory services to the Company
in the future.
It is understood that except as required by law, this letter may not be
quoted or referred to in any filing, report, document, release or other
communication, whether written or oral, made, prepared, issued or transmitted by
the Company without our prior written consent, which will not be unreasonably
withheld.
On the basis of and subject to the matters set forth herein, we are of the
opinion that, as of the date hereof, the consideration to be paid by the Company
pursuant to the Merger Agreement is fair to the Company, from a financial point
of view.
Very truly yours,
/s/ National Westminster Bank Plc
National Westminster Bank Plc
New York Branch
<PAGE>
APPENDIX C
[LETTERHEAD OF SMITH BARNEY]
March 21, 1996
The Board of Directors
The Pet Practice, Inc.
1018 West Ninth Avenue
King of Prussia, Pennsylvania 19406
Members of the Board:
You have requested our opinion as to the fairness, from a financial point of
view, to the holders of the common stock of The Pet Practice, Inc. ("PPI") of
the consideration to be received by such holders pursuant to the terms and
subject to the conditions set forth in the Agreement and Plan of Reorganization,
dated as of March 21, 1996 (the "Agreement"), by and among PPI, Veterinary
Centers of America, Inc. ("VCAI") and Golden Merger Sub, a wholly owned
subsidiary of VCAI ("Sub"). As more fully described in the Agreement, (i) PPI
will be merged with and into Sub (the "Merger") and (ii) each outstanding share
of the common stock, par value $0.01 per share, of PPI (the "PPI Common Stock")
will be converted into the right to receive that number of shares of the common
stock, par value $0.001 per share, of VCAI (the "VCAI Common Stock") equal to
the Exchange Ratio, as described below.
As described in the Agreement, the Exchange Ratio will be determined as follows:
(i) if the average of the closing prices of VCAI Common Stock on the NASDAQ
National Market over the 20 trading day period ending on (and including) the
third trading day immediately preceding the date of PPI's stockholders' meeting
in respect of the Merger (the "Average Price") is between $25.00 and $30.00
(inclusive), the Exchange Ratio will be determined by dividing $10.00 by the
Average Price, (ii) if the Average Price is between $24.00 and $19.00
(inclusive), the Exchange Ratio will be 0.3950 at $24.00 and increased 0.005 for
each whole dollar by which the Average Price is less than $24.00, (iii) if the
Average Price is $18.50 or less, the Exchange Ratio will be 0.4225, (iv) if the
Average Price is equal to or greater than $31.00 and less than $49.00, the
Exchange Ratio will be 0.3350 at $31.00 and reduced 0.005 for each whole dollar
by which the Average Price is greater than $31.00, (v) if the Average Price is
within the ranges described in clause (ii) and (iv) above, but the Average Price
is not a whole dollar, then the Exchange Ratio will be determined as that which
would have been computed at the nearest whole dollar increased or decreased (as
applicable) by an amount equal to 0.005 multiplied by a fraction, the numerator
of which will be the difference between the Average Price and such nearest whole
dollar, and the denominator of which will be $1.00, (vi) if the Average Price is
between $19.00 and $18.50 (exclusive), the Exchange Ratio will be 0.4200
increased by an amount equal to 0.0025 multiplied by a fraction, the numerator
of which is the difference between $19.00 and the Average Price and the
denominator of which is $0.50, (vii) if the Average Price is between $24.00 and
$25.00 (exclusive), the Exchange Ratio will be 0.3950 increased by an amount
equal to 0.005 multiplied by a fraction, the numerator of which is the
difference between the Average Price and $24.00 and the denominator of which is
$1.00, (viii) if the Average Price is between $30.00 and $31.00 (exclusive), the
Exchange Ratio will be 0.3333 increased by an amount equal to 0.0017 multiplied
by a fraction, the numerator of which is the difference between the Average
Price and $30.00 and the denominator of which is $1.00, and (ix) if the Average
Price is greater than $49.00, the Exchange Ratio will be determined by dividing
$12.005 by the Average Price.
<PAGE>
The Board of Directors
The Pet Practice, Inc.
March 21, 1996
Page 2
In arriving at our opinion, we reviewed the Agreement and held discussions with
certain senior officers, directors and other representatives and advisors of PPI
and certain senior officers and other representatives and advisors of VCAI
concerning the businesses, operations and prospects of PPI and VCAI. We examined
certain publicly available business and financial information relating to PPI
and VCAI as well as certain financial forecasts and other data for PPI and VCAI
which were provided to us or otherwise discussed with the respective managements
of PPI and VCAI, including information relating to certain strategic
implications and operational benefits anticipated to result from the Merger. We
reviewed the financial terms of the Merger as set forth in the Agreement in
relation to, among other things: current and historical market prices and
trading volumes of PPI Common Stock and VCAI Common Stock; the respective
companies' historical and projected earnings and operating data; and the
capitalization and financial condition of PPI and VCAI. We also considered, to
the extent publicly available, the financial terms of certain other similar
transactions recently effected which we considered relevant in evaluating the
Merger and analyzed certain financial, stock market and other publicly available
information relating to the businesses of other companies whose operations we
considered relevant in evaluating those of PPI and VCAI. We also evaluated the
potential pro forma financial impact of the Merger on VCAI. In addition to the
foregoing, we conducted such other analyses and examinations and considered such
other financial, economic and market criteria as we deemed appropriate in
arriving at our opinion.
In rendering our opinion, we have assumed and relied, without independent
verification, upon the accuracy and completeness of all financial and other
information publicly available or furnished to or otherwise reviewed by or
discussed with us. With respect to financial forecasts and other information and
data furnished to or otherwise reviewed by or discussed with us, we have been
advised by the managements of PPI and VCAI that such forecasts and other
information and data were reasonably prepared on bases reflecting the best
currently available estimates and judgments of the respective managements of PPI
and VCAI as to the future financial performance of PPI and VCAI and the
strategic implications and operational benefits anticipated to result from the
Merger. We have assumed, with your consent, that the Merger will be treated as a
tax-free reorganization for federal income tax purposes. Our opinion, as set
forth herein, relates to the relative values of PPI and VCAI. We are not
expressing any opinion as to what the value of the VCAI Common Stock actually
will be when issued to PPI stockholders pursuant to the Merger or the price at
which the VCAI Common Stock will trade subsequent to the Merger. We have not
made or been provided with an independent evaluation or appraisal of the assets
or liabilities (contingent or otherwise) of PPI or VCAI nor have we made any
physical inspection of the properties or assets of PPI or VCAI. We were not
asked to consider, and our opinion does not address, the relative merits of the
Merger as compared to any alternative business strategies that might exist for
PPI or the effect of any other transaction in which PPI might engage. Our
opinion is necessarily based upon information available to us, and financial,
stock market and other conditions and circumstances existing and disclosed to
us, as of the date hereof.
Smith Barney has been engaged to render financial advisory services to PPI in
connection with the Merger and will receive a fee for our services, a
significant portion of which is contingent upon the consummation of the Merger.
We will also receive a fee upon the delivery of this opinion. In the ordinary
course of our business, we and our affiliates may actively trade or hold the
securities of PPI and VCAI for our own account or for the account of our
customers and, accordingly, may at any time hold a long or short position in
such securities. We have in the past provided certain investment banking
services to PPI unrelated to the proposed Merger, for which services we have
received
<PAGE>
The Board of Directors
The Pet Practice, Inc.
March 21, 1996
Page 3
compensation. In addition, Smith Barney and its affiliates (including Travelers
Group Inc. and its affiliates) may maintain relationships with PPI, VCAI and
their respective affiliates.
Our advisory services and the opinion expressed herein are provided for the
information of the Board of Directors of PPI in its evaluation of the proposed
Merger, and our opinion is not intended to be and does not constitute a
recommendation to any stockholder as to how such stockholder should vote on the
proposed Merger. Our opinion may not be published or otherwise used or referred
to, nor shall any public reference to Smith Barney be made, without our prior
written consent.
Based upon and subject to the foregoing, our experience as investment bankers,
our work as described above and other factors we deemed relevant, we are of the
opinion that, as of the date hereof, the Exchange Ratio is fair, from a
financial point of view, to the holders of PPI Common Stock.
Very truly yours,
/s/SMITH BARNEY INC.
- --------------------
SMITH BARNEY INC.
<PAGE>
APPENDIX D
VETERINARY CENTERS OF AMERICA, INC.
1996 STOCK INCENTIVE PLAN
ARTICLE 1
GENERAL PURPOSE OF PLAN
The name of this plan is the Veterinary Centers of America, Inc. 1996 Stock
Incentive Plan (the "Plan"). The purpose of the Plan is to enable Veterinary
Centers of America, Inc., a Delaware corporation (the "Company"), and any Parent
or any Subsidiary to obtain and retain the services of the types of employees,
consultants, officers and Directors who will contribute to the Company's long
range success and to provide incentives which are linked directly to increases
in share value which will inure to the benefit of all shareholders of the
Company.
ARTICLE 2
DEFINITIONS
For purposes of the Plan, the following terms shall be defined as set forth
below:
"Board" means the Board of Directors of the Company.
"Code" means the Internal Revenue Code of 1986, as amended from time to
time, or any successor thereto.
"Committee" means a committee of the Board designated by the Board to
administer the Plan and composed of not less than the minimum number of persons
from time to time required both by the Rule and Section 162(m) of the Code, each
of whom is a Disinterested Person and an Outside Director.
"Company" means Veterinary Centers of America, Inc., a corporation
organized under the laws of the State of Delaware (or any successor
corporation).
"Date of Grant" means the date on which the Committee adopts a resolution
expressly granting Stock Options to a Participant, or if a different date is set
forth in such resolution as the Date of Grant, then such date as is set forth in
such resolution.
"Director" means a member of the Board.
"Disability" means permanent and total disability as defined by the
Committee.
"Disinterested Person" shall have the meaning set forth in Rule 16b-
3(c)(2)(i) under the Exchange Act, or any successor definition adopted by the
SEC.
"Election" shall have the meaning set forth in Section 10.3(d)(i) of the
Plan.
"Eligible Person" means an employee, officer, consultant or, subject to the
limitations set forth in Article 5 of the Plan, Director of the Company, any
Parent or any Subsidiary.
"Exchange Act" means the Securities Exchange Act of 1934, as amended.
"Exercise Price" shall have the meaning set forth in Section 6.2(c) of the
Plan.
<PAGE>
"Fair Market Value" per share at any date shall mean (i) if the Stock is
listed on an exchange or exchanges, or admitted for trading in a market system
which provides last sale data under Rule 11Aa3-1 of the General Rules and
Regulations of the SEC under the Exchange Act (a "Market System"), the last
reported sales price per share on the last business day prior to such date on
the principal exchange on which it is traded, or in a Market System, as
applicable, or if no sale was made on such day on such principal exchange or in
such a Market System, as applicable, the last reported sales price per share on
the most recent day prior to such date on which a sale was reported on such
exchange or such Market System, as applicable; or (ii) if the Stock is not then
traded on an exchange or in a Market System, the average of the closing bid and
asked prices per share for the Stock in the over-the-counter market as quoted on
NASDAQ on the day prior to such date; or (iii) if the Stock is not listed on an
exchange or quoted on NASDAQ, an amount determined in good faith by the
Committee.
"Liquidating Event" shall have the meaning set forth in Section 8.1(b) of
the Plan.
"Liquidity Event" means any Reorganization Event which the Committee
determines, in its sole and absolute discretion, to treat as such an event.
"Incentive Stock Option" means a Stock Option intended to qualify as an
"incentive stock option" as that term is defined in Section 422 of the Code.
"Non-Statutory Stock Option" means a Stock Option intended to not qualify
as an Incentive Stock Option.
"Optionee" means a Participant who is granted a Stock Option pursuant to
the Plan.
"Outside Director" means a Director who is not (a) a current employee of
the Company (or any related entity), (b) a former employee of the Company (or
any related entity) who is receiving compensation for prior services (other than
benefits under a tax-qualified retirement plan), (c) a former officer of the
Company (or any related entity), or (d) a consultant or person otherwise
receiving compensation or other remuneration, either directly or indirectly, in
any capacity other than as a Director.
"Parent" means any present or future corporation which would be a "parent
corporation" as that term is defined in Section 424 of the Code.
"Participant" means any Eligible Person selected by the Committee, pursuant
to the Committee's authority set forth in Article 3 of the Plan, to receive
grants of Stock Options.
"Plan" means this Veterinary Centers of America, Inc. 1996 Stock Incentive
Plan, as the same may be amended or supplemented from time to time.
"Reorganization Event" shall have the meaning set forth in Section 8.1(c)
of the Plan.
"Retirement" means retirement from active employment with the Company or
any Parent or Subsidiary as defined by the Committee.
"Rule" means Rule 16b-3 and any future rules promulgated in substitution
therefor under the Exchange Act.
"SEC" means the Securities and Exchange Commission.
"Section 16(b) Person" means a person subject to Section 16(b) of the
Exchange Act.
"Stock" means the Common Stock, par value $.001 per share, of the Company.
2
<PAGE>
"Stock Option" means an option to purchase shares of Stock granted pursuant
to Article 6 of the Plan.
"Stock Option Agreement" shall have the meaning set forth in Section 6.2 of
the Plan.
"Subsidiary" means any present or future corporation which would be a
"subsidiary corporation" as that term is defined in Section 424 of the Code.
"Tax Date" shall have the meaning set forth in Section 10.3(d)(iii) of the
Plan.
"Ten Percent Shareholder" means a person who on the Date of Grant owns,
either directly or through attribution as provided in Section 424(d) of the
Code, Stock possessing more than 10% of the total combined voting power of all
classes of stock of the Company or of any Parent or Subsidiary.
"Withholding Right" shall have the meaning set forth in Section 10.3(c) of
the Plan.
ARTICLE 3
ADMINISTRATION
SECTION 3.1 Committee. The Plan shall be administered by the Committee.
SECTION 3.2 Powers in General. The Committee shall have the power and
authority to grant Stock Options to Eligible Persons, pursuant to the terms of
the Plan.
SECTION 3.3 Specific Powers. In particular, the Committee shall have the
authority: (i) to construe and interpret the Plan and apply its provisions; (ii)
to promulgate, amend and rescind rules and regulations relating to the
administration of the Plan; (iii) to authorize any person to execute, on behalf
of the Company, any instrument required to carry out the purposes of the Plan;
(iv) to determine when Stock Options are to be granted under the Plan; (v) from
time to time to select, subject to the limitations set forth in this Plan, those
Eligible Persons to whom Stock Options shall be granted; (vi) to determine the
number of shares of Stock to be made subject to each Stock Option; (vii) to
prescribe the terms and conditions of each Stock Option, including, without
limitation, the Exercise Price and medium of payment and vesting provisions, to
determine whether the Stock Option is to be an Incentive Stock Option or a Non-
Statutory Stock Option and to specify the provisions of the Stock Option
Agreement relating to such Stock Option; (viii) to amend any outstanding Stock
Options for the purpose of modifying the time or manner of vesting, the Exercise
Price, thereunder or otherwise, subject to applicable legal restrictions and to
the consent of the other party to such agreement; (ix) to determine when a
consultant's relationship with the Company is sufficient to constitute the
equivalent of employment with the Company for purposes of the Plan; (x) to
determine the duration and purpose of leaves of absences which may be granted to
a Participant without constituting termination of his or her employment for
purposes of the Plan; and (xi) to make any and all other determinations which it
determines to be necessary or advisable for administration of the Plan.
SECTION 3.4 Decisions Final. All decisions made by the Committee pursuant
to the provisions of the Plan shall be final and binding on the Company and the
Participants.
SECTION 3.5 The Committee. The Board may, in its sole and absolute
discretion, from time to time delegate any or all of its duties and authority
with respect to the Plan to the Committee whose members are to be appointed by
and to serve at the pleasure of the Board. Once appointed, the Committee shall
continue to serve until otherwise directed by the Board. From time to time, the
Board may increase or decrease (to not less than the minimum number of persons
from time to time required by both the Rule and Section 162(m) of the Code) the
size of the Committee, add additional members to, remove members (with or
without cause) from, appoint new members in substitution therefor, and fill
vacancies, however caused, in the Committee. The Committee shall act pursuant
3
<PAGE>
to a vote of the majority of its members or, in the case of a committee
comprised of only two members, the unanimous consent of its members, whether
present or not, or by the written consent of the majority of its members or, in
the case of a committee comprised of only two members, the unanimous written
consent of its members, and minutes shall be kept of all of its meetings and
copies thereof shall be provided to the Board. Subject to the limitations
prescribed by the Plan and the Board, the Committee may establish and follow
such rules and regulations for the conduct of its business as it may determine
to be advisable.
ARTICLE 4
STOCK SUBJECT TO PLAN
SECTION 4.1 Stock Subject to the Plan. Subject to adjustment as provided
in Article 8, the total number of shares of Stock reserved and available for
issuance under the Plan shall be 1,500,000 shares.
SECTION 4.2 Unexercised Stock Options; Reacquired Shares. To the extent
that any Stock Options expire or are otherwise terminated without being
exercised, the shares of Stock underlying such Stock Options (and shares related
thereto) shall again be available for issuances in connection with future Stock
Options under the Plan. If and to the extent that the Company receives shares of
Stock in payment of all or a portion of the purchase price for any Stock, or in
payment of any tax liabilities, the receipt of such shares will not increase the
number of shares available for issuance under the Plan.
ARTICLE 5
ELIGIBILITY
Outside Directors who are designated as Eligible Persons by the Board of
Directors, Outside Directors who are not so designated as Eligible Persons (but
only to the extent provided by Article 7 hereof), officers, employees and
consultants of the Company, any Parent or any Subsidiary, shall be eligible to
be granted Stock Options hereunder, subject to limitations set forth in this
Plan; provided, however, that only officers and employees shall be eligible to
be granted Incentive Stock Options hereunder.
ARTICLE 6
STOCK OPTIONS
SECTION 6.1 General. Each Stock Option granted under the Plan shall be in
such form and under such terms and conditions as the Committee may from time to
time approve; provided, that such terms and conditions are not inconsistent with
the Plan. The provisions of Stock Option Agreements entered into under the Plan
need not be identical with respect to each Optionee. Stock Options granted under
the Plan may be either Incentive Stock Options or Non-Statutory Stock Options.
SECTION 6.2 Terms and Conditions of Stock Options. Each Stock Option
granted pursuant to the Plan shall be evidenced by a written option agreement
between the Company and the Optionee (the "Stock Option Agreement"), which shall
comply with and be subject to the following terms and conditions.
(a) Number of Shares. Each Stock Option Agreement shall state the number
of shares of Stock to which the Stock Option relates.
(b) Type of Option. Each Stock Option Agreement shall identify the portion
(if any) of the Stock Option which constitutes an Incentive Stock Option.
4
<PAGE>
(c) Exercise Price. Each Stock Option Agreement shall state the price at
which shares subject to the Stock Option may be purchased (the "Exercise
Price"), which, with respect to Incentive Stock Options, shall not be less than
100% of the Fair Market Value of the shares of Stock on the Date of Grant;
provided, however, that in the case of an Incentive Stock Option granted to a
Ten Percent Shareholder, the Exercise Price shall not be less than 110% of such
Fair Market Value.
(d) Value of Shares. The Fair Market Value of the shares of Stock
(determined as of the Date of Grant) with respect to which Incentive Stock
Options are first exercisable by an Optionee under this Plan and all other
incentive option plans of the Company and any Parent or Subsidiary in any
calendar year shall not, for such year, in the aggregate, exceed $________;
provided, however, that if the aggregate Fair Market Value of such shares
exceeds $________, then the incremental portion in excess of $________ shall be
treated as Non-Statutory Stock Options (and not as Incentive Stock Options);
provided, further, that this Section 6.2(d) shall not affect the right of the
Committee to accelerate or otherwise alter the time of vesting of any Stock
Options granted as Incentive Stock Options, even if, as a result thereof, some
of such Stock Options cease being Incentive Stock Options.
(e) Medium and Time of Payment. The Exercise Price shall be paid in full,
at the time of exercise, (i) in cash or cash equivalents, (ii) with the approval
of the Committee, in shares of Stock which have been held by the Optionee for a
period of at least six calendar months preceding the date of surrender and which
have a Fair Market Value equal to the Exercise Price, (iii) in a combination of
cash, cash equivalents and Stock, or (iv) in any other form of legal
consideration acceptable to the Committee, and may be effected in whole or in
part (x) with monies received from the Company at the time of exercise as a
compensatory, cash payment or (y) with monies borrowed from the Company in
accordance with Section 10.5.
(f) Term and Exercise of Stock Options. Stock Options shall vest or become
exercisable over the exercise period at the times the Committee may determine,
as reflected in the related Stock Option Agreements; provided, however, that the
Optionees shall have the right to exercise the Stock Options at the rate of at
least 20% per year over five years from the Date of Grant of such Stock Options.
The exercise period of any Stock Option shall be determined by the Committee,
but shall not exceed ten years from the Date of Grant of the Stock Option. In
the case of an Incentive Stock Option granted to a Ten Percent Shareholder, the
exercise period shall be determined by the Committee. but shall not exceed five
years from the Date of Grant of the Stock Option. A Stock Option may be
exercised, as to any or all full shares of Stock as to which the Stock Option
has become exercisable, by giving written notice of such exercise to the
Company.
ARTICLE 7
MANDATORY GRANTS TO OUTSIDE DIRECTORS
SECTION 7.1 Mandatory Grants to Outside Directors. Notwithstanding any
other provision of this Plan, the grant of Stock Options to Outside Directors
shall be subject to the following limitations of this Article 7.
(a) Upon the initial election or appointment of an Outside Director, the
Committee shall grant to such member, at the first meeting of the Committee
following the date of such election or appointment, a ten year Non-Statutory
Stock Option to purchase 10,000 shares of Stock.
(b) The Committee shall grant to each Outside Director, effective as of
each annual meeting of the Company's stockholders at the conclusion of which the
Outside Director still serves as a Director of the Company, a ten year Non-
Statutory Stock Option to purchase 5,000 shares of Stock.
(c) All Stock Options granted to Outside Directors under this Article 7
shall be exercisable at an Exercise Price equal to 100% of the Fair Market Value
of a share of Stock on the Date of Grant.
5
<PAGE>
(d) All Stock Options granted to Outside Directors under this Article 7
will vest or become exercisable as follows: 33% of the Stock Options (rounded up
to the nearest whole share) shall vest on the first anniversary of the Date of
Grant of the Stock Options, and 33% of the Stock Options (rounded up to the
nearest whole share) shall vest on the second anniversary of the Date of Grant
of the Stock Options, and the remaining Stock Options shall vest on the third
anniversary of the Date of Grant of the Stock Options.
(e) Unless otherwise provided in the Plan, all provisions regarding the
terms of Non-Statutory Stock Options, other than those pertaining to the Date of
Grant, the number of shares covered by such grant, term and Exercise Price shall
be applicable to the Stock Options granted to Outside Directors under this
Article 7.
SECTION 7.2 Prohibition of Other Grants to Outside Directors.
Notwithstanding any other provisions in this Plan, the mandatory grants
described in this Article 7 shall constitute the only grants under the Plan
permitted to be made to Outside Directors unless such persons are designated
Eligible Persons by the Board of Directors.
SECTION 7.3 Prohibition Against Certain Amendments. Notwithstanding any
other provisions of this Plan, the provisions of this Article 7 shall not be
amended more than once every six months, other than to comport with changes in
the Code, the Employee Retirement Income Security Act, or the rules thereunder.
ARTICLE 8
ADJUSTMENTS
SECTION 8.1 Effect of Certain Changes.
(a) Stock Dividends, Splits, etc. If there is any change in the number of
outstanding shares of Stock through the declaration of Stock dividends or
through a recapitalization resulting in Stock splits, or combinations or
exchanges of the outstanding shares, (i) the number of shares of Stock available
for Stock Options, (ii) the number of shares covered by outstanding Stock
Options, (iii) the number of shares set forth under Section 10.1(a) and (iv) the
Exercise Price of any Stock Option, in effect prior to such change, shall be
proportionately adjusted by the Committee to reflect any increase or decrease in
the number of issued shares of Stock; provided, however, that any fractional
shares resulting from the adjustment shall be eliminated.
(b) Liquidating Event. In the event of the proposed dissolution or
liquidation of the Company, or in the event of any corporate separation or
division, including, but not limited to, a split-up, split-off or spin-off
(each, a "Liquidating Event"), the Committee may provide that the holder of any
Stock Options then exercisable shall have the right to exercise such Stock
Options (at the price provided in the agreement evidencing the Stock Options)
subsequent to the Liquidating Event, and for the balance of its term, solely for
the kind and amount of shares of Stock and other securities, property, cash or
any combination thereof receivable upon such Liquidating Event by a holder of
the number of shares of Stock for or with respect to which such Stock Options
might have been exercised immediately prior to such Liquidating Event; or the
Committee may provide, in the alternative, that each Stock Option granted under
the Plan shall terminate as of a date to be fixed by the Board; provided,
however, that not less than 30 days written notice of the date so fixed shall be
given to each Stock Option holder and if such notice is given, each Stock Option
holder shall have the right, during the period of 30 days preceding such
termination, to exercise his or her Stock Options as to all or any part of the
shares of Stock covered thereby, without regard to any installment or vesting
provisions in his or her Stock Options agreement, on the condition, however,
that the Liquidating Event actually occurs; and if the Liquidating Event
actually occurs, such exercise shall be deemed effective (and, if applicable,
the Stock Option holder shall be deemed a shareholder with respect to the Stock
Options exercised) immediately preceding the occurrence of the Liquidating Event
(or the date of record for shareholders entitled to share in such Liquidating
Event, if a record date is set).
6
<PAGE>
(c) Merger or Consolidation. In the case of any capital reorganization,
any reclassification of the Stock (other than a change in par value or
recapitalization described in Section 8.1(a) of the Plan), or the consolidation
of the Company with, or a sale of substantially all of the assets of the Company
to (which sale is followed by a liquidation or dissolution of the Company), or
merger of the Company with another person (a "Reorganization Event"), the
Committee may provide in the Stock Option Agreement, or if not provided in the
Stock Option Agreement, may determine, in its sole and absolute discretion, to
accelerate the vesting of outstanding Stock Options (a "Liquidity Event") in
which case the Company shall deliver to the Stock Option holders at least 15
days prior to such Reorganization Event (or at least 15 days prior to the date
of record for shareholders entitled to share in the securities or property
distributed in the Reorganization Event, if a record date is set) a notice which
shall (i) indicate whether the Reorganization Event shall be considered a
Liquidity Event and (ii) advise the Stock Option holder of his or her rights
pursuant to the agreement evidencing such Stock Options. If the Reorganization
Event is determined to be a Liquidity Event, (i) the Surviving Corporation may,
but shall not be obligated to, tender stock options or stock appreciation rights
to the Stock Option holder with respect to the Surviving Corporation, and such
new options and rights shall contain terms and provisions that substantially
preserve the rights and benefits of the applicable Stock Options then
outstanding under the Plan, or (ii) in the event that no stock options or stock
appreciation rights have been tendered by the Surviving Corporation pursuant to
the terms of item (i) immediately above, the Stock Option holder shall have the
right, exercisable during a 10 day period ending on the fifth day prior to the
Reorganization Event (or ending on the fifth day prior to the date of record for
shareholders entitled to share in the securities or properly distributed in the
Reorganization Event, if a record date is set), to exercise his or her rights as
to all or any part of the shares of Stock covered thereby, without regard to any
installment or vesting provisions in his or her Stock Options agreement, on the
condition, however, that the Reorganization Event is actually effected; and if
the Reorganization Event is actually effected, such exercise shall be deemed
effective (and, if applicable, the Stock Option holder shall be deemed a
shareholder with respect to the Stock Options exercised) immediately preceding
the effective time of the Reorganization Event (or on the date of record for
shareholders entitled to share in the securities or property distributed in the
Reorganization Event, if a record date is set). If the Reorganization Event is
not determined to be a Liquidity Event, the Stock Option holder shall thereafter
be entitled upon exercise of the Stock Options to purchase the kind and number
of shares of stock or other securities or property of the Surviving Corporation
receivable upon such event by a holder of the number of shares of the Stock
which the Stock Options would have entitled the Stock Option holder to purchase
from the Company if the Reorganization Event had not occurred, and in any such
case, appropriate adjustment shall be made in the application of the provisions
set forth in this Plan with respect to the Stock Option holder's rights and
interests thereafter, to the end that the provisions set forth in the agreement
applicable to such Stock Options (including the specified changes and other
adjustments to the Exercise Price) shall thereafter be applicable in relation to
any shares or other property thereafter purchasable upon exercise of the Stock
Options.
(d) Par Value Changes. In the event of a change in the Stock of the
Company as presently constituted which is limited to a change of all of its
authorized shares with par value, into the same number of shares without par
value, or any subsequent change in the par value. the shares resulting from any
such change shall be "Stock" within the meaning of the Plan.
SECTION 8.2 Decision of Committee Final. To the extent that the foregoing
adjustments relate to stock or securities of the Company, such adjustments shall
be made by the Committee, whose determination in that respect shall be final,
binding and conclusive; provided, however, that each Incentive Stock Option
granted pursuant to the Plan shall not be adjusted without the prior consent of
the holder thereof in a manner that causes such Stock Option to fail to continue
to qualify as an Incentive Stock Option.
SECTION 8.3 No Other Rights. Except as expressly provided in this Article
8, no Stock Option holder shall have any rights by reason of any subdivision or
consolidation of shares of Stock or the payment of any dividend or any other
increase or decrease in the number of shares of Stock of any class or by reason
of any Liquidating Event, merger, or consolidation of assets or stock of another
corporation, or any other issue by the Company of shares of stock of any class,
or securities convertible into shares of stock of any class; and except as
7
<PAGE>
provided in this Article 8, none of the foregoing events shall affect, and no
adjustment by reason thereof shall be made with respect to, the number or price
of shares of Stock subject to Stock Options. The grant of Stock Options pursuant
to the Plan shall not affect in any way the right or power of the Company to
make adjustments, reclassification, reorganizations or changes of its capital or
business structures or to merge or to consolidate or to dissolve, liquidate or
sell, or transfer all or part of its business or assets.
SECTION 8.4 No Rights as Shareholder. Except as specifically provided in
this Article 8, a Stock Option holder or a transferee of Stock Options shall
have no rights as a shareholder with respect to any shares covered by the Stock
Options until the date of the issuance of a Stock certificate to him or her for
such shares, and no adjustment shall be made for dividends (ordinary, or
extraordinary, whether in cash, securities or other property) or distributions
of other rights for which the record date is prior to the date such Stock
certificate is issued, except as provided in Section 8.1.
ARTICLE 9
AMENDMENT AND TERMINATION
The Board may amend, alter or discontinue the Plan, but no amendment,
alteration or discontinuation shall be made which would impair the rights of a
Participant under any Stock Options therefore granted without such Participant's
consent, or which without the approval of the shareholders would:
(a) except as provided in Article 8, materially increase the total number
of shares of Stock reserved for the purposes of the Plan;
(b) materially increase the benefits accruing to Participants or Eligible
Persons under the Plan; or
(c) materially modify the requirements for eligibility under the Plan.
The Committee may amend the terms of any award theretofore granted,
prospectively or retroactively, but, subject to Article 3, no such amendment
shall impair the rights of any holder without his or her consent.
ARTICLE 10
GENERAL PROVISIONS
SECTION 10.1 General Restrictions.
(a) Limitation on Granting of Stock Options. Subject to adjustment as
provided in Article 8, no Participant shall be granted Stock Options with
respect to _______ shares of Stock.
(b) No View to Distribute. The Committee may require each person acquiring
shares of Stock pursuant to the Plan to represent to and agree with the Company
in writing that such person is acquiring the shares without a view towards
distribution thereof. The certificates for such shares may include any legend
which the Committee deems appropriate to reflect any restrictions on transfer.
(c) Legends. All certificates for shares of Stock delivered under the Plan
shall be subject to such stop transfer orders and other restrictions as the
Committee may deem advisable under the rules, regulations and other requirements
of the SEC, any stock exchange upon which the Stock is then listed and any
applicable federal or state securities laws, and the Committee may cause a
legend or legends to be put on any such certificates to make appropriate
reference to such restrictions.
8
<PAGE>
SECTION 10.2 Other Compensation Arrangements. Nothing contained in this
Plan shall prevent the Board from adopting other or additional compensation
arrangements, subject to shareholder approval if such approval is required; and
such arrangements may be either generally applicable or applicable only in
specific cases.
SECTION 10.3 Disqualifying Dispositions, Withholding Taxes.
(a) Disqualifying Disposition. The Stock Option Agreements shall require
Optionees who make a "disposition" (as defined in the Code) of all or any of the
Stock acquired through the exercise of Stock Options within two years from the
date of grant of the Stock Option, or within one year after the issuance of
Stock relating thereto, to immediately advise the Company in writing as to the
occurrence of the sale and the price realized upon the sale of such Stock; and
each Optionee shall agree that he or she shall maintain all such Stock in his or
her name so long as he or she maintains beneficial ownership of such Stock.
(b) Withholding Required. Each Participant shall, no later than the date
as of which the value derived from Stock Options first becomes includable in the
gross income of the Participant for income tax purposes, pay to the Company, or
make arrangements satisfactory to the Committee regarding payment of, any
federal, state or local taxes of any kind required by law to be withheld with
respect to the Stock Options or their exercise. The obligations of the Company
under the Plan shall be conditioned upon such payment or arrangements and the
Participant shall, to the extent permitted by law, have the right to request
that the Company deduct any such taxes from any payment of any kind otherwise
due to the Participant.
(c) Withholding Right. The Committee may, in its discretion, grant to a
Stock Option holder the right (a "Withholding Right") to elect to make such
payment by irrevocably requiring the Company to withhold from shares issuable
upon exercise of the Stock Options that number of full shares of Stock having a
Fair Market Value on the Tax Date (as defined below) equal to the amount (or
portion of the amount) required to be withheld. The Withholding Right may be
granted with respect to all or any portion of the Stock Options.
(d) Exercise of Withholding Right. To exercise a Withholding Right, the
Stock Option holder must follow the election procedures set forth below,
together with such additional procedures and conditions as may be set forth in
the related Stock Option Agreement or otherwise adopted by the Committee.
(i) The Stock Option holder must deliver to the Company his or her
written notice of election (the "Election") to have the Withholding Right apply
to all (or a designated portion) of his or her Stock Options prior to the date
of exercise of the Right to which it relates.
(ii) Unless disapproved by the Committee as provided in Subsection
(iii) below, the Election once made will be irrevocable.
(iii) No Election is valid unless the Committee consents to the
Election; the Committee has the right and power, in its sole discretion, with or
without cause or reason therefor, to consent to the Election, to refuse to
consent to the Election, or to disapprove the Election; and if the Committee has
not consented to the Election on or prior to the date that the amount of tax to
be withheld is, under applicable federal income tax laws, fixed and determined
by the Company (the "Tax Date"), the Election will be deemed approved.
(iv) If the Stock Option holder on the date of delivery of the
Election to the Company is a Section 16(b) Person, the following additional
provisions will apply:
(A) the Election cannot be made during the six calendar month
period commencing with the date of the grant of the Withholding Right (even if
the Stock Options to which such Withholding Right relates have been granted
prior to such date); provided, that this Subsection (A) is not applicable to any
Stock Option holder at any time subsequent to the death, Disability or
Retirement of the Stock Option holder;
9
<PAGE>
(B) the Election (and the exercise of the related Stock Option)
can only be made during the Window Period; and
(C) notwithstanding any other provision of this Section 10.3, no
Section 16(b) Person shall have the right to make any Election unless the
Company has been subject to the reporting requirements of Section 13(a) of the
Exchange Act for at least a year prior to the transaction and has filed all
reports and statements required to be filed pursuant to that Section for that
year.
(e) Effect. If the Committee consents to an Election of a Withholding
Right:
(i) upon the exercise of the Stock Options (or any portion thereof)
to which the Withholding Right relates, the Company will withhold from the
shares otherwise issuable that number of full shares of Stock having an actual
Fair Market Value equal to the amount (or portion of the amount, as applicable)
required to be withheld under applicable federal, state and/or local income tax
laws as a result of the exercise; and
(ii) if the Stock Option holder is then a Section 16(b) Person who
has made an Election, the related Stock Options may not be exercised, nor may
any shares of Stock issued pursuant thereto be sold, exchanged or otherwise
transferred, unless such exercise, or such transaction, complies with an
exemption from Section 16(b) provided under Rule 16b-3.
(f) Cash Reimbursements. The Company may make cash bonus payments to Non-
Statutory Stock Option holders to reimburse such Non-Statutory Stock Option
holders for all or part of federal and state taxes payable with respect to the
exercise of Non-Statutory Stock Options.
SECTION 10.4 Indemnification. In addition to such other rights of
indemnification as they may have as Directors or Outside Directors, and to the
extent allowed by applicable law, the Committee shall be indemnified by the
Company against the reasonable expenses, including attorney's fees, actually
incurred in connection with any action, suit or proceeding or in connection with
any appeal therein, to which they or any one of them may be party by reason of
any action taken or failure to act under or in connection with the Plan or any
Stock Option granted under the Plan, and against all amounts paid by them in
settlement thereof (provided that the settlement has been approved by the
Company, which approval shall not be unreasonably withheld) or paid by them in
satisfaction of a judgment in any such action, suit or proceeding, except in
relation to matters as to which it shall be adjudged in such action, suit or
proceeding that such Committee did not act in good faith and in a manner which
such person reasonably believed to be in the best interests of the Company, and
in the case of a criminal proceeding, had no reason to believe that the conduct
complained of was unlawful; provided, however, that within 60 days after
institution of any such action, suit or proceeding, such Committee shall, in
writing, offer the Company the opportunity at its own expense to handle and
defend such action, suit or proceeding.
SECTION 10.5 Loans. The Company may make loans to Optionees (other than
Directors who are not also employees or officers of the Company or any Parent or
any Subsidiary) as the Committee, in its discretion, may determine in connection
with the exercise of outstanding Stock Options granted under the Plan. Such
loans shall (i) be evidenced by promissory notes entered into by the holders in
favor of the Company; (ii) be subject to the terms and conditions set forth in
this Section 10.5 and such other terms and conditions, not inconsistent with the
Plan, as the Committee shall determine; and (iii) bear interest, if any, at such
rate as the Committee shall determine. In no event may the principal amount of
any such loan exceed the Exercise Price less the par value, if any, of the
shares of Stock covered by the Stock Option, or portion thereof, exercised by
the Optionee. The initial term of the loan, the schedule of payments of
principal and interest under the loan, the extent to which the loan is to be
with or without recourse against the holder with respect to principal and
applicable interest and the conditions upon which the loan will become payable
in the event of the holder's termination of employment shall be determined by
the Committee; provided, however, that the term of the loan, including
extensions, shall not exceed 10 years. Unless the Committee determines
otherwise, when a loan shall have been made, shares of Stock
10
<PAGE>
having a Fair Market Value at least equal to the principal amount of the loan
shall be pledged by the holder to the Company as security for payment of the
unpaid balance of the loan and such pledge shall be evidenced by a security
agreement, the terms of which shall be determined by the Committee, in its
discretion; provided, however, that each loan shall comply with all applicable
laws, regulations and rules of the Board of Governors of the Federal Reserve
System and any other governmental agency having jurisdiction.
SECTION 10.6 Non-Transferability of Stock Options. Each Stock Option
Agreement shall provide that the Stock Options granted under the Plan shall not
be transferable otherwise than by will or by the laws of descent and
distribution, and the Stock Options may be exercised, during the lifetime of the
Stock Option holder, only by the Stock Option holder or by his or her guardian
or legal representative.
SECTION 10.7 Regulatory Matters. Each Stock Option Agreement shall provide
that no shares shall be purchased or sold thereunder unless and until (i) any
then applicable requirements of state or federal laws and regulatory agencies
shall have been fully complied with to the satisfaction of the Company and its
counsel; and (ii) if required to do so by the Company, the Optionee shall have
executed and delivered to the Company a letter of investment intent in such form
and containing such provisions as the Committee may require.
SECTION 10.8 Recapitalizations. Each Stock Option Agreement and Stock
Purchase Agreement shall contain provisions required to reflect the provisions
of Article 8.
SECTION 10.9 Delivery. Upon exercise of Stock Options granted under this
Plan, the Company shall issue Stock or pay any amounts due within a reasonable
period of time thereafter. Subject to any statutory obligations the Company may
otherwise have, for purposes of this Plan, 30 days shall be considered a
reasonable period of time.
SECTION 10.10 Rule 16b-3. With respect to persons subject to Section 16 of
the Exchange Act, transactions under this Plan are intended to comply with all
applicable conditions of Rule 16b-3 or its successors under the Exchange Act. To
the extent any provision of the Plan or action by the Committee fails to so
comply, it shall be deemed null and void to the extent permitted by law and
deemed advisable by the Committee.
SECTION 10.11 Other Provisions. The Stock Option Agreements authorized
under the Plan may contain such other provisions not inconsistent with this
Plan, including, without limitation, restrictions upon the exercise of the Stock
Options, as the Committee may deem advisable.
ARTICLE 11
EFFECTIVE DATE OF PLAN
The Plan shall become effective on ___________, 1996, subject to approval
by the Company's stockholders, which approval must be obtained within one year
from the date the Plan is adopted by the Board.
ARTICLE 12
TERM OF PLAN
No Stock Options shall be granted pursuant to the Plan on or after
_____________ but Stock Options therefore granted may extend beyond that date.
11
<PAGE>
ARTICLE 13
INFORMATION TO STOCK OPTION HOLDERS
The Company will cause a report to be sent to each Stock Option holder not
later than 120 days after the end of each fiscal year. Such report shall consist
of the financial statements of the Company for such fiscal year and shall
include such other information as is provided by the Company to its
shareholders.
12
<PAGE>
APPENDIX E
VETERINARY CENTERS OF AMERICA, INC.
1996 EMPLOYEE STOCK PURCHASE PLAN
1. PURPOSE OF PLAN. The purpose of this 1996 Employee Stock Purchase Plan
(the "Plan") is to encourage a sense of proprietorship on the part of employees
of Veterinary Centers of America, Inc., a Delaware corporation (the "Company"),
and its Subsidiary Corporations (as defined below) by assisting them in making
regular purchases of shares of stock of the Company, and thus to benefit the
Company by increasing such employees' interest in the growth of the Company and
subsidiary corporations and in such entities' financial success. Participation
in the Plan is entirely voluntary, and the Company makes no recommendation to
its employees as to whether they should participate.
2. DEFINITIONS.
2.1 "Base Earnings" shall mean the Employee's regular salary rate
before deductions required by law and deductions authorized by the Employee. In
the case of Employees primarily compensated on a commission basis, Base Earnings
may include an amount of commission earnings not to exceed $__________ per
month. Base Earnings do not include: pay for overtime, extended workweek
schedules or any other form of extra compensation; payments by the Company or
Subsidiary Corporations, as applicable, for social security, worker's
compensation, unemployment compensation, any disability payments or other
payments required by statute; or contributions by the Company or Subsidiary
Corporations, as applicable, for insurance, annuity or other employee benefit
plans.
2.2 "Board" shall mean the Board of Directors of the Company.
2.3 "Broker" shall mean the financial institution designated to act
as the Broker under the Plan pursuant to Paragraph 17 hereof.
2.4 "Brokerage Account" shall mean an account established on behalf
of each Participant pursuant to Paragraph 9.1 hereof.
2.5 "Committee" shall mean a Stock Purchase Committee appointed by
the Board.
2.6 "Common Stock" shall mean the Common Stock, par value $0.001 per
share, of the Company.
2.7 "Company" shall mean Veterinary Centers of America, Inc., a
Delaware corporation, or any successor.
2.8 "Company Account" shall mean the account established in the name
of the Company pursuant to Paragraph 7.2 hereof.
2.9 "Employee" shall mean any person who is currently employed by the
Company or one of its Subsidiary Corporations for at least 20 hours per week and
has been so employed continuously during the preceding 90 days (provided that
the Board or the Committee may in its discretion waive such 90-day requirement),
excluding non-Employees and persons on leave of absence. An Employee may also be
referred to herein as a "Participant".
2.10 "Enrollment Form" shall mean the Employee Stock Purchase Plan
Enrollment Form.
2.11 "Interested Party" shall mean the persons described in Paragraph
16 hereof.
2.12 "Plan" shall mean this Employee Stock Purchase Plan.
<PAGE>
2.13 "Subsidiary Corporation" shall mean a corporation, domestic or
foreign, of which not less than 50% of the voting shares are held by the Company
or a Subsidiary Corporation, whether or not such corporation now exists or is
hereafter organized or acquired by the Company or a Subsidiary Corporation.
3. ADMINISTRATION. The Plan shall be administered by the Board or, in the
discretion of the Board, by the Committee which shall consist of not less than
two persons to be appointed by, and to serve at the pleasure of, the Board. No
member of the Board shall be eligible to participate in the Plan. An aggregate
of 250,000 shares of Common Stock shall be subject to the Plan, provided that
such number shall be automatically adjusted to reflect any stock split, reverse
stock split, stock dividend, recapitalization, merger, consolidation,
combination, reclassification or similar corporate change. The Board or the
Committee shall have full authority to construe, interpret, apply and administer
the Plan and to establish and amend such rules and procedures as it deems
necessary or appropriate from time to time for the proper administration of the
Plan. In addition, the Board or the Committee may engage or hire such persons to
provide administrative, recordkeeping and other similar services in connection
with its administration of the Plan, as it may deem necessary or appropriate
from time to time. The members of the Board and the Committee and the officers
of the Company shall be entitled to rely upon all certificates and reports made
by such persons, and upon all opinions given by any legal counsel or investment
adviser selected or approved by the Board or the Committee. The members of the
Board and the Committee and the officers of the Company shall be fully protected
in respect of any action taken or to be taken by them in good faith in reliance
upon any such certificates, reports, opinions or other advice of any such
person, and all actions so taken shall be conclusive upon each of them and upon
all Participants. The Company shall indemnify each member of the Board and the
Committee and any other officer or employee of the Company who is designated to
carry out any responsibilities under the Plan for any liability arising out of
or connected with his or her duties hereunder, except such liability as may
arise from such person's gross negligence or willful misconduct.
4. ELIGIBILITY. Any Employee as defined in Paragraph 2.9 shall be
eligible to participate in the Plan. Any Employee participating in the Plan who,
after the commencement of a particular Offering Period, as defined in Paragraph
5, shall for any reason fail to meet the standards of eligibility, shall be
considered to have withdrawn from the Plan, effective as of the date upon which
the Participant shall have become ineligible. Any reference in the Plan to
withdrawal by a Participant from the Plan shall include ineligibility as
described in this Paragraph 4.
5. OFFERING PERIODS. Shares shall be offered pursuant to this Plan in
consecutive periods ("Offering Periods") of three months duration each,
commencing on the effective date of the Plan pursuant to Paragraph 22 and
continuing thereafter until terminated in accordance with Paragraph 15. The
Board shall have the power to change the duration of Offering Periods if such
change is announced at least 10 days prior to the scheduled beginning of the
first Offering Period to be affected.
6. PARTICIPATION. All Employees of the Company, other than directors and
Executive Officers (as defined below) are eligible to participate in the Plan.
Participation in the Plan is optional. An eligible Employee may apply to
participate in the Plan by submitting to the Company's payroll office an
Enrollment Form authorizing a payroll deduction and purchase of shares. The
Enrollment Form shall be on a form provided by the Company and may be submitted
to the Company at any time. Participation shall not be effective until the
Enrollment Form is reviewed and accepted by the Company by written notice to the
Employee. Once the Enrollment Form has been reviewed and accepted by the
Company, participation in the Plan shall commence immediately. Executive
Officers include the chief executive officer, chief operating officer,
president, chief financial officer, executive vice president, or senior vice
president of the Company or a Subsidiary Corporation.
7. PAYROLL DEDUCTIONS.
7.1 Election. At the time a Participant submits an Enrollment Form,
the Participant shall elect to have payroll deductions made on each payday
during the Offering Period at a whole percentage from 5% to 15% of the Base
Earning which the Participant is to receive on such payday. In the case of
Participants primarily compensated on a commission basis, a Participant can
elect to have payroll deductions made on each payday during
2
<PAGE>
the Offering Period at a whole percentage from 5% to 15% on the commission
portion of said Participant's Base Earnings, not to exceed $__________ per
quarter.
7.2 Holding of Funds. All payroll deductions authorized by each
Participant shall be held in an interest-bearing account with a broker or
financial institution designated by the Board of Directors in the name of the
Veterinary Centers of America, Inc. Employee Stock Purchase Plan (the "Company
Account") until used to purchase Common Stock and shall not be used for any
other purpose. The Company shall maintain records reflecting the amount in the
Company Account for each Participant. Interest accruing on the payroll
deductions credited to the Company Account shall be used to defray costs
associated with administering the Plan and will not be available to purchase
shares of Common Stock under Paragraph 9. All withholding taxes in connection
with a Participant's payroll deduction shall be deducted from the remainder of
the Base Earnings paid to the Participant and not from the amount to be placed
in the Company Account. A Participant may not make any additional payments into
the Company Account except as provided in Paragraph 18. All amounts in the
Company Account derived from payroll deductions shall be referred to as the
"Participant Contribution."
7.3 Changes in Election. Participation in the Plan will continue
until the Participant withdraws from the Plan, is no longer eligible to
participate, or the Plan is terminated. Such participation shall be on the basis
of the payroll deduction election submitted by such Employee to the Company and
then currently in effect. Each such election shall remain in effect until the
effective date of any change in the amount of payroll deduction as requested by
the Participant and accepted by the Company. To be effective in any Offering
Period, a change in the amount of payroll deduction must be requested in writing
and submitted to the Company. A Participant may change his withholding
percentage at any time during an Offering Period but only one time during any
one Offering Period. If a Participant's Base Earnings change during an Offering
Period, the amount of the payroll deduction will be changed to the figure
reflecting the Participant's previously elected deduction percentage applied to
his or her new Base Earnings (but will not in any event be in excess of 15% of
the Participant's Base Earnings).
8. CONTRIBUTION BY THE COMPANY OR A SUBSIDIARY. The Company or a
subsidiary shall make matching contributions (the "Matching Contribution") as
follows:
8.1 Officers and Directors Not Participants. An "Executive Officer"
shall mean a chief executive officer, chief operating officer, president, chief
financial officer, executive vice president, or senior vice president of the
Company or a Subsidiary Corporation and shall be determined as of the end of an
Offering Period.
8.2 All Participants. For each Participant in the Plan who remains an
Employee of the Company or a Subsidiary Corporation for at least one year after
the termination of a particular Offering Period, the Company or Subsidiary
Corporation shall make upon the first anniversary of the date of termination of
such Offering Period a Matching Contribution up to one-fifth of the amount
contributed on behalf of such Participant during such one year earlier Offering
Period, as determined in the discretion of the Committee and subject to
Paragraph 8.3. Withholding taxes as and when required in connection with such
Matching Contribution shall be withheld based upon the person's existing
withholding percentages or as otherwise required by law from the Participants's
Base Earnings.
8.3 Fractional Share Calculations. Fractional shares shall not be
issued regarding the Matching Contribution. If the above calculation results in
an incremental share calculation which is .5, or greater, an additional whole
share shall be issued. If the above calculation results in an incremental share
calculation which is less than .5, no share shall be issued regarding such
fraction.
8.4 Timing of Withholding. The Company shall withhold taxes in two
subsequent pay periods or as otherwise required by law.
9. PURCHASE OF SHARES REGARDING PARTICIPANT'S CONTRIBUTION.
3
<PAGE>
9.1 Brokerage Account. Following the acceptance by the Company of a
Participant's Enrollment Form, the Company shall direct the Broker to open and
maintain an account (the "Brokerage Account") in the name of such Participant
and to purchase shares of Common Stock on behalf of such Participant as
permitted under this Plan.
9.2 Delivery of Funds to Broker from Company. The Company, from time
to time during an Offering Period, shall deliver to the Broker an amount equal
to the total of all Participant Contributions together with a list of the amount
of such Contributions from each Participant.
9.3 Broker's Purchase of Shares. From time to time, the Broker, as
agent for the Participants, shall purchase as many full shares or fractional
shares of Common Stock as such Contributions will permit. The shares to be
purchased shall be purchased at the then current fair market value and may, at
the election of the Company, be either treasury shares, shares authorized but
unissued, or shares purchased on the open market. The amount of Common Stock
purchased by the Broker pursuant to this Paragraph 9.3 shall be allocated to the
respective Brokerage Account of each Participant on the basis of the average
cost of the Common Stock so purchased, in proportion to the amount allocable to
each Participant. At the end of each Offering Period under the Plan, each
Participant shall acquire full ownership of all full shares and fractional
shares of Common Stock purchased for his Brokerage Account. Unless otherwise
requested by the Participant, all such full shares and fractional shares so
purchased shall be registered in the name of the Broker and will remain so
registered until delivery is requested in accordance with Paragraph 9.5.
9.4 Fees and Commissions. The Company shall pay the Broker's
administrative charges for opening and maintaining the Brokerage Accounts for
active Participants and the brokerage commissions on purchases made for such
Brokerage Accounts which are attributable to Participant Contributions and
Matching Contributions under the Plan. Such Brokerage Accounts may be utilized
for other transactions as described in Paragraph 9.5 below, but any fees,
commissions or other charges by the Broker in connection with such other
transactions shall, in certain circumstances described in Paragraph 9.5 be
payable directly to the Broker by the Participant.
9.5 Participant Accounts with Broker. Each Participant's Brokerage
Account shall be credited with all cash dividends paid with respect to full
shares and fractional shares of Common Stock purchased pursuant to Paragraphs
9.3 and 10 unless such shares are registered in the Participant's name. Unless
otherwise instructed by the Participant, dividends on such Common Stock shall
automatically be reinvested in Common Stock as soon as practicable following
receipt of such dividends by the Broker. Applicable fees and brokerage
commissions on the reinvestment of such dividends will be payable by the
Participant. Any stock dividends or stock splits which are made with respect to
shares of Common Stock purchased pursuant to Paragraphs 9.3 and 10 shall be
credited to the Participant's Brokerage Account without charge. Any Participant
may request that a certificate for any or all of the full shares of Common Stock
credited to his Brokerage Account be delivered to him at any time, provided,
however, the Participant shall be charged by the Broker for any fees applicable
to such requests. A Participant may request the Broker at any time to sell any
or all of the full shares or fractional shares of Common Stock credited to his
Brokerage Account. Unless otherwise instructed by the Participant, upon such
sale, the Broker will mail to the Participant a check for the proceeds, less any
applicable fees and brokerage commissions and any transfer taxes, registration
fees or other normal charges which shall be payable by the Participant. Except
as provided in Paragraph 13, a request by the Participant to the Broker to sell
shares of Common Stock or for delivery of certificates shall not affect an
Employee's status as a Participant. A Participant who has a Brokerage Account
with the Broker may purchase additional shares of Common Stock of the Company
for his Brokerage Account at any time by separate purchases arranged through the
Broker. When any such purchases are made the Participant will be charged by the
Broker for any and all fees and brokerage commissions applicable to such
transactions. In addition, any subsequent transactions with respect to such
shares acquired including, but not limited to, purchases, sales, reinvestment or
dividends, requests for certificates and crediting of stock dividends or stock
splits, shall be at the expense of the Participant and the Broker shall charge
the Participant directly for any and all fees and brokerage commissions
applicable to such transactions.
4
<PAGE>
10. ISSUANCE OF SHARES REGARDING MATCHING CONTRIBUTION. Subject to
Paragraph 15, on the first anniversary of the date of termination of an Offering
Period, each Participant's direct employer shall make the Matching Contribution
for each qualified Participant in an amount described in Paragraph 8 by
delivering to the Broker an amount equal to the total funds necessary to make
the Matching Contributions described in Paragraph 8 together with a list of the
number of shares allocable to the Brokerage Account of each Participant. As soon
as practicable thereafter, the Broker shall purchase the number of shares of
Common Stock required in order to make the Matching Contributions. The shares to
be purchased shall be purchased at the then current fair market value and may,
at the election of the Company, be either treasury shares, shares authorized but
unissued, or shares purchased on the open market. At the time of such purchases,
each Participant shall immediately acquire full ownership of all full shares of
Common Stock purchased. Unless otherwise requested by the Participant, all such
shares so purchased shall be registered in the name of the Broker and will
remain so registered until delivery is requested in accordance with Paragraph
9.5.
11. VOTING AND SHARES. All voting rights with respect to the full shares
of Common Stock held in the Brokerage Account of each Participant may be
exercised by each Participant, and the Broker shall exercise such voting rights
in accordance with the Participant's signed proxy instruction duly delivered to
the Broker. Fractional shares cannot be voted.
12. STATEMENT OF ACCOUNT. As soon as practicable after the end of each
Offering Period, the Broker shall deliver to each Participant a statement
regarding all activity in his or her Brokerage Account, including his or her
participation in the Plan for such Offering Period. Such statement will show the
number of shares acquired or sold, the price per share, the transaction date,
stock splits, dividends paid, dividends reinvested and the total number of
shares held in the Brokerage Account. The Broker shall also deliver to each
Participant as promptly as practicable, by mail or otherwise, all notices or
meetings, proxy statements and other material distributed by the Company to its
stockholders, including the Company's annual report to its stockholders
containing audited financial statements.
13. WITHDRAWAL FROM THE PLAN. A Participant may withdraw from the Plan,
effective as of the end of any Offering Period, by giving written notice to the
Company not later than the 15th day prior to the end of such Offering Period.
Upon any such withdrawal, the Participant shall be entitled to receive as
promptly as possible from the Company all the Participant's payroll deductions
credited to the Company Account in his or her name during the applicable
Offering Period, but shall not be entitled to the benefit of any Matching
Contributions. In the event a Participant withdraws from the Plan pursuant to
this Paragraph 13, the Company shall notify the Broker as soon as practicable
and the Broker shall maintain or close the Participant's Brokerage Account in
accordance with the procedures set forth in Paragraph 16. A Participant who
withdraws from the Plan may not reenter the Plan except by execution and
delivery of a new Enrollment Form and payroll deduction election, and his or her
participation shall be effective upon acceptance of the Enrollment Form by the
Company by written notice to the Employee not sooner than 30 days after receipt
of the Enrollment Form, provided that the Company may in its discretion accept
an Enrollment Form prior to the expiration of such 30 days.
14. TERMINATION OF EMPLOYEE. In the event of the termination of a
Participant's employment with the Company or a Subsidiary Corporation for any
reason during an Offering Period, including but not limited to the death of a
Participant, participation in the Plan shall terminate as well as any rights to
Matching Contributions. The Participant or the personal representative of the
Participant shall be entitled to receive an amount of cash determined in the
same manner and payable at the same time as if the Participant had withdrawn
from the Plan by giving notice of withdrawal effective as of the date such
termination occurs. Notwithstanding the foregoing, termination of employment by
one employer for the purpose of being re-employed immediately by the Company or
one of its Subsidiary Corporations shall not be considered termination under
this Paragraph 14. Any reference in this Plan to withdrawal by a Participant
from the Plan shall include termination as described in this Paragraph 14. In
the event of the termination of a Participant's employment pursuant to this
Paragraph 14, the Company shall notify the Broker as soon as practicable and the
Broker shall maintain or close the Participant's Brokerage Account in accordance
with the procedures set forth in Paragraph 16.
5
<PAGE>
15. AMENDMENT AND TERMINATION OF PLAN. This Plan may be amended or
terminated by the Board at any time and such amendment or termination shall be
communicated in writing to all Participants as soon as practicable after the
date of such Board action. If the Plan is terminated, each Participant shall be
entitled to receive as promptly as possible from the Company all payroll
deductions attributable to him or her which have not been used to purchase
Common Stock pursuant to Paragraph 9, together with the accrued interest on the
Participant's funds held in the Company Account (collectively, the "Account
Balance"), but he or she shall not be entitled to the benefit of any Matching
Contributions with respect to such deductions or interest or otherwise for any
past or present Offering Periods. In any event, the Plan shall terminate 20
years from the date the Plan is adopted or the date the Plan is approved by the
stockholders, whichever is earlier. In the event that the Company terminates the
Plan pursuant to this Paragraph 15, the Broker shall maintain or close the
Participant's Brokerage Accounts in accordance with the procedures set forth in
Paragraph 16. Notwithstanding any other provision to the contrary, any provision
of this Plan may be amended by the Board or the Committee as required to obtain
necessary approvals of governmental agencies if such change does not materially
alter the rights and interests of stockholders of the Company. If there are any
changes in the capitalization of the Company, such as through mergers,
consolidations, reorganizations, recapitalizations, stock splits or stock
dividends, appropriate adjustments will be made by the Company in the number of
shares of its Common Stock subject to purchase under the Plan.
16. DISPOSITION OF BROKERAGE ACCOUNT FOLLOWING WITHDRAWAL, DEATH,
TERMINATION OF EMPLOYMENT OR TERMINATION OF PLAN. As soon as practicable
following the notification of the withdrawal of a Participant from the Plan, the
notification of the termination of a Participant's employment with the Company
or a Subsidiary Corporation (which includes the death of the Participant) or of
the notification that the Plan is terminated pursuant to Paragraph 15 hereof,
the Broker shall notify the former Participant, or in the event of his death,
his designated beneficiary, if any, or if no designated beneficiary the estate
of the deceased Participant (collectively, an "Interested Party"), regarding the
disposition of the former Participant's or deceased Participant's Brokerage
Account. As soon as practicable following receipt of the notification set forth
in the preceding sentence, the Interested Party may request the Broker to
dispose of the former Participant's or deceased Participant's Brokerage Account,
at the Interested Party's expense, by any one of the following means:
(a) The Interested Party may request the Broker to maintain the
former Participant's or deceased Participant's Brokerage Account for the
benefit of the Interested Party or any other person. The Interested Party
shall be charged by the Broker for all maintenance fees and any and all
other fees in connection with the Brokerage Account;
(b) The Interested Party may request the Broker to sell all of the
full shares and fractional shares of Common Stock, if any, held in the
former Participant's or deceased Participant's Brokerage Account. Upon such
sale, the Broker will mail to the Interested Party a check for the
proceeds, less any applicable fees and brokerage commissions and any
transfer taxes, registration fees or other charges which shall be payable
by the Interested Party; or
(c) The Interested Party may request the Broker to provide a
certificate for all of the full shares of Common Stock, if any, together
with a check in an amount equal to the proceeds of the sale of any
fractional shares of Common Stock held in the former Participant's or
deceased Participant's Brokerage Account, less any applicable fees and
brokerage commissions and any transfer taxes, registration fees or other
charges which are payable by the Interested Party.
Maintenance of the former Participant's or deceased Participant's Brokerage
Account pursuant to this Paragraph 16 shall confer no rights under the Plan.
17. BROKER. The Company may administer the Plan without the use of a
Broker or may appoint a Broker. Any Broker appointed by the Company shall be
vested with all the powers, rights, duties and immunities described herein. The
relationship between the Broker and the Participant will be the normal
relationship of a broker and its client, and the Company assumes no
responsibility in this respect.
6
<PAGE>
18. INITIAL CONTRIBUTION. Any Participant who files an Enrollment Form
prior to the first Offering Period may elect to make an initial contribution
("Initial Contribution") to be allocated to him or her in the Company Account,
by check payable to the Company, in any amount up to 5% of his or her Base
Earnings for the period between ________________ and the commencement of the
first Offering Period. The amount of the Initial Contribution shall be matched
as provided in Paragraph 8, and withholding taxes in connection with such
Matching Contribution shall be deducted in the same manner as provided in
Paragraph 8.
18.1 Lump Sum Contribution. The Board and/or the Committee may from
time to time in its discretion allow any Participant in the Plan to make a lump
sum contribution ("Lump Sum Contribution") to be credited to him or her in the
Company account, by check payable to the Company, in any amount up to 15% of his
or her Base Earnings, including commissions as set forth in Paragraph 7.1, for a
period prescribed by the Board and/or the Committee. The amount of the Lump Sum
Contribution shall be matched as provided in Paragraph 8, and withholding taxes
in connection with such Matching Contribution shall be deducted in the same
manner as provided in Paragraph 8.
19. CONDITIONS TO ISSUANCE OF SHARES. Shares shall not be issued under the
Plan unless issuance and delivery of such shares pursuant to the Plan shall
comply with all applicable provisions of law, domestic or foreign, including,
without limitation, the Securities Act of 1933, as amended, the Securities
Exchange Act of 1934, as amended, the rules and regulations promulgated
thereunder, the securities laws of the state in which any Employee resides, NASD
requirements and the requirements of any stock exchange upon which the Common
Stock may then be listed, and shall be further subject to the approval of
counsel for the Company with respect to such compliance. By execution of the
Enrollment form, the Participant covenants and agrees that all shares are being
purchased only for investment and without any present intention to sell or
distribute such shares.
20. NOTICE.
20.1 To Company or Subsidiaries. Any notice hereunder to the Company
or to its Subsidiary Corporations shall be in writing and such notice shall be
deemed made only when delivered or three days after being mailed by certified
mail return receipt requested to the Company's principal office at 3420 Ocean
Park Boulevard, Suite 1000, Santa Monica, California 90405 or to such other
address as the Company may designate by notice to the Participants.
20.2 To Participant. Any notice to a Participant hereunder shall be
in writing and any such communication and any delivery to a Participant shall be
deemed made if mailed or delivered to the Participant at such address as the
Participant may have on file with the Company.
21. MISCELLANEOUS.
21.1 No Limitation on Termination of Employment. Nothing in the Plan
shall in any manner be construed to limit in any way the right of the Company or
any of its Subsidiary Corporations to terminate an Employee's employment at any
time, without regard to the effect of such termination on any right such
Employee would otherwise have under the Plan, or give any right to an Employee
to remain employed by the Company in any particular position or at any
particular rate of remuneration.
21.2 Liability. The Company, its Subsidiary Corporations, any member
of the Board or Committee and any other person participating in any
determination of any question under the Plan, or in the interpretation,
administration or application of the Plan, shall have no liability to any party
for any action taken or not taken in good faith under the Plan, or based on or
arising out of a determination of any questions under the Plan or an
interpretation, administration or application of the Plan made in good faith.
21.3 Captions. The captions of the paragraphs of this Plan are for
convenience only and shall not control or affect the meaning or construction of
any of its provisions.
7
<PAGE>
21.4 Assignment. Any rights of Employees hereunder shall be
nonforfeitable, and no Account Balance or contribution made by any employer may
revert or inure to the benefit of the Company or any Subsidiary Corporation,
provided that no Participant shall be entitled to sell, assign, pledge or
hypothecate any right or interest in his or her Account Balance.
21.5 Governing Law. THIS AGREEMENT SHALL BE GOVERNED AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA APPLICABLE TO CONTRACTS MADE
IN AND TO BE PERFORMED WITHIN THAT STATE.
21.6 Severability. In case any provision of this Plan shall be held
illegal or invalid for any reason, said illegality or invalidity shall not
affect the remaining parts hereof, but this Plan shall be construed and enforced
as if such illegal and invalid provision had never been inserted herein.
21.7 Successors. The provisions of this Plan shall bind and inure to
the Benefit of the Company and its successors and assigns. The term "successors"
as used herein shall include any corporate or other business entity which shall
by merger, consolidation, purchase or otherwise acquire all or substantially all
of the business and assets of the Company, and successors of any such
corporation or other business entity.
22. EFFECTIVE DATE OF PLAN. The Plan shall become effective upon the first
day of the month after which the Board approves the Plan, subject to
ratification by the stockholders of the Company, and all necessary approvals of
governmental agencies have been received.
8
<PAGE>
APPENDIX F
EXCHANGE RATES
<TABLE>
<CAPTION>
VCAI PETS EXCHANGE RATIO
------ ----------- --------------
<S> <C> <C>
12.000 5.070 0.4225
12.250 5.176 0.4225
12.500 5.281 0.4225
12.750 5.387 0.4225
13.000 5.493 0.4225
13.250 5.598 0.4225
13.500 5.704 0.4225
13.750 5.809 0.4225
14.000 5.915 0.4225
14.250 6.021 0.4225
14.500 6.126 0.4225
14.750 6.232 0.4225
15.000 6.338 0.4225
15.250 6.443 0.4225
15.500 6.549 0.4225
15.750 6.654 0.4225
16.000 6.760 0.4225
16.250 6.866 0.4225
16.500 6.971 0.4225
16.750 7.077 0.4225
17.000 7.183 0.4225
17.250 7.288 0.4225
17.500 7.394 0.4225
17.750 7.499 0.4225
18.000 7.605 0.4225
18.250 7.711 0.4225
18.500 7.816 0.4225
18.750 7.898 0.4213
19.000 7.980 0.4200
19.250 8.061 0.4188
19.500 8.141 0.4175
19.750 8.221 0.4163
20.000 8.300 0.4150
20.250 8.378 0.4138
20.500 8.456 0.4125
20.750 8.533 0.4113
21.000 8.610 0.4100
21.250 8.686 0.4088
21.500 8.761 0.4075
21.750 8.836 0.4063
22.000 8.910 0.4050
22.250 8.983 0.4038
22.500 9.056 0.4025
22.750 9.128 0.4013
23.000 9.200 0.4000
23.250 9.271 0.3988
23.500 9.341 0.3975
23.750 9.411 0.3963
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
VCAI PETS EXCHANGE RATIO
------ ----------- --------------
<S> <C> <C>
24.000 9.480 0.3950
24.250 9.609 0.3963
24.500 9.739 0.3975
24.750 9.869 0.3988
25.000 10.000 0.4000
25.250 10.000 0.3960
25.750 10.000 0.3883
26.000 10.000 0.3846
26.250 10.000 0.3810
26.500 10.000 0.3774
26.750 10.000 0.3738
27.000 10.000 0.3704
27.250 10.000 0.3670
27.500 10.000 0.3636
27.750 10.000 0.3604
28.000 10.000 0.3571
28.250 10.000 0.3540
28.500 10.000 0.3509
28.750 10.000 0.3478
29.000 10.000 0.3448
29.250 10.000 0.3419
29.500 10.000 0.3390
29.750 10.000 0.3361
30.000 10.000 0.3333
30.250 10.096 0.3338
30.500 10.192 0.3342
30.750 10.288 0.3346
31.000 10.385 0.3350
31.250 10.430 0.3338
31.500 10.474 0.3325
31.750 10.517 0.3313
32.000 10.560 0.3300
32.250 10.602 0.3288
32.500 10.644 0.3275
32.750 10.685 0.3263
33.000 10.725 0.3250
33.250 10.765 0.3238
33.500 10.804 0.3225
33.750 10.842 0.3213
34.000 10.880 0.3200
34.250 10.917 0.3188
34.500 10.954 0.3175
34.750 10.990 0.3163
35.000 11.025 0.3150
35.250 11.060 0.3138
35.500 11.094 0.3125
35.750 11.127 0.3113
36.000 11.160 0.3100
36.250 11.192 0.3088
36.500 11.224 0.3075
36.750 11.255 0.3063
37.000 11.285 0.3050
</TABLE>
2
<PAGE>
<TABLE>
<CAPTION>
VCAI PETS EXCHANGE RATIO
------ ----------- --------------
<S> <C> <C>
37.250 11.315 0.3038
37.500 11.344 0.3025
37.750 11.372 0.3013
38.000 11.400 0.3000
38.250 11.427 0.2988
38.500 11.454 0.2975
38.750 11.480 0.2936
39.000 11.505 0.2950
39.250 11.530 0.2938
39.500 11.554 0.2925
39.750 11.577 0.2913
40.000 11.600 0.2900
40.250 11.622 0.2888
40.500 11.644 0.2875
40.750 11.665 0.2863
41.000 11.685 0.2850
41.250 11.705 0.2838
41.500 11.724 0.2825
41.750 11.742 0.2813
42.000 11.760 0.2880
42.250 11.777 0.2788
42.500 11.794 0.2775
42.750 11.810 0.2763
43.000 11.825 0.2750
43.250 11.840 0.2738
43.500 11.854 0.2725
43.750 11.867 0.2713
44.000 11.880 0.2700
44.250 11.892 0.2688
44.500 11.904 0.2675
44.750 11.915 0.2663
45.000 11.925 0.2650
45.250 11.935 0.2638
45.500 11.944 0.2625
45.750 11.952 0.2613
46.000 11.960 0.2600
46.250 11.967 0.2588
46.500 11.974 0.2575
46.750 11.980 0.2563
47.000 11.985 0.2550
47.250 11.900 0.2538
47.500 11.994 0.2525
47.750 11.997 0.2513
48.000 12.000 0.2500
48.250 12.002 0.2488
48.500 12.004 0.2475
48.750 12.005 0.2463
49.000 12.005 0.2450
49.250 12.005 0.2438
49.500 12.005 0.2425
49.750 12.005 0.2413
50.000 12.005 0.2401
</TABLE>
3
<PAGE>
<TABLE>
<CAPTION>
VCAI PETS EXCHANGE RATIO
------ ----------- --------------
<S> <C> <C>
50.250 12.005 0.2389
50.500 12.005 0.2377
50.750 12.005 0.2366
51.000 12.005 0.2354
51.250 12.005 0.2342
51.500 12.005 0.2331
51.750 12.005 0.2320
52.000 12.005 0.2309
52.250 12.005 0.2298
52.500 12.005 0.2287
57.750 12.005 0.2276
53.000 12.005 0.2265
53.250 12.005 0.2254
53.500 12.005 0.2244
53.750 12.005 0.2233
54.000 12.005 0.2223
54.250 12.005 0.2213
54.500 12.005 0.2203
54.750 12.005 0.2193
55.000 12.005 0.2183
55.250 12.005 0.2173
55.500 12.005 0.2163
55.750 12.005 0.2153
56.000 12.005 0.2144
56.250 12.005 0.2134
56.500 12.005 0.2125
56.750 12.005 0.2115
57.000 12.005 0.2106
57.250 12.005 0.2097
57.500 12.005 0.2088
57.750 12.005 0.2079
58.000 12.005 0.2070
58.250 12.005 0.2061
58.500 12.005 0.2052
58.750 12.005 0.2043
59.000 12.005 0.2035
59.250 12.005 0.2026
59.500 12.005 0.2018
59.750 12.005 0.2009
60.000 12.005 0.2001
</TABLE>
4
<PAGE>
- --------------------------------------------------------------------------------
VETERINARY CENTERS OF AMERICA, INC.
PROXY FOR ANNUAL MEETING OF STOCKHOLDERS
The undersigned, a Stockholder of VETERINARY CENTERS OF AMERICA, INC. a
Delaware corporation, (the "Company") hereby appoints ROBERT L. ANTIN and TOMAS
W. FULLER, and each of them, the proxies of the undersigned, each with full
power of substitution, to attend, vote and act for the undersigned at the
Annual Meeting of Stockholders of the Company, to be held on July 19, 1996, and
any postponements or adjournments thereof, and in connection herewith, to vote
and represent all of the shares of the Company which the undersigned would be
entitled to vote, as follows:
THE BOARD OF DIRECTORS RECOMMENDS A WITH VOTE ON PROPOSAL 1 AND A FOR VOTE ON
PROPOSALS 2, 3, 4 AND 5.
1. ELECTION OF DIRECTORS, as provided in the Company's Proxy Statement:
[_] WITH [_] WITHOUT Authority to vote for the nominees listed below.
(Instructions: To withhold authority for the nominee, line through or
otherwise strike out name below)
Neil Tauber John B. Chickering, Jr.
2. The approval and adoption of the Agreement and Plan of Reorganization,
dated as of March 21, 1996, by and between Veterinary Centers of America,
Inc., Golden Merger Corporation and The Pet Practice, Inc.
[_] FOR [_] AGAINST [_] ABSTAIN
3. The approval of an Amendment to the Certificate of Incorporation to
increase the Company's authorized Common Stock and the Company's authorized
Preferred Stock.
[_] FOR [_] AGAINST [_] ABSTAIN
4. The approval of the Veterinary Centers of America, Inc. 1996 Stock
Incentive Plan.
[_] FOR [_] AGAINST [_] ABSTAIN
5. The approval of the Veterinary Centers of America, Inc. 1996 Employee
Stock Purchase Plan.
[_] FOR [_] AGAINST [_] ABSTAIN
The undersigned hereby revokes any other proxy to vote at such Meeting, and
hereby ratifies and confirms all that said attorneys and proxies, and each of
them, may lawfully do by virtue hereof. With respect to matters not known at
the time of the solicitation hereof, said proxies are authorized to vote in
accordance with their best judgement.
This Proxy will be voted in accordance with the instructions set forth above.
This Proxy will be treated as A GRANT OF AUTHORITY TO VOTE FOR the election of
the Directors named, the Agreement and Plan of Reorganization, the Amendment to
the Certificate of Incorporation, the 1996 Stock Incentive Plan and the 1996
Employee Stock Purchase Plan, and as said Proxy shall deem advisable on such
other business as may come before the Meeting, unless otherwise directed.
- --------------------------------------------------------------------------------
<PAGE>
- --------------------------------------------------------------------------------
The undersigned acknowledges receipt of a copy of the Notice of Annual
Meeting and accompanying Proxy Statement dated June 27, 1996 relating to the
Meeting.
Date: ______________________, 1996
__________________________________
__________________________________
Signature(s) of Stockholder(s)
(See Instructions Below)
The signature(s) hereon should correspond exactly with the name(s) of the
Stockholder(s) appearing on the Stock Certificate. If stock is jointly held, all
joint owners should sign. When signing as attorney, executor, administrator,
trustee or guardian, please give full title as such. If signer is a corporation,
please sign the full corporation name, and give title of signing officer.
THIS PROXY IS SOLICITED BY
THE BOARD OF DIRECTORS OF VETERINARY CENTERS OF AMERICA, INC.
- --------------------------------------------------------------------------------
<PAGE>
- --------------------------------------------------------------------------------
THE PET PRACTICE, INC.
PROXY - SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON JULY 19, 1996
The undersigned, a stockholder of THE PET PRACTICE, INC., hereby constitutes
and appoints Stephen F. Nagy, Peter J. Cohen and Warren D. Barratt, or any of
them, proxies for the undersigned, with full power of substitution or
resubstitution, to represent the undersigned at the Special Meeting of
Stockholders to be held on Friday, July 19, 1996, at 2:00 P.M., local time, or
at any adjournments thereof, upon such matters as may properly come before the
Meeting.
HAYTHE & CURLEY
The undersigned hereby instructs said proxies or their substitutes to vote as
specified below on the following proposal and in accordance with their judgment
on any other matters which may properly come before the Meeting.
The Board of Directors recommends a vote FOR the proposal.
PROPOSAL--Approval and Adoption of the Agreement and Plan of Reorganization.
[_] FOR [_] AGAINST [_] ABSTAIN
THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED HEREIN. IF NO
DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED FOR THE PROPOSAL.
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
(Continued and to be signed on reverse side.)
- --------------------------------------------------------------------------------
<PAGE>
- --------------------------------------------------------------------------------
IMPORTANT: Before returning this Proxy, please sign your name or names on the
line(s) below exactly as shown hereon. Executors, administrators, trustees,
guardians or corporate officers should indicate their full titles when signing.
Where shares are registered in the name of joint tenants or trustees, each
joint tenant or trustee should sign.
Dated ____________________________,1996
________________________________ (L.S.)
________________________________ (L.S.)
Stockholder(s) Sign Here
PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY CARD
PROMPTLY USING THE ENCLOSED ENVELOPE.
- --------------------------------------------------------------------------------
